<SEC-DOCUMENT>0001144204-18-039737.txt : 20190711
<SEC-HEADER>0001144204-18-039737.hdr.sgml : 20190711
<ACCEPTANCE-DATETIME>20180725061038
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001144204-18-039737
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		22
FILED AS OF DATE:		20180725
<PUBLIC-REL-DATE>20190711
DATE AS OF CHANGE:		20180821

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InMode Ltd.
		CENTRAL INDEX KEY:			0001742692
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-02187
		FILM NUMBER:		18967563

	BUSINESS ADDRESS:	
		STREET 1:		TAVOR BUILDING, SHA?AR YOKNEAM
		STREET 2:		POB 533
		CITY:			YOKNEAM
		STATE:			L3
		ZIP:			2069200
		BUSINESS PHONE:		972-4-9097470

	MAIL ADDRESS:	
		STREET 1:		TAVOR BUILDING, SHA?AR YOKNEAM
		STREET 2:		POB 533
		CITY:			YOKNEAM
		STATE:			L3
		ZIP:			2069200
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
  <head>
    <title>tv498959-drs - none - 10.9945628s</title>
  </head>
  <body style="width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:19pt;margin-bottom:21.71pt;margin-left:27pt;width:541pt;">
        <div style="text-align:center; width:541pt; line-height:9pt;">As submitted confidentially to the Securities and Exchange Commission on July 25, 2018. </div>
        <div style="margin-top:-0.41pt; text-align:right; width:541pt; line-height:10pt;">Registration No. 333-&#8199;&#8199;&#8199;&#8199;&#8203;</div>
        <div style="margin-top:3.09pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6pt; text-align:center; width:541pt; line-height:12pt;font-size:12pt;">UNITED STATES <br >SECURITIES AND EXCHANGE COMMISSION</div>
        <div style="text-align:center; width:541pt; line-height:9pt;">WASHINGTON, D.C. 20549</div>
        <div style="margin-top:6.29pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6.79pt; text-align:center; width:541pt; line-height:13pt;font-size:10pt;">
          <font style="font-size:12pt;">FORM F-1</font> <br >REGISTRATION STATEMENT <br >UNDER THE SECURITIES ACT OF 1933 </div>
        <div style="margin-top:8.29pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:7.79pt; text-align:center; width:541pt; line-height:20pt;font-size:18pt;">INMODE LTD.</div>
        <div style="margin-top:-2pt; text-align:center; width:541pt; line-height:7pt;font-weight:normal;font-size:7pt;">(Exact name of registrant as specified in its charter)</div>
        <div style="margin-top:7pt; text-align:center; width:541pt; line-height:9pt;">Not Applicable</div>
        <div style="margin-top:1pt; text-align:center; width:541pt; line-height:7pt;font-weight:normal;font-size:7pt;">(Translation of Registrant&#8217;s name into English) </div>
        <table style="width:541pt;height:25pt;margin-top:6pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:174.34pt;">
              <div style="text-align:center;">State of Israel </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:168.33pt;">
              <div style="text-align:center;">3845 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:174.33pt;">
              <div style="text-align:center;">Not Applicable </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0.833pt 0pt 0.5pt 0pt; width:174.34pt;">
              <div style="text-align:center;">(State or other jurisdiction of <br >incorporation or organization) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0.833pt 0pt 0.5pt 0pt; width:168.33pt;">
              <div style="text-align:center;">(Primary Standard Industrial <br >Classification Code Number </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0.833pt 0pt 0.5pt 0pt; width:174.33pt;">
              <div style="text-align:center;">(I.R.S. Employer <br >Identification No.)</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:9.79pt; text-align:center; width:541pt; line-height:8pt;">Moshe Mizrahy <br >InMode Ltd. <br >Tavor Building, Sha&#8217;ar Yokneam <br >P.O. Box 533 <br >Yokneam 2069200, Israel <br >Tel. +972-4-9097470 <br ><font style="font-weight:normal;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font></div>
        <div style="margin-top:3pt; text-align:center; width:541pt; line-height:8pt;">Invasix Inc. <br >20996 Bake Parkway, Suite 106 <br >Lake Forest, California 96230 <br >Tel. +1-949-387-5711 <br ><font style="font-weight:normal;">(Name, address, including zip code and telephone number, including area code, of agent for service)</font></div>
        <div style="margin-top:6.29pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3.79pt; text-align:center; width:541pt; line-height:10pt;">Copies to:</div>
        <table style="width:541pt;margin-top:2pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:129.25pt;">
              <div style="text-align:center;">Anna T. Pinedo<br >Brian D. Hirshberg<br >Mayer Brown LLP<br >1221 Avenue of the Americas<br >New York, New York 10020-1001<br >Tel. (212) 506-2275<br >Fax (212) 849-5767</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:123.25pt;">
              <div style="text-align:center;">Galia Amir Cheyne<br >Sagi Omer<br >Primes, Shiloh, Givon, Meir<br >Law Firm<br >16 Derech Hayam<br >Haifa 34741, Israel<br >Tel. (972-4) 838-8332<br >Fax (972-4) 838-1401 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:123.25pt;">
              <div style="text-align:center;">Joshua G. Kiernan<br >Nathan Ajiashvili<br >Latham &amp; Watkins LLP<br >885 Third Avenue<br >New York, New York 10022-4834<br >Tel. (212) 906-1200<br >Fax (212) 751-4864</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:129.25pt;">
              <div style="text-align:center;">Chaim Friedland<br >Ari Fried<br >Gornitzky &amp; Co.<br >Zion House<br >45 Rothschild Blvd.<br >Tel Aviv 6578403, Israel<br >Tel. (972-3) 710-9191<br >Fax (972-3) 560-6555</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.29pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:521pt; line-height:9pt;">Approximate date of commencement of proposed sale to the public:<font style="font-weight:normal;"> As soon as practicable after the effective date of this registration statement. </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:541pt; line-height:9pt;font-weight:normal;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, as amended, check the following box. &#9744;</div>
        <div style="text-indent:20pt; margin-top:2pt; width:541pt; line-height:9pt;font-weight:normal;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act of 1933, as amended, check the following box and list the registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>
        <div style="text-indent:20pt; margin-top:2pt; width:541pt; line-height:9pt;font-weight:normal;">If this form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act of 1933, as amended, check the following box and list the registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>
        <div style="text-indent:20pt; margin-top:2pt; width:541pt; line-height:8.5pt;font-weight:normal;">If this form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act of 1933, as amended, check the following box and list the registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>
        <div style="margin-left:20pt; margin-top:2pt; width:521pt; line-height:9pt;font-weight:normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933, as amended. &#9746;</div>
        <div style="text-indent:20pt; margin-top:2pt; width:541pt; line-height:9pt;font-weight:normal;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act of 1933, as amended. &#9744;</div>
        <div style="margin-top:4.29pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="width:541pt;height:47.5pt;margin-top:8.5pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:3px double #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="7">
              <div style="white-space:nowrap; text-align:center;">CALCULATION OF REGISTRATION FEE </div>
            </td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 2.167pt 0pt; width:352.08pt;text-align:left;">
              <div style="white-space:nowrap;">Title of each class of securities to be registered </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 2.167pt 0pt; width:103.93pt;">
              <div style="text-align:center;">Proposed Maximum Aggregate <br >Offering Price<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 2.167pt 0pt; width:60.99pt;">
              <div style="text-align:center;">Amount of <br >Registration Fee<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(2)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:3px double #000000;padding:3.25pt 0pt 2pt 0pt; width:352.08pt;">
              <div style="white-space:nowrap;">Ordinary shares, par value NIS 0.01 per ordinary share </div>
            </td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:3.25pt 0pt 2pt 0pt; width:103.93pt;">$&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:3.25pt 0pt 2pt 0pt; width:60.99pt;">$&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="8">&#8203;</td>
          </tr>
        </table>
        <div style=" float:left; line-height:9pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;">(1)<br ></div>
        <div style=" float:left; margin-top:3pt; margin-bottom:0pt; line-height:9pt; text-align:left; width:520.5pt;font-weight:normal;">Estimated solely for the purpose of calculating the registration fee pursuant to Rule&#160;457(o) under the Securities Act of 1933, as amended. Includes ordinary shares that the underwriters have the option to purchase. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9pt; margin-top:1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;">(2)<br ></div>
        <div style=" float:left; margin-top:1pt; margin-bottom:0pt; line-height:9pt; text-align:left; width:520.5pt;font-weight:normal;">Calculated pursuant to Rule&#160;457(o) based on an estimate of the proposed maximum offering price.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:7.29pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:6.79pt; width:541pt; line-height:8.5pt;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</div>
        <div style="margin-top:5.79pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2pt; width:541pt; line-height:12pt;font-weight:normal;font-size:10pt;"></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:19pt;margin-bottom:21.71pt;margin-left:63pt;width:505pt;">
        <div style="text-align:justify; width:505pt; line-height:10pt;font-weight:bold;color:#FC0014;font-family:Helvetica, Arial, sans-serif;">The information contained in this preliminary prospectus is not complete and may be changed. This preliminary prospectus is not an offer to sell these securities, and we are not soliciting an offer to buy these securities in any jurisdiction where an offer or sale is not permitted.</div>
        <div style="margin-top:6pt; text-align:center; width:505pt; line-height:12pt;color:#FC0014;">Subject to Completion, dated &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2018</div>
        <div style="margin-top:3pt; width:505pt; line-height:14pt;font-size:12pt;">PROSPECTUS</div>
        <div style="margin-top:1.833pt; width:505pt;">
          <div style="margin-left: 0pt; width: 505pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:10.59pt; text-align:center; width:505pt; line-height:18pt;font-size:16pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; Shares </div>
        <div style="position:relative;z-index:-1;margin-top:9.59pt; text-align:center; width:505pt;">
          <img src="lg_inmode.jpg" alt="[MISSING IMAGE: lg_inmode.jpg]" height="65" width="155" >
        </div>
        <div style="margin-top:12.59pt; text-align:center; width:505pt; line-height:24pt;font-size:22pt;">InMode Ltd. </div>
        <div style="margin-top:6pt; text-align:center; width:505pt; line-height:18pt;font-size:16pt;">Ordinary Shares </div>
        <div style="margin-top:8.767pt; text-align:justify; width:505pt;">
          <div style="margin-left: 0pt; width: 505pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:9.59pt; width:505pt; line-height:13.5pt;font-size:11.5pt;">This is our initial public offering of our ordinary shares. We are offering &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; of our ordinary shares. No public market currently exists for our ordinary shares. We currently expect the initial public offering price to be between $&#8199;&#8199;&#8199;&#8199; and $&#8199;&#8199;&#8199;&#8199; per ordinary share. </div>
        <div style="margin-top:6pt; width:505pt; line-height:13pt;font-size:11.4pt;">
          <font style="font-size:11.5pt;">We intend to apply to list our ordinary shares on The Nasdaq Global Market under the symbol &#8216;&#8216;INMD.&#8217;&#8217; </font>
        </div>
        <div style="margin-top:6pt; width:505pt; line-height:13.5pt;font-size:11.5pt;">We are an &#8216;&#8216;emerging growth company&#8217;&#8217; as defined under federal securities laws and, as such, may elect to comply with certain reduced public company reporting requirements.</div>
        <div style="margin-top:6pt; width:505pt; line-height:16pt;font-style:italic;font-size:14pt;">Investing in our ordinary shares involves risks that are described in the &#8220;Risk Factors&#8221; section beginning on <a href="#t2RI">page12</a> of this prospectus. </div>
        <table style="width:505pt;height:59.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:398.72pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Per Ordinary <br >Share </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:398.72pt;text-align:left;">
              <div style="white-space:nowrap;">Price to public </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:13.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:398.72pt;text-align:left;">
              <div style="white-space:nowrap;">Underwriting discounts and commissions<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:398.72pt;text-align:left;">
              <div style="white-space:nowrap;">Proceeds to us (before expenses) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:9.49pt; width:505pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:11.5pt;">(1)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:13.5pt; text-align:left; width:484.5pt;font-size:11.5pt;">See &#8216;&#8216;Underwriting&#8217;&#8217; for a description of the compensation payable to the underwriters. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:6pt; width:505pt; line-height:13.5pt;font-size:11.5pt;">The underwriters may also exercise their option to purchase up to an additional &#8199;&#8199;&#8199;&#8199; ordinary shares from us at the initial public offering price, less underwriting discounts and commissions, for 30&#160;days after the date of this prospectus. </div>
        <div style="margin-top:6pt; width:505pt; line-height:13.5pt;font-size:11.5pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities being offered by this prospectus, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </div>
        <div style="margin-top:6pt; width:505pt; line-height:13.5pt;font-size:11.5pt;">The underwriters expect to deliver the ordinary shares to purchasers on or about &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2018. </div>
        <div style="margin-top:8.257pt; width:505pt;">
          <div style="margin-left: 0pt; width: 505pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:12.79pt; text-align:center; width:505pt; line-height:12pt;font-style:italic;">Joint Book-Running Managers </div>
        <table style="width:505pt;margin-top:2pt;border-collapse: collapse;">
          <tr style="line-height:18pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:18pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:246.5pt;">Barclays</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 0.5pt 0pt; width:246.5pt;text-align:right;">
              <div style="text-align:right;">UBS Investment Bank&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5.29pt; text-align:center; width:505pt;">
          <div style="margin-left: 39.307%; margin-right: 39.307%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:9.79pt; text-align:center; width:505pt; line-height:12pt;font-style:italic;">Lead Manager </div>
        <div style="margin-top:6pt; text-align:center; width:505pt; line-height:13.5pt;font-weight:bold;font-size:11.5pt;">Canaccord Genuity </div>
        <div style="margin-top:11.457pt; text-align:center; width:505pt;">
          <div style="margin-left: 39.307%; margin-right: 39.307%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:9.79pt; text-align:center; width:505pt; line-height:12pt;font-style:italic;">Co-Manager</div>
        <div style="margin-top:6pt; text-align:center; width:505pt; line-height:13.5pt;font-weight:bold;font-size:11.5pt;">Baird </div>
        <div style="margin-top:11.457pt; text-align:center; width:505pt;">
          <div style="margin-left: 39.307%; margin-right: 39.307%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6.79pt; text-align:center; width:505pt; line-height:12pt;">Prospectus dated &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2018 </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">TABLE OF CONTENTS </div>
        <table style="width:456pt;height:391.5pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="3">
              <div style="white-space:nowrap; text-align:center;">Page </div>
            </td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t1PR">Prospectus Summary </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t1PR">1</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t2RI">Risk Factors </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t2RI">12</a>
            </td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t3SP">Special Note Regarding Forward-Looking Statements </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t3SP">41</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t4MA">Market, Industry and Other Data </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t4MA">42</a>
            </td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t5US">Use of Proceeds </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t5US">43</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t6DI">Dividend Policy </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t6DI">44</a>
            </td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t7CA">Capitalization </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t7CA">45</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t8DI">Dilution </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t8DI">47</a>
            </td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t9SE">Selected Consolidated Financial Data </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t9SE">49</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t10MA">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t10MA">50</a>
            </td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t11BU">Business </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t11BU">61</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t12MA">Management </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t12MA">89</a>
            </td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t13CE">Certain Relationships and Related Party Transactions </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t13CE">106</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t14PR">Principal Shareholders </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t14PR">108</a>
            </td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t15DE">Description of Share Capital </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t15DE">110</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t16SH">Shares Eligible for Future Sale </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t16SH">116</a>
            </td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t17TA">Taxation </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t17TA">118</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t18UN">Underwriting </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t18UN">129</a>
            </td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t19LE">Legal Matters </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t19LE">137</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t20EX">Experts </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t20EX">137</a>
            </td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t21EN">Enforceability of Civil Liabilities </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t21EN">138</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t22OT">Other Expenses of Issuance and Distribution </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t22OT">139</a>
            </td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#t23WH">Where You Can Find Additional Information </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#t23WH">140</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIndex">Index to Financial Statements </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tIndex">F-1</a>
            </td>
          </tr>
        </table>
        <div style="margin-top:20.48pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:16.99pt; width:456pt; line-height:12pt;font-weight:bold;">You should rely only on the information contained in this prospectus any amendment or supplement to this prospectus or in any free writing prospectus prepared by us or on our behalf. Neither we nor any of the underwriters have authorized anyone to provide you with different information. We are offering to sell, and seeking offers to buy, ordinary shares only in jurisdictions where offers and sales are permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We own or have rights to trademarks, service marks or trade names that we use in connection with the operation of our business. In addition, our names, logos and website names and addresses are our service marks or trademarks. Other trademarks, service marks and trade names appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus are listed without the &#169;, &#174; and TM symbols, but we will assert, to the fullest extent under applicable law, our rights to these trademarks, service marks and trade names. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">i</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t1PR">&#8203;</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PROSPECTUS SUMMARY </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. You should read the following summary together with the entire prospectus including our audited consolidated financial statements and related notes appearing elsewhere in this prospectus. You should also consider carefully, among other matters, the matters we discuss in the sections titled &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business.&#8221; Unless otherwise indicated, all references in this prospectus to &#8220;InMode&#8221; or the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; &#8220;us&#8221; or similar terms refer to InMode Ltd., together with its consolidated subsidiaries, and &#8220;dollar&#8221; or &#8220;$&#8221; refer to U.S. dollars. The terms &#8220;shekels&#8221; and &#8220;NIS&#8221; refer to New Israeli Shekels, the lawful currency of the State of Israel. Unless otherwise indicated, the information in this prospectus assumes no exercise of the underwriters&#8217; overallotment option.</div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Overview </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are a leading global provider of innovative, energy-based, minimally and non-invasive aesthetic solutions. We have developed and commercialized products utilizing medically-accepted radiofrequency energy, or RF energy, technology, which can penetrate deep into the subdermal fat, allowing adipose tissue&#160;remodeling. We believe our RF energy-based proprietary technologies&#8201;&#8212;&#8201;Radio Frequency Assisted&#160;Lipolysis, or RFAL, and Deep Subdermal Fractional Radio Frequency, or Deep Subdermal Fractional RF&#8201;&#8212;&#8201;represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including liposuction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Our RFAL and Deep Subdermal Fractional RF-based products overcome many of the shortcomings of other aesthetic options by delivering surgical-grade results while significantly minimizing risks of scarring, downtime, pain and other complications typically accompanying surgical procedures. In addition to our minimally-invasive solutions, we design, develop, manufacture and market differentiated, non-invasive medical aesthetic products that target a wide array of procedures. These include simultaneous fat killing and skin tightening, permanent hair reduction through the use of our innovative dual wavelength technology and other treatments targeting skin appearance and texture through the use of our high power intense pulsed light, or IPL, technology. Our products, which we market and sell traditionally to plastic and facial surgeons, aesthetic surgeons, dermatologists and aesthetic obstetricians/&#8203;gynecologists, or aesthetic OB/GYNs, or collectively, our traditional customer base, may be used on a variety of body parts including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition to the existing group of patients who undergo full surgical aesthetic procedures, we believe our minimally-invasive products satisfy an unmet market demand in two incremental groups of patients: (i) those whose skin laxity or other physical attributes have previously prevented them from undergoing surgical aesthetic procedures and (ii) those who would entertain the idea of surgical or minimally-invasive aesthetic procedures, but are averse to the associated costs, downtime and potential safety risks. We believe these potential patient populations will continue to represent a significant opportunity for our differentiated minimally-invasive aesthetic solutions. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe our products have consistently been at the forefront of technological development in the aesthetic solutions market. Since 2010, we have launched five product platforms: <font style="font-style:italic;">BodyTite</font>, <font style="font-style:italic;">Optimas</font>, <font style="font-style:italic;">Votiva</font>, <font style="font-style:italic;">Contoura</font> and <font style="font-style:italic;">Triton</font>. Each product consists of the following components: a platform that incorporates multiple energy sources, one or more handpieces, our proprietary software and a simple, user interface with touch screen. Our platforms have a small footprint and are lightweight compared to our competitors&#8217; systems, which are typically larger and heavier. Our products can be upgraded easily by the user in order to perform additional treatments by adding handpieces and/or installing software in the existing platforms. The ease of upgrades enables our customers to meet demand for aesthetic solutions through additional service offerings.</div>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">1</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our focus on innovation and product development has resulted in a strong track record of new and next-generation pipeline products and applications targeted to our traditional customer base. We expect to launch three new product platforms by the end of 2019. In addition, we intend to expand the medical communities that we serve beyond our traditional customer base to include non-traditional customers, such as general practitioners, ophthalmologists, ear, nose and throat physicians, or ENTs, and aesthetic clinicians, by adapting our products to the expertise and skill level of these providers. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are focused on establishing and using clinical evidence to support and broaden our marketing claims and drive customer awareness and acceptance of our products. Traditionally, the aesthetic solutions market has relied heavily on marketing efforts and &#8220;before-and-after&#8221; pictures in an attempt to distinguish products. We believe our focus on establishing clinical evidence for the efficacy of our products has been important for adoption by our surgically-trained customers, who are accustomed to seeing extensive clinical data in their non-aesthetic practices. To date, we have a portfolio of 36 peer-reviewed publications and some of our products have been, or are in the process of being, used in 54 third-party clinical studies. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">To complement our aesthetic treatment solutions, we offer post-sales training and support services. We provide physicians with training focused on the most beneficial ways to utilize our products, including safety and instructional videos to expand procedural offerings and hands-on, personalized marketing support. We believe that we provide one of the most extensive training and ongoing support programs available to physicians throughout the aesthetic solutions market.</div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our revenues increased to approximately $53.5&#160;million for the year ended December&#160;31, 2017 from approximately $23.1&#160;million for the year ended December&#160;31, 2016. For the year ended December&#160;31, 2017, we recorded a gross margin of approximately 83% and net income of approximately $8.8&#160;million. We have 16 FDA clearances and, in addition to the United States, are permitted to sell our products in Europe, Australia, Brazil, Canada, China, Colombia, Israel, Japan, Mexico, Russia, South Korea, Taiwan and Thailand. We currently sell and market our products in the United States, the United Kingdom and Spain, through a direct sales force of approximately 75 representatives. We also sell and market our products through 29 distributors in 37 countries. As of December 31, 2017, we had an installed base of over 2,225 product platforms (capable of running various multi-use applicators and minimally-invasive consumables), 6,900&#160;multi-use treatment applicators (laser, IPL and RF) and 139,000 minimally-invasive consumable handpieces.</div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Industry </div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Aesthetic Solutions Market Opportunity </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The global market for aesthetic solutions is significant and growing. The American Society for Aesthetic Plastic Surgery, or ASAPS, estimates that U.S. consumers spent more than $8.5&#160;billion on a total of 7.8&#160;million aesthetic procedures in 2017, of which $6.6&#160;billion was spent on surgical aesthetic procedures. According to ASAPS, in 2017 total aesthetic procedures in the United States grew 6%, with surgical aesthetic procedure growth of 11% and non-surgical aesthetic procedure growth of 4%. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">According to the 2016 International Society of Aesthetic Plastic Surgery, or ISAPS, Global Aesthetic Survey, which includes survey results from 35,000 plastic surgeons in the top 30 countries for aesthetic procedures, approximately 23.6&#160;million total aesthetic procedures, including 10.4&#160;million surgical procedures and 13.2&#160;million non-surgical procedures, were performed globally in 2016. Of these total procedures, approximately 18%, or 4.2&#160;million, were performed in the United States. According to ISAPS, the top five surgical and minimally-invasive procedure categories globally in 2016, by number of procedures, that we provide innovative aesthetic solutions for were liposuction (1.5&#160;million), abdominoplasty (0.8&#160;million), face/neck lift (0.7&#160;million), feminine rejuvenation (0.2&#160;million) and arm lift (0.1&#160;million). The top five non-invasive procedure categories globally in 2016 that we provide innovative aesthetic solutions for were facial rejuvenation (2.5&#160;million), hair removal (1.1&#160;million), non-invasive fat reduction (0.4&#160;million), cellulite treatment (0.2&#160;million) and vascular lesions/sclerotherapy (0.1&#160;million). No one treatment procedure is offered by all physicians, and treatments vary in terms of the treatment goal and desired effect. As a result, the total aesthetic market, as reported by ASAPS and ISAPS, does not necessarily represent the market potential for us or any other single product or treatment, but illustrates that each year patients elect to have millions of procedures performed to enhance their appearance. </div>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">2</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">We believe the following factors are contributing to the growth in aesthetic procedures: </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the aging of the population in the western world; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the growing global obesity epidemic; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the increasing desire of many individuals to improve their appearance; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the reduction in procedure costs, which has attracted a broader consumer base; and </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the impact of managed care and reimbursement on physician economics, which has motivated physicians to establish or expand the menu of elective, private-pay aesthetic procedures that they offer. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Within the global aesthetics market, our products and solutions are primarily designed to address three energy-based treatment categories comprised of: (i)&#160;face and body contouring; (ii)&#160;medical aesthetics; and (iii)&#160;women&#8217;s health. Within each of these treatment categories, we believe our products provide a differentiated solution that overcomes many of the limitations of other existing treatment options. </div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Solution </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our minimally and non-invasive energy-based aesthetic solutions are designed to overcome several of the limitations and risks typically associated with other existing surgical, minimally and non-invasive procedures. Key benefits of our aesthetic solutions include: </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Small to no incisions, which reduces the drawbacks and risks typically associated with surgical procedures, such as significant pain, local or widespread scarring, infection, perforation and hemorrhage. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Outpatient procedures that typically do not require general anesthesia, which decreases patient downtime, discomfort and other potential complications and allows for cost-effective repeatability.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Minimally-invasive procedures with similar efficacy to surgical procedures that have the ability to expand the aesthetic solutions market.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Effective and long-lasting aesthetic solutions, many of which are supported by compelling clinical data.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Our differentiated, RF energy-based technology simultaneously kills fat and tightens skin, overcoming the many shortcomings of traditional surgical and minimally-invasive aesthetic procedures.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Typically less expensive than other aesthetic solutions on the market that provide comparable results as a result of less physician time and training required. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Competitive Strengths </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We attribute the growing commercial success of our various platforms and products to the following: </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
            <font style="font-style:italic;">Pioneer of the minimally-invasive aesthetic solutions market. </font>We believe our proprietary technologies represent a paradigm shift in the minimally-invasive aesthetic solutions market. We believe our technologies and products demonstrate numerous performance advantages over other aesthetic options and enable physicians and patients to obtain results that can typically only be achieved with more expensive surgical procedures. We believe our innovative minimally-invasive products overcome many of the limitations of other surgical, minimally and non-invasive procedures, positioning us to address unmet patient needs and expand the aesthetic solutions market.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">3</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
            <font style="font-style:italic;">Strong brand recognition. </font>Our brand has been associated with product leadership, significant technological advances and extensive clinical data, which has led to strong customer loyalty. Unlike many of our competitors, our technology is not laser-based and limited to superficial treatment of the skin. Instead, we have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. We believe our brand is synonymous throughout the physician and patient communities with having the broadest RF energy-based portfolio in the minimally-invasive aesthetics market for fat destruction and remodeling, face and body contouring and skin tightening.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
            <font style="font-style:italic;">Provide comprehensive solutions for physicians and patients.</font> We have an extensive product portfolio that includes solutions for a wide range of both minimally   and non-invasive procedures across the aesthetic  solutions market. For each of our products, we offer post-sale support services including training, installation, practice growth consulting and repair support that minimizes product downtime and associated lost revenues to physicians.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
            <font style="font-style:italic;">Broad regulatory approvals supported by extensive clinical data. </font>We have 16 FDA clearances and in addition to the United States, are permitted to sell our products in Europe, Australia, Brazil, Canada, China, Colombia, Israel, Japan, Mexico, Russia, South Korea, Taiwan and Thailand. We also have a portfolio of 36 peer-reviewed publications and approximately 54 third-party clinical studies have been, or are in the process of being, conducted using some of our products. We believe our focus on demonstrated clinical data and effectiveness differentiates us from our competition and helps to validate our technology with surgically-trained physicians, who we believe are typically the most difficult segment of the market to penetrate.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
            <font style="font-style:italic;">Strong management team with proven track record. </font>Our management team has significant expertise in the medical aesthetics industry with a proven track record of successfully developing and commercializing innovative technology. Led by our co-founders Moshe Mizrahy and Dr.&#160;Michael Kreindel, our senior executive team has an average of over 15&#160;years of medical aesthetics industry experience including co-founding Syneron Medical Ltd. and serving in various senior leadership positions within Cynosure, Inc. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Growth Strategy </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our objective is to expand our technological leadership in the aesthetic solutions market. We intend to achieve this goal by implementing the following strategies: </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
            <font style="font-style:italic;">Increase our sales presence to target and expand our addressable market globally. </font>We plan to expand our direct sales organization and our distribution network and seek to recruit and train exceptionally talented sales representatives in existing and new markets to help us broaden the adoption of our products and drive further market penetration. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">
            <font style="font-style:italic;">United States and Canada: </font>We plan to expand our direct sales team by approximately 15 representatives by the end of 2019. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">
            <font style="font-style:italic;">Europe</font>:  We intend to establish sales and marketing organizations and a network of exclusive European distributors (in addition to our existing network in the United Kingdom and Spain). </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">
            <font style="font-style:italic;">Latin America</font>:  We plan to expand our network of exclusive distributors in Argentina, Brazil, Chile, Colombia, Mexico, Panama and Uruguay. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">
            <font style="font-style:italic;">Asia</font><font style="font-style:italic;">-Pacific</font>:  We intend to establish a direct sales presence in China through our joint venture in Guangzhou, as well as expand our network of exclusive distributors in Australia, Hong Kong, Japan, Philippines, South Korea, Singapore, Taiwan and Thailand.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
            <font style="font-style:italic;">Continue to further penetrate our existing customer base and drive recurring revenues. </font>We believe that there are opportunities for us to generate additional revenue from existing customers who are already familiar with our products. For example, a number of our existing customers have purchased additional aesthetic systems from us to expand their treatment offerings. Additionally, </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">4</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="margin-left:40pt; width:416pt; line-height:12pt;">we are experiencing growth in sales of consumables (handpieces that are, or contain, one-time use applicators that must be replaced following each treatment) in the past three years. Since inception, we have sold over 170,000 consumables. We expect that as our customer base grows, the&#160;percentage of our revenues attributable to consumables will increase. We also expect that certain customers will be candidates for technology upgrades to enhance the capabilities of their existing InMode products. In addition, as we continue to grow our support services program, we expect to seek to increase the number of customers that enter into service contracts and extended warranties, which would provide us with additional recurring revenues. </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
            <font style="font-style:italic;">Leverage our existing technology to expand into new minimally and non-invasive applications. </font>We have an active research and development pipeline focused on additional solutions targeted to our traditional customer base. Our near-term product development portfolio consists of new and second generation solutions for various conditions, including wearable, non-invasive face and body reshaping products, eyelid treatments, cellulite, large area lipolysis, fractional RF treatment of severe vaginal laxity and labiaplasty. We expect to launch three new product platforms by the end of 2019. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
            <font style="font-style:italic;">Expand our customer base beyond traditional </font><font style="font-style:italic;">customers. </font>We intend to develop products that leverage our minimally and non-invasive technologies to address the unmet market needs of a non-traditional customer base, which includes general practitioners, ophthalmologists, ENTs and aesthetic clinicians. We intend to adapt our products to the expertise and skill level of these providers, further expanding our addressable market. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
            <font style="font-style:italic;">Actively pursue business development opportunities. </font>We may seek to engage in targeted business development activities, including acquisitions and strategic partnerships, in order to augment our product and technology portfolio in our existing and potentially adjacent markets. We believe we can leverage our global infrastructure and existing relationships to implement a disciplined tuck-in acquisition strategy. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
            <font style="font-style:italic;">Maintain a strong intellectual property and patent portfolio</font>.  We believe our existing intellectual property and patent portfolio adequately protects our rights to our proprietary technologies and creates a barrier of entry to potential competitors. We intend to strengthen our existing intellectual property and patent portfolio as we develop additional applications and continue to aggressively defend against potential infringement by our competitors. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Associated with Our Business </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our business is subject to a number of risks of which you should be aware of before making an investment decision. These risks are discussed more fully in the &#8220;Risk Factors&#8221; section of this prospectus. These risks include, but are not limited to, the following: </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our success depends upon market acceptance of our products;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">if there is not sufficient demand for the procedures performed with our products, practitioner demand for our products could decline, resulting in unfavorable operating results;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the success and continued development of our products depends, in part, upon maintaining strong relationships with physicians and other healthcare professionals; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we rely heavily on our sales professionals to market and sell our products worldwide. If we are unable to hire, effectively train, manage, improve the productivity of, and retain our sales professionals, our business will be harmed, which would impair our future revenue and profitability; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">due to our limited history of operations, we may not be able to continue our revenue growth and profitability; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the failure to attract and retain key personnel could adversely affect our business; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">5</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">if we do not continue to develop and commercialize new products and identify new markets for our products and technologies, we may not remain competitive, and our revenues and operating results could suffer; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">product liability suits could be brought against us due to defective material or design, or due to misuse of our products, and could result in expensive and time-consuming litigation, payment of substantial damages and an increase in our insurance rates; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our products and operations are subject to extensive and continuing regulatory compliance obligations in the United States and other countries, and failure to meet those obligations could adversely harm our business; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we outsource almost all of the manufacturing of our products to a small number of manufacturing subcontractors. If our subcontractors&#8217; operations are interrupted or if our orders exceed our subcontractors&#8217; manufacturing capacity, we may not be able to deliver our products on time; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">if we are unable to protect our intellectual property rights, our competitive position could be harmed. Our success and ability to compete depends in large part upon our ability to protect our proprietary technology;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">if we fail to obtain and maintain necessary FDA clearances for our products, if clearances for future products and proposed indications are delayed or not issued, if we or any of our third-party suppliers or manufacturers fail to comply with applicable regulatory requirements, or if there are regulatory changes, our commercial operations could be harmed; and</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">as a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and Nasdaq corporate governance rules and are permitted to file less information with the Securities and Exchange Commission, or the SEC, than U.S. domestic public companies, which may limit the information available to holders of our ordinary shares.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Implications of Being an Emerging Growth Company </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As a company with less than $1.07&#160;billion in revenue during our last fiscal year, we qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include, among others: </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a requirement to have only two&#160;years of audited financial statements and only two&#160;years of related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations disclosure in this prospectus; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act; and </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an exemption from compliance with any requirement that the Public Company Accounting Oversight Board, or PCAOB, may adopt regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may take advantage of these provisions for up to five&#160;years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company upon the earliest to occur of&#8201; (1)&#160;the last day of the fiscal year in which we have total annual gross revenues of&#8201; $1.07&#160;billion or more, (2)&#160;the last day of 2023, (3)&#160;the date on which we have issued more than $1.0&#160;billion in nonconvertible debt during the previous three&#160;years, or (4)&#160;the date on which we are deemed to be a large accelerated filer under the rules of the SEC. We may choose to take advantage of some but not all of these reduced burdens, and therefore the information that we provide holders of our ordinary shares may be different than the information you might receive from other public companies in which you hold equity. In addition, </div>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">6</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">Section&#160;107 of the JOBS Act also provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards applicable to public companies. We have irrevocably elected to opt out of such extended transition period. </div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Implications of Being a Foreign Private Issuer </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon consummation of this offering, we will report under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as a non-U.S. company with foreign private issuer status. Even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including: </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information or current reports on Form 8-K relating to the occurrence of specified significant events. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We intend to take advantage of these exemptions for as long as we qualify as a foreign private issuer. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Both foreign private issuers and emerging growth companies are also exempt from certain more stringent executive compensation disclosure rules. Thus, even if we no longer qualify as an emerging growth company but remain a foreign private issuer, we will continue to be exempt from the more stringent compensation disclosures required of companies that are neither an emerging growth company nor a foreign private issuer. </div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Corporate Information </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We were incorporated in the State of Israel on January&#160;2, 2008. In November&#160;2017, our corporate name was changed from Invasix Ltd. to InMode Ltd. Our headquarters are located at Tavor Building, Sha&#8217;ar Yokneam, P.O. Box 533, Yokneam 2069200, Israel. Our phone number is +972-4-9097470. Our website address is www.inmodemd.com. The information contained on or that can be accessed through our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus or in deciding to purchase our ordinary shares.</div>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">7</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">
            <font style="text-transform:uppercase;">The Offering</font></div>
          <div style="width:168pt;">
            <div style="margin-top:6pt; line-height:12pt;">Ordinary shares offered by us </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">&#8199;&#8199;&#8199;&#8199; ordinary shares </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">Ordinary shares to be outstanding after this offering </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">&#8199;&#8199;&#8199;&#8199; ordinary shares (&#8199;&#8199;&#8199;&#8199; ordinary shares if the underwriters exercise their option to purchase additional ordinary shares in full). </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">Option to purchase additional ordinary shares </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">We have granted the underwriters an option, exercisable within 30&#160;days from the date of this prospectus, to purchase up to &#8199;&#8199;&#8199;&#8199; additional ordinary shares. </div>
          <div style="width:168pt;">
            <div style="margin-top:6pt; line-height:12pt;">Use of proceeds </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">We estimate that the net proceeds to us from this offering will be approximately $&#8199;&#8199;&#8199;&#8199;million, assuming an initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds from this offering to expand our sales and marketing operations, to fund our research and development activities, and the remainder for general corporate purposes. See &#8220;Use of Proceeds.&#8221; </div>
          <div style="width:168pt;">
            <div style="margin-top:6pt; line-height:12pt;">Risk factors </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">See &#8220;Risk Factors&#8221; and other information included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our ordinary shares. </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">Proposed Nasdaq Global Market symbol </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">We intend to apply to have our ordinary shares listed on The Nasdaq Global Market, or Nasdaq, under the symbol &#8220;INMD.&#8221;</div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The number of ordinary shares that will be outstanding after this offering is based on 14,885,532 ordinary shares outstanding as of June&#160;30, 2018. The number of ordinary shares referred to above to be outstanding after this offering and, unless otherwise indicated, the other information in this prospectus excludes: </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">5,122,545 ordinary shares issuable upon the exercise of options outstanding as of June&#160;30, 2018 at a weighted-average exercise price of&#8201; $0.94 per ordinary share; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">1,000,000 ordinary shares reserved for future issuance under our 2018 Incentive Plan, as well as ordinary shares that may be issued pursuant to provisions in our 2018 Incentive Plan that automatically increase the ordinary share reserve under our 2018 Incentive Plan; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">&#8199;&#8199;&#8199;&#8199; ordinary shares issuable upon the exercise of Guangzhou Sino-Israel Bio-Industry Investment Fund (LLP)&#8217;s right to convert its non-controlling equity interest in our Chinese joint venture into our ordinary shares assuming a conversion price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, which is calculated based on the midpoint of the price range set forth on the cover page of this prospectus; and </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">&#8199;&#8199;&#8199;&#8199; ordinary shares issuable upon the exercise of Wigmore Medical Limited&#8217;s right to convert its non-controlling equity interest in our U.K. joint venture into our ordinary shares assuming a conversion price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">8</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Unless otherwise indicated, all information contained in this prospectus assumes or gives effect to: </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the adoption and effectiveness of our amended and restated articles of association upon the effectiveness of the registration statement of which this prospectus forms a part; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">no exercise of the outstanding options described above;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">no conversion of the non-controlling equity interests described above; and</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">no exercise by the underwriters of their option to purchase up to&#8199;&#8199;&#8199;&#8199; additional ordinary shares.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">9</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">
            <font style="text-transform:uppercase;">Summary CONSOLIDATED Financial Data</font></div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following tables present our summary consolidated financial data and should be read in conjunction with &#8220;Selected Consolidated Financial Data&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and related notes included elsewhere in this prospectus. The historical results are not necessarily indicative of the results to be expected for any future periods. We derived the summary statements of income data below for the&#160;years ended December&#160;31, 2017 and 2016 and the summary balance sheet data as of December 31, 2017 from our audited financial statements included elsewhere in this prospectus. Our audited consolidated financial statements are prepared in U.S. dollars and in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. </div>
          <table style="width:456pt;height:360.5pt;margin-top:8pt;border-collapse: collapse;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">2017 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">2016 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:324pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.583pt 0pt 0.5pt 0pt; width:0pt;text-align:center;" colspan="10">
                <div style="text-align:center;">(in thousands, except share <br >and per share data) </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">Consolidated Statements of Income Data:</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">
                <div style="white-space:nowrap;">Revenues </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">53,456</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">23,082</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:324pt;text-align:left;">
                <div style="white-space:nowrap;">Cost of revenues </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">9,053</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">5,653</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">
                <div style="white-space:nowrap;">Gross profit </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">44,403</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">17,429</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">Operating expenses:</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">
                <div style="margin-left:10pt;">Research and development </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,575</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,456</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">
                <div style="margin-left:10pt;">Sales and marketing </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">28,514</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,254</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:324pt;text-align:left;">
                <div style="margin-left:10pt;">General and administrative </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">4,364</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">3,050</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:324pt;text-align:left;">
                <div style="margin-left:20pt;">Total operating expenses </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">35,453</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">16,760</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">
                <div style="white-space:nowrap;">Operating income </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">8,950</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">669</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:324pt;text-align:left;">
                <div style="white-space:nowrap;">Financial income, net </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">849</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">4</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">
                <div style="white-space:nowrap;">Income before taxes </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,799</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">673</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:324pt;text-align:left;">
                <div style="white-space:nowrap;">Income tax </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">980</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">337</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 3.25pt 0pt; width:324pt;text-align:left;">
                <div style="white-space:nowrap;">Net income </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">8,819</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">336</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:8.75pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">Net income per ordinary share:</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 3.25pt 0pt; width:324pt;text-align:left;">
                <div style="margin-left:10pt;">Basic </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">0.52</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">0.02</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 3.25pt 0pt; width:324pt;text-align:left;">
                <div style="margin-left:10pt;">Diluted </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">0.46</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">0.02</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">Weighted  average number of ordinary shares:</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 3.25pt 0pt; width:324pt;text-align:left;">
                <div style="margin-left:10pt;">Basic </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">14,691,750</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">14,646,837</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 2.75pt 0pt; width:324pt;text-align:left;">
                <div style="margin-left:10pt;">Diluted </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">16,584,637</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">14,879,319</td>
              <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="height:4pt;line-height:4pt;">
              <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
            </tr>
          </table>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">10</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <table style="width:456pt;height:157pt;margin-top:0pt;border-collapse: collapse;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">As of December&#160;31, 2017 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Actual </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Pro Forma </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:324pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">(unaudited)<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)(2)</font></div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:324pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; width:0pt;text-align:center;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">(in thousands)</div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:324pt;">Consolidated Balance Sheet Data:</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:324pt;text-align:left;">
                <div style="white-space:nowrap;">Cash and cash equivalents </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">17,593</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
              <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:324pt;text-align:left;">
                <div style="white-space:nowrap;">Working capital<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(3)</font></div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">23,694</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:324pt;text-align:left;">
                <div style="white-space:nowrap;">Total assets </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">39,442</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:324pt;text-align:left;">
                <div style="white-space:nowrap;">Total liabilities </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16,923</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:324pt;text-align:left;">
                <div style="white-space:nowrap;">Redeemable non-controlling interest </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,066</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:324pt;text-align:left;">
                <div style="white-space:nowrap;">Retained earnings </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">10,819</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:324pt;text-align:left;">
                <div style="white-space:nowrap;">Total shareholders&#8217; equity </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">19,453</td>
              <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:16pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>
          <div style="margin-top:14.49pt; width:456pt;">
            <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
          </div>
          <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
          <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">The pro&#160;forma consolidated balance sheet data gives effect to the issuance and sale of&#8201; &#8199;&#8199;&#8199;&#8199; ordinary shares by us in this offering at the assumed initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
          <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">Each $1.00 increase (decrease) in the assumed initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share would increase (decrease) our pro&#160;forma cash and cash equivalents, working capital total assets and total shareholders&#8217; equity by $&#8199;&#8199;&#8199;&#8199; million, assuming that the number of ordinary shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of&#8201; &#8199;&#8199;&#8199;&#8199; in the number of ordinary shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) our pro&#160;forma cash and cash equivalents, working capital, total assets and total shareholders&#8217; equity by $&#8199;&#8199;&#8199;&#8199; million, assuming no change in the assumed public offering price per ordinary share. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
          <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">We define working capital as current assets less current liabilities. See our consolidated financial statements included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">11</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t2RI">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">RISK FACTORS</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">Investing in our ordinary shares involves a high degree of risk. You should consider carefully the following risk factors, as well as the other information in this prospectus, before deciding to invest in our ordinary shares. Our business, financial condition or results of operations could be materially and adversely affected if any of these risks occurs and, as a result, the market price of our ordinary shares could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may have similar adverse effects on us. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to Our Business and Industry </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our success depends upon market acceptance of our products. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We design, develop, manufacture and commercialize innovative minimally and non-invasive aesthetic medical products. We have developed products that apply our technology to rejuvenate the skin&#8217;s appearance through body and face reshaping and tightening, the treatment of superficial benign vascular and pigmented lesions, hair removal, wrinkle reduction and the treatment of acne, cellulite and leg veins. We were established in 2008 and have expanded our product offerings to include five product platforms: <font style="font-style:italic;">BodyTite</font>, <font style="font-style:italic;">Optimas</font>, <font style="font-style:italic;">Votiva</font>, <font style="font-style:italic;">Contoura</font> and <font style="font-style:italic;">Triton</font>. We expect to introduce three additional product platforms by the end of 2019. If we fail to significantly penetrate current or new markets with our products and manage the manufacturing and distribution of multiple products, our business, financial condition and results of operations could be negatively impacted. The success of our products depends on adoption and acceptance of our technology. The rate of adoption and acceptance may be affected adversely by perceived issues relating to quality and safety, customers&#8217; reluctance to invest in new technologies, the cost of competitive treatments and widespread acceptance of other technologies. Our business strategy is based, in part, on our expectation that we will continue to make novel product introductions and upgrades that we can sell to new and existing users of our products, and that we will be able to identify new markets for our existing technologies. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">To increase our revenues, we must: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">continue to further penetrate our existing, traditional customer base, such as plastic and facial surgeons, aesthetic surgeons, dermatologists and aesthetic OB/GYNs, and drive recurring revenues by convincing our customers that our products or product upgrades would be an attractive revenue-generating addition to their practices; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expand our customer base to include non-traditional customers, such as general practitioners, ophthalmologists, ENTs and aesthetic clinicians; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">leverage our existing technology to expand into new minimally and non-invasive applications that either add to or significantly improve our current products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">increase our sales presence to target and expand our market globally; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">actively pursue business development opportunities including potential acquisitions and strategic partnerships to augment our product and technology portfolio; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">maintain a strong intellectual property and patent portfolio. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, the aesthetic solutions market is highly competitive and dynamic and marked by rapid and substantial technological development and product innovations. Demand for our products could be diminished by equivalent or superior products and technologies offered by competitors.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">12</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If there is not sufficient demand for the procedures performed with our products, practitioner demand for our products could decline, resulting in unfavorable operating results.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Continued expansion of the global market for laser and other energy-based aesthetic procedures is a material assumption of our business strategy. Most procedures performed using our products are not reimbursable through government or private health insurance and are therefore elective procedures, the cost of which must be borne by the patient. The decision to utilize our products may therefore be influenced by a number of factors, including:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">consumer disposable income and access to consumer credit;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the cost of procedures performed using our products;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the cost, safety and effectiveness of alternative treatments, including treatments which are not based upon laser or other energy-based technologies and treatments which use pharmaceutical products;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the success of our sales and marketing efforts;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the education of our customers and patients on the benefits and uses of our products compared to competitors&#8217; products and technologies; and</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">consumer confidence, which may be impacted by economic and political conditions.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If, as a result of these factors, there is not sufficient demand for the procedures performed with our products, practitioner demand for our products could decline, which could have a material adverse effect on our results of operations.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The success and continued development of our products depends, in part, upon maintaining strong relationships with physicians and other healthcare professionals. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we fail to maintain our working relationships with physicians and other ancillary healthcare professionals, our products may not be developed and marketed in line with the needs and expectations of the professionals who use and support our products. If we are unable to maintain these strong relationships, the development and marketing of our products could suffer, which could have a material adverse effect on our business, financial condition and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We rely heavily on our sales professionals to market and sell our products worldwide. If we are unable to hire, effectively train, manage, improve the productivity of, and retain our sales professionals, our business will be harmed, which would impair our future revenue and profitability. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our success largely depends on our ability to hire, train, manage and improve the productivity levels of our sales professionals worldwide. We train our existing and recently recruited sales professionals to better understand our existing and new product technologies and how they can be positioned against our competitors&#8217; products and increase the revenue of our customers. It may take time for the sales professionals to become productive and there can be no assurance that recently recruited sales professionals will be adequately trained in a timely manner, or that our direct sales productivity will improve, or that we will not experience significant levels of attrition in the future. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Due to the complex nature of some of our products we could be subject to product liability claims, including due to adverse treatment outcomes. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our systems are inherently complex in design and require ongoing scheduled maintenance. Our products may malfunction when used by our customers. Furthermore, our products are sold in jurisdictions that vary as to the specific qualifications or training required for purchasers or operators of the products. There is a risk that our products may be purchased or operated by physicians with varying levels of training, and in some cases, by practitioners such as nurses, chiropractors and technicians who may not be adequately trained. The purchase and use of our products by non-physicians, or persons who lack adequate training may result in the misuse of our products, which could give rise to adverse treatment outcomes. If we are unable to prevent product malfunctions or misuse, or if we fail to do so in a timely manner, we could </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">13</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">also experience, among other things, delays in the recognition of revenues or loss of revenues, particularly in the case of new products; legal actions by customers, patients and other third parties, which could result in substantial judgments against us or settlement costs; action by regulatory bodies; and diversion of development, engineering and management resources. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Such potential adverse effects may cause a significant increase in the premiums under our insurance policies. Further, the coverage limits of our product liability insurance policies may not be adequate to cover future claims. A successful claim brought against us in excess of, or outside of, our insurance coverage could have a material adverse effect on our business, financial condition and results of operations. Even if unsuccessful, such a claim could nevertheless have an adverse impact on us, due to damage to our reputation and diversion of management resources. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Due to our limited history of operations, we may not be able to continue our revenue growth and profitability. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We were incorporated in 2008 and launched our first product in 2010. Consequently, we have a somewhat limited history of operations. The future success of our business will depend, among other things, on our ability to increase product sales, successfully introduce new products, expand our sales force and distribution network and control costs, which we may be unable to do. As a result, we may not be able to continue to experience revenue growth and profitability. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may have difficulty managing our growth which could limit our ability to increase sales and cash flow. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have experienced significant growth in our operations and the number of our employees has significantly increased since inception. This growth has placed significant demands on our management, as well as our financial and operational resources. In order to achieve our business objectives, we will need to continue to grow our business. Continued growth would increase the challenges involved in: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">implementing appropriate operational and financial systems; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expanding our sales and marketing infrastructure and capabilities; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">ensuring compliance with applicable Food and Drug Administration, or FDA, and other regulatory requirements; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">providing adequate training and supervision to maintain high quality standards; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">preserving our culture and values. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If our growth continues, it will require that we continue to develop and improve our operational, financial and other internal controls. If we cannot scale and manage our business appropriately, we will not realize our projected growth and our financial results will suffer. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The failure to attract and retain key personnel could adversely affect our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our success also will depend in large part on our ability to continue to attract, retain and motivate qualified and highly skilled personnel. Competition for highly skilled employees is intense. We may be unable to continue to attract and retain sufficient numbers of highly skilled employees. Our inability to attract and retain additional key employees or the loss of one or more of our current key employees could adversely affect our business, financial condition and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our financial results may fluctuate from quarter to quarter. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We base our production, inventory and operating expenditure levels on anticipated orders. If orders are not received when expected in any given quarter, expenditure levels could be disproportionately high in relation to sales for that quarter. A number of additional factors, over which we have limited control, may contribute to fluctuations in our financial results, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">customer adoption of our products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the willingness of individuals to pay directly for aesthetic medical procedures, in light of the lack of reimbursement by third-party payors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">14</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">continued availability of attractive equipment leasing terms for our customers, which may be negatively influenced by interest rate increases; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">changes in our ability to obtain and maintain regulatory approvals and maintain compliance with applicable regulatory requirements; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">positive or negative coverage in the media or clinical publications of our products or products of our competitors or industry; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">increases in the length of our sales cycle; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">performance of our independent distributors; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">delays in, or failure of, product and component deliveries by our subcontractors and suppliers. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Competition among providers of laser and other energy-based devices for the medical aesthetics market is characterized by rapid innovation. If we do not continue to develop and commercialize new products and identify new markets for our products and technologies, we may not remain competitive, and our revenues and operating results could suffer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The industry in which we operate is subject to continuous technological development and product innovation. If we do not continue to be innovative in the development of new products and applications, our competitive position will likely deteriorate as other companies successfully design and commercialize new products and applications. While we attempt to protect our products through patents and other intellectual property, there are few barriers to entry that would prevent new entrants or existing competitors from developing products that compete directly with ours. We expect that any competitive advantage we may enjoy from our current and future innovations may diminish over time, as companies successfully respond to our, or create their own, innovations. Accordingly, our success depends in part on developing new and innovative applications of laser and other energy-based technology and identifying new markets for and applications of existing products and technology. If we are unable to develop and commercialize new products and identify and penetrate new markets for our products and technology, our products and technology could become obsolete and our revenues and operating results could be adversely affected. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our long-term growth depends on our ability to enhance our products, expand our indications and develop and commercialize additional products. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">It is important to our business that we continue to enhance our products and develop and introduce new products. Developing products is expensive and time-consuming and could divert management&#8217;s attention away from our core business. The success of any new product offering or product enhancement to our current products will depend on several factors, including our ability to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">properly identify and anticipate physician and patient needs; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">develop and introduce new products and product enhancements in a timely manner; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">avoid infringing upon the intellectual property rights of third parties; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">demonstrate, if required, the safety and efficacy of new products with data from preclinical studies and clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">obtain the necessary regulatory clearances or approvals for expanded indications, new products or product modifications; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">be fully FDA-compliant with marketing of new devices or modified products. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we are not successful in expanding our indications and developing and commercializing new products and product enhancements, our ability to increase our revenue may be impaired, which could have a material adverse effect on our business, financial condition and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our inability to compete effectively with our competitors may prevent us from achieving significant market penetration or improving our operating results. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our products compete against products offered by public companies, including Allergan plc, Cutera, Inc., Hologic Inc. and Viveve Medical, Inc., as well as by private companies such as Lumenis Ltd.,</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">15</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">Sisram&#160;Medical Ltd. and Syneron Medical Ltd. Competition with these companies could result in reduced prices and profit margins and loss of market share, any of which could harm our business, financial condition and results of operations. We also face competition from medical products, including Botox, hyaluronic acid injections and collagen injections, and aesthetic procedures, such as face lifts, liposuction, sclerotherapy, electrolysis and chemical peels. Furthermore, we currently sell our products only to trained physicians and face competition from the medical spa market, which may offer a broader range of medical and non-medical products and technologies that are more readily available to customers at a lower cost. Our ability to compete effectively depends upon our ability to distinguish our company and our products from our competitors and their products, and includes the following factors: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">product performance; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">product pricing; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">product safety; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">intellectual property protection; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">quality of customer support; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">success and timing of new product development and introductions; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">development of successful distribution channels. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Furthermore, potential customers also may need to recoup the cost of expensive products that they already have purchased from our competitors and may decide not to purchase our products, or to delay such purchases. If we are unable to achieve continued market penetration, we will be unable to compete effectively and our business will be harmed. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Consolidation in our industry may make it more difficult for us to compete. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The trend towards consolidation in our industry has increased, and may continue to increase, the intensity of the competition in our industry and could result in increased downward pressure on our product prices. Recently, many of our competitors in the aesthetics market have acquired other companies that operate within the same market. If this trend continues, we will be forced to compete primarily with and against larger competitors with greater resources and distribution networks. Our competitors could use their greater financial resources to acquire other companies to gain enhanced name recognition and market share, as well as to develop new technologies or products that could effectively compete with our product lines. If we are unable to effect strategic mergers or acquisitions of our own and are unable to obtain capital and other resources that would allow us to compete effectively, our business will be harmed. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The introduction of disruptive technological breakthroughs, whether pharmaceutical or other newer therapeutic solutions, may present an additional threat to our success in our target markets. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The medical technology industry is intensely competitive. Pharmaceutical alternative treatments compete vigorously with traditional laser and other energy-based procedures, such as those carried out with our products. Some pharmaceutical companies, academic and research institutions or others may develop new, non-invasive or minimally invasive therapies that are more effective, more convenient or less expensive than our current or future products. The introduction of new technologies, along with these potential new therapies, could result in increased competition or make our products obsolete. Moreover, we could expand our business to include new, non-invasive or minimally invasive therapies which may compete with our current product offerings. We may not be able to respond effectively to technological changes and emerging industry standards, or to successfully identify, develop or support new technologies or enhancements to existing products in a timely and cost-effective manner. Any such developments could have a material adverse effect on our business, financial condition and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our markets are characterized by evolving technological standards and changes in customer requirements, and we may not be able to react to such changes and introduce new products in a timely manner. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The aesthetics market is characterized by extensive research and development, technological change, frequent modifications and enhancements, innovations, new applications, evolving industry standards and changes in customer requirements. Our future growth depends in part on our ability to introduce new </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">16</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">products on a timely basis, as well as to introduce other product enhancements that address the evolving customer needs. This requires us to design, develop, manufacture, assemble, test, market and support these new products or product enhancements on a timely and cost-effective basis. It also requires continued substantial investment in research and development. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During each stage of the research and development process we may encounter obstacles that could delay development and consequently increase our expenses. This may ultimately force us to abandon a potential product in which we have already invested substantial time and resources. Technologies in development could prove to be more complex than initially understood or not scientifically or commercially viable. Even if we develop new products and technologies ahead of our competitors, we will still need to obtain the requisite regulatory approvals for such products, including from public agencies, such as the FDA, before we can commercially distribute them. We cannot assure you that we will successfully identify new technological opportunities, develop and bring new or enhanced products to market, obtain sufficient or any patent or other intellectual property protection for such new or enhanced products or obtain the necessary regulatory approvals in a timely and cost-effective manner, or, if such products are introduced, that those products will achieve market acceptance. Our failure to do so, or to address the technological changes and challenges in our markets, could have a material adverse effect on our business, financial condition and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We rely on our own direct sales force to sell our products in certain territories, which may result in higher fixed costs than our competitors and may slow our ability to reduce costs in the face of a sudden decline in demand for our products. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We rely on our own direct sales force to market and sell our products in certain territories. Some of our competitors rely predominantly on independent sales agents and third-party distributors. A direct sales force may subject us to higher fixed costs than those of companies that market competing products through independent third parties, due to the costs that we will bear associated with employee benefits, and training and managing sales personnel. As a result, we could be at a competitive disadvantage. Additionally, these fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for our products, which could have a material adverse effect on our business, financial condition and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">To successfully market and sell our products internationally, we must address many issues with which we have little or no experience. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">International (non-U.S. and Canada) sales accounted for approximately 17% of our total revenue for the year ended December&#160;31, 2017. We believe that an increasing&#160;percentage of our future revenue will come from international sales as we expand our operations and develop opportunities in additional international territories. We currently depend on third-party distributors and a direct sales team in certain regions to sell our products internationally, including in connection with our joint venture in China. If these distributors or direct sales personnel underperform, we may be unable to increase or maintain our level of international revenue. We will need to attract additional distributors to grow our business and expand the territories in which we sell our products. Distributors may not commit the necessary resources to market and sell our products to the level of our expectations. If current or future distributors do not perform adequately, or we are unable to locate distributors in particular geographic areas, we may not realize expected international revenue growth. Additionally, we expect to expand our direct sales force in the United States, Canada, Europe and Latin America. If we are unable to do so successfully, our revenue from international operations will be adversely affected. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">International sales are subject to a number of risks, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">difficulties in staffing and managing our foreign operations; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">difficulties in penetrating markets in which our competitors&#8217; products are more established; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">reduced protection for intellectual property rights in some countries; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">export restrictions, trade regulations and foreign tax laws; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">fluctuating foreign currency exchange rates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">17</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">obtaining and maintaining foreign certification and compliance with other regulatory requirements; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">customs clearance and shipping delays; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">political and economic instability. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If one or more of these risks were realized, it could require us to dedicate significant resources to remedy the situation, and if we are unsuccessful at finding a solution, our revenue may decline. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We outsource almost all of the manufacturing of our products to a small number of manufacturing subcontractors. If our subcontractors&#8217; operations are interrupted or if our orders exceed our subcontractors&#8217; manufacturing capacity, we may not be able to deliver our products on time. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We outsource almost all of the manufacturing of our products to four subcontractors located in Israel, while we manufacture our laser and IPL handpieces in-house in Israel. These subcontractors have limited manufacturing capacity that may be inadequate if our customers place orders for unexpectedly large quantities of our products. In addition, because our subcontractors are located in Israel, they on occasion may feel the impact of potential economic or political instability in the region. If the operations of one or more of our subcontractors were halted or limited, even temporarily, or if they were unable or unwilling to fulfill large orders, we could experience business interruption, increased costs, damage to our reputation and loss of our customers. In addition, finding new subcontractors that meet our manufacturing requirements, comply with regulatory requirements, and are ISO certified could take several&#160;months. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Components used in our products are complex in design, and defects may not be discovered prior to shipment to customers, which could result in warranty obligations, reducing our revenue and increasing our costs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In manufacturing our products, we and our subcontractors depend upon third-party suppliers for various components. Many of these components require a significant degree of technical expertise to produce. If our suppliers fail to produce components to specification, or if the suppliers, our subcontractors, or we, use defective materials or workmanship in the manufacturing process, the reliability and performance of our products will be compromised. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If our products contain defects that cannot be repaired easily and inexpensively, we may experience: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">loss of customer orders and delay in order fulfillment; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">damage to our brand reputation; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">increased cost of our warranty program due to product repair or replacement; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">inability to attract new customers; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">diversion of resources from our manufacturing and research and development departments into our service department; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">product recalls; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">legal action. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">The occurrence of any one or more of the foregoing could materially harm our business, financial condition and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We and our manufacturing subcontractors depend upon third-party suppliers, making us vulnerable to supply shortages, price fluctuations or other degradations in performance of these suppliers, which could harm our business and financial condition. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Many of the components that comprise our products are currently manufactured by a limited number of suppliers. Although each of our components can be obtained from more than one supplier, we do not have the ability to manufacture the components we outsource. Additionally, our subcontractors rely on a limited number of suppliers, or in some cases, one supplier, for some of the materials and components used in our products. If our subcontractors were to lose such suppliers, there can be no assurance that they will be able to identify or enter into agreements with alternative suppliers on a timely basis on acceptable terms, </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">18</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">if at all, which could cause interruptions in their operations. If any of our third-party suppliers fails to adequately perform, our revenue and profitability could be adversely affected. A supply interruption or an increase in demand beyond current suppliers&#8217; capabilities could harm our ability to manufacture our products until we identify and qualify a new source of supply, which could take several&#160;months. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">There is a risk that our suppliers will not always act consistent with our best interests, and may not always supply goods that meet our requirements. Any interruption in the supply of components or materials, or our inability to obtain substitute components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our customers, which would have an adverse effect on our business, financial condition and results of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Transitioning to a new supplier could be time-consuming and expensive, may result in interruptions in our operations and product delivery, could affect the performance specifications of our products or could require that we modify the design of certain product systems. If a change in manufacturer results in a significant change to any product, a new 510(k) clearance from the FDA or similar international regulatory authorization may be necessary before we implement the change, which could cause substantial delays. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">There exists potential for misuse of our products, over which we have very little to no control, which could harm our reputation and our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In the United States, federal regulations allow us to sell our products to or on the order of&#8201; &#8220;licensed practitioners.&#8221; The definition of&#8201; &#8220;licensed practitioners&#8221; varies from state to state. As a result, depending on state law, our products may be purchased or operated by physicians or other licensed practitioners, including nurse practitioners, chiropractors and technicians. Outside the United States, many jurisdictions do not require specific qualifications or training for purchasers or operators of our products. Although we offer training on the use of our products, we do not supervise the treatments performed. Purchase and use of our products by non-physicians may result in product misuse. The potential misuse of our products by physicians and non-physicians may result in adverse treatment outcomes, which could harm our reputation and expose us to costly product liability litigation. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our products include a limited time warranty which could result in substantial additional costs to us should we fail to monitor product quality effectively. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We generally provide a 12-month warranty on our products. After the warranty period, maintenance and support is provided on a service contract basis. If our products malfunction, warranty claims may become significant, which could cause a significant drain on our resources and materially adversely affect our results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Product liability suits could be brought against us due to defective material or design, or due to misuse of our products, and could result in expensive and time-consuming litigation, payment of substantial damages and an increase in our insurance rates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If our products alleged to be are defectively designed, manufactured or labeled, contain defective components or are misused, we may become subject to substantial and costly litigation by our customers or their patients. Misusing our products or failing to adhere to operating guidelines could cause burns, scarring and tissue irregularities. In addition, if our operating guidelines are found to be inadequate, we may be subject to liability. We may in the future be involved, in claims related to the use of our products. Product liability claims could divert management&#8217;s attention from our core business, be expensive to defend and result in sizable damage awards against us. We may not be able to obtain insurance in amounts or scope sufficient to provide us with adequate coverage against all potential liabilities. Any product liability claims brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, could harm our reputation in the industry and reduce product sales. Product liability claims in excess of our insurance coverage would be paid out of cash reserves harming our financial condition and reducing our operating results. In addition, if our cash reserves are not sufficient to cover such contingency, our financial results could be harmed. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">19</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We forecast sales to determine requirements for our products and if our forecasts are incorrect, we may experience either shipment delays or increased costs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our subcontractors keep limited materials and components on hand. To help them manage their manufacturing operations and minimize inventory costs, we forecast anticipated product orders to predict our inventory needs up to six&#160;months in advance and enter into purchase orders on the basis of these forecasts. Our limited historical experience may not provide us with enough data to accurately predict future demand. If our business expands, our demand would increase and our suppliers may be unable to meet our demand. If we overestimate our requirements, our subcontractors will have excess inventory, and may transfer to us any increase in costs. If we underestimate our requirements, our subcontractors may have inadequate components and materials inventory, which could interrupt, delay or prevent delivery of our products to our customers. Any of these occurrences would negatively affect our financial performance and the level of satisfaction our customers have with our business.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Under applicable employment laws, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have entered into non-competition agreements with many of our professional employees. These agreements prohibit our employees, if they cease working for us, from competing directly with us or working for our competitors for a limited period. Under applicable employment laws, we may be unable to enforce these agreements, in whole or in part, and it may be difficult for us to restrict our competitors from gaining the expertise our former employees gained while working for us. For example, Israeli courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts, such as the secrecy of a company&#8217;s confidential commercial information or its intellectual property. If we cannot demonstrate that harm would be caused to us, we may be unable to prevent our competitors from benefiting from the expertise of our former employees. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The expense and potential unavailability of insurance coverage for our customers and our company could adversely affect our ability to sell our products and our financial condition. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Some of our customers and prospective customers are required to maintain liability insurance to cover their operations and use of our products. Medical malpractice carriers are withdrawing coverage in certain states or substantially increasing premiums. If this trend continues or worsens, our customers may discontinue using our products and, industry-wide, potential customers may opt against purchasing light, laser or radio frequency-based products due to the cost or inability to procure insurance coverage.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Global economic and social conditions may adversely affect our business, financial condition and results of operations.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Any negative conditions in the national and global economic environments may adversely affect our business, financial condition and results of operations. During uncertain economic times and in tight credit markets, many of our customers may experience financial difficulties or be unable or unwilling to borrow money to fund their operations, including obtaining credit lines for purchasing our products, and may delay or reduce purchases or reduce the extent of their operations. The market for aesthetic procedures and the market for our premium products can be particularly vulnerable to economic uncertainty, since the end-users of our products may decrease the demand for our products when they have less discretionary income or feel uneasy about spending their discretionary income. In addition, in many instances, the ability of our customers to purchase our products depends in part upon the availability of obtaining financing at acceptable interest rates.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These factors could result in reductions in revenues from sales of our products, longer sales cycles, difficulties in collection of accounts receivable, slower adoption of new technologies and increased price competition. Payment by our customers of our receivables is dependent upon the financial stability of the economies of certain countries. In light of the current economic state of many countries outside of the United States, we continue to monitor the creditworthiness of our customers because weakness in the end-user market could negatively affect the cash flows of our customers who could, in turn, delay paying </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">20</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">their obligations to us. This would increase our credit risk exposure and cause delays in our recognition of revenues on current and future sales to these customers. Any of these events would likely harm our business, and could have a material adverse effect on our business, financial condition and results of operations.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Any acquisitions that we make could disrupt our business and harm our financial condition. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We expect to evaluate potential strategic acquisitions of complementary businesses, products or technologies. We may also consider joint ventures and other collaborative projects. We may not be able to identify appropriate acquisition candidates or strategic partners, or successfully negotiate, finance or integrate any businesses, products or technologies that we acquire. Furthermore, the integration of any acquisition and management of any collaborative project may divert management&#8217;s time and resources from our core business and disrupt our operations. We do not have any experience with acquiring companies or products. If we decide to expand our product offerings, we may spend time and money on projects that do not increase our revenue. Any cash acquisition we pursue would diminish the proceeds from this offering available to us for other uses, and any stock acquisition would be dilutive to our shareholders. While we from time to time evaluate potential collaborative projects and acquisitions of businesses, products and technologies, and anticipate continuing to make these evaluations, we have no present understandings, commitments or agreements with respect to any acquisitions or collaborative projects. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may need to raise additional capital in the future, which may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our intellectual property or future revenue streams. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In the future, we may finance our cash needs through a combination of equity offerings, debt financings, grants, and license and development agreements in connection with any collaborations. We do not have any committed external source of funds. In the event we seek additional funds, we may raise additional capital through the sale of equity or convertible debt securities. In such an event, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our ordinary shares. Debt financing, if available, could result in increased fixed payment obligations and may involve agreements that include restrictive covenants, such as limitations on our ability to incur additional debt, make capital expenditures, acquire, sell or license intellectual property rights or declare dividends, and other operating restrictions that could hurt our ability to conduct our business. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Exchange rate fluctuations may decrease our earnings if we are not able to hedge our currency exchange risks successfully. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A majority of our revenues and a substantial portion of our expenses are denominated in U.S. dollars. However, a portion of our revenues and a portion of our costs, including personnel and some marketing and facilities expenses, are incurred in New Israeli Shekels, Canadian dollars and Euros. Inflation in Israel or Europe may have the effect of increasing the U.S. dollar cost of our operations in that country. If the U.S. dollar declines in value in relation to one or more of these currencies, it will become more expensive for us to fund our operations in the countries that use those other currencies. To date, we have not found it necessary to hedge the risks associated with fluctuations in currency exchange rates. In the future, if we do not successfully engage in hedging transactions, our results of operations may be subject to losses from fluctuations in foreign currency exchange rates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Cyber-attacks as well as improper disclosure or control of personal information could result in liability and harm our reputation, which could adversely affect our business and results of operations. We may face liability if we breach our obligations related to the protection, security, nondisclosure of confidential customer information or disclosure of sensitive data or failure to comply with data protection laws and regulations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our business is heavily dependent on the security of our IT networks and those of our customers. Internal or external attacks on any of those could disrupt the normal operations of our engagements and impede our ability to provide critical services to our customers, thereby subjecting us to liability under our contracts. Additionally, our business involves the use, storage and transmission of information about our employees, our customers and clients of our customers. While we take measures to protect the security of, and unauthorized access to, our systems, as well as the privacy of personal and proprietary information, it is possible that our security controls over our systems, as well as other security practices we follow or those </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">21</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">systems of our customers into which we operate and rely upon, may not prevent the improper access to or disclosure of personally identifiable or proprietary information. Such disclosure could harm our reputation and subject us to liability under our contracts and laws that protect personal data, resulting in increased costs or loss of revenue. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Further, data privacy is subject to frequently changing rules and regulations, which sometimes conflict among the various jurisdictions and countries in which we provide services and continue to develop in ways which we cannot predict. We are subject to U.S. federal and state laws regarding data privacy and security including Section&#160;5 of the Federal Trade Commission Act, or FTC Act. We are also subject to foreign data privacy and security laws, including the Global Data Protection Regulation, or GDPR, the European Union-wide legal framework to govern data collection, use and sharing and related consumer privacy rights. The GDPR includes significant penalties for non-compliance. Our failure to adhere to or successfully implement processes in response to changing regulatory requirements in this area could result in legal liability or impairment to our reputation in the marketplace, which could have a material adverse effect on our business, financial condition and results of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In the course of providing services to our customers, we may have access to confidential customer information, including nonpublic personal data. We are bound by certain agreements to use and disclose this information in a manner consistent with the privacy standards under regulations applicable to our customers and are subject to numerous U.S. and foreign jurisdiction laws and regulations designed to protect this information, such as the European Union Directive on Data Protection and various U.S. federal and state laws governing the protection of health or other individually identifiable information. If any person, including a team member of ours, misappropriates customer confidential information, or if customer confidential information is inappropriately disclosed due to a security breach of our computer systems, system failures or otherwise, we may have substantial liabilities to our customers or our customers&#8217; clients and may incur substantial liability and penalties in connection with any violation of applicable privacy laws and/or criminal prosecution. In addition, in the event of any breach or alleged breach of our confidentiality agreements with our customers, these customers may terminate their engagements with us or sue us for breach of contract, resulting in the associated loss of revenue and increased costs and damaged reputation. We may also be subject to civil or criminal liability if we are deemed to have violated applicable regulations. We cannot assure you that we will adequately address the risks created by the regulations to which we may be contractually obligated to abide. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We are or may become subject to numerous foreign, federal, and state healthcare statutes and regulations; and any failure to comply could result in a material adverse effect to our business and operations. </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">Although none of our products or procedures using our products, are currently covered by any state or federal government healthcare programs, or any private commercial payor, we may become subject to foreign, federal, and state laws intended to prevent healthcare fraud and abuse, including those that apply to all payors. These laws can include state anti-kickback and false claims laws, which may extend to services reimbursable by any payor, as well as state consumer protection laws. We may also be subject to transparency laws that can include requirements to disclose payments to certain healthcare professionals and healthcare entities or disclosures related to sales and marketing, or that can require healthcare professionals to provide notice to their patients of ownership or financial arrangements with manufacturers. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Efforts to ensure that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations may involve substantial costs. These laws and regulations, among other things, constrain our business, marketing and other promotional activities by limiting the kinds of financial arrangements, including financing programs, we may have with physicians or other potential purchasers of our products. It is possible that governmental authorities may conclude that our business practices, including our arrangements with physicians, some of whom received stock options as compensation for services provided, as well as fees for marketing to other physicians, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, monetary fines, individual imprisonment, disgorgement of profits, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations, any of which could adversely affect our ability to operate our business and pursue our strategy. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">22</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We are subject to anti-bribery, anti-corruption and anti-money laundering laws, including the U.S. Foreign Corrupt Practices Act, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of operations and financial condition. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As we grow our international presence and global operations, we will be increasingly exposed to trade and economic sanctions and other restrictions imposed by the United States, the European Union, the State of Israel and other governments and organizations. The U.S. Departments of Justice, Commerce, State and Treasury and other federal agencies and authorities have a broad range of civil and criminal penalties they may seek to impose against corporations and individuals for violations of economic sanctions laws, export control laws, the U.S. Foreign Corrupt Practices Act, or the FCPA, and other federal statutes and regulations, including those established by the Office of Foreign Assets Control, or OFAC. In addition, the U.K. Bribery Act of 2010, or the Bribery Act, prohibits both domestic and international bribery, as well as bribery across both private and public sectors. An organization that &#8220;fails to prevent bribery&#8221; by anyone associated with the organization can be charged under the Bribery Act unless the organization can establish the defense of having implemented &#8220;adequate procedures&#8221; to prevent bribery. Under these laws and regulations, as well as other anti-corruption laws, anti-money laundering laws, export control laws, customs laws, sanctions laws and other laws governing our operations, various government agencies may require export licenses, may seek to impose modifications to business practices, including cessation of business activities in sanctioned countries or with sanctioned persons or entities and modifications to compliance programs, which may increase compliance costs, and may subject us to fines, penalties and other sanctions. A violation of these laws or regulations would negatively affect our business, financial condition and results of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are in the process of implementing policies and procedures designed to ensure compliance by us and our directors, officers, employees, representatives, consultants and agents with the FCPA, OFAC restrictions, the Bribery Act and other export control, anti-corruption, anti-money-laundering and anti-terrorism laws and regulations. We cannot assure you, however, that our policies and procedures are or will be sufficient or that directors, officers, employees, representatives, consultants and agents have not engaged and will not engage in conduct for which we may be held responsible, nor can we assure you that our business partners have not engaged and will not engage in conduct that could materially affect their ability to perform their contractual obligations to us or even result in our being held liable for such conduct. Violations of the FCPA, OFAC restrictions, the Bribery Act or other export control, anti-corruption, anti-money laundering and anti-terrorism laws or regulations may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could have a material adverse effect on our business, financial condition and results of operations.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to Our Intellectual Property </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we are unable to protect our intellectual property rights, our competitive position could be harmed. Our success and ability to compete depends in large part upon our ability to protect our proprietary technology. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our success and ability to compete depends in large part upon our ability to protect our proprietary technology. We rely primarily upon a combination of patents and trademarks, as well as nondisclosure, confidentiality and other contractual agreements to protect the intellectual property related to our brands, products and other proprietary technologies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We generally apply for patents only in those countries where we intend to make, have made, use, offer for sale, or sell products. To date, we have only pursued patents in the United States and South Korea. We do not seek protection in all countries where we sell products and we may not accurately predict all the countries where patent protection would ultimately be desirable. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories in which we do not have patent protection. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our patent portfolio consists of four issued patents and nine pending patent applications in the United States relating to our technology and products. Our pending and future patent applications may not issue as patents or, if issued, may not issue in a form that will be advantageous to us. Any issued patents may be </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">23</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">challenged, invalidated or legally circumvented by third parties. We cannot be certain that our patents will be upheld as valid, proven enforceable or prevent the development of competitive products. Other companies may also design around technologies we have patented. Third parties may have blocking patents that could prevent us from marketing our products or practicing our own patented technology. In addition, competitors could purchase one of our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts, design around our protected technology, or develop their own competitive technologies that fall outside of our intellectual property rights. If our intellectual property is not adequately protected against competitors&#8217; products and methods, our competitive position could be adversely affected, as could our business and financial results. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We rely on a combination of patent and other intellectual property laws and confidentiality, non-disclosure and assignment of inventions agreements, as appropriate, with our employees and consultants, to protect and otherwise seek to control access to, and distribution of, our proprietary information. These measures may not be adequate to protect our technology from unauthorized disclosure, third-party infringement or misappropriation. Parties may breach these agreements, and we may not have adequate remedies for any breach. Also, the laws of certain countries in which we develop, manufacture or sell our products may not protect our intellectual property rights to the same extent as the laws of the United States or Israel. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The aesthetics industry is highly competitive and marked by frequent litigation. New patent applications may be pending or may be filed in the future by third parties covering technology that we currently use or may ultimately use. Third parties may from time to time claim that our current or future products infringe their patent or other intellectual property rights and may seek to prevent, limit or interfere with our ability to make, use, sell or import our products. Moreover, if such a claim were to be decided adversely to us or if we settled such a claim on adverse terms, we could be forced to pay substantial damages, to license the technology in question at high rates or to redesign or modify our products so as to avoid any infringement. Any of those results could adversely affect our sales, margins and results of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If it appears necessary or desirable, we may try to obtain licenses for those patents or intellectual property rights that we are allegedly infringing, may infringe, or desire to use. Although holders of these types of intellectual property rights commonly offer these licenses, we cannot assure you that licenses will be offered or that the terms of any offered licenses will be acceptable to us. Our failure to obtain a license for key intellectual property rights from a third party for technology used by us could cause us to incur substantial liabilities and to suspend the manufacturing and selling of products utilizing the technology. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Alternatively, we could be required to expend significant resources to develop non-infringing technology. We cannot assure you that we would be successful in developing non-infringing technology. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">From time to time, we may be party to, or threatened with, litigation or other proceedings with third parties, including non-practicing entities, who allege that our products, components of our products, services, and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. The types of situations in which we may become a party to such litigation or proceedings include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or processes do not infringe those third parties&#8217; patents; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we or our collaborators may participate at substantial cost in International Trade Commission proceedings to abate importation of products that would compete unfairly with our products </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">24</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">if our competitors file patent applications that claim technology also claimed by us, we may be required to participate in interference, derivation or opposition proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">if third parties initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their product, service, or technology does not infringe our patents or patents licensed to us, we will need to defend against such proceedings; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may be subject to ownership disputes relating to intellectual property, including disputes arising from conflicting obligations of consultants or others who are involved in developing our products; and, </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or misappropriate its patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These lawsuits and proceedings, regardless of merit, are time-consuming and expensive to initiate, maintain, defend or settle, and could divert the time and attention of managerial and technical personnel, which could materially adversely affect our business. Any such claim could also force use to do one or more of the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">incur substantial monetary liability for infringement or other violations of intellectual property rights, which we may have to pay if a court decides that the product, service, or technology at issue infringes or violates the third party&#8217;s rights, and if the court finds that the infringement was willful, we could be ordered to pay treble damages and the third party&#8217;s attorneys&#8217; fees; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">pay substantial damages to our customers or end users to discontinue use or replace infringing technology with non-infringing technology; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">stop manufacturing, offering for sale, selling, using, importing, exporting or licensing the product or technology incorporating the allegedly infringing technology or stop incorporating the allegedly infringing technology into such product, service, or technology; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">obtain from the owner of the infringed intellectual property right a license, which may require us to pay substantial upfront fees or royalties to sell or use the relevant technology and which may not be available on commercially reasonable terms, or at all; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">redesign our products, services, and technology so they do not infringe or violate the third party&#8217;s intellectual property rights, which may not be possible or may require substantial monetary expenditures and time; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">enter into cross-licenses with our competitors, which could weaken our overall intellectual property position; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">lose the opportunity to license our technology to others or to collect royalty payments based upon successful protection and assertion of our intellectual property against others; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">find alternative suppliers for non-infringing products and technologies, which could be costly and create significant delay; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">relinquish rights associated with one or more of our patent claims, if our claims are held invalid or otherwise unenforceable. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In January&#160;2016, Syneron Medical Ltd., or Syneron, filed a claim with the United States District Court for the Central District of California against the Company&#8217;s U.S. and Israeli subsidiaries alleging that certain of the Company&#8217;s products infringed four U.S. patents owned by Syneron that purport to cover </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">25</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">systems and methods for treating skin and arranging electrodes on skin therapy devices. In April&#160;2018, Syneron filed claims with the International Trade Commission and the United States District Court for the District of Massachusetts against our U.S. and Israeli subsidiaries, alleging that certain of our products infringed two U.S. patents owned by Syneron that purport to cover systems and methods for treating skin and arranging electrodes on skin therapy devices. Although we may try to resolve any potential future claims or actions, we may not be able to do so on reasonable terms, if at all. Following a successful third-party action for infringement, we may be required to pay substantial damages and if we cannot obtain a license or redesign our products, we may have to stop manufacturing, selling and marketing our products, and our business could suffer as a result. Infringement and other intellectual property claims, with or without merit, can be expensive and time-consuming to litigate, and could divert management&#8217;s attention from our core business. We do not know whether necessary licenses would be available to us on satisfactory terms, or whether we could redesign our products or processes to avoid infringement. If we lose this kind of litigation, a court could require us to pay substantial damages and could prohibit us from using technologies essential to our products, either of which would have a material adverse effect on our business, results of operations and financial condition. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may become involved in litigation to protect the trademark rights associated with our company name or the names of our products. If we have to change the name of our company or products, we may experience a loss in goodwill associated with our brand name, customer confusion and a reduction in sales. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays, or prohibit us from manufacturing, marketing or otherwise commercializing our products, services and technology. Any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operation, financial condition or cash flows. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, we may indemnify our customers and distributors against claims relating to the infringement of intellectual property rights of third parties related to our products. Third parties may assert infringement claims against our customers or distributors. These claims may require us to initiate or defend protracted and costly litigation on behalf of our customers or distributors, regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of our customers, suppliers or distributors, or may be required to obtain licenses for the products or services they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers may be forced to stop using our products or services. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a material adverse effect on the price of our ordinary shares. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our ordinary shares. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition with potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">26</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We do and may employ individuals who were previously employed at universities or other pharmaceutical or medical device companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, and we are not currently subject to any claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties, we may in the future be subject to such claims. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily address all potential threats to our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The degree of future protection afforded by our intellectual property rights is uncertain because even granted intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">others may be able to develop and/or practice technology that is similar to our technology or aspects of our technology, but that are not covered by the claims of the patents that we own or control, assuming such patents have issued or do issue; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we or any future strategic partners might not have been the first to conceive or reduce to practice the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we or any future strategic partners might not have been the first to file patent applications covering certain of our inventions; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">it is possible that our pending patent applications will not lead to issued patents; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">third parties performing manufacturing or testing for us using our products or technologies could use the intellectual property of others without obtaining a proper license; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may not develop or in-license additional proprietary technologies that are patentable; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may not be able to obtain and maintain necessary licenses on commercially reasonable terms, or at all; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the patents of others may have an adverse effect on our business. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">Should any of these events occur, they could significantly harm our business and results of operations. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">27</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Risks Related to Government Regulation </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our business is subject to extensive and continuing regulatory compliance obligations. If we fail to obtain and maintain necessary market clearances from the FDA and other marketing authorizations from counterpart foreign regulatory authorities for our products and indications, if clearances or other marketing authorizations for future products and indications are delayed or not issued, if we or any of our third-party suppliers or manufacturers fail to comply with applicable regulatory requirements, or if there are U.S. federal or state level or counterparty foreign regulatory changes, our commercial operations could be harmed. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our products are medical devices subject to extensive regulation by the applicable regulatory authorities where our products are or will be sold prior to their marketing for commercial use. In the United States, our products are subject to extensive regulation by the FDA for developing, testing, manufacturing, labeling, sale, marketing, advertising, promotion, distribution, import, export, shipping, establishment registration and device listing, inspections and audits, record keeping, recalls and field safety corrective actions and post-market surveillance, including reporting of certain events. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Before a new medical device, or a new use of, or claim for, an existing product can be marketed in the United States, it must first receive marketing authorization from the FDA unless it is exempt. The FDA marketing authorizations include a 510(k) clearance or premarket approval. A relatively small number of devices may be exempt from 510(k) clearance or may receive marketing authorization through the de novo classification pathway. These processes can be expensive and lengthy. The FDA&#8217;s 510(k) clearance process usually takes from three to 12&#160;months, but it can last longer. The process of obtaining premarket approval is much more costly and uncertain than the 510(k) clearance process and it generally takes from one to three&#160;years, or even longer, from the time the application is filed with the FDA. Our future products and enhancements or changes to products may require new 501(k) clearance or premarket approval from the FDA. All products that we currently market in the United States that require an FDA marketing authorization have received 510(k) clearance for the uses for which they are marketed. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Medical devices may be marketed only for the indications for which they are approved or cleared. We have obtained 510(k) clearance for the current treatments for which we offer our products. However, our clearances can be revoked under certain circumstances. Changes or modifications to an FDA-cleared device that could significantly affect its safety or effectiveness or that constitute a major change or modification in its intended use would require a new 510(k) clearance or possibly premarket approval. We may not be able to obtain additional 510(k) clearances or premarket approvals for new products or for modifications to, or additional indications for, our existing products in a timely fashion, or at all. Delays in obtaining future clearances or approvals would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our revenue and future profitability. We have made modifications to our devices in the past and may make additional modifications in the future that we believe do not or will not require additional clearances or approvals. If the FDA disagrees, and requires new clearances or approvals for the modifications, we may be required to recall and to stop marketing the modified devices. We also are subject to the FDA&#8217;s Medical Device Reporting regulations, which require us to report to the FDA if our products cause or contribute to a death or serious injury, or malfunction in a way that would likely cause or contribute to a death or serious injury. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The FDA or the applicable foreign regulatory bodies can delay, limit or deny clearance or approval of a device for many reasons, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory bodies that our products are safe or effective for their intended uses; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the disagreement of the FDA or the applicable foreign regulatory bodies with the design or implementation of our clinical trials or the interpretation of data from pre-clinical studies or clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">serious and unexpected adverse device effects experienced by participants in our clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">28</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the manufacturing process or facilities we use may not meet applicable requirements; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, the FDA or applicable foreign regulatory bodies may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our future products under development or impact our ability to modify our currently cleared products on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain new clearances, increase the costs of compliance or restrict our ability to maintain our current clearances. For example, as part of the Food and Drug Administration Safety and Innovation Act, or FDASIA, enacted in 2012, Congress reauthorized the Medical Device User Fee Amendments with various FDA performance goal commitments and enacted several &#8220;Medical Device Regulatory Improvements&#8221; and miscellaneous reforms, which are further intended to clarify and improve medical device regulation both pre- and post-clearance and approval. Some of these proposals and reforms could impose additional regulatory requirements upon us that could delay our ability to obtain new 510(k) clearances, increase the costs of compliance or restrict our ability to maintain our current clearances. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Additionally regulatory clearances or approvals to market a product can contain limitations on the indicated uses for such product. Product clearances and approvals can be withdrawn due to failure to comply with regulatory standards or the occurrence of unforeseen problems following initial clearance or approval. FDA regulations depend heavily on administrative interpretation, and there can be no assurance that future interpretations made by the FDA or other regulatory bodies will not adversely affect our operations. We and our manufacturers may be inspected by the FDA from time to time to determine whether we or our manufacturers are in compliance with applicable laws, including the cGMP regulations set forth in the QSR, including those relating to specifications, development, documentation, validation, testing, quality control and product labeling. A determination that we are in violation of FDA or other applicable foreign regulations or any of our product clearances or approvals could lead to imposition of civil penalties, including fines, product recalls or product seizures and, in certain cases, criminal sanctions. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The use, misuse or off-label use of our products may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The use, misuse or off-label use of our products may harm our reputation or the image of our products in the marketplace, result in injuries that lead to product liability suits, which could be costly to our business, or result in legal sanctions if we are deemed or alleged to have engaged in off-label promotion. Our promotion of our products, which are regulated as medical devices, also must comply with FDA requirements and must only use labeling, including advertising and promotional materials, that is consistent with the specific indication(s) for use included in the FDA clearance. If the FDA or other authorities determine that our promotional or training materials constitute the unlawful promotion of an off-label use, they could request that we modify our training or promotional materials and/or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, civil money penalties, seizure, injunction or criminal fines and penalties. Other federal, state or foreign governmental authorities might also take action if they consider our promotion or training materials to constitute promotion of an uncleared or unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement, or exclusion from participation in federal health programs. In that event, our reputation could be damaged and the use of our products in the marketplace could be impaired, or our business could face significant hardship. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, there may be increased risk of injury if physicians or others attempt to use our products off-label. The FDA does not restrict or regulate a physician&#8217;s use of a medical product within the practice of medicine, and we cannot prevent a physician from using our products for an off-label use. The use of our products for indications other than those for which our products have been approved or cleared the FDA may not effectively treat the conditions not referenced in product indications, which could harm our reputation in the marketplace among physicians and patients. Physicians may also misuse our products or </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">29</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">use improper techniques if they are not adequately trained in the particular use, potentially leading to injury and an increased risk of product liability. Product liability claims are expensive to defend and could divert management&#8217;s attention from our primary business and result in substantial damage awards against us. Any of these events could harm our business, results of operations and financial condition. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We are subject to ongoing regulatory obligations and a failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product from the market. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Even after we have obtained the proper regulatory clearance or approval to market a product, we have ongoing responsibilities under FDA regulations and applicable foreign laws and regulations. The FDA, state and foreign regulatory authorities have broad enforcement powers. The regulations to which we are subject are complex and have become more stringent over time. Regulatory changes could result in restrictions on our ability to continue or expand our operations, higher than anticipated costs, or lower than anticipated sales. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our products and/or their use are also subject to state regulations and additional regulations in other foreign jurisdictions outside of the United States, which may change at any time. We cannot predict the impact or effect of future legislation or regulations and any changes in regulations may impede sales. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Furthermore, the FDA and state authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA or state agencies, which may include any of the following sanctions: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">warning letters or untitled letters, fines, injunctions, consent decrees and civil penalties; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">repair, replacement, refunds, recalls, termination of distribution, administrative detention or seizure of our products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">operating restrictions or partial suspension or total shutdown of production; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">refusing our requests for 510(k) clearance or premarket approval of new products, new intended uses, or modifications to existing products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">withdrawing 510(k) clearances or premarket approvals or foreign regulatory approvals that have already been granted, resulting in prohibitions on sales of our products; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">criminal prosecution. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">The occurrence of any of these events could harm our business, financial condition and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we or our subcontractors fail to comply with federal and state regulation, including the FDA&#8217;s Quality System Regulation/Medical Device Good Manufacturing Practices and performance standards, our or our subcontractors&#8217; manufacturing operations could be halted, and our business would suffer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We and our subcontractors currently are required to demonstrate and maintain compliance with the FDA&#8217;s Quality System Regulation/Medical Device Current Good Manufacturing Practices, or QSR. The QSR is a complex regulatory scheme that covers the methods and documentation of the design, testing, control, manufacturing, labeling, quality assurance, packaging, storage and shipping of our products. Because our products use optical energy, including lasers, our products also are covered by a performance standard for lasers set forth in FDA regulations. The laser performance standard imposes specific record-keeping, reporting, product testing and product labeling requirements. These requirements include affixing warning labels to laser products, as well as incorporating certain safety features in the design of laser products. The FDA enforces the QSR and laser performance standards through periodic announced or unannounced inspections. We and our subcontractors are subject to such inspections. Although we place our own quality control employee at each of our subcontractor&#8217;s facilities, we do not have complete control over our subcontractor&#8217;s compliance with these standards. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">30</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Any failure by us or our subcontractors to take satisfactory corrective action in response to an adverse QSR inspection or to comply with applicable laser performance standards could result in enforcement actions against us or our subcontractors, including warning letters or untitled letters; fines, injunctions or civil penalties; suspension or withdrawal of approvals or clearances; seizures or recalls of our products; total or partial suspension of production or distribution; administrative or judicially imposed sanctions; the FDA&#8217;s refusal to grant pending or future clearances or approvals for our products; clinical holds; refusal to permit the import or export of our products; and criminal prosecution of us or our employees. Any of these actions could significantly and negatively impact the supply of our products, and could cause our sales and business to suffer. In addition, we are subject to standards imposed on our activities outside of the United States, such as obtaining KEMA certification (electrical safety testing and certification in Europe) and the Standards Institution of Israel (imposed on our activities in Israel), and failure to comply with such standards could adversely impact our business. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our products may cause or contribute to adverse medical events or other undesirable side effects that we are required to report to the FDA, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are subject to the FDA&#8217;s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA when we receive or become aware of information that reasonably suggests that one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our reporting obligations, the FDA could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance, seizure of our products or delay in clearance of future products. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The FDA and foreign regulatory bodies have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other errors may occur in the future. Depending on the corrective action we take to redress a product&#8217;s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new approvals or clearances for the product before we may market or distribute the corrected product. Seeking such approvals or clearances may delay our ability to replace the recalled products in a timely manner. Moreover, if we do not adequately address problems associated with our products, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals or corrections for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">31</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may be unable to obtain or maintain international regulatory qualifications or approvals for our current or future products and indications, which could harm our business. Additionally, obtaining and maintaining regulatory approval in one jurisdiction does not mean we will be successful in obtaining regulatory approval in for our products in other jurisdictions. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Sales of our products outside the United States are subject to foreign regulatory requirements that vary widely from country to country, including some regulatory requirements that we may not be fully aware, or that may change in ways that affect our ability to sell our products in those jurisdictions. Complying with international regulatory requirements can be an expensive and time-consuming process and approval is not certain. The regulatory process in foreign jurisdictions includes all the risks associated with obtaining FDA clearance, as well as additional risks not present in the FDA process. For example, the time required to obtain foreign clearance or approvals may be longer than that required for FDA clearance or approvals, and requirements for such clearances or approvals may significantly differ from FDA requirements, adding costs and variability. Foreign regulatory authorities may not approve our product for the same uses cleared by the FDA. Although we have obtained regulatory approvals to sell our products in the European Union and other countries outside the United States, we may be unable to maintain regulatory qualifications, clearances or approvals in these countries or to obtain approvals in other countries. We also may incur significant costs in attempting to obtain and in maintaining foreign regulatory approvals or qualifications. If we experience delays in receiving necessary qualifications, clearances or approvals to market our products outside the United States, or if we fail to receive those qualifications, clearances or approvals, we may be unable to market some of our products or enhancements in certain international markets effectively, or at all. Due to the enactment of the Medical Equipment Law in Israel in 2012, we must register our products with the Israeli health authorities in order to continue manufacturing and marketing our products in Israel. We have applied for registration and registered under a fast track approval method for products already approved by other regulatory agencies. Nevertheless, if we are not able to obtain and maintain the necessary registration for any of our products in Israel, we may have to move the manufacturing of such unregistered products to a location outside of Israel and stop selling these products in Israel until the products are registered. We may also suffer harm to our reputation as a result. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">New regulations may limit our ability to sell to non-physicians in the future. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Currently, we sell our products solely to physicians. However, where permitted under applicable laws, we intend to introduce certain of our products in the developing medical spa market, where aesthetic procedures are being performed at dedicated facilities by non-physicians under physician supervision. U.S., state and international regulations could change at any time, disallowing sales of our products to aestheticians, and/or limiting the ability of aestheticians and non-physicians to operate our products. We cannot predict the impact or effect of changes in U.S., state or international laws or regulations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to this Offering </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our ordinary shares have not been publicly traded, and we expect that the price of our ordinary shares will fluctuate substantially. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Before this offering, there has been no public market for our ordinary shares. An active public trading market may not develop after completion of this offering or, if developed, may not be sustained. The lack of a trading market may result in the loss of research coverage by securities analysts. Moreover, we cannot assure you that any securities analysts will initiate or maintain research coverage of our company and our ordinary shares. The price of the ordinary shares sold in this offering will not necessarily reflect the market price of our ordinary shares after this offering. The market price for our ordinary shares after this offering will be affected by a number of factors, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">fluctuations in our operating results or the operating results of our competitors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">changes in the estimates of the future size and growth rate of our market opportunities; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">changes in the general economic, industry and market conditions; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">success of competitive technologies and procedures; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">recruitment or departure of key personnel; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">32</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the announcement of new products or enhancements by us or our competitors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the commencement or outcome of litigation against us, or involving our general industry or both; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">changes in earnings estimates, investors&#8217; perceptions, recommendations by securities analysts or our failure to achieve analysts&#8217; earning estimates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">developments in our industry, including the announcement of significant new technologies, procedures or acquisitions by us or our competitors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">actual or expected sales of our ordinary shares by the holders of our ordinary shares; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the trading volume of our ordinary shares. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, the stock prices of many companies in the medical device industry have experienced wide fluctuations that often have been unrelated to the operating performance of those companies. These factors and price fluctuations may materially and adversely affect the market price of our ordinary shares. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">An active trading market for our ordinary shares may not develop, and you may not be able to resell your ordinary shares at or above the public offering price. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Prior to this offering, there has been no public market for our ordinary shares. The initial public offering price has been determined by negotiation between the representatives of the underwriters and us. This price may not reflect the market price of our ordinary shares following this offering. In addition, an active trading market may not develop following completion of this offering or, if it is developed, may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses, applications or technologies using our shares as consideration. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Purchasers in this offering will experience immediate and substantial dilution in net tangible book value. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The assumed initial public offering price will be substantially higher than the pro&#160;forma net tangible book value per share of our outstanding ordinary shares. As a result, investors purchasing ordinary shares in this offering will incur immediate dilution of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, based on an assumed initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, the midpoint of the range set forth on the cover page of this prospectus. Investors purchasing ordinary shares in this offering will pay a price per ordinary share that substantially exceeds the net tangible book value per ordinary share. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, Guangzhou Sino-Israel Bio-Industry Investment Fund (LLP), a non-controlling partner in our Chinese joint venture (Guangzhou InMode Medical Technology Ltd.), has the right to convert its non-controlling equity interest in such joint venture prior to the consummation of this offering into an aggregate of&#8199;&#8199;&#8199;&#8199; of our ordinary shares assuming a conversion price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, which is calculated based on the midpoint of the price range set forth on the cover page of this prospectus. Additionally, Wigmore Medical Limited, a non-controlling partner in our joint venture in the United&#160;Kingdom (Invasix UK Ltd.), has the right to convert its non-controlling equity interest in such joint venture prior to the consummation of this offering into an aggregate of &#8199;&#8199;&#8199;&#8199; of our ordinary shares assuming a conversion price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, which is calculated based on the&#160;percentage of our U.K. joint venture&#8217;s revenues in relation to our total revenues. Following the consummation of this offering, such non-controlling partners will no longer have the right to convert their non-controlling equity interests into our ordinary shares. If these non-controlling partners exercise their rights to convert their non-controlling equity interests into our ordinary shares, investors purchasing ordinary shares in this offering may experience additional dilution. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, the exercise of outstanding options will, and future equity issuances may, result in further dilution to investors. As of June&#160;30, 2018, there were outstanding options to purchase 5,122,545 of our ordinary shares under our share option plans at a weighted average exercise price of&#8201; $0.94 per ordinary share. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">33</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">A significant share ownership position in our company is held by a small number of existing shareholders, who may make decisions with which you may disagree. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our directors and officers, along with our two largest shareholders, in the aggregate, currently beneficially own or control approximately 75% of our outstanding ordinary shares and will beneficially own or control approximately&#8199;&#8199;&#8199;&#8199;% of our outstanding ordinary shares following the completion of this offering, or&#8199;&#8199;&#8199;&#8199;% if the underwriters exercise their over-allotment option in full. The interests of these shareholders may differ from your interests. These shareholders are not prohibited from selling a controlling interest in us to a third party. While these shareholders will not have the right to appoint board members directly after the closing of this offering, these shareholders, acting together, could exercise significant influence over our operations and business strategy and will have sufficient voting power to influence all matters requiring approval by our shareholders, including the ability to elect or remove directors, to approve or reject mergers or other business combination transactions, the raising of future capital and the amendment of our articles of association, which govern the rights attached to our ordinary shares. In addition, this concentration of ownership may delay, prevent or deter a change in control, or deprive you of a possible premium for your ordinary shares as part of a sale of our company. Furthermore, this concentration of ordinary share ownership may adversely affect the trading price for our ordinary shares because investors may perceive disadvantages in owning shares in companies where persons have a significant interest. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We will have broad discretion in how we use the proceeds of this offering and we may not apply the proceeds to uses that will benefit shareholders. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We intend to use the net proceeds of this offering to expand our sales and marketing operations, to fund our research and development activities, and the remainder for general corporate purposes, including potential acquisitions of complementary products, technologies or businesses and research and development. We have no current agreements or commitments with respect to any investment or acquisition, and we are not engaged in negotiations with respect to any investment or acquisition. Our management will have broad discretion over the use and investment of the net proceeds from this offering, and accordingly investors in this offering will need to rely upon the judgment of our management with respect to the use of proceeds. Our management could spend the proceeds in ways that you do not agree with or that do not improve our results of operations or enhance the value of our ordinary shares. Our failure to apply these proceeds effectively could have a material adverse effect on our business and cause the price of our ordinary shares to decline. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The requirements of being a public company may strain our resources and divert management&#8217;s attention. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The requirements of being a public company may strain our resources and divert management&#8217;s attention. As a public company, whose ordinary shares are listed in the United States, we will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq as applicable to foreign private issuers, and other applicable federal and state securities rules and regulations. We expect that compliance with these rules and regulations will increase our legal, accounting and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our business systems and resources. The Exchange Act requires, among other things, that we file annual and current reports with respect to our business and financial condition. Our management will be required to devote substantial time and attention to our public company reporting obligations and other compliance matters. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our ordinary shares, the price of our ordinary shares could decline. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The trading market for our ordinary shares will rely in part on the research and reports that equity research analysts publish about us and our business, our market or our competitors, if at all. We do not have control over these analysts and we do not have commitments from them to write research reports about us. The price of our ordinary shares could decline if no research reports are published about us or our business, if one or more equity research analysts downgrade our ordinary shares or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business, or if any of those analysts issues a comparatively more favorable recommendation about our competitors. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">34</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Future sales of our ordinary shares could reduce the price of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Sales by shareholders of substantial amounts of our ordinary shares, or the perception that these sales may occur in the future, could materially and adversely affect the market price of our ordinary shares and could impair our ability to raise capital through the sale of additional equity securities and our ability to acquire other companies by using our ordinary shares as consideration. The ordinary shares we are offering for sale in this offering will be freely tradeable immediately following this offering. In addition, a substantial number of ordinary shares held by our current shareholders or issuable upon exercise of options will be eligible for sale in the public market after this offering, and could be sold pursuant to registration under the Securities Act of 1933, as amended, or the Securities Act, or an exemption from registration. Our executive officers, directors, and certain of our shareholders have agreed not to sell their ordinary shares for a period of 180&#160;days after the date of this prospectus. As these restrictions on resale end, the market price of our ordinary shares could drop significantly if the holders of these restricted ordinary shares sell them or are perceived by the market as intending to sell them. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have never paid cash dividends on our ordinary shares and do not anticipate distributing cash or other dividends on our ordinary shares in the foreseeable future. The distribution of dividends on our ordinary shares will depend on our earnings, financial condition and other business and economic factors affecting us at such time as our board of directors may consider relevant. We may only distribute dividends out of&#8201; &#8220;profits,&#8221; as defined by the Israeli Companies Law, 1999, as amended, or the Companies Law, and provided that the distribution is not reasonably expected to impair our ability to fulfill our outstanding and anticipated obligations as they become due. See &#8220;Description of Share Capital&#8201;&#8212;&#8201;Dividend and Liquidation Rights&#8221; for additional information. If we do not distribute dividends, our ordinary shares may be less valuable because a return on your investment will only occur if our the price of our ordinary shares appreciates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We will incur significant increased costs as a result of operating as a public company in the United States, and our management will be required to devote substantial time to new compliance initiatives. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As a public company whose ordinary shares are listed in the United States, we will be subject to an extensive regulatory regime, requiring us, among other things, to maintain various internal controls and facilities and to prepare and file periodic and current reports and statements. Complying with these requirements will be costly and time consuming. We will need to retain additional employees to supplement our current finance staff, and we may not be able to do so in a timely manner, or at all. In the event that we are unable to demonstrate compliance with our obligations as a public company in a timely manner, or are unable to produce timely or accurate financial statements, we may be subject to sanctions or investigations by regulatory authorities and investors may lose confidence in our operating results and the price of our ordinary shares could decline. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may be subject to securities litigation, which is expensive to defend and could divert management&#8217;s attention. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In the past, following periods of market volatility in the price of a company&#8217;s securities or the reporting of unfavorable news, security holders have often instituted class action litigation. If the market value of our securities experience adverse fluctuations and we become involved in this type of litigation, regardless of the outcome, we could incur substantial legal costs and our management&#8217;s attention could be diverted from the operation of our business, causing our business to suffer. Any adverse determination in litigation could also subject us to significant liabilities. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">U.S. investors in the Company could suffer adverse tax consequences if we are characterized as a passive foreign investment company. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe that we were not a passive foreign investment company, or PFIC, for U.S. federal income tax purposes for our taxable year ended December&#160;31, 2017, and we do not expect to be classified as a PFIC for the current year ending December&#160;31, 2018 or the foreseeable future. However, the relevant rules for </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">35</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">determining whether or not we are a PFIC as applied to our business are not entirely clear and certain aspects of such determination will be outside our control. Therefore, no assurance can be given that we will not be classified as a PFIC for any taxable year. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we are determined to be a PFIC at any time during which a U.S. Holder (as defined in &#8220;Taxation&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Considerations to U.S. Holders&#8221;) holds our shares, such U.S. Holder may be subject to materially adverse consequences, including additional U.S. federal income tax liability and tax filing obligations. See &#8220;Taxation&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Considerations to U.S. Holders&#8201;&#8212;&#8201;Passive Foreign Investment Company Considerations.&#8221; U.S. Holders are strongly urged to consult their tax advisors as to whether or not we will be a PFIC. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We are an emerging growth company and the reduced disclosure requirements applicable to emerging growth companies may make our ordinary shares less attractive to investors. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are an emerging growth company, as defined in the JOBS Act, and we may take advantage of certain exemptions from various requirements that are applicable to other public companies that are not emerging growth companies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For as long as we remain an emerging growth company we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not &#8220;emerging growth companies.&#8221; These exemptions include, among others: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">being permitted to provide only two&#160;years of audited financial statements, in addition to any required unaudited condensed consolidated interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We will remain an emerging growth company until the earliest of: (i)&#160;the last day of our fiscal year during which we have total annual gross revenues of at least $1.07&#160;billion; (ii) the last day of our fiscal year following the fifth anniversary of the closing of this offering; (iii) the date on which we have, during the previous three-year period, issued more than $1.0&#160;billion in non-convertible debt; or (iv) the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the Exchange Act. We have opted out of the extended transition period made available to emerging growth companies to comply with newly adopted public company accounting requirements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">When we are no longer deemed to be an emerging growth company, we will not be entitled to the exemptions provided in the JOBS Act discussed above. We cannot predict if investors will find our ordinary shares less attractive as a result of our reliance on exemptions under the JOBS Act. If some investors find our ordinary shares less attractive as a result, there may be a less active trading market for our ordinary shares and our ordinary share price may be more volatile. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Effective internal control over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us, as and when required, conducted in connection with Section&#160;404 of the Sarbanes-Oxley Act, or Section&#160;404, or any subsequent testing by our independent registered public accounting firm, as and when required, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">36</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our ordinary shares. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We are a &#8220;foreign private issuer&#8221; and have disclosure obligations that are different from those of U.S. domestic reporting companies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are a foreign private issuer and are not subject to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we will be subject to reporting obligations that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies. For example, we will not be required to issue quarterly reports or proxy statements that comply with the requirements applicable to U.S. domestic reporting companies. Furthermore, although under regulations promulgated under the Companies Law, as an Israeli public company listed on the Nasdaq, we will be required to disclose the compensation of our five most highly compensated officers on an individual basis, this disclosure will not be as extensive as that required of U.S. domestic reporting companies. We will also have four&#160;months after the end of each fiscal year to file our annual report with the SEC and will not be required to file current reports as frequently or promptly as U.S. domestic reporting companies. Furthermore, our officers, directors and principal shareholders will be exempt from the requirements to report transactions and short-swing profit recovery required by Section&#160;16 of the Exchange Act. Also, as a &#8220;foreign private issuer,&#8221; we are not subject to the requirements of Regulation&#160;FD (Fair Disclosure) promulgated under the Exchange Act. These exemptions and leniencies will reduce the frequency and scope of information and protections available to you in comparison to those applicable to a U.S. domestic reporting companies. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">As a &#8220;foreign private issuer,&#8221; we are permitted, and intend, to follow certain home country corporate governance practices instead of otherwise applicable SEC and Nasdaq requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As a &#8220;foreign private issuer,&#8221; we will be permitted, and intend, to follow certain home country corporate governance practices instead of those otherwise required under the listing rules of Nasdaq for domestic U.S. issuers. For instance, we intend to follow our home country law instead of the listing rules of Nasdaq that require that we obtain shareholder approval for certain dilutive events, such as the establishment or amendment of certain equity based compensation plans, an issuance that will result in a change of control of us, certain transactions other than a public offering involving issuances of a 20% or greater interest in the Company, and certain acquisitions of the stock or assets of another company. We may in the future elect to follow home country corporate governance practices in Israel with regard to other matters. Following our home country corporate governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on Nasdaq may provide less protection to you than what is accorded to investors under the listing rules of Nasdaq applicable to domestic U.S. issuers. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to Our Operations in Israel </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Political, economic and military instability in Israel may impede our ability to operate and harm our financial results. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our principal executive offices and research and development facilities as well as our third-party manufacturers are located in Israel. In addition, all of our subcontractors are located in Israel. Accordingly, political, economic and military conditions in Israel and the surrounding region could directly affect our business. Since the establishment of the State of Israel in 1948, a number of armed conflicts have occurred between Israel and its Arab neighbors, Hamas (an Islamist militia and political group in the Gaza Strip) and Hezbollah (an Islamist militia and political group in Lebanon). Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners could affect adversely our operations. Ongoing and revived hostilities or other Israeli political or economic factors, could prevent or delay shipments of our products, harm our operations and product development and cause our sales to decrease. In the event that hostilities disrupt the ongoing operation of our facilities or the airports and seaports on which we depend to import and export our supplies and products, our operations may be </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">37</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">materially adverse affected. Furthermore, in the past, the State of Israel and Israeli companies have been subjected to economic boycotts. Several countries, principally those in the Middle East, still restrict business with Israel and Israeli companies, and additional countries may impose restrictions on doing business with Israel and Israeli companies if hostilities in Israel or political instability in the region continues or increases. These restrictive laws and policies may seriously limit our ability to sell our products in these countries and may have an adverse impact on our operating results, financial conditions or the expansion of our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, political uprisings and conflicts in various countries in the Middle East are affecting the political stability of those countries. This instability has raised concerns regarding security in the region and the potential for armed conflict. In Syria, a country bordering Israel, a civil war is taking place. In addition, there are concerns that Iran, which has previously threatened to attack Israel, may step up its efforts to achieve nuclear capability. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza and Hezbollah in Lebanon. Additionally, the Islamic State of Iraq and Levant, or ISIL, a violent jihadist group whose stated purpose is to take control of the Middle East, has been growing in influence. The tension between Israel and Iran and/or these groups may escalate in the future and turn violent, which could affect the Israeli economy in general and us in particular. Any potential future conflict could also include missile strikes against parts of Israel, including our offices and facilities. Such instability may lead to deterioration in the political and trade relationships that exist between the State of Israel and certain other countries. Any armed conflicts, terrorist activities or political instability in the region could adversely affect business conditions, could harm our results of operations and could make it more difficult for us to raise capital. Parties with whom we do business may be disinclined to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary in order to meet our business partners face to face. In addition, the political and security situation in Israel may result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions in such agreements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle East or for any resulting disruption in our operations. Although the Israeli government has in the past covered the reinstatement value of direct damages that were caused by terrorist attacks or acts of war, we cannot be assured that this government coverage will be maintained or, if maintained, will be sufficient to compensate us fully for damages incurred and the government may cease providing such coverage or the coverage might not suffice to cover potential damages. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions generally and could harm our results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our operations may be disrupted by the obligations of our personnel to perform military service. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Many of our employees in Israel, including members of our senior management, are obligated to perform up to 36&#160;days, and in some cases longer periods, of military reserve duty annually until they reach the age of 40 (or older, for citizens who hold certain positions in the Israeli armed forces reserves) and, in the event of a military conflict or emergency situations, could be called to immediate active duty for extended periods of time. In response to increases in terrorist activity, there have been periods of significant call-ups of military reservists. It is possible that there will be similar large-scale military reserve duty call-ups in the future. Our operations could be disrupted by the absence due to military service of a significant number of our employees or of one or more of our key employees for extended periods of time, and such disruption could materially adversely affect our business. Additionally, the absence of a significant number of the employees of our Israeli suppliers and subcontractors related to military service or the absence for extended periods of one or more of their key employees for military service may disrupt their operations which may subsequently disrupt our operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and adversely affect our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have entered into assignment of invention agreements with our employees pursuant to which such individuals agree to assign to us all rights to any inventions created during their employment or engagement with us. A significant portion of our intellectual property has been developed by our employees in the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">38</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">course of their employment with us. Under the Israeli Patent Law, 1967, or the Patent Law, inventions conceived by an employee during the scope of his or her employment with a company and as a result thereof are regarded as &#8220;service inventions,&#8221; which belong to the employer, absent a specific agreement between the employee and employer giving the employee service invention rights. The Patent Law also provides that if there is no agreement between an employer and an employee with respect to the employee&#8217;s right to receive compensation for such &#8220;service inventions,&#8221; the Israeli Compensation and Royalties Committee, a body constituted under the Patent Law, shall determine whether the employee is entitled to remuneration for his or her service inventions and the scope and conditions for such remuneration. Although our employees have agreed to assign to us service invention rights, as a result of uncertainty under Israeli law with respect to the efficacy of waivers of service invention rights, we may face claims demanding remuneration in consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional remuneration or royalties to our current and/or former employees, or be forced to litigate such claims, which could negatively affect our business. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our operations may be affected by negative economic conditions or labor unrest in Israel. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">General strikes or work stoppages, including at Israeli ports, have occurred periodically or have been threatened in the past by Israeli trade unions due to labor disputes. These general strikes or work stoppages may have an adverse effect on the Israeli economy and on our business, including our ability to deliver products to our customers and to receive raw materials from our suppliers in a timely manner and could have a material adverse effect on our results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">You may have difficulties enforcing a U.S. judgment against us, our executive officers and directors and Israeli experts named in this prospectus in Israel or the United States, asserting U.S. securities laws claims in Israel or serving process on our officers and directors and these experts in Israel. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are incorporated in Israel and our corporate headquarters are located in Israel. A significant portion of our assets and the assets of certain of our directors and executive officers are located outside the United States. Therefore, a judgment obtained against us or any of them in the United States, including one based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not be enforced by an Israeli court. Further, if a foreign judgment is enforced by an Israeli court, it will be payable in Israeli currency. It also may be difficult for you to assert U.S. securities law claims in original actions instituted in Israel. Additionally, it may be difficult for an investor, or any other person or entity, to initiate an action with respect to U.S. securities laws in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment in Israel, you may not be able to collect any damages awarded by either a United States or foreign court. For more information regarding the enforceability of civil liabilities against us, our directors and our executive officers, please see &#8220;Enforceability of Civil Liabilities.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The tax benefits available to us require us to meet several conditions and may be terminated or reduced in the future, which would increase our costs and taxes. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have generated income and are able to take advantage of tax exemptions and reductions resulting from the &#8220;Benefited Enterprise&#8221; status of our facilities in Israel. Our &#8220;Benefited Enterprise&#8221; status provides us with a ten-year tax exemption for undistributed income. The first year in which we were exempted from tax as stated above was 2012 and such ten-year eligibility period of tax exemption will terminate in 2021. To remain eligible for these tax benefits, we must continue to meet conditions, including making specified investments in property and equipment, and financing a&#160;percentage of investments with share capital. If we fail to meet these conditions in the future, the tax benefits could be canceled and we could be required to refund any tax benefits we might already have enjoyed. These tax benefits may not be continued in the future at their current levels or at any level. The termination or reduction of these tax benefits will increase </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">39</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">our expenses in the future, which would reduce our expected profits or increase our losses. Additionally, if we increase our activities outside of Israel, for example, by future acquisitions, our increased activities generally will not be eligible for inclusion in Israeli tax benefit programs. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Provisions of our amended and restated articles of association and Israeli law may delay, prevent or make difficult an acquisition of our company which could prevent a change of control even when the terms of such transaction are favorable to us and our shareholders and, therefore, could depress the price of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As a company incorporated under the laws of the State of Israel, we are subject to Israeli corporate law. Israeli corporate law regulates mergers, requires tender offers for acquisitions of ordinary shares above specified thresholds, requires special approvals for transactions involving directors, officers or certain significant shareholders and regulates other matters that may be relevant to these types of transactions. In addition, our amended and restated articles of association, which will be effective upon the effectiveness of the registration statement of which this prospectus forms a part, contain provisions that may make it more difficult to acquire us, such as classified board provisions. Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to some of our shareholders. Certain of our agreements require the receipt of consents for change of control transactions. These provisions of our amended and restated articles of association, Israeli law and such other agreements may delay, prevent or make difficult an acquisition of us, which could prevent a change of control and therefore depress the price of our ordinary shares. See &#8220;Description of Share Capital&#8201;&#8212;&#8201;Anti-Takeover Provisions; Mergers and Acquisitions&#8221; for additional information. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Your rights and responsibilities as a holder of our ordinary shares will be governed by Israeli law, which differs in some material respects from the rights and responsibilities of shareholders of U.S. companies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The rights and responsibilities of the holders of our ordinary shares are governed by our articles of association and by Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders in typical U.S. corporations. In particular, a shareholder of an Israeli company has certain duties, including to act in good faith and fairness and in a customary manner in exercising its rights and performing its obligations towards the company and other shareholders and to refrain from abusing its power in the company including, among other things, in voting at the general meeting of shareholders on certain matters, such as an amendment to the company&#8217;s articles of association, an increase of the company&#8217;s authorized share capital, a merger of the company, and approval of related party transactions that require shareholder approval. A shareholder also has a general duty to refrain from discriminating against other shareholders. In addition, a controlling shareholder or a shareholder who knows that it possesses the power to determine the outcome of a shareholder vote or to appoint or prevent the appointment of an officer of the company has a duty to act in fairness towards the company with regard to such vote or appointment. See &#8220;Management&#8201;&#8212;&#8201;Approval of Related Party Transactions under Israeli Law&#8201;&#8212;&#8201;Shareholders&#8221; for additional information. There is limited case law available to assist in understanding the nature of these duties or the implications of these provisions. These provisions may be interpreted to impose additional obligations on holders of our ordinary shares that are not typically imposed on shareholders of U.S. corporations.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">40</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t3SP">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This prospectus contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this prospectus regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to identify and penetrate new markets for our products and technology; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to innovate, develop and commercialize our existing and new products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to obtain and maintain regulatory clearances; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our expectation regarding the safety and efficacy of our products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">commercial experience of our management team; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our commercialization, marketing and manufacturing capabilities and strategy; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our estimates regarding the potential market opportunity for our products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">developments and projections relating to our competitors or our industry; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to differentiate and distinguish our products from those of our competitors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our sales and marketing capabilities and strategy in the United States and internationally; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the implementation of our business model, strategic plans for our business, products and technology; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to attract or retain key personnel; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our intellectual property portfolio and position and our ability to protect our intellectual property rights; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Forward-looking statements are based on our management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management&#8217;s beliefs and assumptions, and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this prospectus, particularly in the &#8220;Risk Factors&#8221; section, that could cause actual results or events to differ materially from the forward-looking statements that we make. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">You should read this prospectus and the documents that we have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this prospectus are made as of the date of this prospectus, and we do not assume any obligation to update any forward-looking statements except as required by applicable law. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">41</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t4MA">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">MARKET, INDUSTRY AND OTHER DATA </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In this prospectus, we have used industry and market data obtained from our own internal estimates and research as well as from industry publications and research, surveys and studies conducted by third parties. We have compiled, extracted and reproduced industry and market data from external sources that we believe to be reliable. We caution prospective investors not to place undue reliance on the above mentioned data. Unless otherwise indicated in the prospectus, the basis for any statements regarding our competitive position is based on our own assessment and knowledge of the market in which we operate. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section titled &#8220;Risk Factors.&#8221; These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">42</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t5US">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">USE OF PROCEEDS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We estimate that the net proceeds to us from our issuance and sale of&#8199;&#8199;&#8199;&#8199; ordinary shares in this offering will be approximately $&#8199;&#8199;&#8199;&#8199;million, based on the assumed initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199;per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Each $1.00 increase (decrease) in the assumed initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, the midpoint of the price range set forth on the cover of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, would increase (decrease) net proceeds to us from this offering by approximately $&#8199;&#8199;&#8199;&#8199; million, assuming that the number of ordinary shares offered by us, as set forth on the cover page of this prospectus, remains the same. We may also increase or decrease the number of ordinary shares we are offering. Each increase (decrease) of&#8201;&#8199;&#8199;&#8199;&#8199; in the number of ordinary shares we are offering would increase (decrease) the net proceeds to us from this offering by approximately $&#8199;&#8199;&#8199;&#8199; million, assuming no change in the assumed public offering price per ordinary share. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The principal purposes of this offering are to obtain additional capital to support our operations, to create a public market for our ordinary shares, to facilitate our future access to the public equity markets and to increase awareness of our Company among potential customers. We intend to use the net proceeds from this offering as follows: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">approximately $&#8199;&#8199;&#8199;&#8199; million to hire additional sales and marketing personnel and expand our global sales and marketing programs; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">approximately $&#8199;&#8199;&#8199;&#8199; million to fund research and development activities; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the remainder for working capital and general corporate purposes. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may also use a portion of the net proceeds from this offering to acquire or invest in products, technologies or businesses that are complementary to our business. However, we currently have no agreements or commitments to complete any such transaction. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend. The amounts and timing of our actual use of net proceeds will vary depending on numerous factors. As a result, our management will have broad discretion in the application of the net proceeds of this offering, and investors will be relying on our judgment regarding the application of the net proceeds. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pending their use, we plan to invest the net proceeds of this offering in short- and intermediate-term interest-bearing investments.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">43</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t6DI">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">DIVIDEND POLICY </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have never declared or paid cash dividends to our shareholders and currently we do not intend to pay cash dividends in the foreseeable future. We intend to reinvest any future earnings in developing and expanding our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our ability to pay cash dividends may be limited by Israeli law, which permits the distribution of dividends only out of profits. See &#8220;Description of Share Capital&#8201;&#8212;&#8201;Dividend and Liquidation Rights.&#8221; In addition, the payment of cash dividends may be subject to Israeli withholding taxes. See &#8220;Taxation&#8201;&#8212;&#8201; Material Israeli Tax Considerations.&#8221;</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">44</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t7CA">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CAPITALIZATION </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">The following table sets forth our cash and cash equivalents and capitalization as of June&#160;30, 2018. Our capitalization is presented: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">on an actual basis; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">on a pro&#160;forma basis to give effect to our issuance and sale of&#8199;&#8199;&#8199;&#8199; ordinary shares in this offering, based on the assumed initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199;per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">You should read this table in conjunction with our consolidated financial statements and related notes appearing elsewhere in this prospectus, as well as the sections of this prospectus titled &#8220;Selected Consolidated Financial Data&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; </div>
        <table style="width:456pt;height:203pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:311.86pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">As of June&#160;30, 2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:311.86pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Actual </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Pro Forma<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:311.86pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">(Unaudited) <br >(dollars in thousands, except share data) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:311.86pt;text-align:left;">
              <div style="white-space:nowrap;">Cash and cash equivalents </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:311.86pt;text-align:left;">Shareholders&#8217; equity:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:311.86pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Ordinary shares, NIS 0.01 par value: 20,000,000 ordinary shares authorized, 14,729,165 shares issued and outstanding, actual; &#8199;&#8199;&#8199;&#8199; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares authorized,&#8199;&#8199;&#8199;&#8199; ordinary shares issued and outstanding, pro&#160;forma </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.86pt;">
              <div style="white-space:nowrap;">Additional paid-in capital </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.86pt;">
              <div style="white-space:nowrap;">Accumulated other comprehensive income </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:311.86pt;text-align:left;">
              <div style="white-space:nowrap;">Retained earnings </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:311.86pt;text-align:left;">
              <div style="margin-left:10pt;">Total shareholders&#8217; equity </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:311.86pt;text-align:left;">
              <div style="white-space:nowrap;">Total capitalization </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.535pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">Each $1.00 increase (decrease) in the assumed initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, the midpoint of the price range set forth on the cover of this prospectus, would increase (decrease) our pro&#160;forma cash and cash equivalents, additional paid-in capital, total stockholders&#8217; equity and total capitalization by approximately $&#8199;&#8199;&#8199;&#8199; million, assuming that the number of ordinary shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares we are offering. Each increase (decrease) of&#8201; &#8199;&#8199;&#8199;&#8199; in the number of ordinary shares we are offering would increase (decrease) our pro&#160;forma cash and cash equivalents, additional paid-in capital, total stockholders&#8217; equity and total capitalization by approximately $&#8199;&#8199;&#8199;&#8199; million, assuming no change in the assumed public offering price per ordinary share, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The outstanding share information in the table above excludes: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">5,122,545 ordinary shares issuable upon the exercise of options outstanding as of June&#160;30, 2018 at a weighted-average exercise price of&#8201; $0.94 per ordinary share; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">1,000,000 ordinary shares reserved for future issuance under our 2018 Incentive Plan, as well as ordinary shares that may be issued pursuant to provisions in our 2018 Incentive Plan that automatically increase the ordinary share reserve under our 2018 Incentive Plan;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">45</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the exercise of Guangzhou Sino-Israel Bio-Industry Investment Fund (LLP)&#8217;s right to convert its non-controlling equity interest in our Chinese joint venture into our ordinary shares assuming a conversion price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, which is calculated based on the midpoint of the price range set forth on the cover page of this prospectus; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the exercise of Wigmore Medical Limited&#8217;s right to convert its non-controlling equity interest in our U.K. joint venture into our ordinary shares assuming a conversion price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">46</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t8DI">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">DILUTION </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our net tangible book value as of June&#160;30, 2018 was $&#8199;&#8199;&#8199;&#8199; million, or $&#8199;&#8199;&#8199;&#8199; per ordinary share. Net tangible book value per ordinary share represents the amount of our total consolidated tangible assets less our total consolidated liabilities, divided by the number of ordinary shares outstanding. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pro&#160;forma net tangible book value dilution per ordinary share represents the difference between the amount per ordinary share paid by purchasers of ordinary shares in this offering and net tangible book value per ordinary share immediately after the completion of this offering on a pro&#160;forma basis. After giving effect to the sale of&#8201; &#8199;&#8199;&#8199;&#8199; ordinary shares by us in this offering at the assumed initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199;per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro&#160;forma net tangible book value would have been approximately $&#8199;&#8199;&#8199;&#8199;million, or approximately $&#8199;&#8199;&#8199;&#8199;per ordinary share based on&#8199;&#8199;&#8199;&#8199; ordinary shares outstanding upon completion of this offering. This represents an immediate increase in pro&#160;forma net tangible book value of $&#8199;&#8199;&#8199;&#8199;per ordinary share to existing shareholders and an immediate dilution of&#8201; $&#8199;&#8199;&#8199;&#8199;per ordinary share to purchasers of ordinary shares in this offering. The following table illustrates this per ordinary share dilution: </div>
        <table style="width:456pt;height:83pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:352pt;text-align:left;">
              <div style="white-space:nowrap;">Assumed initial public offering price per ordinary share </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352pt;text-align:left;">
              <div style="margin-left:10pt;">Net tangible book value per ordinary share as of June&#160;30, 2018 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:352pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Increase in net tangible book value per ordinary share attributable to this offering </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:352pt;text-align:left;">
              <div style="white-space:nowrap;">Pro forma net tangible book value per ordinary share after this offering </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:352pt;text-align:left;">
              <div style="white-space:nowrap;">Dilution per ordinary share to investors in this offering </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="15">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:10.99pt; width:456pt; line-height:12pt;">Each $1.00 increase (decrease) in the assumed initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) our pro&#160;forma net tangible book value by $&#8199;&#8199;&#8199;&#8199; per ordinary share and would increase (decrease) dilution to investors in this offering by $&#8199;&#8199;&#8199;&#8199;per ordinary share, assuming that the number of ordinary shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares we are offering. Each increase (decrease) of&#8201;&#8199;&#8199;&#8199;&#8199; in the number of ordinary shares we are offering would increase (decrease) our pro&#160;forma net tangible book value by $&#8199;&#8199;&#8199;&#8199; per ordinary share and would increase (decrease) dilution to investors in this offering by $&#8199;&#8199;&#8199;&#8199;per ordinary share, assuming no change in the assumed public offering price per ordinary share, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If the underwriters exercise their option to purchase additional ordinary shares in full, our pro&#160;forma net tangible book value after giving effect to this offering would be $&#8199;&#8199;&#8199;&#8199;per ordinary share, which amount represents an immediate increase in pro&#160;forma net tangible book value of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share to existing shareholders and an immediate dilution in net tangible book value of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share to new investors. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If all of our outstanding stock options had been exercised as of June&#160;30, 2018, our pro&#160;forma net tangible book value as of June&#160;30, 2018, before giving effect to the issuance and sale of ordinary shares in this offering, would have been $&#8199;&#8199;&#8199;&#8199; million, or $&#8199;&#8199;&#8199;&#8199; per ordinary share, and our pro&#160;forma net tangible book value as of June&#160;30, 2018 after this offering would have been $&#8199;&#8199;&#8199;&#8199;million, or $&#8199;&#8199;&#8199;&#8199;per share, causing dilution to new investors of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table presents, on a pro&#160;forma basis, as of June&#160;30, 2018, the differences between the number of ordinary shares purchased from us, the total consideration paid to us, and the average price per ordinary share paid by existing shareholders and by new investors purchasing ordinary shares at the assumed initial offering price of&#8201; $&#8199;&#8199;&#8199;&#8199;per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. The total number of ordinary shares does not include ordinary shares issuable upon the exercise of the over-allotment option granted to the underwriters. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">47</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <table style="width:456pt;height:67.5pt;margin-top:0pt;border-collapse: collapse;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:144.47pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Ordinary Shares Purchased </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Total Consideration </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">Average Price Per <br >Ordinary Share </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Number </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Percent </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Percent </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:144.47pt;text-align:left;">
              <div style="white-space:nowrap;">Existing shareholders </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt;" colspan="4">
              <div style="text-align:right;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:1.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-2pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:1.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:144.47pt;text-align:left;">
              <div style="white-space:nowrap;">New investors </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33.75pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8199;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:1.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33.75pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8199;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:1.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-2pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8199;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8199;</td>
            <td style="padding:0pt;padding-left:1.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.265pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.265pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:144.47pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">100.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:1.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-2pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">100.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:1.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:16.98pt; width:456pt; line-height:12pt;">If the underwriters exercise their option to purchase additional ordinary shares in full, the total consideration paid by new investors and the average price per ordinary share paid by new investors would be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, respectively.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The above tables and discussions are based on our ordinary shares outstanding as of June&#160;30, 2018, which gives effect to the pro&#160;forma transactions described above and excludes: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">5,122,545 ordinary shares issuable upon the exercise of options outstanding as of June&#160;30, 2018 at a weighted-average exercise price of&#8201; $0.94 per ordinary share; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">1,000,000 ordinary shares reserved for future issuance under our 2018 Incentive Plan, as well as ordinary shares that may be issued pursuant to provisions in our 2018 Incentive Plan that automatically increase the ordinary share reserve under our 2018 Incentive Plan; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the exercise of Guangzhou Sino-Israel Bio-Industry Investment Fund (LLP)&#8217;s right to convert its non-controlling equity interest in our Chinese joint venture into our ordinary shares assuming a conversion price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, which is calculated based on the midpoint of the price range set forth on the cover page of this prospectus; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the exercise of Wigmore Medical Limited&#8217;s right to convert its non-controlling equity interest in our U.K. joint venture into our ordinary shares assuming a conversion price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The pro&#160;forma information discussed above is illustrative only. Our net tangible book value following the completion of this offering is subject to adjustment based on the actual initial public offering price of our ordinary shares and other terms of this offering determined at pricing.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">48</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t9SE">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SELECTED CONSOLIDATED FINANCIAL DATA </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following tables present our selected consolidated financial data and should be read in conjunction with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and related notes appearing elsewhere in this prospectus. The historical results are not necessarily indicative of the results to be expected for any future. We derived the selected consolidated statements of income data below for the&#160;years ended December&#160;31, 2017 and 2016 and the selected balance sheet data as of December&#160;31, 2017 and 2016 from our audited consolidated financial statements included elsewhere in this prospectus. Our audited consolidated financial statements are prepared in U.S. dollars and in accordance with U.S. GAAP. </div>
        <table style="width:456pt;height:366.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:324pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">(in thousands, except share <br >and per share data) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">Consolidated Statements of Income Data:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">
              <div style="white-space:nowrap;">Revenues </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">53,456</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">23,082</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:324pt;text-align:left;">
              <div style="white-space:nowrap;">Cost of revenues </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">9,053</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">5,653</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">
              <div style="white-space:nowrap;">Gross profit </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">44,403</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">17,429</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">Operating expenses:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">
              <div style="margin-left:10pt;">Research and development </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,575</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,456</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">
              <div style="margin-left:10pt;">Sales and marketing </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">28,514</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,254</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:324pt;text-align:left;">
              <div style="margin-left:10pt;">General and administrative </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">4,364</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">3,050</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:324pt;text-align:left;">
              <div style="margin-left:30pt;">Total operating expenses </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">35,453</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">16,760</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">
              <div style="white-space:nowrap;">Operating income </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">8,950</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">669</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:324pt;text-align:left;">
              <div style="white-space:nowrap;">Financial income, net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">849</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">
              <div style="white-space:nowrap;">Income before taxes </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,799</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">673</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:324pt;text-align:left;">
              <div style="white-space:nowrap;">Income tax </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">980</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">337</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:324pt;text-align:left;">
              <div style="white-space:nowrap;">Net income </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">8,819</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">336</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.75pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">Net income per ordinary share:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:324pt;text-align:left;">
              <div style="margin-left:10pt;">Basic </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">0.52</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">0.02</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:324pt;text-align:left;">
              <div style="margin-left:10pt;">Diluted </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">0.46</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">0.02</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.75pt 0pt 1.5pt 0pt; width:324pt;text-align:left;">Weighted  average number of ordinary shares:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:324pt;text-align:left;">
              <div style="margin-left:10pt;">Basic </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">14,691,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">14,646,837</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:324pt;text-align:left;">
              <div style="margin-left:10pt;">Diluted </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.590000000000003pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">16,584,637</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">14,879,319</td>
            <td style="padding:0pt;padding-left:3.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:155pt;margin-top:13pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:324pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">(in thousands) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:324pt;text-align:left;">Consolidated Balance Sheet Data:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:324pt;text-align:left;">
              <div style="white-space:nowrap;">Cash and cash equivalents </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">17,593</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,696</td>
            <td style="padding:0pt;padding-left:12.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:324pt;text-align:left;">
              <div style="white-space:nowrap;">Working capital </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">23,694</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,933</td>
            <td style="padding:0pt;padding-left:12.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:324pt;text-align:left;">
              <div style="white-space:nowrap;">Total assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">39,442</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16,488</td>
            <td style="padding:0pt;padding-left:12.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:324pt;text-align:left;">
              <div style="white-space:nowrap;">Total liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16,923</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7,384</td>
            <td style="padding:0pt;padding-left:12.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:324pt;text-align:left;">
              <div style="white-space:nowrap;">Redeemable non-controlling interest  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,066</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">183</td>
            <td style="padding:0pt;padding-left:12.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:324pt;text-align:left;">
              <div style="white-space:nowrap;">Retained earnings </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">10,819</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,154</td>
            <td style="padding:0pt;padding-left:12.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:324pt;text-align:left;">
              <div style="white-space:nowrap;">Total shareholders&#8217; equity </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">19,453</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,921</td>
            <td style="padding:0pt;padding-left:12.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">49</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t10MA">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS <br >OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">The following discussion of our financial condition and results of operations should be read in conjunction with &#8220;Selected Consolidated Financial Data&#8221; and our consolidated financial statements and the related notes to those statements included elsewhere in this prospectus. In addition to historical consolidated financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under &#8220;Risk Factors&#8221; and elsewhere in this prospectus. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Overview </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We design, develop, manufacture and commercialize innovative minimally and non-invasive aesthetic medical products. Our proprietary minimally invasive RFAL and Deep Subdermal Fractional RF technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Our non-invasive medical aesthetic products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction through the use of our innovative dual wavelength technology, and other treatments targeting skin appearance and texture through the use of our high power IPL technology. Our products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. Since 2010, we have launched five product platforms (<font style="font-style:italic;">BodyTite</font>, <font style="font-style:italic;">Optimas</font>, <font style="font-style:italic;">Votiva</font>, <font style="font-style:italic;">Contoura</font> and <font style="font-style:italic;">Triton</font>) that we market and sell traditionally to plastic and facial surgeons, aesthetic surgeons, dermatologists and aesthetic OB/GYNs. Our revenues increased to approximately $53.5&#160;million for the year ended December&#160;31, 2017 from approximately $23.1&#160;million for the year ended December&#160;31, 2016. For the year ended December&#160;31, 2017, we recorded a gross profit margin of approximately 83% and net income of approximately $8.8&#160;million. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We were incorporated in January&#160;2008 and have a limited history of operations, having commenced sales in 2010. In February&#160;2016, we received FDA clearance enabling us to market our RFAL-based <font style="font-style:italic;">BodyTite</font> products for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. Additionally, we market our <font style="font-style:italic;">Votiva</font> products for the treatment of sexual dysfunction or as an adjunct to Kegel exercises (tightening of the muscles of the pelvic floor to increase muscle tone). </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We sell our products directly in the United States, Canada, United Kingdom and Spain, and indirectly through third-party distributors in other countries. As a result of these recently received FDA clearances and product launches, during the year ended December&#160;31, 2017, we increased our sales and marketing efforts in connection with product introductions and other marketing activities, as well as expanded the number of our direct salespersons in North America from approximately 23 to 55 representatives. As of December&#160;31, 2017, we had an installed base of over 2,225 product platforms (capable of running various multi-use applicators and minimally-invasive consumables), 6,900 multi-use treatment applicators (laser, IPL and RF) and 139,000 minimally-invasive consumable handpieces. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We outsource a majority of the manufacturing of our products to four subcontractors in Israel, while we manufacture our laser and IPL handpieces in-house in Israel. Outsourcing allows us to carry low inventory levels and maintain fixed unit costs without incurring significant capital expenditures. Our manufacturing subcontractors provide us fully assembled, or &#8220;turn-key,&#8221; services. We control and monitor the quality of our products by having one of our quality control employees at each of our subcontractor&#8217;s facilities. All assembled products are sent to our warehouse in Israel where they are inspected and tested. We ship the finished products to our distributors upon receipt of a purchase order or to our subsidiaries to replenish inventory levels. Usually, products are tested again locally by our distributors or subsidiaries prior to being shipped and sold to the customer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We anticipate that our quarterly results of operations may fluctuate from quarter to quarter due to several factors, including seasonality, unexpected delays in the introduction and market acceptance of our products, unexpected delays in our manufacturing operations, introduction of new and improved products by our competitors and the performance of our direct sales organization. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">50</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We intend to make significant investments to promote revenue growth by increasing the number of sales representatives in our sales and marketing organization and broadening our marketing efforts in existing and new markets. We also intend to continue to make investments in research and development efforts to develop our next generation products. As a result of these and other factors, we expect our operating expenses to increase in the future. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Components of Our Results of Operations </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Revenues </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We generate our revenues primarily from the sale of energy-based medical aesthetic products, which consist of platforms and non-consumable handpieces. To a lesser extent, we generate revenue from the sale of consumables and from the sale of extended warranties. For the year ended December&#160;31, 2017, we derived approximately 93% of our revenues from the sale of medical aesthetic products and approximately 7% of our revenues from the sale of consumables and extended warranties. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We expect our revenues from the sale of consumables and extended warranties to continue to increase over time as our installed base continues to grow. We have experienced growth in sales of consumables in the past three years. Recent revenue growth has been driven by, and we expect continued growth as a result of, increased patient and physician awareness of our medical aesthetic products and additional sales representatives. We have expanded our sales and marketing organization to help us drive and support revenue growth and intend to continue this expansion. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We sell our products directly in the United States, Canada, United Kingdom and Spain, and indirectly through third-party distributors in other countries. For the year ended December&#160;31, 2017, we derived approximately 83% of our revenues in North America compared to approximately 79% of our revenues for the year ended December&#160;31, 2016. In the future, we expect to generate a higher&#160;percentage of our total revenues in Europe and the Asia-Pacific region due to our expanding direct sales organization in those regions. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table provides information regarding the breakdown of our revenue by geographic region for the&#160;years ended December&#160;31, 2017 and 2016: </div>
        <table style="width:416pt;height:120pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Percent of Revenue </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Years ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Geographic region</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">2017 <br >(%) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">2016 <br >(%) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">North America (excluding Mexico) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">83</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">79</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Europe </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">14</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Asia-Pacific </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Other </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">100</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">100</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.98pt; width:456pt; line-height:12pt;">We believe that there are opportunities for us to generate additional revenue from existing customers who are already familiar with our products. For example, a number of our existing customers have purchased additional aesthetic treatment products from us to expand their treatment offerings. We intend to continue to make significant investments in research and development activities and introduce innovative next-generation pipeline products to our customers. As a result, we expect that certain existing customers will be candidates for technology upgrades to enhance the capabilities of their existing InMode products. In addition, as we continue to grow our support services program, we expect to increase the number of customers that enter into service contracts and extended warranties with us, which would result in additional recurring revenues. We also plan to expand to new medical communities in order to reach non-traditional customers, such as general practitioners, ophthalmologists, ENTs and aesthetic clinicians, and generate additional revenue.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">51</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Cost of Revenues </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our cost of revenues consists primarily of the expenses we incur to have our products manufactured and assembled by third parties and the direct costs we incur in order to obtain the materials, labor and overhead that are needed to manufacture and assemble our products. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our cost of revenues also includes shipping, handling, service and warranty expenses, as well as salaries and personnel-related expenses for our operations management team, which is comprised of subcontractor supervisors and purchasing and quality control employees. We expect our cost of revenues to increase in absolute dollars primarily as, and to the extent, our revenue grows. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our cost of revenues as a&#160;percentage of revenues has been, and we expect it to continue to be, affected by a variety of factors, including manufacturing costs, the average selling price of our products, the maturity of our existing products, promotional prices being offered to existing customers for our new products, and to a lesser extent the sales mix between the United States and the rest of the world as our average selling price in the United States tends to be higher than in the rest of the world. We expect our gross margin to be positively affected over time to the extent we are successful in reducing manufacturing costs as our sales volume increases and maintaining our average selling prices. However, our gross margin may fluctuate from period to period. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Research and Development Expenses </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our research and development expenses consist of salaries and personnel-related expenses, including share-based compensation expenses, for our employees that are primarily engaged in research, development and engineering activities. Our research and development expenses also include regulatory-related costs and expenses, external engineering fees, materials used and other overhead expenses that are incurred in connection with the design and development of our products. We expense all of our research and development costs as incurred. While we do not track our research and development spending by technology, product or application, we do expect that our overall research and development costs will increase in absolute dollars in the future as we develop more products and technologies. We expect research and development expenses as a&#160;percentage of revenue to vary over time depending on the level and timing of initiating new product development efforts. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Sales and Marketing Expenses </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our sales and marketing expenses consist primarily of salaries, commissions and personnel-related expenses, including share-based compensation expenses, for our employees that are engaged in sales and marketing activities, which include marketing and public support of our products, participation in trade shows and industry events, promotional and public relations activities, and administrative functions in support of sales and marketing. We expect sales and marketing expenses to continue to increase in absolute dollars as we expand our marketing organization to both drive and support our planned growth in revenue. However, we expect sales and marketing expenses to decrease as a&#160;percentage of revenue primarily as, and to the extent, our revenue grows. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">General and Administrative Expenses </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our general and administrative expenses consist primarily of salaries and personnel-related expenses, including share-based compensation expenses, for executive, accounting and administrative personnel, professional fees and other general corporate expenses. We expect our general and administrative expenses will increase in the future as we increase our headcount and expand our administrative infrastructure to support our growth and operations as a public company. We also expect to see an increase in our share-based compensation expense with the establishment of our new equity plan in connection with this offering and related grants either in the form of restricted stock or options. During the year ended December&#160;31, 2017, the majority of our general and administrative expenses were attributable to legal costs and expenses related to our litigation with Syneron, Inc. and Candela Corporation, or Syneron-Candela. We expect general and administrative expenses to continue to decrease as a&#160;percentage of revenue primarily as, and to the extent, our revenue grows. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">52</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Financial Income, Net </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our financial income, net, consists primarily of the interest we earn on our cash, cash equivalents, deposits, marketable securities and long-term installment sales contracts with end-users, taking into consideration appropriate exchange rate adjustments. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Income Tax </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">We are subject to income taxes in Israel, the United States and numerous foreign jurisdictions. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our facilities in Israel were granted the status of&#8201; &#8220;Benefited Enterprise&#8221; that provides us with a ten-year corporate tax exemption for undistributed income, provided that we meet certain conditions, including making specified investments in property and equipment, and financing a&#160;percentage of investments with share capital. The first year in which we were exempted from Israeli corporate tax was 2012 with the ten-year eligibility period of tax exemption expected to terminate in 2021. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Results of Operations </div>
        <table style="width:456pt;height:252pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:285.38pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">Years ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:285.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:285.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">($) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">(%) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">($) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">(%) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:285.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">(in thousands)</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">(in thousands)</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:285.38pt;text-align:left;">
              <div style="white-space:nowrap;">Revenues </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">53,456</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">23,082</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:285.38pt;text-align:left;">
              <div style="white-space:nowrap;">Cost of revenues </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">9,053</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">5,653</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">24</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:285.38pt;text-align:left;">
              <div style="white-space:nowrap;">Gross profit </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">44,403</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">83</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">17,429</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">76</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:285.38pt;text-align:left;">Operating expenses:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:285.38pt;text-align:left;">
              <div style="margin-left:20pt;">Research and development </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,575</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,456</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:285.38pt;text-align:left;">
              <div style="margin-left:20pt;">Sales and marketing </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">28,514</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">53</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11,254</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">49</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:285.38pt;text-align:left;">
              <div style="margin-left:20pt;">General and administrative </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">4,364</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">3,050</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:285.38pt;text-align:left;">
              <div style="white-space:nowrap;">Total operating expenses </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">35,453</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">66</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">16,760</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">73</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:285.38pt;text-align:left;">
              <div style="white-space:nowrap;">Income from operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,950</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">669</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:285.38pt;text-align:left;">
              <div style="white-space:nowrap;">Financial income, net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">849</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">0</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:285.38pt;text-align:left;">
              <div style="white-space:nowrap;">Income before taxes </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">9,799</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">673</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:285.38pt;text-align:left;">
              <div style="white-space:nowrap;">Income tax </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">980</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">337</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:285.38pt;text-align:left;">
              <div style="white-space:nowrap;">Net income </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">8,819</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:11.25pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">336</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:11.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:22pt; width:456pt; line-height:11pt;font-weight:bold;">Year Ended December&#160;31, 2017 Compared to Year Ended December&#160;31, 2016 </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Revenue.</font>&nbsp;&nbsp;&nbsp;Our revenues increased by approximately $30.4&#160;million, or 132%, to approximately $53.5&#160;million for the year ended December&#160;31, 2017, compared to approximately $23.1&#160;million for the year ended December&#160;31, 2016. This increase was primarily attributable to increased patient and physician awareness of our technologies and product offerings, the expansion of our direct sales organization, an increase in our average selling prices in North America, as well as penetration in the women&#8217;s health category with the commercial launch of our <font style="font-style:italic;">Votiva</font> platform during the third quarter of 2017. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our revenues in North America increased by approximately $26.4&#160;million, or 146%, to approximately $44.6&#160;million for the year ended December&#160;31, 2017, compared to approximately $18.2&#160;million for the year ended December&#160;31, 2016. The increase was primarily attributable to the expansion of our direct sales organization, which increased sales in North America, and the commercial launch of our <font style="font-style:italic;">Votiva</font> platform during the third quarter of 2017. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our revenues in Europe increased by approximately $1.3&#160;million, or 40%, to approximately $4.6&#160;million for the year ended December&#160;31, 2017, compared to approximately $3.3&#160;million for the year ended December&#160;31, 2016. The increase was primarily driven by the establishment of a direct sales team in the United Kingdom and Spain, which increased sales in those regions. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">53</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Our revenues from the sale of consumables and extended warranties for the year ended December&#160;31, 2017 increased by approximately 115% compared to the year ended December&#160;31, 2016. This increase was primarily attributable to the growth in our installed platform base, as well as patients and physicians becoming more familiar with our products. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Cost of Revenues.</font>&nbsp;&nbsp;&nbsp;Our cost of revenues increased by approximately $3.4&#160;million, or 60%, to approximately $9.1&#160;million for the year ended December&#160;31, 2017, compared to approximately $5.7&#160;million for the year ended December&#160;31, 2016. This increase was primarily due to increased costs to purchase manufactured products to support the higher sales volume. Our gross margin increased to approximately 83% for the year ended December&#160;31, 2017, compared to approximately 76% for the year ended December&#160;31, 2016, primarily due to the increase in our average selling prices in North America, as well as a higher&#160;percentage of revenue derived from North America as compared to other regions. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Operating Expenses.</font>&nbsp;&nbsp;&nbsp;Our total operating expenses increased by approximately $18.7&#160;million, or 112%, to approximately $35.5&#160;million for the year ended December&#160;31, 2017, compared to approximately $16.8&#160;million for the year ended December&#160;31, 2016. This increase was primarily attributable to an approximately $17.3&#160;million increase in sales and marketing expenses. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">Research and Development Expenses.</font>&nbsp;&nbsp;&nbsp;Our research and development expenses were relatively flat, increasing by approximately $0.1&#160;million, or 5%, to approximately $2.6&#160;million for the year ended December&#160;31, 2017, compared to approximately $2.5&#160;million for the year ended December&#160;31, 2016. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">Sales and Marketing Expenses.</font>&nbsp;&nbsp;&nbsp;Our sales and marketing expenses increased by approximately $17.3&#160;million, or 153%, to approximately $28.5&#160;million for the year ended December&#160;31, 2017, compared to approximately $11.3&#160;million for the year ended December&#160;31, 2016. This increase was primarily attributable to the expansion of our direct sales organization and an increase in variable compensation in North America. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">General and Administrative Expenses.</font>&nbsp;&nbsp;&nbsp;Our general and administrative expenses increased by approximately $1.3&#160;million, or 43%, to approximately $4.4&#160;million for the year ended December&#160;31, 2017, compared to approximately $3.1&#160;million for the year ended December&#160;31, 2016. This increase was primarily attributable to increase in legal costs and expenses related to our litigation with Syneron-Candela. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Financial Income, Net.</font>&nbsp;&nbsp;&nbsp;Our financial income, net was approximately $0.8&#160;million for the year ended December&#160;31, 2017, compared to approximately $0.0 for the year ended December&#160;31, 2016. This increase in financial income, net was primarily attributable to an increase in interest earned on our long-term installment sales contracts with customers in North America and gain on foreign currency translation in the year ended December&#160;31, 2017, as compared to a loss on foreign currency translation in the year ended December&#160;31, 2016. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Income Tax.</font>&nbsp;&nbsp;&nbsp;Our income taxes increased by approximately $0.6&#160;million, or 191%, to approximately $1.0&#160;million for the year ended December&#160;31, 2017, compared to approximately $0.3&#160;million for the year ended December&#160;31, 2016. As a &#8220;Benefited Enterprise&#8221; in Israel, we are exempt from taxes on any income derived from our &#8220;Benefited Enterprise&#8221; through 2021 and we pay taxes only on income from other sources. In 2017, the tax benefit derived from our &#8220;Benefited Enterprise&#8221; status was approximately $2.3&#160;million, which represents approximately 23% of our income before taxes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Seasonality </div>
        <div style="text-indent:20pt; margin-top:5.8pt; width:456pt; line-height:12pt;">Our business is not significantly impacted by seasonality; however, our fourth quarter has historically generated slightly stronger operating results. We have historically experienced stronger sales in the fourth quarter in correlation with our customer&#8217;s spending patterns and budget cycles. Most physicians operate on an annual budget cycle with a fiscal year that begins on January&#160;1. It is not uncommon to experience a higher level of purchasing activity from physicians in the final&#160;months and weeks of their fiscal year. Consequently, our fourth quarter revenues may be greater than other quarters. Our business is also impacted by general economic conditions, which may impact future seasonal variations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Liquidity and Capital Resources </div>
        <div style="text-indent:20pt; margin-top:5.8pt; width:456pt; line-height:12pt;">Historically, we have funded our operations primarily from cash flows from operations and from private placements of our ordinary shares. Since our inception in January&#160;2008, we have not received any </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">54</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">debt financing from banks or issued any preferred or debt securities. We have received aggregate net proceeds of approximately $4.8&#160;million from issuances of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2017, we had working capital of approximately $23.7&#160;million, and our primary source of liquidity was approximately $25.0&#160;million in cash, cash equivalents and marketable securities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We anticipate that the proceeds of this offering and cash flows from operations will be adequate to fund our expected capital expenditures and other cash requirements and commitments through at least the next 12&#160;months. If existing cash and cash generated from operations are insufficient to satisfy our liquidity requirements, we may seek to sell additional equity or debt securities or obtain a credit facility. If we raise additional funds by issuing equity securities, our shareholders would experience dilution. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our shareholders. Additional financing may not be available at all, or in amounts or on terms unacceptable to us. If we are unable to obtain additional financing, we may be required to delay the development, commercialization and marketing of our aesthetic medical products. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Cash Flows </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The following table represents a summary of our cash flow for the periods indicated:</div>
        <table style="width:416pt;height:135pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Years ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.583pt 0pt 2.167pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;"></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">2017 <br >($) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">2016 <br >($) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">(in thousands) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.75pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">Net cash provided by (used in):</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Operating activities</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">14,609</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,996</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Investing activities</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(5,684<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(426<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Financing activities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,785</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">53</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Effects of exchange rate changes on cash </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">187</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">125</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Net increase in cash and cash equivalents </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,897</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,748</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18.98pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Net Cash Provided by Operating Activities </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Net cash provided by operating activities increased by approximately $11.6&#160;million, or 388%, to approximately $14.6&#160;million for the year ended December&#160;31, 2017, compared to approximately $3.0&#160;million for the year ended December&#160;31, 2016. This increase was primarily attributable to an increase in our net income. As we expect our revenues to continue to grow, we anticipate our accounts receivables and inventory will similarly continue to grow, including our available working capital. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Net Cash Used in Investing Activities </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Net cash used in investing activities increased by approximately $5.3&#160;million, or 1,234%, to approximately $5.7&#160;million for the year ended December&#160;31, 2017, compared to approximately $0.4&#160;million for the year ended December&#160;31, 2016. This increase was primarily attributable to purchases of marketable securities, which increased from approximately $1.6&#160;million as of December&#160;31, 2016 to approximately $7.5&#160;million as of December&#160;31, 2017. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Net Cash Provided by Financing Activities </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Net cash provided by financing activities was approximately $1.8&#160;million for the year ended December&#160;31, 2017, and approximately $0.1&#160;million for the year ended December&#160;31, 2016. This increase was primarily attributable to funding from a non-controlling partner in our Chinese joint venture.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">55</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Contractual Obligations and Commitments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table summarizes our contractual obligations and commitments as of December&#160;31, 2017: </div>
        <table style="width:456pt;height:59pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:144pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">Payments Due by Period </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:144pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Less than <br >1 year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">1&#8201;&#8211;&#8201;3&#160;years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">3&#8201;&#8211;&#8201;5&#160;years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">More than <br >5&#160;years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="31">
              <div style="white-space:nowrap; text-align:center;">($) (in thousands) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;text-align:left;">
              <div style="white-space:nowrap;">Operating lease </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,035</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">341</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">375</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">319</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:20pt; width:456pt; line-height:11pt;font-weight:bold;">Quantitative and Qualitative Disclosure of Market Risks </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Foreign Currency Risk </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our consolidated revenues are generated primarily in U.S. dollars. In addition, a substantial portion of our consolidated costs are incurred in dollars. We believe that the U.S. dollar is the primary currency of the economic environment we operate in. Thus, the U.S. dollar is our functional and reporting currency. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the consolidated statements of income (indicated below), the following exchange rates are used: (i)&#160;for transactions, exchange rates at transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization), historical exchange rates. Currency translation gains and losses are presented in financial income or expenses, as appropriate. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A significant portion of our operations is conducted through operations in countries other than the United States and Israel. Revenues from our global operations that were recorded in U.S. dollars represented approximately 85% of our total revenues for the year ended December&#160;31, 2017. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The functional currencies of our subsidiaries in Canada, China, the United Kingdom, Spain and Japan (the &#8220;Foreign Subsidiaries&#8221;) are their respective local currencies. For purposes of consolidation, the financial statements of the Foreign Subsidiaries are translated into U.S. dollars in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 830, &#8220;Foreign Currency Matters&#8221; (&#8220;ASC 830&#8221;). Assets and liabilities are translated at period-end exchange rates, while revenues and expenses are translated at exchange rates for each transaction. All gains and losses resulting from translation are presented in other comprehensive income within the consolidated statements of comprehensive income. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Interest Rate Risk </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The primary objective of our investment activities is to preserve principal while maximizing the interest income we receive from our investments, without increasing risk. Currently, we do not have any outstanding borrowings. We intend to invest our cash balances primarily in bank deposits and fixed-income securities issued by corporations, the United States and non-U.S. governments. We are exposed to market risks resulting from changes in interest rates relating primarily to our financial investments in cash, cash equivalents, deposits and marketable securities. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in the future as a result of changes in the financial markets; however, we believe any such potential loss would be immaterial to us. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Off Balance Sheet Arrangements </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">As of December&#160;31, 2017, we have not engaged in any off balance sheet arrangements. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Related Parties </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For a description of our related party transactions, see &#8220;Certain Relationships and Related Party Transactions.&#8221; </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">56</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Critical Accounting Policies and Estimates </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our discussion and analysis of our financial condition and results of our operations is based upon our audited consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of our consolidated financial statements requires us to make estimates and judgments that affect the reported amount of assets, liabilities, sales and expenses and related disclosure of contingent assets and liabilities. On a periodic basis, we evaluate our estimates, including those related to revenue recognition, warranty provision, income taxes and share-based compensation. We base our estimates on historical experience, authoritative pronouncements and various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following are our critical accounting policies and the significant judgments and estimates affecting the application of those policies in our consolidated financial statements. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Revenue Recognition </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We recognize revenue in accordance with Accounting Standards Update No. 2014-09 (&#8220;ASC 606&#8221;) &#8220;Revenue from Contracts with Customers,&#8221; when our customers obtain control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements within the scope of ASC 606, we perform the following five steps: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">i.<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">identify the contract(s) with a customer; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">ii.<br ></div>
        <div style=" float:left; margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">identify the performance obligations in the contract&#8201;&#8212;&#8201;we determined that our arrangements are generally comprised of the following elements that are recognized as separate performance obligations: products, consumables and extended warranties. Installation and training services are not essential to the functionality of our products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">iii.<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">determine the transaction price; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">iv.<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">allocate the transaction price to the performance obligations in the contract&#8201;&#8212;&#8201;we estimated the standalone selling prices of the services to be provided based on expected pricing of service contract purchased on a standalone basis and used the residual approach to estimate the selling price of the products; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">v.<br ></div>
        <div style=" float:left; margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">recognize revenue when (or as) the performance obligation is satisfied. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We apply the five-step model to contracts only when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to our customer, after considering any price concession expected to be provided to the customer, when applicable. At contract inception, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We early adopted ASC 606 using the full retrospective transition method. Under this method, we have revised our consolidated financial statements for the year ended December&#160;31, 2016, as if ASC 606 had been effective for that period. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Revenue from product sales to end users in North America can also include a financing component. From time to time, we may decide to enter into installment sales contracts with certain end users that provide them with long-term (generally up to 60&#160;months) financing of the purchase of our product. The interest rate used in these contracts reflects the credit characteristics of the party receiving financing in the contract, as well as any collateral or security provided by the customer. Financing income on these receivables is recognized as earned over the term of the financing. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We recognize any variable consideration at the time that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration mainly includes price concessions related to installment sales contracts. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">57</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We also generate revenues from long-term maintenance contracts, or Extended Warranties. Revenue from Extended Warranties is recognized ratably, on a straight-line basis, over the period of the applicable service contract. Contract liabilities are derived from these maintenance agreements. Revenue from repairs performed in the absence of Extended Warranties is recognized when the related services are performed and it is probable that we will collect the consideration we are entitled to. We classify the portion of contract liabilities not expected to be earned in the subsequent 12&#160;months as long-term. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">We do not grant any right of return, refund, cancelation or termination. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Income Taxes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We account for income taxes in accordance with ASC&#160;740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;), using the liability method whereby deferred tax assets and liability account balances are determined based on the differences between financial reporting and the tax basis for assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We provide a valuation allowance, if necessary, to reduce deferred tax assets to the amounts that are more likely-than-not to be realized. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">ASC 740 also contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. We accrue interest and penalties related to unrecognized tax benefits in our income taxes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Share-Based Compensation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We account for share-based compensation in accordance with ASC 718 which requires that all share-based payments to employees and non-employees be recognized in our consolidated statements of income based on their fair values. The grant date fair value of share-based compensation is recognized as an expense over the requisite service period, net of estimated forfeitures. We recognize compensation expense for awards conditioned only on continued service that have a graded vesting schedule using the accelerated method based on the multiple-option award approach, and classify these amounts in our consolidated statements of income based on the department to which the related employee and non-employee reports. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Option Valuations </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We selected the binomial option-pricing model to determine the fair value of each option grant to our employees and non-employees. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The binomial model includes assumptions regarding dividend yields, expected volatility, and risk-free interest rates, early exercise multiple and expected lives. These assumptions reflect our best estimates, but these items involve inherent uncertainties based on market conditions that are generally outside of our control. As a result, if other assumptions had been used in the current period, share-based compensation expense could have been materially impacted. Furthermore, if management uses different assumptions in future periods, share-based compensation expense could be materially impacted in future&#160;years. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Expected dividend yield</font>:&nbsp;&nbsp;&nbsp; We have never declared or paid any cash dividends and we do not plan to pay cash dividends in the foreseeable future. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;font-style:italic;">Volatility:<font style="font-style:normal;">&nbsp;&nbsp;&nbsp;The expected volatility is based on the historical volatility of comparable companies. </font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Risk-free interest rate:</font>&nbsp;&nbsp;&nbsp;The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the options granted in dollar terms. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Early exercise multiple:</font>&nbsp;&nbsp;&nbsp;Since our ordinary shares are not publicly traded, the early exercise multiple was based on academic empirical findings. The early exercise multiple of grantees in private companies is expected to be higher due to the lack of marketability that leads to a longer exercise period for options. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">58</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">The underlying data used for computing the fair value of the options are as follows: </div>
        <table style="width:416pt;height:97pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:267.43pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">For the Years Ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:267.43pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:62.28pt;">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:62.28pt;">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:267.43pt;text-align:left;">
              <div style="white-space:nowrap;">Dividend yield </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:center;">0% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:center;">0% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:267.43pt;text-align:left;">
              <div style="white-space:nowrap;">Expected volatility </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:center;">39%&#8201;&#8211;&#8201;50% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:center;">41%&#8201;&#8211;&#8201;51% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:267.43pt;text-align:left;">
              <div style="white-space:nowrap;">Risk-free interest rate </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:center;">0.82%&#8201;&#8211;&#8201;2.26% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:center;">0.53%&#8201;&#8211;&#8201;1.67% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:267.43pt;text-align:left;">
              <div style="white-space:nowrap;">Early exercise multiple </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:center;">150%&#8201;&#8211;&#8201;250% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:center;">150%&#8201;&#8211;&#8201;250% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:267.43pt;text-align:left;">
              <div style="white-space:nowrap;">Contractual term </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:center;">7&#160;years </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:center;">7&#160;years</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:16.98pt; width:456pt; line-height:12pt;">These assumptions represent our best estimates and involve inherent uncertainties and the application of our judgment. As a result, if we use significantly different assumptions or estimates, our share-based compensation expense could be materially different. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table shows information concerning options granted to employees and non-employees during the&#160;years ended December&#160;31, 2017 and 2016: </div>
        <table style="width:456pt;height:146.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">Grant Date </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Number of <br >Options <br >Granted </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Exercise <br >Price </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Fair Value <br >per Share </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Intrinsic <br >Value per <br >Share </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">May&#160;3, 2016 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">562,100</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.00</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.78</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.31</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">May&#160;29, 2016 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,333</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.00</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.78</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.29</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">August&#160;29, 2016 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">55,000</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.00</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.78</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.28</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">January&#160;9, 2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">11,500</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.00</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.80</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.28</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">February&#160;16, 2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,309,750</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.00</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.86</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.37</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">June&#160;1, 2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,452,550</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.00</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.04</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.47</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">November&#160;1, 2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">12,000</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.00</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.58</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.58</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">December&#160;31, 2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">20,000</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.00</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">7.35</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.39</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:22.98pt; width:456pt; line-height:11pt;font-style:italic;">Ordinary Share Valuation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In preparation for our initial public offering in July&#160;2018, with the assistance of a third-party valuation firm, we performed retrospective valuations of our ordinary shares as of December&#160;31, 2016, May&#160;31, 2017 and March&#160;31, 2018, which determined that their fair values were $0.78, $1.04 and $9.90 per ordinary share, respectively. For the purpose of determining our equity value, we used the discounted cash flow, or DCF, method. Under the DCF method, our projected after-tax cash flows available to return to holders of invested capital were discounted back to present value, using an appropriate discount rate. Since it is not possible to project our after-tax cash flows beyond a limited number of&#160;years, the DCF method relies on determining a &#8220;terminal value&#8221; representing the aggregate value of the future after-tax cash flows after the end of the period for which annual projections are possible. The discount rate, known as the weighted average cost of capital, or WACC, accounts for the time value of money and the appropriate degree of risk inherent in a business. The DCF method requires significant assumptions, in particular, regarding our projected cash flows and the discount rate applicable to our business. For the purpose of the abovementioned valuations we applied discount rates in the range of 11.0%-16.5%, and projected after-tax cash flows based on the possible scenarios in regards to our prospective as a result of the realization of the legal proceedings against us at each valuation date. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Having determined our equity value, we allocated it among the different elements of our share capital using the option pricing method, or OPM. Under the OPM, each security&#8201;&#8212;&#8201;ordinary shares and options&#8201;&#8212;&#8201;is treated as a call option having an exercise price based on the amount and optimal conversion price. The value of the call option is determined using the Black-Scholes option pricing model. The Black-Scholes model requires significant assumptions and in particular the assumptions regarding the volatility of our ordinary shares.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">59</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Accounts Receivable and Allowance for Doubtful Accounts </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our accounts receivable balance, net of allowance for doubtful accounts, was approximately $5.8&#160;million as of December&#160;31, 2017, compared to approximately $2.9&#160;million as of December&#160;31, 2016. The allowance for doubtful accounts as of December&#160;31, 2017 was approximately $0.4&#160;million compared to approximately $0.2&#160;million as of December&#160;31, 2016. We maintain an allowance, or reserve, for doubtful accounts based upon known collectability issues. While our credit losses have historically been within our expectations and the allowances established, we may not continue to experience the same credit losses that we have in the past, which could cause our provisions for doubtful accounts to increase. We work to mitigate bad debt exposure through our credit evaluation policies and geographical dispersion of sales. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Inventories Valuation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We state all inventories at the lower of cost or net realizable value. We determine our finished products using a &#8220;moving average&#8221; method and we determine our raw materials using a &#8220;first in, first out&#8221; method. Our inventory balance was approximately $5.0&#160;million as of December&#160;31, 2017, compared to approximately $2.8&#160;million as of December&#160;31, 2016. We review the need for inventory allowances when conditions indicate that the selling price could be less than cost due to physical deterioration, usage, obsolescence, reductions in estimated future demand and reductions in selling prices. We balance the need to maintain strategic inventory levels with the risk of obsolescence due to changing technology and customer demand levels. Unfavorable changes in market conditions may result in a need for inventory reserves that could adversely impact our gross margins. Conversely, favorable changes in demand could result in higher gross margins when we sell products. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Product Warranty and Service Costs </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We generally provide, as a standard, a one-year parts delivery and labor warranty on end-user sales of our aesthetic treatment systems. Distributors generally provide a one-year manufacturing warranty on parts only. We estimate and provide for future costs for initial product warranties at the time revenue is recognized. We base product warranty costs on related material costs, delivery cost, technical support labor costs and overhead. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We provide for the estimated cost of product warranties by considering historical material, delivery, labor and overhead expenses and applying the experience rates to the outstanding warranty period for products sold. As we sell new products to our customers, we exercise considerable judgment in estimating the expected failure rates and warranty costs. If actual product failure rates, material usage, service delivery costs or overhead costs differ from our estimates, we would be required to revise our estimated warranty liability. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Recent Accounting Pronouncements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are currently evaluating the impact of the U.S. GAAP standards as issued by the Financial Accounting Standards Board that are effective for the first time for the financial year beginning on or after January&#160;1, 2018 on our consolidated financial statements. See Note 2(u) to our consolidated financial statements included elsewhere in this prospectus. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">JOBS Act </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On April&#160;5, 2012, the JOBS Act was signed into law. Section&#160;107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This means that an &#8220;emerging growth company&#8221; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to utilize this exemption and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. In addition, as a result of this election, our future financial statements may not be comparable to those of public companies that are not emerging growth companies and are required to comply with public company effective dates for new or revised accounting standards. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">60</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t11BU">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">BUSINESS </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Overview </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are a leading global provider of innovative, energy-based, minimally and non-invasive aesthetic solutions. We have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. We believe our RF energy-based proprietary technologies, RFAL and Deep Subdermal Fractional RF, represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including liposuction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Our RFAL and Deep Subdermal Fractional RF-based products overcome many of the shortcomings of current solutions in the market by delivering surgical-grade results while significantly minimizing risks of scarring, downtime, pain and other complications typically accompanying surgical procedures. In addition to our minimally-invasive technologies, we design, develop, manufacture and market differentiated, non-invasive medical aesthetic products that target a wide array of procedures. These include simultaneous fat killing and skin tightening, permanent hair reduction through the use of our innovative dual wavelength technology and other treatments targeting skin appearance and texture through the use of our high power IPL technology. Our products, which we market and sell traditionally to plastic and facial surgeons, aesthetic surgeons, dermatologists and aesthetic OB/GYNs, may be used on a variety of body parts including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition to the existing group of patients who undergo full surgical aesthetic procedures, we believe our minimally-invasive technology has the potential to satisfy an unmet market demand in two incremental groups of patients: (i)&#160;those whose skin laxity or other physical attributes have previously precluded them from undergoing surgical aesthetic procedures and (ii) those who would entertain the idea of surgical or minimally-invasive aesthetic procedures, but are averse to the associated costs, downtime and potential safety risks. We believe these potential patient populations represent a significant opportunity for our differentiated minimally-invasive aesthetic solutions. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe our products have consistently been at the forefront of technological development in the aesthetic solutions market. Since 2010, we have launched five product platforms: <font style="font-style:italic;">BodyTite</font>, <font style="font-style:italic;">Optimas</font>, <font style="font-style:italic;">Votiva</font>, <font style="font-style:italic;">Contoura</font> and <font style="font-style:italic;">Triton</font>. Each product consists of a platform that incorporates multiple energy sources, one or more handpieces, our proprietary software and a simple user interface with touch screen. Our platforms have a small footprint and are lightweight compared to our competitors&#8217; systems, which are typically larger and heavier. Our products can be upgraded easily by the user in order to perform additional treatments by adding handpieces and/or installing software in the existing platform. The ease of upgrades enables our customers to meet demand for aesthetic solutions through additional service offerings. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our focus on innovation and product development has resulted in a strong track record of new and next-generation pipeline products and applications targeted to our traditional customer base. We expect to launch three new product platforms by the end of 2019. In addition, we intend to expand the medical communities that we serve beyond our traditional customer base to include non-traditional customers, such as general practitioners, ophthalmologists, ENTs and aesthetic clinicians, by adapting our products to the expertise and skill level of these providers. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are focused on establishing and using clinical evidence to support and broaden our marketing claims and drive customer awareness and acceptance of our products. Traditionally, the aesthetic solutions market has relied heavily on marketing efforts and &#8220;before-and-after&#8221; pictures in an to attempt to distinguish products. We believe our focus on establishing clinical evidence for the efficacy of our products has been important for adoption by our surgically-trained customers, who are accustomed to seeing extensive clinical data in their non-aesthetic practices. To date, 54 third-party clinical studies have been, or are in the process of being conducted using our products, and we have a portfolio of 36 peer-reviewed publications. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">61</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">To complement our aesthetic treatment solutions, we offer post-sales training and support services. We provide physicians with training focused on the most beneficial ways to utilize our products, including safety and instructional videos to expand procedural offerings and hands-on, personalized marketing support. We believe that we provide one of the most extensive training and ongoing support programs available to physicians throughout the aesthetic solutions market.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our revenues increased to approximately $53.5&#160;million for the year ended December&#160;31, 2017 from approximately $23.1&#160;million for the year ended December&#160;31, 2016. For the year ended December&#160;31, 2017, we recorded a gross margin of approximately 83% and net income of approximately $8.8&#160;million.    We have 16 FDA clearances and in addition to the United States, are permitted to sell our products in Europe, Australia, Brazil, Canada, China, Colombia, Israel, Japan, Mexico, Russia, South Korea, Taiwan and Thailand. We currently sell and market our products in the United States, Canada, Spain and the United Kingdom, through a direct sales force of approximately 75 representatives. We also sell and market our products through 29 distributors in 37 countries. As of December&#160;31, 2017, we had an installed base of over 2,225 product platforms (capable of running various multi-use applicators and minimally-invasive consumables), 6,900 multi-use treatment applicators (laser, IPL and RF) and 139,000 minimally-invasive consumable handpieces.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Industry </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Aesthetic Solutions Market Opportunity </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The global market for aesthetic solutions is significant and growing. ASAPS estimates that U.S. consumers spent more than $8.5&#160;billion on a total of 7.8&#160;million aesthetic procedures in 2017, of which $6.6&#160;billion was spent on surgical aesthetic procedures. According to ASAPS, in 2017 total aesthetic procedures in the United States grew 6%, with surgical aesthetic procedure growth of 11% and non-surgical aesthetic procedure growth of 4%. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">According to the 2016 ISAPS Global Aesthetic Survey, which includes survey results from 35,000 plastic surgeons in the top 30 countries for aesthetic procedures, approximately 23.6&#160;million total aesthetic procedures, including 10.4&#160;million surgical procedures and 13.2&#160;million non-surgical procedures, were performed in 2016. Of these total procedures, approximately 18%, or 4.2&#160;million, were performed in the United States. According to ISAPS, the top five surgical and minimally-invasive procedure categories in 2016, by number of procedures, that we provide innovative aesthetic solutions for were liposuction (1.5&#160;million), abdominoplasty (0.8&#160;million), face and neck lifts (0.7&#160;million), feminine rejuvenation (0.2&#160;million) and arm lifts (0.1&#160;million). The top five non-invasive procedure categories in 2016 that we provide innovative aesthetic solutions for were facial rejuvenation (2.5&#160;million), hair removal (1.1&#160;million), non-invasive fat reduction (0.4&#160;million), cellulite treatment (0.2&#160;million) and vascular lesions/sclerotherapy (0.1&#160;million). No one treatment procedure is offered by all physicians and treatments vary in terms of the treatment goal and desired effect. As a result, the total aesthetic market, as reported by ASAPS and ISAPS, does not necessarily represent the market potential for us or any other single product or treatment, but illustrates that each year patients elect to have millions of procedures performed to enhance their appearance. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">We believe the following factors are contributing to the growth in aesthetic procedures: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the aging of the population in the western world; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the growing global obesity epidemic; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the increasing desire of many individuals to improve their appearance; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the reduction in procedure costs, which has attracted a broader consumer base; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the impact of managed care and reimbursement on physician economics, which has motivated physicians to establish or expand the menu of elective, private-pay aesthetic procedures that they offer. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">62</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Within the global aesthetics market, our products and solutions are primarily designed to address three energy-based treatment categories comprised of: (i) face and body contouring; (ii) medical aesthetics; and (iii) women&#8217;s health. Within each of these treatment categories, we believe our products provide a differentiated solution that overcomes many of the limitations of other existing treatment options. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Face and Body Contouring Market </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The most common face and body contouring treatments typically involve excess fat removal, or liposuction and the correction and reduction of skin laxity, or skin tightening. Within those treatment types, various surgical, minimally-invasive or non-invasive energy-based techniques exist, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Liposuction.</font> The existing surgical and minimally-invasive techniques for fat reduction include surgical liposuction and laser lipolysis, while non-invasive techniques include cryolipolysis, ultrasound lipolysis and other energy-based systems. To date, surgical liposuction remains the most commonly performed plastic surgery procedure in the United States. According to ASAPS, 304,850 liposuction procedures were performed in the United States in 2017, compared to 180,833 non-surgical fat reduction procedures during the same period. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Skin Tightening.</font> The existing surgical techniques for the correction and reduction of skin laxity include facelifts, breast lifts, lower body lifts, arm lifts and tummy tucks, while minimally and non-invasive techniques include radio frequency, ultrasound and other energy-based systems. According to ASAPS, surgical techniques like breast lifts and tummy tucks were among the top five surgical procedures performed in the United States in 2017. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">According to Medical Insight, Inc., the global market for all body shaping and skin tightening device platforms and consumables is expected to reach $1.4&#160;billion in 2018. Through 2022, the overall market is expected to expand by 14% per year, reaching $2.3&#160;billion in 2022. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Medical Aesthetic Market </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Common medical aesthetic treatments include hair reduction, skin rejuvenation and resurfacing, and vascular and pigmented lesion removal. These treatments are predominantly performed in a minimally and non-invasive fashion, using intense pulses of a highly-focused laser or other optical energy to selectively target hair follicles, veins or collagen in the dermis, as well as cells responsible for pigmentation in the epidermis. The most common medical aesthetic treatments, in addition to face and body contouring, include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Permanent Hair Reduction</font>. Non-invasive hair reduction procedures utilizing laser, IPL or other optical energy. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Skin Rejuvenation. </font>A range of non-invasive and ablative procedures that stimulate production of new collagen in the skin to repair wrinkles and other surface imperfections. Surgical treatments using ablative techniques have largely been supplanted by non-invasive and, particularly, fractional techniques. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Acne Reduction. </font>Minimally and non-invasive procedures that target bacteria and cessation of oil production, primarily using light energy-based devices and fractional techniques. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Vascular and Pigmented Lesion Removal. </font>Non-invasive procedures typically performed using laser and IPL energy-based devices to penetrate below the surface of the skin in order to remove vascular and pigmented lesions. Energy-based treatments have displaced alternative surgical techniques, such as sclerotherapy, as they achieve comparable results in a non-invasive manner. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">According to Medical Insight, Inc., the global market for platforms and consumables in the non-invasive medical aesthetic market is expected to reach $1.8&#160;billion in 2018. Through 2022, the overall market is expected to expand by 6% per year, reaching $2.3&#160;billion in 2022. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">63</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;">Women&#8217;s Health Market </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As average life expectancy continues to increase and awareness of women&#8217;s health issues continues to grow, women are more frequently looking for solutions to address vaginal atrophy, vaginal relaxation syndrome, stress urinary incontinence, or SUI, and sexual dysfunction. With over 800&#160;million women between the ages of 50 and 80 worldwide, women&#8217;s health represents a large and growing market. Several popular surgical, minimally-invasive or non-invasive energy-based techniques exist, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Vaginoplasty. </font>A surgical procedure that involves the removal of excess lining within the vagina, and the suturing of the underlying muscles together to reduce the size of the vagina. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Vagina/Labial Remodeling. </font>A minimally-invasive procedure that tightens female genitalia tissue by heating targeted connective tissue with thermal energy, while cooling the mucosal epithelial surface over the targeted tissue. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">CO</font><font style=" position:relative; bottom:-2.25pt;font-style:italic;font-size:7.5pt;">2</font><font style="font-style:italic;"> Laser Therapy. </font>A non-invasive procedure that generates microscopic laser &#8220;spots&#8221; where thermal energy is absorbed by the sub-epithelial layers, rejuvenating the tissue. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Mono and Bipolar Radio Frequency. </font>A precise, non-invasive procedure that provides full depth heating in the subdermal tissue layers, improving elastin and remodeling collagen. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Ultrasound Therapy. </font>A non-invasive procedure that involves sending thermal energy waves into the vaginal tissue, inducing tissue healing and tightening. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">According to Medical Insight, Inc., the global market for women&#8217;s health platforms and consumables is expected to reach $225&#160;million in 2018. Through 2022, the overall market is expected to expand by 16% per year, reaching $413&#160;million in 2022. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Physician and Patient Market Opportunity </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Aesthetic treatment procedures have traditionally been performed by plastic and facial surgeons, aesthetic surgeons, dermatologists and aesthetic OB/GYNs, of whom there are approximately 40,000 in the United States alone based on published membership numbers of professional medical organizations. These physicians represent our traditional customer base. More recently, a broader group of physicians in the United States, including general practitioners, ophthalmologists, ENTs and aesthetic clinicians, have incorporated aesthetic treatment procedures into their practices. These non-traditional customers are motivated to offer aesthetic procedures in order to generate a reliable revenue stream that is unaffected by managed care and government payor reimbursement economics. We believe that there are approximately 300,000 potential non-traditional physician customers in the United States and Canada, representing a significant market opportunity that is only beginning to be addressed by suppliers of energy-based aesthetic equipment. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition to the existing group of patients who undergo full surgical aesthetic procedures, we have identified an unmet market demand for two new additional groups of patients, referred to as the &#8220;Treatment Gap&#8221; group and the &#8220;Sideline&#8221; group. We believe these potential patient populations represent a significant opportunity for our innovative and differentiated minimally-invasive aesthetic solutions. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Treatment Gap group consists of patients, typically ranging from 35 to 55&#160;years of age, who have sufficient financial resources to afford aesthetic solutions but are limited in the types of existing procedural options available to them prior to the introduction of our RFAL and Deep Subdermal Fractional RF technologies. For example, for patients whose skin is not amenable to liposuction, such as those patients whose skin lacks an adequate degree of elastin, thereby preventing the skin from retracting, the only available alternatives to reduce skin looseness were high-cost surgeries requiring full anesthesia, such as an abdominoplasty, facelift, blepharoplasty or brachioplasty. In these procedures, the excess skin is gathered, cut and removed, typically leaving the patient with significant scars. In addition, there is a large population of patients whose skin is not of the quality needed for a liposuction procedure but also not damaged enough to be a candidate for a surgical procedure. We believe this Treatment Gap group represents a significant market opportunity for us. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">64</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">In addition to the Treatment Gap group, we believe there is also a large group of potential patients that would entertain having surgery-like results if the procedure was delivered in a painless, safe and fast manner. We believe this Sideline group has the ability to expand our current market significantly. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Current Treatment Landscape </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Many existing surgical, minimally and non-invasive procedures are available to treat the aforementioned conditions; however, each has certain limitations.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Surgical and Minimally-Invasive Procedures </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although each of these treatments has varying degrees of effectiveness, we believe they present the following limitations: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Surgical risks</font>. Surgical and minimally-invasive procedures carry risks of infection, local or widespread scarring, perforation, and hemorrhage. These procedures generally require a general or local anesthesia, which has additional risks. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Pain and downtime</font>. Surgical procedures may involve pain and require weeks of post-surgical recovery. As a result, patients may need to spend significant time away from work and take prescribed pain medications for extended periods of time post-surgery. In addition, body lifts may severely limit muscle movement in the treated area during recovery, which can limit a patient&#8217;s mobility for a significant period of time. Existing minimally-invasive procedures typically require a relatively large surgical incision, which can also cause pain and discomfort. Patients generally require at least two days of recovery time after a minimally-invasive procedure, which may require the patient to miss work and necessitate prescribed pain medications post-surgery. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Potentially undesired results</font>. Surgical procedures may cause non-uniform fat reduction, dimpling, lumpiness, numbness, scarring, discoloration, or sagging skin in the treated area. Follow-up surgeries may be required to correct these problems. Existing minimally-invasive procedures can cause skin or tissue damage if, among other things, the physician does not carefully control the intensity of energy delivered in the treatment area. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">High cost</font>. Surgical and existing minimally-invasive procedures are significantly more expensive for patients than non-invasive aesthetic procedures. In addition, there is an opportunity cost for physicians as these procedures require direct physician involvement and supervision. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Limited repeatability</font>. The process of removing or destroying fat cells with surgical or existing minimally-invasive procedures triggers the body&#8217;s wound healing response, which leads to the formation of scar tissue in the treated area. If a patient desires further fat reduction or is not satisfied with the aesthetic results from a procedure, the scar tissue in the treated area may prevent the patient from undergoing follow-up procedures to enhance or correct the original treatment results. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Physician skill and technique dependent</font>. The aesthetic results achieved through surgical and existing minimally-invasive procedures often depend upon a particular physician&#8217;s skill and training. In addition, these procedures require significant physician time. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Non-Invasive Procedure Limitations </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although current non-invasive procedures are generally safer and less expensive than surgical and minimally-invasive procedures, we believe these procedures have the following limitations: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Limited, inconsistent</font><font style="font-style:italic;"> and unpredictable results</font>. Existing non-invasive procedures have limited efficacy and produce inconsistent fat reduction and skin rejuvenation results. In addition, the technology used to perform these procedures is not capable of selectively targeting fat cells, blood cells, hair follicles and deeper-lying pigments, which can lead to unpredictable results, including damage to the surrounding tissue. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">65</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Multiple steps required</font>. Existing non-invasive procedures based on radio frequency or laser energy often require multiple steps over several weeks before the patient obtains noticeable aesthetic results, requiring the patient to schedule multiple, time-consuming office visits. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Maintenance or diet and exercise required</font>. Certain existing non-invasive procedures have only a temporary treatment effect, and thus require periodic maintenance treatments to sustain the desired aesthetic results. Additionally, some of these procedures require the patient to change his or her diet habits and exercise routines during the several-week treatment period. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Technique dependent</font>. Existing non-invasive procedures often require highly trained personnel to conduct the treatment. Poor technique may lead to reduced efficacy and inconsistent aesthetic results. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Prior to the introduction of our products, we believed that the market was poised to accept new sophisticated technology that can address the shortcomings of the then-available solutions. We also believe that in selecting solutions, physicians are increasingly focusing on the economics of owning aesthetic treatment equipment, including the likelihood of increased revenues, as well as the predictability of ownership costs and are placing greater emphasis on product reliability, the quality of service provided by the manufacturer, minimization of downtime required for maintenance, the length of warranty coverage and the ongoing cost of purchasing consumables and handpieces following the initial platform purchase. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Solution </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our minimally and non-invasive energy-based aesthetic solutions are designed to overcome several of the limitations and risks typically associated with other existing surgical, minimally and non-invasive procedures as described above. Key benefits of our aesthetic solutions include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Small to no incisions, which reduces the drawbacks and risks typically associated with surgical procedures such as significant pain, local or widespread scarring, infection, perforation and hemorrhage. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Outpatient procedures that typically do not require general anesthesia, which can decrease patient downtime, discomfort and other potential complications and allows for cost-effective repeatability.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Minimally-invasive procedures with similar efficacy to surgical procedures that have the ability to expand the aesthethic solutions market.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Effective and long-lasting aesthetic solutions, many of which are supported by compelling clinical data.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Our differentiated, RF energy-based technology simultaneously kills fat and tightens skin, overcoming the many shortcomings of traditional surgical and minimally-invasive aesthetic procedures.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Typically less expensive than other aesthetic solutions on the market that provide comparable results as a result of less physician time and training required. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Leader in RF Energy </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe we are the leader in using RF energy for both minimally-invasive and subdermal ablative aesthetic purposes. RF energy is different from optical energy because it is not absorbed by the epidermis and is able to be targeted to penetrate deep into the tissue. The application of RF energy in medicine is a well established practice. For example, RF energy is the basis of magnetic resonance imaging, or MRI, and surgical diathermy, used to cauterize blood vessels to prevent excessive bleeding, both commonplace applications administered regularly in medical practice. RF energy is also used in cardiology for ablative interventions and in oncology surgery for tumor/metastasis ablation.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">RF energy can be delivered to the skin in a variety of ways, the most common being monopolar delivery, where RF energy is delivered through a single probe placed on the skin with a grounding pad distant to the probe site, or bipolar delivery, where RF energy is delivered from a probe with two electrodes placed over the treatment area. Bipolar delivery has an important advantage over monopolar delivery, in </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">66</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">that depth of penetration of the RF energy is not dependent on the tissue impedance, or electrical resistance, which varies from person to person, and the cross-sectional area of the probe as it is for monopolar delivery. Instead, depth of penetration of the RF energy in bipolar delivery depends on the distance between the two electrodes on the probe, with increasing distance resulting in increased depth of penetration. We believe we are the leader in the development, design and commercialization of bipolar RF energy devices for minimally-invasive and subdermal ablative aesthetic purposes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Radio-Frequency Assisted Lipolysis </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Using our expertise in bipolar RF energy delivery, we developed what we believe is the next generation of lipolysis and adipose tissue remodeling technology, a new category that delivers a thermal response to the adipose tissue, skin and subdermal matrix. Our RFAL products deliver directional RF energy into the subcutaneous fat to coagulate, liquefy and remodel adipose tissue and heat the subcutaneous fibrous septa, or partitions, resulting in substantial collagen contraction of subdermal space. We believe we are the first company to utilize bipolar radio frequency in a minimally-invasive manner. Our RFAL products generate a higher power and more efficient energy transfer than laser energy systems and allow the treatment of larger volumes of the subcutaneous tissue with optimal thermal profiles, facilitating the significant tightening of the tissue. The shrinkage of tissue is significant and can reach double-digit&#160;percentages of the heated tissue volume. The thermal energy is delivered by an innovative handpiece comprised of two electrodes: the internal electrode is inserted into the fat layer while the other larger electrode is applied externally to the skin surface above the cannula tip. The internal cannula is passed through the subcutaneous fat while the external electrode is moved above and over the skin&#8217;s surface. The small, conductive tip of the cannula delivers RF energy into the subcutaneous fat, liquefying it and simultaneously contracting fibrous septa. The liquefied fat can then be removed from the body through a suction cannula. Our RFAL products also apply gentle uniform heating of the dermis, thereby promoting skin tightening. Figure 1 below shows how the RF energy is delivered through the handpiece to simultaneously liquefy fat and tighten the skin. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our <font style="font-style:italic;">BodyTite</font> platform and the <font style="font-style:italic;">BodyTite</font> and <font style="font-style:italic;">FaceTite</font> handpieces rely on our proprietary RFAL technology. To date, there have been more than 50,000 successful RFAL procedures conducted with positive clinical results using our <font style="font-style:italic;">BodyTite</font> platform and the <font style="font-style:italic;">BodyTite</font> and <font style="font-style:italic;">FaceTite</font> handpieces. We have demonstrated that RFAL has the potential to elicit three-dimensional soft tissue contraction reliably and predictably to both expand the base of otherwise non-traditional liposuction candidates, as well as to improve outcomes in patients for whom liposuction is an option. Figure 2 below shows before and after patient pictures demonstrating significant fat reduction and skin tightening delivered by the <font style="font-style:italic;">BodyTite</font> platform. </div>
        <div style="position:relative;z-index:-1;margin-top:10.98pt; text-align:center; width:456pt;">
          <img src="tv498959_img1.jpg" alt="[MISSING IMAGE: tv498959_img1.jpg]" height="244" width="416" >
        </div>
        <div style="margin-left:71pt; margin-top:13.98pt; width:385pt; line-height:12pt;font-weight:bold;">Figure 1: RFAL mechanism of action.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">67</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="position:relative;z-index:-1;text-align:center; width:456pt;">
          <img src="tv498959_img2.jpg" alt="[MISSING IMAGE: tv498959_img2.jpg]" height="156" width="603" >
        </div>
        <div style="margin-top:13.98pt; width:456pt; line-height:12pt;font-weight:bold;">Figure 2: Before and after patient pictures using the <font style="font-style:italic;">BodyTite</font> platform.</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">L:<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Results one month after a single treatment using the <font style="font-style:italic;">FaceTite</font> handpiece on the neck and jawline. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">R:<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Results six&#160;months after a single treatment using the <font style="font-style:italic;">BodyTite</font> handpiece on the adominal area. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Deep Subdermal Fractional RF </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our Deep Subdermal Fractional RF delivers RF energy into the subdermal fat tissue to depths of up to four millimeters, or mm. Deep Subdermal Fractional RF provides skin tightening and adipose tissue remodeling directly under the dermal layer. Our Deep Subdermal Fractional RF products deliver RF energy under the dermis through an array of pins producing localized heat and small micro-lesion dots in the treatment area. The heat generated by the pins in the subdermal tissue promotes collagen restructuring and tissue reshaping. Physicians can offer a versatile fractional treatment creating a three-dimensional matrix of coagulation volumes inside the tissue. Deep Subdermal Fractional RF can be used for wrinkle treatment, skin tightening and even cellulite. The most common areas of treatment are the face and neck. Our <font style="font-style:italic;">Fractora</font> and <font style="font-style:italic;">FractoraV</font> handpieces rely on our proprietary Deep Subdermal Fractional RF technology and are used in conjunction with our <font style="font-style:italic;">BodyTite, Optimas</font> and <font style="font-style:italic;">Votiva</font> platforms. Figure 3 below shows how the RF energy is delivered through the coated pins on the handpiece to reshape tissue under the dermal layer. Figure 4 below shows before and after patient pictures demonstrating significant wrinkle reduction and improvement in skin pigmentation delivered by the <font style="font-style:italic;">Optimas</font> platform and <font style="font-style:italic;">Fractora</font> handpiece. </div>
        <div style="position:relative;z-index:-1;margin-top:10.99pt; text-align:center; width:456pt;">
          <img src="tv498959_img3.jpg" alt="[MISSING IMAGE: tv498959_img3.jpg]" height="313" width="370" >
        </div>
        <div style="margin-left:90pt; margin-top:19.98pt; width:366pt; line-height:11pt;font-weight:bold;">Figure 3: Deep Subdermal Fractional RF mechanism of action.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">68</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="position:relative;z-index:-1;text-align:center; width:456pt;">
          <img src="tv498959_img4.jpg" alt="[MISSING IMAGE: tv498959_img4.jpg]" height="187" width="601" >
        </div>
        <div style="margin-top:11pt; width:456pt; line-height:12pt;font-weight:bold;">Figure 4: Before and after using the <font style="font-style:italic;">Optimas</font> platform and <font style="font-style:italic;">Fractora</font> handpiece.</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">L:<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Results one month after a single treatment on the neck and jawline. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">R:<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Results four&#160;months after two treatments on the face.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Non-invasive Medical Aesthetic Technologies </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition to our proprietary minimally-invasive solutions, we continue to develop innovative non-invasive medical aesthetic solutions, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Simultaneous non-invasive fat killing and skin tightening</font>. We believe our technology is the first and only RF-based, non-invasive body contouring technology that permanently kills adipose tissue while simultaneously contracting the skin. This technology addresses problematic fatty tissue in large body areas such as the abdomen, back and thighs. Customers use this technology with the <font style="font-style:italic;">Contoura</font> platform and the <font style="font-style:italic;">BodyFX</font> and <font style="font-style:italic;">MiniFX</font> handpieces. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Dual wavelength for permanent hair reduction. </font>Our single-pulse, dual wavelength product for permanent hair reduction, <font style="font-style:italic;">Triton</font>, combines two wavelengths in one platform, which overcomes certain limitations of standard lasers. This optimal mix of wavelengths allows the highest efficiency and safety. We believe <font style="font-style:italic;">Triton</font> is the only FDA-cleared, single-pulse, dual wavelength product for permanent hair reduction. Customers use this technology with the <font style="font-style:italic;">Triton Duo Light</font> and <font style="font-style:italic;">Triton Duo Dark</font> handpieces. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">High-power Intense Pulsed Light</font>. Our high-power IPL is a breakthrough technology that delivers up to three times more energy than typical IPL devices within the 500 to 600 nanometer, or nm, range to improve efficacy for vascular and pigmented lesions. It is optimized to treat a variety of skin types and conditions in a single session. Customers use this technology with the <font style="font-style:italic;">Optimas</font> platform and the <font style="font-style:italic;">Lumecca</font> handpiece. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Controlled continuous RF heating</font>. We believe our controlled continuous RF technology is the first auto-adjusting non-invasive thermal skin treating technology for deep and uniform tissue stimulation. This technology uses bipolar RF energy delivery that allows uniformity between the electrodes to provide a comfortable thermal effect with immediate and subsequent contraction. Customers use this technology with the <font style="font-style:italic;">Optimas</font>, <font style="font-style:italic;">Votiva</font> and <font style="font-style:italic;">Contoura</font> platforms and the <font style="font-style:italic;">Forma</font>, <font style="font-style:italic;">FormaV</font> and <font style="font-style:italic;">Plus</font> handpieces. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Differentiated and Comprehensive Post-Sale Support </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">To complement our innovative aesthetic solutions, we offer post-sale training and support services. We provide physicians training focused on the most beneficial ways to utilize our products, including a disciplined focus on safety. Our clinical training and support program consists of three key components: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">i.<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">A visit by a new physician to one of our many highly qualified plastic surgery facilities for instruction followed by a live patient demonstration; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">ii.<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">A visit to the new physician&#8217;s office by a trained registered nurse or physician&#8217;s assistant to attend the first day of treatments to in-service; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">69</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">iii.<br ></div>
        <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Open house workshops organized by us, wherein the new physician invites his or her patient base and we assist him or her in &#8220;kick starting&#8221; marketing efforts. These events typically secure significant procedural revenues for the physician. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, we offer on-going livestream cases for customers where they can observe and interact in real-time with both our training staff and highly qualified physician instructors on a regular basis. Advanced training is also available for physicians who choose to expand their education on highly skilled procedures, including non-excisional breast lifting or brachioplasty. We are continuing to build a library of on-line instructional videos as both a reference tool and to expand physicians&#8217; procedural offerings. We also provide support to help customers educate and engage patients about the new minimally-invasive procedures available to them through our InPractice program. This program provides hands-on, personalized marketing support for customers&#8217; practices including signage, educational collateral, digital marketing and advertising assets. We believe that we provide one of the most extensive training and ongoing support programs available to physicians throughout the aesthetics industry. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Competitive Strengths </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We attribute the growing commercial success of our various platforms and products to the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Pioneer of the minimally-invasive aesthetic solutions market. </font>We believe our proprietary technologies represent a paradigm shift in the minimally-invasive aesthetic solutions market. We believe our technologies and products demonstrate numerous performance advantages over other aesthetic options and enable physicians and patients to obtain results that can generally only be achieved with more expensive surgical procedures. We believe our innovative minimally-invasive products overcome many of the limitations of other surgical, minimally and non-invasive procedures, positioning us to address unmet patient needs and expand the aesthetic solutions market. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Strong brand recognition. </font>Our brand has been associated with product leadership, significant technological advances and extensive clinical data, which has led to strong customer loyalty. Unlike many of our competitors, our technology is not laser-based and limited to superficial treatment of the skin. Instead, we have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. We believe our brand is synonymous throughout the physician and patient communities with having the broadest RF energy-based portfolio in the minimally-invasive aesthetics market for fat destruction and remodeling, face and body contouring and skin tightening.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Provide comprehensive solutions for physicians and patients. </font>We have an extensive product portfolio that includes solutions for a wide range of both minimally and non-invasive procedures across the aesthetic solutions market. For each of our products, we offer post-sale support services including training, installation, practice growth consulting and repair support that minimizes product downtime and associated lost revenues to physicians.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Broad regulatory approvals supported by extensive clinical data. </font>We have 16 FDA clearances and in addition to the United States, are permitted to sell in Europe, Australia, Brazil, Canada, China, Colombia, Israel, Japan, Mexico, Russia, South Korea, Taiwan and Thailand. We also have a portfolio of 36 peer-reviewed publications and approximately 54 third-party clinical studies have been, or are in the process of being, conducted using some of our products. We believe our focus on demonstrated clinical data and effectiveness differentiates us from our competition and helps to validate our technology with surgically-trained physicians, who we believe are typically the most difficult segment of the market to penetrate.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">70</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Strong management team with proven track record. </font>Our management team has significant expertise in the medical aesthetics industry with a proven track record of successfully developing and commercializing innovative technologies. Led by our co-founders, Moshe Mizrahy and Dr.&#160;Michael Kreindel, our senior executive team has an average of over 15&#160;years of medical aesthetics industry experience including co-founding Syneron Medical Ltd. and serving in various senior leadership positions within Cynosure, Inc. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our Growth Strategy </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our objective is to expand our technological leadership in the aesthetic solutions market. We intend to achieve this goal by implementing the following strategies: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Increase our sales presence to target and expand our addressable market globally. </font>We plan to expand our distribution network and direct sales organization and seek to recruit and train exceptionally talented sales representatives in existing and new markets to help us broaden the adoption of our products and drive further market penetration. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">
          <font style="font-style:italic;">United States and Canada:</font> We plan to expand our direct sales team by approximately 15 representatives by the end of 2019. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">
          <font style="font-style:italic;">Europe</font>: We intend to establish sales and marketing organizations and a network of exclusive European distributors (in addition to our existing networks in the United Kingdom and Spain). </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">
          <font style="font-style:italic;">Latin America</font>: We plan to expand our network of exclusive distributors in Argentina, Brazil, Chile, Colombia, Mexico, Panama and Uruguay. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">
          <font style="font-style:italic;">Asia</font><font style="font-style:italic;">-Pacific</font>: We intend to establish a direct sales presence in China through our joint venture in Guangzhou, as well as expand our network of exclusive distributors in Australia, Hong Kong, Japan, Philippines, South Korea, Singapore, Taiwan and Thailand. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Continue to further penetrate our existing customer base and drive recurring revenues. </font>We believe that there are opportunities for us to generate additional revenue from existing customers who are already familiar with our products. For example, a number of our existing customers have purchased additional aesthetic systems from us to expand their treatment offerings. Additionally, we have experienced growth in sales of consumables over the past three years. Since inception, we have sold over 170,000 consumables. We expect that as our customer base grows, the&#160;percentage of our revenues attributable to consumables will increase. We also expect that certain customers will be candidates for technology upgrades to enhance the capabilities of their existing InMode products. In addition, as we continue to grow our support services program, we expect to seek to increase the number of customers that enter into service contracts and extended warranties, which would provide us with additional recurring revenues. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Leverage our existing technology to expand into new minimally and non-invasive applications. </font>We have an active development pipeline focused on additional solutions targeted to our traditional customer base. Our near-term product development portfolio consists of new and second generation solutions for various conditions, including wearable, non-invasive face and body reshaping products, eyelid treatments, cellulite, large area lipolysis, fractional RF treatment of severe vaginal laxity and labiaplasty. We expect to launch three new product platforms by the end of 2019. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Expand our customer base beyond traditional </font><font style="font-style:italic;">customers. </font>We intend to develop products that leverage our minimally and non-invasive technologies to address the unmet market needs of a non-traditional customer base, which includes general practitioners, ophthalmologists, ENTs and aesthetic clinicians. We intend to adapt our products to the expertise and skill level of these providers, further expanding our addressable market.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">71</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Actively pursue business development opportunities. </font>We may seek to engage in targeted business development activities, including acquisitions and strategic partnerships, in order to augment our product and technology portfolio in our existing and potentially adjacent markets. We believe we can leverage our global infrastructure and existing relationships to implement a disciplined tuck-in acquisition strategy. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">
          <font style="font-style:italic;">Maintain a strong intellectual property and patent portfolio</font>. We believe our existing intellectual property and patent portfolio adequately protects our rights to our proprietary technologies and creates a barrier of entry to potential competitors. We intend to strengthen our existing intellectual property and patent portfolio as we develop additional applications and continue to aggressively defend against potential infringement by our competitors. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Products </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We offer a broad portfolio of aesthetic treatment solutions that provide a variety of minimally and non-invasive aesthetic medical products. The following table provides information concerning our products and their applications. </div>
        <table style="width:456pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #000000;padding:0.167pt 0pt 2.833pt 0pt; width:56pt;text-align:left;">Product <br >Platform </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.167pt 0pt 2.833pt 0pt; width:50pt;">
              <div style="text-align:center;">Energy <br >Source(s) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.167pt 0pt 2.833pt 0pt; width:50pt;">
              <div style="text-align:center;">Year <br >Introduced </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.167pt 0pt 2.833pt 0pt; width:75pt;">
              <div style="white-space:nowrap; text-align:center;">Handpiece(s) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.167pt 0pt 2.833pt 0pt; width:177pt;">
              <div style="white-space:nowrap; text-align:center;">Primary Applications* </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:56pt;text-align:left;">
              <div style="font-weight:bold;">BodyTite</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:50pt;">
              <div style="white-space:nowrap; text-align:center;">Bipolar RF </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:50pt;">
              <div style="text-align:center;">2010 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:75pt;">
              <div style="text-align:center;">BodyTite <br >FaceTite <br >NeckTite </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:177pt;">
              <div style="text-align:center;">Body Contouring (MI) <br >Face Contouring (MI) <br >Neck Contouring (MI) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:56pt;text-align:left;">
              <div style="font-weight:bold;">Optimas</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:50pt;">
              <div style="text-align:center;">Laser <br >Bipolar RF <br >IPL </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:50pt;">
              <div style="text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:75pt;">
              <div style="text-align:center;">Fractora <br >Forma <br >Lumecca <br >DiolazeXL <br >Vasculaze </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:177pt;">
              <div style="text-align:center;">Skin Rejuvenation (MI) <br >Skin Rejuvenation (NI) <br >Skin Rejuvenation &amp; Pigmentation (NI) <br >Hair Removal (NI) <br >Vascular Lesion (NI) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:56pt;text-align:left;">
              <div style="font-weight:bold;">Votiva</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:50pt;">
              <div style="white-space:nowrap; text-align:center;">Bipolar RF </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:50pt;">
              <div style="text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:75pt;">
              <div style="text-align:center;">FractoraV <br >FormaV </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:177pt;">
              <div style="text-align:center;">Feminine Rejuvenation (MI) <br >Feminine Rejuvenation (NI) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:56pt;text-align:left;">
              <div style="font-weight:bold;">Contoura</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:50pt;">
              <div style="white-space:nowrap; text-align:center;">Bipolar RF </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:50pt;">
              <div style="text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:75pt;">
              <div style="text-align:center;">BodyFX <br >MiniFX <br >Plus </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:177pt;">
              <div style="text-align:center;">Body Contouring (NI) <br >Face/Neck Contouring (NI) <br >Skin Tightening (NI) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:56pt;text-align:left;">
              <div style="font-weight:bold;">Triton</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:50pt;">
              <div style="text-align:center;">Laser </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:50pt;">
              <div style="text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:75pt;">
              <div style="text-align:center;">Triton Duo Light <br >Triton Duo Dark </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:177pt;">
              <div style="text-align:center;">Hair Removal (NI) <br >Hair Removal (NI)</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">*<br ></div>
        <div style=" float:left; margin-top:7.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">&#8220;MI&#8221; = Minimally-Invasive and &#8220;NI&#8221; = Non-Invasive </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition to the products described above, prior versions of our products continue to be used by customers. Outside of the United States, we also offer some alternative versions of our aesthetic treatment solutions, in some cases under different trademarks, which are tailored to the specific preferences and needs of certain countries and regions. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Components of Our Products </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Each of our products consists of the following components: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">platform; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">one or more handpieces; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our proprietary software. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Platforms </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our platforms are mostly electronic boxes, comprised of RF energy generators and modules supporting lasers and IPL, as applicable, a 110/220VAC input power supply, controller and a user interface </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">72</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">with touch screen. The user interface allows the physician to select the handpiece and set treatment parameters to meet the requirements of a particular application and patient. Using the touch screen, the physician can independently adjust the energy level, pulse width and other parameters depending on application to optimize treatment&#8217;s safety and effectiveness. The user interface on our multiple energy workstations also allows the user to change energy sources with the press of a button. The control system communicates the operator&#8217;s settings from the user interface to the system&#8217;s modules and manages system operation and performance. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Handpieces </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our handpieces are used to apply the energy to the patient treatment area. The handpieces are designed for specific targeted body areas, type of energy to maximize treatment safety and efficacy for specific treatment. Certain of our handpieces have a contained thermal field that ensures a controlled and safe treatment through our Acquire, Control and Extend, or ACE, technology. Our ACE technology ensures that no areas are under or over treated using therapeutic temperatures safely and efficiently. Built-in safeguards, including real time measurements of skin temperature, impedance monitoring, power cut-off and audible feedback, help ensure patient safety throughout the procedure. A number of our handpieces are, or contain, one-time use applicators, or consumables, that must be replaced following each treatment. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Minimally-Invasive </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">BodyTite&#8201;&#8212;&#8201;</font>The minimally-invasive, consumable <font style="font-style:italic;">BodyTite</font> handpiece, introduced in 2010, utilizes directional RF energy for RFAL treatments using needle-size cannula and external electrodes to apply RF energy to the subcutaneous adipose tissue, heating the tissue to up to 50&#176;C to 70&#176;C to destroy fat and contract connective tissue, and simultaneously remodels the dermis at external temperatures of up to 42&#176;C. This handpiece allows tissue treatment using a 17 centimeter, or cm, cannula that provides treatment depth up to 50mm. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">FaceTite/NeckTite&#8201;&#8212;&#8201;</font>The minimally-invasive, consumable <font style="font-style:italic;">FaceTite</font> and <font style="font-style:italic;">NeckTite</font> handpieces, introduced in 2012, utilize directional RF energy for RFAL treatments using cannula with diameters of 1.8mm and 2.2mm and external electrodes to apply RF energy to the subcutaneous adipose tissue, heating the tissue to up to 50&#176;C to 70&#176;C to destroy fat and contract connective tissue, and simultaneously remodels the dermis at external temperatures up to 42&#176;C. This handpiece allows tissue treatment using a 10cm cannula that provides treatment depth up to 25mm. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Fractora/FractoraV</font>&#8201;&#8212;&#8201;The minimally-invasive <font style="font-style:italic;">Fractora</font> handpiece, introduced in 2011, uses customizable fractional energy superficial fractional resurfacing and for subdermal adipose tissue remodeling. The handpiece offers two treatment depths (skin surface and subdermal) and is safe on all skin types including type IV. The consumable applicator tip contains 24-coated pins with a length of up to 4mm. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Non-Invasive </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">BodyFX/MiniFX</font>&#8201;&#8212;&#8201;The non-invasive <font style="font-style:italic;">BodyFX</font> and <font style="font-style:italic;">MiniFX</font> handpieces, introduced in 2013, combine vacuum and bipolar RF energy with high and low amplitudes to both permanently kill adipose tissue and contract the skin. The <font style="font-style:italic;">BodyFX</font> handpiece, intended for use on various parts of the body, comprises a vacuum cavity with a depth of 0.5 inches, or in, and a size of 2in x 1in. The <font style="font-style:italic;">MiniFX</font> handpiece, better suited to address problematic fatty tissue in smaller areas, uses a chamber size of approximately 1in&#160;x&#160;1in. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">DiolazeXL (810nm)&#8201;&#8212;&#8201;</font>The non-invasive <font style="font-style:italic;">DiolazeXL (810nm)</font> handpiece, introduced in 2017, is a high-speed, gold standard 810nm (diode) laser indicated for permanent hair reduction. <font style="font-style:italic;">DiolazeXL</font>&#8217;s differentiated triple contact cooling technology (pre, parallel and post), or 3PC technology, provides for a safe and comfortable patient experience. The handpiece covers a spot size of 12mm x 26mm to allow for the removal of a variety of hair colors and thickness. This handpiece offers short and long pulse durations and repetition rates that enable treatment times up to 6cm<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">2</font>/second. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">73</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Triton Duo Light (755nm &amp; 810nm)&#8201;&#8212;&#8201;</font>The non-invasive <font style="font-style:italic;">Triton Duo Light</font> handpiece, introduced in 2017, combines two wavelengths for optimal treatment of light skin patients. The handpiece utilizes a blend of 755nm (Alexandrite) and 810nm (diode) laser wavelengths that have been optimized for hair removal on patients with skin types I to IV. We believe the <font style="font-style:italic;">Triton</font> platform is the only FDA-cleared device capable of firing two wavelengths in one pulse. The handpiece covers a spot size of 12mm x 26mm and provides two pulse durations and high repetition rates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Triton Duo Dark (810nm &amp; 1064nm)&#8201;&#8212;&#8201;</font>The non-invasive <font style="font-style:italic;">Triton Duo Dark</font> handpiece, introduced in 2017, combines two wavelengths for optimal treatment of dark skin patients. The handpiece utilizes a blend of 810nm (diode) and 1064nm (Nd:YAG) laser wavelengths that have been optimized for hair removal on patients with skin types I to IV. We believe the <font style="font-style:italic;">Triton</font> platform is the only FDA-cleared device capable of firing two wavelengths in one pulse. The handpiece covers a spot size of 12mm x 26mm and provides two pulse durations and high repetition rates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Forma</font>&#8201;&#8212;&#8201;The non-invasive <font style="font-style:italic;">Forma</font> handpiece, introduced in 2013, uses our ACE technology to deliver auto-adjusting uniform RF energy-generated heat (up to 43&#176;C) for collagen remodeling and skin contraction of the face and neck. We believe <font style="font-style:italic;">Forma</font> is the first thermal face and neck skin tightening device to have both temperature monitoring and automatic, user programmable, RF on/off control. This handpiece has an RF energy output power of up to 65 watts and covers a spot size of 22mm x 20mm. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">FormaV</font>&#8201;&#8212;&#8201;The non-invasive <font style="font-style:italic;">FormaV</font> handpiece, introduced in 2017, uses our ACE technology to deliver auto-adjusting uniform RF energy generated heat (up to 43&#176;C) to the internal vaginal tissue through a consumable applicator to help in the treatment of sexual dysfunction, or as an adjunct to Kegel exercises (tightening of the muscles of the pelvic floor to increase muscle tone). We believe the <font style="font-style:italic;">FormaV</font> is the only RF-based device marketed in the United States for pelvic floor muscle and sexual dysfunction. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Plus</font>&#8201;&#8212;&#8201;The non-invasive <font style="font-style:italic;">Plus</font> handpiece, introduced in 2013, uses our ACE technology to deliver auto-adjusting uniform RF generated heat (up to 43&#176;C) for collagen remodeling and skin contraction of the body. We believe <font style="font-style:italic;">Plus</font> is the first thermal body skin tightening device to have both temperature monitoring and automatic, user programmable, RF on/off control. This handpiece has an RF energy output of up to 65 watts covers a spot size of 45mm x 45mm. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Lumecca</font>&#8201;&#8212;&#8201;The non-invasive <font style="font-style:italic;">Lumecca</font> handpiece, introduced in 2015, is an IPL optimized for both light and dark skin that uses a xenon flash lamp to deliver filtered optical energy in the 515nm to 1200nm range for light skin treatment and 580nm to 1200nm range for darker skin. <font style="font-style:italic;">Lumecca</font> is intended for treatment of superficial vascular and pigmented lesions. The handpiece covers a spot size of 30mm x 10mm with a peak optical power of 10,000 watts. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Vasculaze</font>&#8201;&#8212;&#8201;The non-invasive <font style="font-style:italic;">Vasculaze</font> handpiece, introduced in 2018, is a 1064nm wavelength diode laser intended for use in the coagulation and hemostasis of benign vascular legions such as, but not limited to, reticular leg veins, spider veins, hemangiomas, port wine stains and venus lakes. <font style="font-style:italic;">Vasculaze</font> is optimized with high peak power, strong contact cooling and an ergonomic head intended to maximize treatment efficiency. The handpiece covers a spot size of 3mm x 4mm and has pulse duration of 20 to 100 milliseconds, or msec. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Proprietary Software </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our software permits the user to define treatment parameters to be communicated to the electronic modules in the platform and deliver RF or optical energy through the handpiece to the patient. In addition, our software controls and manages proper system performance and automatic temperature control, system self-calibration, system setup and detection of any malfunction of the system. We believe our software&#8217;s automative capabilities allow physicians to dedicate their attention and focus to patient treatment rather than system monitoring. Our users upgrade their products through the purchase of additional treatment applicators and corresponding software plugs. All of our software complies with applicable medical specifications and regulations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Applications and Procedures </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our products provide our customers with a broad range of applications among both traditional procedures and emerging applications. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">74</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Face and Body Contouring </div>
        <div style="margin-top:10.81pt; width:456pt; line-height:11pt;font-style:italic;">Minimally-Invasive </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">Generally performed by a physician, RFAL delivers directional RF energy into a patient&#8217;s subcutaneous fat to coagulate and liquefy adipose tissue and heat the subcutaneous fibrous septa, resulting in substantial collagen contraction of the subdermal space. RF energy is delivered through an innovative handpiece comprised of two electrodes. The internal electrode is inserted into the fat layer, while the other larger electrode is applied externally to the skin surface above the cannula tip. The internal cannula passes through the subcutaneous fat, while the external electrode slides over the skin&#8217;s surface. The small conductive tip of the cannula concentrates RF energy in the subcutaneous fat, liquefying it and simultaneously contracting the fiber septa. This liquefied fat can then be removed from the body. Our RFAL technology can be administered on all regions of the body and typical treatments are approximately 30 to 90 minutes each under local anesthesia. We received 510(k) FDA clearance for RFAL technology in 2016. Users conduct minimally-invasive face and body contouring using RFAL technology with the <font style="font-style:italic;">BodyTite</font> platform and <font style="font-style:italic;">BodyTite</font> and <font style="font-style:italic;">FaceTite</font> handpieces. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Generally performed by a physician, Deep Subdermal Fractional RF, delivers RF energy into the subcutaneous adipose tissue to depths of up to 4mm through an array of coated needles producing localized heat and matrix of small lesions in the subcutaneous fat. The heat generated by the pins in the subdermal tissue promotes connective tissue restructuring. As a result, physicians can offer a versatile fractional treatment creating a three-dimensional collagen contraction and subdermal fat coagulation. The deep fractional remodeling is used when fat layer is not thick enough to use RFAL technology or when patient wants only superficial result. Deep Subdermal Fractional RF can be used for wrinkle treatment, skin tightening and cellulite. In addition to reshaping, Deep Subdermal Fractional RF provides long term results for inflammatory acne by coagulating enlarged sebaceous glands. The most common areas of treatment are the face and neck. Patients generally receive between one to three treatments for approximately 30 minutes each. Treatments are typically spaced two to three weeks apart. We received two 510(k) FDA clearances for <font style="font-style:italic;">Fractora</font> in 2011 and 2016. Customers use this technology with the <font style="font-style:italic;">BodyTite</font> and <font style="font-style:italic;">Optimas</font> platforms using the <font style="font-style:italic;">Fractora</font> handpiece. </div>
        <div style="margin-top:11.81pt; width:456pt; line-height:11pt;font-style:italic;">Non-Invasive </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">Administered by physicians and other aesthetic practitioners, our differentiated fat reduction solution is based on skin shaping using a vacuum and delivering low amplitude bipolar RF energy for gentle deep tissue heating and high aplitude RF energy to simultaneously kill fat and tighten skin. The handpiece is placed over the desired area of the body and vacuum energy shapes the skin into the cavity for safe and effective RF energy delivery allowing greater volumes of fat to be treated (up to 2.5cm in depth). Subsequently, temperature-controlled RF energy is applied to preheat the tissue and fat uniformly to 42&#176;C to 43&#176;C. High amplitude RF energy delivered in ultra short pulse duration is then administered via electrodes causing apoptosis of adipose tissue and resulting in simultaneous skin contraction. Our technology can be administered on all regions of the body. Patients generally receive six treatments for approximately 10 to 20 minutes each. Treatments are typically spaced one to two weeks apart. We received 510(k) FDA clearance for this technology in 2013. Users conduct non-invasive face and body contouring with the <font style="font-style:italic;">Contoura</font> platform using the <font style="font-style:italic;">BodyFX</font> or <font style="font-style:italic;">MiniFX</font> handpieces. </div>
        <div style="margin-top:11.61pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Medical Aesthetics </div>
        <div style="margin-top:10.61pt; width:456pt; line-height:11pt;font-style:italic;">Skin Rejuvenation/Vascular &amp; Pigmented Lesion Treatment </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">Generally performed by a physician or other aesthetic professional. Depending on the handpiece, different types of energy and treatments are provided. The application of IPL energy enables the improvement of photodamage, as well as other pigmented abnormalities and superficial vascular lesions. A 1064nm laser is used for the treatment of larger and deeper veins. Often patients see result after a single treatment but typically two to three treatments of approximately 15 minutes each are recommended. Treatments are typically spaced two to four weeks apart. We received 510(k) FDA clearance for superficial vascular and pigmented lesion treatments in 2013 and for hair removal and permanent hair reduction in 2017 and 2018. Users rejuvenate the skin with the <font style="font-style:italic;">Optimas</font> platform using the <font style="font-style:italic;">Vasculaze</font> and <font style="font-style:italic;">Lumecca</font> handpieces. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">75</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;">Sub-Necrotic Thermal Tissue Remodeling </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Administered by physicians and other aesthetic practitioners. The application is based on uniform and deep heating of the skin and subdermal layer using bipolar RF energy. The handpiece is moved over the desired area of the treatment area maintaining the designated temperature for the predetermined time for safe and effective collagen remodeling. Subsequently, temperature-controlled RF energy is applied automatically to heat tissue uniformly to 42&#176;C to 43&#176;C. The <font style="font-style:italic;">Forma</font> handpiece is utilized to target fat and heats the tissue to depths of up to 4.5mm while the <font style="font-style:italic;">Plus</font> handpiece is used for larger body areas and provides effect up to 6mm in depth. Patients generally receive six treatments for approximately 10 to 20 minutes each. Treatments are typically spaced one to two weeks apart. We received three 510(k) FDA clearances for this technology in 2014, 2016 and 2017. Users conduct facial treatment with the <font style="font-style:italic;">Optimas</font> platform using the <font style="font-style:italic;">Forma</font> handpiece and body contouring with the <font style="font-style:italic;">Contoura</font> platform using the <font style="font-style:italic;">Plus</font> handpiece. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Permanent Hair Reduction </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The user, who is not necessarily a physician (depending on local regulation), can operate the device for permanent hair reduction. Our differentiated dual wavelength technology incorporated in the <font style="font-style:italic;">Triton</font> platform fires two wavelengths in a single pulse destroying the hair follicles located in the dermis and subdermal layers. This procedure is continued over the target area and can last from a few minutes to 90 minutes depending on the size of the treatment area. In general, permanent hair reduction requires four to six treatments spaced four to eight weeks apart. More sessions may be required for stubborn hairs. Due to our unique dual wavelength technology, our <font style="font-style:italic;">Triton</font> platform allows practitioners to address all skin types and tones. We received 510(k) FDA clearance for our <font style="font-style:italic;">Optimas</font> and dual wavelength <font style="font-style:italic;">Triton</font> platforms for permanent hair reduction treatments in 2016 and 2018, respectively. Users perform permanent hair reduction procedures with our <font style="font-style:italic;">Optimas</font> and <font style="font-style:italic;">Triton</font> platforms using the <font style="font-style:italic;">DiolazeXL</font> and <font style="font-style:italic;">Triton Duo Light</font> and <font style="font-style:italic;">Triton Duo Dark</font> handpieces, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Women&#8217;s Health </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Performed by a physician, the administration of energy addresses vaginal health in postpartum females and treats symptoms associated with vaginal atrophy, vaginal relaxation syndrome and sexual dysfunction. Depending on the handpiece, the administration of bipolar RF energy or subdermal heating is applied to the internal vaginal tissue (<font style="font-style:italic;">FormaV</font>), external vulvar laxity or labial hypertrophy (<font style="font-style:italic;">FractoraV</font>), stimulating collagen and revitalizing the vaginal tissue. Depending on the treatment type, patients typically receive between two to three treatments of approximately 15 minutes each. Treatments are typically spaced two to three weeks apart. We received 510(k) FDA clearance in 2017. We believe <font style="font-style:italic;">Votiva</font> is the only FDA-cleared RF-based device marketed in the United States for pelvic floor muscle and sexual dysfunction. Users conduct feminine rejuvenation treatment with the <font style="font-style:italic;">Votiva</font> platform using the <font style="font-style:italic;">FormaV</font> and <font style="font-style:italic;">FractoraV</font> handpieces. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Sales and Marketing </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our primary strategy to increase market penetration relies on selling directly to our traditional customer base of plastic and facial surgeons, aesthetic surgeons, dermatologists, aesthetic OB/GYNs and other specialists. We believe we are the only company commercializing minimally-invasive aesthetic solutions specifically targeting the surgical community and believe our products represent a significant opportunity for these practitioners to deliver improved patient treatment results and significantly increase their ability to generate additional revenue. We are also targeting a newer aesthetic market opportunity consisting of general practitioners, ophthalmologists, ENTs and aesthetic clinicians as an incremental growth opportunity. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We target potential customers through office visits, trade shows, professional journals and various forms of paid and unpaid media. We also conduct clinical workshops featuring recognized expert panelists and key opinion leaders to promote existing and new treatment techniques using our products. We believe that these workshops enhance customer loyalty and provide us with new sales opportunities. We plan to increase the number of workshops that we conduct from 27 in 2017 to 51 in 2018. We also use direct mail programs to target specific segments of the market that we seek to access, such as members of medical </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">76</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">societies and attendees at meetings sponsored by medical societies or associations. In addition, we maintain an active public relations program that has resulted in treatments based on our products being featured in various televised and printed media outlets including <font style="font-style:italic;">InStyle, Shape, Doctors</font> and <font style="font-style:italic;">Modeliste</font>. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We currently sell and market our products in the United States, Canada, the United Kingdom and Spain through a direct sales force of approximately 75 representatives. We also sell and market our products through 29 distributors in 37 countries. Our U.S. and Canadian sales efforts are headquartered in Lake Forest, California and Toronto, Canada, respectively. To support the continued roll-out of our products and further penetrate the market, we anticipate that our direct salesforce in the United States and Canada will continue to increase. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In international markets, to complement our direct sales force in the United Kingdom and Spain, we sell our products through a network of distributors. As of December&#160;31, 2017, we had an international sales management team of four employees supporting 29 independent distributors. The&#160;percentage of our revenues from customers located outside the United States and Canada was approximately 17% in 2017. We intend to increase penetration of our customer base in international markets and expand into attractive new international markets, including within the United Kingdom and Spain, by identifying and training qualified distributors. In addition, we may opportunistically hire a direct sales force and expand our marketing campaigns in select international markets. We require our distributors to provide customer training, to invest in equipment and marketing and to attend certain exhibitions and industry meetings. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Service and Support </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We support our customers with a range of services, including installation and product training, business and practice development consulting and product service and maintenance. In connection with the direct sales of our products, we arrange for the installation of the system and initial product training. In the United States, our dedicated sales representatives install our systems and our clinical support staff provides customer training. Outside of the United States, our trained third-party distributors install our systems and provide training. The cost of installation and initial training are all included in the purchase price of our systems. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We service our products in three service centers: (1)&#160;the U.S. market is serviced through our facility in Lake Forest, California, (2)&#160;the Canadian market is serviced through our facility in Toronto, Canada, and (3)&#160;the rest of the world is serviced through our distributors and our facility in Yokneam, Israel. In the event of a technical malfunction, our customers first contact us (if in the United States or Canada) or our distributors (if outside of the United States or Canada) telephonically. If a product requires service or repair that cannot be addressed telephonically, we or our distributors ship a temporary &#8220;loaner&#8221; system to the customer as soon as possible, often overnight. This unique &#8220;loaner&#8221; system reduces any product downtime and associated lost revenues for the physician. We then arrange for shipment of the defective product to one of our service centers in the United States or Canada. Outside the United States or Canada, the product is sent to our distributors or our facility in Israel. Either we or our distributors quickly repair the faulty product and ship it back to the customer. We have designed our products in a light-weight, modular fashion to enable quick and efficient service and support. Specifically, we build our platforms to be less than 35 kilograms in weight to ensure acceptance by traditional, commercial third-party logistics providers for next-day delivery of replacement products without requiring specialized shipping procedures. We believe our depot service and support model provides for more efficient and less costly operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our standard warranty term is 12&#160;months, however, many of our products are sold with multi-year warranties. Our standard warranty covers parts, labor, participation in our loaner program and a white glove, door-to-door, shipping service for expedited repair service, and can be extended for an additional charge. We believe that we have a significant opportunity to increase our recurring customer revenue by increasing the number of our customers that enter into service contracts and extended warranties for our systems. All of our distributors have a service department and are required by us to maintain a full inventory of spare parts. All service staff is trained by our service department in Israel. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Manufacturing and Supply </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We rely primarily on outsourced manufacturing to produce our devices while maintaining control over the production process. Outsourcing allows us to carry low inventory levels and maintain fixed unit costs </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">77</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">without incurring significant capital expenditures. Through our strategic arrangement with Flextronics (Israel) Ltd., or Flex, we maintain dedicated manufacturing lines supervised by us in Flex&#8217;s medical grade manufacturing facility in Migdal Haemek, Israel. Within the Flex facility, all proprietary manufacturing, testing and assembly equipment has been built and is owned by us. We also use three separate manufacturers in addition to Flex to produce our products. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe our outsourced manufacturers&#8217; processes comply with all applicable United States and international quality and safety standards, such as ISO 13485:2016, CE and the FDA quality system regulations. We conduct in-house prototype development and present detailed manufacturing documents to our subcontractors, who then purchase most of the necessary components and manufacture the product. These manufacturing subcontractors provide us fully assembled, or &#8220;turn-key,&#8221; services. We control and monitor the quality of our products by having one of our quality control employees at each of our subcontractor&#8217;s facilities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The contracts we have with these manufacturers do not have minimum purchase requirements and allow us to purchase end products entered into on a purchase order basis. The contracts have one-year terms that automatically renew for successive one-year terms unless either we or the manufacturer provide three&#160;months&#8217; written notice prior to the expiration of the term. To date, we have not experienced any significant manufacturing delays. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We manufacture all laser and IPL handpieces in our facility in Yokneam, Israel and procure other major components of our products on behalf of our third-party manufacturers from a limited number of suppliers. We have flexibility to adjust the number of lasers and other components that we either manufacture or procure as well as the delivery schedules. The forecasts that we use are based on historical demands and expected future plans. Lead times may vary significantly depending on the size of the order, time required to fabricate and test the components, specific supplier requirements and current market demand for the components. We intend to reduce any potential for delays of supply by maintaining relationships with multiple suppliers of major components. To date, we have not experienced significant delays in obtaining our major components. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Research and Development </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our research and development activities are conducted internally by a team of ten research and development staff based in Israel. Our research and development efforts are focused on the development of new products, as well as on the extension of our existing products to introduce new applications in the minimally and non-invasive and medical aesthetic markets. We expect to concentrate our research and development efforts in the coming&#160;years on developing procedures and platforms based on both our two major technologies, RFAL and Deep Subdermal Fractional RF, and developing new technologies. We have a number of new projects and products under development, mainly focusing on additional minimally and non-invasive aesthetic and medical treatments. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our research and development expenditures were approximately $2.6&#160;million for the year ended December&#160;31, 2017 and approximately $2.5&#160;million for the year ended December&#160;31, 2016. We expect to continue to increase our expenditures on research and development. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Intellectual Property </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We rely on a combination of patent and trademark laws to protect our intellectual property rights. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Patents and Patent Applications </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of July&#160;24, 2018, we own four issued U.S. patents and one issued Korean patent. As of July&#160;24, 2018, we have filed nine patent applications that are pending in the United States Patent and Trademark Office. Our issued U.S. patents are projected to expire between 2027 and 2038. These patents and patent applications over the technologies described herein. The term of the patents depends on the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is generally 20&#160;years from the earliest claimed filing date of a non-provisional patent application in the applicable country. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">78</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We cannot assure you that patents will issue from any of our pending applications or that, if patents issue, they will be of sufficient scope or strength to provide meaningful protection for our technology. Our policy is to obtain patents and to seek to operate without infringing on the intellectual property rights of third parties. Loss or invalidation of our patents, or a finding of unenforceability or limitation of scope of our patents, could have a material adverse effect on us. The patent position of many inventions in the areas related to our business is highly uncertain, involves many complex legal, factual and technical issues and has recently been the subject of litigation industry-wide. There is no certainty in predicting the breadth of allowable patent claims or the degree of protection afforded under any issued patents. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Notwithstanding the scope of the patent protection available to us, a competitor could develop treatment methods or devices that are not covered by our patents. Furthermore, numerous U.S. and foreign issued patents and patent applications owned by third parties exist in the fields in which we are developing products. Because patent applications can take many&#160;years to issue, there may be applications unknown to us, which applications may later result in issued patents that our existing or future products or proprietary technologies may be alleged to infringe. Third parties may also obtain patents that we may need to license from them in order to conduct our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">It is possible that patents issued to us will be successfully challenged or that patents issued to others may preclude us from commercializing our products under development. Litigation to establish or challenge the validity of patents, to defend against infringement, unenforceability or invalidity claims or to assert infringement, invalidity or unenforceability claims against others, if required, can be lengthy and expensive, and may result in determinations materially adverse to us. We cannot assure you that the products currently marketed or under development by us will not be found to infringe patents issued or licensed to others. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Patent Litigation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may receive allegations from third parties contending that we are infringing their patents. If such third parties were to commence infringement suits against us, and such third party patents were found by a court to be valid, enforceable and infringed upon by us, then we could be required to pay damages and/or make royalty payments, and we could also be enjoined from continuing the infringing activity. Depending on the nature of the patent found to be infringed upon by us, a court order requiring us to cease such infringement could have a material adverse effect on us. We might be unable to design-around such patents or continue offering the products or services found to be infringing, or we could suffer other adverse consequences. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As previously described, in January&#160;2016, Syneron filed a claim with the United States District Court for the Central District of California against the Company&#8217;s U.S. and Israeli subsidiaries alleging that certain of the Company&#8217;s products infringed four U.S. patents owned by Syneron that purport to cover systems and methods for treating skin and arranging electrodes on skin therapy devices. In April&#160;2018, Syneron filed claims with the International Trade Commission and the United States District Court for the District of Massachusetts against our U.S. and Israeli subsidiaries, alleging that certain of our products infringed two U.S. patents owned by Syneron that purport to cover systems and methods for treating skin and arranging electrodes on skin therapy devices. Although we may try to resolve any potential future claims or actions, we may not be able to do so on reasonable terms, if at all. Following a successful third-party action for infringement, we may be required to pay substantial damages and if we cannot obtain a license or redesign our products, we may have to stop manufacturing, selling and marketing our products, and our business could suffer as a result. Infringement and other intellectual property claims, with or without merit, can be expensive and time-consuming to litigate, and could divert management&#8217;s attention from our core business. We do not know whether necessary licenses would be available to us on satisfactory terms, or whether we could redesign our products or processes to avoid infringement. If we lose this kind of litigation, a court could require us to pay substantial damages and could prohibit us from using technologies essential to our products, either of which would have a material adverse effect on our business, results of operations and financial condition. See &#8220;Risk Factors&#8201;&#8212;&#8201;Risks Related to Our Intellectual Property&#8201;&#8212;&#8201;If we are unable to protect our intellectual property rights, our competitive position could be harmed. Our success and ability to compete depends in large part upon our ability to protect our proprietary technology.&#8221;</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">79</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Copyrights, Trademarks and Trade Secrets </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The software programs associated with our products are protected by U.S. copyright law. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We also filed for protection available under trademark law. As of July&#160;24, 2018, we own eight registered trademarks in various jurisdictions outside the United States, including for the marks &#8220;InMode&#8221; and &#8220;RFAL&#8221; and certain key product names, in particular, <font style="font-style:italic;">BodyFX</font>, <font style="font-style:italic;">BodyTite</font>, <font style="font-style:italic;">Diolaze</font>, <font style="font-style:italic;">Fractora</font> and <font style="font-style:italic;">Lumecca</font>. We also have eight pending foreign trademark applications. We also have seven trademark applications in the United States pending for <font style="font-style:italic;">BodyTite</font>, <font style="font-style:italic;">Contoura by InMode</font>, <font style="font-style:italic;">FaceTite</font>, <font style="font-style:italic;">InMode</font>, <font style="font-style:italic;">Optimas by InMode</font>, <font style="font-style:italic;">Triton by InMode</font> and <font style="font-style:italic;">Votiva by InMode</font>. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We also rely upon know-how and continuing technological innovation, and may pursue licensing opportunities in the future, to develop and maintain our competitive position. We seek to protect our proprietary rights through a variety of methods, including confidentiality agreements and proprietary information agreements with suppliers, employees, consultants and others who may have access to proprietary information, under which they are bound to assign to us inventions made during the term of their employment or term of service. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">All professional employees and technical consultants are required to execute confidentiality agreements in connection with their employment and consulting relationships with us. We also require them to agree to disclose and assign to us all inventions conceived in connection with their services to us. However, there can be no assurance that these confidentiality agreements will be enforceable or that they will provide us with adequate protection. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Competition </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our industry is subject to intense competition, subject to rapid change and highly sensitive to the introduction of new products or other market activities of industry participants. We compete against products offered by public companies, including Allergan plc, Cutera, Inc. Hologic Inc. and Viveve Medical, Inc., as well as by private companies, such as Sisram Medical Ltd., Syneron and Lumenis Ltd. In the past few&#160;years, several large pharmaceutical and medical device companies have also entered the aesthetic device market, including Valeant Pharmaceuticals International Inc. and Merz Pharma Group. Our products compete against conventional medical products, including Botox, hyaluronic acid injections and collagen injections, and aesthetic procedures, such as face lifts, liposuction, sclerotherapy, electrolysis, chemical peels and microdermabrasion, that are unrelated to laser, light and RF-based technologies. Our products also compete against laser and other light and radio frequency-based products. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Competition among providers of laser and other light and radio frequency-based products for the aesthetic medical market is characterized by extensive research efforts and rapid technological progress. While we attempt to protect our products through patents and other intellectual property rights, there are few barriers to entry that would prevent new entrants or existing competitors from developing products that would compete directly with ours. There are many companies, both public and private, that are developing innovative devices that use laser and other energy-based and alternative technologies. Many of these competitors have significantly greater financial and human resources than we do and have established reputations, greater brand name recognition, broader product lines, and larger customer bases, as well as worldwide distribution channels that are more effective than ours. Additional competitors may enter the market, and we are likely to compete with new companies in the future. Any business combinations or mergers among our competitors that result in larger competitors with greater resources or distribution networks, or the acquisition of a competitor by a major medical or technology corporation seeking to enter this business, could further result in increased competition. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">To compete effectively, we have to demonstrate that our products are attractive alternatives to other devices and treatments by differentiating our products on the basis of performance, brand name, reputation and price. We have encountered and expect to continue to encounter potential customers who, due to existing relationships with our competitors, are committed to, or prefer the products offered by, these competitors. We expect that competitive pressures may over time result in price reductions and reduced margins for our products.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">80</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Other medical companies, academic and research institutions, or others, may develop new technologies or therapies, including medical devices, surgical procedures or pharmacological treatments and obtain regulatory approval for products utilizing such techniques that are more effective in treating the conditions that we target or are less expensive than our current or future products. Our technologies and products could be rendered obsolete by such developments. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Government Regulation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our products and operations are subject to extensive and rigorous regulation by the relevant governmental authorities in the countries where we market and sell or products. These include the FDA, which enforces, among others, the Food, Drug and Cosmetic Act, or FDCA, as well as other similar laws and regulatory bodies worldwide. The Federal Trade Commission, or FTC, also regulates the advertising of our products in the United States. Further, we are subject to laws directed at preventing fraud and abuse, which subject our sales and marketing, training and other practices to government scrutiny. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In some jurisdictions, such as the United States, Canada, South Korea and Israel, we must complete an application process with the relevant regulator, which includes submitting the results of clinical trials for their review. In other jurisdictions, such as the European Union and certain countries in Asia, we are required to self-certify that our devices meet the applicable standards (which may include the completion of satisfactory clinical trials) but without the requirement of a formal application with, or review of clinical trials by, the relevant regulatory body. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition to the requirements regarding product clearance, many countries also impose product standards, packaging requirements, environmental requirements, labeling requirements and import and export restrictions on our devices. Each country also has its own tariff regulations, duties and tax requirements. Failure to comply with applicable regulatory requirements may result in fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, criminal prosecution, or other consequences. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In the United States, the FDCA and its implementing regulations govern the following activities that we perform and will continue to perform to help ensure that medical products distributed within the United States are safe and effective for their intended uses: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">product design and development; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">product testing; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">product manufacturing; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">product safety; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">product labeling; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">product storage; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">record-keeping; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">premarket clearance or approval; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">advertising and promotion; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">manufacturing and production; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">product sales and distribution; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">import, export and shipping; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">establishment registration and device listing; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">recalls, field safety corrective actions and post-market surveillance. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Each of our currently marketed products has received 510(k) clearance for the uses for which they are being marketed. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">81</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">FDA&#8217;s Premarket Clearance and Approval Requirements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Unless an exemption applies, each medical devise we wish to commercially distribute in the United States requires 510(k) clearance or premarket approval. The FDA classifies medical devices into one of three classes&#8201;&#8212;&#8201;Class&#160;I, Class&#160;II or Class&#160;III&#8201;&#8212;&#8201;depending on the degree of risk associated with the each medical device and the extent of manufacturer and regulatory control needed to ensure safety and effectiveness. Class&#160;I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA&#8217;s General Controls for medical devices, which include compliance with the applicable portions of the QSR, facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials. Class&#160;II devices are subject to the FDA&#8217;s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, post-market surveillance, patient registries and FDA guidance documents. While most Class&#160;I devices are exempt from the 510(k) premarket notification requirement, manufacturers of most Class&#160;II devices are required to submit to the FDA a premarket notification under the Section&#160;510(k) of the FDCA requesting permission to commercially distribute the device. The FDA&#8217;s permission to commercially distribute a device subject to a 510(k) premarket notification is generally known as 510(k) clearance. All of our current products are Class&#160;II devices subject to the 510(k) clearance requirements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Devices deemed by the FDA to pose the greatest risks, such as life-sustaining, life-supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed in Class&#160;III, requiring approval of a premarket approval application, or PMA. Some pre-amendment devices are unclassified, but are subject to the FDA&#8217;s premarket notification and clearance process in order to be commercially distributed. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">510(k) Clearance Pathway </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">When a 510(k) clearance is required, we must submit a premarket notification demonstrating that our proposed device is &#8220;substantially equivalent,&#8221; as defined in the statute, to a previously cleared 510(k) device or a device that was in commercial distribution in the United States before May&#160;28, 1976, the date upon which the Medical Device Amendments of 1976 were enacted, for which the FDA has not yet called for the submission of premarket approval applications. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">After a 510(k) premarket notification is submitted, the FDA determines whether to accept it for substantive review. If it lacks necessary information for substantive review, the FDA will refuse to accept the 510(k) notification. If it is accepted for filing, the FDA begins a substantive review. By statute, the FDA is required to complete its review of a 510(k) notification within 90&#160;days of receiving the 510(k) notification. As a practical matter, if the FDA requires additional information, clearance often takes far longer, and clearance is never assured. Although most 510(k) premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market the device. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If the FDA determines that the device is not &#8220;substantially equivalent&#8221; to a predicate device, or if the device is automatically classified into Class&#160;III, the device sponsor must then fulfill the much more rigorous premarketing requirements of the PMA approval process, or seek reclassification of the device through the <font style="font-style:italic;">de novo</font> process. A manufacturer can also submit a petition for direct <font style="font-style:italic;">de novo</font> review if the manufacturer is unable to identify an appropriate predicate device and the new device or new use of the device presents a moderate or low risk. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change in its intended use, will require a new 510(k) clearance or, depending on the modification, could require a PMA application or <font style="font-style:italic;">de novo</font> classification. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k) or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination. Many minor modifications are accomplished by a letter-to-file in which the manufacture documents the change in an internal letter-to-file. The letter-to-file is in lieu of submitting a new 510(k) to obtain clearance for such change. The FDA can always review these letters to file in an </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">82</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">inspection. If the FDA disagrees with a manufacturer&#8217;s determination regarding whether a new premarket submission is required for the modification of an existing device, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or approval of a PMA is obtained. In addition, in these circumstances, the FDA can impose significant regulatory fines or penalties for failure to submit the requisite PMA(s). </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Laser devices used for aesthetic procedures, such as hair removal, have generally qualified for clearance under 510(k) procedures. In March&#160;2013, we received FDA clearance to market our <font style="font-style:italic;">Optimas</font> platform. In October&#160;2013, we received FDA clearance to market our <font style="font-style:italic;">Contoura</font> platform. In July&#160;2016, we received FDA clearance to market our <font style="font-style:italic;">Votiva</font> platform. In November&#160;2016, we received FDA clearance to market our <font style="font-style:italic;">BodyTite</font> platform. In July&#160;2017, we received FDA clearance to market our <font style="font-style:italic;">Triton</font> platform. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Premarket Approval Pathway </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A PMA must be submitted to the FDA if the device cannot be cleared through the 510(k) process. A PMA must be supported by extensive data, including, but not limited to, technical, preclinical, clinical trials, manufacturing and labeling, to demonstrate the safety and effectiveness of the device to the FDA&#8217;s satisfaction. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">No device that we have developed has required premarket approval, nor do we currently expect that any future device or indication will require premarket approval. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Pervasive and Continuing Regulation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">After the FDA permits a device to enter commercial distribution, numerous regulatory requirements apply. These include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">quality system regulations, or QSR, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">clearance or approval of product modifications to 510(k)-cleared or PMA-approved devices that could affect safety or effectiveness; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or &#8220;off-label&#8221; uses; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">advertising and promotion requirements; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">medical device reporting regulations, which require that manufacturers report to the FDA if their devices may have caused or contributed to deaths or serious injuries or malfunctioned in ways that would likely cause or contribute to deaths or serious injuries if the malfunctions were to recur; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">medical device correction and removal reporting regulations, which require the manufacturers to report to the FDA corrections and removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the devices. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may be subject to similar foreign laws that may include applicable post-marketing requirements such as safety surveillance. Our manufacturing processes are required to comply with the applicable portions of the QSR, which cover the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance of a device master file, device history file, and complaint files. As a manufacturer, our facilities, records and manufacturing processes are subject to periodic scheduled or unscheduled inspections by the FDA. Our failure to maintain compliance with the QSR or other applicable regulatory requirements could result in the shut-down of, or restrictions on, our manufacturing operations and the recall or seizure of our products. The discovery of previously unknown problems with any of our products, including </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">83</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">unanticipated adverse events or adverse events of increasing severity or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice of medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory device recalls. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The FDA has broad post-market and regulatory enforcement powers. We are subject to unannounced inspections by the FDA to determine our compliance with the QSR and other regulations, and these inspections may include the facilities of our manufacturing subcontractors. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We also are regulated under the Radiation Control for Health and Safety Act, which requires laser products to comply with performance standards, including design and operation requirements, and manufacturers to certify in product labeling and in reports to the FDA that their products comply with all such standards. The law also requires laser manufacturers to file new product and annual reports, maintain manufacturing, testing and sales records, and report product defects. Various warning labels must be affixed and certain protective devices installed, depending on the class of the product. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">warning or untitled letters, fines, injunctions, consent decrees and civil penalties; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">unanticipated expenditures, repair, replacement, refunds, recalls, administrative detention or seizure of products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">operating restrictions, partial suspension or total shutdown of production; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">refusing requests for 510(k) clearance or PMAs of new products or new intended uses; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">withdrawing 510(k) clearance or premarket approvals that have already been granted; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">criminal prosecution. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The FDA also has the authority to require us to repair, replace or refund the cost of any medical device that we have manufactured or distributed. If any of these events were to occur, they could have a material adverse effect on our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are also subject to a wide range of federal, state and local laws and regulations, including those related to the environment, health and safety, land use, and quality assurance. We believe that we are in compliance with these laws and regulations as currently in effect, and our compliance with such laws will not have a material adverse effect on our capital expenditures, earnings, and competitive and financial position. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Other Healthcare Laws </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although none of our products or procedures using our products are currently covered by any state or federal government healthcare programs, or any private commercial payor, we may be subject to a number of foreign, federal, and state laws and regulations that may restrict our business practices, including, without limitation, anti-kickback, false claims, physician payment transparency and data privacy and security laws. The government has interpreted these laws broadly as they apply to the marketing and sales activities of manufacturers and distributors. Companies targeted in such prosecutions and in civil litigation have paid substantial fines, penalties, and settlements in the hundreds of millions of dollars or more, have been forced to implement extensive corrective action plans, can be excluded from federal health care programs, and have often become subject to consent decrees, settlement agreements or corporate integrity agreements severely restricting the manner in which they conduct their business. Many U.S. states and countries outside the United States have similar fraud and abuse statutes or regulations that may be broader in scope than the U.S. federal laws, and may apply regardless of payor, in addition to items and services reimbursed under government programs. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">84</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">International Regulations </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">International manufacturing and sales of medical devices are subject to foreign governmental regulations, which vary substantially from country to country. The time required to obtain clearance or approval by a foreign country may be longer or shorter than that required for FDA clearance or approval, and the requirements may be different. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The primary regulatory environment in Europe is that of the European Union, which consists of 28&#160;countries encompassing most of the major countries in Europe. The European Union has adopted numerous directives, and European Standardization Committees have promulgated voluntary standards regulating the design, manufacture, clinical trials, labeling and adverse event reporting for medical devices. Devices that comply with the essential requirements of the EU Medical Devices Directive (Directive 93/42/EEC) will be entitled to bear CE conformity marking, indicating that the device conforms with the essential requirements of the EU Medical Devices Directive and, accordingly, can be commercially distributed throughout the member states of the European Union, the member states of the European Free Trade Association and countries that have entered into a Mutual Recognition Agreement. The method of assessing conformity varies depending on the type and class of the product but normally involves a combination of self-assessment by the manufacturer and a third-party assessment by a Notified Body, an independent and neutral institution appointed by a country to conduct the conformity assessment. This third-party assessment may consist of an audit of the manufacturer&#8217;s quality system and specific testing of the manufacturer&#8217;s device. An assessment by a Notified Body in one member state of the European Union, the European Free Trade Association or one country that has entered into a Mutual Recognition Agreement is required in order for a manufacturer to commercially distribute the product throughout these countries. ISO 9001 and ISO 13845 certification are voluntary harmonized standards. Compliance establishes the presumption of conformity with the essential requirements for a CE Marking. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As a general rule, demonstration of conformity of medical devices and their manufacturers with the essential requirements must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence. All manufacturers placing medical devices into the market in the EEA must comply with the EU Medical Device Vigilance System. Under this system, incidents must be reported to the relevant authorities of the Member States of the EEA, and manufacturers are required to take Field Safety Corrective Actions, or FSCAs, to reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device that is already placed on the market. An incident is defined as any malfunction or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might have led to the death of a patient or user or of other persons or to a serious deterioration in their state of health. An FSCA may include the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its legal representative to its customers and/or to the end users of the device through Field Safety Notices. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On April&#160;5, 2017, the European Parliament passed the Medical Devices Regulation, which repeals and replaces the EU Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EEA member states, the regulations would be directly applicable (<font style="font-style:italic;">i.e.</font>, without the need for adoption of EEA member state laws implementing them) in all EEA member states and are intended to eliminate current differences in the regulation of medical devices among EEA member states. The Medical Devices Regulation, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices and in vitro diagnostic devices and ensure a high level of safety and health while supporting innovation. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Medical Devices Regulation will however only become applicable three&#160;years after publication. Once applicable, the new regulations will among other things: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">strengthen the rules on placing devices on the market and reinforce surveillance once they are available; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">85</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">establish explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices placed on the market; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the European Union; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">strengthened rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These modifications may have an impact on the way we design and manufacture products and the way we conduct our business in the EEA. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Several member states of the European Free Trade Association have voluntarily adopted laws and regulations that mirror those of the European Union with respect to medical devices. Other countries, such as Switzerland, have entered into Mutual Recognition Agreements and allow the marketing of medical devices that meet European Union requirements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In Israel, the Israeli Medical Equipment Law, 2012, or the Medical Equipment Law, generally governs the regulatory process and authorizations required in order to allow the manufacture, marketing and use of medical and aesthetic products in Israel. Under the Medical Equipment Law, we are required to register each of our current and future products with Israeli health authorities. We have applied for registration and registered under a fast track approval route for products already certified by other regulatory agencies (including CE marks in Europe and FDA clearances in the United States). </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Federal Communications Commission and other governmental agencies governing the use of radio frequency energy </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our products generate and use radio frequency energy and therefore may be subject to technical equipment authorization and other regulatory requirements in the countries and regions where they are marketed or distributed. In the United States, our products are subject to the Federal Communications Commission&#8217;s equipment verification procedures, under which the manufacturer is required to determine or verify that the equipment complies with the applicable technical standards and to keep a record of test measurements demonstrating compliance before the equipment can be marketed or sold in the United States. Any modifications to our products may require reverification before we are permitted to market and distribute the modified devices. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We seek to obtain regulatory approvals in countries requiring advance clearance of our products before they are marketed or distributed in those countries. Our failure to comply with the technical, equipment authorization or other regulatory requirements of a specific country or region could impair our ability to commercially market and distribute our products in that country or region. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Data Protection </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our business involves the use, storage and transmission of information about our employees, our customers and, to a certain extent, clients of our customers. In the course of our operations, we may gain access to confidential customer information, including nonpublic personal data. We are bound by certain agreements to use and disclose this information in a manner consistent with the privacy standards under regulations applicable to our customers and are subject to numerous U.S. and foreign jurisdiction laws and regulations designed to protect this information. With the recent increase in publicity regarding data breaches resulting in improper dissemination of consumer information, many states have passed laws regulating the actions that a business must take if it experiences a data breach, such as prompt disclosure to affected customers, governmental entities, and the media. In addition to data breach notification laws, some states have enacted statutes and rules requiring businesses to protect certain types of personal information they hold or to otherwise comply with certain specified data security requirements for personal information. We intend to protect all personal information and to comply with all applicable laws regarding the protection of such information. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">86</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">In the European Union, the GDPR imposes several stringent requirements for controllers and processors of personal data, including, for example, higher standards for obtaining consent from individuals to process their personal data, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention and&#160;secondary use of information, increased requirements pertaining to health data and pseudonymised (<font style="font-style:italic;">i.e.</font>, key-coded) data and additional obligations when we contract third party processors in connection with the processing of the personal data. The GDPR provides that EU member states may make their own further laws and regulations limiting the processing of genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs could increase, and harm our business and financial condition. Failure to comply with the requirements of GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &euro;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. To comply with the new data protection rules imposed by GDPR, we may be required to put in place additional mechanisms ensuring compliance. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">European data protection law also imposes strict rules on the transfer of personal data out of the European Union, including to the United States. These obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other requirements or our practices. In addition, these rules are constantly under scrutiny. We rely on a mixture of mechanisms to transfer personal data from the European Union to the United States, and could be impacted by changes in law as a result of a future review of these transfer mechanisms by European regulators under the GDPR, as well as current challenges to these mechanisms in the European courts. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employees </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of June&#160;30, 2018, we had 155 employees worldwide, including four employees on the executive team, five employees in finance and administration, 112 employees in sales and marketing, 14 employees in research and development and 23 employees in manufacturing and supply chain. As of June&#160;30, 2018, 108 of our employees are located in the United States and Canada, 37 are located in Israel and the remainder are located in Asia, Latin America and Europe. We believe our employee relations are good. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Israeli labor laws govern the length of the workday, minimum wages for employees, procedures for hiring and dismissing employees, determination of severance pay, annual leave, sick days, advance notice of termination of employment, equal opportunity and antidiscrimination laws, and other conditions of employment. Subject to certain exceptions, Israeli law generally requires severance pay upon the retirement, death or dismissal of employees and requires us and our employees to make payments to the National Insurance Institute, which is similar to the U.S. Social Security Administration. Our Israeli employees have pension plans that comply with applicable Israeli legal requirements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">None of our Israeli employees work under any collective bargaining agreements. Extension orders issued by the Israeli Ministry of Economy and Labor apply to us and affect such matters as length of working hours and week, recuperation pay, travel expenses, and pension rights with respect to our Israeli employees. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">All of our employment and consulting agreements include employees&#8217; and consultants&#8217; undertakings with respect to confidentiality, noncompetition and assignment to us of intellectual property rights developed in the course of their employment or engagement with us. However, there can be no assurance that these agreements will be enforceable or that they will provide us with adequate protection. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Facilities </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We lease our main office and research and development facilities, located in the Industrial Zone in Yokneam, Israel, pursuant to a lease that expires in December&#160;2021. We lease approximately 10,290 square feet in the Israeli facility. Our current monthly rent payment is approximately $17,531. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our U.S. subsidiary leases a 7,344-square foot facility in Lake Forest, California pursuant to a lease that expires in August&#160;2022 in consideration for a current monthly rent payment of&#8201; $9,547. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">87</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Our Canadian subsidiary leases a 5,973-square foot facility in Richmond Hill, Ontario pursuant to a lease that expires in June&#160;2022 in consideration for a current monthly rent payment of approximately $5,505. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe our current office space is sufficient to meet our anticipated needs for the foreseeable future and is suitable for the conduct of our business. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Litigation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In January&#160;2016, Syneron Medical Ltd., or Syneron, filed a claim with the United States District Court in the Central District of California against our U.S. and Israeli subsidiaries, alleging that certain of our products infringed four U.S. patents owned by Syneron that purport to cover systems and methods for treating skin and arranging electrodes on skin therapy devices. In the framework of the claim, Syneron has requested the court to enter a permanent injunction enjoining our U.S. and Israeli subsidiaries, officers and others on our behalf from infringing the patents, and to enter a judgment and order requiring us to compensate Syneron for the alleged infringement of the patents. We believe that the claim is without merit and are defending the action vigorously. A trial hearing has been scheduled for November&#160;2018. As of December&#160;31, 2017 and 2016, we have accrued a provision of&#8201; $2.0&#160;million in connection with this litigation. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In April&#160;2017, Syneron, Inc. and Candela Corporation, or Syneron-Candela, filed a lawsuit in the United States District Court for the Western District of Tennessee against us and our wholly-owned subsidiaries in Israel and the United States, asserting claims for inducement to breach contract, interference with employment relationships, tortious interference with business and violation of the Tennessee Uniform Trade Secrets Act with respect to four former employees of Syneron-Candela who subsequently accepted employment with us. In January&#160;2018, we reached a settlement whereby, in exchange for the relief of the foregoing claims, we agreed not to hire any employee of Syneron-Candela (which was defined in the settlement agreement as any person who: (i)&#160;was employed by Syneron-Candela as of April&#160;1, 2017 or thereafter, (ii) was still employed by Syneron-Candela as of the date of the settlement agreement and (iii)&#160;was employed by Syneron-Candela in North America) during the period between the date of the settlement agreement and August&#160;25, 2018. Subsequently, following the reaching of the settlement agreement, the claim was dismissed with prejudice. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In May&#160;2017, Cynosure, Inc., or Cynosure, filed a claim with the United States District Court for the Southern District of Texas (Houston) against us and our U.S. subsidiary, claiming that we unlawfully solicited certain former Cynosure employees, misappropriated Cynosure&#8217;s trade secrets, and aided and abetted the employees&#8217; breach of their fiduciary duties to Cynosure. We reached a settlement in February&#160;2018 whereby in exchange for the relief of the foregoing claims, we agreed (i)&#160;to pay Cynosure an amount of&#8201; $47,500, (ii) not to solicit, directly or indirectly, for a period of 10&#160;months from executing the settlement agreement, any employee of Cynosure or Hologic Inc., the parent company of Cynosure, employed in North America during the said ten-month period, to accept employment with us and (iii) to apply certain search terms provided by Cynosure on the documents and materials in the email accounts of the relevant former employees of Cynosure in order to retrieve sensitive information of Cynosure and destroy such information. Subsequently, following the reaching of the settlement agreement, the claim was dismissed with prejudice. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In April&#160;2018, Syneron filed claims with the International Trade Commission and the United States District Court for the District of Massachusetts against our U.S. and Israeli subsidiaries, alleging that certain of our products infringed two U.S. patents owned by Syneron that purport to cover systems and methods for treating skin and arranging electrodes on skin therapy devices. Given the early stage in the litigation, we are unable to predict the likelihood of success of Syneron&#8217;s infringement claims, but we believe the claim is without merit and we intend to vigorously defend against these claims. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may be party from time to time to various other lawsuits, claims and other legal proceedings that arise in the ordinary course of our business. There can be no assurance that matters that arise in the future, individually or in aggregate, will not have a material adverse effect on our financial condition or results. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">88</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t12MA">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">MANAGEMENT </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Executive Officers, Directors and Director Nominees </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table sets forth information regarding our executive officers, directors and director nominees as of the date of this prospectus. </div>
        <table style="width:456pt;height:164.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:114pt;text-align:left;">
              <div style="white-space:nowrap;">Name </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:24pt;">
              <div style="white-space:nowrap; text-align:center;">Age </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:294pt;">
              <div style="white-space:nowrap; text-align:center;">Position </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:114pt;">Executive Officers</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:294pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:114pt;">Moshe Mizrahy </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">65 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294pt;">Chief Executive Officer and Chairman of Board of Directors </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:114pt;">Yair Malca </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">41 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294pt;">Chief Financial Officer </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:114pt;">Dr.&#160;Michael Kreindel </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">52 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294pt;">Chief Technology Officer and Director Nominee </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:114pt;">Shakil Lakhani </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">35 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294pt;">President, North America </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:114pt;">Dr.&#160;Spero Theodorou </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">47 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294pt;">Chief Medical Officer </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:114pt;">Non-Employee Directors</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:294pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:114pt;">Dr.&#160;Hadar Ron<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)(2)</font></td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">58 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294pt;">Director Nominee </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:114pt;">Bruce Mann<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)(2)</font></td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">83 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294pt;">Director Nominee </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:114pt;">Dr.&#160;Michael Anghel<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)(2)</font></td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">79 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294pt;">Director Nominee</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.48pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">Member of Audit Committee </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">Member of Compensation, Nominating and Corporate Governance Committee </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A brief biography of each person who serves as an executive officer and/or director or director nominee of our Company is set forth below: </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Moshe Mizrahy</font>.&nbsp;&nbsp;&nbsp;Moshe Mizrahy co-founded the Company in 2008 and has been our Chief Executive Officer and Chairman of the board of directors since inception. Prior to that, Mr.&#160;Mizrahy was co-founder and chief executive officer of Syneron Medical Ltd., a medical aesthetic device company based in Israel. Mr.&#160;Mizrahy was also the former chief executive officer of Home Skinovations Ltd., an international medical aesthetic consumer devices company active in the home use market, and is currently the chairman of its board since 2007. In addition to Home Skinovations Ltd., Mr.&#160;Mizrahy currently sits on the board of directors of the following companies: SipNose Ltd., Pet Novations Ltd., Peri-Ness Technologies Ltd., Easy-Lap Ltd, O.B.-Tools Ltd., Urifer Ltd., Easy Notes Ltd., Escape Rescue Systems Ltd., New Forest Wood Products (2012) Ltd., M.N. Business Strategy Ltd., Silk&#8217;n Cure Ltd., Himalaya Family Office Advising Ltd. and Polimer Logistics (Israel) Ltd. Mr.&#160;Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Yair Malca</font>.&nbsp;&nbsp;&nbsp; Yair Malca has served as our Chief Financial Officer since 2017. In his previous role, Mr.&#160;Malca was the Director of Finance for Jazz Semiconductor, Inc., a developer of integrated circuits and semiconductors, from 2013 to 2017. Before that, he served as the controller of Syneron Inc. from 2008 to 2013, as assistant controller of EZchip Semiconductor, a provider of network processors, from 2007 to 2008, as subsidiary controller of Bermad, a provider of hydraulic control valves, from 2005 to 2007, and began his career in public accounting at Ernst &amp; Young from 2002 to 2005. Mr.&#160;Malca holds a B.A. in Accounting and Economics from Haifa University and an MBA from Tel Aviv University, and is a Certified Public Accountant in Israel. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Dr.&#160;Michael Kreindel</font>.&nbsp;&nbsp;&nbsp;Dr.&#160;Michael Kreindel co-founded the Company in 2008 and has served as our Chief Technology Officer since inception. Dr.&#160;Kreindel will serve as a director upon the effectiveness of the registration statement of which this prospectus forms a part. He previously was a co-founder of, and served as CTO of, Syneron Medical Ltd. from 2001 to 2007. Dr.&#160;Kreindel has a Ph.D. in physics and mathematics, and also graduated as an engineer and physicist in experimental and theoretical nuclear physics from Ural Politechnical Institute, Russia.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">89</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Shakil Lakhani</font>.&nbsp;&nbsp;&nbsp;Shakil Lakhani has served as the President of InMode North America, a wholly owned subsidiary of the Company, since 2017. Prior to becoming the President of North America for the Company in August&#160;2017, Mr.&#160;Lakhani was previously the Executive Vice President of Sales for North America since February&#160;2017, where he managed all sales operations and established a new distribution strategy. He graduated with a B.A. from the University of Waterloo, and in 2006 he shifted career paths and moved into the technology space by joining Cynosure. He has held multiple roles at various levels at Cynosure, including Director of Sales from September&#160;2013 through January&#160;2017.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Dr.&#160;Spero Theodorou</font>.&nbsp;&nbsp;&nbsp;Dr.&#160;Spero Theodorou is the Company&#8217;s Chief Medical Officer and is responsible for the development of all of the Company&#8217;s procedures, clinical studies and training. Dr.&#160;Theodorou received his training in plastic and reconstructive surgery at Rush Presbyterian St. Luke&#8217;s Medical Center at Rush University in Chicago, Illinois from 2001 to 2003. Upon completion, he underwent an additional year of training in cosmetic plastic surgery at the Manhattan Eye, Ear and Throat Hospital&#8217;s (MEETH) Aesthetic Plastic Surgery Fellowship Program affiliated with Hofstra University from 2003 to 2004. Dr.&#160;Theodorou is presently on the teaching faculty at MEETH and at the American Society of Aesthetic Plastic Surgery (ASAPS) where he instructs plastic surgeons on the latest advancements in body contouring surgery. He holds an academic appointment as Clinical Assistant Professor of Surgery at Zucker school of Medicine, Hofstra University and is the founder and Surgical Director of bodySCULPT<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">&#174;</font> since November&#160;2007, which is an American Association for Accreditation of Ambulatory Surgery Facilities (AAAASF)-accredited plastic surgery practice in Manhattan, New York.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Dr.&#160;Hadar Ron.</font>&nbsp;&nbsp;&nbsp;Dr.&#160;Hadar Ron will serve as a director upon the effectiveness of the registration statement of which this prospectus forms a part. Since 2000, Dr.&#160;Ron has been the founding and managing partner of Israel Healthcare Ventures Ltd., or IHCV, an Israeli life science venture capital fund. Dr.&#160;Ron also sits on the board of IHCV since January&#160;2002. Dr.&#160;Ron serves as a chairperson of SupPlant, an Israeli agri-tech company, and G.I. View Ltd., a medical device company specializing in colorectal screenings, and as a board member of the following medical companies: Home Skinovations Ltd., SipNose Ltd., Pet Novations Ltd., Peri-Ness Technologies Ltd., Easy-Lap Ltd., O.G.D.H. Ltd., OrSense Ltd., Gamida Cell Ltd. and NanoPass Technologies Ltd. In addition, Dr.&#160;Ron serves as a member of the advisory board of the Momentum Fund&#160;Tech Transfer of Tel Aviv University and is the chairperson of the scientific advisory board of Social Finance Israel&#8217;s Social Impact Bond for the prevention of diabetes and colon cancer. Dr.&#160;Ron is a physician and attorney by education. She holds MD and LLB degrees from Tel Aviv University and has studied at the School of Business Administration at Tel Aviv University. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Bruce Mann.</font>&nbsp;&nbsp;&nbsp;Mr.&#160;Bruce Mann will serve as a director upon the effectiveness of the registration statement of which this prospectus forms a part. Bruce Mann is an independent advisor and consultant on corporate governance, corporate law, and capital markets matters, primarily for emerging technology companies. He was a senior partner, partner, or senior of counsel of Morrison &amp; Foerster LLP for 30&#160;years prior to his retirement in 2017. Mr.&#160;Mann has been a Governor-at-Large of the National Association of Securities Dealers (NASD) and a member of the New York Stock Exchange Legal Advisory Committee. He has held numerous positions in the American Bar Association, including chairing the Senior Lawyers Division, the Federal Regulation of Securities Committee and the Venture Capital and Private Equity Committee of the ABA Business Law Section. Mr.&#160;Mann holds a BBA from the University of Wisconsin and a JD from the University of Wisconsin Law School.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Dr.&#160;Michael Anghel</font>.&nbsp;&nbsp;&nbsp;Dr.&#160;Michael Anghel will serve as a director upon the effectiveness of the registration statement of which this prospectus forms a part. Dr, Anghel has served on the board of directors of BiolineRx Ltd. (Nasdaq:BLRX) since 2010 and on Bioline&#8217;s Investment Monitoring Committee since 2010. From 1977 to 1999, he led the Discount Investment Corporation Ltd. (of the IDB Group) activities in the fields of technology and communications. In 1999, he founded CAP Ventures, an advanced technology investment company. From 2004 to 2005, Dr.&#160;Anghel served as CEO of DCM, the investment banking arm of the Israel Discount Bank (TASE:DSCT). He currently serves on the board of directors of Orbotech Ltd. (Nasdaq:ORBK, GSM:ORBK) and BiolineRx Ltd. (Nasdaq:BLRX). Until recently, he served as the chairman of the Center for Educational Technology. Prior to launching his business career, Dr.&#160;Anghel served as a full-time member of the Graduate School of Business </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">90</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">Administration of the Tel  Aviv University, where he taught finance and corporate strategy. He currently serves as Chairman of the Tel Aviv University&#8217;s Executive Program. Dr.&#160;Anghel holds a B.A. in Economics from the Hebrew University in Jerusalem and an MBA and Ph.D. in Finance from Columbia University, New York. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Corporate Governance Practices </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Companies incorporated under the laws of the State of Israel, whose shares are publicly traded, including companies with shares listed on Nasdaq, are considered public companies under the Companies Law and are required to comply with various corporate governance requirements relating to such matters as the composition and responsibilities of the audit committee and the compensation committee (subject to certain exceptions that we intend to utilize), and a requirement to have an internal auditor. This is the case even if our ordinary shares are not listed on the Tel Aviv Stock Exchange, which our ordinary shares are not expected to be. These requirements are in addition to the corporate governance requirements imposed by Nasdaq rules and other applicable provisions of U.S. securities laws to which we will become subject (as a foreign private issuer) upon the closing of this offering and the listing of our ordinary shares on Nasdaq. Under Nasdaq rules, a foreign private issuer may generally follow its home country rules of corporate governance in lieu of the comparable requirements of Nasdaq rules, except for certain matters including the composition and responsibilities of the audit committee and the independence of its members within the meaning of the rules and regulations of the SEC. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We intend to rely on this &#8220;home country practice exemption&#8221; with respect to the following Nasdaq requirements: </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Quorum</font>.&nbsp;&nbsp;&nbsp;As permitted under the Companies Law and pursuant to our amended and restated articles of association, which will be effective upon the effectiveness of the registration statement of which this prospectus forms a part, the quorum required for an ordinary meeting of shareholders will consist of at least two shareholders present in person, by proxy or by other voting instrument in accordance with the Companies Law, who hold at least 25% of the voting rights in the Company (and in an adjourned meeting, with some exceptions, at least two shareholders holding any number of the voting rights in the Company), instead of 33<font style=" position:relative; bottom:2.66pt;font-size:7pt;">1</font>&#8725;<font style="font-size:7pt;">3</font>% of the issued share capital required under Nasdaq rules. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Nomination of Directors</font>.&nbsp;&nbsp;&nbsp;Our directors are elected through a staggered board mechanism. See &#8220;&#8212;&#8201;Board Practices&#8201;&#8212;&#8201;Board of Directors.&#8221; The nominations for directors, which are presented to our shareholders by our board of directors, are generally made by the board of directors itself or a duly authorized committee thereof, in accordance with the provisions of our amended and restated articles of association and the Companies Law. Nominations need not be made by a nominating committee of our board of directors consisting solely of independent directors, as required under Nasdaq rules. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Proxy Statements</font>.&nbsp;&nbsp;&nbsp;We will not be required to and, in reliance on home country practice, we do not intend to, comply with certain Nasdaq rules regarding the provision of proxy statements for general meetings of shareholders. Israeli corporate law does not have a regulatory regime for the solicitation of proxies. We intend to provide notice convening an annual general meeting, including an agenda and other relevant documents. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Shareholder Approval</font>.&nbsp;&nbsp;&nbsp;We will not be required to and, in reliance on home country practice, we do not intend to, comply with certain Nasdaq rules regarding shareholder approval for certain issuances of securities under Nasdaq Rule&#160;5635. In accordance with the provisions of our amended and restated articles of association and the Companies Law, our board of directors is authorized to issue securities, including ordinary shares, warrants and convertible notes. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Executive Sessions</font>.&nbsp;&nbsp;&nbsp;We will not be required to and, in reliance on home country practice, we do not intend to, comply with certain Nasdaq rules regarding regularly scheduled meetings at which only independent directors are present. In accordance with the provisions of our amended and restated articles of association and the Companies Law, such regularly scheduled meetings at which only independent directors are present are not required. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Other than as stated above, we currently intend to take all actions necessary for us to maintain compliance as a foreign private issuer under the applicable corporate governance requirements of the Sarbanes-Oxley Act, the rules adopted by the SEC and Nasdaq&#8217;s listing standards. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">91</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We may in the future elect to follow home country corporate governance practices in Israel with regard to other matters. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Board Practices </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Board of Directors </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, our board of directors is responsible for setting our general policies and supervising the performance of management. Our board of directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers are responsible for our day-to-day management and have individual responsibilities established by our board of directors. Our Chief Executive Officer is appointed by, and serves at the discretion of, our board of directors, subject to the terms of the consultancy agreement that we have entered into with him. All other executive officers who are not directors are appointed by our Chief Executive Officer, and are subject to the terms of any applicable employment or consultancy agreements that we may enter into with each them. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under our amended and restated articles of association, our board of directors must consist of at least three directors and not more than seven directors. Our board of directors will consist of five directors upon the effectiveness of the registration statement of which this prospectus forms a part. Our directors will be elected in three staggered classes by the vote of a majority of the ordinary shares present, in person or by proxy, at a shareholders&#8217; meeting (excluding abstentions). Each class of directors is to consist, as nearly as possible, of one-third of the total number of directors constituting the entire board of directors (other than the external directors, if applicable). At each annual general meeting of our shareholders, the election or re-election of directors following the expiration of the term of office of the directors of that class of directors will be for a term of office that expires on the third annual general meeting following such election or re-election, such that from 2019 and after, at each annual general meeting the term of office of only one class of directors will expire. Each director holds office until the third annual general meeting of our shareholders, unless the tenure of such director expires earlier pursuant to the Companies Law or unless removed from office as described below. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our directors will be divided among three classes as follows: the Class&#160;I director, consisting of Dr.&#160;Michael Anghel, will hold office until our annual general meeting of shareholders to be held in 2019; the Class&#160;II directors, consisting of Dr.&#160;Hadar Ron and Mr.&#160;Bruce Mann, will hold office until our annual general meeting of shareholders to be held in 2020; and the Class&#160;III directors, consisting of Mr.&#160;Moshe Mizrahy and Dr.&#160;Michael Kreindel, will hold office until our annual general meeting of shareholders to be held in 2021. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The provisions of our amended and restated articles of association relating to the number of directors, staggered board and election and removal of a director from office prior to the lapse of their tenure may be changed only by a resolution adopted by two-thirds of our ordinary shares voting on the proposed change. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, our board of directors is required to employ independent judgment and discretion when voting, and is prohibited from entering into any voting arrangements with respect to actions taken at meetings of the board. Further, the Companies Law provides that in the event a director learns about an alleged breach of law or improper conduct of business relating to a company matter, said director must promptly take action to summon a meeting of the board of directors to address any such breach. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In accordance with the exemptions available to foreign private issuers under Nasdaq rules, we do not intend to follow the requirements of Nasdaq rules with regard to the process of nominating directors. Instead, we intend to follow Israeli law and practice, in accordance with which our board of directors (or a committee thereof) is authorized to recommend to our shareholders director nominees for election. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, our amended and restated articles of association allow our board of directors to appoint directors to fill vacancies on our board of directors, including filling empty board seats up to the maximum number of directors permitted under our amended and restated articles of association, for a term of office equal to the remaining period of the term of office of each director whose office has been vacated. Vacancies on our board of directors may be filled by a vote of a simple majority of the directors then in </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">92</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">office even if they do not constitute a quorum (subject to the limitation on the number of directors and their qualifications). A director so appointed will hold office until the next applicable annual general meeting of our shareholders in which such director&#8217;s class is to be replaced. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Directors may be removed from office by a resolution at a general meeting of shareholders adopted by holders of two-thirds of our ordinary shares voting on the proposed removal, provided that the director being removed from office is given a reasonable opportunity to state his or her case before the general meeting, or under other circumstances set forth in our amended and restated articles of association. If a director is removed from office as set forth above, the general meeting will be entitled, in the same session, to elect another director in his or her place subject to the maximum number of directors permitted as stated above. Should it fail to do so, the board of directors will be entitled to do so. Any director who is appointed in this manner will serve in office for the remainder of the removed director&#8217;s term in office, and will be eligible for re-election. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, we would be required to include on our board of directors at least two members, each of whom qualifies as an external director, and as to whom special qualifications, voting requirements and other provisions would be applicable. We would also be required to include one such external director on each of our board committees. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">However, under regulations promulgated under the Companies Law, Israeli companies whose shares are traded on stock exchanges such as Nasdaq that do not have a controlling shareholder (as defined therein) and which comply with the requirements of the jurisdiction where the company&#8217;s shares are traded with respect to the appointment of independent directors and the composition of an audit committee and compensation committee, may elect not to follow the Companies Law requirements with respect to the composition of its audit committee and compensation committee and the appointment of external directors (provided that in the event that upon the appointment of a certain director all members of the board of directors of the company are from one and the same gender only, a director from the opposite gender will be appointed). As we do not have a controlling shareholder, we intend to comply with the requirements of Nasdaq with respect to the composition of our board and such committees, and therefore we will be exempt from the Companies Law requirements with respect thereto, including the appointment of external directors. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Leadership Structure of the Board </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In accordance with the Companies Law and our amended and restated articles of association, our board of directors is required to appoint one of its members to serve as chairman of the board of directors. Mr.&#160;Moshe Mizrahy currently serves as the Chairman of our board of directors. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, the chairman of the board of directors or his relatives cannot be vested with the authority of the chief executive officer of a company, without the approval of a special majority of such company&#8217;s shareholders. The shareholders&#8217; approval can be provided for a period of five&#160;years following an initial public offering, and subsequently, for additional periods of up to three&#160;years. The shareholders&#8217; special majority consists of a majority vote of the shares present and voting at a shareholders meeting, provided that either: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">such majority includes at least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in approving such resolution that are voted at the meeting, excluding abstentions; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the total number of shares voted by non-controlling shareholders and by shareholders who do not have a personal interest against approving such resolution does not exceed 2% of the aggregate voting rights in the company. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">Our shareholders have approved Mr.&#160;Moshe Mizrahy serving as both our Chief Executive Officer and Chairman of our board of directors and such approval will be valid for a period of five&#160;years following the consummation of this offering. The Companies Law also prohibits a direct or indirect subordinate to the chief executive officer of a company from serving as the chairman of such company&#8217;s board of directors. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">93</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Committees of the Board of Directors </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law and our amended and restated articles of association, our board of directors is permitted to form committees, and to delegate to any such committee powers allotted to the board of directors, subject to certain exceptions. In general, the board of directors may overturn a resolution adopted by a committee it has formed;, however, the board&#8217;s decision shall not affect the ability of third parties, who were not aware of such decision, to rely on the committee&#8217;s resolution prior to the time it is overturned. Only members of the board of directors can be members of a board committee, unless the committee is solely advisory. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Audit Committee </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon the effectiveness of the registration statement of which this prospectus forms a part, our audit committee will consist of Dr.&#160;Michael Anghel, Dr.&#160;Hadar Ron and Mr.&#160;Bruce Mann. Dr.&#160;Anghel will serve as chairperson of the audit committee. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Israeli Companies Law Requirements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, we will be required to appoint an audit committee following the closing of this offering. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Nasdaq Listing Requirements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under Nasdaq rules, we are required to maintain an audit committee consisting of at least three independent directors, each of whom is financially literate and one of whom has accounting or related financial management expertise. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. Our board of directors has determined that Dr.&#160;Michael Anghel is an audit committee financial expert as such term is defined by the SEC rules and has the requisite financial experience as defined by Nasdaq rules. Each of the members of our audit committee is &#8220;independent&#8221; as such term is defined in Rule&#160;10A-3(b)(1) under the Exchange Act and satisfies the independent director requirements under Nasdaq rules. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Audit Committee Role </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our audit committee charter, to be effective upon the effectiveness of the registration statement of which this prospectus forms a part, sets forth the responsibilities of the audit committee consistent with the rules and regulations of the SEC and Nasdaq rules, as well as the requirements for such committee under the Companies Law, including the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors in accordance with Israeli law; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">recommending the engagement or termination of the person filling the office of our internal auditor; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our board of directors. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our audit committee provides assistance to our board of directors in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing, financial reporting, internal control and legal compliance functions by pre-approving the services performed by our independent accountants and reviewing their reports regarding our accounting practices and systems of internal control over financial reporting. Our audit committee also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself that the auditors are independent of management.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">94</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">Under the Companies Law, our audit committee is responsible for: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">determining whether there are deficiencies in the business management practices of our company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the board of directors to improve such practices; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under the Companies Law) (see &#8220;&#8212;&#8201;Approval of Related Party Transactions under Israeli Law&#8201;&#8212;&#8201; Office Holders&#8221;); </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">establishing the approval process for certain transactions with a controlling shareholder or in which a controlling shareholder has a personal interest; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">where the board of directors approves the working plan of the internal auditor, examining such working plan before its submission to the board of directors and proposing amendments thereto; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">examining our internal audit controls and internal auditor&#8217;s performance, including whether the internal auditor has sufficient resources and tools to fulfill his responsibilities; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">examining the scope of our auditor&#8217;s work and compensation and submitting a recommendation with respect thereto to our board of directors or shareholders, depending on which of them is considering the appointment of our auditor; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">establishing procedures for the handling of employees&#8217; complaints as to deficiencies in the management of our business and the protection to be provided to such employees. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Compensation, Nominating and Governance Committee and Compensation Policy </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish a compensation, nominating and corporate governance committee. The members of this committee will be Dr.&#160;Michael Anghel, Dr.&#160;Hadar Ron and Mr.&#160;Bruce Mann. Mr.&#160;Mann will serve as chairperson of the committee.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Israeli Companies Law Requirements</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, the board of directors of a public company must appoint a compensation committee. The duties of the compensation, nominating and corporate governance committee include the recommendation to our board of directors of a policy regarding the terms of engagement of office holders (as defined in the Companies Law), to which we refer as a compensation policy. The term &#8220;office holder&#8221; is defined under the Companies Law as a chief executive officer (referred to in the Companies Law as the general manager), chief business manager, deputy general manager, vice general manager, any other person assuming the responsibilities of any of these positions regardless of that person&#8217;s title, a director and any other manager directly subordinate to the general manager. That policy must be adopted by our board of directors, after considering the recommendations of the compensation, nominating and corporate governance committee, and will need to be approved by our shareholders, which approval requires what we refer to as a Special Majority Approval for Compensation. A Special Majority Approval for Compensation requires shareholder approval by a majority vote of the ordinary shares present and voting at a meeting of shareholders called for such purpose, provided that either: (i)&#160;such majority includes at least a majority of the ordinary shares held by all shareholders who are not controlling shareholders and do not have a personal interest in such compensation arrangement, excluding abstentions; or (ii)&#160;the total number of ordinary shares of non-controlling shareholders and shareholders who do not have a personal interest in the compensation arrangement and who vote against the arrangement does not exceed 2% of the company&#8217;s aggregate voting rights.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Even if our shareholders do not approve the compensation policy, the board of directors may resolve to approve the compensation policy if and to the extent the compensation committee and the board determine, in its judgment following internal discussions and after reconsidering the compensation policy, that approval of the compensation policy is in the best interests of the company.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">95</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Our compensation policy will be approved by our shareholders prior to the effectiveness of the registration statement of which this prospectus forms a part and, in accordance with the regulations promulgated under the Companies Law, will be in effect for a period of five years from the consummation of this offering. The compensation policy will be reviewed from time to time by our compensation committee and our board of directors, according to the requirements of the Companies Law.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The compensation policy must serve as the basis for decisions concerning the financial terms of employment or engagement of office holders, including exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy must relate to certain factors, including advancement of the company&#8217;s long-term objectives, business plan and policies, and creation of appropriate incentives for office holders. It must also consider, among other things, the company&#8217;s risk management, size and the nature of its operations. The compensation policy must furthermore consider the following additional factors:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the education, skills, expertise and accomplishments of the relevant office holder;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the office holder&#8217;s roles and responsibilities and prior compensation agreements with him or her;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the relationship between the terms offered and the average compensation of the company&#8217;s personnel, including those employed through outsourcing firms;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the impact of disparities in salary upon work relationships in the company;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the possibility of reducing variable compensation at the discretion of the board of directors;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the possibility of setting a limit on the exercise value of non-cash variable equity-based compensation; and</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">as to severance compensation, the period of service of the office holder, the terms of his or her compensation during such service period, the company&#8217;s performance during that period of service, the person&#8217;s contribution towards the company&#8217;s achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The compensation policy must also include the following principles: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the link between variable compensation and long-term performance and measurable criteria; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the conditions under which an office holder would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was restated in the company&#8217;s financial statements; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the minimum holding or vesting period for variable, equity-based compensation while referring to an appropriate long-term perspective based incentives; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">maximum limits for severance compensation. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Compensation, Nominating and Corporate Governance Committee Roles </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The compensation, nominating and corporate governance committee is responsible for (i)&#160;recommending the compensation policy to our board of directors for its approval (and subsequent approval by our shareholders) and (ii)&#160;undertaking duties related to the compensation policy and to the compensation of our office holders, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">recommending whether a compensation policy should continue in effect, if the then-current policy has a term of greater than five&#160;years from a company&#8217;s initial public offering, or otherwise three&#160;years (approval of either a new compensation policy or the continuation of an existing compensation policy must in any case occur five&#160;years from a company&#8217;s initial public offering, or otherwise every three&#160;years); </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">recommending to the board of directors periodic updates to the compensation policy; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">96</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">assessing implementation of the compensation policy; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">determining whether to approve the terms of compensation of certain office holders which, according to the Companies Law, require the committee&#8217;s approval; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">determining whether the compensation terms of a candidate for the position of the chief executive officer of the company needs to be brought to approval of the shareholders according to the Companies Law. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our compensation, nominating and corporate governance charter, to be effective upon the effectiveness of the registration statement of which this prospectus forms a part, sets forth the responsibilities of the compensation, nominating and corporate governance committee, which include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the responsibilities set forth in the compensation policy; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">reviewing and approving the granting of options and other incentive awards to the extent such authority is delegated by our board of directors; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">reviewing, evaluating and making recommendations regarding the compensation and benefits for our non-employee directors. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, our compensation, nominating and corporate governance committee is responsible for: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">overseeing our corporate governance functions on behalf of the board; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">making recommendations to the board regarding corporate governance issues; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">identifying and evaluating candidates to serve as our directors consistent with the criteria approved by the board; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">reviewing and evaluating the performance of the board; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">serving as a focal point for communication between director candidates, non-committee directors and our management; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">selecting or recommending to the board for selection candidates to the board; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">making other recommendations to the board regarding affairs relating to our directors. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Disclosure of Compensation of Executive Officers and Directors </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For so long as we qualify as a foreign private issuer, we are not required to comply with the proxy rules applicable to U.S. domestic companies, including the requirement applicable to emerging growth companies to disclose the compensation of our Chief Executive Officer, Chief Financial Officer and other three most highly compensated executive officers on an individual, rather than on an aggregate, basis. Nevertheless, under regulations promulgated under the Companies Law, we are required to disclose the annual compensation of our five most highly compensated office holders on an individual basis. This disclosure will not be as extensive as that required of a U.S. domestic issuer. We intend to commence providing such disclosure, at the latest, in the notice (which is generally part of the proxy statement) for our 2019 annual general meeting of shareholders, which will be filed under cover of a Report of Foreign Private Issuer on Form 6-K and we may elect to provide such information at an earlier date. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For the year ended December&#160;31, 2017, we paid an aggregate of approximately $1.1&#160;million in cash and benefits to our executive officers. We do not pay our non-executive directors. For share incentive grants to our officers and directors, see &#8220;&#8212;&#8201;Employee Benefit Plans.&#8221; We have not set aside or accrued any amount to provide pension, retirement or other similar benefits to our executive officers and directors. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Internal Auditor </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, the board of directors of an Israeli public company must appoint an internal auditor recommended by the audit committee. An internal auditor may not be: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a person (or a relative of a person) who holds more than 5% of the company&#8217;s outstanding shares or voting rights; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">97</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a person (or a relative of a person) who has the power to appoint a director or the general manager of the company; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an office holder (including a director) of the company (or a relative thereof); or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a member of the company&#8217;s independent accounting firm, or anyone on its behalf. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The role of the internal auditor is to examine, among other things, our compliance with applicable law and orderly business procedures, and to report to the chief executive officer, the chairman of the board and the chairman of the audit committee. The internal auditor is entitled to receive notice of audit committee meetings and to participate in them. In addition, the internal auditor may request that the chairman of the audit committee convene a meeting within a reasonable time to discuss an issue raised by the internal auditor. The internal auditor is responsible for preparing a proposal for an annual or periodical audit plan and submit such plan to the board of directors or the audit committee for their approval. We intend to appoint an internal auditor following the closing of this offering. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Code of Business Conduct and Ethics </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We intend to adopt a Code of Business Conduct and Ethics applicable to all of our directors and employees, including our Chief Executive Officer, Chief Financial Officer, controller or principal accounting officer, or other persons performing similar functions, which is a &#8220;code of ethics&#8221; as defined in Item&#160;16B of Form 20-F promulgated by the SEC. Upon the effectiveness of the registration statement of which this prospectus forms a part, the full text of the Code of Business Conduct and Ethics will be posted on our website at www.inmodemd.com. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus and is not incorporated by reference herein. If we make any amendment to the Code of Business Conduct and Ethics or grant any waivers, including any implicit waiver, from a provision of the code of ethics, we will disclose the nature of such amendment or waiver on our website to the extent required by the rules and regulations of the SEC. Under Item&#160;16B of Form 20-F, if a waiver or amendment of the Code of Business Conduct and Ethics applies to our principal executive officer, principal financial officer, principal accounting officer or controller and relates to standards promoting any of the values described in Item&#160;16B(b) of Form 20-F, we are required to disclose such waiver or amendment on our website in accordance with the requirements of Instruction 4 to such Item&#160;16B.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employment and Consulting Agreements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have entered into employment or consulting agreements with all of our executive officers and key employees. These agreements contain standard provisions for a company in our industry regarding non-solicitation, confidentiality of information, non-competition and assignment of inventions. Our executive officers will not receive benefits upon the termination of their respective employment with us, other than payment of salary and benefits (and limited accrual of vacation days) during the required notice period for termination of their employment, which varies for each individual. The agreements are terminable by us at will, subject to prior notice, which varies for each individual.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employee Benefit Plans </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">2008 Plans </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On January&#160;30, 2008, our board of directors adopted the 2008 Israeli Option Plan, or 2008 Israeli Plan, pursuant to the Companies Law and Section&#160;102 of the Israeli Income Tax Ordinance, 1961, or the Tax Ordinance, allowing us to grant options to purchase our ordinary shares to our and our current and future affiliates&#8217; Israeli employees, officers, directors, consultants and service providers. Under Israeli law, no shareholder approval was required to approve the 2008 Israeli Plan. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On January&#160;30, 2008, concurrently with the adoption of the 2008 Israeli Plan, our board of directors also adopted the 2008 Rest of the World Options Plan, or 2008 ROW Plan, allowing us to grant options to purchase our ordinary shares to our and our current and future affiliates&#8217; non-Israeli employees, consultants and service providers. The 2008 ROW Plan was approved by our shareholders on March&#160;16, 2008. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">98</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Options granted under the 2008 Israeli Plan and 2008 ROW Plan generally vest over a period of three&#160;years, but shorter or longer vesting schedules have been set. Any option that is canceled or forfeited before expiration of its vesting period becomes available for future grants. Additionally, options under the 2008 Israeli Plan and 2008 ROW Plan generally expire seven&#160;years after the initial grant date, unless extended by the board of directors. Our board of directors has previously extended the expiration period of certain options prior to their original expiration date. Under the 2008 Israeli Plan, as of June&#160;30, 2018, we have granted options to purchase a total of 1,095,000 ordinary shares, of which no ordinary shares have been issued upon the exercise of such options. Under the 2008 ROW Plan, as of June&#160;30, 2018, we have granted options to purchase a total of 4,330,992 ordinary shares, of which 303,447 ordinary shares have been issued upon the exercise of such options and options to purchase 4,027,545 ordinary shares are outstanding. For more information, see Note 10 to our consolidated financial statements included elsewhere in this prospectus. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table sets forth, as of June&#160;30, 2018, the total number of ordinary shares issuable upon exercise of the options granted to each of our executive officers under the 2008 Israeli Plan and 2008 ROW Plan, the exercise price of such options, the date of grant and the date of expiration. Except for Mr.&#160;Bruce Mann, none of our directors hold options. </div>
        <table style="width:456pt;height:155.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:263.05pt;text-align:left;">
              <div style="white-space:nowrap;">Name</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Number of <br >Options </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Exercise <br >Price </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:40.62pt;">
              <div style="text-align:center;">Date of <br >Grant </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:40.62pt;">
              <div style="text-align:center;">Expiration <br >Date </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:263.05pt;text-align:left;">
              <div style="white-space:nowrap;">Yair Malca </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">70,000</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.00</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:40.62pt;text-align:center;">
              <div style="text-align:center;">6/1/2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:40.62pt;text-align:center;">
              <div style="text-align:center;">6/1/2024 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:263.05pt;text-align:left;">
              <div style="white-space:nowrap;">Shakil Lakhani </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">500,000</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.00</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:40.62pt;text-align:center;">
              <div style="text-align:center;">2/16/2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:40.62pt;text-align:center;">
              <div style="text-align:center;">2/16/2024 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:263.05pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">109,500</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.00</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:40.62pt;text-align:center;">
              <div style="text-align:center;">6/1/2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:40.62pt;text-align:center;">
              <div style="text-align:center;">6/1/2024 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:263.05pt;text-align:left;">
              <div style="white-space:nowrap;">Dr.&#160;Spero Theodorou </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,500</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.00</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:40.62pt;text-align:center;">
              <div style="text-align:center;">4/15/2010 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:40.62pt;text-align:center;">
              <div style="text-align:center;">3/31/2022 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:263.05pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">70,000</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.00</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:40.62pt;text-align:center;">
              <div style="text-align:center;">1/26/2011 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:40.62pt;text-align:center;">
              <div style="text-align:center;">3/31/2022 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:263.05pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">15,000</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.00</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:40.62pt;text-align:center;">
              <div style="text-align:center;">4/4/2012 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:40.62pt;text-align:center;">
              <div style="text-align:center;">4/4/2019 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:263.05pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">177,000</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.00</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:40.62pt;text-align:center;">
              <div style="text-align:center;">6/1/2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:40.62pt;text-align:center;">
              <div style="text-align:center;">6/1/2024 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:263.05pt;text-align:left;">
              <div style="white-space:nowrap;">Bruce Mann </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">15,000</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.00</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:40.62pt;text-align:center;">
              <div style="text-align:center;">6/1/2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:40.62pt;text-align:center;">
              <div style="text-align:center;">6/1/2024</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:16.99pt; width:436pt; line-height:12pt;">The options above are fully vested as of June&#160;30, 2018. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Israeli tax law allows us to choose from among three alternative sets of tax treatment for our 2008 Israeli Plan and for future plans. In approving the 2008 Israeli Plan, our board of directors selected the capital gains tax treatment under Section&#160;102 of the Tax Ordinance described below for grants to Israeli employees and other office holders, including directors. In accordance with the capital gains tax treatment under Section&#160;102 of the Tax Ordinance, the 2008 Israeli Plan allowed for beneficial tax treatment for options issued through a trustee to Israeli employees and other office holders, including directors, provided that options granted thereunder or, upon their exercise, the underlying ordinary shares, are held by a trustee for at least two&#160;years following the date of the option grant. Under Section&#160;102 of the Tax Ordinance, Israeli employees and other office holders, including directors, are (i)&#160;entitled to defer any taxable event with respect to the options until the underlying ordinary shares are sold or withdrawn from the trust, and (ii)&#160;subject to capital gains tax of 25% on the sale of the underlying ordinary shares. In addition, we may not recognize expenses pertaining to the options for Israeli tax purposes. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the 2008 ROW Plan, we were able to grant our non-Israeli employees, officers, directors, consultants and service providers options to purchase our ordinary shares. The 2008 ROW Plan did not allow favorable tax treatment for our U.S., Canadian and other non-Israeli directors, officers, employees and consultants. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The 2008 Israeli Plan and the 2008 ROW Plan expired in January&#160;2018 and additional grants may not be made thereunder; however, options granted under such plans prior to their expiration remain valid following such expiration. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">99</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">2018 Incentive Plan </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In connection with this offering, our board of directors has adopted on June&#160;17, 2018, a new Incentive Plan, or the 2018 Incentive Plan, allowing us to grant options to purchase our ordinary shares, restricted shares or other awards to our and our current and future affiliates&#8217; Israeli and other non-U.S. employees, officers, directors, consultants and service providers. In approving the 2018 Incentive Plan, our board of directors selected the capital gains tax treatment described above for grants to Israeli employees and other office holders, including directors, under the 2018 Incentive Plan. The 2018 Incentive Plan also includes as an appendix a sub-plan, or the U.S. Sub-Plan, allowing us to grant options to purchase our ordinary shares, restricted shares or other incentive awards to our and our current and future affiliates&#8217; U.S. employees, officers, directors, consultants and service providers. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Up to 1,000,000 of our authorized and unissued ordinary shares may be issued pursuant to awards under the 2018 Incentive Plan. Upon adoption of the 2018 Incentive Plan, our board of directors has resolved that the number of reserved authorized and unissued ordinary shares of the company for issuance of awards pursuant to the 2018 Incentive Plan, shall automatically increase on an annual basis in such manner that on the first business day of each calendar year beginning in 2019 such number of reserved ordinary shares equal to the lesser of&#8201; (i)&#160;800,000 ordinary shares, (ii) three&#160;percent (3%) of the number of ordinary shares outstanding as of such date, or (iii) a lesser number of ordinary shares determined by the board of directors, will be added to the reserved authorized and unissued ordinary shares of the company for issuance of awards pursuant to the 2018 Incentive Plan. Awards will be made pursuant to agreements and may be subject to vesting and other restrictions as determined by the board of directors or the compensation committee. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The following paragraphs summarize the terms of the 2018 Incentive Plan: </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Plan&#160;Administration.</font>&nbsp;&nbsp;&nbsp;Our board of directors or the compensation committee acts as the plan administrator. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Types of Awards.</font>&nbsp;&nbsp;&nbsp;The 2018 Incentive Plan permits grants of options, ordinary shares, restricted stock or restricted stock&#160;units. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Exercise Period</font>.&nbsp;&nbsp;&nbsp;Options granted under the 2018 Incentive Plan are exercisable for a period of seven&#160;years following the date of grant, unless otherwise determined by our board of directors or our compensation committee. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Exercise Price</font>.&nbsp;&nbsp;&nbsp;Our board of directors or compensation committee has discretion in determining the exercise price of awards, subject to certain limitations. The 2018 Incentive Plan provides procedures for the cashless exercise of options. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Transactions</font>.&nbsp;&nbsp;&nbsp;The 2018 Incentive Plan provides that in the event of a &#8220;Transaction&#8221; (which is defined as (i)&#160;a merger, acquisition or consolidation of the Company with one or more other entities in which the Company is not the surviving entity; or (ii) a sale or other disposition of all or substantially all, as determined by our board of directors in its discretion, of the outstanding ordinary shares of the Company; or (iii) a sale or other disposition of all or substantially all, as determined by our board of directors in its discretion, of the consolidated assets of the Company and its affiliates), if the unexercised awards then outstanding under the 2018 Incentive Plan are assumed or substituted for securities of the successor company pursuant to the Transaction, then the board of directors or compensation committee, in their sole discretion and subject to applicable laws, may adjust the exercise price and number and type of shares of such unexercised awards to reflect such assumption and/or substitution. All other terms and conditions of the award agreements shall remain unchanged, including but not limited to the vesting period. The 2018 Incentive Plan further provides that our board of directors shall have full power and authority to determine that all outstanding awards shall terminate and cease to be outstanding, except to the extent assumed or substituted as aforesaid. In the event that awards are not assumed or substituted by the successor company, our board of directors may provide the participant the right to exercise the vested awards under such terms and conditions as our board of directors shall determine prior to the Transaction. In addition, our 2018 Incentive Plan further provides that, subject to any applicable law, our board of directors or our compensation committee shall have full power and authority to determine that in certain option awards there shall be a clause providing different provisions with respect to the vesting period of awards underlying such award agreement or any portion thereof in the event of a Transaction. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">100</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Termination</font>.&nbsp;&nbsp;&nbsp;The 2018 Incentive Plan provides that in the event of a participant&#8217;s termination of services as an employee, director, consultant or contractor of the Company and/or its subsidiaries, other than by reason of such participant&#8217;s death or disability or due to termination for cause, all awards which are vested upon the date of termination shall be exercisable during a period of 90&#160;days from the date of termination, unless otherwise determined by our board of directors or our compensation committee. All awards that are not vested upon the date of termination shall terminate immediately. The participant shall forfeit any ordinary shares acquired pursuant to an award of restricted stock that remains unvested as of the date of termination. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Plan&#160;Term</font>.&nbsp;&nbsp;&nbsp;Unless terminated earlier, the 2018 Incentive Plan will continue in effect for a term of ten&#160;years from the date of its adoption. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Approval of Related Party Transactions under Israeli Law </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Office Holders </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Companies Law codifies the fiduciary duties that office holders owe to a company. Each person listed in the table above under &#8220;&#8212;&#8201;Executive Officers, Directors and Director Nominees&#8221; is, or upon the effectiveness of the registration statement of which this prospectus forms a part will be, an office holder under the Companies Law. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Fiduciary duties</font>.&nbsp;&nbsp;&nbsp;An office holder&#8217;s fiduciary duties consist of a duty of loyalty and a duty of care. The duty of loyalty requires the office holder to act in good faith and for the benefit of the company, and includes, among other things, the duty to avoid any conflict of interest between the office holder&#8217;s position in the company and personal affairs, and proscribes any competition with the company or the exploitation of any business opportunity of the company in order to receive personal advantage for himself or herself or others. This duty also requires him or her to reveal to the company any information or documents relating to the company&#8217;s affairs that the office holder has received due to his or her position as an office holder. The duty of care requires an office holder, among other things, to act with a level of care that a reasonable office holder in the same position would employ under the same circumstances. This includes the duty to use reasonable means to obtain information regarding the advisability of a given action submitted for his or her approval or performed by virtue of his or her position and all other relevant information pertaining to these actions. We may approve an act specified above which would otherwise constitute a breach of an office holder&#8217;s duty of loyalty, provided that the office holder acted in good faith, the act or its approval does not harm the Company, and the office holder discloses his or her personal interest in a timely manner before the date for discussion of approval of such act. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Compensation</font>.&nbsp;&nbsp;&nbsp;The compensation of, or an undertaking to indemnify or insure, an office holder who is not a director generally requires approval first by the company&#8217;s compensation committee, then by the company&#8217;s board of directors. If such compensation arrangement or an undertaking to indemnify or insure is inconsistent with the company&#8217;s compensation policy, or if the office holder is the chief executive officer (apart from a number of specific exceptions), then such arrangement is further subject to a Special Majority Approval for Compensation. If the shareholders of a company do not approve the compensation terms of office holders at a meeting of the shareholders, other than directors, the compensation committee and board of directors may override the shareholders&#8217; decision, subject to certain conditions. Arrangements regarding the compensation, indemnification or insurance of a director require the approval of the compensation committee, board of directors and shareholders by simple majority, in that order, and under certain circumstances, a Special Majority Approval for Compensation. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Disclosure of personal interest</font>.&nbsp;&nbsp;&nbsp;The Companies Law requires that an office holder promptly disclose to the company any personal interest that he or she may have and all related documents and material information known to him or her, in connection with any existing or proposed transaction by the company. &#8220;Personal interest,&#8221; as defined by the Companies Law, includes a personal interest of any person in an act or transaction of the company, including a personal interest of his or her relative or of a corporate body in which that person or a relative of that person is a 5% or greater shareholder, a holder of 5% or more of the voting rights, a director or general manager, or in which he or she has the right to appoint at least one director or the chief executive officer. &#8220;Personal interest&#8221; does not apply to a personal interest stemming merely from one&#8217;s ownership of shares in the company. A personal interest also includes (1)&#160;a personal </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">101</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">interest of a person who votes according to a proxy of another person, including in the event that the other person has no personal interest, and (2)&#160;a personal interest of a person who gave a proxy to another person to vote on his or her behalf regardless of whether or not the discretion of how to vote lies with the person voting. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The office holder must make the disclosure of his personal interest promptly and no later than the first meeting of the company&#8217;s board of directors that discusses the particular transaction. This duty to disclose such information does not apply if the personal interest of the office holder derives solely from the personal interest of a relative of the office holder in a transaction unless it is an &#8220;extraordinary transaction.&#8221; The Companies Law defines an extraordinary transaction as a transaction not in the ordinary course of business, not on market terms or that is likely to have a material impact on the company&#8217;s profitability, assets or liabilities, and defines a relative as a spouse, sibling, parent, grandparent, descendent, spouse&#8217;s descendant, sibling or parent, and the spouse of any of the foregoing. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Approvals</font>.&nbsp;&nbsp;&nbsp;The Companies Law provides that a transaction with an office holder or a transaction in which an office holder has a personal interest may not be approved if it is adverse to the company&#8217;s interest. In addition, such a transaction generally requires board approval, unless the transaction is an extraordinary transaction or the articles of association provide otherwise and provided that the transaction is in the company&#8217;s interest and is performed by the office holder in good faith. If the transaction is an extraordinary transaction, first the audit committee and then the board of directors, in that order, must approve the transaction. Under certain circumstances, shareholder approval may also be required. Generally, a director (and any person in general) who has a personal interest in an extraordinary transaction that is considered at a meeting of the board of directors or the audit committee may not attend that meeting or vote on that matter, unless a majority of the board of directors or the audit committee, as the case may be, also has a personal interest in the matter then, in such event, all directors may participate in discussions of the audit committee or the board of directors (as applicable) on such transaction and the voting on approval thereof. If a majority of the board of directors or the audit committee has a personal interest in the transaction, shareholder approval also would be required for the approval of such transaction. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Controlling Shareholders </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Companies Law imposes the same disclosure requirements, as described above, on a controlling shareholder of a public company that it imposes on an office holder. For these purposes, a controlling shareholder is any shareholder that has the ability to direct the company&#8217;s actions, including any shareholder holding 25% or more of the voting rights if no other shareholder owns more than 50% of the voting rights in the company. Two or more shareholders with a personal interest in the approval of the same transaction are deemed to be one shareholder. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Approval of the audit committee or the compensation committee (with respect to compensation arrangements) as the case may be, the board of directors and our shareholders is required for: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a private placement in which a controlling shareholder has a personal interest; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">transactions for the provision of services, whether directly or indirectly, by a controlling shareholder or his or her relative, or a company such controlling shareholder controls, and transactions concerning the terms of engagement of a controlling shareholder or a controlling shareholder&#8217;s relative, whether as an office holder or an employee. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The shareholder approval must include the majority of shares voted at the meeting. In addition, either: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">at least a majority of the shares held by the shareholders who have no personal interest in the transaction and are present and voting at the meeting must be voted in favor of approving the transaction, excluding abstentions; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the total shareholdings of those who have no personal interest in the transaction and who vote against the transaction must not represent more than 2% of the aggregate voting rights in the company. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">102</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">In addition, any extraordinary transaction with a controlling shareholder or in which a controlling shareholder has a personal interest with a term of more than three&#160;years, and under certain conditions, five&#160;years from a company&#8217;s initial public offering, requires the abovementioned approval at the end of such period; however, such transactions not involving the receipt of services or compensation can be approved for a longer term, provided that the audit committee determines that such longer term is reasonable under the circumstances. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pursuant to regulations promulgated under the Companies Law, certain transactions with a controlling shareholder or his or her relative, or with directors or other office holders, that would otherwise require approval of a company&#8217;s shareholders may be exempt from shareholder approval upon certain conditions. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Shareholder Duties </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, a shareholder has a duty to act in good faith and in a customary manner towards the company and other shareholders and to refrain from abusing his or her power in the company including, among other things, when voting in a general meeting of shareholders or in a class meeting on the following matters: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an amendment to the articles of association; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an increase in the company&#8217;s authorized share capital; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a merger; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">approval of related party transactions and acts of office holders that require shareholder approval. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A shareholder also has a general duty to refrain from discriminating against other shareholders. In addition, any controlling shareholder, any shareholder who knows that it possesses the power to determine the outcome of a shareholder vote and any shareholder who, under the company&#8217;s articles of association, has the power to appoint or prevent the appointment of an office holder in the company, or has another power with respect to the company, is under a duty to act with fairness towards the company. The Companies Law does not describe the substance of this duty of fairness except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty to act with fairness, taking the shareholder&#8217;s position in the company into account. There is limited case law available to assist in understanding the nature of these duties or the implications of these provisions.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Exculpation, Indemnification and Insurance of Directors and Officers</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our amended and restated articles of association allow us to indemnify, exculpate and insure our office holders to the fullest extent permitted by the Companies Law, the Israeli Securities Law, 1968, or the Securities Law, and the Restrictive Trade Practices Law, 1988, or the Restrictive Trade Practices Law. Our articles of association also allow us to insure or indemnify any person who is not an office holder, including any employee, agent, consultant or contractor who is not an office holder.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, the Securities Law and the Restrictive Trade Practices Law, a company may indemnify an office holder against the following liabilities, payments and expenses incurred in his or her capacity as an office holder, either in advance of the act or following the act, provided its articles of association authorize such indemnification:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a monetary liability incurred by or imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitration award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and to an amount, or according to criteria, determined by the board of directors as reasonable under the circumstances. Such undertaking shall detail the foreseen events and amount or criteria mentioned above;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">reasonable litigation expenses, including reasonable attorneys&#8217; fees, incurred by the office holder (i)&#160;as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (a)&#160;no indictment was filed </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">103</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">against such office holder as a result of such investigation or proceeding, and (b)&#160;no financial liability was imposed upon him or her as a substitute for a criminal proceeding against them as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that did not require proof of criminal intent; and (ii)&#160;in connection with a monetary sanction;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses incurred by the office holder with respect to proceedings held pursuant to certain provisions of the Restrictive Trade Practices Law;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a monetary liability imposed on the office holder in favor of a payment for a breach offended at an Administrative Procedure (as defined below) as set forth in Section&#160;52(54)(a)(1)(a) of the Securities Law;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses expended by the office holder with respect to an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&#8217; fees; and</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">any other obligation or expense in respect of which it is permitted or will be permitted under applicable law to indemnify an office holder, including, without limitation, matters referenced in Section 56H(b)(1) of the Securities Law.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">An &#8220;Administrative Procedure&#8221; is defined as a procedure pursuant to Chapters&#160;H3 (Monetary Sanction by the Israeli Securities Authority), H4&#160;(Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1&#160;(Arrangement to Prevent Procedures or Interruption of Procedures Subject to Conditions) of the Securities Law.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, the Securities Law and the Restrictive Trade Practices Law, a company may obtain insurance for an office holder against the following liabilities incurred in his or her capacity as an office holder, to the extent provided in the company&#8217;s articles of association:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a breach of the duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a financial liability imposed on the office holder in favor of a third party; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses incurred by the office holder with respect to proceedings held pursuant to certain provisions of the Restrictive Trade Practices Law; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a monetary liability imposed on the office holder in favor of an injured party at an Administrative Procedure pursuant to Section&#160;52(54)(a)(1)(a) of the Securities Law; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses incurred by an office holder in connection with an Administrative Procedure, including reasonable litigation expenses and reasonable attorneys&#8217; fees. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. A company may exculpate an office holder in advance from liability to the company, in whole or part, for damages caused to the company as a result of a breach of the duty of care, but only if a provision authorizing such exculpation is included in its articles of association. A company may not exculpate in advance a director from liability arising out of a breach of a duty of care with respect to a distribution. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, however, a company may not indemnify, exculpate or insure an office holder against any of the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">104</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an act or omission committed with intent to derive illegal personal benefit; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a fine, civil fine, monetary sanction or forfeit levied against the office holder. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Securities Law and the Restrictive Trade Practices Law also provide certain limitations on the ability of a company to indemnify, exculpate and insure office holders. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to obtain directors&#8217; and officers&#8217; liability insurance for the benefit of our office holders and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted by applicable law. In addition, prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to enter into agreements with each of our directors and executive officers exculpating them from a breach of their duty of care to us to the fullest extent permitted by law, and undertaking to indemnify them to the fullest extent permitted by law, including with respect to liabilities resulting from this offering, to the extent that these liabilities are not covered by insurance. Such indemnification will be in addition to any amounts available under our directors&#8217; and office holders&#8217; liability insurance policy. Each office holder who agrees to receive this letter of indemnification will also give his or her approval to terminate all previous letters of indemnification that we have provided to him or her, if any. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">105</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t13CE">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Relationship with Home Skinovations Ltd. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Certain of our shareholders (some of whom also serve as our directors and executive officers), including Moshe Mizrahy, Yoram Sadeh, Michael Bank, Ben Zion Levi, Eli Raveh and a significant beneficial holder, IHCV, hold in the aggregate approximately 56% and &#8199;&#8199;&#8199;&#8199;% of our issued and outstanding share capital immediately prior to and immediately following the completion of this offering, respectively, also are the record holders of approximately 51% of the issued and outstanding shares of Home Skinovations Ltd., or Home Skinovations, an Israeli corporation headquartered in Sha&#8217;ar Yokneam, Yokneam, Israel. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Mr.&#160;Moshe Mizrahy, our Chief Executive Officer and Chairman of our board of directors, serves as the chairman of the board of directors of Home Skinovations and was the Chief Executive Officer of Home Skinovations until June&#160;2018, and Dr.&#160;Hadar Ron, our director nominee, serves on the board of directors of Home Skinovations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Home Skinovations is involved in the development, manufacture and distribution of home-use light-based devices for aesthetic applications. Except as detailed below, we have no commitments to or agreements with Home Skinovations or any of its subsidiaries, including with respect to any mutual research and development, indebtedness, financing, debt or credit lines, or any jointly-owned intellectual property or like arrangements, and we do not share tangible or intangible assets with Home Skinovations or any of its subsidiaries. Any future agreements with Home Skinovations must be reviewed and approved by our audit committee and board of directors. See &#8220;Management&#8201;&#8212;&#8201;Approval of Related Party Transactions under Israeli Law.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Service Agreements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company receives certain services from, and provides certain services to, Home Skinovations. We do not consider these services to be material. The services include mobile phone services, use of certain computer hardware and switchboard infrastructure, certain software licenses and limited personnel services. In relation to these services, Home Skinovations invoiced us approximately $240,000 and $175,000 for the&#160;years ended December&#160;31, 2017 and 2016, respectively, which includes amounts invoiced under the Israel office sublease described below, and the Canadian subsidiary of Home Skinovations invoiced our Canadian subsidiary approximately $128,000 and $116,000 for the&#160;years ended December&#160;31, 2017 and 2016, respectively, for these services. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Israel Office Sublease </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Until May&#160;2018, we subleased our offices in Yokneam, Israel from Home Skinovations (approximately 1,000 square feet in 2016 and our entire lease of 10,290 square feet in 2017). For the&#160;years ended December&#160;31, 2017 and 2016, Home Skinovations invoiced us for an aggregate of approximately $138,000 and $17,000, respectively, for the office sublease. As of June&#160;2018, we lease our offices in Israel directly from an unaffiliated lessor. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Joint Venture Equity Interest Conversion Rights </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Guangzhou Sino-Israel Bio-Industry Investment Fund (LLP), a non-controlling partner in our Chinese joint venture (Guangzhou InMode Medical Technology Ltd.), has the right to convert its non-controlling equity interest in such joint venture prior to the consummation of this offering into an aggregate of &#8199;&#8199;&#8199;&#8199; of our ordinary shares assuming a conversion price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, which is calculated based on the midpoint of the price range set forth on the cover page of this prospectus. Additionally, Wigmore Medical Limited, a non-controlling partner in our joint venture in the United Kingdom (Invasix UK Ltd.), has the right to convert its non-controlling equity interest in such joint venture prior to the consummation of this offering into an aggregate of &#8199;&#8199;&#8199;&#8199; of our ordinary shares assuming a conversion price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, which is calculated based on the&#160;percentage of our U.K. joint venture&#8217;s revenues in relation to our total revenues. Following the consummation of this offering, such non-controlling partners will no longer have the right to convert their non-controlling equity interests into our ordinary shares.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">106</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Indemnification Agreements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to enter into separate indemnification agreements with each of our current office holders exculpating them from a breach of their duty of care to us to the fullest extent permitted by law and undertaking to indemnify them to the fullest extent permitted by law, including with respect to liabilities resulting from this offering to the extent such liabilities are not covered by insurance. See &#8220;Management&#160;&#8212; Exculpation, Indemnification and Insurance of Directors and Officers&#8221; for additional information. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employment and Consulting Agreements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have entered into employment or consulting agreements with all of our executive officers and key employees. These agreements contain standard provisions for a company in our industry regarding non-solicitation, confidentiality of information, non-competition and assignment of inventions. Our executive officers will not receive benefits upon the termination of their respective employment with us, other than payment of salary and benefits (and limited accrual of vacation days) during the required notice period for termination of their employment, which varies for each individual. The agreements are terminable by us at will, subject to prior notice, which varies for each individual.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">107</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t14PR">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PRINCIPAL SHAREHOLDERS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">The following table sets forth information regarding the beneficial ownership of our ordinary shares as of June&#160;30, 2018 and as adjusted to reflect the sale of our ordinary shares in this offering by: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">each person or group of affiliated persons that we know beneficially owns 5% or more of our outstanding ordinary shares; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">each of our named executive officers; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">each of our directors and director nominees; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">all of our directors, director nominees and executive officers as a group. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Beneficial ownership of ordinary shares is determined in accordance with the rules of the SEC and generally includes any ordinary shares over which a person exercises sole or shared voting or investment power. Ordinary shares that are subject to warrants or stock options that are presently exercisable or exercisable within 60&#160;days of June 30, 2018 are deemed to be outstanding and beneficially owned by the person holding the warrant or stock options for the purpose of computing the&#160;percentage ownership of that person, but are not treated as outstanding for the purpose of computing the&#160;percentage ownership of any other person. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Except as indicated in the footnotes to this table, each shareholder in the table has sole voting and investment power for the ordinary shares shown as beneficially owned by them. Percentage ownership is based on 14,885,532 ordinary shares outstanding as of June&#160;30, 2018, and &#8199;&#8199;&#8199;&#8199; ordinary shares outstanding following the closing of the offering, excluding &#8199;&#8199;&#8199;&#8199; ordinary shares that may be issued as part of the underwriters&#8217; option to purchase additional ordinary shares from us, unless otherwise stated. To our knowledge, we have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; holders of record of our equity securities who is a U.S. person. These shareholders hold &#8199;&#8199;&#8199;&#8199;% of our outstanding share capital. Unless otherwise noted below, each shareholder&#8217;s address is c/o&#160;InMode Ltd., Tavor Building, Sha&#8217;ar Yokneam, P.O. Box 533, Yokneam 2069200, Israel. </div>
        <table style="width:456pt;height:265.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:247.97pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">Beneficial Ownership</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:247.97pt;text-align:left;">
              <div style="white-space:nowrap;">Name of Beneficial Owner: </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Number of <br >Ordinary <br >Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Percent of <br >Ordinary Shares <br >Before the Offering</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Percent of Ordinary <br >Shares After the <br >Offering</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:247.97pt;text-align:left;">5% or more Beneficial Owners</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:247.97pt;text-align:left;">
              <div style="margin-left:10pt;">Israel Healthcare Ventures 2 LP Incorporated<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,609,141</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">17.53<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:247.97pt;text-align:left;">
              <div style="margin-left:10pt;">SpaMedica International SRL<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,480,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">16.41</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:247.97pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Directors, Director Nominees and Named Executive Officers</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:247.97pt;text-align:left;">
              <div style="margin-left:10pt;">Moshe Mizrahy<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(3)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,392,553</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">22.79</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:247.97pt;text-align:left;">
              <div style="margin-left:10pt;">Dr.&#160;Michael Kreindel<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(3)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,900,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">19.48</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:247.97pt;text-align:left;">
              <div style="margin-left:10pt;font-size:7.5pt;">
                <font style="font-size:10pt;">Dr.&#160;Hadar Ron</font><font style=" position:relative; bottom:4.25pt;">(</font><font style=" position:relative; bottom:4.25pt;">4</font><font style=" position:relative; bottom:4.25pt;">)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:247.97pt;text-align:left;">
              <div style="margin-left:10pt;font-size:7.5pt;">
                <font style="font-size:10pt;">Bruce Mann</font><font style=" position:relative; bottom:4.25pt;">(</font><font style=" position:relative; bottom:4.25pt;">5</font><font style=" position:relative; bottom:4.25pt;">)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">15,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:247.97pt;text-align:left;">
              <div style="margin-left:10pt;">Dr.&#160;Michael Anghel </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:247.97pt;text-align:left;">
              <div style="margin-left:10pt;font-size:7.5pt;">
                <font style="font-size:10pt;">Yair Malca</font><font style=" position:relative; bottom:4.25pt;">(</font><font style=" position:relative; bottom:4.25pt;">5</font><font style=" position:relative; bottom:4.25pt;">)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">70,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:247.97pt;text-align:left;">
              <div style="margin-left:10pt;font-size:7.5pt;">
                <font style="font-size:10pt;">Shakil Lakhani</font><font style=" position:relative; bottom:4.25pt;">(</font><font style=" position:relative; bottom:4.25pt;">5</font><font style=" position:relative; bottom:4.25pt;">)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">609,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3.93</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:247.97pt;text-align:left;">
              <div style="margin-left:10pt;font-size:7.5pt;">
                <font style="font-size:10pt;">Dr.&#160;Spero Theodorou</font><font style=" position:relative; bottom:4.25pt;">(</font><font style=" position:relative; bottom:4.25pt;">5</font><font style=" position:relative; bottom:4.25pt;">)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">264,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1.75</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:1.917pt 0pt 0.5pt 0pt; width:247.97pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">All directors, director nominees and executive officers as a <br >group (8 persons) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">7,301,553</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">49.05<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:20.93pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.52pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:3.5pt;line-height:3.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="20">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">*<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">Represents less than one (1%) percent.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">108</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">IHCV2 General Partner Limited is the general partner of Israel Healthcare Ventures 2 LP Incorporated. Dr. Hadar Ron, our director nominee, holds an indirect beneficial ownership entitlement of less than 10% in Israel Healthcare Ventures 2 LP Incorporated and is the chief executive officer of its management company. The registered address of Israel Healthcare Ventures 2 LP Incorporated is c/o&#160;Dr.&#160;Hadar Ron, 44 Mordechay Zeira St., Tel Aviv, Israel. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">SpaMedica International SRL is wholly-owned by The SMFT Trust, a Barbados trust that is controlled and managed by its independent trustee. The registered address of SpaMedica International SRL is Suite 203, Building No. 8, Harbour Road, Bridgetown, St. Michael, Barbados W.I. BB11145. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">The beneficial ownership in its entirety is owned as ordinary shares. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">The beneficial ownership in its entirety is owned as ordinary shares by Dr.&#160;Hadar Ron. Dr. Hadar Ron is the chief executive officer of the management company for Israel Healthcare Ventures 2 LP Incorporated (see note 1) and Israel Health Care Ventures LP Incorporated, a life science venture capital fund. Dr. Hadar Ron also holds an indirect beneficial ownership entitlement of less than 10% in each of Israel Healthcare Ventures 2 LP Incorporated (see note 1) and Israel Health Care Ventures LP Incorporated. Israel Health Care Ventures LP Incorporated directly holds 80,000 ordinary shares of the Company. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(5)<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">The beneficial ownership in its entirety is owned as options to purchase ordinary shares of the Company within 60 days of June&#160;30, 2018. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">109</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t15DE">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">DESCRIPTION OF SHARE CAPITAL </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following descriptions of our share capital and provisions of our amended and restated articles of association are summaries and do not purport to be complete. Our amended and restated articles of incorporation are filed with the SEC as an exhibit to our registration statement of which this prospectus forms a part. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Share Capital </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon the effectiveness of the registration statement of which this prospectus forms a part, our authorized share capital will consist of&#8201; &#8199;&#8199;&#8199;&#8199; ordinary shares, par value NIS 0.01 per ordinary share, of&#8201; &#8199;&#8199;&#8199;&#8199; which &#8199;&#8199;&#8199;&#8199; ordinary shares will be issued and outstanding. All of our ordinary shares have identical voting and other rights in all respects. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">All of our issued and outstanding ordinary shares are duly authorized, validly issued, fully paid and non-assessable. Our amended and restated articles of association and the laws of the State of Israel do not restrict the ownership or voting of ordinary shares by non-residents of Israel, except with respect to citizens of countries that are, or have been, in a state of war with Israel. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Establishment and Purposes and Objectives of the Company </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We were incorporated under the laws of the State of Israel on January&#160;2, 2008 under the name Invasix Ltd. and we subsequently changed our name on November&#160;2, 2017 to our current name, InMode Ltd. Our purpose as set forth in our amended and restated articles of association is to engage in any lawful activity. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">The Powers of the Directors </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our board of directors shall direct our policy and shall supervise the performance of our Chief Executive Officer and his actions. Pursuant to the Companies Law and our amended and restated articles of association, our board of directors may exercise all powers and take all actions that are not required under the Companies Law or our amended and restated articles of association to be exercised or taken by our shareholders, including the power to borrow money for Company purposes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Rights Attached to Our Ordinary Shares </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Our ordinary shares shall confer upon the holders thereof: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">equal rights to attend and to vote at all of our general meetings, whether annual or special, with each ordinary share entitling the holder thereof, which attend the meeting and participate in the voting, either in person or by a proxy or by a written ballot, to one vote; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">equal rights to participate in a distribution of dividends on our ordinary shares, if any, whether payable in cash or in bonus shares, in a distribution of assets or in any other distribution, on a per share pro&#160;rata basis; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">equal rights to participate, upon our dissolution, in the distribution of our assets legally available for distribution, on a per share pro&#160;rata basis. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Dividend and Liquidation Rights </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The holders of the ordinary shares to be sold in this offering will be entitled to their proportionate share of any cash dividend, share dividend or dividend in kind declared with respect to our ordinary shares on or after the date of this prospectus. Under the Companies Law, a company may distribute a dividend only if, upon the determination of our board of directors, the distribution does not create a reasonably foreseeable risk that the company will be unable to meet its existing and anticipated obligations as they become due. A company may only distribute a dividend out of the company&#8217;s profits, as defined under the Companies Law. The distribution amount is limited to the greater of the retained earnings or earnings generated over the previous two&#160;years, according to our then last reviewed or audited financial statements, provided that the date of the financial statements is not more than six&#160;months prior to the date of the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">110</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">distribution. If the company does not meet the profit requirement, a court may allow us to distribute a dividend, as long as the court is convinced that there is no reasonable risk that a distribution might prevent the company from being able to meet its existing and anticipated obligations as they become due. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, the declaration of a dividend is determined by the board of directors and does not require the approval of the shareholders of a company unless the company&#8217;s articles of association provide otherwise. Our amended and restated articles of association provide that the board of directors may declare and distribute dividends without the approval of the shareholders. For more information, see &#8220;Dividend Policy.&#8221; In the event of our liquidation, holders of our ordinary shares have the right to share ratably in any assets remaining after payment of liabilities, in proportion to the paid-up par value of their respective holdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Voting, Shareholder Meetings and Resolutions </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Holders of ordinary shares have one vote for each ordinary share held on all matters submitted to a vote of shareholders. This right may be changed if shares with special voting rights are authorized in the future. Our amended and restated articles of association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required under the Companies Law or our articles of association. A shareholder may vote in general meetings in person, by proxy or by a written ballot. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, an annual general meeting of our shareholders should be held once every calendar year, but no later than 15&#160;months from the date of the previous annual general meeting. The quorum required for a general meeting of shareholders consists of at least two shareholders present in person or by proxy holding at least 25% of the voting power in the Company. A meeting adjourned for lack of a quorum generally is adjourned to the same day in the following week at the same time and place (without requirement of additional notification to the shareholders) or any time and place as the directors designate in a notice to the shareholders. Under our amended and restated articles of association, the required quorum for the reconvened adjourned meeting will be, with some exceptions, at least two shareholders holding any number of the voting rights in the Company. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our board of directors may, in its discretion, convene additional meetings as &#8220;special general meetings&#8221; whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides that the board of directors must convene a special general meeting upon the written demand of: (i)&#160;two or more of the directors or such number of directors equal to one fourth of the serving directors, (ii) one or more shareholders having, in the aggregate, (a)&#160;at least 5% of the outstanding share capital and at least 1% of the voting power in the company, or (b)&#160;at least 5% of the voting power in the company. The Companies Law further provides that one or more shareholders holding 1% or more of the outstanding voting power may ask the board to add an item to the agenda of the prospective shareholders&#8217; meeting if the proposal merits discussion at the general meeting, as determined by the board of directors. The chairman of the board of directors presides at each of our general meetings. The chairman of the meeting is not entitled to a vote at a general meeting in his capacity as chairman. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Subject to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the shareholders of record on a date to be decided by the board of directors, which may be between four days and 40&#160;days prior to the date of the meeting. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Most shareholders&#8217; resolutions, including resolutions to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">amend our articles of association (except for amendments relating to the election of directors and the powers, composition and size of the board of directors); </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">make changes in our capital structure such as a reduction of capital, increase of capital or share split, merger or consolidation; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">authorize a new class of shares; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">elect directors, other than external directors (if applicable); </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">111</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">appoint auditors; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">approve transactions with office holders (subject to certain exceptions); </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">will be deemed adopted if approved by the holders of a majority of the voting power represented at a shareholders&#8217; meeting, in person or by proxy, and voting on that resolution (excluding abstentions). </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Transfer of Shares and Notices </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, shareholders&#8217; meetings require prior notice of at least 21&#160;days, and if the agenda of the meeting includes certain matters prescribed under the Companies Law and the regulations promulgated thereunder, among others, the appointment or removal of directors, the approval of related party transactions, or an approval of a merger, notice must be provided at least 35&#160;days prior to the meeting. Under regulations promulgated under the Companies Law, certain exemptions and reliefs with respect to the manner of announcing the convening of the general meeting of shareholders are granted to companies whose securities are traded outside of Israel. We may use these exceptions and reliefs after this offering. Our fully paid ordinary shares are issued in registered form and are freely transferable under our amended and restated articles of association, unless the transfer is restricted or prohibited by another instrument, applicable law, or the rules of a stock exchange on which the ordinary shares are listed for trade. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Modification of Class&#160;Rights </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Companies Law provides that the rights attached to a particular class of shares, such as voting, liquidation and dividend rights, may not be modified without the vote, at a separate meeting of such class, of a majority of the shares of the affected class actually participating in such class meeting, excluding abstentions. The enlargement of an existing class of shares or the issuance of additional shares thereof, shall not be deemed to modify the rights attached to the previously issued shares of such class or of any other class, unless otherwise provided by the terms of the shares. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Election of Directors </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our ordinary shares do not have cumulative voting rights in the election of directors. Therefore, the holders of ordinary shares representing more than 50% of the voting power represented at the general meeting of the shareholders, in person or by proxy, and voting thereon, excluding abstentions, have the power to elect all of the directors whose positions are being filled at that meeting, to the exclusion of the remaining shareholders. In addition, our board of directors is a classified board of directors pursuant to which our directors (other than external directors, if applicable) are elected for staggered terms, which means that shareholders can only elect a limited number of directors in any given year. For additional terms concerning our board of directors and election of directors see &#8220;Management&#8201;&#8212;&#8201;Board Practices&#8201;&#8212;&#8201;Board of Directors.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Access to Corporate Records </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, shareholders have the right to review minutes of our general meetings, our shareholder register and register of significant shareholders (as defined in the Companies Law), our articles of association, our financial statements and any document we are required by law to file publicly with the Israeli Companies Registrar or with the Israel Securities Authority. Any shareholder who specifies the purpose of its request may request to review any document in our possession that relates to any action or transaction with a related party which requires shareholder approval under the Companies Law. We may deny such a request if we determine that the request was not made in good faith, that the document contains a trade secret or patent or that the document&#8217;s disclosure may otherwise impair our interests. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Anti-Takeover Provisions; Mergers and Acquisitions </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Merger </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Companies Law permits merger transactions with the approval of each party&#8217;s board of directors and shareholders (unless certain requirements described under the Companies Law are met). In accordance with the Companies Law, a merger may be approved at a shareholders meeting by a majority of the voting </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">112</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">power represented at the meeting, in person or by proxy, and voting on that resolution and, in the case of the target company, a majority vote of each class of its shares, voted on the proposed merger at a shareholders meeting. For purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of shares represented at the meeting of shareholders that are held by parties other than the other party to the merger, or by any person (or group of persons acting in concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the rights to appoint 25% or more of the directors of the other party, vote against the merger. If, however, the merger involves a merger with a company&#8217;s own controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority approval that governs all extraordinary transactions with controlling shareholders (as described under &#8220;Management&#8201;&#8212;&#8201;Approval of Related Party Transactions Under Israeli Law&#8221;). </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the petition of holders of at least 25% of the voting rights of a company. For such petition to be granted, the court must find that the merger is fair and reasonable, taking into account the respective values assigned to each of the parties to the merger and the consideration offered to the shareholders of the target company. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further give instructions in order to secure the rights of creditors. Moreover, a merger may not be completed until at least 50&#160;days have passed from the time that the merger proposals were filed with the Israeli Registrar of Companies and 30&#160;days have passed since the merger was approved by the shareholders of each merging company. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Special Tender Offer </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Companies Law requires a purchaser to conduct a special tender offer in order to purchase shares in publicly held companies, if as a result of the purchase the purchaser would (i)&#160;become a holder of 25% or more of the voting rights in a company in which no other shareholder holds at least 25% of the voting rights, or (ii) become a holder of more than 45% of the voting rights in a company, if there is no other shareholder who holds more than 45% of the voting rights in the company, in each case, subject to certain exceptions. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A special tender offer must be extended to all shareholders, but the offeror is not required to purchase shares representing more than 5% of the voting power attached to the company&#8217;s outstanding shares, regardless of how many shares are tendered by shareholders. In general, a special tender offer may be consummated only if&#8201; (i)&#160;at least 5% of the voting power of the company&#8217;s outstanding shares will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding the purchaser, controlling shareholders, holders of 25% or more of the voting rights in the company or any person having a personal interest in the acceptance of the tender offer or any other person acting on their behalf, including relatives and entities under such person&#8217;s control). If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Full Tender Offer </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, a person may not purchase shares of an Israeli public company if, following the purchase of shares, the purchaser would hold more than 90% of the company&#8217;s shares or of any class of shares, unless the purchaser makes a tender offer to purchase all of the company&#8217;s shares or all the shares of the particular class, as applicable. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">113</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">However, a tender offer will also be accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the applicable class of shares. The foregoing also applies to the acquisition of voting rights. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, may, within six&#160;months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions, the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli court as described above. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If&#8201; (a)&#160;the shareholders who did not respond or accept the tender offer hold at least 5% of the issued and outstanding share capital of the company or of the applicable class or the shareholders who accept the offer constitute less than a majority of the offerees that do not have a personal interest in the acceptance of the tender offer, or (b)&#160;the shareholders who did not accept the tender offer hold 2% or more of the issued and outstanding share capital of the company (or of the applicable class), the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of the company&#8217;s issued and outstanding share capital or of the applicable class from shareholders who accepted the tender offer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Shares purchased in contradiction to the tender offer rules under the Companies Law will have no rights and will become dormant shares. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Anti-Takeover Measures </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Companies Law allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred or additional rights to voting, distributions or other matters and shares having preemptive rights. Following the closing of this offering, we will not have any authorized or issued shares other than ordinary shares. In the future, if we do create and issue a class of shares other than ordinary shares, such class of shares, depending on the specific rights that may be attached to them, may delay or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization of a new class of shares will require an amendment to our articles of association which requires the prior approval of a majority of our ordinary shares represented and voting at a general meeting. Shareholders voting at such a meeting will be subject to the restrictions under the Companies Law as described in &#8220;&#8212;&#8201;Voting, Shareholder Meetings and Resolutions.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Tax Law </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two&#160;years from the date of the transaction during which sales and dispositions of shares of the participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no disposition of the shares has occurred. These provisions could delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Changes in Our Capital </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our amended and restated articles of association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must be approved by a resolution duly passed by our shareholders at a general meeting. In addition, transactions that have the effect of reducing capital, such as the distribution of dividends in the absence of sufficient retained earnings or profits require the approval of both our board of directors and an Israeli court. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">114</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Transfer Agent and Registrar </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">We intend to engage American Stock Transfer &amp; Trust Company to act as the transfer agent and registrar for our ordinary shares. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Listing </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">We intend to apply to list our ordinary shares on Nasdaq under the symbol &#8220;INMD.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Registration Number </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our registration number with the Israeli Companies Registrar is 514073618. Upon the closing of this offering, our registration number may be changed by the Israeli Companies Registrar to indicate that we are a public company.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">115</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t16SH">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SHARES ELIGIBLE FOR FUTURE SALE </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Prior to this offering, there has been no public market for our ordinary shares. We cannot predict the effect, if any, that market sales of ordinary shares or the availability of ordinary shares for sale will have on the market price prevailing from time to time. As we describe below, only a limited number of ordinary shares will be available for sale shortly after this offering due to contractual and legal restrictions on resale. Nevertheless, sales of our ordinary shares in the public market after the restrictions lapse, or the perception that those sales may occur, could cause the prevailing market price to decrease or to be lower than it might be in the absence of those sales or perceptions. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Sale of Restricted Shares </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon the closing of this offering, we will have &#8199;&#8199;&#8199;&#8199; ordinary shares outstanding. The ordinary shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act. However, if ordinary shares are purchased by &#8220;affiliates,&#8221; as that term is defined in Rule&#160;144 under the Securities Act, their sales of ordinary shares would be subject to volume limitations and other restrictions that are described below other than the holding period requirement. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Other than ordinary shares to be sold in this offering, the remaining ordinary shares outstanding upon completion of this offering were issued and sold in reliance on exemptions from the registration requirements of the Securities Act or in transactions outside of the United States and not subject to the Securities Act. These securities may be sold in the public market only if they are registered under the Securities Act, or if they qualify for an exemption from registration under Section&#160;4(a)(1) of the Securities Act or Rule&#160;144 thereunder. These rules are summarized below. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our ordinary shares outstanding upon closing of this offering will be eligible for sale into the public market as follows: </div>
        <table style="width:456pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:222pt;">
              <div style="white-space:nowrap;">Approximate Number of Ordinary Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:222pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">Description </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:222pt;white-space:normal;">After the date of this prospectus, freely tradeable ordinary shares sold in this offering. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:222pt;white-space:normal;">After 180&#160;days from the date of this prospectus, except as otherwise discussed below, the lock-up period will expire, and these additional ordinary shares will be saleable, subject, in some cases, to holding periods and volume limitations.</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:20pt; width:456pt; line-height:11pt;font-weight:bold;">Rule&#160;144 </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In general, under Rule&#160;144 under the Securities Act as in effect on the date hereof, beginning 90&#160;days after the date hereof, a person who holds restricted ordinary shares (assuming there are any restricted shares) and is not one of our affiliates at any time during the three&#160;months preceding a sale, and who has beneficially owned these restricted ordinary shares for at least six&#160;months, would be entitled to sell an unlimited number of our ordinary shares, provided current public information about us is available. In addition, under Rule&#160;144, a person who holds restricted ordinary shares in us and is not one of our affiliates at any time during the three&#160;months preceding a sale, and who has beneficially owned these restricted ordinary shares for at least one year, would be entitled to sell an unlimited number of ordinary shares immediately upon the closing of this offering without regard to whether current public information about us is available. Beginning 90&#160;days after the date hereof, our affiliates who have beneficially owned our ordinary shares for at least six&#160;months will be entitled to sell within any three month period a number of ordinary shares that does not exceed the greater of: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">1% of the number of ordinary shares then outstanding; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the average weekly trading volume of our ordinary shares on Nasdaq during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale; provided that current public information about us is available and the affiliate complies with the manner of sale requirements imposed by Rule&#160;144. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">116</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Affiliates are also subject to additional restrictions on the manner of sales under Rule&#160;144 and notice filing requirements. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Regulation&#160;S </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Regulation&#160;S under the Securities Act provides that securities owned by any person may be sold without registration in the United States, provided that the sale is effected in an offshore transaction and no directed selling efforts are made in the United States (as these terms are defined in Regulation&#160;S), subject to certain other conditions. In general, this means that our ordinary shares may be sold in some manner outside the United States without requiring registration in the United States. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Rule&#160;701 </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In general, under Rule&#160;701 of the Securities Act as currently in effect, each of our employees, consultants or advisors who purchases our ordinary shares from us in connection with a compensatory share plan or other written agreement executed prior to the completion of this offering is eligible to resell such ordinary shares in reliance on Rule&#160;144, but without compliance with some of the restrictions, including the holding period, contained in Rule&#160;144. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Form S-8 </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Following completion of this offering, we intend to file a registration statement on Form S-8 under the Securities Act to register &#8199;&#8199;&#8199;&#8199; ordinary shares issued or issuable under our share option plans. The registration statement on Form S-8 is expected to become effective automatically upon filing. As of the date of this prospectus, options to purchase &#8199;&#8199;&#8199;&#8199; ordinary shares were issued and outstanding, of which options to purchase &#8199;&#8199;&#8199;&#8199; ordinary shares had vested and had not been exercised. Ordinary shares issued upon exercise of a share option and registered under the Form S-8 registration statement will, subject to vesting provisions and Rule&#160;144 volume limitations applicable to our affiliates, be available for sale in the public market, immediately following the expiration of or release from the lock-up agreements.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">117</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t17TA">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">TAXATION </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">The following description is not intended to constitute a complete analysis of all the tax consequences relating to the acquisition, ownership and disposition of our ordinary shares. You should consult your own tax advisor concerning the tax consequences in your particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Material Israeli Tax Considerations </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following is a summary of the material Israeli tax laws applicable to us, and some Israeli Government programs benefiting us. This section also contains a discussion of some Israeli tax consequences to persons acquiring ordinary shares in this offering. This summary does not discuss all the acts of Israeli tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of this kind of investor include residents of Israel, traders in securities or persons that own, directly or indirectly, 10% or more of our outstanding voting capital, all of whom are subject to special tax regimes not covered in this discussion. Some parts of this discussion are based on new tax legislation which has not been subject to judicial or administrative interpretation, and we cannot assure you that Israeli governmental and tax authorities or the Israeli courts will accept the views expressed below. The discussion below is subject to amendment under Israeli law or changes to the applicable judicial or administrative interpretations of Israeli law, which could affect the tax consequences described below. The discussion should not be construed as legal or professional tax advice and does not cover all possible tax considerations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Potential investors are urged to consult their own tax advisors as to the Israeli or other tax consequences of the purchase, ownership and disposition of our ordinary shares, including, in particular, the effect of any foreign, state or local taxes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">General Corporate Tax Structure in Israel </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Israeli companies are generally subject to tax on their taxable income at the corporate tax rate of 23% in 2018 and thereafter (which was reduced from 24% and 25% in 2017 and 2016, respectively). However, the effective tax rate payable by a company that derives income from a Benefited Enterprise (as discussed below) may be considerably less. Capital gains derived by an Israeli resident company are subject to tax at the regular corporate tax rate. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Tax Benefits under the Law for the Encouragement of Capital Investments, 1959 </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Law for the Encouragement of Capital Investments, 1959, or the Investment Law, provides certain incentives for capital investments in production facilities (or other eligible assets) by &#8220;Industrial Enterprises&#8221; (as defined under the Investment Law). </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">Tax Benefits Under the 2005 Amendment </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">An amendment to the Investment Law, which became effective as of April&#160;1, 2005, or the 2005 Amendment, changed certain provisions of the Investment Law. An eligible investment program under the 2005 Amendment qualifies for benefits as a &#8220;Benefited Enterprise.&#8221; Prior to the 2005 Amendment, investment programs under the Investment Law were called &#8220;Approved Enterprises.&#8221; According to the 2005 Amendment, only Approved Enterprises receiving cash grants require the prior approval of the Investment Center. Rather, a company may claim the tax benefits offered by the Investment Law directly in its tax returns, provided that its facilities meet the criteria for tax benefits set forth in the 2005 Amendment. A company that has a Benefited Enterprise may, in its discretion, approach the Israel Tax Authority for a pre-ruling confirming that it is in compliance with the provisions of the Investment Law. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The duration of the tax benefits for a Benefited Enterprise is limited to the earlier of seven or ten&#160;years (depending on the geographic location of the Benefited Enterprise within Israel) from the Commencement Year (as described below) or 12&#160;years from the first day of the year of election. Commencement Year is defined as the later of the first tax year in which a company had derived taxable income for tax purposes </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">118</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">from the Benefited Enterprise, or the year of election, which is the year in which a company requested to have the tax benefits apply to the Benefited Enterprise. The tax benefits granted to a Benefited Enterprise are determined, depending on the geographic location of the Benefited Enterprise within Israel, according to one of the following: </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">(i) Exemption from corporate tax may be available on undistributed income for a period of two to ten&#160;years, depending on the geographic location of the Benefited Enterprise within Israel, and a reduced corporate tax rate of 10% to 25% for the remainder of the benefits period, depending on the level of foreign investment in each year. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, a company that has a Benefited Enterprise program is eligible for further tax benefits if it qualifies as a Foreign Investors&#8217; Company, or FIC. The level of foreign investment is measured as the&#160;percentage of rights in the company (in the terms of shares, rights to profits, voting and appointment of directors) and of combined share capital and shareholder loans that are owned, directly or indirectly, by persons who are not residents of Israel. The determination as to whether a company qualifies as an FIC is made on an annual basis. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The 2011 Amendment as described below has eliminated the definition of a FIC. However, according to the 2011 Amendment&#8217;s transitional provisions, the tax benefits of companies with Benefited Enterprise plans that opt to remain under the Benefited Enterprise regime in accordance with the Investment Law prior to the 2011 Amendment will be preserved. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If the company pays a dividend out of income derived from the Benefited Enterprise during the tax exemption period, such income will be subject to deferred corporate tax with respect to the amount distributed (grossed up to reflect such pre-tax income that it would have had to earn in order to distribute the dividend) at the corporate tax rate which would have otherwise been applied. The company is required to withhold tax on such distribution at a rate of 15%, or such lower rate may be provided in an applicable tax treaty (subject to the receipt in advance of a valid certificate from the Israel Tax Authority allowing for a reduced tax rate); or </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">(ii) Reduced corporate tax rates for companies with facilities in certain geographical locations in Israel. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our facilities in Israel were granted Benefited Enterprise status and thereunder we enjoy a ten-year tax exemption from corporate tax on our undistributed income derived from the Benefited Enterprise. The first year in which we were exempted from tax was 2012 and the ten-year eligibility period of tax exemption ends in 2021. In order to remain eligible for the tax benefits of a Benefited Enterprise, we must continue to meet certain conditions stipulated in the Investment Law and its regulations, as amended, and with the conditions set forth in a tax ruling we received in connection therewith. If we do not meet these requirements, the tax benefits could be reduced or canceled and we could be required to refund any tax benefits we might already have enjoyed. </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">Tax Benefits Under the 2011 Amendment </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In December&#160;2010, the Israeli Parliament approved amendment 68 to the Investment Law, or the 2011 Amendment. The 2011 Amendment significantly revised the tax incentive regime in Israel and it commenced on January&#160;1, 2011. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The 2011 Amendment provided for a new and additional status of a &#8220;Preferred Enterprise,&#8221; which introduced new benefits for income generated by a &#8220;Preferred Company&#8221; through its Preferred Enterprise. The definition of a Preferred Company, includes, <font style="font-style:italic;">inter alia</font>, a company incorporated in Israel that (1)&#160;is not wholly owned by a government entity, (2)&#160;owns a Preferred Enterprise and (3)&#160;is controlled and managed from Israel and is subject to further conditions set forth in the Investment Law. Moreover, a Preferred Company needs to meet certain condition stipulated in the Investment Law such as being an industrial company (including a minimum threshold of 25% export). </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A Preferred Company is entitled to a reduced corporate tax rate of 16% in 2018 with respect to income attributable to its Preferred Enterprise, unless the Preferred Enterprise is located in a specified development zone, known as Development Zone &#8220;A,&#8221; in which case the rate is currently 7.5% in 2018. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">119</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Dividends paid out of income attributed to a Preferred Enterprise are generally subject to tax at the rate of 20% or such lower rate as may be provided in an applicable tax treaty. However, if such dividends are paid to an Israeli company, no tax is required to be withheld (although, if the funds are subsequently distributed to individuals or non-Israeli residents (individuals and corporations), withholding tax would apply when distributing the dividend to such individuals or non-Israeli residents). </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have examined the possible effect, if any, of the provisions of the 2011 Amendment on our financial statements and have decided, at this time, not to apply for the new benefits under the 2011 Amendment. </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">New Tax Benefits Under the 2017 Amendment </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Additional amendments to the Investment Law became effective in January&#160;2017, or the 2017 Amendment. Under the 2017 Amendment, and provided the conditions stipulated therein are met, income derived by Preferred Companies from &#8220;Preferred Technological Enterprises,&#8221; or PTE (as defined in the 2017 Amendment), would be subject to reduced corporate tax rates of 7.5% in Development Zone &#8220;A&#8221; and 12% elsewhere in Israel, or 6% in the case of a &#8220;Special Preferred Technological Enterprise,&#8221; or SPTE (as defined in the 2017 Amendment) regardless of the company&#8217;s geographical location within Israel. A Preferred Company distributing dividends from income derived from its PTE or SPTE, would subject the recipient to a 20% tax (or lower, if so provided under an applicable tax treaty). The 2017 Amendment further provides that, in certain circumstances, a dividend distributed to a corporate shareholder who is not an Israeli resident for tax purposes would be subject to a 4% tax (<font style="font-style:italic;">inter alia</font>, if the amount of foreign investors in the distributing company exceeds 90%). Such taxes would generally be withheld at source by the distributing company. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On June&#160;14, 2017, the Encouragement of Capital Investments Regulations (Preferred Technology Income and Capital Profits for a Technological Enterprise), 2017, or the Regulations, were published, which adopted Action 5 under the base erosion and profit shifting, or BEPS, regulations. The Regulations describe, inter alia, the mechanism used to determine the calculation of the benefits under the PTE and under the SPTE regimes and determine certain requirements relating to documentation of intellectual property for the purpose of a PTE. According to these provisions, a company that complies with the terms under the PTE regime may be entitled to certain tax benefits with respect to income generated during the company&#8217;s regular course of business and derived from the preferred intangible asset (as determined in the Investments Law), excluding income derived from intangible assets used for marketing and income attributed to production activity. In the event that intangible assets used for marketing purposes generate over 10% of the PTE&#8217;s income, the relevant portion, calculated using a transfer pricing study, would be subject to regular corporate income tax. If such income does not exceed 10%, the PTE will not be required to exclude the marketing income from the PTE&#8217;s total income. The Regulations set a presumption of direct production expenses plus 10% with respect to income related to production, which can be countered by the results of a supporting transfer pricing study. Tax rates applicable to such production income expenses will be similar to the tax rates under the Preferred Enterprise regime, to the extent such income would be considered as eligible. In order to calculate the preferred income, the PTE is required to take into account the income and the research and development expenses that are attributed to each single preferred intangible asset. However, the transitional provisions allow companies to take into account the income and research and development expenses attributed to all of the preferred intangible assets they have. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the transitional provisions of the 2017 Amendment, a company is allowed to continue to enjoy the tax benefits available under the Investment Law prior to the 2017 Amendment until the end of the period of benefits, as defined in the Investment Law. In each year during the period of benefit under its Benefited Enterprise status, the Company will be able to opt-in for application of the 2017 Amendment, thereby making itself available to the tax rates described above. A company&#8217;s decision to opt-in for application of the 2017 Amendment is irrecoverable. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2017 and 2016, we decided not to adopt the application of the 2017 Amendment.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">120</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Law for the Encouragement of Industry (Taxes), 1969 </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe that we currently qualify as an &#8220;Industrial Company&#8221; within the meaning of the Law for the&#160;Encouragement of Industry (Taxes), 1969, or the Industry Encouragement Law. The Industry Encouragement Law defines an &#8220;Industrial Company&#8221; as an Israeli-resident company, incorporated in Israel, of which 90% or more of its income in any tax year, other than of income from defense loans, capital gains, interest and dividends, is derived from an &#8220;Industrial Enterprise&#8221; owned by it and located in Israel or in the &#8220;Area,&#8221; in accordance with the definition in the section 3a of the Tax Ordinance. An &#8220;Industrial Enterprise&#8221; is defined as an enterprise which is held by an Industrial Company whose principal activity in a given tax year is industrial production. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The following tax benefits, among others, are available to Industrial Companies: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">amortization of the cost of purchased know-how, patents and certain other intangible property rights (other than goodwill), which are used for the development or promotion of the Industrial Enterprise, over an eight-year period for tax purposes, commencing in the year where the Industrial Company began to utilize them; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">accelerated depreciation rates on equipment and buildings; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">under specified conditions, an election to file consolidated tax returns with additional related Israeli Industrial Companies; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses related to a public offering are deductible in equal amounts over three&#160;years, beginning from the year of the offering. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Eligibility for the benefits under the Industry Encouragement Law is not subject to receipt of prior approval from any governmental authority. We cannot assure that we will continue to qualify as an &#8220;Industrial Company&#8221; or that the benefits described above will be available to us in the future. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Capital Gains Taxes Applicable to Israeli Resident and Non-Israeli Resident Shareholders </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Capital gains tax is imposed on the sale of capital assets by an Israeli resident and on the sale of such assets by non-Israeli residents if those assets are either: (i)&#160;located in Israel, (ii) shares or rights to shares in Israeli resident companies, or (iii) represent, directly or indirectly, rights to assets located in Israel, unless a specific exemption is available under Israeli tax law or unless a treaty between Israel and the country of the non-resident provides otherwise. The Tax Ordinance distinguishes between &#8220;Real Capital Gain&#8221; and the &#8220;Inflationary Surplus.&#8221; Real Capital Gain is the excess of the total capital gain over Inflationary Surplus. You should consult with your own tax advisor as to the method you should use to determine the Inflationary Surplus. Inflationary Surplus is not subject to tax in Israel. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Generally, the tax rate applicable to real capital gains derived by individuals on the sale of our ordinary shares acquired in this offering will be taxed at the rate of 25%, unless such shareholder claims a deduction for interest and linkage differences expenses in connection with such shares, in which case the gain will generally be taxed at a rate of 30%. If the individual shareholder is a Controlling Shareholder at the time of the sale or at any time during the 12-month period preceding such sale, such gain will be taxed at the rate of 30%. A &#8220;Controlling Shareholder&#8221; is defined as a person who holds, directly or indirectly, including together with others, at least 10% of any means of control in the company (including, among other things, the right to receive profits of the company, voting rights, the right to receive the proceeds upon the company&#8217;s liquidation and the right to appoint a director). </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Real capital gains derived by corporations will be generally subject to the regular corporate tax rate (23% in 2018 and thereafter). Individual and corporate shareholders dealing in securities are taxed at the tax rates applicable to business income: 23% for corporations in 2018 and thereafter and a marginal tax rate of up to 47% in 2018 and thereafter for individuals plus an additional excess tax of 3% as described below.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">121</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;">Non-Israeli Resident Shareholders </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Non-Israeli residents (individuals and corporations) are generally exempt from Israeli capital gains tax on any gains derived from the sale, exchange or disposition of shares of Israeli companies publicly traded on a recognized stock exchange outside of Israel, provided, among other things, that such shareholders did not acquire their shares prior to the company&#8217;s initial public offering and the gains were not derived from a permanent establishment of such shareholders in Israel. However, shareholders that are non-Israeli entities will not be entitled to such exemption if Israeli residents: (1)&#160;have directly and directly, alone or together, with another a controlling interest of more than 25% of any of the means of control in such non-Israeli corporation or (2)&#160;are the beneficiaries of or are entitled to 25% or more of the revenues or profits of such non-Israeli entity, whether directly or indirectly. This exemption is not applicable to a person whose gains from selling or otherwise disposing of the shares are deemed to be business income. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, a sale of shares may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty and subject to the receipt in advance of a valid certificate from the Israeli tax authorities allowing of such exemption. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For example, pursuant to the Convention Between the Governments of the United States and Israel with respect to Taxes of Income, as amended, or the U.S.-Israel Tax Treaty, the sale, exchange or disposition of ordinary shares by a person who qualifies as a resident of the United States within the meaning of the U.S.-Israel Tax Treaty and who holds the shares as a capital asset and is entitled to claim the benefits afforded to such person by the U.S.-Israel Tax Treaty generally will not be subject to the Israeli capital gains tax unless: (i)&#160;such person holds, directly or indirectly, shares representing 10% or more of our voting power during any part of the 12-month period preceding such sale, exchange or disposition, subject to certain conditions; (ii) the capital gains from such sale, exchange or disposition can be allocated to a permanent establishment of the shareholder in Israel or (iii) such person is an individual and was present in Israel for a period or periods of 183&#160;days or more in the aggregate during the relevant tax year. In any such case, the sale, exchange or disposition of such shares would be subject to Israeli tax, to the extent applicable. Eligibility to benefit from tax treaties is conditioned upon the shareholder presenting a withholding certificate issued by the Israel Tax Authority prior to the applicable payment. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Withholding and Reporting </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Either the purchaser, the Israeli stockbrokers or financial institutions through which the shares are held is obliged to withhold tax on the amount of consideration paid upon the sale of our ordinary shares (or on the capital gain realized on the sale, if known), at the Israeli corporate tax rate for Israeli companies (23% in 2018 and thereafter). In case the seller is an individual, the applicable withholding tax rate would be 25% of the amount of consideration paid upon the sale of shares (or on the capital gain realized on the sale, if known). </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In some instances where our shareholders may be liable for Israeli tax on the sale of our ordinary shares, the payment of the consideration may be subject to the withholding of Israeli tax at source. Shareholders, including non-Israeli resident shareholders, may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale. In transactions involving a sale of all of the securities of an Israeli resident company, in the form of a merger or otherwise, the Israel Tax Authority may require non-Israeli resident shareholders who are not liable for Israeli tax to sign a declaration in a form specified by the Israel Tax Authority or obtain a specific exemption from the Israel Tax Authority to confirm their status as a non-resident of Israel, and, in the absence of such declarations or exemptions, may require the purchaser of the securities to withhold taxes at source. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The sale of securities traded on a stock exchange, requires that a detailed return, including a computation of the tax due, be filed and an advanced payment must be paid on January&#160;31 and July&#160;31 of every tax year in respect of sales of securities made within the previous six&#160;months. However, if all tax due was withheld at source according to applicable provisions of the Tax Ordinance and the regulations promulgated thereunder, then the aforementioned return need not be filed and no advance payment must be made. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">122</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Taxation of Dividend Distributions </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A distribution of dividends from income, which is not attributed to an Approved Enterprise/Benefited Enterprise/Preferred Enterprise/Technology Enterprises to an Israeli resident individual, will generally be subject to income tax at a rate of 25%. However, a 30% tax rate will apply if the dividend recipient is a &#8220;Controlling Shareholder&#8221; (as defined above) at the time of the distribution or at any time during the preceding 12-month period. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Tax Ordinance generally provides that a non-Israeli resident (either individual or corporation) is subject to Israeli income tax on the receipt of dividends at the rate of 25% (30% if the dividends recipient is a &#8220;Controlling Shareholder&#8221; (as defined above), at the time of the distribution or at any time during the preceding 12&#160;months). </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Generally, Israeli resident corporations are not subject to Israeli tax on the receipt of dividends paid on shares of Israeli corporations, other than with respect to dividends distributed from income that has accrued during the benefits period and attributed to a Benefited Enterprise as described above. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Payers of dividends on our shares, including the Israeli stockbrokers or the financial institutions through which the shares are held, are generally required, subject to reduced tax rates and the demonstration of a shareholder of his, her or its foreign residency, to withhold taxes upon the distribution of dividends at a rate of 25% (whether or not the recipient is a &#8220;Controlling Shareholder&#8221;) provided that the shares are registered with a nominee company (for corporations and individuals), unless a reduced tax rate under the provisions of an applicable double tax treaty (subject to the receipt in advance of a valid certificate from the Israel Tax Authority allowing for a reduced tax rate) is available. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Dividends paid out of income attributed to a Benefited Enterprise are generally subject to withholding tax at source at the rate of 15% or such lower rate as may be provided in an applicable tax treaty. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For example, under the U.S.-Israel Tax Treaty, the following rates will apply in respect of dividends distributed by an Israeli resident company to a U.S. resident (for purposes of the U.S.-Israel Treaty): (i)&#160;with regard to a dividend distributed from income which is not attributed to an Approved Enterprise/Benefited Enterprise/Preferred Enterprise/Preferred Technology Enterprise or Special Preferred Technology Enterprise, if the U.S. resident is a corporation which holds during that portion of the taxable year which precedes the date of payment of the dividend and during the whole of its prior taxable year (if any), at least 10% of the outstanding shares of the voting stock of the Israeli resident paying corporation and not more than 25% of the gross income of the Israeli resident paying corporation for such prior taxable year (if any) consists of certain types of interest or dividends&#8201;&#8212;&#8201;the maximum tax rate of withholding is 12.5% if a certificate for a reduced withholding tax rate would be provided in advance from the Israel Tax Authority, (ii) with regard to a dividend distributed from income derived from an Approved Enterprise/Benefited Enterprise/Preferred Enterprise under the Investments Law, if the U.S. resident is a corporation which holds during that portion of the taxable year which precedes the date of payment of the dividend and during the whole of its prior taxable year (if any), at least 10% of the outstanding shares of the voting stock of the Israeli resident paying corporation and not more than 25% of the gross income of the Israeli resident paying corporation for such prior taxable year (if any) consists of certain types of interest or dividends, the tax rate of withholding 15% will be applicable if a certificate for a reduced withholding tax rate would be provided in advance from the Israel Tax Authority, and (iii) in all other cases, the tax rate is 25%, or the domestic rate (if such is lower). The aforementioned rates under the U.S.-Israel Tax Treaty will not apply if the dividend income was derived through a permanent establishment of the U.S. resident in Israel. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If the dividend is attributable partly to income derived from an Approved Enterprise, Benefited Enterprise or Preferred Enterprise, and partly from other sources of income, the income tax rate will be a blended rate reflecting the relative portions of the types of income. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A non-Israeli resident who receives dividend income derived from or accrued from Israel, from which the full amount of tax was withheld at source, is generally exempt from the obligation to file tax returns in Israel with respect to such income, provided that (i)&#160;such income was not generated from a business conducted in Israel by the taxpayer, and (ii) the taxpayer has no other taxable sources of income in Israel with respect to which a tax return is required to be filed. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">123</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We have never declared or paid cash dividends to our shareholders and currently we do not intend to distribute cash or other dividends in the foreseeable future. We cannot assure you that, in the event we declare a dividend, we will designate the profits that are being distributed in a way that will reduce shareholders&#8217; tax liability. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Foreign Exchange Regulations </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Non-residents of Israel who hold our ordinary shares are able to receive any dividends, and any amounts payable upon the dissolution, liquidation and winding up of our affairs, freely repayable in non-Israeli currency at the rate of exchange prevailing at the time of conversion. However, Israeli income tax is generally required to have been paid or withheld on these amounts. In addition, the statutory framework for the potential imposition of currency exchange controls has not been eliminated, and may be restored at any time by administrative action. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Excess Tax </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Individuals who are subject to tax in Israel are also subject to an additional tax at a rate of 3% on annual income exceeding a certain threshold (NIS 641,880 for 2018), which amount is linked to the annual change in the Israeli consumer price index, including, but not limited to income derived from dividends, interest and capital gains, subject to the provisions of an applicable tax treaty. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Estate and Gift Tax </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Israeli law presently does not impose estate or gift taxes. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Material U.S. Federal Income Tax Considerations to U.S. Holders</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following discussion is a description of the material U.S. federal income tax considerations applicable to an investment in the ordinary shares by U.S. Holders who acquire their ordinary shares pursuant to this offering and who hold the ordinary shares as capital assets for U.S. federal income tax purposes, generally, for investment. As used in this section, the term &#8220;U.S. Holder&#8221; means a beneficial owner of an ordinary share who, for U.S. federal income tax purposes, is or is treated as any of the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a citizen or resident of the United States; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a corporation created or organized in or under the laws of the United States or any political subdivision thereof, including the District of Columbia; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a trust if the trust has elected validly to be treated as a United States person for U.S. federal income tax purposes or if a U.S. court is able to exercise primary supervision over the trust&#8217;s administration and one or more United States persons have the authority to control all of the trust&#8217;s substantial decisions. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This description is based on provisions of the U.S. Internal Revenue Code of 1986, as amended, referred to in this discussion as the Code, existing and proposed U.S. Treasury regulations and administrative and judicial interpretations, each as available and in effect as of the date of this prospectus. These sources may change and are open to differing interpretations, possibly with retroactive effect in a manner that could adversely affect a U.S. Holder of our ordinary shares. This description does not discuss all aspects of U.S. federal income taxation that may be applicable to investors in light of their particular circumstances or to investors who are subject to special treatment under U.S. federal income tax law, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">insurance companies; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">dealers in stocks, securities or currencies; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">financial institutions and financial services entities; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">124</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">real estate investment trusts; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">regulated investment companies; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">partnerships and other pass-through entities, and investors in such entities; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">persons that receive ordinary shares as compensation for the performance of services; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">tax-exempt organizations; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">persons that hold ordinary shares as a position in a straddle or as part of a hedging, conversion or other integrated instrument or persons entering into a constructive sale with respect to the ordinary shares; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">persons subject to special tax accounting rules under Section&#160;451(b) of the Code; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">individual retirement and other tax-deferred accounts; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expatriates of the United States; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">persons having a functional currency other than the U.S. dollar; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">direct, indirect or constructive owners of 10% or more of our ordinary shares and/or other equity by vote or value. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This discussion does not address any U.S. state or local or non-U.S. tax consequences or any U.S. federal gift or estate tax or alternative minimum tax considerations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds ordinary shares, the U.S. federal income tax consequences relating to an investment in the ordinary shares will depend in part upon the status and activities of such entity or arrangement and the particular partner and certain determinations made at the partner level. Any such entity or arrangement should consult its own tax advisor regarding the U.S. federal income tax consequences applicable to it and its partners of the purchase, ownership and disposition of ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We urge you to consult with your own tax advisor regarding the tax consequences of investing in the ordinary shares, including the effects of federal, state, local, foreign and other tax laws. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Distributions Paid on the Ordinary Shares </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As described under the section entitled &#8220;Dividend Policy&#8221; in this prospectus, we have never paid cash dividends and we currently do not intend to pay cash dividends in the foreseeable future. Subject to the discussion below under &#8220;&#8212;&#8201;Passive Foreign Investment Company Considerations,&#8221; a U.S. Holder generally will be required to include in gross income as ordinary dividend income the amount of any distributions paid on the ordinary shares, including the amount of any Israeli taxes withheld, to the extent that those distributions are paid out of our current or accumulated earnings and profits as determined for U.S. federal income tax purposes. Subject to the discussion below under &#8220;&#8212;&#8201;Passive Foreign Investment Company Considerations,&#8221; distributions in excess of our earnings and profits will be applied against and will reduce the U.S. Holder&#8217;s tax basis in its ordinary shares and, to the extent they exceed that tax basis, will be treated as gain from a sale or exchange of those ordinary shares. Our dividends will not qualify for the dividends-received deduction applicable in some cases to U.S. corporations. Dividends paid in NIS, including the amount of any Israeli taxes withheld, will be includible in the income of a U.S. Holder in a U.S. dollar amount calculated by reference to the exchange rate in effect on the day they are received by the U.S. Holder. Any gain or loss resulting from currency exchange fluctuations during the period from the date the dividend is includible in the income of the U.S. Holder to the date that payment is converted into U.S. dollars generally will be treated as ordinary income or loss. Because we may not account for our earnings and profits in accordance with U.S. federal income tax principles, U.S. Holders should expect all distributions to be reported to them as dividends. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Distributions on ordinary shares that are treated as dividends generally will constitute income from sources outside the United States for foreign tax credit purposes and generally will constitute passive category income. Subject to certain complex conditions and limitations, Israeli taxes withheld on any distributions on ordinary shares may be eligible for credit against a U.S. Holder&#8217;s federal income tax </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">125</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">liability. The rules relating to the determination of the U.S. foreign tax credit are complex, and U.S. Holders should consult their tax advisors regarding the availability of a foreign tax credit in their particular circumstances and the possibility of claiming an itemized deduction (in lieu of the foreign tax credit) for any foreign taxes paid or withheld. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Dividends paid by a &#8220;qualified foreign corporation&#8221; to non-corporate U.S. Holders are eligible for taxation at a reduced capital gains rate rather than the marginal tax rates generally applicable to ordinary income provided that certain requirements are met. Each U.S. Holder is advised to consult its tax advisors regarding the availability of the reduced tax rate on dividends with regard to its particular circumstances. Distributions on ordinary shares that are treated as dividends generally will not be eligible for the &#8220;dividends received&#8221; deduction generally allowed to corporate shareholders with respect to dividends received from U.S. corporations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A corporation organized outside of the United States, or a non-U.S. corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation (a)&#160;if it is eligible for the benefits of a comprehensive tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange of information provision, or (b)&#160;with respect to any dividend it pays on ordinary shares that are readily tradable on an established securities market in the United States. We believe that we qualify as a resident of Israel for purposes of, and are eligible for the benefits of, the U.S.-Israel Treaty, although there can be no assurance in this regard. Further, the Internal Revenue Service, or IRS, has determined that the U.S.-Israel Treaty is satisfactory for purposes of the qualified dividend rules and that it includes an exchange of information provision. Therefore, subject to the discussion below under &#8220;&#8212;&#8201;Passive Foreign Investment Company Considerations,&#8221; if the U.S.-Israel Treaty is applicable, such dividends will generally be &#8220;qualified dividend income&#8221; in the hands of individual U.S. Holders, provided that certain conditions are met, including holding period and the absence of certain risk reduction transaction requirements. Each U.S. Holder is advised to consult its tax advisors regarding the availability of the reduced tax rate on dividends with regard to its particular circumstances. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Disposition of Ordinary Shares </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Subject to the discussion below under &#8220;&#8212;&#8201;Passive Foreign Investment Company Considerations,&#8221; a U.S. Holder generally will recognize capital gain or loss for U.S. federal income tax purposes upon the sale, exchange or other disposition of ordinary shares in an amount equal to the difference, if any, between the amount realized (i.e., the amount of cash plus the fair market value of any property received) on the sale, exchange or other disposition and such U.S. Holder&#8217;s adjusted tax basis in the ordinary shares. Such capital gain or loss generally will be long-term capital gain taxable at a reduced rate for non-corporate U.S. Holders or long-term capital loss if, on the date of sale, exchange or other disposition, the ordinary shares were held by the U.S. Holder for more than one year. Any capital gain of a non-corporate U.S. Holder that is not long-term capital gain is taxed at ordinary income rates. The deductibility of capital losses is subject to limitations. Any gain or loss recognized from the sale or other disposition of ordinary shares will generally be gain or loss from sources within the United States for U.S. foreign tax credit purposes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Passive Foreign Investment Company Considerations </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe that we were not a PFIC for our taxable year ended December&#160;31, 2017, and we do not expect to be classified as a PFIC for U.S. federal income tax purposes for the current year ending December&#160;31, 2018 or the foreseeable future. However, the relevant rules for determining whether or not we are a PFIC as applied to our business are not entirely clear and certain aspects of the relevant tests will be outside our control. Therefore, no assurance can be given that we will not be a PFIC for any taxable year. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In general, a non-U.S. corporation will be treated as a PFIC, for any taxable year in which either (1)&#160;at least 75% of its gross income is &#8220;passive income,&#8221; referred to as the PFIC income test, or (2)&#160;on average at least 50% of its assets, determined on a quarterly basis, are assets that produce passive income or are held for the production of passive income, referred to as the PFIC asset test. Passive income for this purpose generally includes, among other things, dividends, interest, royalties, rents, and gains from the sale or exchange of property that gives rise to passive income. Assets that produce or are held for the production of </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">126</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">passive income generally include cash, even if held as working capital or raised in a public offering, marketable securities, and other assets that may produce passive income. Generally, in determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we are a PFIC in any taxable year during which a U.S. Holder owns ordinary shares, the U.S. Holder could be liable for additional taxes and interest charges under the &#8220;PFIC excess distribution regime&#8221; upon (1)&#160;a distribution paid during a taxable year that is greater than 125% of the average annual distributions paid in the three preceding taxable&#160;years, or, if shorter, the U.S. Holder&#8217;s holding period for the ordinary shares, and (2)&#160;any gain recognized on a sale, exchange or other disposition, including, under certain circumstances, a pledge, of the ordinary shares, whether or not we continue to be a PFIC. Under the PFIC excess distribution regime, the tax on such distribution or gain would be determined by allocating the distribution or gain ratably over the U.S. Holder&#8217;s holding period for ordinary shares. The amount allocated to the current taxable year (i.e., the year in which the distribution occurs or the gain is recognized) and any year prior to the first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year. The amount allocated to other taxable&#160;years will be taxed at the highest marginal rates in effect for individuals or corporations, as applicable, to ordinary income for each such taxable year, and an interest charge, generally applicable to underpayments of tax, will be added to the tax. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we are a PFIC for any year during which a U.S. Holder holds ordinary shares, we must generally continue to be treated as a PFIC by that holder for all succeeding&#160;years during which the U.S. Holder holds the ordinary shares, unless we cease to meet the requirements for PFIC status and the U.S. Holder makes a &#8220;deemed sale&#8221; election with respect to the ordinary shares. If the election is made, the U.S. Holder will be deemed to sell the ordinary shares it holds at their fair market value on the last day of the last taxable year in which we qualified as a PFIC, and any gain recognized from such deemed sale would be taxed under the PFIC excess distribution regime. After the deemed sale election, the U.S. Holder&#8217;s ordinary shares would not be treated as shares of a PFIC unless we subsequently become a PFIC. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we are a PFIC for any taxable year during which a U.S. Holder holds ordinary shares and one of our non-U.S. corporate subsidiaries is also a PFIC (i.e., a lower-tier PFIC), such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC and would be taxed under the PFIC excess distribution regime on distributions by the lower-tier PFIC and on gain from the disposition of shares of the lower-tier PFIC even though such U.S. Holder would not receive the proceeds of those distributions or dispositions. Each U.S. Holder is advised to consult its tax advisors regarding the application of the PFIC rules to our non-U.S. subsidiaries. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we are a PFIC, a U.S. Holder will not be subject to tax under the PFIC excess distribution regime on distributions or gain recognized on ordinary shares if such U.S. Holder makes a valid &#8220;mark-to-market&#8221; election for our ordinary shares. A mark-to-market election is available to a U.S. Holder only for &#8220;marketable stock.&#8221; Our ordinary shares will be marketable stock as long as they remain listed on Nasdaq and are regularly traded, other than in <font style="font-style:italic;">de minimis</font> quantities, on at least 15&#160;days during each calendar quarter. If a mark-to-market election is in effect, a U.S. Holder generally would take into account, as ordinary income for each taxable year of the U.S. Holder, the excess of the fair market value of ordinary shares held at the end of such taxable year over the adjusted tax basis of such ordinary shares. The U.S. Holder would also take into account, as an ordinary loss each year, the excess of the adjusted tax basis of such ordinary shares over their fair market value at the end of the taxable year, but only to the extent of the excess of amounts previously included in income over ordinary losses deducted as a result of the mark-to-market election. The U.S. Holder&#8217;s tax basis in ordinary shares would be adjusted to reflect any income or loss recognized as a result of the mark-to-market election. Any gain from a sale, exchange or other disposition of ordinary shares in any taxable year in which we are a PFIC would be treated as ordinary income and any loss from such sale, exchange or other disposition would be treated first as ordinary loss (to the extent of any net mark-to-market gains previously included in income) and thereafter as capital loss. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A mark-to-market election will not apply to ordinary shares for any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable year in which we become a PFIC. Such election will not apply to any non-U.S. subsidiaries that we may organize or acquire in the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">127</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">future. Accordingly, a U.S. Holder may continue to be subject to tax under the PFIC excess distribution regime with respect to any lower-tier PFICs that we may organize or acquire in the future notwithstanding the U.S. Holder&#8217;s mark-to-market election for the ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The tax consequences that would apply if we are a PFIC would also be different from those described above if a U.S. Holder were able to make a valid qualified electing fund, or QEF, election. At this time, we do not expect to provide U.S. Holders with the information necessary for a U.S. Holder to make a QEF election. Prospective investors should assume that a QEF election will not be available. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Each U.S. person that is an investor of a PFIC is generally required to file an annual information return on IRS Form 8621 containing such information as the U.S. Treasury Department may require. The failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the statute of limitations with respect to U.S. federal income tax. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The U.S. federal income tax rules relating to PFICs are very complex. Prospective U.S. investors are strongly urged to consult their own tax advisors with respect to the impact of PFIC status on the purchase, ownership and disposition of ordinary shares, the consequences to them of an investment in a PFIC, any elections available with respect to the ordinary shares and the IRS information reporting obligations with respect to the purchase, ownership and disposition of ordinary shares of a PFIC. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Medicare Tax </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Certain U.S. Holders that are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax on all or a portion of their net investment income, which may include their gross dividend income and net gains from the disposition of ordinary shares. If you are a U.S. person that is an individual, estate or trust, you are encouraged to consult your tax advisors regarding the applicability of this Medicare tax to your income and gains in respect of your investment in ordinary shares. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Information Reporting and Back-up Withholding </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">U.S. Holders may be required to file certain U.S. information reporting returns with the IRS with respect to an investment in ordinary shares, including, among others, IRS Form 8938 (Statement of Specified Foreign Financial Assets). As described above under &#8220;&#8212;&#8201;Passive Foreign Investment Company Considerations,&#8221; each U.S. Holder who is a shareholder of a PFIC must file an annual report containing certain information. U.S. Holders paying more than $100,000 for ordinary shares may be required to file IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) reporting this payment. Substantial penalties may be imposed upon a U.S. Holder that fails to comply with the required information reporting. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Dividends on and proceeds from the sale or other disposition of ordinary shares may be reported to the IRS unless the U.S. Holder establishes a basis for exemption. Backup withholding may apply to amounts subject to reporting if the holder (1)&#160;fails to provide an accurate United States taxpayer identification number or otherwise establish a basis for exemption (usually on IRS Form W-9), or (2)&#160;is described in certain other categories of persons. However, U.S. Holders that are corporations generally are excluded from these information reporting and backup withholding tax rules. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund or a credit against a U.S. Holder&#8217;s U.S. federal income tax liability if the required information is furnished by the U.S. Holder on a timely basis to the IRS. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">U.S. Holders should consult their own tax advisors regarding the backup withholding tax and information reporting rules. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-weight:bold;">EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN ORDINARY SHARES IN LIGHT OF THE INVESTOR&#8217;S OWN CIRCUMSTANCES.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">128</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t18UN">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">UNDERWRITING </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Barclays Capital Inc. and UBS Securities LLC are acting as the representatives of the underwriters and joint book-running managers of this offering. Under the terms of an underwriting agreement, which will be filed as an exhibit to the registration statement, each of the underwriters named below has severally agreed to purchase from us the respective number of ordinary shares shown opposite its name below: </div>
        <table style="width:416pt;height:102pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:368.42pt;">
              <div style="white-space:nowrap;">Underwriters </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:35.58pt;text-align:center;">
              <div style="text-align:center;">Number of <br >Ordinary <br >Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:368.42pt;">
              <div style="white-space:nowrap;">Barclays Capital Inc. </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt; width:35.58pt;text-align:right;">
              <div style="text-align:right;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:368.42pt;">
              <div style="white-space:nowrap;">UBS Securities LLC </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 0.5pt 0pt; width:35.58pt;text-align:right;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:368.42pt;">
              <div style="white-space:nowrap;">Canaccord Genuity LLC </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 0.5pt 0pt; width:35.58pt;text-align:right;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:368.42pt;">
              <div style="white-space:nowrap;">Robert W. Baird &amp; Co., Incorporated </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0.5pt 2.5pt 0pt; width:35.58pt;text-align:right;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:368.42pt;">
              <div style="margin-left:10pt;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:0pt 0.5pt 2pt 0pt; width:35.58pt;text-align:right;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="5">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:10pt; width:456pt; line-height:12pt;">The underwriting agreement provides that the underwriters&#8217; obligation to purchase ordinary shares depends on the satisfaction of the conditions contained in the underwriting agreement including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the obligation to purchase all of the ordinary shares offered hereby (other than those ordinary shares covered by their option to purchase additional ordinary shares as described below), if any of the ordinary shares are purchased; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the representations and warranties made by us to the underwriters are true; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">there is no material change in our business or the financial markets; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we deliver customary closing documents to the underwriters. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Commissions and Expenses </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table summarizes the underwriting discounts and commissions we will pay to the underwriters. These amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase additional ordinary shares. The underwriting fee is the difference between the initial price to the public and the amount the underwriters pay to us for the ordinary shares. </div>
        <table style="width:416pt;height:47.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">No <br >Exercise </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Full <br >Exercise </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Per ordinary share </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:14.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:14pt; width:456pt; line-height:12pt;">The representatives have advised us that the underwriters propose to offer the ordinary shares directly to the public at the public offering price on the cover page of this prospectus and to selected dealers, which may include the underwriters, at such offering price less a selling concession not in excess of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share. If all the ordinary shares are not sold at the initial offering price following the initial offering, the representatives may change the offering price and other selling terms. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The expenses of the offering that are payable by us are estimated to be approximately $ &#8199;&#8199;&#8199;&#8199; (excluding underwriting discounts and commissions). We have also agreed to reimburse the underwriters for certain of their expenses, in an amount up to $ &#8199;&#8199;&#8199;&#8199;, incurred in connection with review by the Financial Industry Regulatory Authority, Inc. of the terms of this offering, as set forth in the underwriting agreement. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Option to Purchase Additional Ordinary Shares </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have granted the underwriters an option exercisable for 30&#160;days after the date of this prospectus to purchase, from time to time, in whole or in part, up to an aggregate of&#8201; &#8199;&#8199;&#8199;&#8199; ordinary shares from us at the public offering price less underwriting discounts and commissions. To the extent that this option is exercised, each underwriter will be obligated, subject to certain conditions, to purchase its pro&#160;rata portion of these additional ordinary shares based on the underwriter&#8217;s&#160;percentage underwriting commitment in the offering as indicated in the table at the beginning of this Underwriting section. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">129</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Lock-Up Agreements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We, all of our directors and executive officers, and substantially all of the holders of our outstanding ordinary shares have agreed that, for a period of 180&#160;days after the date of this prospectus subject to certain limited exceptions, we will not directly or indirectly, without the prior written consent of Barclays Capital Inc. (1)&#160;offer for sale, sell, pledge, or otherwise dispose of&#8201; (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition by any person at any time in the future of) any ordinary shares (including, without limitation, ordinary shares that may be deemed to be beneficially owned by us in accordance with the rules and regulations of the SEC and ordinary shares that may be issued upon exercise of any options or warrants) or securities convertible into or exercisable or exchangeable for ordinary shares (other than shares issued pursuant to employee benefit plans, qualified stock option plans, or other employee compensation plans existing on the date of this prospectus or pursuant to currently outstanding options, warrants or rights not issued under one of those plans), or sell or grant options, rights or warrants with respect to any ordinary shares or securities convertible into or exchangeable for ordinary shares (other than the grant of options pursuant to option plans existing on the date of this prospectus), (2)&#160;enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of ordinary shares, whether any such transaction described in clause (1)&#160;or (2)&#160;above is to be settled by delivery of ordinary shares or other securities, in cash or otherwise, (3)&#160;make any demand for or exercise any right or file or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any ordinary shares or securities convertible, exercisable or exchangeable into ordinary shares or any of our other securities (other than any registration statement on Form S-8), or (4)&#160;publicly disclose the intention to do any of the foregoing. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The foregoing paragraph will not apply to a transfer that (a)&#160;is a bona fide gift or gifts; (b)&#160;is to a trust for the direct or indirect benefit of such officers, directors or holders or the immediate family of such officers, directors or holders; (c)&#160;if not an individual, is a transfer or pledge to its subsidiaries, affiliates or any investment fund or other entity controlled or managed by, or under common control or management with, it; (d)&#160;is the exercise of ordinary share options granted pursuant to our existing incentive plans; (e)&#160;is a disposition solely to satisfy tax withholding obligations in connection with outstanding ordinary share options; (f)&#160;involves ordinary shares acquired in open market purchases after the completion of this offering; (g)&#160;involves the establishment of a written trading plan designed to comply with Rule&#160;10b5-1 of the Exchange Act; (h)&#160;is by will or intestacy to a legal representative, heir or legatee; (i)&#160;if not an individual, distributions of ordinary shares to members, affiliates, limited partners or stockholders; or (j)&#160;is with the prior written consent of Barclays Capital Inc. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Barclays Capital Inc., in its sole discretion, may release the ordinary shares and other securities subject to the lock-up agreements described above in whole or in part at any time. When determining whether or not to release ordinary shares and other securities from lock-up agreements, Barclays Capital Inc. will consider, among other factors, the holder&#8217;s reasons for requesting the release, the number of ordinary shares and other securities for which the release is being requested and market conditions at the time. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Offering Price Determination </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Prior to this offering, there has been no public market for our ordinary shares. The initial public offering price was negotiated between the representatives and us. In determining the initial public offering price of our ordinary shares, the representatives considered: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the history and prospects for the industry in which we compete; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our financial information; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the ability of our management and our business potential and earning prospects; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the prevailing securities markets at the time of this offering; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the recent market prices of, and the demand for, publicly traded shares of generally comparable companies. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">130</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Indemnification </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make for these liabilities. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Stabilization, Short Positions and Penalty Bids </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The representatives may engage in stabilizing transactions, short sales and purchases to cover positions created by short sales, and penalty bids or purchases for the purpose of pegging, fixing or maintaining the price of the ordinary shares, in accordance with Regulation&#160;M under the Exchange Act: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">A short position involves a sale by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase in the offering, which creates the syndicate short position. This short position may be either a covered short position or a naked short position. In a covered short position, the number of shares involved in the sales made by the underwriters in excess of the number of shares they are obligated to purchase is not greater than the number of shares that they may purchase by exercising their option to purchase additional shares. In a naked short position, the number of shares involved is greater than the number of shares in their option to purchase additional shares. The underwriters may close out any short position by either exercising their option to purchase additional shares and/or purchasing shares in the open market. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through their option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in the offering. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Syndicate covering transactions involve purchases of the ordinary shares in the open market after the distribution has been completed in order to cover syndicate short positions. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Penalty bids permit the representatives to reclaim a selling concession from a syndicate member when the ordinary shares originally sold by the syndicate member is purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our ordinary shares or preventing or retarding a decline in the market price of the ordinary shares. As a result, the price of the ordinary shares may be higher than the price that might otherwise exist in the open market. These transactions may be effected on Nasdaq or otherwise and, if commenced, may be discontinued at any time. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of the ordinary shares. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these stabilizing transactions or that any transaction, once commenced, will not be discontinued without notice. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Electronic Distribution </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A prospectus in electronic format may be made available on the Internet sites or through other online services maintained by one or more of the underwriters and/or selling group members participating in this offering, or by their affiliates. In those cases, prospective investors may view offering terms online and, depending upon the particular underwriter or selling group member, prospective investors may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of ordinary shares for sale to online brokerage account holders. Any such allocation for online distributions will be made by the representatives on the same basis as other allocations. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">131</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Other than the prospectus in electronic format, the information on any underwriter&#8217;s or selling group member&#8217;s web site and any information contained in any other web site maintained by an underwriter or selling group member is not part of the prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or any underwriter or selling group member in its capacity as underwriter or selling group member and should not be relied upon by investors. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Listing on Nasdaq</div>
        <div style="margin-left:20pt; margin-top:5.8pt; width:436pt; line-height:12pt;">We intend to apply to list our ordinary shares on Nasdaq under the symbol &#8220;INMD.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Discretionary Sales </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">The underwriters have informed us that they do not expect to sell more than 5% of the ordinary shares in the aggregate to accounts over which they exercise discretionary authority. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Stamp Taxes </div>
        <div style="text-indent:20pt; margin-top:5.8pt; width:456pt; line-height:12pt;">If you purchase ordinary shares offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Other Relationships </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriters and certain of their affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for the issuer and its affiliates, for which they received or may in the future receive customary fees and expenses. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In the ordinary course of their various business activities, the underwriters and certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments of the issuer or its affiliates. If the underwriters or their affiliates have a lending relationship with us, certain of those underwriters or their affiliates routinely hedge, and the underwriters or their affiliates may hedge, their credit exposure to us consistent with their customary risk management policies. Typically, the underwriters and their affiliates would hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the ordinary shares offered hereby. Any such credit default swaps or short positions could adversely affect future trading prices of the ordinary shares offered hereby. The underwriters and certain of their affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Selling Restrictions </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">This prospectus does not constitute an offer to sell to, or a solicitation of an offer to buy from, anyone in any country or jurisdiction (i)&#160;in which such an offer or solicitation is not authorized, (ii) in which any person making such offer or solicitation is not qualified to do so or (iii) in which any such offer or solicitation would otherwise be unlawful. No action has been taken that would, or is intended to, permit a public offer of the ordinary shares or possession or distribution of this prospectus or any other offering or publicity material relating to the ordinary shares in any country or jurisdiction (other than the United States) where any such action for that purpose is required. Accordingly, each underwriter has undertaken that it will not, directly or indirectly, offer or sell any ordinary shares or have in its possession, distribute or publish any prospectus, form of application, advertisement or other document or information in any country or jurisdiction except under circumstances that will, to the best of its knowledge and belief, result in compliance with any applicable laws and regulations and all offers and sales of ordinary shares by it will be made on the same terms. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">132</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">European Economic Area </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a &#8220;Relevant Member State&#8221;) an offer to the public of any ordinary shares which are the subject of the offering contemplated herein may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of any ordinary shares may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">to legal entities which are qualified investors as defined under the Prospectus Directive; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">by the underwriters to fewer than 100, or, if the Relevant Member State has implemented the relevant provisions of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives of the underwriters for any such offer; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">in any other circumstances falling within Article&#160;3(2) of the Prospectus Directive, </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">provided that no such offer of ordinary shares shall result in a requirement for us or any underwriter to publish a prospectus pursuant to Article&#160;3 of the Prospectus Directive or supplement a prospectus pursuant to Article&#160;16 of the Prospectus Directive. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Each person in a Relevant Member State who receives any communication in respect of, or who acquires any ordinary shares under, the offers contemplated here in this prospectus will be deemed to have represented, warranted and agreed to and with each underwriter and us that: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">it is a qualified investor as defined under the Prospectus Directive; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">in the case of any ordinary shares acquired by it as a financial intermediary, as that term is used in Article&#160;3(2) of the Prospectus Directive, (i)&#160;the ordinary shares acquired by it in the offering have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Relevant Member State other than qualified investors, as that term is defined in the Prospectus Directive, or in the circumstances in which the prior consent of the representatives of the underwriters has been given to the offer or resale or (ii) where ordinary shares have been acquired by it on behalf of persons in any Relevant Member State other than qualified investors, the offer of such ordinary shares to it is not treated under the Prospectus Directive as having been made to such persons. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For the purposes of this representation and the provision above, the expression an &#8220;offer of ordinary shares to the public&#8221; in relation to any ordinary shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any ordinary shares to be offered so as to enable an investor to decide to purchase or subscribe for the ordinary shares, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State, the expression &#8220;Prospectus Directive&#8221; means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in each Relevant Member State and the expression &#8220;2010 PD Amending Directive&#8221; means Directive 2010/73/EU. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">United Kingdom </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This prospectus has only been communicated or caused to have been communicated and will only be communicated or caused to be communicated as an invitation or inducement to engage in investment activity (within the meaning of Section&#160;21 of the Financial Services and Markets Act of 2000 (the &#8220;FSMA&#8221;)) as received in connection with the issue or sale of the ordinary shares in circumstances in which Section&#160;21(1) of the FSMA does not apply to us. All applicable provisions of the FSMA will be complied with in respect to anything done in relation to the ordinary shares in, from or otherwise involving the United Kingdom. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">133</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Canada </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The ordinary shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the ordinary shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (&#8220;NI&#160;33-105&#8221;), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Switzerland </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The ordinary shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under Article&#160;652a or Article&#160;1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under Article&#160;27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Neither this document nor any other offering or marketing material relating to the offering, the Company or the ordinary shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of ordinary shares will not be supervised by, the Swiss Financial Market Supervisory Authority, FINMA, and the offer of ordinary shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of ordinary shares. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Australia </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001, or the Corporations Act, and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Any offer in Australia of the ordinary shares may only be made to persons, which we refer to as Exempt Investors, who are &#8220;sophisticated investors&#8221; (within the meaning of Section&#160;708(8) of the Corporations Act), &#8220;professional investors&#8221; (within the meaning of Section&#160;708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in Section&#160;708 of the Corporations Act so that it is lawful to offer the ordinary shares without disclosure to investors under Chapter 6D of the Corporations Act. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The ordinary shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12&#160;months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">134</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">an exemption under Section&#160;708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring ordinary shares must observe such Australian on-sale restrictions. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This prospectus contains general information only and does not take account of the investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their needs, objectives and circumstances and, if necessary, seek expert advice on those matters. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Hong Kong </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The ordinary shares may not be offered or sold in Hong Kong by means of any document other than (i)&#160;in circumstances which do not constitute an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of Hong Kong), or Companies (Winding Up and Miscellaneous Provisions) Ordinance, or which do not constitute an invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or Securities and Futures Ordinance, or (ii) to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance and any rules made thereunder, or (iii) in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to the ordinary shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; in Hong Kong as defined in the Securities and Futures Ordinance and any rules made thereunder. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Singapore </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the ordinary share may not be circulated or distributed, nor may the ordinary shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&#160;to an institutional investor under Section&#160;274 of the Securities and Futures Act, Chapter 289 of Singapore (the &#8220;SFA&#8221;) (ii) to a relevant person pursuant to Section&#160;275(1), or any person pursuant to Section&#160;275(1A), and in accordance with the conditions specified in Section&#160;275, of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Where the ordinary shares are subscribed or purchased under Section&#160;275 of the SFA by a relevant person which is a corporation (which is not an accredited investor (as defined in Section&#160;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor, the securities (as defined in Section&#160;239(1) of the SFA) of that corporation shall not be transferable for 6&#160;months after that corporation has acquired the ordinary shares under Section&#160;275 of the SFA except: (1)&#160;to an institutional investor under Section&#160;274 of the SFA or to a relevant person (as defined in Section&#160;275(2) of the SFA), (2)&#160;where such transfer arises from an offer in that corporation&#8217;s securities pursuant to Section&#160;275(1A) of the SFA, (3)&#160;where no consideration is or will be given for the transfer, (4)&#160;where the transfer is by operation of law, (5)&#160;as specified in Section&#160;276(7) of the SFA, or (6)&#160;as specified in Regulation&#160;32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations&#160;2005 of Singapore, or Regulation&#160;32. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Where the ordinary shares are subscribed or purchased under Section&#160;275 of the SFA by a relevant person which is a trust (where the trustee is not an accredited investor (as defined in Section&#160;4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the trust is an accredited investor, the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferable for 6&#160;months after that trust has acquired the or under Section&#160;275 of the SFA except: (1)&#160;to an institutional investor under Section&#160;274 of the SFA or to a relevant person (as defined in Section&#160;275(2) of the SFA), </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">135</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">(2)&#160;where such transfer arises from an offer that is made on terms that such rights or interest are acquired at a consideration of not less than $200,000 (or its equivalent in a foreign currency) for each transaction (whether such amount is to be paid for in cash or by exchange of securities or other assets), (3)&#160;where no consideration is or will be given for the transfer, (4)&#160;where the transfer is by operation of law, (5)&#160;as specified in Section&#160;276(7) of the SFA, or (6)&#160;as specified in Regulation&#160;32. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Japan </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">No registration pursuant to Article&#160;4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948, as amended) (the &#8220;FIEL&#8221;) has been made or will be made with respect to the solicitation of the application for the acquisition of the ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Accordingly, the ordinary shares have not been, directly or indirectly, offered or sold and will not be, directly or indirectly, offered or sold in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for re-offering or re-sale, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the registration requirements, and otherwise in compliance with, the FIEL and the other applicable laws and regulations of Japan. </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">For Qualified Institutional Investors, or QII </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article&#160;4 of the FIEL) in relation to the ordinary shares constitutes either a &#8220;QII only private placement&#8221; or a &#8220;QII only secondary distribution&#8221; (each as described in Paragraph 1, Article&#160;23-13 of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article&#160;4 of the FIEL, has not been made in relation to the ordinary shares. The ordinary shares may only be transferred to QIIs. </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">For Non-QII Investors </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article&#160;4 of the FIEL) in relation to the ordinary shares constitutes either a &#8220;small number private placement&#8221; or a &#8220;small number private secondary distribution&#8221; (each as is described in Paragraph 4, Article&#160;23-13 of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article&#160;4 of the FIEL, has not been made in relation to the ordinary shares. The ordinary shares may only be transferred en bloc without subdivision to a single investor. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Israel </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In the State of Israel, this document is being distributed only to, and is directed only at, and any offer of the securities offered hereby is directed only at, (i)&#160;a limited number of persons in accordance with the Securities Law and (ii) investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&#160;million and &#8220;qualified individuals,&#8221; each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors will be required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">136</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t19LE">&#8203;</a><a name="t20EX">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">LEGAL MATTERS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The validity of the ordinary shares and other legal matters in connection with this offering with respect to Israeli law will be passed upon for us by Primes, Shiloh, Givon, Meir law firm, Haifa, Israel. Legal matters with respect to U.S. federal law will be passed upon for us by Mayer Brown LLP, New York, New&#160;York. Certain legal matters in connection with this offering will be passed upon for the underwriters by Gornitzky &amp; Co., Tel Aviv, Israel, with respect to Israeli law, and by Latham &amp; Watkins LLP, New York, New York, with respect to U.S. federal law. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">EXPERTS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The financial statements as of December&#160;31, 2017 and 2016 and for each of the two&#160;years in the period ended December&#160;31, 2017 included in this prospectus have been so included in reliance on the report of Kesselman &amp; Kesselman, Certified Public Accountants (Israel), an independent registered public accounting firm and a member firm of PricewaterhouseCoopers International Limited, given on the authority of said firm as experts in auditing and accounting.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">137</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t21EN">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">ENFORCEABILITY OF CIVIL LIABILITIES </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are incorporated in Israel and some of our directors and officers and the Israeli experts named in this prospectus reside outside the United States. Service of process upon them may be difficult to effect within the United States. Furthermore, because substantially all of our assets, and those of our non-United States directors and officers and the Israeli experts named herein, are located outside the United States, any judgment obtained in the United States against us or any of these persons may not be collectible within the United States. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have been informed by our legal counsel in Israel that there is doubt as to the enforceability of civil liabilities under the Securities Act or the Exchange Act, pursuant to original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum to hear such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact by expert witnesses which can be a time-consuming and costly process. Certain matters of procedure may also be governed by Israeli law. However, subject to particular time limitations and legal procedures, executory judgments of a U.S. court for monetary damages in civil matters may be enforced by an Israeli court, provided that: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the judgment was obtained after due process before a court of competent jurisdiction, that recognizes and enforces similar judgments of Israeli courts, and the court had authority according to the rules of private international law currently prevailing in Israel; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">adequate service of process was effected and the defendant had a reasonable opportunity to be heard and to present his or her evidence; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the judgment is not contrary to the law, public policy, security or sovereignty of the State of Israel and its enforcement is not contrary to the laws governing enforcement of judgments; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the judgment was not obtained by fraud and does not conflict with any other valid judgment in the same matter between the same parties; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the judgment is no longer appealable; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have irrevocably appointed Invasix Inc. as our agent to receive service of process in any action against us in any United States federal court or the courts of the State of New York arising out of this offering or any purchase or sale of ordinary shares in connection therewith. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Foreign judgments enforced by Israeli courts generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred out of Israel. Under existing Israeli law, a foreign judgment payable in foreign currency may be paid in Israeli currency at the rate of exchange in force on the date of the payment. Current Israeli exchange control regulations also permit a judgment debtor to make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to Israel&#8217;s consumer price index plus interest at the annual statutory rate set by Israeli regulations prevailing at that time. Judgment creditors must bear the risk of unfavorable exchange rates.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">138</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t22OT">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table sets forth the costs and expenses, other than underwriting discounts and commissions, payable by our company in connection with the sale of ordinary shares in this offering. All amounts are estimates except the SEC registration fee and the FINRA fee. </div>
        <table style="width:416pt;height:144pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:350pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">SEC registration fee </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;*</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">FINRA filing fees </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">Nasdaq Global Market listing fee </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">Printing and engraving expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">Legal fees and expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">Accounting fees and expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">Transfer agent and registrar fees </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">Miscellaneous </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:350pt;text-align:left;">
              <div style="margin-left:10pt;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="8">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:6.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">*<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">To be filed by amendment.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">139</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t23WH">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">WHERE YOU CAN FIND ADDITIONAL INFORMATION </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have filed with the SEC a registration statement on Form F-1 under the Securities Act with respect to the ordinary shares that are being offered by this prospectus. This prospectus, which is a part of the registration statement, does not contain all of the information set forth in the registration statement and the exhibits and schedules to the registration statement. Refer to the registration statement, exhibits and schedules for further information with respect to the ordinary shares offered by this prospectus. Statements contained in this prospectus regarding the contents of any contract or other documents are only summaries. With respect to any contract or document filed as an exhibit to the registration statement, you should refer to the exhibit for a copy of the contract or document, and each statement in this prospectus regarding that contract or document is qualified by reference to the exhibit. The registration statement, including all exhibits, may be inspected without charge at the SEC&#8217;s Public Reference Room at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Information on the operation of the Public Reference Room can be obtained by calling the SEC at 1-800-SEC-0330. Our SEC filings also are available to the public from the SEC&#8217;s website at www.sec.gov. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon completion of this offering, we will be subject to the information reporting requirements of the Exchange Act applicable to foreign private issuers and will fulfill the obligations with respect to those requirements by filing reports with the SEC. Those other reports or other information may be inspected without charge at the locations described above. As a foreign private issuer, we will be exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section&#160;16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. However, we will file with the SEC, within 120&#160;days after the end of each fiscal year, an annual report on Form 20-F containing financial statements audited by an independent public accounting firm. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We maintain a corporate website at www.inmodemd.com. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">140</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC2">&#8203;</a><a name="tIndex">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">INMODE LTD.<br >&#8199; <br ><font style="font-weight:normal;">CONSOLIDATED FINANCIAL STATEMENTS </font></div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;">INDEX TO FINANCIAL STATEMENTS: </div>
        <table style="width:456pt;height:142.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 3pt 0pt;text-align:center;" colspan="3">
              <div style="white-space:nowrap; text-align:center;">Page </div>
            </td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.75pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <a href="#tA1">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.75pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.75pt 0pt 2pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <a href="#tA1">F-2</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:10pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">CONSOLIDATED FINANCIAL STATEMENTS:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tA2">Consolidated Balance Sheets </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <a href="#tA2">F-3</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tA3">Consolidated Statements of Income </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <a href="#tA3">F-4</a>
            </td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tA4">Consolidated Statements of Comprehensive Income </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <a href="#tA4">F-5</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tA5">Consolidated Statements of Changes in Shareholders&#8217; Equity </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <a href="#tA5">F-6</a>
            </td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tA6">Consolidated Statements of Cash Flows </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <a href="#tA6">F-7</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tA7">Notes to Consolidated Financial Statements </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.67pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <a href="#tA7">F-8</a>
            </td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-1</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tA1">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="position:relative;z-index:-1;width:456pt;">
          <img src="lg_pwc.jpg" alt="[MISSING IMAGE: lg_pwc.jpg]" height="49" width="64" >
        </div>
        <div style="margin-top:19.98pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;">To the Board of Directors and shareholders of </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">InMode Ltd. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Opinion on the Financial Statements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have audited the accompanying consolidated balance sheets of InMode Ltd. and its subsidiaries as of December&#160;31, 2017 and 2016 and the related consolidated statements of income, comprehensive income, changes in shareholders&#8217; equity and cash flows for each of the two&#160;years in the period ended December&#160;31, 2017, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2017 and 2016, and the results of their operations and their cash flows for each of the&#160;years in the two-year period ended December&#160;31, 2017 in conformity with accounting principles generally accepted in the United States of America. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Basis for Opinion </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </div>
        <table style="width:456pt;margin-top:26pt;border-collapse: collapse;">
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:150pt;">Tel Aviv, Israel <br >July 25, 2018</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:294pt;">/s/ Kesselman &amp; Kesselman <br >Certified Public Accountants (lsr.) <br >A member firm of International PricewaterhouseCoopers Limited</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:16.98pt; width:436pt; line-height:12pt;">We have served as the Company&#8217;s auditor since 2008.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-2</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tA2">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >CONSOLIDATED BALANCE SHEETS <br >(U.S. dollars in thousands, except for per share data) </div>
        <table style="width:456pt;height:598.5pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:354pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:354pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">Assets</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">CURRENT ASSETS:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Cash and cash equivalents </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">17,593</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,696</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Marketable securities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7,447</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,588</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Accounts receivable, net of allowance for doubtful accounts </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,763</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,895</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Other receivables </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,311</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">362</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Inventories </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">5,035</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">2,760</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL CURRENT ASSETS</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">37,149</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">14,301</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">NON-CURRENT ASSETS:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Accounts receivable </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,137</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,553</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Deferred income taxes, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">810</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">230</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Property and equipment, net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">346</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">404</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL NON-CURRENT ASSETS</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,293</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,187</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL ASSETS</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">39,442</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">16,488</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:10pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">Liabilities and shareholders&#8217; equity</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">CURRENT LIABILITIES:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Accounts payable </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,064</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,601</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Contract liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,134</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">406</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Other liabilities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">9,257</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">5,361</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL CURRENT LIABILITIES</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">13,455</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7,368</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">NON-CURRENT LIABILITIES:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Contract liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,362</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Deferred income taxes </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">106</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL NON-CURRENT LIABILITIES</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">3,468</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL LIABILITIES</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">16,923</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">7,384</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.25pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="font-weight:bold;">COMMITMENTS AND CONTINGENCIES <font style="font-weight:normal;">(Note 9)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">REDEEMABLE NON-CONTROLLING INTEREST</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">3,066</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">183</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.25pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">SHAREHOLDERS&#8217; EQUITY:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:354pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Ordinary shares, NIS 0.01 par value, authorized: 20,000,000 shares, issued and outstanding: 14,729,165 and 14,673,218 shares at December&#160;31, 2017 and 2016, respectively </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">41</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">41</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Additional paid-in capital </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,052</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,560</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Retained earnings </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">10,819</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,154</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Accumulated other comprehensive income </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">541</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">166</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL SHAREHOLDERS&#8217; EQUITY</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">19,453</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">8,921</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">39,442</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">16,488</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-3</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tA3">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:222.5pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font> <br >CONSOLIDATED STATEMENTS OF INCOME <br >(U.S. dollars in thousands, except for per share data) </div>
        <table style="width:456pt;height:347.5pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.17pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31,</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="font-weight:bold;">REVENUES</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">53,456</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">23,082</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">COST OF REVENUES</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">9,053</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">5,653</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">GROSS PROFIT</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">44,403</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">17,429</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">OPERATING EXPENSES:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">Research and development </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,575</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,456</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">Sales and marketing </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">28,514</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,254</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">General and administrative </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">4,364</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">3,050</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">TOTAL OPERATING EXPENSES</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">35,453</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">16,760</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">INCOME FROM OPERATIONS</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">8,950</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">669</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">Finance income, net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">849</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">INCOME BEFORE TAXES</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,799</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">673</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">INCOME TAX</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">980</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">337</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">NET INCOME</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">8,819</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">336</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.75pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">NET INCOME PER SHARE:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">Basic </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">0.52</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">0.02</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">Diluted </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">0.46</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">0.02</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:7.417pt 0pt 0.833pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN <br >COMPUTATION OF NET INCOME PER SHARE</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">Basic </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">14,691,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">14,646,837</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">Diluted </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">16,584,637</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">14,879,319</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;"></div>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-4</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tA4">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:466.5pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME <br >(U.S. dollars in thousands, except for per share data) </div>
        <table style="width:456pt;height:103.5pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:359.8pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:359.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:359.8pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">NET INCOME</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8,819</td>
            <td style="padding:0pt;padding-left:8.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.87pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">336</td>
            <td style="padding:0pt;padding-left:8.87pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:359.8pt;text-align:left;">OTHER COMPREHENSIVE INCOME:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.87pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.87pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.8pt;text-align:left;">
              <div style="margin-left:10pt;">Change in foreign currency translation adjustment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">73</td>
            <td style="padding:0pt;padding-left:8.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.87pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">114</td>
            <td style="padding:0pt;padding-left:8.87pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:359.8pt;text-align:left;">
              <div style="margin-left:10pt;">Change in net unrealized gains of marketable securities, net of tax </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.37pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">302</td>
            <td style="padding:0pt;padding-left:8.37pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.87pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">51</td>
            <td style="padding:0pt;padding-left:8.87pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:359.8pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL OTHER COMPREHENSIVE INCOME, <font style="font-weight:normal;">net </font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.37pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9,194</td>
            <td style="padding:0pt;padding-left:8.37pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.87pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">501</td>
            <td style="padding:0pt;padding-left:8.87pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10pt; width:456pt; line-height:12pt;"></div>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-5</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tA5">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:264.03pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY <br >(U.S. dollars in thousands, except for per share data) </div>
        <table style="width:456pt;height:284pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:208.64pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">Shareholders&#8217; Equity </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:208.64pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Ordinary Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Additional <br >paid-in <br >capital </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Retained <br >earnings </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Accumulated <br >other <br >comprehensive <br >income </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="white-space:nowrap; text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:22.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Number of <br >shares issued </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:208.64pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">BALANCE AT JANUARY 1, 2016 </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">14,602,085</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">41</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,397</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,818</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,257</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:208.64pt;">CHANGES DURING 2016:</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:208.64pt;text-align:left;">
              <div style="margin-left:10pt;">Net income </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">336</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">336</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:208.64pt;text-align:left;">
              <div style="margin-left:10pt;">Other comprehensive income, net </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">165</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">165</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:208.64pt;text-align:left;">
              <div style="margin-left:10pt;">Stock-based compensation </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">125</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">125</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:208.64pt;text-align:left;">
              <div style="margin-left:10pt;">Exercise of options </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">71,133</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">38</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.53pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">38</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:208.64pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">BALANCE AT DECEMBER 31, 2016 </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">14,673,218</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">41</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,560</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,154</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">166</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,921</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:208.64pt;">CHANGES DURING 2017:</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:208.64pt;text-align:left;">
              <div style="margin-left:10pt;">Net income </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,819</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,819</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:208.64pt;text-align:left;">
              <div style="margin-left:10pt;">Other comprehensive income, net </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">375</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">375</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:208.64pt;text-align:left;">
              <div style="margin-left:10pt;">Stock-based compensation </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,436</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,436</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:208.64pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Adjustment to redemption value of redeemable non-controlling interest </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.53pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(1,154<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(1,154<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:208.64pt;text-align:left;">
              <div style="margin-left:10pt;">Exercise of options </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">55,947</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">56</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.53pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">56</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:208.64pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">BALANCE AT DECEMBER 31, 2017 </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">14,729,165</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">41</td>
            <td style="padding:0pt;padding-left:8.29pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">8,052</td>
            <td style="padding:0pt;padding-left:6.1pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.53pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,819</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">541</td>
            <td style="padding:0pt;padding-left:16.25pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">19,453</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="38">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:6.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">*<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">Representing an amount less than one thousand.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-6</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tA6">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:37pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font> <br >CONSOLIDATED STATEMENTS OF CASH FLOWS <br >(U.S. dollars in thousands, except per share data) </div>
        <table style="width:456pt;height:534.5pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:354pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:354pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">CASH FLOWS FROM OPERATING ACTIVITIES:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Net income </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,819</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">336</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:354pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Adjustments required to reconcile net income to net cash provided by operating activities:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:20pt;">Depreciation and amortization </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">204</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">151</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:20pt;">Stock-based compensation expense </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,436</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">125</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:20pt;">Allowance for doubtful accounts </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">186</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">35</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:20pt;">Changes in marketable securities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:20pt;">Provision for deferred income taxes, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(580<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(94<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Changes in operating assets and liabilities:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:20pt;">(Increase) in accounts receivable </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(2,699<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,045<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:20pt;">(Increase) decrease in other receivables </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(1,021<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">232</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:20pt;">(Increase) in inventories </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(2,342<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(368<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:20pt;">Increase in accounts payable </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,506</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">190</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:20pt;">Increase in other liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,982</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">3,228</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:20pt;">Increase in contract liabilities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">4,090</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">211</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Net cash provided by operating activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">14,609</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,996</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.25pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">CASH FLOWS FROM INVESTING ACTIVITIES:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Purchase of fixed assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(189<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(188<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Purchase of marketable securities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(5,697<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(588<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Proceeds from sale of marketable securities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">202</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">350</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Net cash (used in) investing activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(5,684<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(426<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.25pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">CASH FLOWS FROM FINANCING ACTIVITIES:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Transaction with redeemable non-controlling interest </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,729</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Exercise of options </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">56</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">38</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Net cash provided by financing activities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,785</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">53</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">187</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">125</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">NET INCREASE IN CASH AND CASH EQUIVALENTS</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">10,897</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,748</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">6,696</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">3,948</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">CASH AND CASH EQUIVALENTS AT END OF PERIOD</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">17,593</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">6,696</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:10pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">SUPPLEMENTAL DISCLOSURES OF CASH FLOWS INFORMATION:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 0.5pt 0pt; width:354pt;text-align:left;">
              <div style="margin-left:10pt;">Income taxes paid, net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">737</td>
            <td style="padding:0pt;padding-left:4.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">306</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:3.5pt;line-height:3.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8.5pt; width:456pt; line-height:12pt;"></div>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-7</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tA7">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font> <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS <br >(U.S. dollars in thousands, except per share amounts) </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 1&#8201;&#8212;&#8201;GENERAL </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">InMode Ltd. (formerly Invasix Ltd.) (separately and together with its subsidiaries, the &#8220;Company&#8221;) was incorporated on January&#160;2, 2008 and commenced operations shortly thereafter. The Company&#8217;s headquarters are located in Israel.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company is a leading global provider of innovative, energy-based, minimally and non-invasive aesthetic solutions. The Company has developed and commercialized products utilizing medically-accepted radiofrequency energy-based technologies. These technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including liposuction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. In addition to its minimally-invasive solutions, the Company designs, develops, manufactures and markets differentiated non invasive medical aesthetic products that target a wide array of procedures. These include simultaneous fat killing and skin tightening, permanent hair reduction through the use of our innovative dual wavelength technology, and other treatments targeting skin appearance and texture through the use of its high power intense pulsed light technology. The Company&#8217;s products, which it markets and sells traditionally to plastic and facial surgeons, aesthetic surgeons, dermatologists and aesthetic obstetricians/gynecologists, may be used on a variety of body parts including the face, neck, abdomen, upper arms, thighs and intimate feminine regions.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company has five wholly-owned subsidiaries located in the United States, Canada, Japan, Spain and Israel. In addition, the Company has two subsidiaries located in the United Kingdom and China and holds a 51% interest in each of those subsidiaries. The Company&#8217;s seven subsidiaries are referred to collectively herein as the &#8220;Subsidiaries.&#8221; The Company sells its products primarily through its Subsidiaries. See Note&#160;14 regarding the establishment of InMode Asia Ltd.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In December&#160;2016, the Company signed a joint venture agreement with Guangzhou Sino-Israel Bio-Industry Investment Fund (LLP) (&#8220;GIBF&#8221;), an investment fund established by the Guangzhou government, to invest in Israeli companies, pursuant to which an Equity Joint Venture Company (&#8220;JVC&#8221;) was established. According to the agreement, the Company provides to the JVC a license to use the Company&#8217;s knowledge in exchange for a 51% interest, and GIBF will invest RMB 50&#160;million (approximately $7.2&#160;million), in exchange for a 49% interest, in the JVC. The investment will be paid in three installments following the achievement of three specified milestones: (i)&#160;30 days after closing&#8201;&#8212;&#8201;25% of the invested amount, (ii) upon initiation of the production and manufacturing line&#8201;&#8212;&#8201;35% of the invested amount, and (iii) upon completion of sales and installation of ten platforms in China&#8201;&#8212;&#8201;40% of the invested amount. The Company will distribute the Company&#8217;s products in China and develop and manufacture new products for the Chinese market under the Company&#8217;s license. In 2017, the JVC satisfied the first milestone and GIBF invested approximately $1.7&#160;million. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The non-controlling partner in the JVC has the right to convert its equity interest in the JVC in connection, <font style="font-style:italic;">inter alia</font>, with an initial public offering (&#8220;IPO&#8221;) of the Company, into ordinary shares of the Company, based upon the aggregate gross amounts extended by the non-controlling partner in the JVC and at the price set forth in the IPO. Additionally, the non-controlling partner in the Company&#8217;s subsidiary in the United Kingdom (&#8220;Invasix UK&#8221;), has the right to convert its equity interest in Invasix UK in connection, <font style="font-style:italic;">inter alia</font>, with an IPO of the Company. The number of ordinary shares to be issued upon the conversion will be based on the&#160;percentage of Invasix UK&#8217;s revenues in relation to the total revenues of the Company. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The non-controlling partners&#39; conversion rights are presented as part of the redeemable non-controlling interest which is classified as &#8220;mezzanine.&#8221; The Company adjusts the carrying amount of its redeemable non-controlling interest to its redemption value to retained earnings. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On October&#160;26, 2017, the Company&#8217;s name was changed to &#8220;InMode Ltd.&#8221; in accordance with the decision made at the Company&#8217;s shareholders meeting. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-8</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 2&#8201;&#8212;&#8201;SIGNIFICANT ACCOUNTING POLICIES </div>
        <div style="margin-top:10.81pt; width:456pt; line-height:11pt;font-weight:bold;">a. Basis of presentation </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">The Company&#8217;s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;). </div>
        <div style="margin-top:11.81pt; width:456pt; line-height:11pt;font-weight:bold;">b. Use of estimates </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions include those relating to revenue recognition (especially in relation to price concession), provision for doubtful accounts, warranty provision, deferred tax assets and fair value of options to purchase the Company&#8217;s securities. </div>
        <div style="margin-top:11.81pt; width:456pt; line-height:11pt;font-weight:bold;">c. Functional currency </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">The U.S. dollar (&#8220;U.S. dollar&#8221; or &#8220;$&#8221;) is the currency of the primary economic environment in which the operations of the Company and its subsidiaries in the United States and Israel are conducted. Revenues and a substantial portion of the operational costs are denominated in U.S. dollars. Accordingly, the functional currency of the Company and its subsidiaries in the United States and Israel is the U.S. dollar. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non-U.S. dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (i)&#160;for transactions&#8201;&#8212;&#8201;exchange rates at transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization)&#8201;&#8212;&#8201;historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses, as appropriate. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The functional currencies of the Company&#8217;s subsidiaries in Canada, China, the United Kingdom, Spain and Japan (the &#8220;Foreign Subsidiaries&#8221;) are their respective local currencies. For purposes of consolidation, the financial statements of the Foreign Subsidiaries are translated into U.S. dollars in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 830, &#8220;Foreign Currency Matters&#8221; (&#8220;ASC 830&#8221;). Assets and liabilities are translated at period-end exchange rates, while revenues and expenses are translated at exchange rates for each transaction. All gains and losses resulting from translation are presented in other comprehensive income within the consolidated statements of comprehensive income. </div>
        <div style="margin-top:11.62pt; width:456pt; line-height:11pt;font-weight:bold;">d. Principles of consolidation and presentation </div>
        <div style="text-indent:20pt; margin-top:5.8pt; width:456pt; line-height:12pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany transactions and balances are eliminated in consolidation. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Non-controlling interests in subsidiaries represent the equity in subsidiaries not attributable, directly or indirectly, to the Company. Non-controlling interests are presented in equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they result in a negative balance of non-controlling interests in the consolidated statements of income. </div>
        <div style="margin-top:11.61pt; width:456pt; line-height:11pt;font-weight:bold;">e. Cash and cash equivalents </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">The Company considers cash equivalents to be all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three&#160;months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-9</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 2&#8201;&#8212;&#8201;SIGNIFICANT ACCOUNTING POLICIES&#8201;(continued)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">f. Marketable securities </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Marketable securities consist of marketable equity securities, debt securities and mutual fund securities classified as available-for-sale and are recorded at fair value. The fair value of quoted securities is based on current market value. Changes in fair value, net of taxes, are reflected in other comprehensive income. Realized gains and losses on the sale of the securities, as well as any premium or discount amortization, are included in the consolidated statement of income as finance income or expense. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">g. Inventories </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Inventories include raw materials and finished products and are valued at the lower of cost or net realizable value. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Cost is determined as follows: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Raw materials: first in, first out (&#8220;FIFO&#8221;) method. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Finished products: using the &#8220;moving average&#8221; basis. The moving average is calculated as each additional inventory unit is purchased.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company regularly evaluates its ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, estimated current and future market values and new product introductions. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">h. Property and equipment </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Property and equipment is stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the following estimated useful lives: </div>
        <table style="width:416pt;height:40pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:202pt;">Computers </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:202pt;text-align:center;">
              <div style="text-align:center;">3&#8201;&#8211;&#8201;4&#160;years </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:202pt;">Molds </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:202pt;text-align:center;">
              <div style="text-align:center;">4&#8201;&#8211;&#8201;10&#160;years </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:202pt;">Equipment and furniture </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:202pt;text-align:center;">
              <div style="text-align:center;">10&#8201;&#8211;&#8201;17&#160;years</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:14pt; width:456pt; line-height:12pt;">Leasehold improvements are amortized on a straight-line basis over the expected lease term, which is typically shorter than the estimated useful life of the improvements. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">i. Impairment of long-lived assets </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company tests long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the sum of the expected undiscounted cash flow is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount over the fair value of the asset, using the expected future discounted cash flows.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2017 and 2016, the Company did not recognize an impairment loss on its long-lived assets. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">j. Legal and other contingencies </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Certain conditions may exist as of the date of the consolidated financial statements, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company&#8217;s management assesses such contingent liabilities and estimated legal fees, if any, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-10</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 2&#8201;&#8212;&#8201;SIGNIFICANT ACCOUNTING POLICIES&#8201;(continued)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:12pt;">proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company&#8217;s management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Management applies the guidance in ASC 450-20, &#8220;Loss Contingencies&#8221; when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability is recorded as accrued expenses in the Company&#8217;s consolidated financial statements. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Legal costs incurred in connection with loss contingencies are expensed as incurred. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2017 and 2016, the Company has recorded a provision of&#8201; $2,000 in relation to an ongoing litigation (see also Note 9(c)(1)). </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">k. Income taxes </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">1)<br ></div>
        <div style=" float:left; margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC&#160;740&#8221;). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2015-17. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">2)<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Upon the distribution of dividends from the tax-exempt income of a Benefited Enterprise (see also Note 11(a)(2)), the amount distributed is subject to tax at the rate that would have been applicable had the Company not been exempted from payment thereof. The Company intends to permanently reinvest the amounts of tax-exempt income and it does not intend to distribute dividends. Therefore, no deferred income taxes have been provided in respect of such tax-exempt income. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">3)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The Company may incur an additional tax liability in the event of an inter-company dividend distribution from Foreign Subsidiaries; no additional deferred income taxes have been provided, since the Company does not expect to distribute dividends in the foreseeable future that may result in additional tax liability. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">4)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Taxes that would apply in the event of disposal of investments in Subsidiaries have not been taken into account in computing the deferred income taxes, as it is the Company&#8217;s intent and ability to hold these investments. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">5)<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The Company accounts for uncertain tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits under taxes on income (tax benefit). </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-11</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 2&#8201;&#8212;&#8201;SIGNIFICANT ACCOUNTING POLICIES&#8201;(continued)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">l. Share-based compensation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company grants share options to its employees, directors and non-employees in consideration for services rendered. See Note 10 for details on outstanding share  capital. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company accounts for share-based payment awards classified as equity awards using the grant-date fair value method. The fair value at grant-date of the issued equity award is recognized as an expense on a straight-line basis over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions at the time of grant and revises such estimates in subsequent periods if actual forfeitures differ from those estimates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company elected to recognize share-based compensation cost for awards with only service conditions that have a graded vesting schedule using the straight-line method based on the multiple-option award approach. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">When options are granted as consideration for services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the consideration received or the fair value of the options issued, whichever is more reliably measurable. The fair value of the options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">m. Revenue recognition </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company early adopted ASC 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;), using the full retrospective transition method. Under this method, the Company has revised its consolidated financial statements for the year ended December&#160;31, 2016, as if Topic 606 had been effective for that period. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii) identify the performance obligations in the contract&#8201;&#8212;&#8201;the Company determined that its arrangements are generally comprised of the following elements that are recognized as separate performance obligations: products, consumables and extended warranties. Installation and training services are not essential to the functionality of the Company products; (iii) determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract&#8201;&#8212;&#8201;the Company estimates the standalone selling prices of the services to be provided based on expected pricing of service contract purchased on a standalone basis and used the residual approach to estimate the selling price of the products; and (v)&#160;recognize revenue when (or as) the performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer, after considering any price concession expected to be provided to the customer, when applicable. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following is a description of the principal activities from which the Company generates its revenue. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Product Revenue, Net </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Revenues from product sales are recognized when the customer obtains control of the Company&#8217;s product, typically upon shipment to the customer. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-12</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 2&#8201;&#8212;&#8201;SIGNIFICANT ACCOUNTING POLICIES&#8201;(continued)<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The Company may enter into installment sales contracts with end users, in North America, that provide them with long-term (generally up to 60&#160;months) financing for the purchase of the Company&#8217;s products. The interest rate used in these contracts reflects the credit characteristics of the party receiving financing in the contract, as well as any collateral or security provided by the customer. Interest income on these receivables is recognized as finance income and earned over the terms of the contract. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Variable consideration mainly includes price concessions related to installment sales contracts. The Company recognizes any variable consideration at the time that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The Company does not grant a right of return, refund, cancelation or termination. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Service Revenue </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company also generates revenues from long-term maintenance contracts (&#8220;Extended Warranty&#8221;). Revenue from Extended Warranty is recognized ratably, on a straight-line basis, over the period of the applicable service contract. Contract liabilities are derived from these maintenance agreements. Revenue from repairs performed in the absence of Extended Warranty is recognized when the related services are performed and it is probable that the entity will collect the consideration it is entitled to. The Company classifies the portion of contract liabilities not expected to be earned in the subsequent 12&#160;months as long-term. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">n. Allowance for doubtful accounts </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of customers to make required payments. The Company reviews the accounts receivable on a periodic basis and records an allowance when there is doubt as to the collectability of individual balances in the period in which such loss is determined to be probable based on an assessment of specific evidence indicating doubtful collection, historical experience, account balance aging and prevailing economic conditions. Doubtful account balances are written off and deducted from the allowance when the receivable is deemed uncollectible, after all collection efforts have been exhausted and the potential for recovery is considered remote. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">o. Warranty reserve </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company provides a one-year standard warranty for its products. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company&#8217;s warranty reserve include the number of&#160;units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table sets forth activity in the Company&#8217;s accrued warranty account for each of the&#160;years ended December&#160;31, 2017 and 2016: </div>
        <table style="width:416pt;height:82.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Balance at beginning of year </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">355</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">305</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Charged to expense </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(547<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(572<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Costs incurred </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">572</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">622</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Balance at end of year </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">380</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">355</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-13</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 2&#8201;&#8212;&#8201;SIGNIFICANT ACCOUNTING POLICIES&#8201;(continued)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">p. Cost of revenues </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Cost of revenues consists of (i)&#160;products purchased from the Company&#8217;s subcontractors that are responsible for the production of most of the Company&#8217;s products under the Company&#8217;s directions and supervision, (ii)&#160;raw materials for the Company&#8217;s in-house assembly line, (iii)&#160;shipping and handling costs to customers and to subsidiaries, (iv)&#160;salary and other employee related expenses, (v)&#160;overhead expenses of the Company&#8217;s internal manufacturing lines and (vi)&#160;service costs associated with product warranties.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">q. Research and development costs </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Research and development costs are expensed as incurred and includes salaries and employee related expenses, overhead expenses, material and third-party contractor&#8217;s charges related to product development, regulatory affairs and clinical studies. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">r. Net income per share </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">Basic earnings per share are computed by dividing net income by the weighted average number of the Company&#8217;s ordinary shares, par value NIS 0.01 per ordinary share, outstanding for each period.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For the diluted earnings per share calculation, the weighted average number of shares outstanding during the year is adjusted for the average number of shares that are potentially issuable in connection with employee share-based payment, using the treasury stock method.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company deducts the accretion of the redeemable non-controlling interest in computing the basic and diluted earnings per share.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">s. Fair value measurement </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In the absence of active markets for identical assets or liabilities, such measurements involve developing assumptions based on market observable data and, in the absence of such data, internal information that is consistent with what market participants would use in a hypothetical transaction that occurs at the measurement date. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company&#8217;s market assumptions. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The three levels of inputs that may be used to measure fair value are as follows: </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Level&#160;1&#8201;&#8212;&#8201;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Level&#160;2&#8201;&#8212;&#8201;Observable prices that are based on identical or similar instruments not quoted on active markets, but corroborated by observable market data, or quoted prices for similar instruments in active markets. The Company had no Level&#160;2 assets or liabilities as of December&#160;31, 2017 and 2016. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Level&#160;3&#8201;&#8212;&#8201;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs. The Company had no Level&#160;3 assets or liabilities as of December&#160;31, 2017 and 2016. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company maintains policies and procedures to determine the fair value of financial assets and liabilities using what it considers to be the most relevant and reliable market data available. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-14</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 2&#8201;&#8212;&#8201;SIGNIFICANT ACCOUNTING POLICIES&#8201;(continued)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">t. Segments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. The Company&#8217;s chief operating decision-maker evaluates the performance of its business based on financial data consistent with the presentation in the accompanying financial statements. The Company concluded that its unified business is conducted globally and accordingly represents one operating segment. As of December&#160;31, 2017 and 2016, most of the Company&#8217;s long-lived assets were maintained in Israel. See Note 12 for details relating to revenue by geography. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">u. Newly issued and recently adopted accounting pronouncements </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">Recently adopted accounting pronouncements: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">1)<br ></div>
        <div style=" float:left; margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">In May&#160;2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU&#160;No. 2014-09, which amends the guidance for accounting for revenue from contracts with customers. This ASU supersedes the revenue recognition requirements in ASC&#160;605, &#8220;Revenue Recognition&#8221; and creates a new ASC&#160;606, &#8220;Revenue from Contracts with Customers.&#8221; In 2015 and 2016, the FASB issued additional ASUs related to ASC 606 that delayed the effective date of the guidance and clarified various aspects of the new revenue guidance, including principal versus agent considerations, identifying performance obligations, and licensing, and they include other improvements and practical expedients. The effective date using the full retrospective transition method was January&#160;1, 2016. The Company has elected to use the following practical expedients that are permitted under the rules of the adoption, which have been applied consistently to all contracts within all reporting periods presented: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8201;&#8212;&#8201;<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">Applying the practical expedient in paragraph 340-40-25-4, the Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:40pt; margin-top:6pt; width:416pt; line-height:12pt;">The most significant impact of the standard relates to revenue from the Company&#8217;s long-term installments contracts. The cumulative effect as of January&#160;1, 2016 for the adoption of this ASU&#160;was immaterial. </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">2)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">In March&#160;2016, the FASB issued ASU No.&#160;2016-09, &#8220;Compensation&#8201;&#8212;&#8201;Stock Compensation (Topic&#160;718): Improvements to Employee Share-Based Payment Accounting&#8221; (&#8220;ASU 2016-09&#8221;). ASU 2016-09 identifies areas for simplification involving several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. The Company adopted this standard as of January&#160;1, 2017, and elected to continue to estimate forfeiture rate when recognizing stock compensation expense, based on its experience. The adoption of this standard had no material impact on the Company&#8217;s consolidated financial statements.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-15</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 2&#8201;&#8212;&#8201;SIGNIFICANT ACCOUNTING POLICIES&#8201;(continued)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">u. Newly issued and recently adopted accounting pronouncements (continued): </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">Accounting pronouncements issued but not yet adopted: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">3)<br ></div>
        <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">In January&#160;2016, the FASB issued ASU No.&#160;2016-01, &#8220;Financial Instruments&#8201;&#8212;&#8201;Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities&#8221; (&#8220;ASU 2016-01&#8221;), which relates to certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. Most prominent among the changes in the standard is the requirement for changes in the fair value of the Company&#8217;s equity investments, with certain exceptions, to be recognized through net income rather than other comprehensive income. ASU 2016-01 will be effective for annual reporting periods and interim periods within those&#160;years beginning after December&#160;15, 2017. The Company evaluated the impact of the adoption of ASU 2016-01 on its consolidated financial statements and the resulting reclassification of&#8201; $316 from other comprehensive income to retained earnings in the shareholders&#8217; equity starting in the first quarter of 2018. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">4)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">In February&#160;2016, the FASB issued ASU No.&#160;2016-02 &#8220;Leases (Topic 842)&#8221; (&#8220;ASU 2016-02&#8221;), which revises lease accounting guidance. Under ASU 2016-02, lessees will be required to recognize a right-of-use asset and a lease liability for all leases, other than leases that meet the definition of a short-term lease. The liability and the right-of-use asset arising from the lease will be measured at the present value of the lease payments. ASU 2016-02 is effective for fiscal&#160;years beginning after December&#160;15, 2018, including interim periods within those fiscal&#160;years. Early adoption is permitted. ASU 2016-02 must be adopted using a modified retrospective transition approach. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its consolidated financial statements. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">5)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">In August&#160;2016, the FASB issued ASU No.&#160;2016-15, &#8220;Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (Topic 230)&#8221; (&#8220;ASU 2016-15&#8221;), which addresses the diversity of practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows with respect to eight specific cash flow issues. The new standard is effective for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2017. The Company is currently evaluating the impact of the adoption of ASU&#160;2016-15 on its consolidated financial statements. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">6)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">In June&#160;2018, the FASB issued ASU No.&#160;2018-07 (Topic 718) &#8220;Improvements to Nonemployee Share-Based Payment Accounting&quot; that expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for certain exemptions specified in the amendment. The guidance is effective for fiscal&#160;years beginning after December&#160;15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted, but no earlier than an entity&#8217;s adoption date of Topic 606. The Company is currently evaluating the impact of the guidance on its consolidated financial statements. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 3&#8201;&#8212;&#8201;<font style="text-transform:uppercase;">Marketable Securities</font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Marketable securities as of December&#160;31, 2017 and 2016 consist of the Company&#8217;s marketable equity securities, debt securities and mutual fund securities. These marketable securities are classified as available-for-sale and are recorded at fair value. Changes in fair value, net of taxes (if applicable), are reflected in other comprehensive income or loss. Realized gains and losses on sales of marketable securities, as well as premium or discount amortization, are included in the consolidated statements of operation as finance income or expense.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-16</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 3&#8201;&#8212;&#8201;<font style="text-transform:uppercase;">Marketable Securities</font>&#8201;(continued)<br >&#8199;</div>
        <div style="margin-left:20pt; margin-top:1pt; width:436pt; line-height:12pt;">The following table sets forth the Company&#8217;s marketable securities for the periods indicated: </div>
        <table style="width:416pt;height:82.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Marketable equity securities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,234</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">643</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Corporate bonds </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,655</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">945</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Mutual funds </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">558</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">7,447</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,588</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:17.79pt; width:456pt; line-height:12pt;">At December&#160;31, 2017 and 2016, the fair value, cost and gross unrealized holding gains or losses of marketable securities owned by the Company were as follows: </div>
        <table style="width:456pt;height:100.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:210pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, 2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:210pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Fair <br >value </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Cost or <br >amortized <br >cost </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Gross <br >unrealized <br >holding loss </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Gross <br >unrealized <br >holding gains </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:210pt;text-align:left;">
              <div style="white-space:nowrap;">Marketable equity securities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,234</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,832</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(45<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">447</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:210pt;text-align:left;">
              <div style="white-space:nowrap;">Corporate bonds </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,655</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,604</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(17<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">68</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:210pt;text-align:left;">
              <div style="white-space:nowrap;">Mutual funds </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">558</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">550</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.335pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:17.335pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:210pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">7,447</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">6,986</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.335pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(62<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.335pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">523</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:100.5pt;margin-top:13pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:210pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, 2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:210pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Fair <br >value </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Cost or <br >amortized <br >cost </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Gross <br >unrealized <br >holding loss </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Gross <br >unrealized <br >holding gains </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:210pt;text-align:left;">
              <div style="white-space:nowrap;">Marketable equity securities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">643</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">592</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(16<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">67</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:210pt;text-align:left;">
              <div style="white-space:nowrap;">Corporate bonds </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">945</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">928</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(1<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:210pt;text-align:left;">
              <div style="white-space:nowrap;">Mutual funds </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.335pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:17.335pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:210pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,588</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,520</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.335pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(17<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.335pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">85</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:17.79pt; width:456pt; line-height:12pt;">As of December&#160;31, 2017 and 2016, the Company&#8217;s marketable securities are all categorized in Level&#160;1 for fair value measurement purposes. See also Note 2(s). </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During the&#160;years ended December&#160;31, 2017 and 2016, the Company received proceeds of&#8201; $202 and $350, respectively, upon sale and maturity of marketable securities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2017 and 2016, the Company&#8217;s debt securities had the following maturity dates: </div>
        <table style="width:416pt;height:111pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Market value </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Due within one year </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">200</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">3 to 4&#160;years </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">169</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">4 to 5&#160;years </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">820</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">171</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">More than 5&#160;years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,466</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">774</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,655</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">945</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:17.99pt; width:436pt; line-height:12pt;">Regarding new accounting pronouncements related to this topic see also Note 2(u)(3). </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-17</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 4&#8201;&#8212;&#8201;ACCOUNTS RECEIVABLE </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Accounts receivable consists of the following: </div>
        <table style="width:416pt;height:113pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Trade </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">6,759</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,635</td>
            <td style="padding:0pt;padding-left:13.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Notes receivable </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">528</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">14</td>
            <td style="padding:0pt;padding-left:13.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Less&#8201;&#8211;&#8201;allowance for doubtful accounts </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(387<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(201<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">6,900</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,448</td>
            <td style="padding:0pt;padding-left:13.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Less&#8201;&#8211;&#8201;non-current accounts receivable </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,137<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,553<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">5,763</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.98pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,895</td>
            <td style="padding:0pt;padding-left:13.98pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:22pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 5&#8201;&#8212;&#8201;INVENTORIES </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Inventories consisted of the following: </div>
        <table style="width:416pt;height:67.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Raw materials </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,407</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,518</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Finished products </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,628</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,242</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Total inventories </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5,035</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,760</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:22pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 6&#8201;&#8212;&#8201;PROPERTY AND EQUIPMENT, NET </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Composition of property and equipment grouped by major classifications is as follows: </div>
        <table style="width:416pt;height:128pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Computers </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">128</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">109</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Office furniture and equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">96</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">178</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Molds </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">737</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">683</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Leasehold improvements </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">120</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">37</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,081</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,007</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Less: accumulated depreciation </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(735<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(603<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Total property and equipment, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">346</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">404</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:18.98pt; width:456pt; line-height:12pt;">Total depreciation and amortization in respect of property and equipment were $204 and $151 for the&#160;years ended December&#160;31, 2017 and 2016, respectively. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-18</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 7&#8201;&#8212;&#8201;OTHER LIABILITIES </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Other liabilities consist of the following: </div>
        <table style="width:416pt;height:112.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Employees and related expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,014</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,723</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Government institutions </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,070</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">397</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Accrued contingencies </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,000</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,000</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Income tax </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,024</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">212</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Other </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,149</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,029</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9,257</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5,361</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:22pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 8&#8201;&#8212;&#8201;EMPLOYEE SEVERANCE BENEFITS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company is required to make severance payments upon dismissal of an employee or upon termination of employment in certain circumstances. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In accordance with the current employment terms with all of its employees (Section&#160;14 of the Israeli Severance Pay Law, 1963) located in Israel, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&#8217;s full retirement benefit obligation. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company balance sheet, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The amounts of severance payment expenses were $154 and $134 for the&#160;years ended December&#160;31, 2017 and 2016, respectively. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company expects to contribute approximately $166 in the year ending December&#160;31, 2018 to insurance companies in connection with its expected severance liabilities for the year. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 9&#8201;&#8212;&#8201;COMMITMENTS AND CONTINGENT LIABILITIES </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">a. Leases </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company had a lease agreement for its headquarter offices in Israel that expired in December&#160;2018, with an option to extend an additional three&#160;years at the Company&#8217;s discretion. The lease is with related parties. Rent for this lease agreement is linked to the Israeli Consumer Price Index. For the purpose of ensuring the Company&#8217;s obligation to the lessor, the Company provided the lessor with a bank guarantee of 50&#160;thousand NIS (approximately $14). In May&#160;2018, the Company signed a new lease agreement for its headquarter offices in Israel that expires in December&#160;2021. See Note 14 for additional information regarding subsequent events. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The Company&#8217;s U.S. subsidiary has a lease agreement for its offices that expires in August&#160;2022. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s Canadian subsidiary has a lease agreement for its offices that expires in June&#160;2022. The lease is with related parties.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-19</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 9&#8201;&#8212;&#8201;COMMITMENTS AND CONTINGENT LIABILITIES&#8201;(continued)<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The minimum lease payments of the Company for the next five&#160;years, at rates in effect at December&#160;31, 2017, are as follows: </div>
        <table style="width:416pt;height:100.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:350pt;text-align:left;">Year ending December&#160;31:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;text-align:left;">
              <div style="margin-left:10pt;">2018 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">341</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;text-align:left;">
              <div style="margin-left:10pt;">2019 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">184</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;text-align:left;">
              <div style="margin-left:10pt;">2020 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">191</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350pt;text-align:left;">
              <div style="margin-left:10pt;">2021 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">197</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:350pt;text-align:left;">
              <div style="margin-left:10pt;">2022 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">122</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:350pt;text-align:left;">
              <div style="margin-left:20pt;">Total future minimum lease payments </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,035</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="9">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:17.19pt; width:456pt; line-height:12pt;">Rent expense amounted to approximately $287 and $283 for the&#160;years ended December&#160;31, 2017 and 2016, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">b. Subcontracting agreement </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company has entered into turnkey manufacturing agreements with its major subcontractors in Israel in connection with manufacturing and assembling of the Company&#8217;s products. The agreement is renewed automatically every year, unless either the Company or the subcontractor gives written notice three&#160;months prior to the expiration of the term. Additionally, the Company or the subcontractor has the ability to terminate the contract at any time and for any reason with prior written notice of four&#160;months. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">According to the agreements, the Company does not have a minimum order obligation but the Company provides the subcontractors a six-month rolling forecast with the projected demand for its products. In the case of termination of an agreement, the Company has to compensate the subcontractor for non-returnable inventory, materials in orders that cannot be cancelled and finished products inventory. As of December&#160;31, 2017, the subcontractor&#8217;s finished goods inventory, raw material and open orders amounted to approximately $2&#160;,000. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">c. Litigation and contingencies </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company is involved in various claims, legal proceedings and investigations, including those described below. While it is not feasible to predict the outcome of such pending claims, proceedings and investigations with certainty, management is of the opinion that their ultimate resolution should not have a material adverse effect on the Company&#8217;s financial position, cash flows, or results of operations, except where noted below: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">1)<br ></div>
        <div style=" float:left; margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">In January&#160;2016, Syneron Medical Ltd. (&#8220;Syneron&#8221;) filed a claim against the Company&#8217;s U.S. subsidiary and its Israeli subsidiary in the United States District Court in the Central District of California, claiming alleged infringement of four U.S. patents of Syneron. In the framework of the claim, Syneron requests the court enter a permanent injunction enjoining the named Subsidiaries, officers and others on its behalf from infringing the patents, and to enter a judgment and order requiring defendants to compensate Syneron for the alleged infringement of the patents. A trial hearing was scheduled for November&#160;2018. As of December&#160;31, 2017 and 2016, the Company has accrued a provision of&#8201; $2,000 in connection with this litigation. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">2)<br ></div>
        <div style=" float:left; margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">In April&#160;2017, Syneron, Inc. and Candela Corporation filed a claim against the Company&#8217;s U.S. subsidiary, the Israeli subsidiary and the Company in the United States District Court in Tennessee, claiming that the defendants interfered with the plaintiffs&#8217; business, misappropriated plaintiffs&#8217; trade secrets, interfered with plaintiffs&#8217; employment relationships, and induced the breach of plaintiffs&#8217; employment agreements with several former employees. The plaintiffs filed a </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-20</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 9&#8201;&#8212;&#8201;COMMITMENTS AND CONTINGENT LIABILITIES&#8201;(continued)<br >&#8199;</div>
        <div style="margin-left:40pt; margin-top:1pt; width:416pt; line-height:12pt;">motion for expedited discovery. The Company filed a motion to dismiss the action on procedural grounds. The parties reported the case as settled in September&#160;2017. The full and final settlement agreement was signed by all parties in February&#160;2018 for an immaterial amount. </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">3)<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">In May&#160;2017, Cynosure, Inc. (&#8220;Cynosure&#8221;) filed a claim against the Company&#8217;s U.S. subsidiary in the United States District Court for the Southern District of Texas (Houston). The case was transferred to the District of Massachusetts. Cynosure claimed that the Company&#8217;s U.S. subsidiary unlawfully solicited certain former Cynosure employees, misappropriated Cynosure&#8217;s trade secrets, and aided and abetted the employees&#8217; breaches of their fiduciary duties to Cynosure. A full and final settlement agreement was executed in February&#160;2018 for an immaterial amount. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 10&#8201;&#8212;&#8201;SHARE CAPITAL </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">a. Ordinary shares </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Each holder of the Company&#8217;s ordinary shares is entitled to one vote. The holders of the Company&#8217;s ordinary shares are also entitled to receive dividends whenever funds are legally available, when and if declared by the Company&#8217;s Board of Directors. Since inception, the Company has not declared any dividends. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">b. Share-based compensation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On January&#160;30, 2008, the Company&#8217;s board of directors adopted two share option plans as follows (collectively, the &#8220;2008 Plans&#8221;): </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">1.<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">2008 Israeli Option Plan (&#8220;2008 Israeli Plan&#8221;) allowing the Company to grant options to purchase ordinary shares to Israeli employees, officers, directors, consultants and service providers. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">2.<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">2008 ROW Option Plan (&#8220;2008 ROW Plan&#8221;) allowing the Company to grant options to purchase ordinary shares to non-Israeli employees, officers, directors, consultants and service providers. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">As of December&#160;31, 2017, 741,326 options were available for grant under the 2008 Plans. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June&#160;2018, the Company&#8217;s board of directors adopted a new incentive plan (&#8220;2018 Incentive Plan&#8221;), allowing the Company to grant options to purchase ordinary shares, restricted shares or other awards to Israeli and other non-U.S. employees, officers, directors, consultants and service providers of the Company. The 2018 Incentive Plan also includes as an appendix a sub-plan allowing the Company to grant options to purchase ordinary shares, restricted shares or other incentive awards to U.S. employees, officers, directors, consultants and service providers, of the Company. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The grant of options to Israeli employees, officers and directors under the 2008 Israeli Plan and the 2018 Incentive Plan is subject to the terms stipulated by Sections&#160;102 and 102A of the Israeli Income Tax Ordinance. Each option grant is subject to the track chosen by the Company, either Section&#160;102 or Section&#160;102A of the Israeli Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim as an expense for tax purposes the amounts credited to employees as benefits, including amounts recorded as salary benefits in the Company&#8217;s accounts, in respect of options granted to employees under the 2008 Israeli Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For consultants and service providers, the 2008 Israeli Plan and the 2018 Incentive Plan is subject to Section&#160;3(i) of the Israeli Income Tax Ordinance. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon the adoption of the 2018 Incentive Plan, the then current pool of options available for future grants under the 2008 Plans was canceled and returned to the Company&#8217;s authorized and un-issued share capital. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-21</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 10&#8201;&#8212;&#8201;SHARE CAPITAL&#8201;(continued)<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">Upon adoption of the 2018 Incentive Plan, up to 1,000,000 of the Company&#8217;s authorized and unissued ordinary shares may be issued pursuant to awards under the 2018 Incentive Plan. The number of reserved, authorized and unissued ordinary shares of the Company available for issuance of awards pursuant to the 2018 Incentive Plan, shall automatically increase on an annual basis as follows: on the first business day of each calendar year beginning in 2019, the number of options equal to the lesser of&#8201; (i)&#160;800,000 ordinary shares, (ii) three&#160;percent of the number of shares outstanding as of such date, or (iii) a lesser number of ordinary shares as shall be determined by the board of directors. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">1) Options granted to employees </div>
        <table style="width:456pt;height:192.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:186pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:186pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:186pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Number Of <br >Options </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted <br >average <br >exercise <br >price* </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Number of <br >options </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted <br >Average <br >Exercise <br >price* </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">Outstanding at beginning of year </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,430,450</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.84</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,193,525</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.78</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">Changes during the year:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="margin-left:10pt;">Granted </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,128,300</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">400,433</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="margin-left:10pt;">Exercised </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(44,447<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(71,133<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.54</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="margin-left:10pt;">Forfeited </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(598,318<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(70,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:186pt;text-align:left;">
              <div style="margin-left:10pt;">Expired </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(155,008<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(22,375<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">Outstanding at end of year </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,760,977</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.94</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,430,450</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.84</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">Exercisable at end of year </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,073,644</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.89</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,033,199</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.78</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">*<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">In dollars per ordinary share. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2017, the weighted-average remaining contractual life of exercisable options was 4.74&#160;years. The total intrinsic value of options exercised during 2017 and 2016 was approximately $199 and $22, respectively. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The fair value of each option granted to employees is estimated on the date of grant using the binomial option-pricing model, with the following assumptions: </div>
        <table style="width:416pt;height:108.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:218pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:84pt;">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:90pt;">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:218pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value of one ordinary share </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:3.25pt 0pt 2.5pt 0pt; width:84pt;">
              <div style="text-align:center;">$0.86&#8201;&#8211;&#8201;$5.58 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:3.25pt 0pt 2.5pt 0pt; width:90pt;">
              <div style="text-align:center;">$0.78 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 3.25pt 0pt; width:218pt;text-align:left;">
              <div style="white-space:nowrap;">Dividend yield </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:84pt;">
              <div style="text-align:center;">0% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:90pt;">
              <div style="text-align:center;">0% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 3.25pt 0pt; width:218pt;text-align:left;">
              <div style="white-space:nowrap;">Expected volatility </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:84pt;">
              <div style="text-align:center;">39%&#8201;&#8211;50% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:90pt;">
              <div style="text-align:center;">41%&#8201;&#8211;&#8201;51% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 3.25pt 0pt; width:218pt;text-align:left;">
              <div style="white-space:nowrap;">Risk-free interest rate </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:84pt;">
              <div style="text-align:center;">0.82%&#8201;&#8211;&#8201;2.26% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:90pt;">
              <div style="text-align:center;">0.53%&#8201;&#8211;&#8201;1.67% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 3.25pt 0pt; width:218pt;text-align:left;">
              <div style="white-space:nowrap;">Early exercise multiple (EEM) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:84pt;">
              <div style="text-align:center;">150%&#8201;&#8211;&#8201;250% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:90pt;">
              <div style="text-align:center;">150%&#8201;&#8211;&#8201;250% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2.75pt 0pt; width:218pt;text-align:left;">
              <div style="white-space:nowrap;">Contractual term </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2pt 0pt; width:84pt;">
              <div style="text-align:center;">7&#160;years </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2pt 0pt; width:90pt;">
              <div style="text-align:center;">7&#160;years</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="8">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:18.99pt; width:436pt; line-height:12pt;">The expected volatility is based on the historical volatility of comparable companies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the options granted in dollar terms.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-22</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 10&#8201;&#8212;&#8201;SHARE CAPITAL&#8201;(continued)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">b. Share-based compensation (continued):</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Since the Company&#8217;s ordinary shares are not publicly traded, the early exercise multiple (&#8220;EEM&#8221;) was based on academic empirical findings. The EEM of grantees in private companies is expected to be higher due to the lack of marketability that leads to a longer exercise period for options. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The weighted average grant date fair value of employee options granted during the&#160;years ended December&#160;31, 2017 and 2016 was $1,301 and $126, respectively. As of December&#160;31, 2017, the Company had 1,321,750 unvested options. The total unrecognized compensation cost of employee options at December&#160;31, 2017 is $363 which is expected to be recognized over a weighted average period of 0.53&#160;years.</div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">2) Options granted to consultants and other service providers: </div>
        <table style="width:456pt;height:191pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:186pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:186pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:186pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Number of <br >options </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted <br >average <br >exercise <br >price* </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Number of <br >options </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted <br >average <br >exercise <br >price* </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">Outstanding at beginning of year </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">964,500</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.94</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">744,500</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.92</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">Changes during the year &#8201;&#8211;&#8201;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="margin-left:10pt;">Granted </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">677,500</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">220,000</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="margin-left:10pt;">Exercised </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(11,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="margin-left:10pt;">Forfeited </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(100,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:186pt;text-align:left;">
              <div style="margin-left:10pt;">Expired </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(7,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">Outstanding at end of year </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,523,500</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.96</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">964,500</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.94</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">Exercisable at end of year </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">999,583</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.94</td>
            <td style="padding:0pt;padding-left:15.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">845,750</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.93</td>
            <td style="padding:0pt;padding-left:18.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">*<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">In dollars per ordinary share. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The fair value of each option granted to non-employees is estimated on the date of grant using the binomial option-pricing model, with the following assumptions: </div>
        <table style="width:416pt;height:108.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:218pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:84pt;">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:90pt;">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:218pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value of one ordinary share </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:3.25pt 0pt 2.5pt 0pt; width:84pt;">
              <div style="text-align:center;">$0.8&#8201;&#8211;&#8201;$7.35 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:3.25pt 0pt 2.5pt 0pt; width:90pt;">
              <div style="text-align:center;">$0.78 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 3.25pt 0pt; width:218pt;text-align:left;">
              <div style="white-space:nowrap;">Dividend yield </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:84pt;">
              <div style="text-align:center;">0% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:90pt;">
              <div style="text-align:center;">0% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 3.25pt 0pt; width:218pt;text-align:left;">
              <div style="white-space:nowrap;">Expected volatility </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:84pt;">
              <div style="text-align:center;">39%&#8201;&#8211;&#8201;50% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:90pt;">
              <div style="text-align:center;">41%&#8201;&#8211;&#8201;51% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 3.25pt 0pt; width:218pt;text-align:left;">
              <div style="white-space:nowrap;">Risk-free interest rate </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:84pt;">
              <div style="text-align:center;">0.82%&#8201;&#8211;&#8201;2.26% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:90pt;">
              <div style="text-align:center;">0.53%&#8201;&#8211;&#8201;1.67% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 3.25pt 0pt; width:218pt;text-align:left;">
              <div style="white-space:nowrap;">Early exercise multiple </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:84pt;">
              <div style="text-align:center;">150%&#8201;&#8211;&#8201;250% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:90pt;">
              <div style="text-align:center;">150%&#8201;&#8211;&#8201;250% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2.75pt 0pt; width:218pt;text-align:left;">
              <div style="white-space:nowrap;">Contractual term </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2pt 0pt; width:84pt;">
              <div style="text-align:center;">7&#160;years </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2pt 0pt; width:90pt;">
              <div style="text-align:center;">7&#160;years</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="8">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:16.19pt; width:456pt; line-height:12pt;">The assumptions for expected volatility, risk-free interest rate and EEM are the same as for options granted to employees.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The weighted average grant date fair value of non-employee options granted during the&#160;years ended December&#160;31, 2017 and 2016 was $417 and $66, respectively. As of December&#160;31, 2017, the Company had 482,250 unvested options. The total unrecognized compensation cost of non-employee options at December&#160;31, 2017 is $1,491 which is expected to be recognized over a weighted average period of 0.5&#160;years. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-23</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 10&#8201;&#8212;&#8201;SHARE CAPITAL&#8201;(continued)<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">3) The following tables summarize information concerning outstanding and exercisable options as of December&#160;31, 2017: </div>
        <table style="width:456pt;height:116.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="25">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, 2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="13">
              <div style="white-space:nowrap; text-align:center;">Options outstanding </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Options exercisable </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:85.2pt;">
              <div style="white-space:nowrap; text-align:center;">Exercise prices* </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Number of <br >options <br >outstanding <br >at end <br >of year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted <br >average <br >remaining <br >contractual <br >Life </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Number of <br >options <br >exercisable <br >at end <br >of year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted <br >average <br >remaining <br >contractual <br >life </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:85.2pt;text-align:center;">
              <div style="text-align:center;">$0.35 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">405,000</td>
            <td style="padding:0pt;padding-left:19.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:30.745pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.86</td>
            <td style="padding:0pt;padding-left:30.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">405,000</td>
            <td style="padding:0pt;padding-left:19.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:33.745pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.86</td>
            <td style="padding:0pt;padding-left:33.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:85.2pt;text-align:center;">
              <div style="text-align:center;">$0.78 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">111,000</td>
            <td style="padding:0pt;padding-left:19.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:30.745pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.87</td>
            <td style="padding:0pt;padding-left:30.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">111,000</td>
            <td style="padding:0pt;padding-left:19.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:33.745pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.87</td>
            <td style="padding:0pt;padding-left:33.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:85.2pt;text-align:center;">
              <div style="text-align:center;">$1.00 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">4,768,477</td>
            <td style="padding:0pt;padding-left:19.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:30.745pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.48</td>
            <td style="padding:0pt;padding-left:30.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,557,227</td>
            <td style="padding:0pt;padding-left:19.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:33.745pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.57</td>
            <td style="padding:0pt;padding-left:33.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">*<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">In dollars per ordinary share. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The aggregate intrinsic value of total vested and exercisable options as of December&#160;31, 2017 is $19,792. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">4) The following table illustrates the effect of share-based compensation on the statements of operations: </div>
        <table style="width:416pt;height:97.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Cost of sales </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">36</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Research and development expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">21</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">12</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Selling and marketing expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,277</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">General and administrative expenses </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">102</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,436</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">125</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:22pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 11&#8201;&#8212;&#8201;TAXES ON INCOME </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">a. InMode Ltd. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The Company is taxed according to Israeli tax laws: </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">1) Measurement of results for tax purposes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Since 2008, the Company has measured the results of the Company for tax purposes in nominal terms in NIS. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These financial statements are presented in U.S. dollars. The changes in the exchange rate of the U.S. dollar, both on an annual and a cumulative basis, cause a difference between taxable income and net income reflected in these financial statements. ASC 740-10-25 prohibits the recognition of deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are re-measured from the local currency into U.S. dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the above-mentioned differences were not reflected in the computation of deferred tax assets and liabilities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">2) Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (hereinafter, the &#8220;Investments Law&#8221;) </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-24</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 11&#8201;&#8212;&#8201;TAXES ON INCOME&#8201;(continued)<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">Under the Investments Law, including Amendment No. 60 thereof as published in April&#160;2005, by virtue of its &#8220;Benefited Enterprise&#8221; status, the Company is entitled to various tax benefits as follows: </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">a) Reduced tax rates</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In 2009, the Company received a tax ruling (the &#8220;Ruling&#8221;) approving the activities of the Company&#8217;s facilities in Israel as a Benefited Enterprise. The Ruling provides the Company with a ten-year corporate tax exemption for undistributed income, provided that it meets certain conditions set forth in the Ruling. The first year in which the Company was exempted from Israeli corporate tax was 2012 with the ten-year eligibility period of tax exemption expected to terminate in 2021.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In the event of a distribution of dividends (or deemed dividends) from income that was tax exempt as discussed above, the Company will be required to pay the applicable corporate tax that would otherwise have been payable on such income (10%&#8201;&#8211;&#8201;25%). In addition, upon distribution of dividends from tax-exempt income, the recipient shall be subject to tax at the rate of 15% (or lower, if so provided under an applicable tax treaty), which would generally be withheld by the Company. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">b) Conditions for entitlement to benefits </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s entitlement to the benefits described above is subject to its fulfilling the conditions stipulated in the Ruling, pursuant to the Investments Law and the rules and regulations thereunder. These conditions include, among other things, that the production, directly or through subcontractors, of all the Company&#8217;s products, are performed in certain areas of Israel. If there is any failure by the Company to comply with these conditions, the benefits may be cancelled and the Company may be required to refund the amount of the benefits, in whole or in part, with interest. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">c) Amendments of the Law for the Encouragement of Capital Investments, 1959 </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Additional amendments to the Investment Law became effective in January&#160;2011 and were further amended in August&#160;2013 (the &#8220;2011 Amendment&#8221;). Under the 2011 Amendment, income derived by &#8216;Preferred Companies&#8217; from &#8216;Preferred Enterprises&#8217; (both as defined in the 2011 Amendment) would be subject to a uniform rate of corporate tax for an unlimited period as opposed to the incentives prior to the 2011 Amendment that were limited to income from Approved or Benefited Enterprises during their benefits period. According to the 2011 Amendment, the tax rate applicable to such income, referred to as &#8216;Preferred Income,&#8217; would be 10% in areas in Israel that are designated as Development Zone &#8220;A&#8221; and 15% elsewhere in Israel in 2011 and 2012, 7% and 12.5%, respectively, in 2013, 9% and 16% respectively, in 2014, 2015 and 2016, and 7.5% and 16%, respectively, from 2017 and thereafter. Income derived by a Preferred Company from a &#8216;Special Preferred Enterprise&#8217; (as defined in the Investment Law) would enjoy further reduced income tax rates for a period of ten&#160;years of 5% in Development Zone &#8220;A&#8221; and 8% elsewhere. As of January&#160;1, 2014, dividends distributed from Preferred Income would subject the recipient to a 20% tax (or lower, if so provided under an applicable tax treaty), which would generally be withheld at source by the distributing company, provided, however, that dividends distributed from &#8216;Preferred Income&#8217; from one Israeli corporation to another, would not be subject to tax. Under the transitional provisions of the 2011 Amendment, companies may elect to irrevocably implement the 2011 Amendment with respect to their existing Approved and Benefited Enterprises while waiving benefits provided under the legislation prior to the 2011 Amendment or keep implementing the legislation prior to the 2011 Amendment. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">While the Company may incur additional tax liability in the event of distribution of dividends from tax exempt income generated from its Approved and Benefited Enterprises as previously described, no additional tax liability will be incurred by the Company in the event of distribution of dividends from Preferred Income.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company examined the possible effect, if any, of the provisions of the 2011 Amendment on its financial statements and decided not to apply for the new benefits under the 2011 Amendment.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-25</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 11&#8201;&#8212;&#8201;TAXES ON INCOME&#8201;(continued)<br >&#8199;</div>
        <div style="margin-left:20pt; margin-top:1pt; width:436pt; line-height:12pt;">c) Amendments of the Law for the Encouragement of Capital Investments, 1959 (continued):</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Additional amendments to the Investment Law became effective in January&#160;2017 (the &#8220;2017 Amendment&#8221;). Under the 2017 Amendment, and provided the conditions stipulated therein are met, income derived by Preferred Companies from &#8216;Preferred Technological Enterprises&#8217; (&#8220;PTE&#8221;) (as defined in the 2017 Amendment), would be subject to reduced corporate tax rates of 7.5% in Development Zone &#8220;A&#8221; and 12% elsewhere, or 6% in case of a &#8216;Special Preferred Technological Enterprise&#8217; (&#8220;SPTE&#8221;), as defined in the 2017 Amendment) regardless of the company&#8217;s geographical location within Israel. A Preferred Company distributing dividends from income derived from its PTE or SPTE, would subject the recipient to a 20% tax (or lower, if so provided under an applicable tax treaty). The 2017 Amendment further provides that, in certain circumstances, a dividend distributed to a corporate shareholder who is not an Israeli resident for tax purposes, would be subject to a 4% tax (<font style="font-style:italic;">inter</font><font style="font-style:italic;"> alia</font>, if the amount of foreign investors in the distributing company exceeds 90%). Such taxes would generally be withheld at source by the distributing company.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On June&#160;14, 2017, the Encouragement of Capital Investments Regulations (Preferred Technology Income and Capital Profits for a Technological Enterprise), 2017 (the &#8220;Regulations&#8221;) were published, which adopted Action 5 under the base erosion and profit shifting (&#8220;BEPS&#8221;) regulations. The Regulations describe, <font style="font-style:italic;">inter alia</font>, the mechanism used to determine the calculation of the benefits under the PTE and under the SPTE Regime and determine certain requirements relating to documentation of intellectual property for the purpose of the PTE. According to these provisions, a company that complies with the terms under the PTE regime may be entitled to certain tax benefits with respect to income generated during the company&#8217;s regular course of business and derived from the preferred intangible asset (as determined in the Investments Law), excluding income derived from intangible assets used for marketing and income attributed to production activity. In the event that intangible assets used for marketing purposes generate over 10% of the PTE&#8217;s income, the relevant portion, calculated using a transfer pricing study, would be subject to regular corporate income tax. If such income does not exceed 10%, the PTE will not be required to exclude the marketing income from the PTE&#8217;s total income. The Regulations set a presumption of direct production expenses plus 10% with respect to income related to production, which can be countered by the results of a supporting transfer pricing study. Tax rates applicable to such production income expenses will be similar to the tax rates under the Preferred Enterprise regime, to the extent such income would be considered as eligible. In order to calculate the preferred income, the PTE is required to take into account the income and the research and development expenses that are attributed to each single preferred intangible asset. Nevertheless, it should be noted that the transitional provisions allow companies to take into account the income and research and development expenses attributed to all of the preferred intangible assets they have. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the transitional provisions of the Investments Law, a company is allowed to continue to enjoy the tax benefits available under the law prior to its amendment until the end of the period of benefits, as defined in the Investments Law. In each year during the period of benefits as a Benefited Enterprise, the Company will be able to opt for application of the amendment, thereby making available the tax rates discussed above. The Company&#8217;s election to apply the amendment is irrecoverable. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2017 and 2016, the Company&#8217;s management decided not to adopt the application of the 2017 Amendment. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">3) Corporate tax rate in Israel </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In January&#160;2016, the Law for the Amendment of the Income Tax Ordinance (No. 216) was published, enacting a reduction of corporate tax rate beginning in 2016 and thereafter, from 26.5% to 25%. In December&#160;2016, additional legislation was enacted, reducing the corporate tax rate to 24% for 2017 and to 23% for 2018 and thereafter. There is no impact on the financial statements of the Company as a result of the changes in the Israeli corporate tax rate. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-26</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 11&#8201;&#8212;&#8201;TAXES ON INCOME&#8201;(continued)<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">Capital gains are subject to capital gains tax according to the corporate tax rate applicable in the year which the assets are sold. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">b. Subsidiaries outside Israel </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Subsidiaries that are incorporated outside of Israel are assessed taxes under the tax laws in their countries of residence. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On December&#160;22, 2017, the &#8220;Tax Cuts and Jobs Act&#8221; (the &#8220;U.S. Tax Legislation&#8221;) was enacted in the United States. Except for certain provisions, the U.S. Tax Legislation is effective for tax&#160;years beginning on or after January&#160;1, 2018. The U.S. Tax Legislation significantly revises several sections of the U.S. Internal Revenue Code of 1986 including, among other things, lowering the corporate income tax rate from 35% to 21% effective January&#160;1, 2018, limiting deductibility of interest expense and implementing a territorial tax system that imposes a repatriation tax on deemed repatriated earnings of foreign subsidiaries. The Company has evaluated the effect of the U.S. Tax Legislation on the Company&#8217;s  U.S. subsidiary&#8217;s deferred tax balances and accordingly reduced deferred tax assets by $406 for the year ended December&#160;31, 2017, due to the change in the statutory tax rate. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">c. Deferred income taxes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The components of the Company&#8217;s net deferred tax assets (liabilities) at December&#160;31, 2017 and 2016 were as follows: </div>
        <table style="width:416pt;height:174.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">Deferred tax assets in respect of:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Subsidiary net operating loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">253</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">308</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Other temporary differences </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">256</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">129</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Share-based compensation </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">554</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">101</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Total deferred tax asset before valuation allowance </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,063</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">538</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Valuation allowance </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(253<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(308<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Total deferred tax asset </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">810</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">230</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Deferred tax lability in respect to other comprehensive income </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(106<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(16<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Total deferred tax liability </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(106<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(16<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Deferred tax asset, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">704</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">214</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:18.99pt; width:456pt; line-height:12pt;">Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse. Since the Company is entitled to a tax exemption in Israel for a period of ten&#160;years, the tax rate used in the computation of deferred taxes on timing differences is zero (except for deferred taxes on unrealized gains from marketable securities). Therefore deferred taxes are computed mainly from the Company&#8217;s U.S. subsidiary. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company records net deferred tax assets to the extent it believes these assets will more likely than not be realized. As of each reporting date, management considers new evidence, both positive and negative, that could impact management&#8217;s view with regards to the future realization of deferred tax assets for each jurisdiction. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-27</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 11&#8201;&#8212;&#8201;TAXES ON INCOME&#8201;(continued)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">d. Reconciliation of theoretical tax expense to actual tax expense </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following is a reconciliation of the theoretical provision for income tax, assuming all income is taxed at the statutory corporate tax rate applicable to Israeli corporations, and the actual tax on income:</div>
        <table style="width:416pt;height:195.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Income before taxes on income </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">9,799</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">673</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Statutory corporate tax rate </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">24<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">25<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Theoretical tax expenses at the statutory rate  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,352</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">168</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">Increase (decrease) in taxes on income due to:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Benefits to the Benefited Enterprise </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,256<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(221<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Different effective tax rates applicable to the subsidiaries </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">87</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">103</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Changes in tax rate in the United States </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">406</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Valuation allowance </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">119</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">221</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Non-deductible expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">247</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">66</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Previous year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">980</td>
            <td style="padding:0pt;padding-left:10.98pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">337</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:24.99pt; width:456pt; line-height:11pt;font-weight:bold;">e. Tax assessments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In accordance with the Israel Income Tax Ordinance, as of December&#160;31, 2017, all tax assessments on the Company and the Company&#8217;s subsidiary in Israel through tax year 2012 are considered final. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">A summary of open tax&#160;years by jurisdictions is presented below: </div>
        <table style="width:416pt;height:113.5pt;margin-left:20pt;margin-top:14pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:338pt;">
              <div style="white-space:nowrap;">Jurisdiction </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:66pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">Years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:338pt;">Israel </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:66pt;text-align:center;">
              <div style="text-align:center;">2013&#8201;&#8211;&#8201;2017 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338pt;">United States </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;text-align:center;">
              <div style="text-align:center;">2013&#8201;&#8211;&#8201;2017 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338pt;">Japan </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;text-align:center;">
              <div style="text-align:center;">2013&#8201;&#8211;&#8201;2017 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338pt;">United Kingdom </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;text-align:center;">
              <div style="text-align:center;">2014&#8201;&#8211;&#8201;2017 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338pt;">Canada </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;text-align:center;">
              <div style="text-align:center;">2013&#8201;&#8211;&#8201;2017 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338pt;">China </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;text-align:center;">
              <div style="text-align:center;">2016&#8201;&#8211;&#8201;2017 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338pt;">Spain </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;text-align:center;">
              <div style="text-align:center;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8199;&#8199;2017</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-28</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 11&#8201;&#8212;&#8201;TAXES ON INCOME&#8201;(continued)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">f. Income before income taxes is composed of the following: </div>
        <table style="width:416pt;height:67.5pt;margin-left:20pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">The Company </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">9,400</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">883</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Subsidiaries outside Israel </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">399</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(210<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9,799</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">673</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:24.98pt; width:456pt; line-height:11pt;font-weight:bold;">g. Tax expenses: </div>
        <table style="width:416pt;height:233.5pt;margin-left:20pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">Current:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">In Israel </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Subsidiaries </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,535</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">430</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,535</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">431</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:10pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">Previous year:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">In Israel </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Subsidiaries </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.25pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">Deferred:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">In Israel </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Subsidiaries </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(580<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">(94<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(580<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">(94<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Total taxes on incomes </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">980</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">337</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:22pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 12&#8201;&#8212;&#8201;REVENUE </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;">a.</font> Revenues by geographic area were as follows: </div>
        <table style="width:416pt;height:97.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">North America </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">44,592</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">18,161</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Europe </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,598</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,274</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Asia-Pacific </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,136</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,523</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Other </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">1,130</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">124</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Total revenues:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">53,456</div>
            </td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">23,082</div>
            </td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-29</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;">
          <font style="font-weight:bold;">INMODE LTD.</font>
          <br >NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br >(U.S. dollars in thousands, except per share amounts)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 12&#8201;&#8212;&#8201;REVENUE&#8201;(continued)<br >&#8199;</div>
        <div style="margin-left:20pt; margin-top:1pt; width:436pt; line-height:12pt;font-weight:bold;">b.<font style="font-weight:normal;"> The changes in contract liabilities relating to Extended Warranty commitments are as follows</font>:</div>
        <table style="width:416pt;height:138.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Balance at beginning of the period </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">406</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">195</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:290pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Increases due to issuance of new contracts, excluding amounts recognized as revenue during the period </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,418</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">387</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:290pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Revenue recognized that was included in the contract liability balance at the beginning of the period </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(328<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(176<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Balance at end of the period </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,496</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">406</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Contract liability presented in non-current liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,362</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Contract liability presented in current liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,134</td>
            <td style="padding:0pt;padding-left:12.645pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">406</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:22pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 13&#8201;&#8212;&#8201;RELATED PARTIES: </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company receives certain services from Home Skinnovations Ltd., a related party. The services include an office sublease, use of certain computer hardware and switchboard infrastructure, certain software licenses and limited personnel services. The chief executive officer of the Company is a board member of Home Skinnovations Ltd. and was the chief executive officer of Home Skinnovations Ltd. until June&#160;2018. The Company recorded expenses related to services received from Home Skinnovations Ltd. of $240 and $175 for the&#160;years ended December&#160;31, 2017 and 2016, respectively. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s subsidiary in Canada receives certain services from a subsidiary of Home Skinnovations Ltd. in Canada. The services include mobile phone services, an office sublease, use of certain computer hardware and switchboard infrastructure, certain software licenses and limited personnel services. In relation to these services, the Company recorded expenses in the amount of $128 and $116 for the&#160;years ended December&#160;31, 2017 and 2016, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 14&#8201;&#8212;&#8201;SUBSEQUENT EVENTS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In preparing the consolidated financial statements as of and for the year ended December&#160;31, 2017, the Company has evaluated subsequent events for recognition and measurement purposes through July 25, 2018, and the audited annual consolidated financial statements were available for issuance. The Company has concluded the following event requires disclosure in the accompanying consolidated financial statements:</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">In February&#160;2018, the Company established a wholly owned subsidiary located in Hong Kong. As of July&#160;2018, this subsidiary is still inactive.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In May&#160;2018, the Company signed a new lease agreement for its headquarter offices in Israel that expires on December&#160;2021. Rent under the new lease agreement is linked to the Israeli Consumer Price Index. For the purpose of ensuring the Company&#8217;s obligation to the lessor, the Company has provided the lessor with a bank guarantee of 231&#160;thousand NIS (approximately $66).</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company has evaluated subsequent events from the balance sheet date through the date at which the consolidated financial statements were available to be issued and determined there are no other items requiring disclosure beyond those already disclosed, and there were no material subsequent events that required recognition in these consolidated financial statements. </div>
        <div style="margin-top:2pt; width:456pt; line-height:10pt;"></div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-30</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:12pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:28pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;</div>
        <div style="margin-top:24pt; text-align:center; width:456pt; line-height:18pt;font-weight:bold;font-size:16pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;Shares&#8199;</div>
        <div style="position:relative;z-index:-1;margin-top:10.58pt; text-align:center; width:456pt;">
          <img src="lg_inmode.jpg" alt="[MISSING IMAGE: lg_inmode.jpg]" height="65" width="155" >
        </div>
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:21pt;font-weight:bold;font-size:20pt;">InMode Ltd. </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:18pt;font-weight:bold;font-size:16pt;">Ordinary Shares </div>
        <div style="margin-top:72.947pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:19.78pt; text-align:center; width:456pt; line-height:14pt;">Prospectus <br >&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2018</div>
        <div style="margin-top:12.623pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:65pt; text-align:center; width:456pt; line-height:11pt;font-style:italic;font-size:10pt;">Joint Book-Running Managers </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:21pt;font-weight:bold;font-size:20pt;">Barclays </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:21pt;font-weight:bold;font-size:20pt;">UBS Investment Bank </div>
        <div style="margin-top:18.613pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:13.79pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-size:10pt;">Lead Manager</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:13pt;font-weight:bold;">Canaccord Genuity </div>
        <div style="margin-top:17.613pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:13.78pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-size:10pt;">Co-Manager</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:13pt;font-weight:bold;">Baird </div>
        <div style="margin-top:24pt; width:456pt; line-height:14pt;">Until &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2018 (25&#160;days after the date of this prospectus), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers&#8217; obligation to deliver a prospectus when acting as an underwriter and with respect to their unsold allotments or subscriptions. </div>
        <div style="margin-top:24pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp; </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PART II <br >&#8199;<br >Information Not Required in Prospectus </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;6.&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Israeli Companies Law, 1999, as amended, or the Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. A company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care, but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated articles of association to be effective upon the closing of this offering include such a provision. A company may not exculpate in advance a director from liability arising out of a breach of the duty of care with respect to a distribution. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, the Israeli Securities Law, 1968, or the Securities Law, and the Israeli Restrictive Trade Practices Law, 1988, or the Restrictive Trade Practices Law, a company may indemnify an office holder with respect to the following liabilities, payments and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder (1)&#160;as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i)&#160;no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2)&#160;in connection with a monetary sanction; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses incurred by the office holder with respect to proceedings held pursuant to certain provisions of the Restrictive Trade Practices Law; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a monetary liability imposed on the office holder in favor of a payment for a breach offended at an Administrative Procedure (as defined below) as set forth in Section&#160;52(54)(a)(1)(a) of the Securities Law; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses expended by the office holder with respect to an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&#8217; fees; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">any other obligation or expense in respect of which it is permitted or will be permitted under applicable law to indemnify an office holder, including, without limitation, matters referenced in Section&#160;56H(b)(1) of the Securities Law.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-1</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">An &#8220;Administrative Procedure&#8221; is defined as a procedure pursuant to Chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to Prevent Procedures or Interruption of Procedures Subject to Conditions) of the Securities Law. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, the Securities Law, and the Restrictive Trade Practices Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder, if and to the extent provided in the company&#8217;s articles of association: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a breach of the duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a financial liability imposed on the office holder in favor of a third party; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses incurred by the office holder with respect to proceedings held pursuant to certain provisions of the Restrictive Trade Practices Law; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a monetary liability imposed on the office holder in favor of an injured party at an Administrative Procedure pursuant to Section&#160;52(54)(a)(1)(a) of the Securities Law; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses incurred by an office holder in connection with an Administrative Procedure, including reasonable litigation expenses and reasonable attorneys&#8217; fees. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an act or omission committed with intent to derive illegal personal benefit; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a fine, civil fine, monetary sanction or forfeit levied against the office holder. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Securities Law and the Restrictive Trade Practices Law also provide certain limitations on the ability of a company to indemnify, exculpate and insure office holders. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Companies Law, exculpation, indemnification and insurance of office holders in a public company, subject to certain exceptions, must be approved by the compensation committee and the board of directors and, with respect to certain office holders or controlling shareholders, their relatives and third parties in which such controlling shareholders have a personal interest, also by the shareholders. See &#8220;Management&#8201;&#8212;&#8201;Approval of Related Party Transactions under Israeli Law&#8201;&#8212;&#8201;Office Holders.&#8221; </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our amended and restated articles of association to be effective upon the closing of this offering will permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by the Companies Law, the Securities Law and the Restrictive Trade Practices Law. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Prior to the consummation of this offering, we intend to obtain directors and officers liability insurance for the benefit of our office holders and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted by applicable law. In addition, prior to the closing of this offering, we intend to enter into agreements with each of our directors and executive officers exculpating them from liability to us for damages caused to us as a result of a breach of duty of care and undertaking to indemnify them, in each case, to the fullest extent permitted by our amended and restated articles of association to be effective upon the closing of this offering and applicable law, including with respect to liabilities resulting from this offering to the extent that these liabilities are not covered by </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-2</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">insurance. Such indemnification amounts will be in addition to any amounts available under our directors&#8217; and office holders&#8217; liability insurance policy. Each office holder who agrees to receive this letter of indemnification will also give his or her approval to terminate all previous letters of indemnification that we have provided to him or her, if any. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Insofar as the indemnification for liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, may be permitted to directors, officers or persons controlling us, we have been informed that in the opinion of the Securities and Exchange Commission, or the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;7.&nbsp;&nbsp;&nbsp;Recent Sales of Unregistered Securities </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During the past three&#160;years, we have issued the following securities pursuant to the exercise of stock options under our equity compensation plans at exercise prices ranging from $0.35 to $1.00 per ordinary share: </div>
        <table style="width:416pt;height:168pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:250.34pt;text-align:left;">
              <div style="white-space:nowrap;">Name of Exercising Shareholder </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">No. of <br >Options Exercised </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:81.04pt;">
              <div style="text-align:center;">Date of <br >Issuance </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:250.34pt;text-align:left;">
              <div style="white-space:nowrap;">Thomas Goslau </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:81.04pt;text-align:center;">
              <div style="text-align:center;">May&#160;2, 2016 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:250.34pt;text-align:left;" rowspan="2">
              <div style="white-space:nowrap; line-height:12pt; padding-bottom:0pt;">Mark Robert Rodriguez </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">112,682</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:81.04pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center; line-height:12pt;">February&#160;20, 2018 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,417</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:81.04pt;text-align:center;">
              <div style="text-align:center;">April&#160;11, 2018 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:250.34pt;text-align:left;">
              <div style="white-space:nowrap;">Benedict Kavanaugh Hutson III </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">36,668</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:81.04pt;text-align:center;">
              <div style="text-align:center;">January&#160;11, 2018 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:250.34pt;text-align:left;">
              <div style="white-space:nowrap;">Christian Fretheim </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">21,133</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:81.04pt;text-align:center;">
              <div style="text-align:center;">June&#160;16, 2016 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:250.34pt;text-align:left;">
              <div style="white-space:nowrap;">Paul Michael Chuy </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">37,775</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:81.04pt;text-align:center;">
              <div style="text-align:center;">October&#160;18, 2017 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:250.34pt;text-align:left;">
              <div style="white-space:nowrap;">Anna Evengelos Petropoulos </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">11,500</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:81.04pt;text-align:center;">
              <div style="text-align:center;">January&#160;29, 2017 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:250.34pt;text-align:left;">
              <div style="white-space:nowrap;">Alexander Gregory Kile </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,600</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:81.04pt;text-align:center;">
              <div style="text-align:center;">June&#160;10, 2018 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:250.34pt;text-align:left;">
              <div style="white-space:nowrap;">Eugene Lawarance Schantz </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">6,672</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:81.04pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">December&#160;18, 2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:250.34pt;text-align:left;">
              <div style="margin-left:10pt;">TOTAL</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">283,447</td>
            <td style="padding:0pt;padding-left:13.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:81.04pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:14.99pt; width:456pt; line-height:12pt;">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. We believe these transactions were exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act, Regulation S under the Securities Act, or Rule&#160;701 promulgated under Section&#160;3(b) of the Securities Act as transactions by an issuer not involving any public offering, sales by an issuer in an offshore transaction, or pursuant to benefit plans and contracts relating to compensation as provided under Rule&#160;701. The sales of these securities were made without any general solicitation or advertising. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;8.&nbsp;&nbsp;&nbsp;Exhibits and Financial Statement Schedules </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(a)<br ></div>
        <div style=" float:left; margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The Exhibit&#160;Index is hereby incorporated by reference herein. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(b)<br ></div>
        <div style=" float:left; margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Financial Statement Schedules. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;9.&nbsp;&nbsp;&nbsp;Undertakings </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-3</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">officer, or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The undersigned Registrant hereby undertakes that: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">for purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this Registration Statement in reliance upon Rule&#160;430A and contained in a form of prospectus filed by the Registrant pursuant to Rule&#160;424(b)(1) or (4)&#160;or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared effective; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-4</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;min-height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">EXHIBIT INDEX </div>
        <table style="width:456pt;height:497.5pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:42pt;">Exhibit&#160;<br >No. </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:402pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">Description </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.75pt 0pt 2pt 0pt; width:42pt;">
              <div style="text-align:center;">1.1*&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.75pt 0pt 2pt 0pt; width:402pt;text-align:left;">Form of Underwriting Agreement </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:42pt;">
              <div style="text-align:center;">3.1&nbsp;&nbsp;&nbsp; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:402pt;text-align:left;">Articles of Association, as currently in effect </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:42pt;">
              <div style="text-align:center;">3.2*&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:402pt;text-align:left;">Form of Articles of Association to be effective upon the closing of this offering </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:42pt;">
              <div style="text-align:center;">4.1*&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:402pt;text-align:left;">Form of Share Certificate </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:42pt;">
              <div style="text-align:center;">5.1*&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:402pt;text-align:left;">Opinion of Primes, Shiloh, Givon, Meir Law Firm</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:42pt;">
              <div style="text-align:center;">8.1*&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:402pt;text-align:left;">Opinion of Mayer Brown LLP </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:42pt;">
              <div style="text-align:center;">10.1&nbsp;&nbsp;&nbsp;&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:402pt;text-align:left;">Invasix Ltd. 2008 ROW Option Plan </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:42pt;">
              <div style="text-align:center;">10.2&nbsp;&nbsp;&nbsp;&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:402pt;text-align:left;">Invasix Ltd. 2008 Israeli Option Plan (English translation) </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:42pt;">
              <div style="text-align:center;">10.3*&nbsp;&nbsp;&nbsp; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:402pt;text-align:left;">InMode Ltd. 2018 Incentive Plan </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:42pt;">
              <div style="text-align:center;">10.4*&nbsp;&nbsp;&nbsp; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:402pt;text-align:left;">Form of Indemnification Agreement </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42pt;">
              <div style="text-align:center;">10.5&nbsp;&nbsp;&nbsp;&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.667pt 0pt 1.333pt 0pt; width:402pt;white-space:normal;text-align:left;">Consultancy Agreement, dated July&#160;1, 2017, by and between Invasix Ltd. and Mr.&#160;Moshe Mizrahy </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42pt;">
              <div style="text-align:center;">10.6&nbsp;&nbsp;&nbsp;&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.667pt 0pt 1.333pt 0pt; width:402pt;white-space:normal;text-align:left;">Employment Agreement, dated July&#160;1, 2017, by and between Invasix Corp. and Dr.&#160;Michael Kreindel </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:42pt;">
              <div style="text-align:center;">10.7*&#8199;&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:402pt;text-align:left;">Form of Director/Officer Option Award </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42pt;">
              <div style="text-align:center;">10.8*&#8199;&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.667pt 0pt 1.333pt 0pt; width:402pt;white-space:normal;text-align:left;">Equity Joint Venture Agreement, dated January&#160;11, 2017, by and between Guangzhou Sino-Israel Bio-Industry Investment Fund (LLP) and Invasix Ltd. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42pt;">
              <div style="text-align:center;">10.9&nbsp;&nbsp;&nbsp;&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.667pt 0pt 1.333pt 0pt; width:402pt;white-space:normal;text-align:left;">Turn-Key Manufacturing Agreement, dated April&#160;1, 2011, by and between Invasix Ltd. and Flextronics Israel Ltd. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42pt;">
              <div style="text-align:center;">10.10&#8199;&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.667pt 0pt 1.333pt 0pt; width:402pt;white-space:normal;text-align:left;">Turn-Key Manufacturing Agreement, dated November&#160;7, 2013, by and between Invasix Ltd. and STI Laser Industries Ltd. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42pt;">
              <div style="text-align:center;">10.11&#8199;&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.667pt 0pt 1.333pt 0pt; width:402pt;white-space:normal;text-align:left;">Lease Agreement, dated April&#160;16, 2018, by and between Sha&#8217;ar Yokneam Limited Partnership and InMode Ltd. (English translation) </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:42pt;">
              <div style="text-align:center;">21.1&#8199;&#8199;&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:402pt;text-align:left;">List of Subsidiaries </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:42pt;">
              <div style="text-align:center;">23.1*&#8199;&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:402pt;text-align:left;">Consent of Primes, Shiloh, Givon, Meir Law Firm (included in Exhibit&#160;5.1) </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42pt;">
              <div style="text-align:center;">23.2*&#8199;&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.667pt 0pt 1.333pt 0pt; width:402pt;white-space:normal;text-align:left;">Consent of Kesselman &amp; Kesselman, Certified Public Accountants (Israel), independent registered public accounting firm and member firm of PricewaterhouseCoopers International Limited </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:42pt;">
              <div style="text-align:center;">23.3&#8199;&#8199;&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:402pt;text-align:left;">Consent of Director Nominee (Dr. Hadar Ron)</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:42pt;">
              <div style="text-align:center;">23.4&#8199;&#8199;&#8199;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:402pt;text-align:left;">Consent of Director Nominee (Bruce Mann) </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:42pt;">&#8199;23.5&#8199; </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:402pt;">Consent of Director Nominee (Dr. Michael Anghel)</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:42pt;">
              <div style="text-align:center;">24.1&#8199;&#8199;&#8199; </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:402pt;text-align:left;">Power of Attorney (included in signature page hereto)</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">*<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">To be filed by amendment. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;min-height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Signatures </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Yokneam, Israel on this &#8199;&#8199;&#8199;&#8199; day of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2018. </div>
        <table style="width:234pt;height:70.5pt;margin-left:222pt;margin-top:14pt;border-collapse: collapse;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;" colspan="7">INMODE LTD. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:11.5pt 0pt 1.5pt 0pt; width:23.5pt;">By:</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:11.5pt 0pt 1.5pt 0pt; width:0pt;" colspan="4">&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:23.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:32pt;">Name: </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:176.5pt;">Moshe Mizrahy </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:23.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:32pt;">Title: </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:176.5pt;white-space:normal;">Chief Executive Officer and Chairman of the Board of Directors</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:22.99pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Power of Attorney </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Each of the undersigned officers and directors of InMode Ltd. hereby constitutes and appoints Moshe Mizrahy, with full power to act alone, the individual&#8217;s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for the person and in his or her name, place and stead, in any and all capacities, to sign this registration statement of InMode Ltd. on Form F-1, and any other registration statement relating to the same offering (including any registration statement, or amendment thereto, that is to become effective upon filing pursuant to Rule&#160;462(b) under the Securities Act of 1933, as amended), and any and all amendments thereto (including post-effective amendments to the registration statement), and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons for InMode Ltd. in the capacities indicated, on the dates indicated. </div>
        <table style="width:456pt;height:98.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:150pt;text-align:left;">
              <div style="white-space:nowrap;">Signature </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:204pt;">
              <div style="white-space:nowrap; text-align:center;">Title </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:78pt;">
              <div style="white-space:nowrap; text-align:center;">Date </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:25.417pt 0pt 1.333pt 0pt; width:150pt;">
              <div style="text-align:justify;">
                <div style="margin-left: 0pt; width: 150pt; margin-top: 23.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">Moshe Mizrahy </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:25.417pt 0pt 1.333pt 0pt; width:204pt;white-space:normal;">Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer) </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:25.417pt 0pt 1.333pt 0pt; width:78pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2018</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:13.667pt 0pt 1.333pt 0pt; width:150pt;">
              <div>
                <div style="margin-left: 0pt; width: 150pt; margin-top: 11.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">Yair Malca </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:13.667pt 0pt 1.333pt 0pt; width:204pt;white-space:normal;">Chief Financial Officer (Principal Financial and Accounting Officer)</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:13.667pt 0pt 1.333pt 0pt; width:78pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2018</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;min-height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Authorized Representative in the United States </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pursuant to the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of InMode Ltd., has signed this Registration Statement in the city of Lake Forest, the State of California, on &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2018. </div>
        <div style="margin-left:220pt; margin-top:6pt; width:236pt; line-height:12pt;font-weight:bold;">INVASIX INC. </div>
        <div style="margin-left:220pt; margin-top:6pt; width:236pt; line-height:12pt;">By:</div>
        <div style="margin-left:240pt; margin-top:4.5pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">Name: <br >Title: </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: right; text-indent: -27.3pt">Exhibit
3.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: center; text-indent: -27.3pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: center; text-indent: -27.3pt"><FONT STYLE="font-size: 12pt">INVASIX
LTD.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: center; text-indent: -27.3pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: center; text-indent: -27.3pt"><FONT STYLE="font-size: 12pt">ARTICLES
OF ASSOCIATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: left; text-indent: -27.3pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: center; text-indent: -27.3pt"><FONT STYLE="font-size: 12pt">Duly
adopted on March 6, 2008</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: center; text-indent: -27.3pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center; text-indent: -28.35pt">TABLE
OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: right; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; text-align: right; text-indent: 0in; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: center; text-indent: 0in; font-weight: bold"><FONT STYLE="font-size: 10pt">PAGE</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INTERPRETATION</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1</B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>PURPOSE AND LIMITATIONS</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>2</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>CAPITAL, SHARES AND RIGHTS</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>3</B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>CALL ON SHARES</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>3</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>FORFEITURE AND LIEN</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>4</B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>TRANSFER OF SHARES</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>5</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>BRING ALONG</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>5</B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>RIGHT OF FIRST REFUSAL</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>6</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>TRANSMISSION OF SHARES</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>8</B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>ALTERATIONS OF THE AUTHORIZED CAPITAL</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>8</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>MODIFICATION OF CLASS RIGHTS</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>9</B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>GENERAL MEETINGS</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>9</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>PROCEEDINGS AT GENERAL MEETINGS</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>10</B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>VOTE OF SHAREHOLDERS</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>10</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>DIRECTORS</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>12</B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>PROCEEDINGS OF THE DIRECTORS</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>12</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>COMMITTEES</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>13</B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>MINUTES</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>13</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>CEO &amp; SECRETARY</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>14</B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>INSURANCE, INDEMNITY AND EXCULPATION</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>14</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>VALIDITY OF ACTS</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>15</B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>BUSINESS AND BORROWING POWERS</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>16</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>FINANCIAL REPORTS, AUDITOR</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>16</B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>SIGNATORIES</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>16</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>DISTRIBUTIONS</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>16</B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>MERGERS</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>17</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>WINDING - UP</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>17</B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>REGISTERS AND DOCUMENTS</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>17</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>DONATIONS</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>18</B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>NOTICES</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt"><B>18</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">ARTICLES OF ASSOCIATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INVASIX LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>INTERPRETATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">1.</TD><TD STYLE="text-align: justify">In these Articles the following words shall bear the meanings set opposite to them, unless inconsistent
with the subject or context:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 28.35pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TERM</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 73%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEANING</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Affiliate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An Affiliate of a Shareholder is an entity controlling, controlled by or under common control with such Shareholder, and the term &ldquo;control&rdquo; means that the controlling party holds 50% or more of the shares or voting rights in the controlled party.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These Articles of Association as originally adopted or as altered from time to time in accordance with their terms.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As-converted basis</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Means as if all the issued shares of the Company, of all classes, and all securities of the Company convertible into or exchangeable for shares of the Company, have been fully converted into Ordinary Shares.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditor</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An independent certified accountant, appointed in order to undertake auditing functions as set out in the Law and in these Articles.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board of Directors of the Company</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Invasix Ltd.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members of the Board, elected as provided in these Articles.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dollar</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Dollar or an amount in NIS equal to the value of US Dollar, based on the representative rate of exchange of the NIS to the US Dollar as last published by the Bank of Israel or any other commercial body authorized to do so, prior to the relevant date.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Securities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means any securities evidencing an ownership interest in the Company, or any securities convertible into or exercisable for any shares of the foregoing, or any agreement or commitment to issue any of the foregoing, including the Ordinary Shares.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IPO</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means an initial public offering of the Company's shares in a public offering pursuant to a registration statement in any locality.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">M&amp;A Transaction</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means (i) any event of consolidation, merger or reorganization of the Company, in one transaction or series of related transactions, following which holders of the majority of the Company&rsquo;s Ordinary Shares outstanding immediately prior to such transaction or series of related transactions, hold less than 50% of the issued and outstanding shares of the entity surviving such transaction or series of related transactions or an entity controlling such surviving entity; or (ii) the sale or transfer by the Company of all or substantially all of its assets for cash or other consideration, or licensing (excluding business licenses granted in the ordinary course of business) of all or substantially all of the intellectual property of the Company or sale of all or substantially all of the Company's issued and outstanding share capital, to, any other company, or any other entity or person, other than a wholly-owned subsidiary of the Company.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 28.35pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 73%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registered office of the Company.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office Holder</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As such term is defined in the Law.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&rsquo;s Ordinary Shares, NIS 0.01 par value each.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pari passu</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Means that each share participating in a certain right or distribution, shall have the same rights as any other share of the same class, regardless of the amount paid for the share.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permitted Transferee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined in Article 28.9 below.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Person</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A physical person or a legal entity.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro Rata</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Means that a certain quantity or amount is distributed among the members of a certain group according to the ratio of the shares held by each participating member to the total number of shares held by all the members of the relevant group.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualified Holder</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Shareholder holding 1% or more of the outstanding share capital of the Company.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Register</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The register of the Shareholders.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any Person or entity that is the owner of at least one share, individually or jointly, in the Company, as registered in the Register.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shekel or NIS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Israeli Shekel.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statutes</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Companies law 1999 (the &ldquo;<B>Law</B>&rdquo;) and the Companies Ordinance (New Version) 5743-1983 if and to the extent it applies, and any other law in force from time to time concerning joint stock companies and affecting the Company and the Articles, as amended from time to time.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">2.</TD><TD STYLE="text-align: justify">Writing shall include printing and any other mode or modes of representing or reproducing words
in a visible form.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Words importing the singular number
shall include the plural number, and vice-versa.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Words importing the masculine
gender shall include the feminine and neuter gender, and vice-versa.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Words importing persons
shall include corporate bodies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>PURPOSE AND LIMITATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">3.</TD><TD STYLE="text-align: justify">The Company is:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">3.1</TD><TD STYLE="text-align: justify">Incorporated for the purpose of engaging in any lawful act or activity for which companies may
be organized under the Law, as shall be designated by the Board from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">3.2</TD><TD STYLE="text-align: justify">Limited by the following legal restrictions:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 35.45pt">3.2.1</TD><TD STYLE="text-align: justify">The right to transfer shares in the Company is restricted in the manner provided in these Articles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 35.45pt">3.2.2</TD><TD STYLE="text-align: justify">The number of Shareholders at any time is limited to 50 (exclusive of persons who are in the employment
of the Company and of persons who, having been formerly in the employment of the Company were while in such employment and have
continued after the termination of such employment to be Shareholders); provided, that where two or more persons jointly hold one
or more shares in the Company they shall, for the purpose of this paragraph be treated as a single Shareholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 35.45pt">3.2.3</TD><TD STYLE="text-align: justify">Any invitation to the public to subscribe for any shares or debentures of the Company is hereby
prohibited.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>CAPITAL, SHARES AND RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">4.</TD><TD STYLE="text-align: justify">The authorized share capital of the Company is NIS 200,000, divided into 20,000,000 Ordinary Shares,
each with a par value of NIS 0.01.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">All issued shares of the Company
of the same class shall rank equal among them as concerning the rights attached to the shares irrespective of the price per share
paid for such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">The liability of each Shareholder
for the Company's debts is limited to the full payment of the original issue price of the shares allotted to him. Once such price
is paid, there is no further liability of the holder and his transferees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">5.</TD><TD STYLE="text-align: justify">Each issued Ordinary Share shall entitle its holder to the rights as described below:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">5.1</TD><TD STYLE="text-align: justify">One vote in all General Meetings.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">5.2</TD><TD STYLE="text-align: justify">The right to participate, pari passu, in the distribution of cash or stock dividends.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">5.3</TD><TD STYLE="text-align: justify">The right to participate, pari passu, in the distribution of assets available for distribution
in the event of liquidation of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">6.</TD><TD STYLE="text-align: justify">The Company may pay any person commission for signing or underwriting, or consenting to sign or
underwrite, the Company's shares, either subject to pre-conditions or not, so long as the rate or amount to be paid as commission
shall not surpass the rate or amount set out by the Directors. The commission shall be paid in cash or in the Company's shares
fully or partially paid, or part in cash and part in shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">7.</TD><TD STYLE="text-align: justify">A Person holding shares of the Company in trust for another (&ldquo;<B>Trustee</B>&rdquo;) must
inform the Company of that fact no later than the date of allocation/transfer of the shares to the Trustee. The Company shall register
that fact in the Register in respect of said shares. The Trustee shall be deemed to be the sole holder of said shares and the Company
shall not be bound by or required to recognize any equitable, contingent, future or partial interest in any share or any right
whatsoever in respect of any share other than an absolute right to the entirety thereof in the registered holder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">8.</TD><TD STYLE="text-align: justify">Every Shareholder shall be entitled without payment to receive, after allotment or registration
of the transfer of shares, one or more certificates for the shares registered in his name, specifying the number and denoting numbers
of the shares in respect of which it is issued, provided that in the case of joint holders the Company shall not be bound to issue
more than one certificate to all the joint holders, and delivery of such certificate to any one of them shall be sufficient delivery
to all. Every certificate shall be signed by one Director and countersigned by another Director or by the Secretary or some other
person nominated by the Directors for that purpose.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">9.</TD><TD STYLE="text-align: justify">If any share certificate be defaced, worn out, destroyed or lost, it may be renewed on such evidence
being produced and such indemnity (if any) being given as the Directors shall require and (in case of defacement or wearing out)
on delivery up of the old certificate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>CALL ON SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">10.</TD><TD STYLE="text-align: justify">The Directors may, subject to the provisions of these Articles, from time to time, make such calls
upon the Shareholders in respect of all moneys unpaid on their shares (if any), provided that at least fourteen (14) days notice
is given of each call, and each Shareholder shall be liable to pay the amount of every call so made upon him by the installments
(if any) and at the times and places appointed by the Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">11.</TD><TD STYLE="text-align: justify">No Shareholder shall be entitled to receive any dividend or to exercise any privileges as a Shareholder
until he shall have paid the full sum of calls duly made on account of the shares issued to him, whether alone or jointly with
any other person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">The joint holders
of a share shall be jointly and severally liable for the payment of all calls and installments in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">12.</TD><TD STYLE="text-align: justify">If a payment of a call or installment payable in respect of a share is not paid on time, the holder
or allottee of the share shall pay linkage differentials to the Consumer Price Index or to the Dollar plus interest on the amount
of the call or installment at such rate per annum as the Directors shall fix, from the day appointed for payment thereof to the
time of actual payment, but the Directors may waive payment of such interest wholly or in part.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">13.</TD><TD STYLE="text-align: justify">Any sum which by the terms of allotment of a share is made payable upon allotment or at any fixed
date, whether on account of the amount of the share or by way of premium, shall for all purposes of these Articles, be deemed to
be a call duly made, and payable on the date fixed for payment, and in case of non-payment the provisions of these Articles as
to payment of interest and expenses, forfeiture and the like, and all other relevant provisions of these Articles, shall apply
as if such sum were a call duly made and notified as hereby provided.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">14.</TD><TD STYLE="text-align: justify">The Directors may, if they think fit, receive from any Shareholder willing to advance the same,
all or any part of the moneys due upon his shares beyond the sums actually called up thereon, and upon the moneys so paid in advance,
or so much thereof as exceeds the amount for the time being called upon on the shares in respect of which such advance has been
made, the Directors may pay or allow such interest as may be agreed between them and such Shareholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>FORFEITURE AND LIEN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">15.</TD><TD STYLE="text-align: justify">If any Shareholder fails to pay any call or installment by no later than the day appointed for
the payment of the same, the Directors may at any time thereafter during such time as the call or installment remains unpaid serve
a notice on such Shareholder requiring him to pay the same together with interest and any expenses incurred by the Company by reason
of such non payment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">16.</TD><TD STYLE="text-align: justify">The notice shall name a day (being not less than 14 days from the date of such notice) and a place
on and at which such call or installment and such interest and expenses as aforesaid are to be paid. The notice shall also state
that in the event of non-payment at or before the time and at the place appointed, the shares in respect of which the call was
made or installment is payable will be liable to be forfeited.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">17.</TD><TD STYLE="text-align: justify">If the requirements of any such notice as aforesaid are not complied with, any shares in respect
of which such notice has been given may at any time thereafter (as long as payment of all calls or installments, interest and expenses,
due in respect thereof is not fully made), be forfeited by a resolution of the Directors. Such forfeiture shall include all dividends,
cash or other, declared in respect of the forfeited shares, whether actually paid or not paid, or whether granted or not granted,
before forfeiture, and any other rights applicable to the forfeited share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">18.</TD><TD STYLE="text-align: justify">The Directors may sell, re-allot or otherwise dispose of any share so forfeited in such manner
as they may think fit, subject to the provisions hereof, whether with or without all or any part of the amount previously paid
on the share being credited as paid. Until such re-sale or re-allotment, the forfeited shares shall be deemed to be dormant shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">19.</TD><TD STYLE="text-align: justify">The Directors may, at any time before any shares so forfeited shall have been sold, re-allotted
or otherwise disposed of, annul the forfeiture thereof upon such conditions as they think fit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">20.</TD><TD STYLE="text-align: justify">A Shareholder whose shares have been forfeited shall, despite the forfeiture, be liable to pay
to the Company all calls made and not paid on such shares up to the time of forfeiture with maximum interest thereon till the date
of payment in the same manner in all respects as if the shares had not been forfeited and to satisfy all claims and demands which
the Company might have enforced in respect of the shares at the time of forfeiture, without any deduction or allowance for the
value of the shares at the time of forfeiture. Such Shareholder's liability shall cease upon receipt by the Company in full of
the amount due in respect of the shares so forfeited including interest and expenses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">21.</TD><TD STYLE="text-align: justify">The Company shall have a first and paramount lien upon all of the shares (not being fully paid-up)
registered in the name of each Shareholder (whether solely or jointly with others) and upon the proceeds of sale thereof for the
moneys (whether presently payable or not) called or payable at a fixed time in respect of that share, and the Company shall also
have a lien on all shares (other than fully paid-up shares), registered in the name of a Shareholder for all moneys presently payable
by him or his estate to the Company, whether such debts are due solely from him or jointly with others. This lien shall also apply
to dividends declared from time to time on these shares. The registration of a transfer of shares by the Company shall operate
as a waiver of the Company's lien (if any) upon the shares, but shall be without prejudice to the rights of the Company against
the transferor for moneys owed for the transferred shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">22.</TD><TD STYLE="text-align: justify">For the purpose of enforcing such lien the Directors may sell the shares subject thereto in such
manner as they think fit, subject to the other provisions herein. However, no sale shall be made until such period as aforesaid
shall have arrived and until notice in writing of the intention to sell shall have been served on such Shareholder, his heirs,
executors, or administrators and default shall have been made by him or them in payment, fulfillment or discharge of such debts
or engagements for 30 days after such notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">23.</TD><TD STYLE="text-align: justify">The net proceeds of any sale of forfeited shares or shares sold by way of executing a lien, after
payment of the expenses of such sale, shall be applied in or towards satisfaction of the debts or engagements (including interest)
of such Shareholder. From the residue (if any), the Shareholder shall be paid the amount he did pay, if at all, and the same to
his heirs, executors, administrators or assignees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">24.</TD><TD STYLE="text-align: justify">Upon any sale after forfeiture or enforcement of a lien in purported exercise of the powers hereinbefore
given, the Directors will cause the purchaser's name to be entered in the Shareholders Register in respect of the shares sold,
and the purchaser shall not be bound to see to the regularity of the proceedings or to the application of the purchase money, and
after his name has been entered in the Register in respect of such shares, the validity of the sale shall not be impeached by any
person, and the remedy of any person aggrieved by the sale shall be in damages only and against the Company exclusively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">An affidavit signed by a Director
stating that a share has been duly forfeited on a certain date or a lien has been executed, shall be deemed sufficient and conclusive
evidence in respect with any person claiming to have rights to said share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>TRANSFER OF SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">25.</TD><TD STYLE="text-align: justify">Until an IPO, and except for transfers of shares as permitted in Articles 25 through 30 below,
and except for encumbrance of shares which receive the prior written consent of the Board, no Shareholder may sell, assign, transfer,
pledge, hypothecate, or otherwise encumber or dispose of in any way, all or any part of or any interest in the Equity Securities
to any person (a &ldquo;<B>Transfer</B>&rdquo;) now or hereafter owned or held by them, except in accordance with the provisions
of these Articles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">Notwithstanding
the above-stated and unless approved by the Board, no Shareholder will Transfer Equity Securities to a competitor of the Company
as determined by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">Any transfer
of shares shall be subject to the prior approval of the Board and shall become effective only if the Shareholder has complied with
all of the terms of these Articles and further provided that in the event of a Transfer by a Shareholder that is party to a then
in effect agreement between shareholders of the Company, such transferee shall become party to such agreement by executing an agreement
to accept all the rights and obligation of the transferring shareholder according to the said agreement. The Board shall be deemed
to have approved such transfer within 14 days of the date all the pre-conditions to transfer have been complied with, unless the
Board objects to the transfer within the said period. Any Transfer of Equity Securities not made in conformance with these Articles
shall be null and void, shall not be recorded on the books of the Company and shall not be recognized by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B>BRING
ALONG</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">26.</TD><TD STYLE="text-align: justify">Bring-Along</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">26.1</TD><TD STYLE="text-align: justify">Prior to the consummation of an IPO or M&amp;A Transaction and notwithstanding anything herein
to the contrary in the event Shareholders holding more than seventy percent (70%) of the Company&rsquo;s issued and outstanding
share capital, calculated on an as-converted basis (the &ldquo;<B>Proposing Holders</B>&rdquo;), accept an offer to sell all of
their Equity Securities to a buyer (the &ldquo;<B>Buyer</B>&rdquo;) pursuant to a bona fide written offer, and such sale is conditioned
upon the sale of all remaining Equity Securities to the Buyer, then at the closing of such offered purchase of all the issued and
outstanding shares of the Company: (i) all of the shareholders of the Company will transfer their shares to such Buyer on the same
terms and conditions (the &ldquo;<B>Bring Along Sale</B>&rdquo;); (ii) all the Shareholders of the Company agree with respect to
all Equity Securities of the Company which it/they own(s) or otherwise exercises voting or dispositive authority, as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.65pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.65pt; text-align: justify; text-indent: -21.3pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.65pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt">(i)</TD><TD STYLE="text-align: justify">In the event such transaction is to be brought to a vote at a Shareholders meeting, after receiving
proper notice of any meeting of shareholders of the Company, to be present, in person or by proxy, as a holder of shares of voting
securities, at all such meetings and be counted for the purposes of determining the presence of a quorum at such meetings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.65pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt">(ii)</TD><TD STYLE="text-align: justify">to vote (in person, by proxy or by action by written consent, as applicable) all shares of the
Company as to which it has beneficial ownership in favor of such Bring Along Sale and in opposition of any and all other proposals
that could reasonably be expected to delay or impair the ability of the Company or the Proposing Holders to consummate such Bring
Along Sale;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.65pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 21.3pt">(iii)</TD><TD STYLE="text-align: justify">to execute and deliver all related documentation and take such other action in support of the Bring
Along Sale as shall reasonably be requested by the Company; and, neither any of the Shareholders of the Company nor any Affiliates
thereof, shall deposit any shares of the Company beneficially owned by such Shareholder or Affiliate in a voting trust or subject
any such shares to any arrangement or agreement with respect to the voting of such shares unless such trust, arrangement or agreement
are subject to the provisions hereof; and the Company will be authorized to cancel all share certificates, to register the shares
in the name of the purchaser in the Company&rsquo;s share register and to issue the purchaser a share certificate representing
all shares sold pursuant to this Article.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">26.2</TD><TD STYLE="text-align: justify">The aforesaid seventy percent (70%) shareholding requirement is hereby determined also for the
purposes of Sections 341 of the Law, and the procedure set forth in Section 341 of the Law regarding the method by which shareholders
who do not sign all related documentation shall be forced to sell their securities shall apply.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">27.</TD><TD STYLE="text-align: justify">The term &ldquo;Buyer&rdquo; may include an existing Shareholder or its Affiliates, in which case
the vote of the Proposing Holders shall not include such Shareholder&rsquo;s holdings in calculating the outstanding share capital
and the required 70% majority in Article 26 above shall be calculated from the remaining outstanding share capital excluding the
holding of the Buyer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B>RIGHT
OF FIRST REFUSAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">28.</TD><TD STYLE="text-align: justify">Right of First Refusal</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">28.1</TD><TD STYLE="text-align: justify">If at any time prior to an IPO any shareholder proposes to transfer Equity Securities to one or
more buyers, then such shareholder (&ldquo;<B>Transferor</B>&rdquo;) shall give the Company written notice of the Transferor&rsquo;s
intention to make the Transfer (&ldquo;<B>Transfer Notice</B>&rdquo;), which Transfer Notice shall include (i)&nbsp;a description
of the Equity Securities to be transferred (&ldquo;<B>Offered Shares</B>&rdquo;), (ii)&nbsp;the identity of the prospective buyer(s)
and (iii)&nbsp;the consideration and the material terms and conditions upon which the proposed Transfer is to be made, including
payment terms and closing conditions. The Company shall forward such Transfer Notice to each Qualified Holder. Each Qualified Holder
undertakes to hold in strict confidence all the above information disclosed to them with respect to the Offered Shares and to use
such information only for the purpose of evaluation whether it wishes to purchase any or all of the Offered Shares from the Transferor
pursuant to this Article 28.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">28.2</TD><TD STYLE="text-align: justify">Qualified Holders&rsquo; Option. Prior to an IPO or an M&amp;A Transaction, the Qualified Holders
shall have an option, for a period of fourteen (14) days from receipt of the Transfer Notice, to elect to purchase their respective
Pro Rata shares of the Offered Shares at the same price and subject to the same terms and conditions as described in the Transfer
Notice. Each Qualified Holder may exercise such purchase option and, thereby, purchase all or any portion of its Pro Rata share
of the Offered Shares, by notifying the Transferor and the Company in writing, before expiration of the fourteen (14) day period
as to the number of such shares which it wishes to purchase. The Qualified Holder shall further notify the Transferor of any additional
shares that such Qualified Holder wishes to purchase (the &ldquo;<B>Extra Shares</B>&rdquo;), in addition to its Pro Rata shares.
Such notices shall be irrevocable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">28.3</TD><TD STYLE="text-align: justify">Each Qualified Holders&rsquo; Pro Rata share of the Offered Shares shall be a fraction of the Offered
Shares, of which the number of Equity Securities owned by such Qualified Holder on the date of the Transfer Notice shall be the
numerator and the total number of Equity Securities held by all Qualified Holders on the date of the Transfer Notice shall be the
denominator.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">28.4</TD><TD STYLE="text-align: justify">To the extent that any Offered Shares are not purchased in full by the Qualified Holders (the &ldquo;<B>Overallotment
Shares</B>&rdquo;), those Qualified Holders who have notified the Transferor of their wish to purchase Extra Shares (the &ldquo;<B>Electing
Holders</B>&rdquo;) shall purchase such number of Extra Shares which was requested by such Electing Holder (in addition to their
Pro Rata share). In the event that the total number of the requested Extra Shares is greater than the total number of the Overallotment
Shares, then each of the Electing Holders shall purchase such number of Overallotment Shares as shall equal the number of Overallotment
Shares multiplied by a fraction, the numerator of which shall be the number of Extra Shares that such Electing Holder has requested
to purchase and the denominator shall be the total number of Extra Shares that were requested by the Electing Shareholders, at
the same price and subject to the same material terms and conditions as described in the notice to the Transferor. Provided however
that such Electing Holder shall not be obligated to purchase more than the number of Extra Shares included in his notice. The Transferor
selling the Offered Shares shall notify the Company and each of the Electing Shareholders within five (5) days of the date of the
notice given by the Electing Shareholders of the number of the Extra Shares to be purchased by each of them according to the above
calculation, if any.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">28.5</TD><TD STYLE="text-align: justify">Each Qualified Holder shall be entitled to apportion Offered Shares and the Overallotment Shares
to be purchased among its Permitted Transferees, as this term is defined below, provided that such Qualified Holder notifies the
Transferor of such allocation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">28.6</TD><TD STYLE="text-align: justify">If a Qualified Holder gives the Transferor notice that it desires to purchase its Pro Rata share
of the Offering Shares and, as the case may be, any of the Extra Shares, then payment for its Pro Rata share of the Offered Shares
and, as the case may be, its Extra Shares, shall be in the same method as specified in the Transfer Notice, against delivery of
the Shares to be purchased at a place agreed upon between the parties according to the payment terms and at the time of the scheduled
closing as were intended in the original offer therefore, as set forth in the Transfer Notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">28.7</TD><TD STYLE="text-align: justify">If the total number of shares requested to be purchased by the Qualified Holders does not reach
the number of Offered Shares, the Company may purchase the remaining shares on the same terms as those offered by the Buyer for
a period of 7 days.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">28.8</TD><TD STYLE="text-align: justify">If the number of shares requested to be purchased by the Qualified Holders and the Company together
does not reach the number of Offered Shares, the Transferor may sell the remaining un-purchased Offered Shares or all of the Offered
Shares, at the Transferee&rsquo;s sole discretion, to the Buyer; always provided that: (a) the Board resolves that the admittance
of the Buyer as a Shareholder is not detrimental to the Company; (b) the terms of the sale to such Buyer/s shall not be more beneficial
to the Buyer/s than those offered in the Transfer Notice, and (c) that the sale to the Buyer/s is completed within 90 days after
the expiration of the first refusal period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">28.9</TD><TD STYLE="text-align: justify"><U>Limitations to Rights of Refusal</U><B>.</B> The right of first refusal as set forth in Article
28 above shall not apply in the following transfers, and such transfers shall not require approval of the Board or the shareholders,
and any of the Shareholders (i) may sell, transfer or otherwise assign, with or without consideration, Equity Securities to any:
(a) spouse or member of the transferring Shareholder&rsquo;s immediate family; or (b) between a trustee and beneficiary and vice-a-versa;
or (c) in the case of any Shareholder which is a limited or general partnership, to any of its partners or affiliated partnerships
managed by the same management company or managing (general) partner or by an entity which controls, is controlled by, or is under
common control with, such management company or managing (general) partner; or (ii) may sell, transfer or otherwise assign, with
or without consideration, Equity Securities to any entity controlling, controlled by or under common control with such Shareholder
and the term control shall have the same meaning as set out in the securities law; (each a &quot;<B>Permitted Transferee</B>&quot;),
<I><U>provided that</U></I>, such Permitted Transferee has agreed in writing to assume the obligations of the transferor under
all agreements involving the Company and these Articles including undertakings towards the Office of the Chief Scientist if the
transferee is a foreign citizen or entity, restrictions on transferability and more.. Additionally, the Right of First Refusal
shall not apply in an event of Bring Along as set forth in Article 26 above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">29.</TD><TD STYLE="text-align: justify">No transfer of shares shall be registered unless the transferor delivers to the Company a duly
signed proper instrument of transfer in a form approved by the Company, and the transferor shall be deemed to remain the holder
of the shares until the name of the transferee is entered in the Register in respect thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Every transfer must be in writing
and signed by both the transferor and the transferee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Such transfer form must be duly
stamped (if needed according to law), must be left at the Office, accompanied by the certificate of the Shares to be transferred,
and such other evidence (if any) as the Directors may require to prove the title of the intending Transferor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">30.</TD><TD STYLE="text-align: justify">The Directors may refuse to register transfer of shares that are not fully paid up.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">The Directors may refuse transfer
to a Person whose holding of shares may, in their reasonable judgment, be detrimental to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">The Directors may suspend transfer
of shares during the 14 days period prior to a General Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">The Directors
may not register any transfer of shares if the transfer does not comply with the provisions of Articles 26 through 29 above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B>TRANSMISSION
OF SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">31.</TD><TD STYLE="text-align: justify">In the case of the death, liquidation, bankruptcy, dissolution, winding-up or a similar occurrence
regarding a Shareholder, the legal successors of such Shareholder shall be the only persons recognized by the Company as having
any title to his shares, but nothing herein contained shall release the estate of the predecessor from any liability in respect
of any share held by him.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">The legal successors
may, upon producing such evidence of title as the Directors shall require, be registered themselves as the holder/s of the share/s,
or subject to the provisions as to transfers herein contained, transfer the same to some other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">32.</TD><TD STYLE="text-align: justify">A person entitled to shares by transmission as set forth in Article 31 above shall not be entitled
with respect of such shares to receive notices of, or to attend or vote at meetings of the Company, or, save as aforesaid, to exercise
any of the rights or privileges of a Shareholder, except with respect to accrue dividends or other moneys payable in respect of
such shares, unless and until he shall become and be registered as a Shareholder with respect of such shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ALTERATIONS OF THE AUTHORIZED CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">33.</TD><TD STYLE="text-align: justify">Subject to the other provisions of these Articles, the General Meeting may from time to time resolve
to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">33.1</TD><TD STYLE="text-align: justify">Alter or add classes of shares that shall constitute the Company's Authorized Capital, including
shares with preference rights, deferred rights, conversion rights or any other special rights or limitations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">33.2</TD><TD STYLE="text-align: justify">Increase the Company's authorized share capital by the creation of new shares whether all the shares
for the time being authorized shall have been issued or all the shares for the time being issued shall have been fully called up
or not.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">33.3</TD><TD STYLE="text-align: justify">Consolidate and divide all or any of its share capital into shares of larger or smaller amounts
than the existing shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">33.4</TD><TD STYLE="text-align: justify">Cancel any shares not taken or agreed to be taken by any Person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">34.</TD><TD STYLE="text-align: justify">The Company shall be entitled to issue redeemable securities which will be, or at the option of
the Company may be, redeemed on such terms and in such manner as shall be determined by the Company. Redeemable securities shall
not constitute part of the Company's equity, except as provided in section 312 of the Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">35.</TD><TD STYLE="text-align: justify">Except as far as otherwise provided by or pursuant to these Articles or by the conditions of issue,
any new share capital of a certain class shall be considered as part of the original share capital of the same class, and shall
be subject to the same provisions with reference to the payment of calls, lien, transfer, transmission, forfeiture and otherwise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>MODIFICATION OF CLASS RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">36.</TD><TD STYLE="text-align: justify">If at any time the share capital is divided into different classes of shares, the rights attached
to any class (unless otherwise provided by the terms of issue of the shares of that class) may be varied by a resolution passed
at a separate General Meeting of the holders of the shares of the said class. The provisions of these Articles relating to General
Meetings shall, mutatis mutandis, apply to any class meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>GENERAL MEETINGS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">37.</TD><TD STYLE="text-align: justify">Annual General Meetings shall be held at least once in every calendar year, at such time not being
more than fifteen (15) months after the holding of the last preceding Annual General Meeting, and at such place as may be determined
by the Directors. Such General Meetings shall be called &quot;Annual Meetings&quot; and all other meetings of the Shareholders
shall be called &quot;Special Meetings&quot;. The Annual Meeting shall receive and consider the Directors' Report, the Financial
Reports, shall appoint Directors and the Auditor and shall transact any other business which under these Articles or by the Law
are to be transacted at an Annual Meeting of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">In accordance
with Section 61 to the Law and without derogating from any right granted herein, the Board may resolve that an Annual Meeting shall
not be convened, unless to the extent that an appointment of the Auditor is required. In the event that the Annual Meeting is not
held as aforementioned, the Board shall send each of the Shareholders in the Register the Company&rsquo;s Financial Statements
by not later than the date on which the Annual Meeting was to take place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">38.</TD><TD STYLE="text-align: justify">The Directors may decide to convene a Special Meeting whenever they think fit, and they shall be
required to convene a Special Meeting should they receive a request, in writing, from a person or persons entitled, under the Law,
to request such meeting, provided however, that in every calendar year there shall be no more than two (2) Special Meetings convened
by any one Shareholder.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify">Any request for convening
a Special Meeting must specify the purposes for which the meeting is to be called, shall be signed by the persons requesting the
meeting, and shall be delivered to the Office. In addition, subject to the Law, the Board may accept a request of a shareholder
to include a subject in the agenda of a general meeting, only if the request also sets forth: (a) the name and address of the Shareholder
making the request; (b) a representation that the Shareholder is a holder of record of shares of the Company entitled to vote at
such meeting and intends to appear in person or by proxy at the meeting; (c) a description of all arrangements or understandings
between the Shareholder and any other person or persons (naming such person or persons) in connection with the subject which is
requested to be included in the agenda; and (d) a declaration that all the information that is required under the Statutes to be
provided to the Company in connection with such subject, if any, has been provided. In addition, if such subject includes a nomination
to the Board in accordance with the Articles, the request shall also set forth the consent of each nominee to serve as a Director
of the Company if so elected and a declaration signed by each nominee declaring that there is no limitation under the Law for the
appointment of such nominee. Furthermore, the Board may, in its discretion and to the extent it deems necessary, direct that the
Shareholders making the request provide additional information necessary so as to include a subject in the agenda of a General
Meeting, as the Board may reasonably require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">39.</TD><TD STYLE="text-align: justify">The Board shall decide upon the agenda for the General Meeting and shall include in the meeting
the issues listed in the requisition as per Article 38 above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">40.</TD><TD STYLE="text-align: justify">At least 7 days and no more than 60 days prior notice of any General Meeting (Annual and Special)
shall be given to the Shareholders, unless either generally or in any particular case all of the Shareholders, by written notice
to the Company, waive the necessity of such notice or agree to a shorter notice. A waiver may be given retrospectively even after
the date of the meeting. A list of the matters to be dealt with at a General Meeting shall be given together with the notice convening
the meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">41.</TD><TD STYLE="text-align: justify">The Company is obligated to give notice of each General Meeting, whether Annual or Special, to:
(i) any Shareholder entitled to receive notice in accordance with these Articles; and (ii) any person who is the legal representative
in connection with the death, liquidation, bankruptcy, dissolution, winding-up of a Shareholder, provided the original Shareholder
had such right and provided that the successor has submitted to the Company proof of his status.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">The accidental omission to give
notice of any meeting to or the non-receipt of any such notice by any of the Shareholders shall not invalidate any resolution passed
at any such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B>PROCEEDINGS
AT GENERAL MEETINGS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">42.</TD><TD STYLE="text-align: justify">Notwithstanding anything in these Articles to the contrary, no business shall be transacted at
any General Meeting unless a quorum of Shareholders is present at the opening of the Meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Save as provided in the following
Article with regard to an adjourned Meeting, the quorum for any General Meeting shall be at least two Shareholders holding together
more than 50% of the voting power in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">43.</TD><TD STYLE="text-align: justify">If within half an hour from the time appointed for the holding of a General Meeting a quorum is
not present, the Meeting shall stand adjourned to the same day one week later at the same time and place or to such other day,
time and place as the Board may appoint by notice to the Shareholders. At such adjourned Meeting the necessary quorum for the business
for which the original Meeting was called shall be any number of shareholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">The aforesaid notwithstanding,
if a General Meeting is called in order to deal solely with issues presented by a Shareholder(s) as provided in Article 38 above,
and a quorum is not present, such General Meeting shall be canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">44.</TD><TD STYLE="text-align: justify">The Chairman (if any) of the Board shall preside as the chairman at every General Meeting, but
if there shall be no such Chairman or if at any meeting he shall not be present within fifteen minutes after the time appointed
for holding the same, or shall be unwilling to act as Chairman, the Shareholders present shall choose another Director, or if no
Director be present or if all the Directors present decline to take the chair, they shall choose a Shareholder present to be Chairman
of the meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">45.</TD><TD STYLE="text-align: justify">The Chairman may, with the consent of a General Meeting at which a quorum is present, and shall
if so directed by the General Meeting, adjourn any meeting from time to time and from place to place as the meeting shall determine.
Whenever a meeting is adjourned for 30 days or more, notice of the adjourned meeting shall be given in the same manner as in the
case of the original meeting. Save as aforesaid, no Shareholder shall be entitled to any notice of an adjournment or of the business
to be transacted at an adjourned meeting. No business shall be transacted at any adjourned meeting other than the business which
might have been transacted at the meeting from which the adjournment took place.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">46.</TD><TD STYLE="text-align: justify">A vote in respect of the election of the Chairman of the Meeting or regarding a resolution to adjourn
the meeting shall be carried out immediately. All other matters shall be voted upon during the meeting at such time as directed
by the Chairman.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B>VOTE
OF SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">47.</TD><TD STYLE="text-align: justify">All resolutions proposed at any General Meeting will require a simple majority of the participating
votes (excluding abstentions), unless otherwise required by the Statutes or in these Articles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Subject to the modification of
class rights as provided in Article 36 above, no separate Class Meeting shall be required for an amendment of these Articles in
the event the Company's outstanding shares are divided into more than one class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">An amendment to these Articles
requiring a Shareholder to purchase additional shares, or increasing his liability, shall not be binding upon a Shareholder without
his consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">48.</TD><TD STYLE="text-align: justify">At all General Meetings a resolution put to the vote of the meeting shall be decided upon by an
open vote. A declaration by the Chairman of the meeting that a resolution has been carried, or has been carried unanimously or
by a particular majority, or rejected, or not carried by a particular majority, shall be conclusive, and an entry to that effect
in the minutes of the meeting shall be conclusive evidence thereof (without need to prove the number or proportion of the votes
in favor of or against such resolution).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">49.</TD><TD STYLE="text-align: justify">If two or more persons are jointly entitled to a share, the vote of the senior one who tenders
a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other registered holders of the share,
and for this purpose seniority shall be determined by the order in which the names stand in the Register.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">50.</TD><TD STYLE="text-align: justify">Votes may be given either personally or by proxy. A proxy need not be a Shareholder of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">51.</TD><TD STYLE="text-align: justify">Any instrument appointing a proxy (whether for a specified meeting or otherwise) shall be in the
form as the Directors will from time to time approve.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">The instrument appointing a proxy
shall be in writing under the hand of the appointor or of his attorney in fact duly authorized in writing, or if such appointor
is a corporation, under the hand of a duly authorized officer of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">The appointment must be submitted
to the Chairman of the General Meeting no later than at the opening of the first General Meeting to be attended by such proxy.
Such appointment may be by a facsimile transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">52.</TD><TD STYLE="text-align: justify">A proxy may be appointed in respect of only some of the shares held by a Shareholder, and a Shareholder
may appoint more than one proxy, each empowered to vote by virtue of some of the shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">53.</TD><TD STYLE="text-align: justify">A Shareholder being of unsound mind or pronounced to be unfit to vote by a competent court of law
may vote through a legally appointed guardian or any other representative appointed by a court of law to vote on behalf of said
Shareholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">54.</TD><TD STYLE="text-align: justify">No person shall be entitled to vote at any General Meeting or be taken into account in a quorum
with regard to any shares whilst any call shall be due and payable to the Company in respect of those shares of such Shareholder,
unless otherwise resolved by the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">55.</TD><TD STYLE="text-align: justify">A Shareholder entitled to vote may signify his approval of or dissent from any resolution passed
or intended to be proposed at a General Meeting or any amendment in any such resolution by a written communication (including fax
or electronic form) to the Company, and such Shareholder shall be taken into account in determining the quorum as if such Shareholder
was present at the meeting and his vote counted pursuant to the vote indicated.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Furthermore, a Resolution in writing
signed by all the Shareholders entitled to vote in a General Meeting shall be as valid and effectual as if it had been passed at
a General Meeting duly convened and held. Any such Resolution may consist of several documents in like form, each signed by one
or more Shareholders (including fax or electronic form).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">56.</TD><TD STYLE="text-align: justify">The Chairman shall be responsible for recording the minutes of the General Meeting and any resolution
adopted. The Company shall keep the Minutes at the Office for a period of 7 years after the date of the meeting. The Minutes shall
be available for review by the Shareholders, and any Shareholder may request a copy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">57.</TD><TD STYLE="text-align: justify">The Board shall have and execute all powers, authorities and responsibilities not specifically
allocated to the CEO or the General Meeting by the Statutes or in these Articles.<BR>
The Board shall consist of up to <B>ten (10) Directors</B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">The Directors shall be appointed
by a majority vote of the Shareholders in a general meeting of all the shareholders on an as converted basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">A Director need
not hold any qualification shares nor be a Shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">58.</TD><TD STYLE="text-align: justify">Subject to the foregoing, if a seat be vacated on the Board, the remaining Directors may at any
time act, notwithstanding any such vacancy, provided a legal quorum exists.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify; text-indent: -27.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27.3pt">59.</TD><TD STYLE="text-align: justify">Subject to the Law, a Director shall be entitled at any time and from time to time to appoint in
writing any person who is qualified to serve as a Director, to act as his/her alternate and to terminate the appointment of such
person. The appointment of an alternate Director does not negate the responsibility of the appointing Director and such responsibility
shall continue to apply to such appointing Director - taking into account the circumstances of the appointment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify; text-indent: -27.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify; text-indent: 0pt">Alternate Directors
shall be entitled, while holding office, to receive notices of meetings of the Board and to attend and vote as a Director at any
meeting at which the appointing Director is not present and generally to exercise all the powers, rights, duties and authorities
and to perform all functions of the appointing Director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">The document
appointing an alternate Director must be submitted to the Chairman no later than at the opening of the first Board meeting to be
attended by such alternate Director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">60.</TD><TD STYLE="text-align: justify">The Directors shall be entitled to remuneration by virtue of their office, if and to the extent
so resolved by a General Meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">61.</TD><TD STYLE="text-align: justify">No person shall be appointed to the office of a Director if such person:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">61.1</TD><TD STYLE="text-align: justify">Has been convicted of a crime as provided in section 226 to the Law, during the last five years
prior to his appointment; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">61.2</TD><TD STYLE="text-align: justify">Becomes bankrupt or unduly suspends payment to his creditors; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">61.3</TD><TD STYLE="text-align: justify">Be found lunatic or becomes of unsound mind - as determined by a competent court of law; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">61.4</TD><TD STYLE="text-align: justify">If an incorporated entity is a Director and has filed for liquidation or a liquidation writ or
order has been granted against it.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">62.</TD><TD STYLE="text-align: justify">The office of a Director shall be vacated if one or more of the events mentioned in Article 61
has occurred, or:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">62.1</TD><TD STYLE="text-align: justify">If the Director resigns his office by notice in writing given to the Company; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">62.2</TD><TD STYLE="text-align: justify">If the Director is removed, replaced, substituted or his appointment terminated by the General
Meeting who nominated the Director; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">63.</TD><TD STYLE="text-align: justify">A Director may hold any other office or deal in any other business outside the Company, and a Director
may do business with the Company, subject to his duty to disclose his interest in the transaction and any other duty imposed by
the Statutes or any other relevant law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B>PROCEEDINGS
OF THE DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">64.</TD><TD STYLE="text-align: justify">The Directors shall meet together for the dispatch of business, adjourn and otherwise regulate
their meetings as they think fit - subject to these Articles. The Board shall meet no less than once every calendar quarter.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">65.</TD><TD STYLE="text-align: justify">The Chairman may, and on the request of any Director shall, at any time summon a meeting of the
Board. Written notice of any meeting of the Board and the agenda setting out the matters to be discussed at such meeting, shall
be given to all Directors at least three (3) days (or such shorter notice as all the Directors may agree) before the meeting. The
Directors may waive the necessity of such notice either beforehand or retrospectively. In the event a meeting of the Board is not
convened within 14 days of request, any Director may convene the meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">66.</TD><TD STYLE="text-align: justify">Notwithstanding anything in these Articles to the contrary, no business shall be transacted at
any meeting of the Board unless a quorum of Directors is present at the opening of the meeting. Save as provided in this Article
with regard to an adjourned meeting, a quorum shall be formed with the presence, personally or by proxy, of at least a majority
of the Directors actually nominated at that time, provided always that the matters to be discussed at any such meeting shall only
be those matters that were set out in the agenda previously circulated.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">If within half an hour from the
time appointed for the holding of a Board meeting a quorum is not present, the Board meeting shall stand adjourned to the same
time and place on the next business day or to such other day, time and place as the Chairman may appoint by notice to the Directors,
and at such adjourned Board meeting the necessary quorum for the business for which the original Board Meeting was called shall
be at least two (2) Directors present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">67.</TD><TD STYLE="text-align: justify">The Board shall elect the Chairman of the Board from time to time and shall decide upon the period
in which the Chairman shall preside.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">The Chairman shall preside at meetings
of the Directors, but if at any meeting the Chairman is not present within (15) minutes after the time appointed for holding the
meeting, the Directors shall choose a present Director to be Chairman of such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">68.</TD><TD STYLE="text-align: justify">The Chairman or any other chairman of the Meeting will not have a second and/or a casting vote.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">69.</TD><TD STYLE="text-align: justify">Some or all of the Directors may attend meetings of the Board through computer network, telephone
or any other media of communication, enabling the Directors to communicate with each other, in the deemed presence of all of them,
provided that due prior notice detailing the time and manner of holding a given meeting is served (orally or otherwise) upon all
the Directors. Any resolution adopted by the Directors in such a meeting will be recorded in writing and signed by the Chairman
of the Board or the Chairman of the meeting, and shall be valid as if adopted at a meeting of the Board duly convened and held.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">70.</TD><TD STYLE="text-align: justify">A resolution in writing signed by all the Directors, or to which all the Directors have agreed
in writing or by fax or electronic mail, shall be as valid and effective for all purposes as if passed at a meeting of the Board
duly convened and held.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Any such Resolution may consist
of several documents in like form, each signed by one or more Directors. Such resolution in writing (including fax and e-mail)
shall be effective as of the last date of the resolution, or if the resolution is signed in two or more counterparts, as of the
last date appearing on the counterparts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">71.</TD><TD STYLE="text-align: justify">While exercising his voting right, each Director shall have one vote. Resolutions of the Board
will be decided by a simple majority of the voting Directors, except as otherwise provided in these Articles or by the Statutes.
In the event of a dead lock, or in the event that the required majority vote is not reached with respect to any resolution tabled
at a meeting of the Board, the resolutions shall be deemed rejected.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">A Director, as such, shall not
be party to a voting agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><B>COMMITTEES</B></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">72.</TD><TD STYLE="text-align: justify">The Directors may delegate their powers (not including their powers as listed in section 112(a)
of the Law) to committees consisting of such Director or Directors of their body as they think fit. Any committee so formed shall
in the exercise of the powers so delegated conform to any regulations that may be imposed on it by the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Meetings of committees and proceedings
thereat (including the convening of the meetings, the election of the chairman and the votes) shall be governed by the provisions
herein contained for regulating the meetings and proceedings of the Board so far as the same are applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><B>MINUTES</B></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">73.</TD><TD STYLE="text-align: justify">The resolutions of the Board and committees shall be recorded in the minutes book of the Company.
A declaration by the Chairman that a resolution has been carried, or has been carried unanimously or by a particular majority,
or rejected, or not carried by a particular majority, shall be conclusive, and an entry to that effect in the minutes of the meeting
shall be conclusive evidence thereof (without need to prove the number or proportion of the votes in favor of or against such resolution).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">74.</TD><TD STYLE="text-align: justify">Every Director shall have the right to inspect the Company's books and receive copies thereof and
review the Company's assets, solely for the purpose of executing his duties as a Director in the Company. The Board may restrict
or prevent a Director from reviewing certain documents or assets if the Board is of the opinion that the Director is not acting
in good faith or that the review may be contrary to the Company's interests.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B>CEO &amp;
SECRETARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">75.</TD><TD STYLE="text-align: justify">The Board may appoint any person to be Chief Executive Officer (may such Person&rsquo;s title be
the Chief Executive Officer, President, General Manager or such other title as the Directors will determine - in these Articles
referred to as &ldquo;<B>CEO</B>&rdquo;). The Board, subject to the rights of certain shareholders according to agreements between
them and the Company, for such period and upon such terms as they think fit, and may vest in such person such powers as provided
by the Law and such powers may be made exercisable for such period or periods and upon such conditions and subject to such restrictions
and generally upon such terms as to remuneration and otherwise as they may determine. The remuneration of the person/s mentioned
above may be by way of salary or commission or participation in profits, or by any or all of these modes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">76.</TD><TD STYLE="text-align: justify">The CEO, if appointed, shall have all managing and execution powers not given to the Board or the
General Meeting, and shall be under the supervision of the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">77.</TD><TD STYLE="text-align: justify">The CEO may delegate any of his powers to his subordinates, subject to the approval of the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">78.</TD><TD STYLE="text-align: justify">The CEO shall report to the Chairman of the Board any material issues which are outside the normal
course of business, and shall submit to the Board periodical reports as may be required by the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">79.</TD><TD STYLE="text-align: justify">The Directors may appoint a Secretary of the Company on any terms they think proper, and they may
from time to time appoint a temporary substitute for the Secretary - who shall be deemed to be Secretary during the term of his
appointment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>INSURANCE, INDEMNITY AND EXCULPATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">80.</TD><TD STYLE="text-align: justify">The Company may insure the liability of an Office Holder, subject to the following provisions and
the restrictions as set out in the Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">The Company may
enter into a contract to insure an Office Holder for liabilities imposed on him/her in consequence of an act performed in his/her
capacity as an Office Holder, in any of the following cases:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">80.1</TD><TD STYLE="text-align: justify">a breach of the duty of care to the Company or to another person;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">80.2</TD><TD STYLE="text-align: justify">a breach of the duty of loyalty to the Company, provided that the Office Holder acted in good faith
and had a reasonable basis to believe that the act would not harm the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">80.3</TD><TD STYLE="text-align: justify">a monetary obligation imposed on him in favor of another person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">80.4</TD><TD STYLE="text-align: justify">any other act which is insurable under the Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">81.</TD><TD STYLE="text-align: justify">The Company may indemnify an Office Holder, subject to the following provisions:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">81.1</TD><TD STYLE="text-align: justify">The Company may undertake to indemnify an Office Holder for future obligation or expense imposed
on him/her in consequence of an act done in his/her capacity as an Office Holder, as specified below:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(a)</TD><TD STYLE="text-align: justify">a monetary obligation imposed on him/her in favor of another person pursuant to a judgment, including
a judgment given in settlement or a court approved settlement or arbitrator's award;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(b)</TD><TD STYLE="text-align: justify">reasonable legal fees, incurred by an Office Holder or which he is ordered to pay by a court, in
proceedings filed against him by the Company or on its behalf or by another person, or in a criminal charge of which he is acquitted,
or in a criminal charge of which he is convicted of an offence that does not require proof of criminal intent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(c)</TD><TD STYLE="text-align: justify">reasonable legal fees, including attorneys fees, incurred by an Office Holder in an investigatory
proceeding or other proceeding filed by a governmental authority, which has terminated without the filing of criminal charges and
without imposing a fine, or with imposing a fine in lieu of a criminal charge which does not require proof of criminal intent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: 0pt">The termination
of a proceedings without the filing of criminal charge in a matter in which a criminal investigations was initiated &ndash; means
the closing of such file in accordance with Section 62 to the Criminal Procedure Act [Combined Version], 1982 (in this article
the &ldquo;<B>Criminal Procedure Act</B>&rdquo;), or the stay of proceedings by the attorney general in accordance to section 231
of the Criminal Procedure Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify; text-indent: 0pt">The term &ldquo;imposing
a fine in lieu of a criminal charge&rdquo; means that a fine is imposed in accordance with applicable law in lieu of a criminal
procedure, including administrative fines according to the Administrative Offense Law, 1985, and including fines on such offenses
as are recognized to be fine offenses in accordance with the Criminal Procedure Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">(d)</TD><TD STYLE="text-align: justify">Any other obligation or expense, which is allowable according to the Law.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">81.2</TD><TD STYLE="text-align: justify">The Company may undertake in advance to indemnify an Office Holder for:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">(a)</TD><TD STYLE="text-align: justify">Obligations and expenses as set out in Article 81.1(a) above, provided that such undertaking is
limited to events which in the Boards' opinion are foreseeable at the time of providing the indemnity undertaking in view of the
Company&rsquo;s activities at that time, and in such amount and/or criteria as the Board deems foreseeable in view of the Company&rsquo;s
activities at that time; and the undertaking instrument must specify such events, sums and criteria.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">(b)</TD><TD STYLE="text-align: justify">Obligations and expenses as set out in sub-Articles 81.1(b), 81.1(c) and 81.1(d).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">81.3</TD><TD STYLE="text-align: justify">Without prejudice to the aforesaid provisions, the Company may retroactively indemnify an Office
Holder, for events specified in sub-Article 81.1 above, beyond the limits set forth in sub-Article 81.2 above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">82.</TD><TD STYLE="text-align: justify">The Company may waive in advance any claim against an Office Holder for all or any of his/her liability
for damage in consequence of a breach of his duty of care to the Company. Such waiver in advance shall not apply to breach of duty
of care in a Distribution.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">83.</TD><TD STYLE="text-align: justify">The provisions of Articles 80, 81 and 82 shall not apply in the following cases: (a) a breach of
the duty of loyalty to the Company, unless the Office Holder acted in good faith and had reasonable foundation for presuming that
the act would not harm the Company; (b) a breach of a duty of care committed intentionally or recklessly; (c) an act done with
intent to make unlawful personal profit; or (d) a fine or forfeit imposed upon the Office Holder, except for a conviction in a
felony which does not require criminal intent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">84.</TD><TD STYLE="text-align: justify">The above provisions with regard to insurance, exculpation and indemnification shall not limit
the Company with regard to its entering into an insurance contract and/or with regard to indemnity and/or with regard to exculpation
provided to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">84.1</TD><TD STYLE="text-align: justify">a person who is not an Office Holder, including employees, contractors or consultants who are not
Office Holders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">84.2</TD><TD STYLE="text-align: justify">Office Holders, to the extent that the insurance, waiver or indemnification are not expressly prohibited
by the Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>VALIDITY OF ACTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">85.</TD><TD STYLE="text-align: justify">All acts bona fide done by any meeting of the Board or of a committee of the Board, shall, notwithstanding
it be afterwards discovered that there was some defect in the appointment of any such Director or person acting as aforesaid, or
that they or any of them were disqualified, be as valid as if every such person had been duly appointed and was qualified to be
Director.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>BUSINESS AND BORROWING POWERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3.3pt"></TD><TD STYLE="width: 26.7pt">86.</TD><TD STYLE="text-align: justify">The Company may engage in any type of business which is allowed under the Statutes, at any time
and during any period that is deemed beneficial to the Company, and it may cease engagement in any such business; all subject to
the resolutions of the Board and to these Articles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">87.</TD><TD STYLE="text-align: justify">The Company may, from time to time, raise or borrow or secure the payment of any sum or sums of
money for the purposes of the Company. The Company may also raise or secure the payment or repayment of such sum or sums in such
manner and upon such terms and conditions in all respects as the Board deems fit, and in particular by the issue of debentures
or debenture stock of the Company charged upon all or any part of the property of the Company (both present and future) including
its unissued and/or its uncalled capital for the time being.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>FINANCIAL REPORTS, AUDITOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">88.</TD><TD STYLE="text-align: justify">The Company shall keep accounts and shall cause financial reports to be prepared in accordance
with the guidelines set out in the Law and any other relevant Statute.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify; text-indent: -27.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27.3pt">89.</TD><TD STYLE="text-align: justify">Subject to the Statutes, the Annual Meeting shall appoint an Auditor for a period ending at the
next Annual Meeting, or for a longer period - but no longer than until the third Annual Meeting after the meeting at which the
Auditor has been appointed. The same Auditor may be re-appointed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify; text-indent: -27.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify; text-indent: 0pt">Subject to the
Statutes, the fees of the Auditor for the audit services shall be determined by the Board or a committee of the Board if such determination
was delegated to a committee. The Board shall report the fees of the Auditor to the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify; text-indent: -27.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>SIGNATORIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">90.</TD><TD STYLE="text-align: justify">The signature of any person or persons appointed from time to time by the Board, generally or for
any particular occasion, together with the rubber stamp or printed or typed name of the Company, shall be binding upon the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt; text-align: left"><B>DISTRIBUTIONS</B></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify; text-indent: -27.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27.3pt">91.</TD><TD STYLE="text-align: justify">The Board may decide upon a Distribution (as such term is defined in the Law), subject to the provisions
set forth in the Law and these Articles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify; text-indent: -27.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27.3pt">92.</TD><TD STYLE="text-align: justify">Whenever the Board decides upon distribution of dividends (cash, shares or in kind), the dividends
shall be paid in the same manner to all the outstanding shares having rights to receive dividends on the date of the resolution
(or a later date as determined by the Board), subject to preferred rights (if any) of any class of shares in respect of the distribution.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify; text-indent: -27.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27.3pt">93.</TD><TD STYLE="text-align: justify">Notice of the declaration of any Distribution, shall be given to all registered holders of shares
eligible to such Distribution, as determined by the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">94.</TD><TD STYLE="text-align: justify">The Board will determine the method of payment of any Distribution.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0in">The cashing
of a check or the wiring of the sum to such person whose name appears on the record date on the Register as the owner of any share,
or in the case of joint holders, of any one of such joint holders, shall serve as confirmation of receipt with respect to all the
payments made in connection with that share.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify; text-indent: 0in">All dividends
unclaimed after having been declared may be invested or otherwise used by the Directors for the benefit of the Company until claimed.
Unpaid dividends shall not bear interest nor accrue linkage differentials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify; text-indent: -27.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27.3pt">95.</TD><TD STYLE="text-align: justify">If a Distribution requires a written instrument between the Company and the Shareholders according
to the Law, the Board may appoint one representative on behalf of all the Shareholders entitled to receive such Distribution and
such appointment shall be deemed due appointment by all participating Shareholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify; text-indent: -27.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify; text-indent: -27.3pt"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.3pt; text-align: justify; text-indent: -27.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27.3pt">96.</TD><TD STYLE="text-align: justify">For the purpose of implementing any resolution concerning any Distribution, the Board may settle,
as it deems fit, any difficulty that may arise with respect to the Distribution, including the value for the purpose of the said
Distribution of certain assets, and may decide that payments in cash shall be made to the Shareholders based on the value so determined,
and the Board may determine provisions with respect to fractions of shares or with respect to the non-payment of small sums.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">97.</TD><TD STYLE="text-align: justify">If two or more Persons are registered as joint holders of any shares, any one of such Persons may
give effectual receipts for any dividend or other moneys in respect of such share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>MERGERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">98.</TD><TD STYLE="text-align: justify">The Company may, by a simple majority resolution of the General Meeting but subject to the other
provisions of these Articles, decide to merge with another company - in accordance with the provisions set out in the Law and in
these Articles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>WINDING - UP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">99.</TD><TD STYLE="text-align: justify">Should any Shareholder request the winding up of the Company, such Shareholder shall offer his
shares in the Company to the Company and the other Shareholders, and if the Company or the other Shareholders or some of them agree
to purchase such shares at a price agreed between them (which shall not be more than the aggregate investment amount invested by
the selling shareholder), then the shares will be sold to the Company or to such Shareholders, and the request for winding up will
be canceled.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">100.</TD><TD STYLE="text-align: justify">If the Company shall be wound up, whether voluntarily or otherwise, the liquidators may, with the
sanction of a resolution as provided in the Statutes and subject to the terms of these Articles, divide among the Shareholders
in specie any part of the assets of the Company, and may with the like sanction vest any part of the assets of the Company in trustees
upon such trusts for benefit of the Shareholders as the liquidators with the like sanction shall think fit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">101.</TD><TD STYLE="text-align: justify">On any sale of the assets of the Company, subject to the special rights of any class of shares,
the Directors or the liquidators on a winding-up may, if authorized by a resolution as provided in the Ordinance, and subject to
the other provisions of these Articles, accept fully paid up shares, debentures or securities of any other company, whether Israeli
or foreign, either then existing or to be formed for the purchase in whole or in part of the property of the Company; and the Directors
(if the profits of the Company permit), or the liquidators (on a winding-up), may distribute such shares or securities or any other
property of the Company amongst the Shareholders without realization, and any such resolution may provide for the distribution
or appropriation of the cash, shares or other securities, benefits or property, otherwise than in accordance with the strict legal
rights of the Shareholders, and for the valuation of any such securities or property at such price and in such manner as the Meeting
may approve, and all holders of shares shall be bound to accept and shall be bound by any valuation or distribution so authorized.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>REGISTERS AND DOCUMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">102.</TD><TD STYLE="text-align: justify">The Company shall keep at the Office:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">102.1</TD><TD STYLE="text-align: justify">These Articles as amended from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">102.2</TD><TD STYLE="text-align: justify">Minutes of the meetings of the General Meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">102.3</TD><TD STYLE="text-align: justify">Minutes of the meetings of the Board and Board Committees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">102.4</TD><TD STYLE="text-align: justify">Copies of all notices sent by the Company to the Shareholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">102.5</TD><TD STYLE="text-align: justify">The Company's Financial Reports.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">102.6</TD><TD STYLE="text-align: justify">The Shareholders Register</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">102.7</TD><TD STYLE="text-align: justify">The list of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">103.</TD><TD STYLE="text-align: justify">The Company may keep the above-mentioned documents solely in the form of electronic data, provided
that a person entitled to review said documents shall be able to receive hard copies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">104.</TD><TD STYLE="text-align: justify">Subject to and in accordance with the provisions of the Statutes, the Company shall be at liberty
to cause to be kept in any country to which the said provisions may be extended a branch Register or Register of Shareholders resident
in any such country as aforesaid, and to exercise all the other powers mentioned in the Statutes relating to such branch registers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>DONATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">105.</TD><TD STYLE="text-align: justify">The Company may make donations of reasonable amounts of money for purposes which the Board deems
to be worthy causes, even if the donations are not made in relation to business considerations for increasing the Company's profits.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">106.</TD><TD STYLE="text-align: justify">Subject to the Statutes, notice or any other document which the Company shall deliver and which
it is entitled or required to give pursuant to the provisions of these Articles and/or the Statutes shall be delivered by the Company
to any person, in any one of the following manners as the Company may choose: in person, by mail, transmission by fax or by electronic
means such as e-mail.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Any notice or other document which
is sent to the Shareholders or the Directors, shall be deemed to have reached its destination: on the 7th day after the day of
mailing if sent by registered mail or regular mail, or on the first day after transmission if delivered in person, transmitted
by fax or electronic means (e-mail etc.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Should it be required to prove
delivery, it shall be sufficient to prove that the notice or document was sent to the correct address - as registered in the Register,
or as provided by the Shareholder or Director, or as otherwise reasonably determined by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Subject to the Statutes, the Company
shall not be required to send notices to any Shareholder who is not registered in the Register or has not provided the Company
with accurate and sufficient mailing details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">107.</TD><TD STYLE="text-align: justify">In cases where it is necessary to give advance notice of a particular number of days or notice
which shall remain in effect for a particular period, the day the notice is sent shall be excluded and the scheduled day of the
meeting or the last date of the period shall be included in the count.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">108.</TD><TD STYLE="text-align: justify">Any notice to be given to the Shareholders shall be given, with respect to joint shareholders,
to the person whose name appears first in the Register as the holder of the said share, and any notice so given shall be sufficient
notice for all holders of the said share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">109.</TD><TD STYLE="text-align: justify">Any notice or other document served upon or sent to any Shareholder in accordance with these Articles
shall, notwithstanding that he be then deceased or bankrupt, and whether the Company received notice of his death or bankruptcy
or not, be deemed to be duly served or sent in respect of any shares held by him (either alone or jointly with others) until some
other person is registered in his stead as the holder or joint holder of such shares, and such service or sending shall be a sufficient
service or sending on or to his heirs, executors, administrators or assigns and all other persons (if any) interested in such share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">110.</TD><TD STYLE="text-align: justify">The accidental omission to give notice to any Shareholder or the non-receipt of any such notice,
shall not cancel or annul any action made in reliance on the notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">111.</TD><TD STYLE="text-align: justify">The provisions of Articles 106 thorough to Article 109 shall apply in the same manner, subject
to required adjustments, on any notice or other document that is sent by a Director or Shareholder to the Company, or to another
Director or any other Shareholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center">***********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: right"><FONT STYLE="text-transform: none">Exhibit
10.1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 3px double; text-align: center; font-size: 10pt; text-transform: uppercase; font-weight: bold">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="text-transform: none">INVASIX
LTD.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2008 ROW OPTION PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 3px double; text-align: center; font-size: 10pt; text-transform: uppercase; font-weight: bold">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B><U>TABLE
OF CONTENTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 8%"><FONT STYLE="font-size: 10pt; text-transform: uppercase">1.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 84%"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Purpose</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 8%; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">2</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">2.</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Definitions</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">2</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">3.</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Stock Subject to the Plan</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">5</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">4.</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Administration of the Plan</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">5</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">5.</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Eligibility</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">6</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">6.</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Terms and Conditions of Awards</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">7</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">7.</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Award Exercise or Purchase Price</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">8</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">8.</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Exercise of Award</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">9</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">9.</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Conditions Upon Issuance of Shares</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">10</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">10.</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Adjustments Upon Changes in Capitalization</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">10</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">11.</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Corporate Transactions</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">11</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">12.</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Effective Date and Term of Plan</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">11</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">13.</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Amendment, Suspension or Termination of the Plan</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">11</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">14.</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Reservation of Shares</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">12</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">15.</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">No Effect on Terms of Employment/Consulting</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">12</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">16.</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">No Effect on Retirement and Other Benefit Plans</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">12</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">17.</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Stockholder Approval</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">12</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;<U>Purposes
of the Plan</U>. The Plan is intended to provide an incentive to retain, in the employ of the Company and its Related Entities,
persons of training, experience, and ability, to attract new Employees, Directors, and Consultants which the Board shall decide
their services are considered valuable to the Company, to encourage the sense of proprietorship of such persons, and to stimulate
the active interest of such persons in the development and financial success of the Company by providing them with opportunities
to purchase shares in the Company, pursuant to the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;<U>Definitions</U>.
As used herein, the following definitions shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&ldquo;<U>Administrator</U>&rdquo;
means the Board or any of the Committees appointed to administer the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&ldquo;<U>Applicable
Laws</U>&rdquo; means the legal requirements relating to the administration of stock incentive plans, if any, under applicable
provisions of Israel, United States, Canada and other applicable countries tax including the Code and securities laws, Israeli
Companies Law, the rules of any applicable stock exchange or national market system, and the rules of any jurisdiction applicable
to Awards granted to residents therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&ldquo;<U>Assumed</U>&rdquo;
means that pursuant to a Corporate Transaction either (i)&nbsp;the Award is expressly affirmed by the Company or (ii)&nbsp;the
contractual obligations represented by the Award are expressly assumed (and not simply by operation of law) by the successor entity
or its Parent in connection with the Corporate Transaction with appropriate adjustments to the number and type of securities of
the successor entity or its Parent subject to the Award and the exercise or purchase price thereof which at least preserves the
compensation element of the Award existing at the time of the Corporate Transaction as determined in accordance with the instruments
evidencing the agreement to assume the Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&ldquo;<U>Award</U>&rdquo;
means the grant of an Option, Restricted Stock, or other right or benefit under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&ldquo;<U>Award
Agreement</U>&rdquo; means the written agreement evidencing the grant of an Award executed by the Company and the Grantee, including
any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&ldquo;<U>Board</U>&rdquo;
means the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(g)&nbsp;&nbsp;&ldquo;<U>Cause</U>&rdquo;
means, with respect to the termination by the Company, or a Related Entity of the Grantee&rsquo;s Continuous Service, that such
termination is for &ldquo;Cause&rdquo; as such term is expressly defined in a then-effective written agreement between the Grantee
and the Company, or such Related Entity, or in the absence of such then-effective written agreement and definition, shall mean:
(i) conviction of any felony involving moral turpitude or affecting the Company or a Related Entity; (ii) any refusal to carry
out a reasonable directive of the chief executive officer, the Board or the Optionee&rsquo;s direct supervisor, which involves
the business of the Company or a Related Entity and was capable of being lawfully performed; (iii) embezzlement of funds of the
Company or a Related Entity; (iv) any breach of the Optionee&rsquo;s fiduciary duties or duties of care of the Company or a Related
Entity; including without limitation disclosure of confidential information of the Company or a Related Entity; and (v) any conduct
(other than conduct in good faith) reasonably determined by the Board to be materially detrimental to the Company or a Related
Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(h)&nbsp;&nbsp;&ldquo;<U>Code</U>&rdquo;
means the USA Internal Revenue Code of 1986, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&ldquo;<U>Committee</U>&rdquo;
means any committee appointed by the Board to administer the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(j)&nbsp;&nbsp;
&ldquo;<U>Company</U>&rdquo; means Invasix Ltd., a corporation organized under the laws of the State of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(k)&nbsp;&nbsp;&ldquo;<U>Consultant</U>&rdquo;
means any person (other than an Employee or a Director, solely with respect to rendering services in such person&rsquo;s capacity
as a Director) who is engaged by the Company or any Related Entity to render consulting or advisory services to the Company or
such Related Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(l)&nbsp;&nbsp;
&ldquo;<U>Continuous Service</U>&rdquo; means that the provision of services to the Company or a Related Entity in any capacity
of Employee, Director or Consultant, is not interrupted or terminated. Continuous Service shall not be considered interrupted in
the case of (i) any approved leave of absence, (ii) transfers among the Company, any Related Entity, or any successor, in any capacity
of Employee, Director or Consultant, or (iii) any change in status as long as the individual remains in the service of the Company
or a Related Entity in any capacity of Employee, Director or Consultant (except as otherwise provided in the Award Agreement).
An approved leave of absence shall include sick leave, military leave, or any other authorized personal leave. For purposes of
each Incentive Stock Option granted under the Plan, if such leave exceeds ninety (90) days, and reemployment upon expiration of
such leave is not guaranteed by statute or contract, then the Incentive Stock Option shall be treated as a Non-Qualified Stock
Option on the day three (3) months and one (1) day following the expiration of such ninety (90) day period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(m)&nbsp;
&ldquo;<U>Corporate Transaction</U>&rdquo; means any of the following transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;a
merger or consolidation in which the Company is not the surviving entity, except for a transaction the principal purpose of which
is to change the jurisdiction in which the Company is incorporated;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;the
sale, transfer or other disposition of all or substantially all of the assets of the Company (including the capital stock of the
Company&rsquo;s subsidiary corporations);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;the
complete liquidation or dissolution of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(iv)&nbsp;&nbsp;any
reverse merger in which the Company is the surviving entity but in which securities possessing more than fifty percent (50%) of
the total combined voting power of the Company&rsquo;s outstanding securities are transferred to a person or persons different
from those who held such securities immediately prior to such merger; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(v)&nbsp;&nbsp;&nbsp;acquisition
by any person or related group of persons (other than the Company or by a Company-sponsored employee benefit plan) of beneficial
ownership (within the meaning of Rule&nbsp;13d-3 of the Exchange Act) of securities possessing more than fifty percent (50%) of
the total combined voting power of the Company&rsquo;s outstanding securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(n)&nbsp;&nbsp;&ldquo;<U>Director</U>&rdquo;
means a member of the Board or the board of directors of any Related Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(o)&nbsp;&nbsp;&ldquo;<U>Disability</U>&rdquo;
means as defined under the long-term disability policy of the Company or the Related Entity to which the Grantee provides services
regardless of whether the Grantee is covered by such policy. If the Company or the Related Entity to which the Grantee provides
service does not have a long-term disability plan in place, &ldquo;Disability&rdquo; means that a Grantee is unable to carry out
the responsibilities and functions of the position held by the Grantee by reason of any medically determinable physical or mental
impairment. A Grantee will not be considered to have incurred a Disability unless he or she furnishes proof of such impairment
sufficient to satisfy the Administrator in its discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(p)&nbsp;&nbsp;&ldquo;<U>Employee</U>&rdquo;
means any person, including an Officer or Director, who is an employee of the Company or any Related Entity. The payment of a director&rsquo;s
fee by the Company or a Related Entity shall not be sufficient to constitute &ldquo;employment&rdquo; by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(q)&nbsp;&nbsp;&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(r)&nbsp;&nbsp;&ldquo;<U>Fair
Market Value</U>&rdquo; means, as of any date, the value of the Ordinary Shares determined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;If
the Shares are listed on any established stock exchange or a national market system, the Fair Market Value shall be the closing
sales price for such Shares (or the closing bid, if no sales were reported), as quoted on such exchange or system on the date of
determination, as reported in the Wall Street Journal, or such other source as the Board deems reliable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;If
the Shares are regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value shall
be the mean between the high bid and low asked prices for the Shares on the date of determination, or;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;In
the absence of an established market for the Shares, the Fair Market Value thereof shall be determined in good faith by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(s)&nbsp;&nbsp;
&ldquo;<U>Grantee</U>&rdquo; means an Employee, Director or Consultant who receives an Award under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(t)&nbsp;&nbsp;&nbsp;&ldquo;<U>Incentive
Stock Option</U>&rdquo; means an Option intended to qualify as an incentive stock option within the meaning of Section&nbsp;422
of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(u)&nbsp;&nbsp;&ldquo;<U>Israeli
Companies Law</U>&rdquo; means the Israeli Companies Law 1999, as amended or replaced from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(v)&nbsp;&nbsp;&ldquo;<U>Non-Qualified
Stock Option</U>&rdquo; means an Option not intended to qualify as an Incentive Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(w)&nbsp;&ldquo;<U>Officer</U>&rdquo;
means a person who is an officer of the Company or a Related Entity within the meaning of Section&nbsp;16 of the Exchange Act and
the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(x)&nbsp;&nbsp;&ldquo;<U>Option</U>&rdquo;
means an option to purchase one (1) Ordinary Shares pursuant to an Award Agreement granted under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(y)&nbsp;&nbsp;&ldquo;<U>Ordinary
Shares</U>&rdquo; means the ordinary shares par value NIS 0.01 per share of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(z)&nbsp;&nbsp;
&ldquo;<U>Parent</U>&rdquo; means a &ldquo;parent corporation,&rdquo; whether now or hereafter existing, as defined in Section&nbsp;424(e)
of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(aa)&nbsp;&nbsp;&ldquo;<U>Plan</U>&rdquo;
means this 2008 ROW Option Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(bb)&nbsp;&nbsp;&ldquo;<U>Post-Termination
Exercise Period</U>&rdquo; means the period specified in the Award Agreement (or if not mentioned therein &ndash; as specified
in this Plan) commencing on the date of termination (other than termination by the Company or any Related Entity for Cause) of
the Grantee&rsquo;s Continuous Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(cc)&nbsp;&nbsp;&ldquo;<U>Related
Entity</U>&rdquo; means any Parent or Subsidiary of the Company and any business, corporation, partnership, limited liability company
or other entity in which the Company or a Parent or a Subsidiary of the Company holds a substantial ownership interest, directly
or indirectly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(dd)&nbsp;&nbsp;&ldquo;<U>Replaced</U>&rdquo;
means that pursuant to a Corporate Transaction&nbsp;the Award is replaced with a comparable stock award or a cash incentive program
of the Company, the successor entity (if applicable) or Parent of either of them which at least preserves the compensation element
of such Award existing at the time of the Corporate Transaction and provides for subsequent payout in accordance with the same
(or a more favorable) vesting schedule applicable to such Award. The determination of Award comparability shall be made by the
Administrator and its determination shall be final, binding and conclusive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(ee)&nbsp;&nbsp;&ldquo;<U>Restricted
Stock</U>&rdquo; means Shares issued under the Plan to the Grantee for such consideration, if any, and subject to such restrictions
on transfer, rights of first refusal, repurchase provisions, forfeiture provisions, and other terms and conditions as established
by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(ff)&nbsp;&nbsp;&nbsp;&ldquo;<U>Rule&nbsp;16b-3</U>&rdquo;
means Rule 16b-3 promulgated under the Exchange Act or any successor thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(gg)&nbsp;&nbsp;&ldquo;<U>Share</U>&rdquo;
means a share of the Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(hh)&nbsp;&nbsp;&ldquo;<U>Subsidiary</U>&rdquo;
means a &ldquo;subsidiary corporation,&rdquo; whether now or hereafter existing, as defined in Section&nbsp;424(f) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;<U>Stock
Subject to the Plan</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;Subject
to the provisions of Section&nbsp;10, below, the maximum aggregate number of Shares which may be issued pursuant to all Awards
is 180,000 Shares, plus any increase to be added from time to time as determined by the Board. Out of such maximum aggregate number
of Shares (as may be increased from time to time), any number of Shares may be issued pursuant to Incentive Stock Options arrangements.
The Shares to be issued pursuant to Awards may be authorized, but unissued, or reacquired Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;Any
Shares covered by an Award (or portion of an Award) which is forfeited, canceled or expires (whether voluntarily or involuntarily)
shall be deemed not to have been issued for purposes of determining the maximum aggregate number of Shares which may be issued
under the Plan. Shares that actually have been issued under the Plan pursuant to an Award shall not be returned to the Plan and
shall not become available for future issuance under the Plan, except that if unvested Shares are forfeited, or repurchased by
the Company at the lower of their original purchase price or their Fair Market Value at the time of repurchase, such Shares shall
become available for future grant under the Plan. To the extent not prohibited by Section&nbsp;422(b)(1) of the Code (and the corresponding
regulations thereunder), the listing requirements of The Nasdaq National Market (or other established stock exchange or national
market system on which the Common Stock is traded) and Applicable Law, any Shares covered by an Award which are surrendered (i)&nbsp;in
payment of the Award exercise or purchase price or (ii)&nbsp;in satisfaction of tax withholding obligations incident to the exercise
of an Award shall be deemed not to have been issued for purposes of determining the maximum number of Shares which may be issued
pursuant to all Awards under the Plan, unless otherwise determined by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;<U>Administration
of the Plan</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;<U>Plan
Administrator.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Administration
with Respect to Directors and Officers</U>. With respect to grants of Awards to Directors or Employees who are also Officers or
Directors of the Company, the Plan shall be administered by (A)&nbsp;the Board or (B)&nbsp;a Committee designated by the Board,
which Committee shall be constituted in such a manner as to satisfy the Applicable Laws and to permit such grants and related transactions
under the Plan to be exempt from Section 16(b) of the Exchange Act in accordance with Rule&nbsp;16b-3. Once appointed, such Committee
shall continue to serve in its designated capacity until otherwise directed by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;<U>Administration
With Respect to Consultants and Other Employees</U>. With respect to grants of Awards to Employees or Consultants who are neither
Directors nor Officers of the Company, the Plan shall be administered by (A) the Board or (B) a Committee designated by the Board,
which Committee shall be constituted in such a manner as to satisfy the Applicable Laws. Once appointed, such Committee shall continue
to serve in its designated capacity until otherwise directed by the Board. The Board may authorize one or more Officers to grant
such Awards and may limit such authority as the Board determines from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;<U>Administration
Errors</U>. In the event an Award is granted in a manner inconsistent with the provisions of this subsection&nbsp;(a), such Award
shall be presumptively valid as of its grant date to the extent permitted by the Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;<U>Powers
of the Administrator</U>. Subject to Applicable Laws and the provisions of the Plan (including any other powers given to the Administrator
hereunder), and except as otherwise provided by the Board, the Administrator shall have the authority, in its discretion:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;to
select the Employees, Directors and Consultants to whom Awards may be granted from time to time hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;to
determine whether and to what extent Awards are granted hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;to
determine the number of Shares or the amount of other consideration to be covered by each Award granted hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(iv)&nbsp;&nbsp;to
approve forms of Award Agreements for use under the Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(v)&nbsp;&nbsp;&nbsp;to
determine the terms and conditions of any Award granted hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(vi)&nbsp;&nbsp;to
amend the terms of any outstanding Award granted under the Plan, provided that any amendment that would adversely affect the Grantee&rsquo;s
rights under an outstanding Award shall not be made without the Grantee&rsquo;s written consent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(vii)&nbsp;&nbsp;to
construe and interpret the terms of the Plan and Awards, including without limitation, any notice of award or Award Agreement,
granted pursuant to the Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(viii)&nbsp;to
establish additional terms, conditions, rules or procedures, to accommodate the rules or laws of applicable foreign jurisdictions
and to afford Grantees favorable treatment under such rules or laws; provided, however, that no Award shall be granted under any
such additional terms, conditions, rules or procedures with terms or conditions which are inconsistent with the provisions of the
Plan; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;&nbsp;(ix)&nbsp;to
take such other action, not inconsistent with the terms of the Plan, as the Administrator deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;<U>Indemnification</U>.
In addition to such other rights of indemnification as they may have as members of the Board or as Officers or Employees of the
Company or a Related Entity, members of the Board and any Officers or Employees of the Company or a Related Entity to whom authority
to act for the Board, the Administrator or the Company is delegated shall be defended and indemnified by the Company to the extent
permitted by law on an after-tax basis against all reasonable expenses, including attorneys&rsquo; fees, actually and necessarily
incurred in connection with the defense of any claim, investigation, action, suit or proceeding, or in connection with any appeal
therein, to which they or any of them may be a party by reason of any action taken or failure to act under or in connection with
the Plan, or any Award granted hereunder, and against all amounts paid by them in settlement thereof (provided such settlement
is approved by the Company) or paid by them in satisfaction of a judgment in any such claim, investigation, action, suit or proceeding,
except in relation to matters as to which it shall be adjudged in such claim, investigation, action, suit or proceeding that such
person is liable for gross negligence, bad faith or intentional misconduct; provided, however, that within thirty (30) days after
the institution of such claim, investigation, action, suit or proceeding, such person shall offer to the Company, in writing, the
opportunity at the Company&rsquo;s expense to defend the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;<U>Eligibility</U>.
Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants. Incentive Stock Options may be
granted only to Employees of the Company or a Parent or a Subsidiary of the Company. An Employee, Director or Consultant who has
been granted an Award may, if otherwise eligible, be granted additional Awards. Awards may be granted to such Employees, Directors
or Consultants who are residing in foreign jurisdictions as the Administrator may determine from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;<U>Terms
and Conditions of Awards</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;<U>Type
of Awards</U>. The Administrator is authorized under the Plan to award any type of arrangement to an Employee, Director or Consultant
that is not inconsistent with the provisions of the Plan and that by its terms involves or might involve the issuance of (i) Shares,
(ii) an Option or similar right with a fixed or variable price related to the Fair Market Value of the Shares and with an exercise
or conversion privilege related to the passage of time, the occurrence of one or more events, or the satisfaction of performance
criteria or other conditions, or (iii) any other security with the value derived from the value of the Shares. Such awards include,
without limitation, Options or sales or bonuses of Restricted Stock, and an Award may consist of one such security or benefit,
or two (2) or more of them in any combination or alternative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;<U>Designation
of Award</U>. Each Award shall be designated in the Award Agreement. In the case of an Option, the Option shall be designated as
either an Incentive Stock Option or a Non-Qualified Stock Option. However, notwithstanding such designation, to the extent that
the aggregate Fair Market Value of Shares subject to Options designated as Incentive Stock Options which become exercisable for
the first time by a Grantee during any calendar year (under all plans of the Company or any Parent or Subsidiary of the Company)
exceeds $100,000, such excess Options, to the extent of the Shares covered thereby in excess of the foregoing limitation, shall
be treated as Non-Qualified Stock Options. For this purpose, Incentive Stock Options shall be taken into account in the order in
which they were granted, and the Fair Market Value of the Shares shall be determined as of the grant date of the relevant Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;<U>Conditions
of Award</U>. Subject to the terms of the Plan, the Administrator shall determine the provisions, terms, and conditions of each
Award including, but not limited to, the Award vesting schedule, repurchase provisions, rights of first refusal, forfeiture provisions,
form of payment (cash, Shares, or other consideration) upon settlement of the Award, payment contingencies, and satisfaction of
any performance criteria. The performance criteria established by the Administrator may be based on any one of, or combination
of, increase in share price, earnings per share, total stockholder return, return on equity, return on assets, return on investment,
net operating income, cash flow, revenue, economic value added, personal management objectives, or other measure of performance
selected by the Administrator. Partial achievement of the specified criteria may result in a payment or vesting corresponding to
the degree of achievement as specified in the Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;<U>Acquisitions
and Other Transactions</U>. The Administrator may issue Awards under the Plan in settlement, assumption or substitution for, outstanding
awards or obligations to grant future awards in connection with the Company or a Related Entity acquiring another entity, an interest
in another entity or an additional interest in a Related Entity whether by merger, stock purchase, asset purchase or other form
of transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;<U>Separate
Programs</U>. The Administrator may establish one or more separate programs under the Plan for the purpose of issuing particular
forms of Awards to one or more classes of Grantees on such terms and conditions as determined by the Administrator from time to
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;<U>Early
Exercise</U>. The Award Agreement may, but need not, include a provision whereby the Grantee may elect at any time while an Employee,
Director or Consultant to exercise any part or all of the Award prior to full vesting of the Award. Any unvested Shares received
pursuant to such exercise may be subject to a repurchase right in favor of the Company or a Related Entity or to any other restriction
the Administrator determines to be appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(g)&nbsp;&nbsp;<U>Term
of Award</U>. The term of each Award shall be the term stated in the Award Agreement, provided, however, that the term of an Award
shall be no more than seven&nbsp;(7) years from the date of grant thereof. However, in the case of an Incentive Stock Option granted
to a Grantee who, at the time the Option is granted, owns stock representing more than ten&nbsp;percent (10%) of the voting power
of all classes of stock of the Company or any Parent or Subsidiary of the Company, the term of the Incentive Stock Option shall
be five&nbsp;(5) years from the date of grant thereof or such shorter term as may be provided in the Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(h)&nbsp;&nbsp;<U>Transferability
of Awards</U>. No Option or any right with respect thereto, purchasable hereunder, whether fully paid or not, shall be assignable,
transferable or given as collateral, or any right with respect to it given to any third party whatsoever, except as specifically
allowed under the Plan. During the lifetime of the Grantee, each and all of such Grantee's rights to purchase Shares hereunder
shall be exercisable only by the Grantee. Vested options are transferable by will or by law of descent and distribution. Any such
action made directly or indirectly, for an immediate validation or for a future one, shall be void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;<U>Time
of Granting Awards</U>. The date of grant of an Award shall for all purposes be the date on which the Administrator makes the determination
to grant such Award, or such other date as is determined by the Administrator. Notice of the grant determination shall be given
to each Employee, Director or Consultant to whom an Award is so granted within a reasonable time after the date of such grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;<U>Award
Exercise or Purchase Price, Consideration and Taxes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;<U>Exercise
or Purchase Price</U>. The exercise or purchase price, if any, for an Award shall be as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;In
the case of an Incentive Stock Option:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2in">(A)&nbsp;&nbsp;granted
to an Employee who, at the time of the grant of such Incentive Stock Option owns stock representing more than ten percent (10%)
of the voting power of all classes of stock of the Company or any Parent or Subsidiary of the Company, the per Share exercise price
shall be not less than one hundred ten percent (110%) of the Fair Market Value per Share on the date of grant; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2in">(B)&nbsp;&nbsp;granted
to any Employee other than an Employee described in the preceding paragraph, the per Share exercise price shall be not less than
one hundred percent (100%) of the Fair Market Value per Share on the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;In
the case of a Non-Qualified Stock Option, the per Share exercise price shall be not less than one hundred percent (100%) of the
Fair Market Value per Share on the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;In
the case of other Awards, such price as is determined by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(iv)&nbsp;&nbsp;Notwithstanding the foregoing provisions of this Section 7(a), in the case of an Award issued pursuant to Section 6(d),
above, the exercise or purchase price for the Award shall be determined in accordance with the principles of Section 424(a)
of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;<U>Consideration</U>.
Subject to Applicable Laws, the consideration to be paid for the Shares to be issued upon exercise or purchase of an Award including
the method of payment, shall be determined by the Administrator (and, in the case of an Incentive Stock Option, shall be determined
at the time of grant). In addition to any other types of consideration the Administrator may determine, the Administrator is authorized
to accept as consideration for Shares issued under the Plan the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;cash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;check;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;wire
transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">The Administrator may at
any time or from time to time, by adoption of or by amendment to the standard forms of Award Agreement described in Section&nbsp;4(b)(iv),
or by other means, grant Awards which do not permit all of the foregoing forms of consideration to be used in payment for the Shares
or which otherwise restrict one or more forms of consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;<U>Taxes</U>.
No Shares shall be delivered under the Plan to any Grantee or other person until such Grantee or other person has made arrangements
acceptable to the Administrator for the satisfaction of any foreign, federal, state, or local income and employment tax withholding
obligations, including, without limitation, obligations incident to the receipt of Shares or the disqualifying disposition of Shares
received on exercise of an Incentive Stock Option. Upon exercise of an Award the Company shall withhold or collect from Grantee
an amount sufficient to satisfy such tax obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;<U>Exercise
of Award</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;<U>Procedure
for Exercise; Rights as a Stockholder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;Any
Award granted hereunder shall be exercisable at such times and under such conditions as determined by the Administrator under the
terms of the Plan and specified in the Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;An
Award shall be deemed to be exercised when written notice of such exercise has been given to the Company in accordance with the
terms of the Award by the person entitled to exercise the Award and full payment for the Shares with respect to which the Award
is exercised is actually received and cleared.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;<U>Exercise
of Award Following Termination of Continuous Service</U>. In the event of termination of a Grantee&rsquo;s Continuous Service for
any reason other than Disability or death (but not in the event of a Grantee&rsquo;s change of status from Employee to Consultant
or from Consultant to Employee), such Grantee may, but only during the Post-Termination Exercise Period (but in no event later
than the expiration date of the term of such Award as set forth in the Award Agreement), exercise the portion of the Grantee&rsquo;s
Award that was vested at the date of such termination or such other portion of the Grantee&rsquo;s Award as may be determined by
the Administrator. The Grantee&rsquo;s Award Agreement may provide that upon the termination of the Grantee&rsquo;s Continuous
Service for Cause, the Grantee&rsquo;s right to exercise the Award shall terminate concurrently with the termination of Grantee&rsquo;s
Continuous Service. In the event of a Grantee&rsquo;s change of status from Employee to Consultant, an Employee&rsquo;s Incentive
Stock Option shall convert automatically to a Non-Qualified Stock Option on the day three (3) months and one day following such
change of status. To the extent that the Grantee&rsquo;s Award was unvested at the date of termination, or if the Grantee does
not exercise the vested portion of the Grantee&rsquo;s Award within the Post-Termination Exercise Period, the Award shall terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;<U>Disability
of Grantee</U>. In the event of termination of a Grantee&rsquo;s Continuous Service as a result of his or her Disability, such
Grantee may, but only within twelve&nbsp;(12) months from the date of such termination (or such longer or shorter period as specified
in the Award Agreement but in no event later than the expiration date of the term of such Award as set forth in the Award Agreement),
exercise the portion of the Grantee&rsquo;s Award that was vested at the date of such termination; provided, however, that if such
Disability is not a &ldquo;disability&rdquo; as such term is defined in Section&nbsp;22(e)(3) of the Code, in the case of an Incentive
Stock Option such Incentive Stock Option shall automatically convert to a Non-Qualified Stock Option on the day three (3) months
and one day following such termination. To the extent that the Grantee&rsquo;s Award was unvested at the date of termination, or
if Grantee does not exercise the vested portion of the Grantee&rsquo;s Award within the time specified herein, the Award shall
terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;<U>Death
of Grantee</U>. In the event of a termination of the Grantee&rsquo;s Continuous Service as a result of his or her death, or in
the event of the death of the Grantee during the Post-Termination Exercise Period or during the twelve (12) month period following
the Grantee&rsquo;s termination of Continuous Service as a result of his or her Disability, the Grantee&rsquo;s estate or a person
who acquired the right to exercise the Award by bequest or inheritance may exercise the portion of the Grantee&rsquo;s Award that
was vested as of the date of termination, within twelve (12) months from the date of death (or such longer or shorter period as
specified in the Award Agreement but in no event later than the expiration of the term of such Award as set forth in the Award
Agreement). To the extent that, at the time of death, the Grantee&rsquo;s Award was unvested, or if the Grantee&rsquo;s estate
or a person who acquired the right to exercise the Award by bequest or inheritance does not exercise the vested portion of the
Grantee&rsquo;s Award within the time specified herein, the Award shall terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;<U>Extension
if Exercise Prevented by Law</U>. Notwithstanding the foregoing, if the exercise of an Award within the applicable time periods
set forth in this Section&nbsp;8 is prevented by the provisions of Section&nbsp;9 below, the Award shall remain exercisable until
one (1) month after the date the Grantee is notified by the Company that the Award is exercisable, but in any event no later than
the expiration of the term of such Award as set forth in the Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;<U>Post
Termination Forfeiture</U>. The reason of termination of Continuous Service notwithstanding, if during the Post-Termination Exercise
Period, the Grantee breaches the confidentiality, non-competition, non-solicitation, non-use or assignment of intellectual property
undertakings binding upon such Grantee, the Company shall have the right to effect a forfeiture of all of the Grantee&rsquo;s then
outstanding Awards (whether vested or non-vested).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;<U>Conditions
Upon Issuance of Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;Shares
shall not be issued pursuant to the exercise of an Award unless the exercise of such Award and the issuance and delivery of such
Shares pursuant thereto shall comply with all Applicable Laws, and shall be further subject to the approval of counsel for the
Company with respect to such compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;As
a condition to the exercise of an Award, the Company may require the person exercising such Award to represent and warrant at the
time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or
distribute such Shares if, in the opinion of counsel for the Company, such a representation is required by any Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.&nbsp;&nbsp;<U>Adjustments
Upon Changes in Capitalization</U>. Subject to any required action by the stockholders of the Company, the number of Shares covered
by each outstanding Award, and the number of Shares which have been authorized for issuance under the Plan but as to which no Awards
have yet been granted or which have been returned to the Plan, the exercise or purchase price of each such outstanding Award, as
well as any other terms that the Administrator determines require adjustment shall be proportionately adjusted for (i)&nbsp;any
increase or decrease in the number of issued Shares resulting from a stock split, reverse stock split, stock dividend, combination
or reclassification of the Shares, or similar transaction affecting the Shares, (ii)&nbsp;any other increase or decrease in the
number of issued Shares effected without receipt of consideration by the Company, or (iii)&nbsp;as the Administrator may determine
in its discretion, any other transaction with respect to Common Stock including a corporate merger, consolidation, acquisition
of property or stock, separation (including a spin-off or other distribution of stock or property), reorganization, liquidation
(whether partial or complete) or any similar transaction; provided, however that conversion of any convertible securities of the
Company shall not be deemed to have been &ldquo;effected without receipt of consideration.&rdquo; Such adjustment shall be made
by the Administrator and its determination shall be final, binding and conclusive. Except as the Administrator determines, no issuance
by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and
no adjustment by reason hereof shall be made with respect to, the number or price of Shares subject to an Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;<U>Corporate
Transactions.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;<U>Termination
of Award to Extent Not Assumed.</U> Effective upon the consummation of a Corporate Transaction, all outstanding Awards under the
Plan shall terminate. However, all such Awards shall not terminate to the extent they are Assumed in connection with the Corporate
Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;<U>Acceleration
of Award Upon Corporate Transaction</U>. Except as provided otherwise in an individual Award Agreement, in the event of a Corporate
Transaction, for the portion of each Award that is neither Assumed nor Replaced, such proportional part of the Award, calculated
by dividing the sum of the then vested Options by the total Options granted to a Grantee time the total number of un-vested Options
(see example below), shall automatically become fully vested and exercisable and be released from any repurchase or forfeiture
rights (other than repurchase rights exercisable at Fair Market Value) for all of the Shares at the time represented by such portion
of the Award, immediately prior to the specified effective date of such Corporate Transaction, provided that the Grantee&rsquo;s
Continuous Service has not terminated prior to such date. The portion of the Award that is not Assumed shall terminate under subsection
(a) of this Section 11 to the extent not exercised prior to the consummation of such Corporate Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">Example for proportional
acceleration of Options:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 13%; border-bottom: Black 1pt solid; text-align: center; text-indent: 0in"><B>Example</B></TD>
    <TD STYLE="width: 1%; text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 14%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Options </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Awarded</B></P></TD>
    <TD STYLE="width: 1%; text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 11%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Vested </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Options</B></P></TD>
    <TD STYLE="width: 1%; text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 15%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Un-vested </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Options</B></P></TD>
    <TD STYLE="width: 1%; text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid; text-align: center; text-indent: 0in"><B>Formula</B></TD>
    <TD STYLE="width: 1%; text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 7%; border-bottom: Black 1pt solid; text-align: center; text-indent: 0in"><B>Total</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in">1</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">400</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">100</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">300</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">100 + (300 x 100/400)</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">175</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in">2</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">400</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">200</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">200</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">200 + (200 x 200/400)</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">300</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in">3</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">400</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">300</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">100</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">300 + (100 x 300/400)</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">175</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;<U>Effect
of Acceleration on Incentive Stock Options.</U> The portion of any Incentive Stock Option accelerated under this Section&nbsp;11
in connection with a Corporate Transaction shall remain exercisable as an Incentive Stock Option under the Code only to the extent
the $100,000 dollar limitation of Section&nbsp;422(d) of the Code is not exceeded. To the extent such dollar limitation is exceeded,
the accelerated excess portion of such Option shall be exercisable as a Non-Qualified Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;<U>Effective
Date and Term of Plan</U>. The Plan shall become effective upon the earlier to occur of its adoption by the Board or its approval
by the stockholders of the Company. It shall continue in effect for a term of ten (10) years unless sooner terminated. Subject
to Section&nbsp;17, below, and Applicable Laws, Awards may be granted under the Plan upon its becoming effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">13.&nbsp;&nbsp;<U>Amendment,
Suspension or Termination of the Plan</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;The
Board may at any time amend, suspend or terminate the Plan; provided, however, that no such amendment shall be made without the
approval of the Company&rsquo;s stockholders to the extent such approval is required by Applicable Laws, or if such amendment would
change any of the provisions of Section&nbsp;4(b)(vi) or this Section 13(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;No
Award may be granted during any suspension of the Plan or after termination of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;Any
amendment, suspension or termination of the Plan (including termination of the Plan under Section 12, above) shall not affect Awards
already granted, and such Awards shall remain in full force and effect as if the Plan had not been amended, suspended or terminated,
unless mutually agreed otherwise between the Grantee and the Administrator, which agreement must be in writing and signed by the
Grantee and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">14.&nbsp;&nbsp;<U>Reservation
of Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;The
Company, during the term of the Plan, will at all times reserve and keep available such number of Shares as shall be sufficient
to satisfy the requirements of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;The
inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company&rsquo;s
counsel to be necessary to the lawful issuance and sale of any Shares hereunder, shall relieve the Company of any liability in
respect of the failure to issue or sell such Shares as to which such requisite authority shall not have been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">15.&nbsp;&nbsp;<U>No
Effect on Terms of Employment/Consulting Relationship</U>. The Plan shall not confer upon any Grantee any right with respect to
the Grantee&rsquo;s Continuous Service, nor shall it interfere in any way with his or her right or the Company&rsquo;s right to
terminate the Grantee&rsquo;s Continuous Service at any time, with or without Cause, and with or without notice. The Company&rsquo;s
ability to terminate the employment of a Grantee who is employed at will is in no way affected by its determination that the Grantee&rsquo;s
Continuous Service has been terminated for Cause for the purposes of this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">16.&nbsp;&nbsp;<U>No
Effect on Retirement and Other Benefit Plans</U>. Except as specifically provided in a retirement or other benefit plan of the
Company or a Related Entity, Awards shall not be deemed compensation for purposes of computing benefits or contributions under
any retirement plan of the Company or a Related Entity, and shall not affect any benefits under any other benefit plan of any kind
or any benefit plan subsequently instituted under which the availability or amount of benefits is related to level of compensation.
The Plan is not a &ldquo;Retirement Plan&rdquo; or &ldquo;Welfare Plan&rdquo; under the U.S. Employee Retirement Income Security
Act of 1974, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">17.&nbsp;&nbsp;<U>Stockholder
Approval</U>. The grant of Incentive Stock Options under the Plan shall be subject to approval by the stockholders of the Company
within twelve (12) months before or after the date the Plan is adopted excluding Incentive Stock Options issued in substitution
for outstanding Incentive Stock Options pursuant to Section&nbsp;424(a) of the Code. Such stockholder approval shall be obtained
in the degree and manner required under Applicable Laws. The Administrator may grant Incentive Stock Options under the Plan prior
to approval by the stockholders, but until such approval is obtained, no such Incentive Stock Option shall be exercisable. In the
event that stockholder approval is not obtained within the twelve (12) month period provided above, all Incentive Stock Options
previously granted under the Plan shall be exercisable as Non-Qualified Stock Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">****************************************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: right"><FONT STYLE="text-transform: none">Exhibit
10.2</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="text-transform: none">INVASIX
LTD.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE 2008 ISRAEL OPTION PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Invasix
Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>2008
Israel Option Plan </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>1.</B></TD><TD><B><U>NAME OF THE PLAN </U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This plan, and the amendments
to be made thereto from time to time, shall be named the 2008 Israel Option Plan of Invasix Ltd. (hereinafter: the &ldquo;<B>Plan</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.</B></TD><TD><B><U>SCOPE AND PURPOSEOF THE PLAN </U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Plan is intended to
provide an incentive to attract new employees, directors, consultants and service providers, and to retain in the service of the
Company experienced and capable professionals by providing them with opportunities to purchase shares in the Company, pursuant
to the Plan, which was approved by the board of directors of the Company (hereinafter: the &ldquo;<B>Board</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Plan shall serve as
a &ldquo;Master Plan&rdquo; for the Company worldwide, therefore, as required, annexes may be added, which include adjustments
according to the local laws of the international subsidiaries of the Company, and in order to adapt the Plan to the various circumstances
where this Plan does not extend, at the discretion of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The options to be granted
under this Plan shall be granted in accordance with applicable law, including the Income Tax Ordinance (New Version) &ndash; 1961,
and subject to any law, regulation, order, judgment committee, circular or procedure existing and/or to be published thereafter,
and/or to be amended from time to time (hereinafter jointly: the &ldquo;<B>Ordinance</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As such, the options to
be granted under this Plan may be subject to conditions that may turn the options into options that are allocated in accordance
with a plan with a trustee or in accordance with any other method permitted compatible with the law. All options mentioned above
shall be referred to hereinafter: the &ldquo;<B>Options</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At any time, the Board
may order the translation of the Plan into English, and turn the translation into the binding version. The translation may be done
in a manner that shall preserve the meaning of the arrangements included in the Plan, even if it is not an accurate translation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>3.</B></TD><TD><B><U>ADMINISTRATION OF THE PLAN</U></B></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board or the Options Committee to be appointed by the Board (hereinafter: the &ldquo;<B>Committee</B>&rdquo;) shall administer
the Plan. Notwithstanding the above, the Board shall have residual authority if the Committee is not constituted or if such Committee
shall cease to operate for any reason. The Board shall appoint the members of the Committee, and may from time to time add members
to, and replace members of the Committee. In this Plan, any reference to the term &ldquo;Committee&rdquo; shall also mean the Board
- if no Options Committee is operating at that time in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Committee shall select one of its members to serve as its Chairman, and shall hold its meetings at such times and places as the
Chairman shall determine. The resolutions of the Committee that are adopted by the majority of Committee members present shall
be valid, and written resolutions adopted by all members of the Committee shall be considered valid resolutions of the Committee.
The Committee shall determine internal procedures for the conduct of its business, and shall appoint a secretary who shall document
the meetings in the minutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Committee shall fulfill the following tasks: (1) designate grantees to whom Options shall be granted (hereinafter: &ldquo;<B>Grantee</B>&rdquo;
or &ldquo;<B>Participant</B>&rdquo;); and (2) recommend to the Board to grant Options to the Grantees. Notwithstanding the above,
the Board is authorized to allot shares in respect of Options on behalf of the Company, which were granted and exercised as required.
If the Articles of Association so permit, and upon the consent of the Board, the Committee may grant options and allot shares in
respect thereof within the quantity reserved under the Plan and under the directives of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the terms of this Plan, the Committee shall have the full power and authority, to determine from time to time and at any time,
the terms included in the Option agreements to be signed between the Company and each of the Grantees (hereinafter: the &ldquo;<B>Option
Agreement</B>&rdquo;). Including (but not limited), to determine: (1) the type of option granted; (2) the date or dates and terms
according to which the option shall become vested (including by way of achieving goals); (3) the duration and nature of restriction
on offenses; (4) additional special conditions for a certain Grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Committee shall be
authorized to: (1) interpret the Plan, to monitor and vise the administration of the Plan; (2) amend, modify or replace conditions
and rules in a certain Option Agreement or in a number of Option Agreements (it shall be emphasized that such action that shall
be done for one or more Grantees shall not automatically entitle the other Grantees to the same entitlement, and in the event that
said action shall have a significant negative influence on the rights of the Grantee, such modification must be agreed upon by
the Grantee whose rights were derogated from); (3) convert granted un-vested Options from previous plans to Options under the Plan
&ndash; subject to applicable law; and (4) any other matter that is necessary, desirable or incidental to the administration of
the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Committee shall adopt from time to time rules for the implementation of the Plan in a manner that it believes to be best. No Board
member or Committee member shall be liable for any action or resolution made in good faith in connection with the Plan or the grant
of Options in the framework thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board or Committee member may receive options according to the Plan during his tenure on the Committee, subject to the provisions
of the Companies Law, 1999 (hereinafter: the &ldquo;<B>Companies Law</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
meaning and interpretation given by the Committee to any terms of the Plan or to any Option granted pursuant thereto shall be final
and exclusive, unless otherwise determined by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent permitted by law, each member of the Board or the Committee shall be indemnified and held harmless by the Company against
any reasonable expense incurred (including attorneys&rsquo; fees) or any liability (including any sum paid in settlement of a claim
with the approval of the Company) arising out of any act or omission to act in connection with the Plan of the Board / Committee
member, unless said act or omission were done fraudulently or in bad faith. Such indemnification shall be in addition to any rights
of indemnification the member may have, if any, as a Board or Committee member by virtue of him being a Board member under the
Company's articles of association, agreement, resolutions or any vote of shareholders or disinterested directors, insurance policy
or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>4.</B></TD><TD><B><U>DESIGNATION OF GRANTEES </U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the limitations and restrictions set forth in applicable law, Options may be granted to: office holder, employee in a key position,
other employee of the Company, Board member, consultant or service provider of the Company, provided that: (1) the employees who
are taxed under the laws of the State of Israel are granted Options only in accordance with Section 102 of the Ordinance; (2) the
controlling shareholders, as such term is defined in the Ordinance, consultants and service providers who are taxed under the laws
of the State of Israel are granted Options only under Section 3(i) of the Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
grant of an Option hereunder shall neither entitle the Grantee to participate nor disqualify the Grantee from participating in
any other grant of Options pursuant to this Plan or any incentive or any other plan of the Company or its affiliates..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing in this Plan, the grant of options to office holders (as defined in the Companies Law) shall be approved in the manner
prescribed by the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company chose, as its first choice, to apply the <U>capital gains track with a trustee</U> to all Grantees who are taxed under
Israeli law and are eligible to be included in this Plan as part of the capital gains track. The Board may decide to modify the
track to an ordinary income track in accordance with the provisions of the Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.</B></TD><TD><B><U>TRUST AND ADDITIONAL TERMS UNDER SECTION 102 OF THE ORDINANCE</U></B></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
Option to be granted in the framework of a track with a trustee and/or shares of the Company to be allotted following the exercise
of Options under a trustee shall be held by a trustee to be appointed by the Board (hereinafter: the &ldquo;<B>Trustee</B>&rdquo;)
in accordance with the terms set forth in the Ordinance, in accordance with the Trust Agreement, a copy of which is attached hereto
and constitutes an integral part of this Plan, and in accordance with the provisions of the Company, to be given from time to time.
Each Grantee hereby consents to the terms of the trust agreement, which includes an indemnification clause and waiver of the Grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Grantee&rsquo;s signature on the Option agreement constitutes consent on behalf of the Grantee to release the Trustee from any
liability in respect of any action or decision taken and executed in good faith in relation with the Plan, or any Option or Share
granted to the Grantees. It is hereby clarified that the Trustee serves as a Trustee for the payment of tax and execution of the
relevant sections of the Ordinance, and he does not serve as the Trustee of the Grantee or the Company, with the exception as stated
explicitly in the Trust Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Trustee may resign and the Company may terminate the appointment of the Trustee at any time, subject to the provision of advance
notice as required in the Trust Agreement. The Company may, at its discretion, determine the identity of the new Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
derogating from the aforesaid, the following restrictions shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 113.4pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13%"></TD><TD STYLE="width: 7%">5.4.1</TD><TD STYLE="text-align: justify; width: 80%">In accordance with the provisions of Section 102 of the Ordinance, Options in a Trustee track shall
be issued to the Trustee, and held in trust for the benefit of the Grantees for such period of time to commence on the date of
deposit of the Options in trust, and shall end, at the earliest, upon the completion of the Holding Period, as defined in the Ordinance
(the &ldquo;<B>Restricted Period</B>&rdquo;). During the Restricted Period, the Options and/or shares, as the case may be, shall
not be exercised, transferred or be subject to an attachment, unless and to the extent permitted by the Ordinance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 113.4pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13%"></TD><TD STYLE="width: 7%">5.4.2</TD><TD STYLE="text-align: justify; width: 80%">Following the lapse of the Restricted Period, the Trustee shall release the Options to the Grantee
at the Grantee&rsquo;s request, only after, to the Trustee&rsquo;s satisfaction, all requirements of the Tax Authorities were satisfied
in accordance with the Ordinance (including payment of the required tax).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 99.25pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13%"></TD><TD STYLE="width: 7%">5.4.3</TD><TD STYLE="text-align: justify; width: 80%">During the Restricted Period, all rights received from the Options / shares, including bonus shares,
shall be deposited with the Trustee for the duration of the Holding Period, and the capital gains track and the provisions of Section
102 of the Ordinance shall apply to said benefits.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 99.25pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13%"></TD><TD STYLE="width: 7%">5.4.4</TD><TD STYLE="text-align: justify; width: 80%">If a Grantee ceases to be employed by the Company before exercising all of the Options that he
may exercise, and before selling all of his shares, the Grantee shall provide a security or guarantee in favor of the Company,
to its satisfaction, which shall ensure timely tax payment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>6.</B></TD><TD><B><U>SCOPE OF THE PLAN</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At first, the Company reserves
from the registered unpaid capital of the Company 90,000 ordinary shares, par value 0.01 NIS per share of the Company (hereinafter:
the &ldquo;<B>Shares</B>&rdquo;) for the Plan, subject to adjustments, if any, as stated in Section 11 below. The Board may increase
this initial amount from time to time. As long as the Plan is in effect, any Share reserved for this Plan, for which the Option
expired for any reason or ended without being exercised, shall become available for grant again in accordance with this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>7.</B></TD><TD><B><U>GRANT OF OPTIONS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Committee, at its discretion, may grant Options for the purchase of shares of the Company under the Plan. Options can be granted
under the Plan throughout the duration of the Plan specified in Section 13 below. The grant date of each Option shall be the date
determined by the Committee on the date of its decision to grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
grant of Options under the Plan shall be evidence by a written Option Agreement. The Option Agreement shall determine, inter alia,
whether the Options granted are Options under the Trustee track, the number of Options granted, the vesting dates (subject to Section
9.1), the exercise price and other terms and conditions which the Committee shall prescribe, at its discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>8.</B></TD><TD><B><U>EXERCISE PRICE</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The exercise price of each
Share shall be determined by the Committee, subject to any guidelines as may be determined by the Board from time to time, as long
as the exercise price is not less that the par value of the Shares. Each Option Agreement will contain the Exercise Price determined
for each Grantee. Each Option granted shall entitle the Grantee the right to purchase one share in exchange of the exercise price
and subject to the terms of the Plan, the Options Agreement, the Trust Agreement (if relevant) and the law, including the tax laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>9.</B></TD><TD><B><U>TERM AND EXERCISE OF THE OPTIONS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vested
Options may be exercised provided that in no case shall the Option be exercised after the lapse of 7 years from the date it was
granted, unless a different term (longer or shorter) was explicitly determined in the terms of the Option Agreement and subject
to the shortening thereof in accordance with the provisions of Section 10 below (hereinafter: the &ldquo;<B>Exercise Period</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The vesting schedule as
appears in the grant notice shall be extended in case of unpaid leave for the duration of the leave.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
vested Option, or any part thereof, shall be exercisable upon the signature of the Grantee on the Exercise Notice and its delivery
to the Company (and to the Trustee when the Options are under a Trustee) at its principal office. The format of the Exercise Notice
and its content shall be determined by the Committee from time to time. The Exercise Notice shall be accompanied by payment of
the exercise price, in accordance with the Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the content of this Plan, if any Option or any part thereof is not exercised and the Shares included therein are not paid for during
the Exercise Period, these Options and the right to purchase the Shares under these Options and any right of the Grantee in respect
of the Option shall expire. If the Company created an actual trust of Shares for said Options, such trust shall expire, and the
Trustee shall maintain these Shares for the Company until the Company informs him of the creation of a new trust for the other
Grantee(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
for Shares shall be made for an entire Share amount, without the right to purchase fractions of Shares; the payment shall be made
in cash or by a cashier&rsquo;s check or in any other of payment as may be customary in the Company, and shall be accompanied by
the Exercise Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before
exercising the Shares, the Grantees shall not have rights of shareholders in the Company in connection with the Options granted.
Furthermore, the Grantees shall not be considered a class of shareholders or creditors of the Company for purposes of the Company&rsquo;s
activities according to the Companies Law, inter alia, in connection with Sections 350 and 351 of the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>10.</B></TD><TD><B><U>TERMINATION OF EMPLOYMENT </U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event the employee&rsquo;s employment with the Company is terminated, or in the event that consulting services / services provided
by a consultant to the Company shall be terminated (hereinafter, jointly: &ldquo;<B>Termination of Employment</B>&rdquo;), all
Options granted to a Grantee which are vested on the Termination of Employment date may be exercised within a period of up to 6
months following the Termination of Employment date (or within another period to be determined by the Committee (the &ldquo;<B>Extension
Period</B>&rdquo;), provided that it shall not be later than the Exercise Period determined by this Plan or the Option Agreement
(if another date was determined). If, on the Employment Termination date, not all Options are vested or in the event that the vested
Options are not exercised during the Exercise Period and the Extension Period &ndash; these Options shall expire, and the Shares
reserved in favor of these Options shall be returned to the total unallocated amount reserved for future grants under the Plan,
and the Grantee shall have no right in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
of Employment for Cause</U>. Despite the aforementioned, in the event that a Grantee is terminated from his employment in the Company
&ldquo;for cause&rdquo; as defined below, all Options not yet exercised by the Grantee (whether vested or unvested) shall expire
immediately, unless the Committee determines otherwise, and the Shares reserved in favor of these Options shall be returned to
the total unallocated amount reserved for future grants under the Plan, and the Grantee shall have no right in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;For Cause&rdquo;
for purposes of this Plan: (1) a conviction for any offense with which there is moral turpitude or an offense that is harmful to
the Company; (2) refusal to follow a reasonable instruction of the CEO or of the Board, which is related to the Company&rsquo;s
business, provided that it could be followed legally; (3) embezzlement of the Company's funds or assets; (4) material breach of
the Grantee&rsquo;s duty of loyalty or care towards the Company, including breach of the duty of confidentiality, prohibition of
competition and non-use; (5) material breach of the terms of the employment agreement and/or the terms of this Agreement, which
have not been corrected within 15 days of receipt of written notice; (6) in liquidation, receivership and/or termination of a Grantee
which is an incorporated entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Retirement</U>.
Without derogating from the aforementioned in Section 10.2 above, if a Grantee retires, the Committee may, at its discretion, allow
a Grantee to continue enjoying his rights under the Plan for a period as prescribed by the same terms and conditions which the
Committee shall determine, at its discretion. The aforementioned in this Section shall not apply to a Grantee which is an incorporated
entity (not a human).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
of Employment as a result of Death or Disability of the Grantee</U>. In the event of the Grantee&rsquo;s termination of employment
with the Company as a result of death or disability (as defined below), any vested Options available to the Grantee on the employment
termination date may be exercised by the Grantee, the Grantee&rsquo;s guardian, estate or any individual that has the right to
exercise the Option by virtue of an inheritance or an estate within a period of twelve (12) months after the date of such termination
(or another period which the Committee shall determine in the Option Agreement), however, in any case, no later than the lapse
of the Exercise Period, as set forth in the Option Agreement. If, on the termination date, the Options are not vested, the Shares
reserved in favor of these Options shall be returned to the total unallocated amount reserved for future grants under the Plan.
If the vested Options are not exercised on the dates stated herein, the Options shall expire and the Shares reserved in favor of
these Options shall be returned to the total unallocated amount reserved for future grants under the Plan, and the Grantee, his
survivors and heirs shall have no right in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the purpose stated
above, the term &ldquo;disability&rdquo; means complete and permanent inability due to illness or injury, preventing or expected
to prevent the Grantee from performing tasks required of the position in which he was employed on the eve of the onset of the disability,
as determined by the Committee, based on medical evidence acceptable to the Committee. Section 10.4 does not apply to Grantees
who are incorporated entities (i.e. not humans).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Forfeiture
of Options following Termination of Employment</U>. Regardless of the reason for the Termination of Employment, if at any period
following the Termination of Employment during which the Grantee may still exercise options, the Grantee breaches the duty of confidentiality,
prohibition of competition with the Company, prohibition of solicitation of employees, suppliers or customers of the Company, prohibition
of use of the intellectual property of the Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">The reason of termination
notwithstanding, if during the period after the Termination of Employment during which the Grantee may still exercise Options,
the Grantee breaches the duty of confidentiality, non-competition, non-solicitation of employees, suppliers and customers of the
Company, non-use of intellectual property of the Company, or fails to sign documents transferring knowledge in favor of the Company
&ndash; binding the Grantee, the Company shall have the right to effect a forfeiture of all of the Grantee&rsquo;s Options and
the Shares reserved in favor of such Options shall revert to the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Continuity
of Rights</U>. For the purpose of Section 10, transfer of the Grantee from performing his position for the Company to a company
associated with the Company (and vice versa), and the transfer from status of a consultant or contractor to an employee (and vice
versa), shall not be considered Termination of Employment, to the extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>11.</B></TD><TD><B><U>ADJUSTMENTS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon the occurrence of
any of the following described events, a Grantee's rights to purchase Shares under the Plan shall be adjusted as hereafter provided:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that the ordinary Shares of the Company are split into or consolidated with a larger or smaller number of Shares, as
applicable, or that the ordinary Shares of the Company are replaced with other securities of the Company, then during the exercise
of the Options, a Grantee shall be entitled to purchase a number of ordinary Shares or an amount of other securities of the Company
which replaced the ordinary Shares, equal to the number the Grantee was entitled to purchase on the eve of the split, consolidation,
replacement or other adjustment, in addition to the adjustment made for that amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that the Company merges with or into another corporation, in the framework of which the Company is liquidated, or that
all or most of its assets or shares are sold (hereinafter: the &ldquo;<B>Transaction</B>&rdquo;), and at that time there are Options
within the Plan that have not yet been exercised, the Company shall try to ensure that these Options are replaced with parallel
Options of the purchasing company, and their amount, exercise price, etc. shall be determined accordingly. The type of Shares which
may be purchased from the exercise of the new Options shall be the same type which the holders of Ordinary Shares of the Company
received in exchange for their Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the new entity refuses
to replace said Options, the Exercise Period shall be shortened to the Determining Date (as determined by the Committee) prior
to the completion of the Transaction. If the Options are not replaced, as stated above, partial acceleration of the unvested Options
shall apply, in a manner in which the number of vested Options, divided by the overall number of Options granted, multiplied by
the number of unvested Options, shall be accelerated and shall become vested Options. Numerical examples are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 98%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; border: Black 1pt solid; text-align: left; text-indent: 0in; vertical-align: bottom"><B>Example</B></TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><B>No.
    of<BR>
 Granted<BR>
 Options</B></TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; text-indent: 0in; vertical-align: bottom"><B>No.
    of<BR>
 Vested<BR>
 Options</B></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; text-indent: 0in; vertical-align: bottom"><B>No.
    of <BR>
Unvested<BR>
 Options</B></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; text-indent: 0in; vertical-align: bottom"><B>Calculation</B></TD>
    <TD STYLE="width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; text-indent: 0in; vertical-align: bottom"><B>Total
    amount of<BR>
 Vested Options</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; text-indent: 0in">1.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">400</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">100</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">300</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">100 + (300 x 100/400)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">175</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; text-indent: 0in">2.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">400</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">200</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">200</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">200 + (200 x 200/400)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">300</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; text-indent: 0in">3.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">400</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">300</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">100</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">300 + (100 x 300/400)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">375</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The conditions that shall
apply to the vested Options by virtue of the acceleration shall be identical to the Options already granted, and the provisions
of Section 11.2 shall apply thereto, and if they are not exercised as stated, they shall expire together with the remaining vested
Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Without derogating from
the aforesaid, the Committee, at its exclusive discretion, may include in certain Option Agreements different provisions regarding
acceleration of the Vesting Period regarding unvested Options in the event of a Transaction, as stated above, or upon the occurrence
of other events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Options which have not
been exercised by the Determining Date shall expire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The abovementioned conditions
are subject to the actual completion of the Transaction. If the Transaction is not completed, any action taken in accordance with
sub-Section 11.2 shall be canceled until the situation is restored.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Company issues Ordinary Shares or other securities of the Company as bonus shares which the holders of Ordinary Shares of the
Company are entitled to, then on the date the Grantee exercises Options, if he so chooses, he shall also be entitled to receive
that amount of bonus shares that he would have received had he held the same amount of Shares he now wishes to purchase, on the
eve of the distribution of the bonus shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Committee shall determine the specific adjustments to be made in the framework of Section 11, and its resolution shall be decisive
and final. The Committee&rsquo;s resolution may be different from one Grantee to another, with the exception of its resolutions
regarding the adjustments determined in Sections 11.1 and 11.3, which shall be implemented in the same manner for all appropriate
Grantees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>12.</B></TD><TD><B><U>ASSIGNMENT AND SALE OF OPTIONS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">12.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options
that are exercised by virtue of this Plan shall not be assignable unless in accordance with applicable law and the Company&rsquo;s
Articles of Association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">12.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Options shall not be sold, pledged, assigned or transferred in any other way, except by way of inheritance or according to a will.
As long as the Grantee is alive, only the Grantee may exercise the Options. These limitations of assignment apply also to direct
transfer or by way of change of control of incorporated entities, unless said transfer is approved the Committee in advance and
in writing &ndash; at the Committee&rsquo;s sole discretion. The terms of the Plan and the Option Agreement shall apply and bind
the guardians, heirs and transferees of the Grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>13.</B></TD><TD><B><U>DURATION OF THE PLAN AND AMENDMENTS THERETO</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">13.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Plan shall expire 10 years after its approval by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">13.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board may, at any time and from time to time, terminate or amend the Plan in any manner, provided that the Company shall not alter
or impair material rights granted to the Grantee, without the consent of the Grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>14.</B></TD><TD><B><U>CONTINUANCE OF EMPLOYMENT</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Neither the Plan nor the
Option Agreement with the Grantee shall impose any obligation on the Company or an Affiliate thereof, to continue to employ any
employee or to continue to receive services provided from the Grantee, and nothing in the Plan or in any Option granted pursuant
thereto shall confer upon any Grantee any right to continue to be employed or provide services to the Company, and shall not restrict
the right of the Company to terminate such engagement with said employee or service provider or consultant at any time, with or
without cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>15.</B></TD><TD><B><U>APPLICABLE LAW</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Plan and all accompanying
documents thereof or related thereto shall be governed by and construed in accordance with the laws of the State of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>16.</B></TD><TD><B><U>TAX CONSEQUENCES</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any tax consequences arising
from the grant or exercise of any Option, the payment for Shares covered or the sale or transfer of Shares or any other act or
event related thereto (whether by the Grantee or by the Company or the Trustee), shall be borne solely by the Grantee. The Company
and/or the Trustee shall withhold taxes according to the requirements under the applicable laws, rules, and regulations, including
withholding taxes. Furthermore, the Grantee agrees to compensate and indemnify the Company and/or the Trustee and/or the shareholders
of the Company and/or the Board members and/or the office holders and hold them harmless against and from any and all liability
for any such tax or interest, including without limitation, liabilities relating to the necessity to withhold any such tax from
any payment made to the Grantee. Except as otherwise determined by law, the Company shall not be obliged to accept the exercise
of any Option by or on behalf of a Grantee until the tax consequences (if any) created as a result of the exercise of the Options
and/or sale of the Shares and/or any related action shall be resolved in a manner reasonably acceptable to the Company (and to
the Trustee &ndash; if the Shares are in a trust track).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>17.</B></TD><TD><B><U>MULTIPLE AGREEMENTS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The terms set forth in
each Option and in each Option Agreement may differ from one another, even if the Options or Option Agreements were signed at the
same time or at any other time. The Committee may also grant more than one Option to a given Grantee during the term of the Plan,
in addition to one or more Options previously granted to that Grantee. Granting of a number of Options shall be accompanied by
one notice per Grantee or by a number of notices per Grantee, as determined by the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>18.</B></TD><TD><B><U>NON-EXCLUSIVITY OF THE PLAN</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The adoption of the Plan
by the Board shall not be construed as amending, modifying or rescinding any previous incentive arrangement or as creating any
limitations on the power of the Board to adopt such other incentive arrangements, including the granting of Options not under the
Plan, and such arrangement may be applicable generally or only in specific cases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">***************************************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.5</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: right; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center; text-indent: -28.35pt">CONSULTANCY
AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Invasix Ltd.,</B> duly incorporated under
the laws of the State of Israel, located at Tavor Building, Sha&rsquo;ar Yokneam, P.O. Box 533, Yokneam 20692, Israel (the &ldquo;<B>Company</B>&rdquo;);
and <B>M.N. Business Strategy Ltd.</B> Israeli incorporation number 512297508, of 2 Yatziz St., Tel-Aviv, Israel, via its sole
principal <B>Mr. Moshe Mizrahy </B>(respectively the &quot;<B>Consultant</B>&quot; and the &quot;<B>Principal</B>&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(Each a &quot;<B>Party</B>&quot; and together
the &quot;<B>Parties</B>&quot;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Whereas</B></TD><TD STYLE="text-align: justify">the Principal is an investor and shareholder of the Company and has been providing the Company
with various management services and acting as the CEO of the Company since the incorporation of the Company and up until the Effective
Date (as defined below) for no consideration received;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: -63.8pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Whereas</B></TD><TD STYLE="text-align: justify">the Principal is the sole principal and shareholder of the Consultant; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: -63.8pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Whereas</B></TD><TD STYLE="text-align: justify">as of the Effective Date (as defined below) the Parties wish to establish the terms and basis of
continuous engagement of the Principal as the CEO of the Company and the Group (as defined below), and to provide his management
services to the Company via the Consultant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: -63.8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: -63.8pt"><B>Now, therefore</B>,
the parties have agreed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: -63.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">1.</TD><TD STYLE="text-align: justify"><B><U>Consultancy Agreement</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">1.1.</TD><TD STYLE="text-align: justify">The preamble hereto and the appendices attached hereto form integral and binding parts of this
Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">1.2.</TD><TD STYLE="text-align: justify">The term &quot;<B>Group</B>&quot; as used in this Agreement shall mean the Company and any of the
Company's present or future subsidiaries in which the Company is a shareholder, directly or indirectly, as currently exist and
as may exist in the future.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">1.3.</TD><TD STYLE="text-align: justify">Effective as of July 1, 2017 (the &ldquo;<B>Effective Date</B>&rdquo;), the Company wishes to retain
the Consultant&rsquo;s services described in the attached <B><U>Appendix A</U></B> (the &ldquo;<B>Services</B>&rdquo;) pursuant
to the terms set out herein, and the Consultant agrees to provide these Services. The scope of the Services will be as set forth
in <B><U>Appendix A</U></B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">1.4.</TD><TD STYLE="text-align: justify">The Principal shall be entitled to enter into indemnification and exemption agreement with the
Company and to be included in the Company's D&amp;O Insurance, once consummated by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">1.5.</TD><TD STYLE="text-align: justify">The Consultant will provide the Services solely via the Principal and neither the Consultant nor
the Principal may employ/retain other persons for the performance of the Services, or assign or sub-contract the performance hereunder
to any third party, without the prior written consent of the Company. The Consultant agrees to cause the Principal to dedicate
his time (to the extent agreed upon), experience, talent, expertise and knowledge for the provision of the Services, and to perform
the Services in a loyal and dedicated manner and in accordance with the Company&rsquo;s policies and instructions.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">1.6.</TD><TD STYLE="text-align: justify">The Consultant hereby declares that neither it nor the Principal are under any restrictions regarding
the rendering of the Services to the Company and the execution of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">1.7.</TD><TD STYLE="text-align: justify">The Consultant is an independent contractor. The Parties do not intend, and this Agreement and
the performance hereunder shall not be construed to give effect to employment, partnership, joint venture or agency relations between
the Parties and/or between the Company and the Principal. The Consultant and the Principal undertake not to present any claims
against the Company in that regard.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">1.8.</TD><TD STYLE="text-align: justify">Should the Consultant, the Principal or any other party on their behalf present any claim against
the Company for compensation, based upon allegation of employee-employer relations or otherwise, the Consultant will indemnify
and hold the Company harmless for and against such claims, and the Company may offset any sum it may owe the Consultant against
the due indemnification sums. Furthermore, the Consultant agrees that if a claim is filed by the Principal or any other party on
its behalf against the Company based on alleged employee-employer relations, and a competent court of law accept such claims, then:
(i) the monthly gross salary due will be calculated as 60% of the Consulting Fee (as per Section 2.1 below), (ii) the Consultant
shall refund to the Company all sums previously paid by the Company in excess of such gross salary, and (iii) the Company shall
use the refund amounts towards satisfaction of employer's obligations arising from the aforesaid court-recognized employee-employer
relations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">1.9.</TD><TD STYLE="text-align: justify">All reasonable procedures, policies and directives of the Company (present and future) applicable
to subjects of work behavior, discipline etc., will have a binding effect on the Consultant and the Principal as if they were included
in this Agreement, provided however, that such policies have been brought to the Consultant's or Principal&rsquo;s attention in
advance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">1.10.</TD><TD STYLE="text-align: justify">The Services performed hereunder are &quot;work for hire&quot;, and the Consultant and the Principal
shall have no rights or title in such Services, or any part thereof or any of its products or results, and the Company shall own
all rights to such work in its name or otherwise, including copyrights, patents, trademarks and other rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">1.11.</TD><TD STYLE="text-align: justify">The Consultant shall (and shall cause the Principal to) perform the Services according to all laws,
rules and regulations applicable to it.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><B>2.</B></TD><TD STYLE="text-align: justify"><B><U>Remuneration &amp; Scope</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">2.1.</TD><TD STYLE="text-align: justify">In consideration of the provision of the Services by the Consultant via the Principal, and all
other obligations of the Consultant and Principal hereunder, the Company will pay to the Consultant a gross monthly consulting
fee in the amount set out in the attached <B><U>Appendix A</U></B> (the &quot;<B>Consulting Fee</B>&quot;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">2.2.</TD><TD STYLE="text-align: justify"><U>Expenses:</U> in addition to the Consulting Fee, the Consultant shall be reimbursed for all
Service-related out of pocket expenditures incurred by it in connection with the performance of the Services, including travel
abroad and other business expenses, subject to prior written approval of the Company and in accordance with the Company&rsquo;s
reasonable expense return policy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">2.3.</TD><TD STYLE="text-align: justify">At the end of each calendar month, the Consultant will submit an Invoice for the Consulting Fee
due for the applicable month. If applicable, VAT will be added at the rate applicable at the time of each payment. The Company
will pay the monthly Invoice within 10 business days after receipt thereof. Withholding taxes will be deducted according to applicable
laws to the extent applicable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">2.4.</TD><TD STYLE="text-align: justify">The Consultant shall bear, be responsible for, and shall indemnify and hold the Company harmless
from, all payments required to be made to the tax authorities, National Insurance Institute, health and life insurance and any
other obligatory payments related to the provision of the Services hereunder or to the remuneration provided in connection therewith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">2.5.</TD><TD STYLE="text-align: justify">The Parties confirm that the remuneration detailed in this Section 2 above is the full and exclusive
remuneration due to the Consultant for the Services hereunder, and constitute the total cost to the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><B>3.</B></TD><TD STYLE="text-align: justify"><B><U>Secrecy, Non-Compete and other Intellectual Property Issues</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">3.1.</TD><TD STYLE="text-align: justify">The Consultant undertakes to (and shall cause the Principal to) execute, perform and abide by the
Secrecy, Non-Compete and Intellectual Property Undertakings as attached hereto as <B><U>Appendix B</U></B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><B>4.</B></TD><TD STYLE="text-align: justify"><B><U>Period of the Agreement </U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">4.1.</TD><TD STYLE="text-align: justify">This Agreement is made for an un-defined period, subject to the right of each party, at any time,
to terminate it by giving prior notice: (i) 90 days prior notice if termination is provided by either party at will; or (ii) immediately
- if termination is made for cause.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">The term &ldquo;<B>cause</B>&rdquo;
in this agreement shall be defined as any of the following events or acts of the Consultant and/or Principal: (a) self-dealing,
embezzlement or misappropriation of the Company&rsquo;s property or serious damage to the Company&rsquo;s property which is intentionally
caused, (b) gross negligence or gross misconduct which represents also a breach of duty of loyalty as defined in the Companies
Law, (c) criminal behavior as determined by a court of law, except as for traffic violations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">4.2.</TD><TD STYLE="text-align: justify">The Company shall have the right to terminate the Agreement immediately without cause, provided
however that it pays to the Consultant the Consulting Fee due for the entire notice period, on the termination date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">4.3.</TD><TD STYLE="text-align: justify">Except as provided by law, termination of this Agreement is without liability of the Company for
any claims or payments beyond those earned or accrued in the course of the engagement hereunder; and the Consultant hereby waives
any and all such claims towards the Company, its affiliates and any other third party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">4.4.</TD><TD STYLE="text-align: justify">The termination of this Agreement will not entitle either party to any compensation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">4.5.</TD><TD STYLE="text-align: justify">The provisions of Sections 1.7, 1.8, 1.10, 2.4, 4.3, 4.4 and 5.1 through 5.5 of this Agreement
shall remain valid and binding regardless the termination of this Agreement, and will survive such termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><B>5.</B></TD><TD STYLE="text-align: justify"><B><U>General Provisions</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">5.1.</TD><TD STYLE="text-align: justify">This Agreement forms the complete and exclusive agreement between the Parties as to its subject
matter; and they cancel any prior verbal or written agreement related thereto. Any change to this Agreement requires a duly signed
document.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">5.2.</TD><TD STYLE="text-align: justify">The failure or delay of either Party to require the performance of any term under this Agreement,
or the waiver by either Party of any breach under this Agreement, shall not prevent subsequent enforcement of such terms, nor be
deemed a waiver of any subsequent or prolonged breach.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">5.3.</TD><TD STYLE="text-align: justify">Any notice sent by one Party to the other by registered mail will be deemed to have been received
on the 7<SUP>th</SUP> business day after the day of mailing. Fax and electronic messages will be deemed to have been received on
the first business day following the day of transmission.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">5.4.</TD><TD STYLE="text-align: justify">This Agreement may be executed in counterparts, each of which shall be deemed an original, and
all of which taken together shall constitute one and the same instrument, with the same effect as if the signatures thereto were
upon the same instrument. The exchange of signature pages (in counterparts or otherwise) by electronic transmission in electronic
files or by facsimile copies shall have the same legal effect as the exchange of signed originals and shall be sufficient to bind
the Parties to the terms and conditions of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">5.5.</TD><TD STYLE="text-align: justify">The exclusive law of this Agreement is the law of Israel, as it applies to agreements made and
to be performed in Israel, without regard to &ldquo;choice of law&rdquo; provisions. The courts of Israel (in the city of Haifa)
will have exclusive jurisdiction over all claims arising out of or relating to this Agreement, and each Party hereby consents and
submits to such exclusive jurisdiction. However, in matters involving a breach or infringement of intellectual property rights,
the Company shall be entitled to bring action against the Consultant in any other competent court. Judgements, verdicts and decrees
of any of the aforesaid courts shall be enforceable against either Party in any country.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center; text-indent: -28.35pt">In
Witness Hereof, the parties execute this Agreement on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1/7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U> ,&nbsp;2017 effective as of the Effective Date&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; line-height: 115%; border-bottom: Black 1pt solid; text-align: center">/s/ Moshe Mizrahy</TD>
    <TD STYLE="width: 10%; line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 45%; line-height: 115%; border-bottom: Black 1pt solid; text-align: center">/s/ Moshe Mizrahy</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; line-height: 115%"><B>Invasix Ltd.</B></TD>
    <TD STYLE="text-align: center; line-height: 115%"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: center; line-height: 115%"><B>M.N. Business Strategy Ltd.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; line-height: 115%"><B>The Company</B></TD>
    <TD STYLE="text-align: center; line-height: 115%"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: center; line-height: 115%"><B>The Consultant</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-indent: 0in; text-align: justify"><B><U>Confirmation</U>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, the undersigned, being the above referenced
Principal pursuant to the above Agreement, hereby confirm and undertake towards the Company with respect to all of the undertakings
and representations of the Consultant and the Principal as detailed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Moshe Mizrahy</FONT></TD>
    <TD STYLE="width: 55%; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mr. Moshe Mizrahy</B></FONT></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date of signature as of the Effective Date</B></FONT></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center; text-indent: -28.35pt"><U>APPENDIX
A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><B>1.</B></TD><TD STYLE="text-align: justify"><B><U>The Services</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">1.1.</TD><TD STYLE="text-align: justify">Pursuant to Section 1.3 to the Agreement, the Services provided by the Consultant via the Principal
shall be the Chief Executive Officer of the Group (as defined in the Agreement) or another such executive position as may be determined
by the Board of Directors of the Company.</TD></TR>                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">1.2.</TD><TD STYLE="text-align: justify">The Principal shall report to the Board of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><B>2.</B></TD><TD STYLE="text-align: justify"><B><U>The Scope of the Services</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">2.1.</TD><TD STYLE="text-align: justify">The Parties confirm that the Consultant&rsquo;s Services to the Company will be in a scope required
for the performance of the Services which may be less than of a full time position, requiring work at long and irregular hours
including extensive travel abroad.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"><B>3.</B></TD><TD STYLE="text-align: justify"><B><U>Consulting Fee</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">3.1.</TD><TD STYLE="text-align: justify">As per Section 2.1 to the Agreement, the Consultant shall be entitled to a gross monthly Consulting
Fee equal to US $10,000 plus VAT, if applicable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center; text-indent: -28.35pt"><B>APPENDIX
B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center; text-indent: -28.35pt"><B>SECRECY;
INTELLECTUAL PROPERTY AND NON-COMPETE UNDERTAKINGS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration of the disclosure by the Company
to the Consultant and Principal of information relating to the Services and the remuneration as set out in the Agreement, the Consultant
and the Principal agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">1.</TD><TD STYLE="text-align: justify">In this Appendix B, the term &ldquo;<B>Group</B>&rdquo; shall mean the Company and any of the Company&rsquo;s
present or future subsidiaries in which the Company is a shareholder, directly or indirectly, and the Company&rsquo;s affiliates,
as currently exist and as may exist in the future.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">2.</TD><TD STYLE="text-align: justify">The term &ldquo;<B>Proprietary Information</B>&rdquo; means any and all confidential and/or proprietary
knowledge, data or information of the Group or of any third party which is disclosed to Consultant and/or Principal or which it/he
otherwise obtains or generates as a result of the Services (including the implications, results and applications of the Services
and any knowhow, intellectual property and other rights relating to the results of the Services), including without limitation
technical, business, marketing, financial, administrative, management and commercial information related to the Group, its products,
current or prospective, knowhow, technology, trade secrets, software, copyright, process, commercial relations, actual and potential
clients and suppliers, business or other plans, and any other information of a proprietary or confidential nature. Without derogating
from the generality of the above said, information which by nature is deemed to be proprietary and non-public information and any
information discussed and presented at any meeting of the Group in which the Principal attended shall also be recognized as Proprietary
Information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">3.</TD><TD STYLE="text-align: justify">The term &ldquo;Proprietary Information&rdquo; does not include information (i) which is, at the
date of signature hereof or thereafter, enters the public domain, through no act or omission by the Consultant and/or Principal,
(ii) information which was known to Consultant and/or Principal prior to its disclosure (in the case of information disclosed by
Group) or prior to its generation (in the case of Proprietary Information generated by Consultant and/or Principal), as evidenced
by its/his written records at the time of disclosure or generation (as applicable), (iii) which reflects information generally
known in the industries or trades in which the Company operates, (iv) received by Consultant and/or Principal at any time from
other sources that were legally entitled to receive and transfer such information without any obligation of confidentiality to
the Group.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">4.</TD><TD STYLE="text-align: justify">Proprietary Information and any part thereof are recognized by Consultant and Principal as being
confidential and the exclusive and sole property of the Group.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">5.</TD><TD STYLE="text-align: justify">The Consultant and the Principal undertake to maintain the confidentiality of the Proprietary Information,
not to disclose or make available to any third party any of the Proprietary Information nor to make any use or enable others to
make any use thereof other than for purposes of the Services, without the express prior written approval of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">If required by
law or pursuant to discovery requirements of a stock exchange or pursuant to securities laws and regulations, if applicable to
the Company, Consultant and/or Principal may disclose Proprietary Information to a governmental authority and/or stock exchange
or by order of a court of competent jurisdiction, provided that: (a) unless restricted by such authority, Consultant and/or Principal,
as applicable, shall immediately notify Company and take reasonable steps to assist Company in contesting such request, requirement
or order or otherwise protecting Company&rsquo;s rights; and (b) Consultant and/or Principal, as applicable, shall limit the scope
of such disclosure only to such portion of the Proprietary Information that it/he is legally required to disclose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">The confidentiality
and non-use obligations contained herein will remain valid and binding regardless of the termination of the Agreement and shall
survive for a period of seven (7) years from the date of termination of this Agreement, and with respect to technological and technical
information of the Group including trade secrets, the post termination period of compliance shall remain until said information
comes into the public domain through no fault of the Consultant and/or Principal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">6.</TD><TD STYLE="text-align: justify">The term &ldquo;<B>Proprietary Rights</B>&rdquo; shall mean all inventions, discoveries, ideas,
know-how, works of authorship and confidential information, including copyrights, patents and patent applications, trade secrets,
trademarks, service marks, design marks, any registrations or applications relating to any of the foregoing, which are in the in
the field of medical aesthetic products for the medical/professional markets and explicitly excluding any business Home Skinovations
Ltd. does, directly or indirectly with respect to medical/aesthetic products for home-use and the non-professional markets (the
foregoing shall be referred to as the &quot;<B>Field</B>&quot;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Inventions, if any, patented or
unpatented, made by Consultant and/or Principal prior to his first date of engagement with the Company are excluded from the scope
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Consultant and Principal hereby
assign and agree to assign in the future (when any such inventions in the Field or Proprietary Rights are first reduced to practice
or first fixed in a tangible medium, as applicable) to the Group all their right, title and interest in and to any and all Proprietary
Rights whether or not patentable or registrable under copyright or similar statutes, made or conceived or reduced to practice or
generated by Consultant and/or Principal, either alone or jointly with others, in the performance of the Services for the Company
during the period of the Agreement. Inventions in the Field assigned to the Company, or to a third party as directed by the Company
pursuant to this Section 6, are hereinafter referred to as &ldquo;<B>Company Inventions</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Consultant and Principal hereby
irrevocably waive any right to any additional compensation to which it/he may be entitled with respect to any such assigned Company
Inventions pursuant to any applicable law, in any jurisdiction, including (but not limited to) pursuant to the Israeli Patents
Law-1967, or any provision that may supersede it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">The Consultant and the Principal
acknowledge that all original works of authorship which are made by Consultant and/or Principal (solely or jointly with others)
in the performance of the Services for the Company and which are protectable by copyright are &ldquo;works made for hire&rdquo;
and are the property of the Company pursuant to applicable copyright law. Any assignment of copyright hereunder (and any ownership
of a copyright as a work made for hire) includes all rights of paternity, integrity, disclosure and withdrawal and any other rights
that may be known as or referred to as &ldquo;moral rights&rdquo; (collectively &ldquo;<B>Moral Rights</B>&rdquo;). To the extent
such Moral Rights cannot be assigned under applicable law and to the extent the following is allowed by the laws in the various
countries where Moral Rights exist, the Consultant and the Principal hereby waive such Moral Rights and consent to any action of
the Group that would violate such Moral Rights in the absence of such consent including the right to prevent changes in such works
and/or to be named in its/his name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Consultant and Principal will assist
the Group in every proper way to obtain, and from time to time enforce, any patent rights relating to Company Inventions in any
and all countries, at Company&rsquo;s expense. To that end Consultant and Principal will execute, verify and deliver such documents
and perform such other acts (including appearances as a witness) as the Company may reasonably request for use in applying for,
obtaining, perfecting, evidencing, sustaining and enforcing such patent rights and the assignment thereof. In addition, Consultant
and Principal will execute, verify and deliver such assignments of such patent rights to the Company or its designee as the Company
may reasonably request. The Company shall compensate Consultant and/or Principal, as applicable, at a reasonable rate for the time
actually spent by Consultant and/or Principal at the Company&rsquo;s request on such assistance. Consultant's and Principal's obligation
to assist the Group with respect to patent rights relating to such Company Inventions in any and all countries shall continue beyond
the termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">The Consultant and the Principal
hereby agree that it/he shall not be entitled to any additional compensation for the assignments described in this Section 6 above
and beyond the consideration set forth in the Agreement. The Consultant and the Principal acknowledge and agree that it/he will
not be entitled to additional royalties, consideration or other payments with regard to any of the Proprietary Rights assigned
to Company as set forth above, and do hereby explicitly, irrevocably and unconditionally waive the right to receive any such additional
royalties, consideration or other payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">7.</TD><TD STYLE="text-align: justify">Neither the Consultant nor the Principal shall use any third party's intellectual property, materials,
documents, other resources or confidential information in the performance of the Services.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">8.</TD><TD STYLE="text-align: justify">The Company hereby irrevocably waives any claim against the Consultant and/or Principal concerning
conflict of interests between Consultant's and/or Principal's other business interests and activities and their position as consultant
to the Company. Nevertheless, the Parties confirm that Consultant and Principal are active in various other entities in the cosmetic,
dermatologic and medical fields and they may continue to be involved therewith, provided that, during the period of this Agreement,
they do not hold an executive position in an entity directly competing with the Group's business in the professional medical aesthetic
market, without receiving the prior written consent of the Company's Board of Directors</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">The Consultant
and/or the Principal, as applicable, shall report to the Company&rsquo;s Chairman of the Board during the period of the Agreement
of their intention to provide services which creates conflict of interest between Consultant's and/or Principal's other business
interests and their position as a consultant to the Company. Within ten (10) business days from such notification, the Company
shall inform the Consultant and/or Principal, as applicable, whether it agrees or objects to such new engagement by Consultant
and/or Principal. In the event that the Company notifies the Consultant and/or Principal that it objects such new engagement, either
Party may terminate the Agreement for convenience by giving the other Party a 90 days prior written notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">9.</TD><TD STYLE="text-align: justify">Without prejudice to the generality of the foregoing, each of the Consultant and the Principal
agrees that during the period of this Agreement and for an additional period of 6 months following termination, the Consultant
and the Principal will not, directly or indirectly, for their own account or for the account of others, including without limitation
as a stockholder (other than as the holder of not more than 5% of the total outstanding stock of a publicly held company), director,
officer, employee/employer, investor, partner, consultant, sole proprietor or independent contractor, do or participate or assist
or allow to do any of the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(a)</TD><TD STYLE="text-align: justify">Directly compete or assist others to compete with the business of the Company in the Field;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(b)</TD><TD STYLE="text-align: justify">Request or advise any past, present or future business associate of the Company to decrease or
cancel their business with the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(c)</TD><TD STYLE="text-align: justify">Cause any employee or consultant of the Company to terminate his relations with the Company or
to work for the Consultant and/or Principal or for any party associated with them.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">The term &ldquo;business
of the Company in the Field&rdquo; in this Section 9 shall mean developing, producing, marketing or selling products or services
of the kind or type developed or currently contemplated to be developed, produced, marketed or sold or contemplated to be developed,
produced, marketed or sold, by the Group in the Field.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">The Parties confirm
that during the provision of the Services hereunder, the Consultant and the Principal will be exposed to confidential Proprietary
Information of the Company; and that any activity as forbidden under subsections (a), (b) and (c) above is bound to breach the
right of the Company to the exclusive use of such Proprietary Information; and therefore the Parties agree that the above post-termination
period is intended to ensure such rights of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">10.</TD><TD STYLE="text-align: justify">Upon termination of the Agreement, the Consultant and the Principal shall immediately return to
the Company or delete from their network all materials of any kind (whether in written or electronic form, computer files or otherwise)
concerning the Proprietary Information, including all copies thereof, and they shall not retain any copies of such materials and
shall erase such from all of their files and records in any format.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">11.</TD><TD STYLE="text-align: justify">The provisions of this Appendix B shall apply to the Parties, effective as of their first date
of engagement on January 9, 2008.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center; text-indent: -28.35pt">And in Witness
hereof the Parties sign this Appendix B on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1/7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 28.35pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; border-bottom: Black 1pt solid; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 39%; border-bottom: Black 1pt solid; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 10%; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center; line-height: 115%"><B>Invasix Ltd.</B></TD>
    <TD STYLE="text-align: center; line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 115%"><B>M.N. Business Strategy Ltd.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; line-height: 115%">/s/ Moshe Mizrahy</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 115%">By: Mr. Moshe Mizrahy</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center; line-height: 115%"><B>Mr. Moshe Mizrahy</B></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center; line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right">Exhibit 10.6</P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Employment Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Employment Agreement (the &ldquo;<B>Agreement</B>&rdquo;)
is entered into by and between:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Invasix Corp., </B>a company incorporated
under the laws of Canada, whose head office address is: 30 East Beaver Creek Road, Unit 115, Richmond Hill Ontario, Toronto Canada
(the &ldquo;<B>Company</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">And</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Dr. Michael Kreindel, </B>Canadian Passport
Number 918328121, of 20 Sorrento Dr., Richmond Hill, Canada L4C 0J8 (the &ldquo;<B>Employee</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(Each a &quot;<B>Party</B>&quot; and together
the &quot;<B>Parties</B>&quot;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Whereas</B></TD><TD STYLE="text-align: justify">the Employee is an investor and shareholder of the Company's parent company Invasix Ltd. (the &ldquo;<B>Parent</B>&rdquo;)
and has been providing the Group (as defined below) with various management services and acting as the CTO of the Group since the
incorporation of the Parent in January 2008 and up until the Effective Date (as defined below) for no consideration received; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: -63.8pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Whereas</B></TD><TD STYLE="text-align: justify">as of the Effective Date the Parties wish to establish the terms and basis of continuous engagement
of the Employee as the CTO of the Company and the Group, and to retain the Employee as an employee of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: -63.8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.45pt; text-align: justify; text-indent: -1.45pt"><B>Now, therefore</B>,
in consideration of the employment of the Employee by the Company and the mutual covenants and promises contained in this Employment
Agreement (the &ldquo;<B>Agreement</B>&rdquo;), the Company and the Employee agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: -63.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">1.</TD><TD STYLE="text-align: justify"><B><U>Employment.</U></B> Effective as of July 1, 2017 (the &ldquo;<B>Effective Date</B>&rdquo;),
the Company employs the Employee in the capacity of the Chief Technology Officer of the Group, and the Employee accepts such employment
under and subject to the terms and conditions of this Agreement. In this Agreement, the term &quot;<B>Group</B>&quot; shall include
the Company, its Parent and any of its present or future subsidiaries and affiliated entities in which the Parent is a shareholder,
directly or indirectly, as currently exist and as may exist in the future. Certain provisions of this Agreement will apply to the
relations between the Employee and the Group. Nothing in this Agreement will create the relationship of employer and employee between
the Employee and any member of the Group except the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">Scope of employment:
Full time position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">2.</TD><TD STYLE="text-align: justify"><B><U>Duties.</U></B> The place of work of the Employee shall be Toronto, Canada. The Employee
shall perform his duties as the CTO of the Group and such additional duties consistent with his position as may from time to time
be assigned by the Group. The Employee shall report to Mr. Moshe Mizrahy, CEO of the Group and the Parent's Board of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">During the Employee's
employment with the Company, except for illness, permitted vacation periods and permitted leaves of absence, the Employee will
devote his full business time and best efforts to the faithful performance of such duties and to the promotion and advancement
of the business and affairs of the Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">The Employee
is not authorized to obligate and/or bind the Company and/or any entity of the Group except in the ordinary course of business
to the extent customary for an employee in his position and subject to the policies and directives of the Company and the Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">All reasonable
policies, procedures and directives of the Company and/or the Group (present and future) applicable to subjects of work behavior,
discipline, privacy, confidentiality, will be considered integral parts of this Agreement. The Employee will on request from time
to time sign acknowledgments and agreements to be bound by certain policies applicable to the Group, including without limitation
insider trading and reporting requirements, questionable practices, intellectual property and information technology requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">3.</TD><TD STYLE="text-align: justify"><B><U>Indemnification, Exemption and D&amp;O Insurance.</U></B> The Employee shall be entitled
to enter into indemnification and exemption agreement with the Group and to be included in the Group's D&amp;O Insurance, once
approved and consummated by the Group.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30pt; text-align: justify; text-indent: -30pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">4.</TD><TD STYLE="text-align: justify"><B><U>COMPENSATION</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(a)</TD><TD STYLE="text-align: justify"><B><U>Base Salary.</U></B> In consideration of the services to be rendered by the Employee under
this Agreement, the Company will pay the Employee a gross annual salary in the amount of <B>US $120,000</B> per annum, to be paid
by the Company in Canadian Dollars in equal monthly installments in arrears based on the CAD/USD representatives exchange rate
applicable on the Effective Date (the &ldquo;<B>Base Salary</B>&rdquo;). The Employee acknowledges that his position may require
extensive travel, overtime work and work at irregular places and hours, and agrees that the Base Salary includes the proper and
agreed compensation for all these factors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(b)</TD><TD STYLE="text-align: justify"><B><U>Payments.</U></B> The Base Salary shall be paid monthly in arrears or at such other frequency
as the Company may establish as its normal payroll practice. All benefits due to the Employee as set forth in this Agreement or
by law shall be provided on the Base Salary. Taxes, social security payments, social benefits and other obligatory payments which
are to be borne by the Employee according to applicable laws and regulations - will be deducted from the Base Salary.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(c)</TD><TD STYLE="text-align: justify"><B><U>Benefits.</U></B> In addition to the Base Salary, the Employee shall, during the Term, be
entitled to participate in the Company's Medical, Dental, life and disability insurance plans, as customary in the Company for
employees at the same rank as the Employee and subject to the terms and conditions of such plans.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(d)</TD><TD STYLE="text-align: justify"><B><U>Vacation.</U></B> The Employee shall be entitled to <B>15</B> annual paid vacation days.
vacation entitlement shall be calculated and vacations shall be taken in accordance with the Company's vacation policy as in effect
from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(e)</TD><TD STYLE="text-align: justify"><B><U>Expenses.</U></B> The Company shall reimburse the Employee for all reasonable expenses actually
incurred by the Employee in connection with the business affairs of the Company and the Group and the performance of his duties.
The Employee shall comply with such reasonable policies, limitations and reporting requirements with respect to such expenses as
the Company may establish from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">5.</TD><TD STYLE="text-align: justify"><B><U>Secrecy, Non-Compete and Other Intellectual Property Issues</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">The Employee
undertakes to execute, perform and abide by the Secrecy, Non-Compete and Intellectual Property Undertakings as attached hereto
as <B><U>Exhibit A.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 28.35pt">6.</TD><TD STYLE="text-align: justify"><B><U>PERIOD OF EMPLOYMENT</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(a)</TD><TD STYLE="text-align: justify"><B><U>Term.</U></B> Subject to termination provisions set out in this Section 4, the Employee will
be employed for a term commencing on the Effective Date and continuing until is terminated by either Party (the &ldquo;<B>Term</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(b)</TD><TD STYLE="text-align: justify"><B><U>At Will Employment.</U></B> Employee further understands that this Agreement is not for a
set term and that no particular length of employment has been expressed or implied, and that no circumstances arising out of Employee's
employment will alter his &quot;at will&quot; employment relationship unless expressed in writing signed by the Employee and the
Company. Employee's employment with the Company is &quot;at will&quot; and can be terminated at any time, at the option of either
the Company or the Employee, by providing a 90 days prior notice if termination is provided by either Party at will, or immediately
&ndash; if termination is made for cause.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">The term &ldquo;<B>cause</B>&rdquo;
in this Agreement shall be defined as any of the following events or acts of the Employee: (a) self-dealing, embezzlement or misappropriation
of the Company&rsquo;s and or the Group's property or serious damage to the Company&rsquo;s and/or the Group's property which is
intentionally caused, (b) gross negligence or gross misconduct which represents also a breach of duty of loyalty as defined in
the Israeli Companies Law, (c) criminal behavior as determined by a court of law, except as for traffic violations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">The Company shall have the right
to terminate this Agreement immediately without cause, provided however that it pays to the Employee the entire amount due to the
Employee for the entire notice period due on the termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(c)</TD><TD STYLE="text-align: justify"><B><U>Termination Payments and Benefits.</U></B> Upon termination of this Agreement all payments,
salary and other banafits hereunder shall cease at the effective date of termination. The Employee shall be entitled to receive
all payments and benefits accrued hereunder, and reimbursement of all expenses incureed, through the effective date of termination.
Except as provided by law, termination of this Agreement is without liability of the Company for any claims or payments beyond
those earned or accrued in the course of the employment hereunder; and the Employee hereby waives any and all such claims towards
the Company and any other entity in the Group.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">7.</TD><TD STYLE="text-align: justify"><B><U>No Conflicting Obligations.</U></B> The Employee represents and warrants to the Company that
the execution and delivery of this Agreement and the fulfillment of its terms (a) will not constitute a default under or breach
of any agreement or other instrument to which he is a party or by which he is bound, including, without limitation, any confidentiality
or non-competition agreement, (b) do not require the consent of any person or entity, and (c) the Employee shall not utilize, during
the Term of his employment, any proprietary information of any third party, including, without limitation, former employers of
the Employee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">8.</TD><TD STYLE="text-align: justify"><B><U>Severable Provisions.</U></B> The provisions of this Agreement are severable and the invalidity
of any one or more provisions shall not affect the validity of any other provision.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">9.</TD><TD STYLE="text-align: justify"><B><U>No Waiver or Default.</U></B> No failure by any of the Parties to insist on strict performance
of any covenant, agreement, term or condition (the &quot;<B>Provision</B>&quot;) of this Agreement, or to exercise any right or
remedy consequent on the breach of any Provision, and no acceptance of partial payment during the continuance of any such breach,
shall constitute a waiver of any such breach or of such Provision. No waiver of any breach shall affect or alter this Agreement,
but each and every provision of this Agreement shall continue in full force and effect with respect to any other existing or subsequent
breach of such provision.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">10.</TD><TD STYLE="text-align: justify"><B><U>Notices.</U></B> All notices under this Agreement, to be effective, shall be in writing and
shall be delivered by hand, by mail, by certified mail, postage and fees prepaid, or by facsimile or e-mail to the Company and
to the Employee at the addresses set out above in this Agreement, or to such other address as a Party may notify the other party
from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">11.</TD><TD STYLE="text-align: justify"><B><U>MISCELLANEOUS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(a)</TD><TD STYLE="text-align: justify"><B><U>Modifications.</U></B> This Agreement, including the attached Exhibits, constitute the entire
agreement between the Parties with regard to the subject matter hereof, superseding any and all prior understandings and agreements,
whether written or oral. This Agreement may not be amended or revised except by a written document signed by the Parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"><B></B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(b)</TD><TD STYLE="text-align: justify"><B><U>Captions.</U></B> Captions herein have been inserted solely for convenience of reference
and in no way define, limit or describe the scope or substance of any provision of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(c)</TD><TD STYLE="text-align: justify"><B><U>Independent Advice.</U></B> The Employee acknowledges and agrees that: (i) the Employee has
not relied upon the advice of the Company or any of its officers, directors, employees or agents, nor has he relied on te advice
of the Company's solicitors or agents in connection with this Agreement, and (ii) the Employee has been advised and has had the
opportunity to seek independent legal, tax, and financial advice in connection with this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(d)</TD><TD STYLE="text-align: justify"><B><U>Governing Law.</U></B> This Agreement is deemed to be made in the Province of Ontario and
for purposes of all legal proceedings shall be deemed to have been performed in the Province of Ontario. This Agreement, and the
rights and remedies provided hereunder, and all claims, disputes and controversies arising hereunder or related thereto, shall
be governed by and construed under and enforced in accordance with the laws of the Province of Ontario, without reference to choice
of law or conflicts of law principles. The Employee consents to the jurisdiction of any court located within the Province of Ontario,
and further waives any objection to jurisdiction and venue of any action instituted hereunder, and further agrees not to assert
any defense based on lack of jurisdiction or venue, including forum non convenience. Personal service of any summons, complaint
or other process may be made by any means permitted by law. Any action brought to enforce or relating to this Agreement shall,
subject to the next sentence, be brought exclusively in the courts in the Province of Ontario. Nothing in this Section will prevent
the Company from suing the Employee in any other jurisdiction in which the Employee may reside or be physically present at the
time of commencement of such litigation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(e)</TD><TD STYLE="text-align: justify"><B><U>Counterparts.</U></B> This Agreement may be executed by the Parties in separate counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>And in Witness, the Parties sign and execute
this Agreement, on this </B><U>&nbsp;&nbsp;&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;</U> <B>day of </B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U><B>&nbsp;2017 effective as of the Effective Date</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Moshe Mizrahy</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Michael Kreindel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-weight: normal; text-align: center"><B>Invasix Corp.</B></TD>
    <TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: center"><B>Dr. Michael Kreindel</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 40%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 10%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 45%; font-weight: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal">Moshe Mizrahy</TD>
    <TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center; text-indent: -28.35pt"><B>APPENDIX
A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center; text-indent: -28.35pt"><B>SECRECY;
INTELLECTUAL PROPERTY AND NON-COMPETE UNDERTAKINGS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration of the disclosure by the Company
to the Employee of information relating to his services to the Group and the compensation as set out in the Agreement, the Employee
agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">1.</TD><TD STYLE="text-align: justify">In this Appendix A, the term &ldquo;<B>Group</B>&rdquo; shall include the Company, its Parent and
any of its present or future subsidiaries and affiliated entities in which the Parent is a shareholder, directly or indirectly,
as currently exist and as may exist in the future.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">2.</TD><TD STYLE="text-align: justify">The term &ldquo;<B>Proprietary Information</B>&rdquo; means any and all confidential and/or proprietary
knowledge, data or information of the Group or of any third party which is disclosed to Employee or which he otherwise obtains
or generates as a result of his engagement (including the implications, results and applications of his services and any knowhow,
intellectual property and other rights relating to the results of the services), including without limitation technical, business,
marketing, financial, administrative, management and commercial information related to the Group, its products, current or prospective,
knowhow, technology, trade secrets, software, copyright, process, commercial relations, actual and potential clients and suppliers,
business or other plans, and any other information of a proprietary or confidential nature. Without derogating from the generality
of the above said, information which by nature is deemed to be proprietary and non-public information and any information discussed
and presented at any meeting of the Group in which the Employee attended shall also be recognized as Proprietary Information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">3.</TD><TD STYLE="text-align: justify">The term &ldquo;Proprietary Information&rdquo; does not include information (i) which is, at the
date of signature hereof or thereafter, enters the public domain, through no act or omission by the Employee, (ii) information
which was known to Employee prior to its disclosure (in the case of information disclosed by Group) or prior to its generation
(in the case of Proprietary Information generated by Employee), as evidenced by his written records at the time of disclosure or
generation (as applicable), (iii) which reflects information generally known in the industries or trades in which the Company operates,
(iv) received by the Employee at any time from other sources that were legally entitled to receive and transfer such information
without any obligation of confidentiality to the Group.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">4.</TD><TD STYLE="text-align: justify">Proprietary Information and any part thereof are recognized by the Employee as being confidential
and the exclusive and sole property of the Group.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">5.</TD><TD STYLE="text-align: justify">The Employee undertakes to maintain the confidentiality of the Proprietary Information, not to
disclose or make available to any third party any of the Proprietary Information nor to make any use or enable others to make any
use thereof other than for purposes of performing his duties as required for his position in the Company, without the express prior
written approval of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">If required by
law or pursuant to discovery requirements of a stock exchange or pursuant to securities laws and regulations, if applicable to
the Company, the Employee may disclose Proprietary Information to a governmental authority and/or stock exchange or by order of
a court of competent jurisdiction, provided that: (a) unless restricted by such authority, the Employee shall immediately notify
Company and take reasonable steps to assist Company in contesting such request, requirement or order or otherwise protecting Company&rsquo;s
rights; and (b) the Employee shall limit the scope of such disclosure only to such portion of the Proprietary Information that
he is legally required to disclose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">The confidentiality
and non-use obligations contained herein will remain valid and binding regardless of the termination of the Agreement and shall
survive for a period of seven (7) years from the date of termination of this Agreement, and with respect to technological and technical
information of the Group including trade secrets, the post termination period of compliance shall remain until said information
comes into the public domain through no fault of the Employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt; text-align: left">6.</TD><TD STYLE="text-align: justify">The term &ldquo;<B>Proprietary Rights</B>&rdquo; shall
mean all inventions, discoveries, ideas, know-how, works of authorship and confidential information, including copyrights, patents
and patent applications, trade secrets, trademarks, service marks, design marks, any registrations or applications relating to
any of the foregoing, which are in the field of medical aesthetic products for the medical/professional markets (the foregoing
shall be referred to as the &quot;<B>Field</B>&quot;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">Inventions, if any, patented or
unpatented, made by the Employee prior to his first date of engagement with the Company are excluded from the scope of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">The Employee hereby assigns and
agrees to assign in the future (when any such inventions in the Field or Proprietary Rights are first reduced to practice or first
fixed in a tangible medium, as applicable) to the Group all his right, title and interest in and to any and all Proprietary Rights
whether or not patentable or registrable under copyright or similar statutes, made or conceived or reduced to practice or generated
by the Employee, either alone or jointly with others, in the performance of his services for the Company during the period of the
Agreement. Inventions in the Field assigned to the Company, or to a third party as directed by the Company pursuant to this Section
6, are hereinafter referred to as &ldquo;<B>Company Inventions</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">The Employee hereby irrevocably
waives any right to any additional compensation to which he may be entitled with respect to any such assigned Company Inventions
pursuant to any applicable law, in any jurisdiction, including (but not limited to) pursuant to the Israeli Patents Law-1967, or
any provision that may supersede it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">The Employee acknowledges that
all original works of authorship which are made by Employee (solely or jointly with others) in the performance of his services
for the Company and which are protectable by copyright are &ldquo;works made for hire&rdquo; and are the property of the Company
pursuant to applicable copyright law. Any assignment of copyright hereunder (and any ownership of a copyright as a work made for
hire) includes all rights of paternity, integrity, disclosure and withdrawal and any other rights that may be known as or referred
to as &ldquo;moral rights&rdquo; (collectively &ldquo;<B>Moral Rights</B>&rdquo;). To the extent such Moral Rights cannot be assigned
under applicable law and to the extent the following is allowed by the laws in the various countries where Moral Rights exist,
the Employee hereby waives such Moral Rights and consent to any action of the Group that would violate such Moral Rights in the
absence of such consent including the right to prevent changes in such works and/or to be named in his name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">The Employee will assist the Group
in every proper way to obtain, and from time to time enforce, any patent rights relating to Company Inventions in any and all countries,
at Company&rsquo;s expense. To that end the Employee will execute, verify and deliver such documents and perform such other acts
(including appearances as a witness) as the Company may reasonably request for use in applying for, obtaining, perfecting, evidencing,
sustaining and enforcing such patent rights and the assignment thereof. In addition, the Employee will execute, verify and deliver
such assignments of such patent rights to the Company or its designee as the Company may reasonably request. The Company shall
compensate the Employee at a reasonable rate for the time actually spent by Employee at the Company&rsquo;s request on such assistance.
The Employees' obligation to assist the Group with respect to patent rights relating to such Company Inventions in any and all
countries shall continue beyond the termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">The Employee hereby agrees that
he shall not be entitled to any additional compensation for the assignments described in this Section 6 above and beyond the compensation
set forth in the Agreement. The Employee acknowledges and agrees that he will not be entitled to additional royalties, consideration
or other payments with regard to any of the Proprietary Rights assigned to Company as set forth above, and do hereby explicitly,
irrevocably and unconditionally waives the right to receive any such additional royalties, consideration or other payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">7.</TD><TD STYLE="text-align: justify">The Employee shall not use any third party's intellectual property, materials, documents, other
resources or confidential information in the performance of his services.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">8.</TD><TD STYLE="text-align: justify">The Company hereby irrevocably waives any claim against the Employee concerning conflict of interests
between Employee's other business interests and activities and his position as an employee of the Company. Nevertheless, the Parties
confirm that the Employee is active in various other entities in the cosmetic, dermatologic and medical fields and he may continue
to be involved therewith, provided that, during the period of this Agreement, he does not hold an executive position in an entity
directly competing with the Group's business in the professional medical aesthetic market, without receiving the prior written
consent of the Company's Board of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">The Employee
shall report to the Company&rsquo;s Chairman of the Board during the period of the Agreement of his intention to provide services
which creates conflict of interest between Employee's other business interests and his position as an employee of the Company.
Within ten (10) business days from such notification, the Company shall inform the Employee whether it agrees or objects to such
new engagement by the Employee. In the event that the Company notifies the Employee that it objects such new engagement, either
Party may terminate the Agreement for convenience by providing the other Party with a 90 days prior written notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">9.</TD><TD STYLE="text-align: justify">Without prejudice to the generality of the foregoing, the Employee agrees that during the period
of this Agreement and for an additional period of 6 months following termination, the Employee will not, directly or indirectly,
for his own account or for the account of others, including without limitation as a stockholder (other than as the holder of not
more than 5% of the total outstanding stock of a publicly held company), director, officer, employee/employer, investor, partner,
consultant, sole proprietor or independent contractor, do or participate or assist or allow to do any of the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(a)</TD><TD STYLE="text-align: justify">Directly compete or assist others to compete with the business of the Company in the Field;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(b)</TD><TD STYLE="text-align: justify">Request or advise any past, present or future business associate of the Company to decrease or
cancel their business with the Company;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">(c)</TD><TD STYLE="text-align: justify">Cause any employee or consultant of the Company to terminate his relations with the Company or
to work for the Employee or for any party associated with him.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">The term &ldquo;business
of the Company in the Field&rdquo; in this Section 9 shall mean developing, producing, marketing or selling products or services
of the kind or type developed or currently contemplated to be developed, produced, marketed or sold or contemplated to be developed,
produced, marketed or sold, by the Group in the Field.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 0pt">The Parties confirm
that during the Employee's employment hereunder, the Employee will be exposed to confidential Proprietary Information of the Company;
and that any activity as forbidden under subsections (a), (b) and (c) above is bound to breach the right of the Company to the
exclusive use of such Proprietary Information; and therefore the Parties agree that the above post-termination period is intended
to ensure such rights of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">10.</TD><TD STYLE="text-align: justify">Upon termination of the Agreement, the Employee shall immediately return to the Company or delete
from his network all materials of any kind (whether in written or electronic form, computer files or otherwise) concerning the
Proprietary Information, including all copies thereof, and they shall not retain any copies of such materials and shall erase such
from all of his files and records in any format.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">11.</TD><TD STYLE="text-align: justify">The provisions of this Appendix A shall apply to the Parties, effective as of their first date
of engagement on January 9, 2008.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: left">And in Witness
hereof the Parties sign this Appendix A on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1/7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: left; text-indent: -28.35pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 28.35pt">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">/s/ Moshe Mizrahy</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">/s/ Michael Kreindel</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><B>Invasix Corp.</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>Mr. Michael Kreindel</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Moshe Mizrahy</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: left; text-indent: -28.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;<B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.05pt; text-align: right"><B>Exhibit 10.9</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TURN - KEY MANUFACTURING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 12.6pt; text-align: justify; text-indent: -12.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Turn - Key Manufacturing Agreement (the
&ldquo;<B>Agreement</B>&rdquo;) is effective as of the 1.4.2011 (the &ldquo;<B>Effective Date</B>&rdquo;) by and between:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>INVASIX LTD</B>., with a principal place
of business at Tavor Building, Shaar Yokneam, POB 533, Yokneam 20692, Israel. Hereinafter referred to as &ldquo;<B>Customer</B>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">And</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>FLEXTRONICS ISRAEL LTD</B>. with a principal
place of business at Industrial Zone Migdal Haemek 23108 P.O.B. 867, Israel. Hereinafter referred to as &ldquo;<B>Contractor</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.25pt; text-align: justify; text-indent: -46.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-style: normal"><B>Whereas</B></FONT></TD><TD STYLE="text-align: justify">Customer designs, manufactures and sells the Products as
defined in <B><U>Exhibit A</U></B> attached hereto, which includes subassemblies components and know- how, that is confidential
and proprietary property of Customer;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-style: normal"><B>Whereas</B></FONT></TD><TD STYLE="text-align: justify">Customer desires to buy manufacturing services;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-style: normal"><B>Whereas</B></FONT></TD><TD STYLE="text-align: justify">Contractor is in the business of Turn &ndash; Key projects;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-style: normal"><B>Whereas</B></FONT></TD><TD STYLE="text-align: justify">Customer acknowledges that Contractor&rsquo;s expertise is manufacturing and that Contractor&rsquo;s responsibility
related to the Customer&rsquo;s Products is limited to this extent;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-style: normal"><B>Whereas</B></FONT></TD><TD STYLE="text-align: justify">Contractor declares that it has all the capabilities to
supply manufacturing services for Customer&rsquo;s Products; and</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Whereas</B></TD><TD STYLE="text-align: justify">Contractor desires to sell and deliver its manufacturing
services in accordance with Customer specifications all subject to the terms and conditions contained herein.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Now therefore, the parties hereto have agreed
and do hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">1.</TD><TD STYLE="text-align: justify"><B><U>Precedence</U></B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in">1.1</TD><TD STYLE="text-align: justify">The terms and conditions and appendices herein shall govern all services performed by Contractor
pertaining to the subject matter.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">1.2</TD><TD STYLE="text-align: justify">It is the intent of the parties that this Agreement and
its appendices represent the entire agreement and prevail over the terms and conditions of any purchase order, acknowledgment
form or order instruction.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">2.</TD><TD STYLE="text-align: justify"><B><U>Term</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">This Agreement shall commence on
the Effective Date and shall continue for an initial term of year as of the Effective Date. This Agreement shall automatically
be renewed for successive one (1) year increments unless either party request in writing, at least ninety (90) days prior to the
anniversary date, that this Agreement not to be renewed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">3.</TD><TD STYLE="text-align: justify"><B><U>Scope Of Work</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">Contractor will, pursuant to the
written specifications given by Customer and pre approved by Contractor (&ldquo;Specifications&rdquo;), perform manufacturing services
on behalf of Customer. These manufacturing services shall include, but not be limited to, labor, materials, testing, packaging
and delivery to Customer, all subject to the terms and conditions contained in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">4.</TD><TD STYLE="text-align: justify"><B><U>Contractor&rsquo;s Obligations</U></B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">4.1</TD><TD STYLE="text-align: justify">Contractor shall provide Customer with the following services:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">-&nbsp;&nbsp;&nbsp;Material
planning</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">-&nbsp;&nbsp;&nbsp;Material
procurement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">-&nbsp;&nbsp;&nbsp;Incoming
Inspection</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">-&nbsp;&nbsp;&nbsp;Assembly
of printed circuit boards &amp; cables</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">-&nbsp;&nbsp;&nbsp;Final
assembly &amp; integration of the Product</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">-&nbsp;&nbsp;&nbsp;In
Circuit test</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">-&nbsp;&nbsp;&nbsp;Functional
test</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">-&nbsp;&nbsp;&nbsp;Packaging
and delivery</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">4.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-style: normal"><B><U>Customer&rsquo;s
                                         production facilities</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">Contractor will be obliged to allocate
to Customer, production and storage space as well as trained production and testing personnel as an integral part of this Agreement.
Contractor shall apply for and receive the ISO13488 standard for the production facility, by no later than <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.
During the term of this Agreement, the manufacturing services provided by the Contractor hereto shall confirm in all material respects
with the ISOl3488 standard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 25pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">5.</TD><TD STYLE="text-align: justify"><B><U>Customer&rsquo;s obligations</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">Customer will provide the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">-&nbsp;&nbsp;&nbsp;Technical specifications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">-&nbsp;&nbsp;&nbsp;Standard
Operation Procedures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">-&nbsp;&nbsp;&nbsp;Drawings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">-&nbsp;&nbsp;&nbsp;Bill
of Materials</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">-&nbsp;&nbsp;&nbsp;Approved
Vendors list</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">-&nbsp;&nbsp;&nbsp;Gerber
data, CAD files</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">-&nbsp;&nbsp;&nbsp;Quality
requirements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">-&nbsp;&nbsp;&nbsp;Technical
support, as required</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">-&nbsp;&nbsp;&nbsp;Any
additional information reasonably requested by Contractor or otherwise required hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">6.</TD><TD STYLE="text-align: justify"><B><U>Material Procurement</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">The material procurement undertaking,
pursuant to this Agreement, will be carried-out by the Contractor.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">6.1</TD><TD STYLE="text-align: justify">Contractor is authorized
                                         to purchase materials using standard purchasing practices including, but not limited
                                         to acquisition of materials recognizing Economic Order Quantity, ABC buy policy and long
                                         lead time components management, in order to meet the requirements of Customer&rsquo;s
                                         orders and forecasts.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify; text-indent: -22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">6.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-style: normal"><B STYLE="font-style: normal; font-weight: normal"><U>Economic
                                         Order Quantity</U></B> <FONT STYLE="font-weight: normal">(&ldquo;EOQ&rdquo;) for items
                                         which are un-returnable to vendor or unusable for other clients of the Contractor must
                                         be pre-approved by Customer. For such pre-approved EOQ&rsquo;s, Customer shall advance
                                         to the Contractor sums on account of future deliveries equal to the cost attributed to
                                         the quantity ordered exceeding the 3 months forecast.</FONT></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">6.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-style: normal"><B STYLE="font-style: normal; font-weight: normal"><U>Long
                                         Lead Items</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">In order to manage demand fluctuations
Contractor shall suggest from time to time a list of LLI&rsquo;s to be approved by the Customer. Contractor shall maintain in inventory
certain quantities of LLI. &ldquo;LLI&rdquo; shall mean Long Lead Item materials required in order to complete manufacture and supply
of Products. For the avoidance of doubt Customer shall have no additional liability with respect to the holding of LLI other than
the liability provided herein below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">The usage of LLI by Contractor for
the manufacture of Items shall be by a written order by Customer in accordance with this Agreement, stipulating the quantity Customer
wishes Contractor to use. If Contractor holds LLIs based on any written requirement for more than three (3) months, Customer shall
be required to purchase such LLIs at their direct costs plus a handling fee of 2% of Product price. The purchase terms of such
LLI&rsquo;s, set forth in Section 8.2 hereof.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">6.4</TD><TD STYLE="text-align: justify">Contractor is responsible for monitoring supplier&rsquo;s
quality, according to the Specifications provided by Customer for all purchased materials.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">6.5</TD><TD STYLE="text-align: justify">In the event of termination of this Agreement or a cancellation
of a Purchase Order, and/or discontinuance of a Product, or excess materials created by an Engineering Change, Customer agrees
to compensate Contractor for unused material inventory which are affected by such termination, cancellation or discontinuance,
as follows:</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">The cost of material inventory, whether in raw form or
work in process, which are not returnable to the vendor without charge (unless the charge was approved by Customer, or usable
for other Contractor&rsquo;s customers, including EOQ of unique parts.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">The cost of materials on order which cannot be cancelled
without charge (unless the charge was approved by Customer.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">To the above applicable compensation, the Contractor shall
be entitled to a handling fee of 2% of the compensation due. The compensation under this Sub-section shall be the sole compensation
due to Contractor with respect to handling the Products/materials.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.25in; text-align: left">(v)</TD><TD STYLE="text-align: justify">Payment shall be made to Contractor against delivery of
the compensated materials to Customer. The compensation for finished Products is as set out in Section 7.3 below.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">6.6</TD><TD STYLE="text-align: justify">Contractor shall use its commercially reasonable efforts
to cancel all applicable materials purchase orders and reduce materials inventory through return for credit programs or allocate
materials for alternate programs, if applicable.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">Without derogating from the aforesaid,
Customer shall pay in advance the same amount it is obligated to pay under this Section 6, on account of such inventory. Such advance
shall be non refundable except to the extent such inventory was consumed by Contractor in order to manufacturing Customer&rsquo;s Products
under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 23.2pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">7.</TD><TD STYLE="text-align: justify"><B><U>Forecasts and Purchase Orders</U></B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">7.1</TD><TD STYLE="text-align: justify">Customer shall issue to Contractor, on a monthly basis,
a six (6) month rolling forecast setting forth projected demand for the Products (the &ldquo;<B>Forecast</B>&rdquo;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">Contractor shall use all reasonable
commercial efforts, including expediting materials and allocating capacity, in order to support Customer&rsquo;s request for increased
production.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">7.2</TD><TD STYLE="text-align: justify">Contractor will supply all orders that do not exceed the
forecast at the delivery times set forth in each Purchase Order. In the event Contractor anticipates at any time that it will
not deliver Products within the prescribed timetable as set forth in the applicable Purchase Order, Contractor shall promptly
so inform Customer by written notice of such delay. Contractor shall submit proposed revisions to the timetable that reflect Contractor&rsquo;s
best estimates of what can realistically be achieved and shall use its best commercial efforts to achieve such timeline, unless
otherwise directed by Customer and confirmed by Contractor.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">7.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal">Purchase
                                         Orders. Customer will issue written purchase orders, which specify all Products to be
                                         delivered within a minimum three (3) months period commencing on the date of acceptance
                                         of the purchase order by Contractor (&ldquo;</FONT><FONT STYLE="font-style: normal"><B>Purchase
                                         Order</B><FONT STYLE="font-weight: normal">&rdquo;). Contractor shall accept or reject
                                         (in writing summarizing the rejection causes) each Purchase Order according to its terms
                                         (including the delivery date) within five (5) working days of receipt of such order,
                                         if an order has not been confirmed within such period it shall be deemed rejected.</FONT></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">7.4</TD><TD STYLE="text-align: justify"><U>Finished Goods Inventory</U></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.5in">7.4.1</TD><TD STYLE="text-align: justify">In order to manage demand fluctuations, Contractor shall maintain an amount of additional units
of each Product as FGI, in a minimum level of two (2) weeks of supply and a maximum of four (4) weeks of supply of each Product
set forth in the most recent Customer&rsquo;s Forecast. &ldquo;FGI&rdquo; shall mean rolling finished goods inventory that Contractor shall
be obligated to hold in inventory for Customer in addition to any Purchase Order amounts. The actual quantity of FGI required to
be held by Contractor will be specified on a monthly basis in a formal document provided by Customer to Contractor for this
purpose. For the avoidance of doubt Customer shall have no additional liability with respect to the holding of FGI other than the
liability provided in Section 7.4.3 below.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.5in">7.4.2</TD><TD STYLE="text-align: justify">When Customer draws from the FGI, Contractor shall replenish the FGI no later than sixty (60) days
from such date that Customer draws from FGI, provided the drawing of FGI shall be by the issuance of a written order by Customer
in accordance with this Agreement, stipulating the quantity Customer wishes to withdraw from the FGI.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.5in">7.4.3</TD><TD STYLE="text-align: justify">If Contractor holds any FGI based on any forecast for more than three (3) months from the original
delivery date specified in the applicable purchase order, Customer shall be required to purchase any and all such goods from Contractor
for 100% of Contract Price of such goods and Section 8.3 below shall not apply.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.3pt; text-align: justify; text-indent: -28.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">7.5</TD><TD STYLE="text-align: justify"><U>Customer tooling, etc.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 16pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">All
Customers&rsquo; materials, tooling and equipment furnished to Contractor or paid for by Customer in connection with this
Agreement and all paid for Products shall be clearly marked and remain the Customer&rsquo;s property. Contractor will
maintain the tooling as provided in <B><U>Exhibit B</U></B><U>.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">8.</TD><TD STYLE="text-align: justify"><B><U>Customer Liability for Forecasts</U></B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">8.1</TD><TD STYLE="text-align: justify">Customer&rsquo;s liability with respect to any and all
demand signals provided by Customer, including but not limited to &ldquo;purchase orders,&rdquo; &ldquo;forecasts,&rdquo; &ldquo;schedules,&rdquo;
&ldquo;pick lists,&rdquo; with respect to any Products manufactured, produced, procured, stored or delivered by Contractor, including,
but not limited to, any direct or indirect costs related thereto or related to components, work in progress and/or raw materials
shall be limited to the amounts set forth in this Section 8 with respect to finished Products and in Section  6 concerning
components, work in progress and/or raw materials.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">8.2</TD><TD STYLE="text-align: justify">In the event that Customer has either cancelled or delayed
delivery of a Purchase Order and Customer has not taken delivery of the Products ordered under that Purchase Order within three
(3) months from the original delivery date, then; (i) Contractor shall submit a claim for reimbursement for such cancelled or
delayed Products within thirty (30) days from the end of such three (3) month period; (ii) Customer shall be liable to pay Contractor
100% of the Contract Price of such cancelled or delayed Products and (iii) Contractor shall hold the cancelled or delayed Products
in its inventory and make them available to Customer (upon Customer&rsquo;s request) for a period of six (6) months from receipt
of payment for such Products free of charge. 30 days before the lapse of the 6  month period, the Contractor shall notify
the Customer of the upcoming lapse of the term. In the event that Customer, at its sole discretion, decides to repurchase any
(or all) of the Products in said Period, and subject to the fulfillment of all Customer&rsquo;s obligations in this Sections 8.2
(i.e. 100% of the Contract Price has been paid to Contractor), then the price for such repurchase shall be 0% of the Contract
Price. Thereafter, the Customer shall pay Contractor all direct costs in connection therewith. Provided Customer hereby authorizes
Contractor to transfer such Products to a warehouse operated by Contractor or a third party as instructed by Customer.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">8.3</TD><TD STYLE="text-align: justify">In the event that
                                         for any reason whatsoever, Customer has not ordered any Products for a period of three
                                         (3) months, then: (i) Contractor shall submit a claim for reimbursement for Products
                                         that were forecasted for the upcoming three months in the last Forecast sent three (3)
                                         months ago (the &ldquo;<B>Last Forecast</B>&rdquo;); (ii) Customer shall be liable to
                                         pay Contractor: 100% of the Contract Price of the Product s forecasted for days 0-30
                                         in the Last Forecast which were not delivered to Customer; and (iii) Contractor shall
                                         hold the Forecasted Products in its inventory and make them available to Customer (upon
                                         Customer&rsquo;s request) for a period of six (6) months of receipt of payment for such
                                         Products free of charge. 30 days before the lapse of the 6 month period, the Contractor
                                         shall notify the Customer of the upcoming lapse of the term. In the event that Customer
                                         at its sole discretion decides to repurchase any (or all) of the Forecasted Products
                                         in said Period and subject to the fulfillment of all Customer&rsquo;s obligations in
                                         this Section 8.3 (i.e. 100% of the Contract Price has been paid to Contractor), then
                                         the price for such repurchase shall be 0% of the Contract Price. Thereafter, the Customer
                                         shall pay Contractor all direct costs in connection therewith. Provided Customer hereby
                                         authorizes Contractor to transfer such Products to a warehouse operated by Contractor
                                         or a third party as instructed by Customer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">9.</TD><TD STYLE="text-align: justify"><B><U>Quality</U></B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">9.1</TD><TD STYLE="text-align: justify">Contractor shall permit Customer to audit its quality procedures,
upon three (3) business day advance written notice to Contractor and shall provide all assistance which is reasonably necessary
for Customer to evaluate the quality of the Products.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">9.2</TD><TD STYLE="text-align: justify">Contractor shall maintain quality assurance standards in
accordance with ISO 13488, Seller&rsquo;s Quality Assurance, Control and Inspection shall be in compliance with all material ISO
13488 standards during the Terms of this Agreement.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">9.3</TD><TD STYLE="text-align: justify">If a Product did not pass Customer&rsquo;s Automatic Test
Process then Contractor will perform two rounds of repairs on the Product, if after such two rounds the Product still did not
pass the ATP then Contractor will send the Product with a qualified personnel to Customer for repair. If after Customer tried
to repair the Product and failed Customer will be obligated to pay for such defected product (if the reason is other than workmanship).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">10.</TD><TD STYLE="text-align: justify"><B><U>Express Limited Warranty</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">For the purpose of this Agreement,
&ldquo;Warranty Period&rdquo; shall mean twelve (12) months as of the date of delivery to Customer. Contractor represents and warrants
that, for the Warranty Period, the Products (i) will be free from defects in workmanship, material (only to the same extent as
the original manufacturer of the material warrants the Contractor), and manufacture; (ii) will comply the Specifications IPC610.B
standard (in all material respects and unless otherwise was instructed by Customer). Contractor further represents and warrants
that the Product will consist of new materials. The warranty provided in this Section shall not apply to (1) Customer&rsquo;s materials,
tooling and equipment (2) Products modified by Customer or any third party without Contractor&rsquo;s prior written consent, (2) Products
installed or operated by Customer or any third party in a manner inconsistent with the Specifications or the terms and conditions
of this Agreement, or (3) Products damaged, abused, altered or misused by Customer or any third party, or as the result of fire,
casualty, or other external cause (4) defects resulting directly or indirectly, wholly or partially, from Customer&rsquo;s Specifications
or the design of the Products, (5) First articles, prototypes, pre-production units, test units or other similar Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">Upon any failure of a Product to
comply with the above warranty, Contractor&rsquo;s sole obligation, and Customer&rsquo;s sole remedy, is for Contractor, at its option, to
promptly repair or replace such Product and return it to Customer freight prepaid. Customer shall return Products covered by the
warranty freight prepaid after completing a failure report and obtaining a return material authorization number from Contractor
to be displayed on the shipping container. Customer shall bear all risks, costs and expenses, associated with Products that have
been returned to Contractor for which there is no defect found and/or with Products not covered under the warranty above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.7pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">Customer will not pass through to
end users or other third parties the warranties made by Contractor under this Agreement. Furthermore, Customer will not make any
representations to end users or other third parties on behalf of Contractor, and Customer will expressly indicate that the end
users and third parties must look solely to Customer in connection with any problems, warranty claim or other matters concerning
the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">EXCEPT AS SPECIFICALLY SET FORTH
HEREIN, CONTRACTOR MAKES NO OTHER WARRANTIES OR CONDITIONS ON THE PRODUCTS, EXPRESS, IMPLIED, STATUTORY, OR IN ANY OTHER PROVISION
OF THIS AGREEMENT OR COMMUNICATION WITH CUSTOMER, AND CONTRACTOR SPECIFICALLY DISCLAIMS ANY IMPLIED WARRANTY OR CONDITION OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">11.</TD><TD STYLE="text-align: justify"><B><U>Engineering Changes</U></B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">11.1</TD><TD STYLE="text-align: justify">Customer may, upon advance written notice to Contractor,
submit engineering changes for incorporation into the Products. Contractor will review the engineering change and report to Customer
within two (2) working days of any implications of the proposed changes. The report should include all possible implications on
materials, delivery schedule, manufacturing process, quality and product cost and shall also quote the Contractors costs for implementing
the changes.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">Customer and Contractor will agree on all aspects
of implications and shall accordingly make revisions in outstanding Purchase Orders &ndash; if requested by Customer and subject to Contractor&rsquo;s
consent in writing.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">11.2</TD><TD STYLE="text-align: justify">Contractor shall assure quick implementation of engineering
changes.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">12.</TD><TD STYLE="text-align: justify"><B><U>Delivery and Inspection, Title and shipping</U></B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in">12.1</TD><TD STYLE="text-align: justify">Contractor undertakes to report to Customer once (1) a week, or per Customer request, the quantity
of Products ready for delivery</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in">12.2</TD><TD STYLE="text-align: justify">Customer will notify Contractor, from time to time, quantities of Products and destinations to
which to ship the Products.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in">12.3</TD><TD STYLE="text-align: justify">If the delivery destination is within Israel, excluding port/airport (&ldquo;<B>Limited Delivery
Territory</B>&rdquo;) than the delivery shall be made by Contractor at no additional cost and to such destination of delivery Contractor
shall incur insurance transport costs. Upon delivery or the placement of an invoice by Contractor, whichever is earlier, Risk of
loss and title will pass to Customer.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in">12.4</TD><TD STYLE="text-align: justify">The price for Deliveries to other destinations outside the Limited Delivery Territory, including
for export will be agreed by the parties. All risk of loss, responsibility and cost shall be borne by the Customer Ex-Factory.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in">12.5</TD><TD STYLE="text-align: justify">To each delivery, Contractor shall include all required documentation (e.g. bill of lading, QA/QC
certificate). Upon delivery to Customer, Customer will sign the bill of lading. Such signature shall only be deemed as acknowledgement
of receipt of the delivery and not confirmation as to the delivered Products&rsquo; condition and quality.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20.7pt; text-align: justify; text-indent: -20.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">12.6</TD><TD STYLE="text-align: justify">Subject to the above limitations, the Contractor will ship
and deliver the Products according to Customer&rsquo;s instructions in the best and safest means of transportation, to the extent
commercially reasonable.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">13.</TD><TD STYLE="text-align: justify"><B><U>Price and Price Reviews</U></B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in">13.1</TD><TD STYLE="text-align: justify">Pricing conditions for manufacturing services supplied under this Agreement are defined in <B><U>Appendix
C.</U></B> All prices will be quoted in US Dollars.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in">13.2</TD><TD STYLE="text-align: justify"><B><U>Price Review</U></B>. Contractor and Customer will meet every three (3) months, during the
term of this Agreement to review pricing and determine the actions required by both sides in order to achieve cost reduction. The
new prices that will be agreed to and the said new prices will come into effect, will be reflected in the Purchase Orders submitted
after such review.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">13.3</TD><TD STYLE="text-align: justify">It is agreed that, for the sake of facilitating uninterrupted
manufacturing, Contractor may purchase materials for Customer&rsquo;s Products at prices higher than those agreed to with the
following limitations:</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.5in; text-align: left">13.3.1</TD><TD STYLE="text-align: justify">For price change which has a cost impact less than US $200,
based on one (1) quarter consumption will not require prior authorization from Customer. Contractor will be obliged to submit
comprehensive written report to Customer, subsequent to such event.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.5in">13.3.2</TD><TD STYLE="text-align: justify">For price change which has cost impact greater than US $200, based on one (1) quarter consumption
will require prior written authorization from Customer.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.5in">13.3.3</TD><TD STYLE="text-align: justify">Customer shall answer urgent requests for approvals for price change, within three (3) working
days.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.5in">13.3.4</TD><TD STYLE="text-align: justify">Maintain Credit Line. Customer agrees to provide all necessary financial information required by
Contractor from time to time and as available to Customer in order to make a proper assessment of the creditworthiness of Customer.
That includes full annually audited financials statements and, subjected the credit limit analysis request, Quarterly financial
statements (P&amp;L, BS and Cash Flow statements). Contractor will, in good faith, review Customer&rsquo;s creditworthiness periodically
and may provide more favorable terms once it feels it is prudent to do so.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.5in">13.3.5</TD><TD STYLE="text-align: justify">Upon Contractor&rsquo;s request at any time during the term of this Agreement, Customer shall obtain
and maintain appropriate securities, such as letter of credit, escrow account, bank guarantees and /or pre-payments in an amount
equal to the total value of all risks associated with the performance of any of the services under this Agreement, on an aggregate
basis.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.3pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">14.</TD><TD STYLE="text-align: justify"><B><U>Terms of Payments</U></B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">14.1</TD><TD STYLE="text-align: justify">Contractor will invoice Customer per each delivery or as
provided in Sections 6 and 8 hereinabove. The invoice shall include all purchase order details. The invoice will be quoted in
US Dollars.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">14.2</TD><TD STYLE="text-align: justify">Contractor and Customer agree to terms of payments of current
plus thirty (30) days from the date of invoice. Payment shall be affected in US Dollars.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">15.</TD><TD STYLE="text-align: justify"><B><U>Termination</U></B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">15.1</TD><TD STYLE="text-align: justify"><U>Termination for cause</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify">If either party fails to meet anyone
or more of the terms and conditions as stated in either this Agreement or the Appendices, Contractor and Customer agree to negotiate
in good faith to resolve such default. If the defaulting party fails to cure such default or submit an acceptable written plan
to resolve such default within thirty (30) days following notice of default, the non-defaulting party shall have the right to terminate
this Agreement by furnishing the defaulting party with sixty (60) days written notice of termination.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">15.2</TD><TD STYLE="text-align: justify"><U>Termination without cause</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify">Notwithstanding anything to the
contrary stated in this Agreement, either party may terminate this Agreement at any time without cause by giving to the other party,
not less than four (4) months written notice.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">15.3</TD><TD STYLE="text-align: justify">A Party may immediately terminate this Agreement should
the other party:</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">become insolvent;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">enter into or filing a petition, arraignment or proceeding seeking an order for relief under the
bankruptcy/insolvency laws of its respective jurisdiction;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">enter into a receivership of any of its assets; or</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.5in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">enter into a dissolution of liquidation of its assets or
an assignment for the benefit of its creditors.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">16.</TD><TD STYLE="text-align: justify"><B><U>Effect of Termination</U></B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">16.1</TD><TD STYLE="text-align: justify">in the case of termination, unless otherwise stipulated and subject to Customer fulfillments
                                                                               of all its payments obligations under this Agreement, Contractor will deliver all Products, materials to Customer and
                                                                               Customer will pay all amounts due under this Agreement, for all Products, materials mentioned on a Purchase Order or Change
                                                                               Order accepted by Contractor before expiration or termination date.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">16.2</TD><TD STYLE="text-align: justify">Except where the termination is a result of Contractor&rsquo;s
material default Customer agrees to compensate Contractor for Products and materials as stipulated in Sections 6 and 8 of this
Agreement.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">16.3</TD><TD STYLE="text-align: justify">Each party will promptly return to the other party, all.
technical documentation (e.g. drawings, work instructions, data and design sheets) and/or Confidential Documents related to the
present Agreement</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">16.4</TD><TD STYLE="text-align: justify">Subject to Customer fulfillments of all its obligations
under this Agreement, Contractor will return to customer all consigned materials, equipment and tooling stipulated in section
7.5 of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">17.</TD><TD STYLE="text-align: justify"><B><U>Dispute Resolutions</U></B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">17.1</TD><TD STYLE="text-align: justify">In the spirit of continued cooperation, the parties intend
to and hereby establish the following dispute resolution procedure to be utilized in the unlikely event any controversy should
arise out of or concerning the performance of this Agreement.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">17.2</TD><TD STYLE="text-align: justify">It is the intent
                                         of the parties that any dispute be resolved informally and promptly through good faith
                                         negotiations between Contractor and Customer. Either party may initiate negotiation proceedings
                                         by written notice to the other party setting forth the particulars of the dispute. The
                                         parties agree to meet in good faith to jointly define the scope and method to remedy
                                         the dispute. If these proceedings are not productive of <FONT STYLE="font-weight: normal; font-style: normal">a
                                         re</FONT>solution, then senior management of Contractor and Customer are authorized to
                                         and will meet personally to confer in a bona fide attempt to resolve the matter.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">17.3</TD><TD STYLE="text-align: justify">Should the foregoing procedure not bring a mutually satisfactory
solution within 30 days, each party will be free to proceed according to applicable law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">18.</TD><TD STYLE="text-align: justify"><B><U>Limitation of Liability</U></B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">18.1</TD><TD STYLE="text-align: justify">Customer shall
                                         defend, indemnify and hold harmless Contractor from all claims, liabilities, costs, damages,
                                         judgments and attorney&rsquo;s fees resulting from or arising out of any alleged and/or
                                         actual infringement or other violation of any patents, patent rights, trademarks, trademark
                                         rights, trade names, trade name rights, copyrights, trade secrets, proprietary rights
                                         and processes or other such rights elated to the Product or claims relating to Customer&rsquo;s
                                         instructions, tooling, specifications and designs (&ldquo;<B>Claims</B>&rdquo;) provided
                                         that: (i) Contractor will provide the Customer with prompt written notice of any Claim
                                         no later than three (3) business days following receipt of notice by Contractor; (ii)
                                         Contractor will grant Customer sole control of the defense and settlement of Claims,
                                         taking into account any reasonable request of Contractor; and (iii) Contractor will provide
                                         Customer with reasonable assistance, at Customer&rsquo;s sole expense. Customer assumes
                                         no liability for any Claims made by any third party to the extent that such Claims result
                                         from the use of specifications other than the Specification, unaltered by Contractor
                                         or anyone on its behalf. If such Claim is brought, or Customer in good faith determines
                                         a Claim is likely to be made, Customer shall notify Contractor and either: (1) procure
                                         for Contractor the right to continue to perform this Agreement; (2) modify the Specification
                                         so that there will no longer be an infringement or misappropriation or (3) terminate
                                         this Agreement and pay Contractor the consideration due under this Agreement for all
                                         services performed until the date of termination, including all payments set forth in
                                         Sections 6 and 8.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">18.2</TD><TD STYLE="text-align: justify">Contractor shall defend, indemnify and hold harmless Customer
from all claims, liabilities, costs, damages, judgments and attorney&rsquo;s fees resulting from or arising out of any alleged
and/or actual infringement or other violation of any patents, patent rights, trademarks, trademark rights, trade names, trade
name rights, copyrights, trade secrets, proprietary rights and processes or other such rights as a result of the manufacturing
methods employed by Contractor but excluding Claims as defined above) (&ldquo;<B>Manufacturing Claims</B>&rdquo;) provided that:
(i) Customer will provide Contractor with prompt written notice of any Manufacturing Claim no later than three (3) business days
following receipt of notice by Customer; (ii) Customer will grant Contractor sole control of the defense and settlement of Manufacturing
Claims, taking into account any reasonable request of Customer; and (iii) Customer will provide Contractor with reasonable assistance,
at Contractor sole expense. If a Manufacturing Claim is brought, or Contractor in good faith determines a Manufacturing Claim
is likely to be made, Contractor shall notify Customer and either: (1) procure for Customer the right to continue to perform this
Agreement; (2) modify its manufacturing methods so that there will no longer be an infringement or misappropriation or (3) terminate
this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify; text-indent: -20pt">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">18.3</TD><TD STYLE="text-align: justify">THE FOREGOING STATES THE ENTIRE LIABILITY OF THE PARTIES
TO EACH OTHER CONCERNING INFRINGEMENT OF PATENT, COPYRIGHT, TRADE SECRET OR OTHER INTELLECTUAL PROPERTY RIGHTS.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">18.4</TD><TD STYLE="text-align: justify"><U>No Other Liability</U>. IN NO EVENT SHALL EITHER PARTY
BE LIABLE TO THE OTHER FOR ANY INCIDENTAL, CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES OF ANY KIND OR NATURE ARISING OUT OF THIS
AGREEMENT OR THE SALE OF PRODUCTS, WHETHER SUCH LIABILITY IS ASSERTED ON THE BASIS OF CONTRACT, TORT (INCLUDING THE POSSIBILITY
OF NEGLIGENCE OR STRICT LIABILITY), OR OTHERWISE, EVEN IF THE PARTY HAS BEEN WARNED OF THE POSSIBILITY OF ANY SUCH LOSS OR DAMAGE.
AND EVEN IF ANY OF THE LIMITED REMEDIES IN THIS AGREEMENT FAIL OF THEIR ESSENTIAL PURPOSE. IN ADDITION, NOTWITHSTANDING ANYTHING
TO THE CONTRARY HEREIN OR OTHERWISE, THE PARTIES ACKNOWLEDGE THAT AS AN ELECTRONIC MANUFACTURING SERVICES PROVIDER WORKING ON
A COST PLUS BASIS SUPPLIER MUST LIMIT ITS LIABILITY IN CONNECTION HEREWITH AND THEREFORE, CONTRACTOR&rsquo;S LIABILITY IS FURTHER
LIMITED IN ANY EVENT, UNDER ANY LAW, RULE OR REGULATION, TO ANY AMOUNT IT ACTUALLY RECEIVED IN CONSIDERATION OF THE MANUFACTURING
SUBJECT MATTER OF THE RESPECTIVE CLAIM OR DEMAND BY CUSTOMER OR ANY THIRD PARTY.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">19.</TD><TD STYLE="text-align: justify"><B><U>Confidentiality</U></B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left"></TD><TD STYLE="text-align: justify">Customer&rsquo;s product and designs contain certain elements
that are proprietary to Customer. Furthermore, in the course of this agreement, technical and commercial information of the Customer
may be revealed or become known to the Contractor. Contractor shall keep in confidence all information relating to the foregoing,
shall not use any part of it for any purpose except the performance of this Agreement or in connection therewith, and shall not
enable any third party to use ft without the prior written consent of Customer or unless such information becomes public domain.
Contractor shall ensure that all employees who directly participate in any of the services performed under this Agreement and
may accordingly receive certain confidential information of the Customer are subject to similar non-disclosure and non-use undertakings
and are made aware of the proprietary and confidential nature of the information.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify">The provisions of this Section 19
shall survive termination or expiration of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">20.</TD><TD STYLE="text-align: justify"><B><U>Non-Competition</U></B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">20.1</TD><TD STYLE="text-align: justify">The Contractor and the Customer will not be allowed to
employ employees of the other party, directly or indirectly, for one (1) year from the date the employee has ceased to be employed
by the other party. The above mentioned restriction may be waived by either party provided that it is done by a written and specific
consent.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.85pt; text-align: justify; text-indent: -22.85pt">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">20.2</TD><TD STYLE="text-align: justify">During the Term, of this Agreement and for an additional
period of two (2) years from the date of termination of this Agreement, the Contractor undertakes not to develop on its own account
any Product.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">21.</TD><TD STYLE="text-align: justify"><B><U>General</U></B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">21.1</TD><TD STYLE="text-align: justify">Force Majeur. Neither party shall be liable for any failure
or delay in its performance under this Agreement due to acts of God, acts of civil or military authority, fires, floods, earthquakes,
riots, wars, sabotage, labor disputes, material unavailability due to unwarranted production stoppage by supplier or any other
cause beyond the reasonable control of the delayed party provided that the delayed party, (i) gives the other party written notice
of such cause, and (ii) uses its reasonable efforts to remedy such delay in its performance.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">22.2</TD><TD STYLE="text-align: justify">Severability. If any provision of this Agreement is held
by a court of competent jurisdiction to be unenforceable, such provision shall be deemed null and void, and the remainder of the
Agreement shall continue to be in full force and effect, while the parties shall negotiate in good faith to replace the provision
with another enforceable one reflecting as closely as possible the parties initial intention.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">22.3</TD><TD STYLE="text-align: justify">Relationship of the Parties. Each of the parties shall
at all times during the term of this Agreement act as, and shall represent itself to be, an independent contractor. Neither Party
shall have any right or authority to assume or create any obligations or to make any representations or warranties on behalf of
the other parry whether express or implied, or to bind the other party in a respect whatsoever.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">22.4</TD><TD STYLE="text-align: justify">Governing Law. The construction, interpretation and performance
of this Agreement and all transactions under it shall be governed by the law of the State of Israel, without giving effect to
choice of law rules, and both Parties consent to jurisdiction by the courts of the City of Haifa.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">22.5</TD><TD STYLE="text-align: justify">Choice of Language. The original of this Agreement has
been written in English. Any notices provided by any party as required by this Agreement shall be written in the English language.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">22.6</TD><TD STYLE="text-align: justify">Notifications. Any and all notices and other communications
whatsoever under this Agreement shall be in writing, sent by registered mail or by, email or facsimile to the address set forth
above. Notices sent via registered mail shall be deemed to have been delivered within 3 business days after the date posted. With
regards to the normal course of business, notices sent via email or facsimile shall be deemed to have been received 1 business
day following the date of transmission.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">22.7</TD><TD STYLE="text-align: justify">Entire Agreement. No amendment of this Agreement will be
valid unless made in writing signed by a duly authorized representative of both parties. No provision of this Agreement will be
deemed waived and breach or default excused unless the waiver or excuse is in writing and signed by the party issuing it. The
terms and conditions contained in this Agreement terminate and supersede all prior oral or written understanding between the parties
and shall constitute the entire agreement between them concerning the subject matter of this Agreement.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">22.8</TD><TD STYLE="text-align: justify">This Agreement may be executed in one or more counterparts,
each of which will be deemed the original, but all of which will constitute but one and the same document.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify">The parties agree that this Agreement and its
appendices may not be modified except in writing, signed by both parties.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">22.9</TD><TD STYLE="text-align: justify">Set-off. Amounts due hereunder may not be set off except
with mutual prior written consent.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">22.10</TD><TD STYLE="text-align: justify">Insurance. Customer specifically agrees to maintain insurance
coverage for any finished Products or materials which passes to Customer pursuant to this Agreement and which is stored on the
premises of Contractor.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left">22.11</TD><TD STYLE="text-align: justify">Successors, Assignment. This Agreement shall be binding
upon and inure to the benefit of the Parties hereto and their respective permitted successors, permitted assigns and legal representatives.
Neither Party shall have the right to assign or otherwise transfer its rights or obligations under this Agreement except with
the prior written consent of the other Party, not to be unreasonably withheld or delayed. Notwithstanding the foregoing, Contractor
shall be entitled to assign its rights to be paid hereunder to banks or first tier financial institutions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.85pt; text-align: justify; text-indent: -22.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>In Witness whereof, the Parties have caused
this Agreement to be duly executed for and on behalf of:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><B></B></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><B>Flextronics (Israel) Ltd.</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><B>INVASIX LTD 514073618</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-variant: normal"><B><U>Contractor</U></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-variant: normal"><B><U>Customer</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 35%">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal">Date: </FONT></TD>
    <TD STYLE="text-align: justify"></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal">Date: </FONT></TD>
    <TD STYLE="text-align: justify"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal">Name: </FONT></TD>
    <TD STYLE="text-align: justify"> </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal">Name: </FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">MOSHE MIZRAHY</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal">Title: </FONT></TD>
    <TD STYLE="text-align: justify"></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal">Title: </FONT></TD>
    <TD STYLE="text-align: justify">CEO</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal">Signature:</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid"><IMG SRC="tv498959_ex10-9img1.jpg" ALT=""></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal">Signature:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; vertical-align: bottom">/s/ Moshe Mizrahy</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>8
<FILENAME>filename8.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-style: normal; font-variant: normal"><B>Exhibit
10.10</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-style: normal; font-variant: normal"><B>TUNRKEY
MANUFACTURING AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">This
agreement is effective as of the November 7, 2013 (the Effective Date) by and between: </FONT><FONT STYLE="font-style: normal; font-variant: normal"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B>INVASIX
Ltd., </B><FONT STYLE="font-weight: normal">with a principal place of business at Tavor building, POB 533, Yokneam, Israel, Hereinafter
referred to as </FONT><B>&ldquo;Customer&rdquo;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">And</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.1pt; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B>STI
Laser Industries Ltd., </B><FONT STYLE="font-weight: normal">with a principal place of business at Industrial Zone Or Aqiva 3065001
P.O.B. 34, Israel</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.1pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.1pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Hereinafter
referred to as </FONT><FONT STYLE="font-style: normal; font-variant: normal"><B>&ldquo;Contractor&rdquo;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.1pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Whereas</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Customer
designs, manufactures and sells a medical device for use in the area of liposuction which includes subassemblies, components and
know-how that is confidential and proprietary property of Customer; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Whereas</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Customer
desires to buy manufacturing services; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Whereas</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
is in the business of manufacturing and assemblies; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Whereas</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
declares that it has an approved enterprise status for the manufacturing and assembly of medical devices, and it has no knowledge
of circumstances that should bring to the termination of such status; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-variant: normal">Whereas</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal">Contractor declares
that it has all the capabilities and equipment to supply manufacturing services for Customer&rsquo;s Products stipulated in <B><U>Appendix
A</U></B> attached hereto; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Whereas</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
desires to supply its manufacturing services to Customer and use in accordance with Customer specifications and standards as well
as other general commercial practices.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.45pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Now
therefore, the Parties hereto have agreed and do hereby agree as follows: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.45pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.45pt; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>1.
Precedence</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">The
terms and conditions and appendices herein shall govern all services performed by Contractor pertaining to the subject matter.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.1pt; text-align: justify; text-indent: -25.9pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">It
is the intent of the Parties that this Agreement and its appendices represent the entire agreement and prevail over the terms
and conditions of any purchase order, acknowledgment form or order instruction.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><P STYLE="margin: 0">Turnkey Agreement November 2013</P></TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal"><B><U>2.
Term</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">This
Agreement shall commence on the Effective Date and shall continue for an initial term until December 2014. This Agreement shall
automatically be renewed for successive one (1) year increments unless either Party requests in writing, at least ninety (90) days
prior to the anniversary date, that this Agreement not to be renewed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal"><B><U>3.
Scope of Work</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
will pursuant to the specifications given by Customer, perform manufacturing services on behalf of Customer on a turnkey basis.
These manufacturing services shall include, but not be limited to, labor, materials, testing, packaging and delivery to Customer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal"><B><U>4. </U></B></FONT><B><U>Contractor&rsquo;s
Obligations</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29.15pt; text-align: justify; text-indent: -0.4in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Except
as otherwise expressly provided for in this Agreement, Contractor shall furnish all of the personnel, equipment (except for dedicated
equipment as listed in Clause 5 below) and any other items that are necessary or appropriate to perform the Work, and will bear
all costs and expenses involved in the maintenance, repair and operation of the Equipment and the performance of the Work. The
Personnel shall be trained and efficient and qualified to perform the Work and the Equipment shall be adequate, serviceable and
maintained in first-class operating condition, to the extent applicable. Contractor shall also, as part of the Work, apply for
and obtain all governmental permits and approvals required for the Work.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29.15pt; text-align: justify; text-indent: -0.4in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">4.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
shall provide Customer among other with the following services, based on Customers written supplied procedures:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29.15pt; text-align: justify; text-indent: -0.4in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: left; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">-&nbsp;&nbsp;&nbsp;Material
planning</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: left; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: left; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">-&nbsp;&nbsp;&nbsp;Material
procurement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: left; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: left; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">-&nbsp;&nbsp;&nbsp;Manufacturing
quality records</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: left; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: left; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">-&nbsp;&nbsp;&nbsp;Final
assembly and integration of the Product</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: left; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: left; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">-&nbsp;&nbsp;&nbsp;In
circuit test</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: left; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: left; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">-&nbsp;&nbsp;&nbsp;Functional
test</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: left; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: left; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">-&nbsp;&nbsp;&nbsp;Packaging
and delivery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><P STYLE="margin: 0">Turnkey Agreement November 2013</P></TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">4.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor&rsquo;s
production facilities</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
will be obliged to allocate to Customer, production and storage space as well as trained production and testing personnel as an
integral part of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
shall have the EN IS013485 standard for the production facility. During the term of this agreement, the manufacturing services
provided by the Contractor hereto shall confirm in all respects with the EN ISO13485 standard.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>5.
Customer&rsquo;s obligations</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Customer
will provide the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">-&nbsp;&nbsp;Dedicated
Equipment according to the Customer&rsquo;s assembly instructions (Annex I)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Whereas
the Contractor shall be responsible for the routine maintenance of Customer&rsquo;s dedicated equipment (as listed in Annex I), the Customer
shall bear all expenses required for annual calibration on a cost + 20% basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">All
necessary equipment validations (related to Dedicated Equipment) shall be solely under Customer&rsquo;s responsibility. Contractor will
support such activities as may be requested by Customer but Customer shall bear the responsibility and all related expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">-&nbsp;&nbsp;Technical
specifications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">-&nbsp;&nbsp;Standard
Operation Procedures</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">-&nbsp;&nbsp;Drawings</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">-&nbsp;&nbsp;Bill
of Materials</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">-&nbsp;&nbsp;Approved
Vendors list</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">-&nbsp;&nbsp;Gerber
data, CAD files</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">-&nbsp;&nbsp;Quality
requirements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">-&nbsp;&nbsp;All
external laboratory tests related to product/process validation shall be carried out by the Customer at his own responsibility.
In cases where the Contractor shall be requested to manage such external tests, the Customer shall bear all expenses based on cost
+ 20%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">-&nbsp;&nbsp;Technical
support, as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><P STYLE="margin: 0">Turnkey Agreement November 2013</P></TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>6.
Material Procurement </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">The
material procurement undertaking, pursuant to this Agreement, will be carried-out by the Contractor. The Contractor carries full
responsibility to the material procurement. The Customer will advance 50% of the total value of the manufacturing of the first
2000 units (according to an average price of US$70 per unit) from the Effective Day to finance material procurement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.1pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">6.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
is authorized to purchase materials using standard purchasing practices including, but not limited to acquisition of materials
recognizing Economic Order Quantity, HSN buy policy and long lead time components management, in order to meet the requirements
of Customer&rsquo;s orders and forecasts.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.1pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">6.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal"><U>Economic Order Quantity</U>
(&ldquo;EOQ&rdquo;) for items which are un-returnable to vendor or unusable for other clients of the Contractor must be pre-approved
by Customer. For such pre-approved EOQ&rsquo;s, Customer shall advance to the Contractor sums on account of future deliveries equal to
125% of the cost attributed to the quantity ordered&rsquo; exceeding the 3 months forecast and FGI&rsquo;s finish goods inventory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">6.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal"><U>Long
Lead Items</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">In
order to manage demand fluctuations Contractor shall suggest from time to time a list of LLI&rsquo;s to be approved by the Customer,
based on Customer&rsquo;s forecast submitted in writing. Contractor shall maintain in inventory certain quantities of LLI. &ldquo;LLI&rdquo;
shall mean Long Lead Item materials required in order to complete manufacture and supply of Products. For the avoidance of doubt
Customer shall have no additional liability with respect to the holding of LLI other than the liability provided herein below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">The
usage of LLI by Contractor for the manufacture of Products shall be by a written order by Customer in accordance with this Agreement,
stipulating the quantity Customer wishes Contractor to use. If Contractor holds LLIs based on any written requirement for more
than six (6) months after the last shipment of any Product to Customer, Customer shall be required to purchase such LLIs at 125%
of part cost (in case no work done). The purchase terms of such LLI&rsquo;s, are similar to those set forth in Section 8.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.1pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">6.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
is responsible for monitoring suppliers&rsquo; quality according to the specifications provided by Customer for all purchased
materials.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.1pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">6.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Subject
to section 15 hereto, in the event of termination of this Agreement or a cancellation of a Purchase Order, and/or discontinuance
of a Product, or excess materials created by an Engineering Change, Customer agrees to compensate Contractor for unused material
inventory which are affected by such termination, cancellation or discontinuance, as follows:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><P STYLE="margin: 0">Turnkey Agreement November 2013</P></TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">(i)
The cost+25% of material inventory, whether in raw form or work in process, which are not returnable to the vendor or usable for
other Contractor&rsquo;s customers, including economic order quantities of unique parts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">(ii)
The cost+25% of materials on order which cannot be cancelled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">(iii)
Payment shall be made to Contractor against delivery of the compensated materials to Customer. The above compensation shall be
the sole compensation due to Contractor as a result thereof. The compensation for finished Products is as set out in Section 8.2
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.7pt; text-align: justify; text-indent: -27.7pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">6.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
shall undertake all possible efforts to cancel all applicable materials purchase orders and reduce materials inventory through
return for credit programs or allocate materials for alternate programs, if applicable.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.7pt; text-align: justify; text-indent: -27.7pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">6.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Notwithstanding
anything to the contrary herein customer shall be initial whenever it is obligated to pay for inventory to contractor, according
to part 6 to make an advance in the same amount, on account of such inventory with advanced shell be nonrefundable except to extend
to such inventory is consume in manufacturing of products for customer here after.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>7.
Forecasts</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -28.1pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">7.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Customer shall
                                                                                                                                                                 issue to Contractor, on a monthly basis, a five (5) month rolling forecast setting forth projected demand for Product
                                                                                                                                                                 Products. In the event that the forecast will be delivered after the 15th day of the calendar month, then Customer will
                                                                                                                                                                 provide Contractor with a six (6) month rolling forecast (the &ldquo;Forecast&rdquo;).</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29.15pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
shall undertake all reasonable efforts, including expediting materials and allocating capacity, in order to support Customer&rsquo;s
request for increased production.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -28.1pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">7.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
will supply all orders that do not exceed the forecast at the delivery times set forth in each purchase order. Late deliveries
will carry (without prejudice) a late delivery charge at the rate of 0.25% per week for the first 14 days, 0.5% for per week thereafter
and not more than 2.5%, to be deducted from the consideration due to the Contractor for labor and mark-ups. To dispel any doubt
late deliveries will carry a late delivery charge only if the cause of such late deliveries is due to Contractor negligence.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -28.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><P STYLE="margin: 0">Turnkey Agreement November 2013</P></TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">7.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal"><U>Customer
tooling, etc.</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.1pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">All
Customers&rsquo; materials, tooling and equipment furnished to Contractor or paid for by Customer in connection with this Agreement and
all paid for Products shall:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.35in; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Be
clearly marked and remain the Customer&rsquo;s property.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.1pt; text-indent: 0in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.35in; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Be
kept free of liens and encumbrances.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.1pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.35in; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
is responsible for the maintenance of the tooling and equipment.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.1pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;<BR>
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>8.
Customer Liability for Forecasts</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify; text-indent: -28.1pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">8.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Customer&rsquo;s
liability with respect to any and all demand signals provided by Customer, including but not limited to &ldquo;purchase orders&rdquo;
&ldquo;forecasts&rdquo; &ldquo;schedules&rdquo; &ldquo;pick lists&rdquo; with respect to any Products manufactured, produced,
procured, stored or delivered by Contractor, including, but not limited to, any direct or indirect costs related thereto or related
to components, work in progress and/or raw materials shall be limited to the amounts set forth in this Section 8 with respect
to finished Products and in Section 6 concerning components, work in progress and/or raw materials.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>9.
Quality</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">9.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
shall permit Customer to audit its quality procedures, upon three (3) working days advance notice to Contractor and shall provide
all assistance which is reasonably necessary for Customer to evaluate the quality of the Products.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -0.4in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">9.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
shall maintain quality assurance standards in accordance with EN ISO 13488. Contractor&rsquo;s Quality Assurance, Control and
Inspection shall be in full compliance with EN ISO 13485 standards during the Terms of this Agreement.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -0.4in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">9.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">If
a product did not pass Customer&rsquo;s Test Process then Contractor will perform two rounds of repairs on the Product, if after
such two rounds the Product still did not pass the ATP then Contractor will send the Product with a qualified personnel to Customer
for repair.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -0.4in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">9.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">In
case of vigilance and recall STI will allow audits of Notified Body when deemed necessary.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -0.4in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">9.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
shall establish internal instruction / procedures that conform to Customer Quality System.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.15pt"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><P STYLE="margin: 0">Turnkey Agreement November 2013</P></TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>10.
Warranty</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">For
the purpose of this Agreement, &ldquo;Warranty Period&rdquo; shall mean twelve (12) months as of the date of delivery to Customer.
Contractor represents and warrants that, for the Warranty Period, the Products (i) will be free from defects in workmanship, material
(to the same extent as the original manufacturer of the material warrants the Contractor), and manufacture; (ii) will comply with
the requirements of this Agreement, including all Specifications; and (iii) all services performed in connection with this Agreement
will be performed in a competent, professional and workmanlike manner, free from defects. Contractor further represents and warrants
that the Products will consist of new (not used or recycled) material, and the warranty pro<U STYLE="text-decoration: none">vide</U>d in this Section shall not
apply to any Products that are (1) modified by Customer or any third party without Contractor&rsquo;s written consent, (2) installed
or operated by Customer or any third party in a manner inconsistent with the Specifications or the terms and conditions of this
Agreement, or (3) damaged as the result of any negligence or misuse by Customer or any third party, or as the result of fire, casualty,
or other external cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.45pt"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal"><B><U>11.
Engineering Changes</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">11.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Customer
may, upon advance written notice to Contractor, submit engineering changes for incorporation into the Products. Contractor will
make all efforts to review the engineering change and report to Customer within seven (7) working days of any implications of
the proposed changes. The report should include all possible implications on materials, delivery schedule, manufacturing process,
quality and product cost and shall also quote the Contractors costs for implementing the changes.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29.5pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Customer
and Contractor will agree on all aspects of implications and shall accordingly make revisions in outstanding Purchase Orders -
if requested by Customer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">11.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
shall undertake all efforts to assure quick implementation of engineering changes.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal"><B><U>12.
Delivery and Inspection. Title and Shipping</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.25pt; text-align: justify; text-indent: -27.7pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">12.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
undertakes to report to Customer once (1) a week, or per Customer request, the quantity of Products ready for delivery.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.25pt; text-align: justify; text-indent: -27.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal"><B><U>13.
Price and Price Reviews</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.25pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">13.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Pricing
conditions for manufacturing services supplied under this Agreement are defined in Appendix B. All prices will be quoted in US
Dollars.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.25pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">13.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal"><U>Price
Review</U>: Contractor and Customer will meet every three (3) months, during the term of this Agreement to review pricing and
determine the actions required by both sides in order to achieve cost reduction. The new prices that will be agreed to and the
said new prices that will come into effect will be reflected in the Purchase Orders submitted after such review.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.35pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><P STYLE="margin: 0">Turnkey Agreement November 2013</P></TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">13.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">It
is agreed that, for the sake of facilitating uninterrupted manufacturing, Contractor may purchase materials for Customer&rsquo;s
products at prices higher than those agreed to with the following limitations:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.2pt; text-align: justify; text-indent: -42.5pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.35in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">13.3.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">For
price change which has a cost impact less than US$200, based on one (1) quarter consumption will not require prior authorization
from Customer. Contractor will be obliged to submit comprehensive written report to Customer, subsequent to such event.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.55pt; text-align: justify; text-indent: -41.75pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">13.3.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">For price change which
has cost impact greater than US$200, based on one (1) quarter consumption will require prior written authorization from Customer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.55pt; text-align: justify; text-indent: -41.75pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">13.3.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Customer shall answer
urgent requests for approvals for price change, within three (3) working days.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>14.
Terms of Payments</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -27.7pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">14.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
will invoice Customer per each delivery. The invoice shall include all purchase order details. The invoice will be quoted in US
Dollars. Total invoice amount will be converted to NIS according to official exchange rate published by official authority in
Israel pursuant to clause 14.3.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Each
invoice will be added by official VAT rate according to tax laws of state of Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -27.7pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">14.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor and Customer
agree to terms of payments of current plus thirty (30) days from the date of invoice.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -27.7pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">14.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Prices will be in US$,
in any event, the exchange rate would be not less than 3.8 shekels to one US$ for 50% of the total Invoice, whereas the remaining
50% will be based on published official representative exchange rate.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -27.7pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">14.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">The Customer shall
forward to the Contractor a lump sum as an advanced payment equivalent to 50% of the payment due for the first 2000 units for financing
initial raw material purchasing. In case of increasing purchase orders the customer will pay advance payment of 50% from total
price of increased items for three (3) months.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -27.7pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">14.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Delay of payment to
Contractor will bear interest according Bank Hapoalim published rate of annual exceptional interest.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><P STYLE="margin: 0">Turnkey Agreement November 2013</P></TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">14.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Delay
of payment for more than thirty (30) days will be considered breach of Agreement and cause for Termination.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal"><B><U>15.
Termination</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">15.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal"><U>Termination
for cause</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.35pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">If
either Party fails to meet any one or more of the terms and conditions as stated in either this Agreement or the Appendices, Contractor
and Customer agree to negotiate in good faith to resolve such default. If the defaulting Party fails to cure such default or submit
an acceptable written plan to resolve such default within thirty (30) days following notice of default, the non-defaulting Party
shall have the right to terminate this Agreement by furnishing the defaulting Party with sixty (60) days written notice of termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">15.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal"><U>Termination
without cause</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.7pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Notwithstanding
anything to the contrary stated in this Agreement, either Party may terminate this Agreement at any time without cause by giving
to the other party, not less than four (4) months written notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">15.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">A
Party may immediately terminate this Agreement should the other party:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.1pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.35in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">become
insolvent;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">enter into or
                                                                                                                                                     filing a petition, arraignment or proceeding seeking an order for relief under the bankruptcy/insolvency laws of its
                                                                                                                                                     respective jurisdiction; (iii) enter into a receivership of any of its assets; or, (iv) enter into a dissolution of
                                                                                                                                                     liquidation of its assets or an assignment for the benefit of its creditors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal"><B><U>16.
Effect of Termination</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">16.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">In
the case of termination and unless otherwise stipulated, Contractor will deliver all services and/or deliverables and Customer
will pay in advance and prior to delivery for all items mentioned on a Purchase Order or Change Order accepted by Contractor before
expiration or Termination date.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">16.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Except
where the termination is a result of Contractor&rsquo;s default, Customer agrees to compensate Contractor for Products and materials
as stipulated in Sections 6 and 8 of this Agreement.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">16.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Each
Party will promptly return to the other Party, all technical documentation (e.g. drawings, work instructions, data and design
sheets) and/or Confidential Documents related to the present Agreement.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.35pt; text-align: justify; text-indent: -27pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><P STYLE="margin: 0">Turnkey Agreement November 2013</P></TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">16.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Contractor
will return to customer all consigned materials, equipment and tooling stipulated in section 7.4 of this Agreement.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>17.
Dispute Resolutions</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">17.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">In the spirit of continued
cooperation, the Parties intend to and hereby establish the following dispute resolution procedure to be utilized in the unlikely
event any controversy should arise out of or concerning the performance of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">17.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">It is the intent of
the Parties that any dispute be resolved informally and promptly through good faith negotiations between Contractor and Customer.
Either Party may initiate negotiation proceedings by written notice to the other Party setting forth the particulars of the dispute.
The parties agree to meet in good faith to jointly define the scope and method to remedy the dispute, If these proceedings are
not productive of a resolution, then senior management of Contractor and Customer are authorized to and will meet personally to
confer in a bona fide attempt to resolve the matter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">17.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Should the foregoing
procedure not bring a mutually satisfactory solution within thirty (30) days, each Party will be free to proceed according to applicable
law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.1pt; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.1pt; text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>18.
Limitation of Liability</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify; text-indent: -27pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">18.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Neither Party shall
be liable to the other for any indirect, incidental, special or consequential damages resulting from this Agreement, including
but not limited to loss of profit, loss of production loss of contracts, even if either party or an authorized representative has
been advised of the possibility of such damages.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify; text-indent: -27pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">18.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Each Party (&ldquo;Defaulting
Party&rdquo;) agrees to protect, defend, indemnify and hold harmless the other Party (&ldquo;Innocent Party&rdquo;) from all sums,
costs, expenses and reasonable attorney&rsquo;s fees which the Innocent Party may incur or actually be obligated to pay as a result of
any or all claims, demands, causes of action or final judgments in favor of any third person that relate to or arise from (i) a
breach of the obligations of the Defaulting Party as set forth herein, or (ii) a tort by the Defaulting Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.25pt; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">The
Innocent Party undertakes to: (i) give the Defaulting Party prompt notice of any such claims, (ii) render reasonable assistance
to the Defaulting Party thereon, and (iii) permit the Defaulting Party to direct the defense of the settlement of such claims,
provided, that the Defaulting Party will enable the Innocent Party to be present in meetings with legal counsel to the defense
and court hearings, Settlement of claims outside of court will require the approval of the Innocent Party unless as part of the
settlement, a full waver is made in favor of such Innocent Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><P STYLE="margin: 0">Turnkey Agreement November 2013</P></TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal"><B><U>19.
Patents Copyrights and Trademarks Indemnity</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 25.55pt; text-align: justify; text-indent: -0.35in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">19.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">As part of the general
indemnification set forth in Section 18.2 above, each Defaulting Party shall defend, indemnify and hold harmless the Innocent Party
from any claims by a third party of infringement of intellectual properties resulting from the acts of the indemnifying party pursuant
to this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 25.55pt; text-align: justify; text-indent: -0.35in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">19.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">Customer&rsquo;s product
and designs contain certain elements that are proprietary to Customer. Furthermore, in the course of this agreement, technical
and commercial information of the Customer may be revealed or become known to the Contractor. Contractor shall keep in confidence
all information relating to the foregoing, shall not use any part of it for any purpose except the performance of this Agreement
and shall not enable any third party to use it, unless such information becomes public domain through no fault of the Contractor.
Contractor shall ensure that all employees privy to such proprietary and confidential information of the Customer are subject to
similar non-disclosure and non-use undertakings and are made aware of the proprietary and confidential nature of the information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.1pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: left; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">The
provisions of this clause 19.2 shall survive termination or expiration of the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal"><B><U>20.
Non-competition</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.1pt; text-align: justify; text-indent: -27.7pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">20.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">The Contractor and
the Customer will not be allowed to employ employees of the other Party, directly or indirectly, for one (1) year from the date
the employee has ceased to be employed by the other Party. The above mentioned restriction may be waived by either Parties provided
that it is done by a written and specific consent.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.1pt; text-align: justify; text-indent: -27.7pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">20.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">During the Term of
this Agreement and for an additional period of two (2) years from the date of termination of this Agreement, the Contractor undertakes
not to produce on its own account and/or render manufacturing services to another customer who&rsquo;s equipment is in the field of non-invasive
devises using light or radio frequency energy for the medical-aesthetic market.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><P STYLE="margin: 0">Turnkey Agreement November 2013</P></TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal"><B><U>21.
General</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29.5pt; text-align: justify; text-indent: -28.1pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">21.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal"><U>Force
Majeure</U>. Neither Party shall be liable for any failure or delay in its performance under this Agreement due to acts of God,
acts of civil or military authority, fires, floods, earthquakes, riots, wars, sabotage, labor disputes, material unavailability
due to unwarranted production stoppage by supplier or any other cause beyond the reasonable control of the delayed party provided
that the delayed Party, (i) gives the other Party written notice of such cause, and (ii) uses its reasonable efforts to remedy
such delay in its performance.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify; text-indent: -28.45pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">22.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal"><U>Severability</U>.
If any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable, such provision shall be deemed
null and void, and the remainder of the Agreement shall continue to be in full force and effect, while the Parties shall negotiate
in good faith to replace the provision with another enforceable one reflecting as closely as possible the Parties initial intention.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify; text-indent: -28.1pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">22.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal"><U>Relationship of
the Parties</U>. Each of the Parties shall at all times during the term of this Agreement act as, and shall represent itself to
be, an independent contractor. Neither Party shall have any right or authority to assume or create any obligations or to make any
representations or warranties on behalf of the other Party whether express or implied, or to bind the other party in any respect
whatsoever.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify; text-indent: -28.1pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">22.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal"><U>Governing Law</U>.
The construction, interpretation and performance of this Agreement and all transactions under it shall be governed by the law of
the State of Israel, and both Parties consent to jurisdiction by the courts of the City of Haifa.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify; text-indent: -28.1pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">22.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal"><U>Choice of Language</U>.
The original of this Agreement has been written in English. Any notices provided by any Party as required by this Agreement shall
be written in the English language.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify; text-indent: -28.1pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">22.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal"><U>Notifications</U>.
Any and all notices and other communications whatsoever under this Agreement shall be in writing, sent by registered mail or by
email or facsimile to the address set forth above. Notices sent via registered mail shall be deemed to have been delivered within
three (3) business days after the date posted. With regards to the normal course of business, notices sent via email or facsimile
shall be deemed to have been received one (1) business day following the date of transmission.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.45pt; text-align: justify; text-indent: -28.1pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">22.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal"><U>Entire Agreement</U>.
No amendment of this Agreement will be valid unless made in writing signed by a duly authorized representative of both Parties.
No provision of this Agreement will be deemed waived and breach or default excused unless the waiver or excuse is in writing and
signed by the Party issuing it. The terms and conditions contained in this Agreement terminate and supersede all prior oral or
written understanding between the Parties and shall constitute the entire agreement between them concerning the subject matter
of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.35pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><P STYLE="margin: 0">Turnkey Agreement November 2013</P></TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">22.8</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">This
Agreement may be executed in one or more counterparts each of which will be deemed the original, but all of which will constitute
but one and the same document. The Parties agree that this Agreement and its appendices may not be modified except in writing,
signed by both Parties.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.35pt; text-align: justify; text-indent: -27.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">In
Witness whereof, the Parties have caused this Agreement to be duly executed for and on behalf of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-variant: normal"><B><U>Contractor:</U></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-variant: normal"><B><U>Customer:</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 35%">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal">Date: </FONT></TD>
    <TD STYLE="text-align: justify">7/11/13</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal">Date: </FONT></TD>
    <TD STYLE="text-align: justify">7/3/13</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal">Name: </FONT></TD>
    <TD STYLE="text-align: justify">TOVY SIVAN</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal">Name: </FONT></TD>
    <TD STYLE="text-align: justify">MOSHE MIZRAHY</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal">Title: </FONT></TD>
    <TD STYLE="text-align: justify">CEO</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal">Title: </FONT></TD>
    <TD STYLE="text-align: justify">CEO</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal">Signature:</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">/s/ Tovy Sivan</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal">Signature:</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">/s/ Moshe Mizrahy</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><P STYLE="margin: 0">Turnkey Agreement November 2013</P></TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>9
<FILENAME>filename9.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OFFICES LEASE AGREEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">November 2015 Version</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 10%; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Chapter</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 78%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 10%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">The Preamble And Appendices</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Definitions</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">5</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">The Lease Transaction</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">9</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">The Parties Declarations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">9</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">The Area Of The Premises</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">10</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">6.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">The Purpose Of The Lease</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">11</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">7.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">The Lease Period</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">13</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">8.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Rent</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">16</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">9.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Value Added Tax</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">18</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">10.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Additional Payments</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">19</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">11.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Cancelled</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">22</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">12.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Construction Works In The Complex And In The Premises</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">22</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">13.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Deliver Of Possession And Delivery Protocol</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">28</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">14.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">The Business Activity In The Complex And In The Premises</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">30</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">15.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Managing The Complex</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">32</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">16.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Advertising</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">17.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Parking Lots And Parking Fee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">18.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Liability In Torts And Indemnification</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">19.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Insurance</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">38</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">20.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Permits</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">46</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">21.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Maintaining And Managing The Premises</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">48</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">22.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Additions And Changes</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">51</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">23.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Conveying Rights</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">52</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">24.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Relief And Remedies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">56</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">25.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Vacating The Premises</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">61</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">26.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Securities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">27.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">No Tenant Protection Rights</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">68</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">28.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Crediting Payments And No Right To Set Off</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">69</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">29.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Force Majeure</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">70</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">30.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Performing Undertaking Instead Of Other Party</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">70</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">31.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Building On The Land</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">71</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">32.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Jurisdiction</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">72</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">33.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Miscellaneous</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">72</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B>&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>UNPROTECTED LEASE CONTRACT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Executed and Signed In Herzliya on __
of February, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>By</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; text-align: left; ">&nbsp;</TD>
    <TD STYLE="width: 85%; text-align: left; "><FONT STYLE="font-size: 10pt"><B>Sha&rsquo;ar Yokneam, </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>Registered Limited Partnership Number 550014666</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt">&ldquo;Ofer Sha&rsquo;ar Yokneam&rdquo;, Hakidma 28, Yokneam</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; ">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt">(Hereinafter: <B>&quot;The Landlord&quot;)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt">Of 1 Abba Even Blvd.&nbsp;&nbsp;Herzliya</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Of the First Part;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><B>And Between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; text-align: justify; ">&nbsp;</TD>
    <TD STYLE="width: 85%; text-align: justify; "><FONT STYLE="font-size: 10pt"><B>InMode Ltd. Private Company 51-407361-8</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; ">&nbsp;</TD>
    <TD STYLE="text-align: justify; ">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; ">&nbsp;</TD>
    <TD STYLE="text-align: justify; "><FONT STYLE="font-size: 10pt">(Hereinafter: &ldquo;<B>The Tenant&rdquo;</B>)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; ">&nbsp;</TD>
    <TD STYLE="text-align: justify; "><FONT STYLE="font-size: 10pt">(After receiving possession the Tenant&rsquo;s address will also be the premises in the complex)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: right"><B><U>Of The Second Part</U></B>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; text-align: left; "><FONT STYLE="font-size: 10pt"><B>Whereas</B></FONT></TD>
    <TD STYLE="width: 80%; text-align: justify; "><FONT STYLE="font-size: 10pt">The Landlord is the owner of the rights in the complex as defined <B><U>in Appendix A</U></B> to this contract and which includes, <I>inter alia</I>, the premises as defined below;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; ">&nbsp;</TD>
    <TD STYLE="text-align: justify; ">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>And Whereas</B></FONT></TD>
    <TD STYLE="text-align: justify; "><FONT STYLE="font-size: 10pt">The Tenant is interested in leasing the premises from the Landlord pursuant to an unprotected lease and to sign, <I>inter alia</I>, the management agreement with the Management Company and the Appendices to this contract, all subject to and in accordance with all the provisions in this contract;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; text-align: justify; "><FONT STYLE="font-size: 10pt"><B>And Whereas</B></FONT></TD>
    <TD STYLE="width: 80%; text-align: justify; "><FONT STYLE="font-size: 10pt">The parties wish to define, organize and incorporate in writing their rights and obligations in connection with leasing the premises, all as detailed in this lease contract below;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Therefore, It Is Agreed, Declared
And Stipulated Between The Parties As Follows</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: left; text-indent: -35.45pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-weight: normal; text-align: left; text-indent: 0in; "><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in; "><FONT STYLE="font-size: 10pt"><B><U>PREAMBLE AND APPENDICES </U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in; ">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in; ">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal; text-align: justify; text-indent: 0in; ">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: justify; text-indent: 0in; "><FONT STYLE="font-size: 10pt">The preamble to this contract, the declarations contained herein and the Appendices to this contract, constitute an integral part of the body of the contract. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding-left: 17.05pt; font-weight: normal; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 10%; font-weight: normal; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B><U>Appendices</U></B></FONT></TD>
    <TD STYLE="width: 5%; font-weight: normal; text-align: right; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 78%; font-weight: normal; text-align: justify; text-indent: 0in; padding-left: 0.125in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 17.05pt; font-weight: normal; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>Appendix A</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: right; text-indent: 0in"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Completions and Special Terms Appendix</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 17.05pt; font-weight: normal; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>Appendix B</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: right; text-indent: 0in"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">The blueprint of the Contract and its Surroundings</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 17.05pt; font-weight: normal; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>Appendix C</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: right; text-indent: 0in"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Rules to provide electricity</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 17.05pt; font-weight: normal; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>Appendix D</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: right; text-indent: 0in"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">The Management Agreement </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 17.05pt; font-weight: normal; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>Appendix E</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: right; text-indent: 0in"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Bylaws</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 17.05pt; font-weight: normal; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>Appendix F</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: right; text-indent: 0in"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Personal Guarantee</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 17.05pt; font-weight: normal; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>Appendix G</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: right; text-indent: 0in"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Bank Guarantee</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 17.05pt; font-weight: normal; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>Appendix H</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: right; text-indent: 0in"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Promissory Note</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 17.05pt; font-weight: normal; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>Appendix I1</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: right; text-indent: 0in"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Format of the Confirmation pertaining to the Tenant&rsquo;s works insurance policies</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 17.05pt; font-weight: normal; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>Appendix I2</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: right; text-indent: 0in"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Format of the Tenant&rsquo;s Permanent Insurance Policies</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 17.05pt; font-weight: normal; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>Appendix J</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: right; text-indent: 0in"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Format of the Authorization to Charge Account.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 17.05pt; font-weight: normal; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>Appendix K</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: right; text-indent: 0in"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Format of the Storage Spaces Lease Agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 17.05pt; font-weight: normal; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>Appendix L</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: right; text-indent: 0in"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Format of the Tenant&rsquo;s Works</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-weight: normal; text-align: left; text-indent: 0in; "><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in; "><FONT STYLE="font-size: 10pt"><B><U>DEFINITIONS</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 30pt; text-align: justify; ">&nbsp;</TD>
    <TD STYLE="padding-right: 30pt; text-align: justify; ">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; ">&nbsp;</TD>
    <TD STYLE="text-align: justify; "><FONT STYLE="font-size: 10pt">In this contract the phrases below will assume the interpretation and meaning stated alongside them:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 127.55pt 0pt 0; text-align: justify; text-indent: -127.55pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: left; ">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;The Land&rdquo; </B></FONT></TD>
    <TD STYLE="width: 10%; text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 64%; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">As defined in <U>Appendix A.</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: right; ">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0.125in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&ldquo;The CBP&rdquo;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>(City Building Plan)</B></P></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Any master plan and/or leniency and/or permit to make non-conforming use, insofar as approved, from time to time, in relation to the Land.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: right; ">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0.125in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;The Complex&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">The complex, as defined in <U>Appendix A</U>, serving for various and other business designations, including and/or likely to include, <I>inter alia</I>, offices, stores, clinics, academic institutions, embassies, coffee shops, eating establishments and cinemas, all or part of which will be established on the Land and/or will be extended and/or reduced in the future, and which are intended to be leased or for sale, all according to the Landlord&rsquo;s sole discretion, and which includes public spaces as defined below.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: right; ">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;The Landlord&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Including but not limited to the Landlord&rsquo;s engineer and including but not limited to whoever is lawfully appointed by the Landlord from time to time to be its agent or representative in general or for a specific matter.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: right; ">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;The Premises&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">As defined in <U>Appendix A</U> to this contract and marked with the color red in <B><U>Appendix B</U></B> to this contract.&nbsp;&nbsp;Insofar as the premises also includes a storage space, then the provisions in Appendix K will apply thereto.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: right; ">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;The Area of the Premises&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">As defined in Section 5 below and as described and detailed in <U>Appendix A</U> to this contract.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: left; ">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;Gallery&rdquo;</B></FONT></TD>
    <TD STYLE="width: 10%; text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 64%; padding-left: 0.125in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: left">Any horizontal division creating an interim
        floor within the premises and separating the floor of the premises and its ceiling.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;The Bank&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">A defined in <U>Appendix A</U>.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&ldquo;Index&rdquo;</B></P></TD>
    <TD STYLE="text-align: right">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">-</P></TD>
    <TD STYLE="padding-left: 0.125in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The Consumer Prices Index &ndash; general,
        including fruits and vegetables, published by the Central Statistics Bureau. In the event this index is no longer published by
        the Central Statistics Bureau then an identical or similar in nature index replacing it that is published by the Central Statistics
        Bureau or any other authorized entity.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;The Basic Index&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-left: 0.125in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: left">As defined in <U>Appendix A</U> to this contract.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;Linked&rdquo;, &ldquo;In addition to Linkage Differentials&rdquo;, &ldquo;Linkage Differentials&rdquo;, &ldquo;Linked Values&rdquo; and any similar expression.</B></FONT></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-left: 0.125in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Multiplying the relevant amount by the
        ratio rate between the index recorded at the time the relevant payment was made and the basic index. Or by the ratio rate between
        other indexes provided that in any case such a ratio is not less than 1 and that a given payment for it the linkage differentials
        was calculated for a given period will not be less than the payment including the linkage differentials for a given earlier period.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&ldquo;The Municipality&rdquo;, &ldquo;The
        Local Authority&rdquo;</B></P></TD>
    <TD STYLE="text-align: right">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">-</P></TD>
    <TD STYLE="padding-left: 0.125in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The Authority stipulated in <U>Appendix
        A</U>, which is the local authority within its jurisdiction the Land is located or any other local authority that the Land is within
        the boundaries of its municipal jurisdiction.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;The Management Company&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-left: 0.125in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">As defined in Section 15 below, including
        but not limited to whoever duly is appointed by the Management Company to be its agent or representative in general or for a specific
        matter. Insofar as the Landlord also serves as the Management Company, then anywhere stating the &ldquo;Management Company&rdquo;
        will be replaced with &ldquo;The Landlord&rdquo;.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;Public Areas&rdquo;</B></FONT></TD>
    <TD STYLE="width: 10%; text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 64%; padding-left: 0.125in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Unless stated to the contrary &ndash; both
        the internal public areas and the external public areas as defined below.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;Internal Public Areas&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-left: 0.125in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">All the areas within the complex, including
        but not limited to all the buildings, additions and changes made to it from time to time, and roofs, passageways, entrances and
        exits, partitions, walls, and columns that do not constitute part of the leased areas, the utility area and rooms, internal streets
        and/or utility corridors, roads and service roads within the area of the complex. The areas designed and/or to be designed to operate
        the parking lot, service rooms, technical spaces and such as electricity, air conditioning and systems room, loading and unloading
        spaces, elevators, escalators, steps and any other area within the complex intended or actually serving the public and/or the customers
        of the complex and/or a number of tenants in the complex and/or areas serving from time to time or permanently to place booths
        and/or exhibitions and protected spaces and all to the exclusion of those areas intended to be leased and/or actually leased by
        the Landlord.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;External Public Areas&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-left: 0.125in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">All the areas outside the area of the complex
        intended to serve the public at large and/or the customers of the complex and/or a number of tenants in the complex, including
        areas intended and/or designated to operate parking lots, roads, access ways, steps, gardens, signs, passageways and such like.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;The Lease Period&rdquo;</B></FONT></TD>
    <TD STYLE="width: 10%; text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 64%; padding-left: 0.125in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">As defined in Section 7 below and in <U>Appendix
        A</U> to this contract and if not stated expressly to the contrary &ndash; both during the first lease period, as defined in <U>Appendix
        A</U> and all the additional lease periods, insofar as determined in <U>Appendix A</U>, insofar as applicable.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;Rent&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-left: 0.125in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">As this is defined in this contract and
        as stipulated in <U>Appendix A</U>.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;Management Fees&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-left: 0.125in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">All the payments the Tenant must pay to
        the Management Company in accordance with the provisions in this contract and the management agreement.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;The Tenant&rsquo;s Payments&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-left: 0.125in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">All the payments the Tenant must pay in
        accordance with the provisions in this contract and the provisions in the law, including but not limited to payments to the Landlord
        and/or the Management Company and/or any government or municipal authority and/or any other third party.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;Quarter&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-left: 0.125in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The months of January through to March,
        April through to June, July through to September and October through to December of each calendar year.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;The Delivery Date&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-left: 0.125in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The date upon which possession of the premises
        is delivered to the Tenant in accordance with the provisions in Section 12 below, and as determined in <U>Appendix A</U> to this
        agreement.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;The Architect&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-left: 0.125in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Whoever is appointed by the Landlord, from
        time to time, as the architect responsible for the complex.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt"><B>&ldquo;The Contract&rdquo; </B>or <B>&ldquo;The Lease Contract&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: right; "><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">This lease contract and all of its appendices, including the management agreement, and any addendums and/or corrections thereto, insofar as applicable from time to time.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 162.95pt 0pt 0; text-align: justify; text-indent: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><B><U>THE LEASE TRANSACTION</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Subject to the
correctness of the Tenant&rsquo;s declarations and fulfillment of all of the Tenant&rsquo;s undertakings pursuant to this contract,
the Landlord hereby undertakes to lease to the Tenant, and the Tenant hereby undertakes to lease from the Landlord the premises
as detailed in the terms in this lease contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><B><U>THE PARTIES DECLARATIONS</U></B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.1.</TD><TD STYLE="text-align: justify">The Landlord hereby declares that it owns the rights in the complex and to the best of its knowledge
there is no hindrance preventing it from engaging in this contract with the Tenant subject to all the stipulations, arrangements
and provisions detailed in this contract.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.2.</TD><TD STYLE="text-align: justify">The Tenant declares that it saw and inspected the Land and the surroundings in which the Land is
located and the complex including but not limited to the premises, and in relation to all of these &ndash; their physical, zoning,
statutory, records, licensing and legal status, their designation, including but not limited to all the systems and infrastructures
of the premises and complex, and examined and inspected the rights associated with all of these and it is aware of the CBP details,
and it saw and inspected the complex plans including the plans of the premises and the location of the premises within the complex,
the premises suiting the purpose of the lease and the possibility of obtaining the necessary licenses to operate its business from
within the premises. It received all the information that it found relevant in connection with the complex and its construction
and in connection with the premises and the purpose of the lease and found all of these to be to its complete satisfaction from
all aspects and it hereby finally, absolutely and irrevocably waives any allegation of incompatibility and/or defect and/or any
demand in connection with any of the said issues.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.3.</TD><TD STYLE="text-align: justify">The Tenant declares that it was not given any representations and/or undertakings form the Landlord
and/or on its behalf with regard to the chances of the Tenant&rsquo;s business succeeding in the premises and/or the number of
visitors and/or customers and/or mix of the complex and such like, and that it does not and will not have any allegations and/or
demands and/or claims toward the Landlord and/or anyone on its behalf in connection with any of these.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify"><B><U>THE AREA OF THE PREMISES</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The
boundaries of the premises are as marked in <U>Appendix B</U> to this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -70.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Insofar
as payments are concerned that the Tenant must pay the Landlord and/or the Management Company pursuant to this contract, deriving
from the area of the premises, the calculation will be done according to the &ldquo;area of the premises&rdquo; as stipulated in
<U>Appendix A</U>, which is determined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B>&ldquo;Area
of the Premises&rdquo; &ndash; </B>The measured area of the premises pursuant to the following principles in addition to the load
of a relative part of the public areas of a rate of 25% (Hereinafter: &ldquo;<B>The Load</B>&rdquo;) of the measured area of the
premises, whereby the load calculation stated above will be done in the following manner. The measured area of the premises pursuant
to the principles detailed below, divided by 0.75. The measured area of the premises is determined and/or will be determined by
a survey executed by the architect and/or certified surveyor on the Landlord&rsquo;s behalf. Upon measuring the area of the premises
the contour area of the premises was taken into account, i.e. the area of the floor of the premises including the area of the columns,
internal walls, exterior walls (with respect to the area of the walls common to the premises and the other premises in the complex
only one half of the area upon which the wall was built will be taken into account), the area of the storage and utilities spaces,
the area of the gallery or the second floor of the premises, if applicable, and the area of the balconies if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Signed
confirmation by the architect and/or certified surveyor pertaining to the measured area of the premises as determined in such a
survey will be considered final and conclusive proof of the area of the premises (before adding the load) for such charges purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">To the
measured area, as stated above, the load rate will be added and the total load area is the gross area for the purpose of calculating
the Tenant&rsquo;s charges pursuant to the agreement and its appendices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">To avoid
doubt, the execution of the loan calculation will not grant the Tenant rights in the public areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Notwithstanding
the above, it is clarified that for the purpose of charging the Tenant the payments to the municipality or the local authority
(such as rates) for the premises, the area of the premises will be determined by the municipality or local authority, as applicable,
pursuant to its calculations. Additionally the Tenant will be charged the municipality or local authority payments for its share
of the premises in the public areas pursuant to that determined in Section 10 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify"><B><U>THE PURPOSE OF THE LEASE</U></B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.1.</TD><TD STYLE="text-align: justify">The Tenant declares and undertakes that it is a tenant of the premises solely for the purpose of
the lease as detailed and defined in <U>Appendix A</U> to this contract, and solely for this purpose.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.2.</TD><TD STYLE="text-align: justify">The Tenant undertakes to operate its business from the premises solely within the purpose of the
lease without any non-conformities or deviations from the purpose of the please and additionally will operate the premises in a
manner that complies with the provisions in the law. Any change or broadening of the purpose of the lease is subject to obtaining
the Landlord&rsquo;s written consent in advance, who may refuse to agree to such a change or broadening for any reason of the Landlord&rsquo;s
discretion and without having to reason its refusal. In the event of a doubt or dispute between the parties with regard to that
included or not included in the purpose of the lease, the purpose of the lease will be construed narrowly and pursuant to the circumstances
that exist and are known on the date this contract is signed and without referring to future changes in the Tenant&rsquo;s activity
and/or the Tenant&rsquo;s field of business and/or the purpose of the lease.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.3.</TD><TD STYLE="text-align: justify">Without prejudicing the generality of the provisions above, the Tenant confirms that it is aware
that operating the premises pursuant to a change or nonconformity with the purpose of the lease, other than constituting a material
breach of this contract, may cause a breach of other lease contracts between the Landlord and other tenants in the complex, and
therefore the Landlord may, without prejudicing its right to any other relief or remedy, in any event of managing a business in
the premises pursuant to a nonconforming purpose or deviation from the purpose of the lease, receive an injunction against such
operation and/or bring the lease contract to an end after giving notice of 7 days and the Tenant will not have any allegation and
demand as a result thereof. Whereupon the lease contract was brought to an end as stated above, the provisions in Section 25 below
will apply <I>mutatis mutandis</I>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.4.</TD><TD STYLE="text-align: justify">The Tenant declares and undertakes that it has the know-how, experience and ability to operate
its business as detailed in the purpose of the lease. The Tenant will endeavor, while exploiting all of the resources available
to it, for its business in the premises to succeed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.5.</TD><TD STYLE="text-align: justify">The Tenant is aware of the fact that the Landlord may, if it so chooses, grant uniqueness and/or
exclusivity to certain businesses in the complex and/or to prevent the operation of certain businesses and to strike a given business
balance to the best of its understanding and sole and absolute discretion in connection with the type of businesses to operate
from within the complex and the Tenant hereby waives by a final, absolute and irrevocable waiver any allegation and/or claim and/or
demand in connection thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.6.</TD><TD STYLE="text-align: justify">The Tenant further declares that it was not granted nor was it promised any uniqueness and/or exclusivity
as stated above in connection with the premises and the business to be run from within and that the Landlord may lease areas in
the complex for the purpose of managing similar, parallel and even identical businesses to that of the Tenant, and that it waives,
by a final, absolute and irrevocable waiver any allegation and/or claim insofar as such an issue is concerned.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.7.</TD><TD STYLE="text-align: justify">Operating the premises by the Tenant and use thereof will only be pursuant to and in accordance
with the provisions in the law and none of the provisions in this contract constitute authorization on the Landlord&rsquo;s part
for the Tenant to act in the premises and/or use it in a manner that conflicts with any statutory provisions. It is clarified that
without derogating from the provisions in this contract, the Tenant will be exclusively responsible and at its expense to obtain
all the licenses and/or permits required to operate its business in the premises.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: -36.75pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify"><B><U>THE LEASE PERIOD</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The first
lease period pursuant to this contract is as detailed in <U>Appendix </U>A to this contract (Hereinafter: &ldquo;<B>The First Lease
Period</B>&rdquo;). At the end of the first lease period and subject to the early fulfillment of the provisions in Sections 7.1,
7.2 and 7.3 below, the lease period will be extended by a period/ additional periods, once each time, if and insofar as so determined
in <U>Appendix A </U> to this contract (Hereinafter: &ldquo;<B>The Additional Lease Period</B>&rdquo; <B>or &ldquo;The Additional
Lease Periods&rdquo;</B>, as applicable) (both the first lease period, as defined in <U>Appendix A</U> and any additional lease
period, insofar as determined in <U>Appendix A</U>, and insofar as applicable will be referred to jointly as &ldquo;<B>The Lease
Period</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.1.</TD><TD STYLE="text-align: justify">Subject to the provisions in Section 7.2 below, each lease period as described in <U>Appendix A
</U>will automatically be extended by the following lease additional period periods unless the Tenant gives written, unconditional,
unreserved and irrevocable notice to be received by the Landlord at least 180 (One Hundred and Eighty) days before the end of the
relevant lease period of its wish not to extend the lease (Hereinafter: &ldquo;<B>Non-Extending Notice</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in"></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.2.</TD><TD STYLE="text-align: justify">Notwithstanding the provisions in Section 7.1 above, it is agreed that the Landlord may determine,
in a notice to be delivered to the Tenant at least 30 days before the closest date to deliver a non-extending notice, that the
lease period (or the relevant additional lease period) will not be extended, and this upon the fulfillment of any of these:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">7.2.1.</TD><TD STYLE="text-align: justify">During the lease period preceding the extension, the Tenant did not fulfill or uphold all of its
undertakings pursuant to this contract, in full and on time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 112.3pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">7.2.2.</TD><TD STYLE="text-align: justify">Legal proceedings (including but not limited to arbitration or mediation) and/or other disputes
and/or were conducted between the Landlord and/or the Management Company and the Tenant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.3.</TD><TD STYLE="text-align: justify">The Tenant hereby undertakes by an undertaking whereby the breach thereof will constitute a material
breach of this contract, to furnish to the Landlord, at least 60 (Sixty) days before the end of the relevant lease period, confirmation
pertaining to extending all the insurance policies and securities that the Tenant must execute and maintain pursuant to this contract,
thus they will be in full effect during the course of any additional lease period. Nonperformance of the actions listed in this
section will grant the Landlord, <I>inter alia</I>, and without derogating form the rest of its rights and relief pursuant to this
contract and by law, the right to prevent the Tenant access to the premises until the confirmation is furnished as required.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.4.</TD><TD STYLE="text-align: justify">For the avoidance of doubt, if the Tenant remits a non-extending notice on time as stated in Section
7.1 above and/or the Landlord determined that the lease period will not be extended pursuant to the provisions in Section 7.2 above,
then the Tenant <U>will not</U> have a right to extend the relevant lease period, and therefore the lease agreement will come to
an end at the end of the relevant lease period, and the Tenant will not have any allegation and/or demand and/or claim against
the Landlord in connection with not realizing the additional lease period, and it undertakes to vacate the premises immediately
at the end of the relevant lease period, in accordance with the provisions in this contract.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">Whereupon
the lease period is not extended in accordance with the provisions above, the Tenant will vacate the premises by the end of the
relevant lease period, pursuant to the provisions in Section 25 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.5.</TD><TD STYLE="text-align: justify">The Tenant will not be entitled to terminate the lease and/or vacate the premises and/or terminate
the management of its business in the premises before the end of the lease period, however the provisions above do not prejudice
the Landlord&rsquo;s rights pursuant to this contract and/or by law to instruct the Tenant to vacate the premises and all this
without derogating from the Landlord&rsquo;s right to any relief and/or remedy reserved to the Landlord, in accordance with the
provisions in this contract and/or by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">If, notwithstanding
the above, the Tenant vacates the premises before the end of the lease period or ceases to run its business from within the premises,
the Tenant will be charged all the payments applicable to it pursuant to this contract, all until the end of the lease period and
the Tenant will be seen as having waived all of its rights in accordance with the provisions in this contract, including but not
limited to the right to possess the premises and the Tenant will be seen as giving its explicit consent to the Landlord, irrevocably,
to take possession back of the premises and do with it as owners are entitled to do and this without derogating from any other
right and/or relief available to the Landlord pursuant to this contract and/or by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">The terms
in this contract will apply in full during the course of the lease periods and subject to the special provisions in this contract
referring to certain lease periods only, and except the Tenant&rsquo;s right to extend the lease period beyond the additional lease
periods determined in <U>Appendix A</U>, insofar as determined.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify"><B><U>THE RENT</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Tenant
will pay the Landlord for the lease period rent as detailed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.1.</TD><TD STYLE="text-align: justify">For each month during the lease period the Tenant will pay the Landlord rent of a sum determined
in <U>Appendix A</U> to this contract (Hereinafter: &ldquo;<B>The Rent</B>&rdquo;), linked to the basic index and VAT stipulated
by law will be added thereto. It is clarified that in any event the rent in a given month (in addition to linkage differentials)
will not be less than the rent paid (in addition to linkage differentials) for the preceding month.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.2.</TD><TD STYLE="text-align: justify">For each month during the entire additional lease period, as detailed in <U>Appendix A</U> to this
contract, the Tenant will pay the Landlord rent in accordance with the rates fixed in Appendix A to this contract in relation to
rent for the last month of the previous lease period, in addition to 10% (Ten Percent) thereon and in addition to linkage differentials
linked to the basic index.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.3.</TD><TD STYLE="text-align: justify">It is agreed that the Tenant will pay rent for each quarter in advance during the course of the
lease period, on the first business day of each quarter by way of an authorization to charge the Tenant&rsquo;s account as stated
in the section below. &ldquo;<B>Business Day</B>&rdquo; means one of the weekdays &ndash; Sunday- Thursday, upon which banks in
Israel are actually open for business between the hours of 08:30 -11:00.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.4.</TD><TD STYLE="text-align: justify">To avoid any doubt, linkage differentials will be considered for all senses and purposes as an
integral part of the rent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right"></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.5.</TD><TD STYLE="text-align: justify">To ease the collection of the rent payments and any other amount owing to the Landlord and/or the
Management Company from the Tenant in accordance with this contract, the Tenant undertakes to deliver to the Landlord, upon signing
this contract, an authorization to charge its account in the format attached to this contract as <B><U>Appendix J</U></B> or in
another format acceptable to the bank. The Tenant undertakes that the authorization to charge the Tenant&rsquo;s account as stated
above will be valid for the entire lease period and it is clarified that the Tenant will not be entitled to cancel it for any reason.
It is further stressed that the payments deriving from this contract and its appendices will not be paid in any case in cash.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.6.</TD><TD STYLE="text-align: justify">For the avoidance of doubt, it is hereby declared that under no circumstances will the granting
of the authorization to charge the account and/or any demand pursuant thereto will not be considered payment until all the payments
are paid in full and on time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.7.</TD><TD STYLE="text-align: justify">If one or more of the rent payments are not paid to the Landlord with 7 (Seven) days of the date
fixed for payment thereof in accordance with this contract &ndash; including but not limited to not transferring the rent amount
in full by the bank to the Landlord pursuant to the authorization to charge the Tenant&rsquo;s account &ndash; then the balance
of the rent not yet paid for the rest of the lease period will become payable immediately and this without prejudicing any relief
and remedy available to the Landlord due to a material breach of the contract by the Tenant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.8.</TD><TD STYLE="text-align: justify">For the avoidance of doubt it is hereby declared that the obligation to pay rent and the rest of
the payments owing to the Landlord from the Tenant, are imposed upon the Tenant absolutely, even if it did not receive a bill for
such rent or the rest of the payments from the Landlord, provided that the Tenant was aware of the payment charge.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.9.</TD><TD STYLE="text-align: justify">The Tenant undertakes to pay the rent to the Landlord and the management fees to the Landlord or
the Management Company as stated in Section 15 below for the entire lease period, unconditionally, whether it makes use of the
premises or not and whether the premises were made available to it or not, for any reason.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.10.</TD><TD STYLE="text-align: justify">The Tenant declares that it is aware that for the purpose of guaranteeing repayment of the loan
and/or credit extended by the bank to the Landlord, the Landlord assigned and charged to the bank, by a charge of first degree
all of its rights pursuant to this contract or the Landlord will assign or charge its rights to the bank as stated above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">Without derogating
from the generality of the provisions above, the Tenant undertakes to sign any document it is instructed to sign by the Landlord
in connection thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">By the Tenant
merely signing this contract it gives its irrevocable consent to record and/or to correct such a charge in favor of the bank and
it may not object to doing so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">The Landlord
will be entitled to change from time to time the method to make the payment and/or the Landlord&rsquo;s account details in accordance
with the Bank&rsquo;s written instructions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">Additionally,
if the Bank so instructs, the monies will be transferred to a different account and/or to a third party or to the bank directly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -70.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify"><B><U>VALUE ADDED TAX</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">For each
one of the payments the Tenant is to pay the Landlord and/or the Management Company, in accordance with the provisions in this
contract and which is subject to the payment of value added tax, the Tenant will pay, together with that payment, value added tax
of the rate in effect from time to time pursuant to the law and/or any tax or levy replacing it and/or any tax which pursuant to
the law that is imposed and must be paid by the Tenant in accordance with the provisions in this contract (above and below: &ldquo;<B>VAT</B>&rdquo;
or &ldquo;<B>Value Added Tax</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">For the avoidance
of doubt, insofar as the Tenant&rsquo;s obligation to pay payments in accordance with this contract is concerned, the Value Added
Tax or any other tax to apply as stated above is the same as the payment for which it is being paid. A duly issued tax invoice
by the Landlord for the payment of the VAT will be delivered to the Tenant just after payment of the payment and the tax amount
thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify"><B><U>ADDITIONAL PAYMENTS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">For the entire
lease period the Tenant will pay, in addition to the rent and the management fees, all the payments detailed in all the sub-sections
of this Section 10 and the payments, levies, rates, taxes and mandatory payments of any type, municipal and/or governmental or
others, including but not limited to any fee, licensing fee and licenses of any type and relating to the premises and/or the operation
thereof and/or maintenance thereof and/or use thereof and/or to playback and/or exhibit creations therein, including but not limited
to those for which a payment demand was sent to the Landlord and/or the Management Company. Taxes and/or levies and/or fees and/or
participation fees in connection with the premises, operation thereof, maintenance, the business being run from within or in connection
with the rent imposed in the future and which do not exist on the date this contract is signed will apply to the Tenant, whether
these taxes apply by law to owners, a tenant or occupier. The Landlord on its part will bear, in connection with the complex, all
the payments of taxes, applicable explicitly by law to owners of real estate properties, as opposed to occupiers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.1.</TD><TD STYLE="text-align: justify">Without prejudicing the generality of the above the Tenant will bear, during the entire lease period
all the payments for the supply of water (including but not limited to the charge for sewerage), electricity, telephone, gas, canaling,
rates, business tax, sign fee or any other expense relating to the possession and/or use and/or operation of the premises, whether
it actually makes use of the premises or not.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.2.</TD><TD STYLE="text-align: justify">The Tenant will bear, for the entire lease period, any tax and/or levy and/or royalties applicable
and/or to be imposed in the future on the use of the premises and any activity performed in the premises, including but not limited
to tax and/or levy for playing music, royalties to ACUM &ndash; The <FONT STYLE="color: #222222; background-color: white">Society
of Authors, Composers and Music Publishers in Israel and/or any other entity and any other similar association as well as, any
payment for the use of a third party intellectual property and fees to the Broadcasting Authority.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right; color: #222222"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.3.</TD><TD STYLE="text-align: justify"><FONT STYLE="color: #222222; background-color: white">The Tenant will bear, for the entire lease
period, payments and/or taxes and/or levies applicable and/or to apply to the public areas in the complex, if applicable, including
but not limited to rates, pursuant to its relative share according to the area of the premises of the total leased area in the
complex, as determined in accordance with the Landlord&rsquo;s discretion and/or the Management Company and/or the Authorities,
as applicable, insofar as the Management Company bears these payments, the Tenant will pay the Management Company its share thereof
and this in addition to the management fees as stated in this contract.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right; color: #222222"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.4.</TD><TD STYLE="text-align: justify"><FONT STYLE="color: #222222; background-color: white">The Tenant will bear for the entire lease
period the payments owing for the maintenance and management of the complex as detailed in the provisions in Section 15 below and
for the use of the parking areas in accordance with the provisions in Section 17 below.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">The Tenant undertakes
to notify in writing, the local authority, the water corporation and the rest of the bodies relating to the mater about it leasing
the premises. Just after the date the lease period begins, the Tenant undertakes that if the Landlord so instructed, to convey
to the Tenant&rsquo;s name the water and/or telephone and/or electricity and/or municipality bills and/or any other bill relating
to a payment and/or tax applicable to the premises. At the end of the lease period the Tenant will put the bills back into the
Landlord&rsquo;s name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.5.</TD><TD STYLE="text-align: justify">The Tenant undertakes to make all the payments imposed upon it pursuant to the provisions above,
on the lawful date to do so or on the date it is required to do so pursuant to the demand of the relevant authority. Such payments
that the Tenant must pay through the Landlord or the Management Company, will be paid by the Tenant on the date stipulated in the
payment demand it receives from the Landlord and/or the Management Company for which such a periodic payment was imposed for a
whole year. If only part of the year is within the lease period, the Tenant will pay the relative part of such a payment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.6.</TD><TD STYLE="text-align: justify">Insofar as the supply of electricity to the premises and/or the complex is executed by and/or through
the Landlord and/or the Management Company within the framework of a &ldquo;bulk supply&rdquo; arrangement with the Management
Company, the Tenant will pay the Landlord and/or the Management Company the full payments for the electricity services as stated
in <B><U>Appendix C</U></B> to this contract, and this by an authorization to charge the Tenant&rsquo;s account as stated in Section
8.5 above and in any event no later than 7(Seven) days of the date the bill and/or the charge notice was received from the Landlord
and/or the Management Company and the Tenant further undertakes to comply with all of its undertakings as stated in <B><U>Appendix
C</U></B>. alternatively, insofar as the electricity is supplied to the premises directly through the Electricity Corporation,
the Tenant will engage with the Electricity Corporation in a consumer contract and will bear at its expense and responsibility
all the payments and charges demanded by the Electricity Company from time to time and will pay them directly to the Electricity
Corporation, on the date determined to do so. It is clarified that the Landlord may determine, from time to time, of its absolute
and sole discretion, the manner the electricity will be supplied to the complex and to the premises therein and the Tenant will
not have any allegations and/or demands toward the Landlord and/or anyone on its behalf in connection thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.7.</TD><TD STYLE="text-align: justify">The Tenant undertakes not to contact the Local Authority to request a discount on the payments
or rates applicable to the premises for the lease period by virtue of Regulation 13 (Discount on Rates for an Empty Property) to
the State Economy Arrangements Regulations (Discount on Rates), 5753 &ndash; 1993 (or any law or other regulation and/or repealing
it). In any event the Tenant contacts the Local Authority to request a discount on the rates payments as stated above, contrary
to the provisions above, and such a discount is granted to it, the Landlord will be entitled, without prejudicing any other relief
granted to it pursuant to this contract or by law, to receive from the Tenant, upon its first demand and even after the end of
the lease period, the discounted amount in addition to linkage differentials and interest in arrears as stated in Section 24.8
below.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">It is clarified
that the provisions in this Section 10 do not derogate form the Tenant&rsquo;s obligations in accordance with Section 15 below
and that all of the payments above will be paid by the Tenant in addition to the payment of the management fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify"><B><U>Cancelled.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">12.</TD><TD STYLE="text-align: justify"><B><U>CONSTRUCTION WORKS IN THE COMPLEX AND IN THE PREMISES</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.1.</TD><TD STYLE="text-align: justify">Commencing from the delivery date, as defined in <U>Appendix A</U> to this agreement, the Tenant
will execute all the adjustment works and/or assembly and/or installation works in the internal design of the premises, insofar
as required for the purpose of opening the Tenant&rsquo;s business in the premises, at its sole expense and responsibility. The
architect will remit general instructions for the execution and design of stores and the Tenant undertakes to act pursuant thereto
and pursuant to any other instruction given to it in this context.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">If the Tenant
does not perform any work of any type and kind in the premises other than in accordance with the plans and specifications approved
in advance and in writing b the architect and/or the Landlord whereby these plans are coordinated, to the Landlord&rsquo;s satisfaction,
with the complex&rsquo;s systems plans (all such works as approved by the Architect as stated above will be referred to below as:
&ldquo;<B>The Tenant&rsquo;s Works</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">The detailed
architectural plans will be furnished by the Tenant to the Landlord by and no later than 21 (Twenty One) days before the delivery
date. It is clarified that in the event the Tenant does not furnish the said plans by the aforementioned date the Landlord may
(however is not obligated) to rescind this contract within 72 (Seventy Two) hours of delivering a written notice to the Tenant
without the Tenant having any allegation and/or demand resulting therefrom and all provided that during the course of the said
period the Tenant did not delivery the plans to the Landlord&rsquo;s satisfaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">The Landlord
will be entitled, of its sole discretion, to approve the aforementioned plans and technical specifications, to make corrections
thereto, or not approve them. If the specifications and plans are not approved, the Tenant will submit new technical specifications
and plans to the Landlord pursuant to the Landlord&rsquo;s instructions during the course of the period of time stipulated by the
Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">For the avoidance
of doubt, it is clarified that instructions being given and/or the Tenant&rsquo;s plans being approved and/or approving performance
of the Tenant&rsquo;s works as stated above does not impose upon the Landlord and/or the Management Company and/or the architect
and/or anyone on behalf of these, liability of any type and kind in connection with the Tenant&rsquo;s works, as defined above,
and all sole liability to perform the Tenant&rsquo;s works and/or in connection to all of them and/or deriving from them, will
apply exclusively to the Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">It is clarified
that the Tenant releases the Landlord, the Management Company and all those under their service of any liability of any type and
kind in connection with performing the Tenant&rsquo;s works.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.</TD><TD STYLE="text-align: justify">The provisions in <B><U>Appendix L</U></B> to this contract will apply to the Tenant&rsquo;s works,
and the Tenant undertakes to comply with all of its undertakings as determined in the said appendix.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.3.</TD><TD STYLE="text-align: justify">It is clarified that a condition precedent to starting the performance of any works by the Tenant
or for it in the premises is furnishing the Tenant&rsquo;s works insurance policies confirmation as stated in Section 19.2 below,
the authorization to charge the Tenant&rsquo;s account as stated in Section 8 above and all the securities as stated in section
26 below, and payment in advance for all of the Tenant&rsquo;s charges for the first month&rsquo;s rent. Not furnishing any of
the above will prevent commencement of any of the works, however will not defer the start of the Tenant making its payments.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.4.</TD><TD STYLE="text-align: justify">The Tenant undertakes to complete the performance of all the Tenant&rsquo;s works by such a manner
that the premises will be ready to open for regular business and customers, as soon as possible, and all by and no later than the
date stipulated in <U>Appendix A</U> as the date to complete the Tenant&rsquo;s Works.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">If the opening
of the premises is deferred due to delays with the Tenant&rsquo;s works and/or not completing the Tenant&rsquo;s works by such
a date and/or delays in delivering the Tenant&rsquo;s plans required by the Landlord, this will constitute a material breach of
the contract and the following provisions will apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">12.4.1.</TD><TD STYLE="text-align: justify">The Landlord will not be liable for any delay or deferment in completing the premises and the Tenant
must indemnify and/or compensate the Landlord and/or the Management Company for any loss, damage or expense sustained due to such
a delay.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 121.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 121.5pt; text-align: justify; text-indent: 0in"></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">The Tenant,
and it alone, will be liable for any damage and/or loss it and/or the Landlord and/or the Management Company sustain in the event
the Tenant does not complete the performance of the Tenant&rsquo;s works by the date stipulated to finish the Tenant&rsquo;s works
and/or does not open the premises for business on such a date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 121.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">Without derogating
from any of the provisions above the Tenant will pay the rent and will bear the rest of the payments it must bear pursuant to this
contract and will meet all the rest of its undertakings as detailed in this contract, and this commencing from the delivery date
as defined in this contract and this whether or not the premises actually opened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 121.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">12.4.2.</TD><TD STYLE="text-align: justify">In the event the delay by the Tenant in completing the Tenant&rsquo;s works exceeds 30 (Thirty)
days, the Landlord will have the right to rescind this lease contract and the Tenant will not be entitled to any indemnification
and/or reimbursement for the works performed and/or facilities added to the premises.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><U>Installing
Systems and Supplying Electricity</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.5.</TD><TD STYLE="text-align: justify">The Tenant is responsible to make any adjustments, insofar as necessary from time to time of the
systems existing in the premises to its purposes and for them to be in line with the public systems in the complex, including but
not limited to &ndash; the cooling tower/s central system and the chilled water system for the premises air conditioning system,
the fire alert system, including but not limited to sprinklers and additional systems, all this at the Tenant&rsquo;s expense.
These works will be executed subject to receiving instructions from the Landlord with regard to the systems and early specific
coordination, in advance and in writing with the complex&rsquo;s maintenance manager.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.6.</TD><TD STYLE="text-align: justify">The supply of electricity to the premises and/or the complex will be done pursuant to the method
to be determined by the Landlord from time to time, and the supply of electricity to the premises and/or the complex may also be
done through the Electricity Company (direct connection to the national grid) and/or other provider and may also be done through
the &ldquo;bulk supply&rdquo; method by and/or through the Landlord and/or the Management Company &ndash; all pursuant to the Landlord&rsquo;s
sole determination from time to time insofar as the Landlord determines that the supply of electricity will be bulk. The provisions
in <U>Appendix C</U> to this contract will apply and the Tenant undertakes to act in accordance with the provisions in <U>Appendix
C</U> as stated above, any time the Landlord notifies it that the supply of electricity will be through the bulk method.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.7.</TD><TD STYLE="text-align: justify">Insofar as the supply of electricity to the premises and/or complex is through the bulk method
then payment for the bulk electricity will be made by way of an authorization to charge the Tenant&rsquo;s account as stated in
Section 8.5 above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.8.</TD><TD STYLE="text-align: justify">It is agreed that the Landlord will have the right to determine that the electricity supplier will
be another entity, instead of the Electricity Corporation, provided that the substitute entity holds a lawful license to supply
electricity, and in such a case the provisions in this contract relating to the Electricity Corporation will apply to the substitute
entity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.9.</TD><TD STYLE="text-align: justify">The Tenant confirms that it is aware that the electricity meters are positioned by the Landlord
centrally and/or in central areas, of the Landlord&rsquo;s choice, and the Tenant agrees to the location of the meters and to charge
it pursuant to a reading of the meter without questioning the reading or an allegation against it, including but not limited to
any change to the location of the Landlord&rsquo;s choice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0"><U>General
Provisions In Connection With Performing Works In The Complex</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.10.</TD><TD STYLE="text-align: justify">The Landlord may at any time, without the need for the Tenant&rsquo;s consent, perform any change
or addition or renovation in the complex and/or any part thereof and/or in any premises, of its sole discretion, both before the
start of the lease period and thereafter, including but not limited to additions or reductions or splitting areas of any type,
joining and building floors, areas or wings in the complex, whether under the complex and/or the premises or above them, adding
office buildings, adding parking spaces, turning closed or open public areas into areas for sole use by various users, changing
openings and passageways, extensions to various buildings and any other change in a building and/or plans in the complex and/or
use of the areas in the complex and/or its surroundings.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">The Tenant
undertakes not to interfere and not to object to any such a change or extension for any reason, including but not limited to interruptions
it may sustain, if sustained while the extensions or change is being carried out provided that the change or extension does not
cause it a material, continuous and unreasonable interruption to the management of its business in the premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">The Tenant
declares that it is aware that the extensions will be added to the complex building. If added they will be part of the complex
but not part of the premises or the Tenant&rsquo;s rights in the premises, and they do not and will not and/or the use thereof
and/or the leasing thereof will not derogate from the Tenant&rsquo;s obligations to fulfill all of its undertakings, in full and
on time, in accordance with this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.11.</TD><TD STYLE="text-align: justify">The Landlord may, without the any need for the Tenant&rsquo;s consent to transfer through the complex
and through the premises and to install itself or through someone on its behalf or through any authority, institution or other
body, all types of pipes, infrastructures, including but not limited to air conditioning ducts, water pipes, gas, cable and electrical
wires, cable for television communication and/or telephone and/or other cables whether they serve the Tenant and/or the premises
and/or the complex or not, and the Tenant undertakes to allow the Landlord or to whoever on the Landlord&rsquo;s behalf to enter
the premises to perform such works and all associated thereto during the course of the lease period. The Landlord will notify the
Tenant of its intention to perform such works a reasonable time in advance pursuant to the circumstances of the matter at hand.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.12.</TD><TD STYLE="text-align: justify">It is clarified that the delivery date as defined in this contract is an estimated date and that
it may be deferred due to the premises not being vacated by the current tenant (as defined in Section 13.4 below) and/or for any
other reason such as, but not only &ndash; a state of war, exceptional reserve duty drafting, extreme and exceptional weather conditions
or other natural disasters, orders, regulations or laws that cause a delay in delivery, strikes or go-slows, or any other cause
not within the Landlord&rsquo;s control. In such a case, the delivery date will be deferred without this being considered a breach
of the contract by the Landlord, for the period of time necessary based on the foregoing circumstances or any one of them, as applicable
and in addition to Twenty One (21) days for organizational purposes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.13.</TD><TD STYLE="text-align: justify">Any dispute concerning adjustments in the premises to the blueprint and/or the delivery date and/or
adjustments of the various plans and/or any matter concerning the existence of an event stated in Section 12.12 above and for the
duration of the deferred time deriving therefrom, as applicable and/or any other matter concerning the performance of the construction
works in the complex and/or the premises, the architect or whoever is appointed by him, will serve as an expert and not as an arbitrator
and his ruling will be final, decisive and binding upon the parties for all senses and purpose as if they had consented from the
outset.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right"></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.14.</TD><TD STYLE="text-align: justify">For the avoidance of doubt, the Tenant and it alone, will be responsible to obtain all the permits
and/or licenses required and/or that will be required by law (including but not limited to from the Local Authority and/or the
firefighting service and/or any other authorized authority) to perform the Tenant&rsquo;s works as detailed in this contract, and
this before performance begins, and for the purpose of opening the Tenant&rsquo;s business in the premises and operation thereof,
and will bear the expenses associated thereto, including but not limited to complying with any demand by any authority to make
adjustments and/or additions to allow for such an authority&rsquo;s approval to be received as stated above, provided that the
Tenant received approval from the Landlord to do so as stated in Section 12.1 above, in advance and in writing. The Tenant undertakes
to comply with all the requisite conditions to obtain such permits, to run its business pursuant to their conditions and to maintain
the validity thereof during the entire lease period, and not to make any nonconforming use in the premises and not to manage businesses
therein that are not permitted by the applicable law or that will apply.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -70.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify"><B><U>DELIVERY OF POSSESSION AND DELIVERY PROTOCOL</U></B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.1.</TD><TD STYLE="text-align: justify">The Landlord will deliver possession of the premises to the Tenant on the date detailed in <U>Appendix
A</U> to this contract hereby determined as an estimated date (Hereinafter: &ldquo;<B>The Delivery Date</B>&rdquo;). On the delivery
date the premises will be delivered to the Tenant in the condition on the date this contract is signed, &ldquo;As Is&rdquo;, whereby
the standard systems therein, if they exist, operate and are in working order, and free and clear of any person and object to the
exclusion of such standard systems and equipment that were agreed to remain in the premises and this without the Landlord being
required to execute any renovations and/or adjustment and/or revamping in the premises.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">13.2.</TD><TD STYLE="text-align: justify">The Tenant undertakes to sign a delivery protocol and to receive possession on the delivery date
and confirms that in any event it does not sign the delivery protocol as stated above and/or does not show up to receive possession
on this date, for any reason, it will be seen as having received possession of the premises to its full satisfaction, without any
reservations with regard to its condition, totally suited to the provisions in this contract and the obligation to pay rent will
apply to the Tenant from the delivery date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">13.3.</TD><TD STYLE="text-align: justify">Without derogating from the provisions above, upon delivery the Tenant undertakes to carry out
the following actions:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72.4pt"></TD><TD STYLE="width: 58.5pt">13.3.1.</TD><TD STYLE="text-align: justify">To receive possession of the premises. Receipt of possession of the premises by the Tenant will
constitute approval on its part that the premises was delivered to it fully suited to the provisions in this contract and to its
absolute satisfaction, and that it does not and will not have any claims and/or allegations and/or demands concerning the premises
and this contract, subject to the fulfillment of the Landlord&rsquo;s undertakings pursuant to this contract; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72.4pt"></TD><TD STYLE="width: 58.5pt">13.3.2.</TD><TD STYLE="text-align: justify">To furnish to the Landlord the confirmation of the insurance policies as detailed in Section 19
below.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 177.2pt; text-align: justify; text-indent: -70.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt"></TD><TD STYLE="width: 36.7pt">13.4.</TD><TD STYLE="text-align: justify">The Tenant declares that it is aware that the premises is not vacant and that the premises is occupied
by the current tenant (above and below: &ldquo;<B>The Current Tenant</B>&rdquo;). It is hereby agreed that insofar as the current
tenant does not vacate the premises of any person and object by the date determined in this contract for delivery of possession
of the premises to the Tenant, the delivery date will be deferred to such a date that the premises is actually vacated by the current
tenant and the rest of the dates stipulated in this contract will be deferred accordingly. Insofar as the delay exceeds more than
a month, the Landlord may, (however is not obligated) to rescind the contract. If the Landlord decides to rescind this contract,
the Landlord will be released of all of its undertakings pursuant to this contract and the Tenant will not have and hereby waives
any allegation, claim and/or demand in connection with this contract.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 23.85pt">14.</TD><TD STYLE="text-align: justify"><B><U>THE BUSINESS ACTIVITY IN THE COMPLEX AND IN THE PREMISES</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: -36.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">14.1.</TD><TD STYLE="text-align: justify">The hours of operation of the businesses in the complex will be, subject to the provisions in the
law, including and in particular the municipal bylaws and in accordance with the procedures determined from time to time by the
Management Company (whether with regard to a specific business or types of businesses). Until a notice is received to the contrary
from the Management Company, the hours of operation of the Management Company in the complex are &ndash; between 09:00 and 21:00
Sundays through to Thursdays inclusive, and between 09:00 and 15:30 on Fridays and eves of holidays and one hour after the Sabbath
or holiday ends and up to 22:30 on Saturdays and holidays.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">14.2.</TD><TD STYLE="text-align: justify">The Tenant declares and undertakes that it does not and will not have any allegation and/or demand
and/or claim against the Landlord and/or anyone on its behalf and/or tenants and/or business establishments in the complex, in
connection with the dates and hours of operation of their businesses, including but not limited to operating them on Saturdays
and on holidays, insofar as applicable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">14.3.</TD><TD STYLE="text-align: justify">The Tenant undertakes to use the premises and its surroundings, by such a manner that does not
cause any interruption and/or nuisance to other tenants in the complex and their enjoyment from their premises, while keeping the
part adjacent to the premises clean. Without derogating from the provisions above, the Tenant undertakes not to use the premises
or any part thereof in a manner whereby as a result thereof noise, odors, pollutions or other hazards are caused exceeding that
which is reasonable bearing in mind the nature of the complex in general and the nature of the proximate surroundings of the premises,
in particular.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: -36.75pt">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">14.4.</TD><TD STYLE="text-align: justify">The Tenant undertakes to take the measures necessary to prevent any damage or malfunction to the
premises and/or any part thereof and/or the proximate surroundings and/or facilities and/or equipment in the premises and to immediately
repair and at its expense any damage caused to the premises and/or equipment and/or the facilities therein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">14.5.</TD><TD STYLE="text-align: justify">In the event the Tenant does not maintain the premises, including but not limited to the equipment
and/or facilities therein or those belonging to it, in a good state of repair and of a high quality, and/or does not immediately
repair any disrepair as stated in sub-section 14.4 above, the Landlord may, however is not obligated, to carry out the repair and
perform any action, of its discretion to repair the damage and/or put the premises and/or its facilities belonging to it to a high
standard and quality, suited to the complex, and this at the Tenant&rsquo;s expense and the Tenant undertakes to compensate the
Landlord for the above and this in accordance with the provisions in Section 30 below. To this end, the Landlord may enter the
premises after giving 48 (Forty Eight) hours&rsquo; notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">14.6.</TD><TD STYLE="text-align: justify">The Tenant declares that it is aware that in the premises stores, clinics, schools, cinemas, coffee
shops, restaurants, kiosks may operate in the complex. Eating establishments of all types, businesses of all types, offices, health
clubs, clinics, embassies and cultural, entertainment, music and promotional activities in the public areas, including but not
limited to exhibitions, fashion shows, presentations and such like, and it declares and undertakes that it will not have any allegation
in connection thereto, whether applicable or not, including but not limited to in connection with the field of activity therein,
the hours of operation, entry and exit arrangements, noise crowding, odors nuisances or any other nuisance caused by their activities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: -36.75pt">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 35.45pt">15.</TD><TD STYLE="text-align: justify"><B><U>MANAGING THE COMPLEX</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: -5.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0">The Landlord
may appoint a corporation to engage in the management of the complex and its maintenance (above and below &ndash; &ldquo;<B>The
Management Company</B>&rdquo;). If the appointment of the Management Company ends or so long as a Management Company was not appointed,
the Landlord will serve as the Management Company for the purpose of this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">The Management
Company will determine, from time to time arrangements and procedures concerning the management of the complex and the maintenance
thereof and will determine bylaws to apply with regard to all the tenants and users of the complex, or the type of businesses therein
and will monitor the execution thereof. The Tenant undertakes to sign, on the date this contract is signed, a management agreement
with the Management Company attached as <B><U>Appendix D</U></B> to this contract and the bylaws attached as <B><U>Appendix E</U></B>
to this contract. The bylaws will be valid in this format so long as no changes thereto were promulgated by the Management Company.
The Tenant undertakes to comply with the management agreement, the bylaws and procedures, including but not limited to changes
therein, made from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in">The Management
Company will render services (Hereinafter: &ldquo;<B>The Services</B>&rdquo;) in the complex whether itself or through sub-contractors
as stated in the management agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.1.</TD><TD STYLE="text-align: justify">The Tenant will participate in all the Management Company&rsquo;s expenses to render the services
on the basis of their cost, including but not limited to financing expenses, on the basis of foreign currency linked or index,
of the Management Company&rsquo;s choice and in addition to a fee to the Management Company and VAT stipulated by law. It is clarified
that insofar as this contract is used, use of the phrase &ldquo;<B>management fees</B>&rdquo; &ndash; this refers to the Management
Company&rsquo;s expenses and the Management Company&rsquo;s fee as stated above, as defined in this management agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -35.8pt">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.2pt">For the avoidance
of doubt, the Management Company will be entitled to transfer the Management Company&rsquo;s fee to its parent company, or to whoever
the parent company so instructs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.8pt"></TD><TD STYLE="width: 36.4pt">15.2.</TD><TD STYLE="text-align: justify">If the Tenant will pay the management fees relative to the area of the premises in relation to
the other premises in the complex, in accordance with the dates, rates and defined legends in the management agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.8pt"></TD><TD STYLE="width: 36.4pt">15.3.</TD><TD STYLE="text-align: justify">The Tenant refusing and/or unwillingness and/or not wishing to receive a given service and/or its
wish to stop the rending of all or some of the services will not release the Tenant of its undertakings pursuant to this entire
Section 15 and/or pursuant to the management agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.8pt"></TD><TD STYLE="width: 36.4pt">15.4.</TD><TD STYLE="text-align: justify">The Tenant signing this contract constitutes a direct undertaking toward the Management Company
once appointed or established, if established, insofar as things concern it, and the Tenant&rsquo;s undertaking toward the Landlord
to uphold all of its undertakings toward the Management Company, whether specified in this contract or detailed in the management
agreement, and a breach of the management agreement will constitute a breach of this contract and accordingly, the Landlord may
make use of the securities extended by the Tenant in accordance with the provisions in Section 26 to this contract also to secure
the Tenant&rsquo;s obligations in accordance with the provisions in the management agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.8pt"></TD><TD STYLE="width: 36.4pt">15.5.</TD><TD STYLE="text-align: justify">The Tenant agrees that it is possible that changes will be made to the format of the management
agreement, including but not limited to resulting from changing the Management Company, and in such a case the Tenant will sign
a management agreement as prepared and approved by the Landlord and the Management Company, and this immediately upon receiving
the Landlord and/or Management Company&rsquo;s demand to do so.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.8pt"></TD><TD STYLE="width: 36.4pt">15.6.</TD><TD STYLE="text-align: justify">For the avoidance of doubt, any allegation the Tenant has against the Management Company, including
but not limited to an allegation by virtue of the management agreement, will not constitute a cause of action and/or set off on
the Tenant&rsquo;s part against the Landlord.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 35.45pt">16.</TD><TD STYLE="text-align: justify"><B><U>ADVERTISING</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in">The Tenant
is aware and it agrees to the fact that the Landlord and/or the Management Company will be entitled, however not obligated, to
prompt events and actions in the promotion of the complex field and the businesses therein, both within the complex, including
but not limited to signs, pamphlets and such like, and external advertising, including but not limited to advertising through the
various means of communication, including but not limited to television and/or radio and/or local or general press, all in the
manner, of the scope and on the dates of the Landlord and/or Management Company&rsquo;s sole discretion and the Tenant will not
have any allegation in connection thereto, including but not limited to the scope, manner and content of the advertising of the
complex and/or businesses in the complex in general, and with regard to the scope of the content and manner the business operating
from the premises in particular is advertised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 35.45pt">17.</TD><TD STYLE="text-align: justify"><B><U>PARKING LOTS AND PARKING FEES</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: -36.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">17.1.</TD><TD STYLE="text-align: justify">It is clarified that within the framework of the complex there are covered and/or open air parking
areas that are included and/or will be included (Hereinafter: &ldquo;<B>The Parking Lots</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">17.2.</TD><TD STYLE="text-align: justify">The Landlord may, of its absolute discretion and subject to the law, decided from time to time
to operate the parking lots as paid parking lots and charge the customers of the complex and its visitors a payment for parking
in the parking lots in any manner and according to any method its deems fit (Hereinafter: &ldquo;<B>The Parking Fee</B>&rdquo;),
whether itself or through others, including but not limited to the Management Company, to lease them to sub-contractors to operate
as paid parking lots and/or to determine usage, operation, parking, entry and exit arrangements for the parking lots and to change
all of these from time to time and the Tenant will not have any allegations in connection thereto. All the revenue from the parking
fees will belong solely to the Landlord.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">The Tenant
undertakes to comply, from time to time with any such determination and all arrangements and technical procedures to be determined
by the Landlord or the Management Company in this regard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">17.3.</TD><TD STYLE="text-align: justify">It is agreed that since the parking lots are intended to allow for convenient parking for the customers
of the complex with the quickest turnaround possible of users of the parking lots, the Tenant will not be entitled to use them
for any of its employees and/or businesses and/or on its behalf for parking, to the exclusion of its customers and to the exclusion
of a number of vehicles to be approved by the Landlord and/or the Management Company in advance and in writing, and pursuant to
conditions to be approved as stated above, and in consideration of payment of fixed and/or annual and/or monthly and/or ad hoc
subscription fees as determined by the Landlord (Hereinafter: &ldquo;<B>Parking Subscription Fees</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">17.4.</TD><TD STYLE="text-align: justify">If the Landlord allows the complex customers to park without paying a parking fee for the first
two hours at least, the Tenant will pay the Landlord, for the entire lease period, a sum of NIS 5 (Five) in addition to VAT stipulated
by law, for each square meter of the area of the premises for each of the months of the lease period (Hereinafter: &ldquo;<B>Payment
for Parking</B>&rdquo;). The payment for parking will be linked to the index published for the month of May 2013 (106.25 points,
Base 2010) and will be paid for each month in advance, at the same time as the minimum rent payment for that month.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">The payment
for parking will be revised at the beginning of each additional lease period beyond the first lease period, by a rate of 10% (Ten
Percent) as opposed to the estimated rate prior to the start of such an additional period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">It is clarified
that payment for parking is not and will not constitute in any manner and form part of the rent as defined in this contract, or
of the management fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">17.5.</TD><TD STYLE="text-align: justify">The provisions in this section constitute direct undertakings of the Tenant toward the Landlord
and/or the Management Company and/or any person or other body operating the parking lots from time to time, as applicable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 23.85pt">18.</TD><TD STYLE="text-align: justify"><B><U>LIABILITY IN TORTS AND INDEMNIFICATION</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">18.1.</TD><TD STYLE="text-align: justify">The Landlord, Management Company and anyone under their service will not be liable in any manner
for any damage and/or harm the Tenant and/or its business and/or property and/or anyone on its behalf and/or any other person in
the premises sustain, including and without prejudicing the generality of the provisions above, damage or harm caused due to the
Landlord and/or the Management Company and/or anyone under their service entering the premises, unless the damage is caused maliciously
by the Landlord or the Management Company, and the Tenant hereby waives any such claim, allegation and demand against the Landlord
and/or the Management Company and/or anyone on their behalf exceeding their liability as stated above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">18.2.</TD><TD STYLE="text-align: justify">The Tenant will assume liability toward the Landlord and/or the Management Company for any loss
and/or damage the premises and/or the complex and/or its contents and/or any person and/or corporation sustains, including but
not limited to its employees and/or the Landlord and/or the Management Company and/or anyone on their behalf and/or to the customers
and/or the visitors to the complex and/or any other person, caused by it and/or by anyone on its behalf (including but not limited
to its employees and/or customers and/or visitors and/or contractors and/or consultants on its behalf) and/or which is its responsibility
by virtue of the provisions in this contract and all in connection with the premises, management of its business in the premises
and/or possession and/or use of the premises and/or from any other action of the Tenant and/or its employees and/or its visitors
and/or vendors and/or anyone on its behalf and/or its customers. The provisions in this section do not derogate from the Tenant&rsquo;s
undertakings toward third parties pursuant to the law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">18.3.</TD><TD STYLE="text-align: justify">Any action that is taken in the premises will be done solely at the Tenant&rsquo;s responsibility
and the Landlord and/or the Management Company will not be liable in any manner for such actions. Without derogating from the generality
of the provisions above, the Tenant will be exclusively liable for any damage and for any responsibility due to a violation and/or
nonfulfillment, in full of the provisions in the law and/or license and/or permit in connection with the use of the premises.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">18.4.</TD><TD STYLE="text-align: justify">The Tenant undertakes to compensate and/or indemnify the Landlord and/or the Management Company
and/or anyone on their behalf for any damage and/or expense and/or charge they are likely to undertake to pay or are forced to
pay or paid, including but not limited to within the framework of a civil or criminal claim to be filed against them for any damage
within the Tenant&rsquo;s responsibility pursuant to this contract and/or by law, and for all the expenses the Landlord and/or
the Management Company and/or anyone on their behalf incurred to defend such a demand and/or claim, including but not limited to
attorneys fees, and all within 30 (Thirty) days of the date the Landlord and/or Management Company&rsquo;s first written demand
is received. The Landlord and/or the Management Company, as relevant, will notify the Tenant of them receiving any claim and/or
demand as stated above, just after it is received and will allow the Tenant, insofar as dependent upon them, a reasonable opportunity
to defend itself.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: -36.75pt">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 35.45pt">19.</TD><TD STYLE="text-align: justify"><B><U>INSURANCE </U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: -36.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.1.</TD><TD STYLE="text-align: justify">Without derogating from the Tenant&rsquo;s liability pursuant to this contract and/or pursuant
to the law the Tenant undertakes to execute and maintain the insurance policies detailed below with a certified and reputable insurance
company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">It is agreed
that insofar as the Tenant is required to perform protection, defending works against break-ins and/or theft and/or to install
a defense system, alarm, alert, smoke and fire detector and such like (Hereinafter: &ldquo;<B>The Protection Works</B>&rdquo;)
for the purpose of complying with the insurance policy terms of any of the insurance policies included in the confirmation pertaining
to executing the Tenant&rsquo;s insurance policies attached as <B><U>Appendix I2</U></B>, the Tenant alone will bear all the costs
of the protection works and will not have any allegation in connection thereto against the Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -70.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.2.</TD><TD STYLE="text-align: justify">Subject to the provisions in this contract insofar as receiving authorization to perform works
in the premises is concerned, and should any works be performed in the premises by the Tenant and/or someone on its behalf before
the premises are first occupied by the Landlord and/or on any date during the course of the lease period, the Tenant undertakes
to furnish to the Landlord and to the Management Company the confirmation pertaining to executing the Tenant&rsquo;s works insurance
policy attached to this contract and constituting an integral part hereof and marked as <B><U>Appendix I1</U></B> (respectively
below &ldquo;<B>The Tenant&rsquo;s Works Insurance Policies Confirmation</B>&rdquo; and &ldquo;<B>The Tenant&rsquo;s Works Insurance
Policies</B>&rdquo;) signed by the Tenant&rsquo;s Insurer. The Tenant declares that it is aware that furnishing the Tenant&rsquo;s
works insurance policies is a suspending and preliminary condition to performing any works in the premises, and the Landlord and/or
the Management Company will be entitled (however not obligated) to prevent the Tenant from carrying out works in the premises,
should such confirmation not be furnished to them before the performance of such works begin.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.3.</TD><TD STYLE="text-align: justify">For the entire lease period the Tenant undertakes to execute and maintain the insurance policies
detailed in the execution of the insurance policies confirmation attached to this contract and constituting an integral part hereof
and marked as <U>Appendix I2</U> (respectively &ndash; Hereinafter: &ldquo;<B>The Tenant&rsquo;s Permanent Insurance Policies Confirmation</B>&rsquo;
and &ldquo;<B>The Tenant&rsquo;s Permanent Insurance Policies</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.4.</TD><TD STYLE="text-align: justify">Without the need for any demand on the Landlord's part and/or on the Management Company&rsquo;s
part, the Tenant undertakes to furnish to the Landlord and to the Management Company, no later than the date to receive possession
of the premises or before the date any properties are placed in the premises, (other than properties that are part of the Insured
works pursuant to Section 19.2 above) whichever is earlier - the Tenant&rsquo;s permanent insurance policies confirmation, signed
by its Insurer. The Tenant declares that it is aware that furnishing the Tenant&rsquo;s Permanent Insurance Policies confirmation
is a suspending and preliminary condition to receiving possession of the premises and/or placing any properties (other than properties
that are part of the Insured works pursuant to Section 19.2 above) in the premises and the Landlord and/or the Management Company
will be entitled (however not obligated) to prevent the Tenant from receiving possession of premises and/or putting any properties
as mentioned above in the event the confirmation is not furnished before the date that was mentioned above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">Without derogating
from the provisions above, in any event the Tenant&rsquo;s permanent insurance policies confirmation and/or confirmation pertaining
to it being renewed, is not furnished to the Landlord even 3 (Three) business days after the date a demand is delivered to the
Tenant, the Landlord and/or the Management Company may prevent the Tenant from entering the premises, disconnect the supply of
electricity to the premises and to take any other action of their discretion to stop the activity in the premises until such confirmation
is received, to their satisfaction. Additionally, the Tenant will pay the Landlord a pre-determined and agreed payment of a sum
of NIS 2,000 for each day the Tenant&rsquo;s permanent insurance policies confirmation, valid, is not furnished to the Landlord,
without derogating from any right and/or allegation and/or claim of the Landlord. The payment above will be paid in addition to
linkage differentials commencing from the date this contract is signed and will be paid in addition to VAT stipulated by law, pursuant
to the Landlord&rsquo;s first written demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.5.</TD><TD STYLE="text-align: justify">It is agreed that the Tenant may choose not execute a consequential loss insurance policy, (in
full or in part), as detailed in Section (2) to the Tenant&rsquo;s permanent insurance policies confirmation, however the exemption
as detailed in Section 19.8 below will apply as if such policies were executed in full. Similarly, the Tenant may choose not to
execute the premises glass breakages insurance policy as detailed in Section (1) to the Tenant&rsquo;s permanent insurance policies
confirmation, however in such a case the Tenant will bear the expenses of replacing the glass in the premises as stated above and
the exemption stated in Section 19.8 below will apply.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.6.</TD><TD STYLE="text-align: justify">If in the Tenant&rsquo;s opinion there is a need to execute an additional and/or complementary
insurance policy to the Tenant&rsquo;s works insurance policies and/or the Tenant&rsquo;s permanent insurance policies, the Tenant
undertakes to execute and maintain such additional and/or complementary policies. In any additional and/or complementary property
insurance policy as stated above, a section will be included pertaining to the waiver of the right to subrogation toward the Landlord,
the Management Company and toward those acting on their behalf, as well as other tenants, residents and other rights holders in
the complex (hereinafter the other tenants, residents and other rights holders as stated above will be referred to jointly as:
&ldquo;<B>The Other Rights Holders</B>&rdquo;) whose property insurance policies as stated above and/or in the property chapter
to the contractors works insurance policy executed by them contains a waiver of the right to subrogation toward the Tenant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.7.</TD><TD STYLE="text-align: justify">The Tenant undertakes to revise, from time to time (and at least every insurance period) the insurance
amounts for the insurance policies executed by it pursuant to Sections (1) and (2) to the Tenant&rsquo;s permanent insurance policies
confirmation to always reflect the full value of the insured subject pursuant thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.8.</TD><TD STYLE="text-align: justify">The Tenant exempts the Landlord, the Management Company and anyone acting on their behalf and the
other rights holders whereby in the other right holders lease agreements or any other agreement granting the other right holders
rights in the complex contain a parallel exemption of liability toward the Tenant for damage that it is entitled to indemnification
for pursuant to the policies executed in accordance with Section (1) to the Tenant&rsquo;s works insurance policies confirmation,
Sections (1) and (2) to the Tenant&rsquo;s permanent insurance policies confirmation and the additional property insurance policies
that it executed as stated in Section 19.6 above (or would have been entitled to indemnification for but for the deductibles stipulated
in such policies), however the exemption from liability as stated above will not apply in favor of a person who maliciously caused
damage.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.9.</TD><TD STYLE="text-align: justify">No later than 14 (Fourteen) days before the end of the Tenant&rsquo;s permanent insurance policies
period date, the Tenant undertakes to deposit with the Landlord and with the Management Company the Tenant&rsquo;s permanent insurance
policies confirmation for extending the validity thereof for an additional insurance period. The Tenant undertakes to deposit the
Tenant&rsquo;s permanent insurance policies approval on the stipulated dates, each insurance period as long as this contract is
in force.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.10.</TD><TD STYLE="text-align: justify">Each time the Tenant&rsquo;s Insurer notifies the Landlord and/or the Management Company that any
one of the Tenant&rsquo;s permanent insurance policies is about to be cancelled or a detrimental change is about to be made thereto,
as stated at the end of <U>Appendices I1 and I2</U>, as stated above, the Tenant undertakes to renew that insurance policy and
to furnish the new insurance policy confirmation 30 (Thirty) days before the cancellation date or the detrimental change in the
policy date, as stated above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.11.</TD><TD STYLE="text-align: justify">For the avoidance of doubt it is clarified that not furnishing the insurance policy confirmations
on time, as stated in Sections 19.2, 19.4, 19.9 and 19.10 above, will not prejudice the Tenant&rsquo;s undertakings pursuant to
this contract, including but not limited to and without prejudicing the generality of the provisions above, any payment obligation
applicable to the Tenant, and the Tenant undertakes to comply with all of its undertakings pursuant to the agreement even if it
shall be prevented from executing works and/or from receiving possession of the premises and/or inserting properties into the premises
and/or operating its business in the premises, due to not presenting the confirmations on time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.12.</TD><TD STYLE="text-align: justify">The Landlord and/or the Management Company may review the insurance policies confirmations furnished
by the Tenant as required under Sections 19.2, 19.4, 19.9 and 19.10 above, and the Tenant undertakes to make any change or correction
necessary for it to comply with the Tenant&rsquo;s undertakings stated in this Section 19. The Tenant declares that the Landlord
and/or the Management Company's right to inspect the insurance policies confirmations and the right to instruct that they be corrected
as specified above, does not impose upon the Landlord and/or the Management Company and/or anyone on their behalf any obligation
and/or any liability insofar as the insurance policies confirmations are concerned, the nature, scope and the validity of the insurance
policies executed pursuant thereto or regarding the lack thereof, and the right to inspect does not derogate from any duty imposed
on the Tenant pursuant to this contract and/or the law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.13.</TD><TD STYLE="text-align: justify">The Tenant undertakes to comply with the terms of the insurance policies executed by it, to pay
the premiums on time and in full, and to ensure that the Tenant's permanent insurance policies are renewed from time to time according
to need and they will be valid the entire Lease Period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.14.</TD><TD STYLE="text-align: justify">For the avoidance of doubt it is agreed that the required limits on liability as stated in <U>Appendices
I1 and I1</U> are considered a minimum requirement imposed upon the Tenant. The Tenant declares and confirms that it will be estopped
from raising any allegation and/or demand against the Landlord and/or the Management Company and/or anyone on their behalf insofar
as such limits on liability are concerned.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.15.</TD><TD STYLE="text-align: justify">Additionally and without derogating from the provisions elsewhere in this contract, at all stages
of performing on the agreement the Tenant undertakes to comply with all the requirements and provisions in the National Insurance
Law and the National Health La and all orders, regulations and such like enacted pursuant to the foregoing laws, and primarily
and without prejudicing the generality of the provisions above, by such a manner that all of its employees, agents and those under
its service during the agreement period, including but not limited to those hired incidentally and temporarily, will at all times
and during the entire agreement period entitled to all the rights pursuant to the foregoing laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.16.</TD><TD STYLE="text-align: justify">The Tenant hereby declares that it is aware that the Landlord and/or the Management Company do
not undertake to provide security guards and/or other security means at the complex and/or in the premises, and if they do so this
will not create any liability or undertaking toward the Tenant. It is further explicitly agreed that the Keepers Law, 5727 &ndash;
1967 does not apply to the agreement and its appendices and under no circumstances will the Landlord and/or the Management Company
or anyone on their behalf be considered as paid or non-commissioned security guards.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.17.</TD><TD STYLE="text-align: justify">The Landlord undertakes to execute and maintain for the entire lease period, itself or through
the Management Company, the insurance policies detailed further on in this section with a duly authorized and reputable insurance
company:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.75in">19.17.1.</TD><TD STYLE="text-align: justify">Insurance insuring those parts of the building in the complex owned by the Landlord or that the
Landlord undertook to insure (including but not limited to the premises building), against loss or damage due to the risks that
are acceptable in extended fire insurance policies, including but not limited to fire, smoke, lighting, explosions, earthquake,
storm and blizzard, flood, liquid damages and burst pipes, damage by vehicles, damage by aircrafts, riots, strikes, malicious damage
and any breaking damages. Such insurance will include a section pertaining to the waiver of the right to subrogation toward the
Tenant, however such a waiver will not apply in favor of a person who maliciously causes damage. For the avoidance of doubt, it
is explicitly agreed that such insurance will not include content and/or additions, improvements or extensions made by and/or on
behalf of and/or for the Tenant and/or the other rights holders and will not include glass, windows, partitions from glass and
glass door insurance whereby the obligation to insure them is imposed upon the Tenant as stated in Section (1) to the Tenant&rsquo;s
permanent insurance policies confirmation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.75in">19.17.2.</TD><TD STYLE="text-align: justify">Consequential loss insurance policy insuring loss of rent and loss of management fees due to damage
caused to parts of the building in the complex owned by the Landlord or that the Landlord undertook to insure (including but not
limited to the premises building) due to the risks detailed in Section 19.17.1 above, and this for an indemnification period of
at least 12 (Twelve) months. Such insurance will include a section pertaining to the waiver of the right to subrogation in favor
of the Tenant, however such a waiver will not apply in favor of a person maliciously causing damage.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in">It is agreed
that the Landlord and/or the Management Company may opt not to execute a consequential loss insurance policy insuring loss of rent
and loss of management fees as stated in this Section 19.17.2 above, in full or in part, however the provisions in Section 19.20
below will apply as if such an insurance policy was executed in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.18.</TD><TD STYLE="text-align: justify">As stated in Section 3.1.7 to the management agreement, the Landlord may of its sole discretion
execute additional insurance policies in addition to those detailed in Section 19.17 above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.19.</TD><TD STYLE="text-align: justify">It is explicitly agreed that executing the insurance policies detailed in Section 19.17 above doers
not add any liability to the Landlord and/or the Management Company beyond that stated in this contract and/or does not derogate
from the Tenant&rsquo;s liability pursuant to the agreement and/or by law (other than as explicitly stated at the end of Section
19.20 below).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">19.20.</TD><TD STYLE="text-align: justify">The Landlord exempts the Tenant of liability for damage it is entitled to indemnification for pursuant
to the policies executed in accordance with Sections 19.17.1 and 19.17.2 above (or would have been entitled to indemnification
for but for the deductibles stipulated in such policies), however the exemption from liability as stated above will not apply in
favor of a person who maliciously caused damage.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">Notwithstanding
the above should an insurance peril manifest that is insured pursuant to Sections 19.17.1. and 19.17.2 above, pursuant to circumstances
for which the Tenant is liable under this contract and/or by law, the Tenant will bear the damage and/or loss amount sustained
up to the deductible amounts applicable pursuant to such policies; provided that the amount the Tenant bears for each insurance
peril is no less than an amount equal to $20 (US) multiplied by the area of the premises in square meters (however no less than
a sum of $1,000 (US) and not to exceed a sum of $ 20,000 (US).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.95pt"></TD><TD STYLE="width: 35pt">20.</TD><TD STYLE="text-align: justify"><B><U>PERMITS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">20.1.</TD><TD STYLE="text-align: justify">For the entire lease period, the Tenant, and it alone will be responsible to obtain the licenses
required by law at any time to run its business from within the premises, to renew them and to ensure they are valid. Should the
management of the Tenant&rsquo;s business in the premises require obtaining a business license and/or any other permit then the
Tenant is liable and undertakes to obtain the necessary permit/s, all at its expense. The Tenant declares that it is well versed
and experienced in the business it intends to run from within the premises and all the licensing and permits issue that are required
to run the business as stated above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">20.2.</TD><TD STYLE="text-align: justify">The Landlord undertakes to sign as an &ldquo;owners signature&rdquo; as rights holder in the complex,
at the Tenant&rsquo;s request, any document and/or application reasonably required to obtain the business license and/or other
permit required to operate the business for the purpose of the lease by virtue of the law and subject to the provisions in this
contract and by law, provided that no undertaking, obligation or liability will apply to the Landlord as a result thereof and also
that the Landlord will not incur as a result thereof any expenses. For the avoidance of doubt it is clarified that this conduct
by the Landlord does not derogate from the Tenant&rsquo;s liability and undertaking to obtain such a license or permit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">20.3.</TD><TD STYLE="text-align: justify">Without derogating from the provisions above, the Tenant undertakes to run its business and to
comply with all the requirements by virtue of the Business Licensing Law, 5728 &ndash; 1968 (Hereinafter in this section: &ldquo;<B>The
Law</B>&rdquo;), to obtain any license and permit required pursuant to the law to run the Tenant&rsquo;s business from within the
premises in accordance with the purpose of the lease, and to renew it from time to time, as required by law and to complete all
the works and/or requirements on the authorities behalf to obtain and/or renew any license and permit required by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">20.4.</TD><TD STYLE="text-align: justify">The Tenant and it alone will be responsible for any instance that offenses and/or violations of
the law have been committed in the premises and/or by the Tenant, its employees and/or by anyone on the Tenant&rsquo;s behalf even
outside the premises, including but not limited to pursuant to the Prevention of Smoking in Public Places and Exposure to Smoking
Law, 5743 &ndash; 1983 (Hereinafter: &ldquo;<B>The Prevention of Smoking Law</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">20.5.</TD><TD STYLE="text-align: justify">The Tenant undertakes that the design of the premises, the construction and operation thereof will
be done in accordance with the statutory requirements, as in effect from time to time, insofar as accessibility is concerned, including
but not limited to in accordance with the Equal Rights for Persons with Disabilities Law, 5758 &ndash; 1998 and the secondary legislation
pursuant thereto, in the format in effect from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">20.6.</TD><TD STYLE="text-align: justify">The Tenant will alone pay any fine or punishment imposed for running the business and/or use of
the premises by the Tenant and/or its employees and/or agents and/or customers without a permit or nonconforming to a permit, whether
imposed upon the Landlord or upon the Management Company or if imposed upon the Tenant. In any event of a violation of the provisions
in the Prevention of Smoking Law and/or secondary legislation by virtue thereof, in the premises and/or by the Tenant and/or someone
on its behalf, including but not limited to its employees even outside the premises &ndash; the Tenant will be liable to bear any
fine and/or penalty imposed as a result thereof and undertakes to instruct its employees to avoid violating the provisions in the
Prevention of Smoking Law and/or the secondary legislation by virtue thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">20.7.</TD><TD STYLE="text-align: justify">None of the above will be considered authorization by the Landlord to the Tenant to use the premises
and/or manage its business without a permit and/or not conforming to the permit. For the avoidance of doubt it is clarified that
if and insofar as an order and/or demand and/or directive and/or notice is received from any authorized authority, to shut down
and/or stop and/or suspend the activity being conducted from within the premises, the Tenant will act in accordance with such a
demand by the authorities and this by the date determined to do so by the authorities and without this being authorization not
to uphold the Tenant&rsquo;s undertakings pursuant to this contract.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">20.8.</TD><TD STYLE="text-align: justify">It is agreed that not obtaining a license the Tenant needs to manage its business from the premises
will not release the Tenant from fulfilling any of its undertakings pursuant to this contract, in the event the Tenant is forced
to stop or suspend its activity in the premises in accordance with the provisions in Section 20.7 above and/or in accordance with
the provisions in the law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 35.45pt">21.</TD><TD STYLE="text-align: justify"><B><U>MAINTAINING THE PREMISES AND MANAGEMENT THEREOF</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: -36.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">21.1.</TD><TD STYLE="text-align: justify">The Tenant undertakes to run its business from within the premises in accordance with the provisions
in the law applicable to the matter and without causing any nuisance including but not limited to noise, odors (including but not
limited to installing and operating fume hoods), pollution and not to cause any interruption or nuisance to occupiers and/or users
of the rest of the complex and its surroundings.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">Without prejudicing
the generality of the provisions above the Tenant undertakes not to operate in the premises or its surroundings announcement stems
and/or speakers and to maintain a high cleanliness and maintenance standard in the premises and in its surroundings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">21.2.</TD><TD STYLE="text-align: justify">The Tenant undertakes not to run in the complex outside the premises any activity relating to its
business and not to keep any goods and/or equipment and/or inventory and/or other chattels (hereinafter referred to as: &ldquo;<B>Chattels</B>&rdquo;)
outside the premises in the complex unless it receives approval in writing and in advance from the Landlord and the Management
Company any time chattels belonging to the Tenant are found outside the premises as stated above. The Landlord or the Management
Company may (however are not obligated) to remove them at the Tenant&rsquo;s expense forthwith without notice and without the Landlord
or the Management Company being liable for the completeness thereof or for damages the Tenant sustains as a result thereof, if
sustained. Additionally the Tenant will pay the Landlord and/or the Management Company a pre-determined and agreed payment of a
sum of NIS 500 (Five Hundred New Shekels) for each hour the chattels are outside the premises without the Landlord and/or the Management
Company&rsquo;s approval as stated above (and the relative part of the aforementioned amount for any part of an hour). The payment
stated above will be paid in addition to linkage differentials commencing from the date this contract is signed and will be paid
in addition to VAT stipulated by law, immediately upon the Landlord and/or the Management Company&rsquo;s first written demand.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">21.3.</TD><TD STYLE="text-align: justify">The Tenant will run its business in the premises while complying with all the procedures and instructions
determined by the Management Company by virtue of its power as stated in Section 15 above and all of its sub-sections, including
but without prejudicing the generality of the above, the Tenant will ensure to stringently adhere to all of the Management Company
and/or the Landlord&rsquo;s instructions in connection with the days and hours of operation, in connection to hauling, inserting
and removing goods and packages into the premise and from it, and in particular in relation to hours and ways of performing these
actions. The Tenant undertakes that all those in commercial contact with it, including but not limited to vendors, will adhere
to the Management Company&rsquo;s instructions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">21.4.</TD><TD STYLE="text-align: justify">The Tenant undertakes to keep the premises, during the entire lease period in a good and proper
state of repair, and will fix, without delay and at its expense any malfunction, damage or disrepair that is discovered therein,
in its systems and facilities and should the Tenant fail to do so within 7 (Seven) days of the occurrence of the damage and/or
malfunction, the Landlord and/or the Management Company may enter the premises and do so instead of the Tenant and the provisions
in Section 30 to this contract will apply.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">21.5.</TD><TD STYLE="text-align: justify">The Landlord and/or the Management Company will be entitled to enter, from time to time, the premises
to check if the provisions in this lease contract are being complied with and/or to carry out works and repairs, whether for the
premises or for other premises, provided that as little interruption as possible is caused to the Tenant and in the event repairs
are being carried out &ndash; to return the previous condition, insofar as possible and within reason.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">The Landlord
will notify the Tenant, insofar as possible, of its intention to enter the premises, a reasonable time in advance, pursuant to
the circumstances, to the exclusion of emergencies with regard to which the Landlord will not be required to give such early notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">21.6.</TD><TD STYLE="text-align: justify">The Tenant will not affix and/or install signs or notices on the external walls of the premises
or the complex and not on the glass doors of the premises on either side (if applicable) without the Landlord and/or the Management
Company&rsquo;s approval in advance and in writing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">Signs for
the premises will only be allowed subject to the architect and/or Management Company&rsquo;s approval and in accordance with the
rules determined by them in this respect, and subject to the fact that the Tenant receives any permit required by law to place
signs and complies with the terms thereof and will bear any fee or other charge with respect thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">Without derogating
from the provisions above, it is clarified and agreed that the Landlord and/or the architect and/or the Management Company may,
however are not obligated, at any time, to demand from the Tenant, at its expense and responsibility, to change the location of
the signs and/or size and/or content and/or shape and/or demand that the Tenant renew it and/or replace the signs with new signs
and such like, and all in accordance with their sole discretion and the Tenant will not have any allegation and/or demand toward
the Landlord and/or the architect and/or the Management Company in connection thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 35.45pt">22.</TD><TD STYLE="text-align: justify"><B><U>ADDITIONS AND CHANGES</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in">The Tenant
will not be entitled to make any changes, improvements or additions in the premises, whether internal changes or external, without
obtaining the Landlord&rsquo;s consent to do so in advance and in writing (Hereinafter: &ldquo;<B>Changes and Additions</B>&rdquo;).
In the event the Landlord permits the Tenant to make any changes and additions in the premises the provisions in Section 12.3 to
this contract will apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in">Without prejudicing
and/or derogating from the provisions above, if and when the Tenant executes and/or carries out in the premises changes and additions
and including but not limited to the Tenant&rsquo;s works in the premises and/or in its systems, then, on the date possession of
the premises is returned to the Landlord, for any reason, the Tenant will remove at its expense the changes and additions and will
restore the premises to the condition it was in on the day the premises were opened and without the changes and additions, unless
the Landlord demands, in writing, that the changes and additions, and/or some of them remain, and in such a case they will become
the Landlord&rsquo;s property and the Tenant will not have any claim and/or demand against the Landlord for the changes and additions
and/or for its investment therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 35.45pt">23.</TD><TD STYLE="text-align: justify"><B><U>CONVEYING RIGHTS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: -36.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">23.1.</TD><TD STYLE="text-align: justify">The Tenant will not have a right to convey and/or endorse and/or charge its rights and/or its undertakings
pursuant to this contract and/or in connection to all or some, hereof, in any manner unless it obtains the express advance and
written consent from the Landlord and in accordance with the terms determined by the Landlord of its sole discretion. The Tenant
will not lease the premises or any part thereof pursuant to a sub-lease, will not convey the premises or any part thereof, for
consideration or without consideration, will not deliver or part thereof possession to another and will not permit in any part
thereof use by another, for consideration or without consideration, not even through a concessionaire, and will not charge or pledge
any of its rights pursuant to this contract.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">Without derogating
from the provisions above, conveying of the Tenant&rsquo;s rights in the premises will be possible only subject to the fulfillment
of all the following accumulative terms:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 49.5pt">23.1.1.</TD><TD STYLE="text-align: justify">All of the Tenant&rsquo;s debts in connection with the premises and this contract were paid to
the Landlord&rsquo;s satisfaction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 121.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 49.5pt">23.1.2.</TD><TD STYLE="text-align: justify">The Landlord gave its consent in advance and in writing to convey such rights, the identity of
the transferee, its financial robustness, the nature of its activity and it fitting in with the mix of the businesses operating
in the complex, and to any other parameter that the Landlord deems fitting to approve within the framework of conveying the rights
as stated above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 49.5pt">23.1.3.</TD><TD STYLE="text-align: justify">The Transferee and the Tenant signed a conveyance of rights instrument, pursuant to the terms and
in the format as determined by the Landlord in accordance with its discretion;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 49.5pt">23.1.4.</TD><TD STYLE="text-align: justify">The Transferee gave the Landlord an authorization to charge its account, deposited all the securities
and furnished confirmation pertaining to executing the insurance policies to the Landlord, and all in accordance with the provisions
in this contract and the rights conveyance instrument;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 49.5pt">23.1.5.</TD><TD STYLE="text-align: justify">The Transferee and the Tenant fulfilled all of the conditions and requirements in connection with
the conveyance of rights as stated above, as determined by the Landlord, on time and in full.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 121.5pt; text-align: justify; text-indent: 0in">It is clarified
to avoid any doubt that the provisions set forth in this Section 23.1 above do not constitute a final and exhaustive list of the
conditions to convey such rights and the Landlord reserves the right to determine additional conditions and requirements, of its
discretion, as a condition precedent to approving the conveyance of the rights without having to reason its decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 121.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">23.2.</TD><TD STYLE="text-align: justify">Cancelled.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">23.3.</TD><TD STYLE="text-align: justify">If the Tenant is a corporation, the Tenant undertakes that during the entire lease period no changes
will apply to the controlling shareholders, direct or indirect in the corporation (up to a flesh and blood level), voluntarily
or involuntarily and will remain in the hands of the <B><U>individuals</U></B> detailed <U>in Appendix A</U> to this contract.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&ldquo;<B>Control</B>&rdquo;
for the purpose of this section: holding at least 51% of the shares and rights of any type and kind in the corporation, including
but not limited to appointing at least 51% of the directors and the right to appoint the CEO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">23.4.</TD><TD STYLE="text-align: justify">If the Tenant is incorporated as a partnership, whether registered or not, it undertakes that during
the entire lease period no change of partners and/or adding a partner and/or a partner resigning and/or any other change in the
composition of the partnership as in effect on the date this contract is signed will apply. Should a change occur in the composition
of the partnership voluntarily or involuntarily, without obtaining the Landlord&rsquo;s consent thereto or contrary to the conditions
determined by the Landlord, the provisions in Section 24.5 below will apply.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">23.5.</TD><TD STYLE="text-align: justify">The Landlord and/or the Management Company may charge and/or pledge and/or convey and/or endorse,
in whole or in part, their rights and/or undertakings in the Land and/or the complex and/or pursuant to this contract, in whole
or in part, and/or make any other disposition, and to have any entity or body share in the management and/or ownership of the Land
and/or complex and/or in any part thereof, as they deem fit and pursuant to their exclusive and absolute discretion and without
any need to obtain the Tenant&rsquo;s consent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">23.6.</TD><TD STYLE="text-align: justify">The Landlord and/or the Management Company will be entitled to charge and/or pledge and/or convey
and/or endorse, in whole or in part, their rights and/or obligations pursuant to this contract, in whole or in part, and all provided
that the Tenant&rsquo;s rights under this contract are not prejudiced. The Tenant undertakes to cooperate and sign any document
required of it if required by the Landlord to approve and/or perform the provisions in this section.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">The Tenant
confirms that it is aware that the rights in the Land upon which the complex was built is pledged and charged in favor of the bank
and/or that the Landlord may pledge and charge them again and/or refinance, and that the bank&rsquo;s rights take priority and
will take preference of first degree and exclusively over the Landlord&rsquo;s rights and/or anyone on its behalf in the Land,
including but not limited to the Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">The Landlord
may give the Tenants an irrevocable instruction to pay all the monies and payments owing to the Landlord from the Tenant pursuant
to this contract to a bank account that the Landlord so instructs the Tenant, and to it alone, and the Tenant hereby undertakes
irrevocably to comply with this provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">23.7.</TD><TD STYLE="text-align: justify">Without derogating from the provisions in Section 24.5 below, it is hereby declared that the right
to the lease pursuant to this contract and all of the rights granted to the Tenant pursuant to this contract &ndash; cannot be
bequeathed, and in the event, heaven forbid, the Tenant dies &ndash; this contract will expire forthwith, and the provisions in
this contract pertaining to ending the lease period and vacating the premises will apply.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">23.8.</TD><TD STYLE="text-align: justify">It is hereby agreed that the Tenant will not be entitled to collect any payment for the conveyance
of the lease by it to another entity, including but not limited to the conveyance being executed with the Landlord&rsquo;s approval
(and it is again stressed that the Tenant is prohibited from conveying rights and/or its undertakings pursuant to the lease contract
without the Landlord&rsquo;s consent to be given in advance and in writing and subject to the conditions stipulated by the Landlord,
insofar as stipulated), no matter what this &ldquo;vacating fee&rdquo; is called or any other name. If the Tenants receives such
a payment &ndash; it must immediately pay it to the Landlord.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">23.9.</TD><TD STYLE="text-align: justify">Without derogating from the provisions in Section 24.5 below, if the Tenant&rsquo;s rights pursuant
to this contract were conveyed to another, voluntarily or involuntarily, without obtaining the Landlord&rsquo;s consent in accordance
with the provisions in this Section 23 or not in accordance with the conditions stipulated by the Landlord for such a conveyance
of rights, then without derogating from any other relief available to the Landlord by law, the Landlord may give notice that the
lease period has ended and in such a case this contract will come to an end and the provisions in this contract will apply applicable
to the end of the lease period, and <I>inter alia</I> with regard to vacating the premises, and the Tenant will have no allegation
and/or demand and/or claim in connection thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 35.45pt">24.</TD><TD STYLE="text-align: justify"><B><U>RELIEF AND REMEDIES</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: -36.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">24.1.</TD><TD STYLE="text-align: justify">Whereupon a party to this contract breaches any of its provisions that injured party will be entitled
to all the relief determined in the Contracts Law (Remedies for Breach of Contract), 5731 &ndash; 1970, even in the event a specific
relief or remedy is granted in this contract for such a breach, and this without derogating from the provisions in this contract
or the provisions in the law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: -36.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">24.2.</TD><TD STYLE="text-align: justify">Without derogating from its right to compensation of a higher amount or to any other relief, in
the event of a material breach of this contract by the Tenant, the Landlord will be entitled to pre-determined, agreed and estimated
compensation of an amount equal to the rent, management fees and VAT thereon, for six months&rsquo; rent, whereby this amount will
be linked to the Index and up to the index recorded on the date the payment is actually made (Hereinafter: &ldquo;<B>The Liquidated
Damages</B>&rdquo;), and this whether the Landlord opted to uphold the contract or not or opted to rescind it. The parties declare
that they view the said amount as agreed and suitable compensation for the damage the parties perceived as a probable result of
a material breach of this lease contract by the Tenant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">24.3.</TD><TD STYLE="text-align: justify">Any breach of any of the provisions detailed below of the contract will be considered a material
breach hereof:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 122.8pt; text-align: left; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 40.5pt">24.3.1</TD><TD STYLE="text-align: justify">A breach of any of the provisions in Sections 6, 7, 8, 9, 10, 12, 13, 14, 15, 17, 18, 19, 20, 21,
22, 23, 24, 25 and 26 to this contract, and all of their sub-sections.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 122.8pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 40.5pt">24.3.2</TD><TD STYLE="text-align: justify">A delay in making any payment that the Tenant must pay pursuant to the provisions in this contract,
for a period exceeding 7 (Seven) days and/or a delay in payment of two consecutive and sequential payments and/or a delay in making
3 (Three) payments that the Tenant must pay during the entire lease period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 122.8pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 40.5pt">24.3.4</TD><TD STYLE="text-align: justify">The provisions above do not derogate from the provisions in Section 24.5 below.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">24.4.</TD><TD STYLE="text-align: justify">In any event the Tenant stops the operation of the business in the premises or the lease contract
for any reason whatsoever, the Tenant must pay all the payments applicable to it by virtue of the provisions in this contract until
the end of the lease period and this without derogating from the rest of the Tenant&rsquo;s obligations pursuant to this contract
and/or any of the Landlord&rsquo;s rights pursuant to the law and pursuant to this contract, including but not limited to the right
to receive the liquidated damages.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">24.5.</TD><TD STYLE="text-align: justify">The Landlord will be entitled to rescind this contract, notwithstanding any provision in the contract
in connection with the lease period and demand that the Tenant vacate the premises forthwith in an early notice of Ten (10) days
(Hereinafter: &ldquo;<B>The Rescission Notice</B>&rdquo;) and return possession thereof to it as stated in Section 25.7 below,
and this in each one of the following instances:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 40.5pt">24.5.1.</TD><TD STYLE="text-align: justify">The Tenant materially breached this contract or a material provisions herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 112.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 40.5pt">24.5.2.</TD><TD STYLE="text-align: justify">The Tenant breached this contract not by a material breach and did not remedy the breach within
14 days of the day it was required to do so or that the Tenant breached the provisions in this contract at least 3 (Three) times,
accumulatively, during the course of the entire contract period. To avoid doubt, it is clarified that in regard to the number of
breaches by the Tenant as stated above, all of the Tenant&rsquo;s breaches will be taken into account, including but not limited
to breaches that were remedied on the date determined to do so.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 40.5pt">24.5.3.</TD><TD STYLE="text-align: justify">The Tenant, or any of its individuals or any of the guarantors to this contract, as applicable,
died and/or a petition was filed with the authorized court to have it wind up, declare it bankrupt, to appoint a trustee, liquidator,
temporary liquidator, pre-liquidator, receiver over a material part of its assets, and/or to impose a lien over a material part
of its assets, and an order was issued pursuant to the petition or the petition was cancelled or dismissed within 45 (Forty Five)
days of it being filed with the court and/or if the Tenant and/or any one of the guarantors to this contract filed a petition to
wind it up and/or declare it bankrupt and/or to execute a creditors arrangement and/or stay of proceedings notwithstanding the
above. In the event of one of the foregoing events happening with regard to a guarantor to this contract, the Tenant will be entitled
to furnish one guarantor whose identity is agreeable to the Landlord of the Landlord&rsquo;s sole discretion, and this within 15
(Fifteen) days of the occurrence of that event.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>



<P STYLE="margin: 0"></P>
<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 40.5pt">24.5.4.</TD><TD STYLE="text-align: justify">All or some of the other guarantees and/or securities that were given to uphold this contract expired
or were cancelled or were declared by the authorized court as void or invalid for any reason, or were forfeited by the Landlord
and/or the Management Company without the Tenant complementing them and resubmitting them on time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 40.5pt">24.5.5.</TD><TD STYLE="text-align: justify">The Tenant did not give the Landlord any one of the execution of insurance policies confirmation
that it is to furnish to the Landlord pursuant to Section 19 above, including but not limited to confirmation that they were renewed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">24.6.</TD><TD STYLE="text-align: justify">Whereupon a cancellation notice was given the provisions in Section 25 below will apply and the
following provisions:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 40.5pt">24.6.1.</TD><TD STYLE="text-align: justify">The Landlord and the Management Company will have the right to a lien over all of the Tenant&rsquo;s
equipment and inventory in the premises and/or in the complex as security for payment of all the compensation and monies owing
to the Landlord and/or the Management Company in such a case from the Tenant. The Landlord and/or the Management Company will be
entitled to forfeit the equipment and the inventory and/or to collect on them by selling them or by any other manner to settle
the Tenant&rsquo;s debts toward them if they are not settled within 15 (Fifteen) days of the date the first written demand is received.
It is clarified that the Landlord and/or the Management Company will not be subject to keepers debts whether as a paid keeper or
without payment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 112.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 40.5pt">24.6.2.</TD><TD STYLE="text-align: justify">The Tenant will not have any right to object in any manner and/or to try to delay or prevent the
Landlord engaging with any other tenant and/or to try prevent or delay execution of leasing the premises to a substitute tenant.
All of the above will apply both to the relations between the Landlord and the Tenant and the relations between the Tenant and
the substitute tenant will be considered, <I>inter alia</I>, as contractual provisions in favor of a third party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">24.7.</TD><TD STYLE="text-align: justify">In any event the Tenant breaches this contract, whether the Landlord chose to rescind this contract
or not, the Tenant will be responsible to reimburse the Landlord and the Management Company immediately upon receiving its first
written demand, all the expenses, damages and losses they sustain due to a breach of the contract by the Tenant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">24.8.</TD><TD STYLE="text-align: justify">A delay on the Tenant&rsquo;s part in making any payment to the Landlord and/or to the Management
Company will accrue interest at the maximum rate permitted by law at that time and if there is no restriction pursuant to the law
on the interest rate, interest in arrears at the maximum rate that Bank Leumi Le&rsquo;Israel Ltd. charges on unauthorized overdrafts
at that time for the period in arrears (Hereinafter: &ldquo;<B>Interest in Arrears</B>&rdquo;), and this without derogating from
the Landlord and/or Management Company&rsquo;s right to compensation at a higher rate or any other relief.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">Written confirmation
by one of the bank branches managers pertaining to said interest rate will constitute determining and sufficient proof of the interest
rate as stated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">24.9.</TD><TD STYLE="text-align: justify">Any discount and/or benefit and/or grant and/or consideration in money and/or equivalent and/or
exemption from payment of rent and/or management fees and/or participation in investing in the adjustments to the premises, offered
to the Tenant by the Landlord and/or the Management Company, insofar as offered during the course of and/or before the lease period,
are contingent upon the Tenant fulfilling all of its undertakings pursuant to this contract in full and on time. whereupon the
Tenant violates any of its said undertakings and/or does not fulfill them in full and on time then any benefit and/or grant and/or
exemption and/or participation amount in adjustment costs as stated above are voided, and the Tenant will be required to reimburse
any amount and/or the value of the benefit it received as stated above, and this without derogating from the rest of the Landlord&rsquo;s
relief and remedies pursuant to the law and/or pursuant to this contract.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 35.45pt">25.</TD><TD STYLE="text-align: justify"><B><U>VACATING THE PREMISES</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">25.1.</TD><TD STYLE="text-align: justify">The Tenant undertakes to vacate the premises at the end of the lease period, or on the earlier
date if shortened due to the contract being rescinded or expiring for any reason, all according to the earliest date and as applicable
and to return the premises to the exclusive possession of the Landlord whereby the premises will be in the same condition the premises
was in on the delivery date, including removal of any object and/or addition and/or permanent facility installed by the Tenant
(to the exclusion of the Landlord demanding that they remain in the premises) by such a manner that the removal thereof will not
damage the premises and its internal and external appearance, and all subject to reasonable wear and tear, however in any event
&ndash; the premises must be in good condition, orderly and whitewashed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">25.2.</TD><TD STYLE="text-align: justify">The Tenant must return the premises free and clear of any person and object, and in accordance
with the provisions in Section 22 above, and all at the Tenant&rsquo;s expense.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">25.3.</TD><TD STYLE="text-align: justify">Uninstalling affixtures and/or systems in the premises owned by the Tenant (unless the Landlord
demands that they remain in the premises) will be executed in accordance with the engineer&rsquo;s instructions and by contractors
approved to do so by the Landlord only, and in any event, without damaging the building in the complex and/or the premises and/or
the systems installed therein and serving them and/or the other tenants and/or the complex&rsquo;s regular activity and/or that
of other tenants therein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">25.4.</TD><TD STYLE="text-align: justify">Upon vacating the premises, for any reason, the Tenant will furnish to the Landlord confirmation
from all the municipal and/or government and/or other authority and/or from any body that the Tenant undertook in this contract
to make various payments directly to it attesting to the Tenant paying all the payments relating to the lease period and that it
has no debt or undertaking to any of the said bodies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">25.5.</TD><TD STYLE="text-align: justify">For the avoidance of doubt, in the event the Tenant does not furnish all the aforementioned approvals
on time, it will be seen, with regard to this contract as if it did not pay the said payments and the Landlord will have all the
rights in connection thereto, including but not limited to the right to realize the securities given to it to secure the Tenant&rsquo;s
undertakings or any part thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">25.6.</TD><TD STYLE="text-align: justify">For each day the Tenant is late in vacating the premises the Tenant will pay the Landlord pre-determined,
agreed and estimated compensation of a sum equal to the rent owing to the Landlord for the last month&rsquo;s rent divided by 10
(Ten), and all subject to the linkage provisions in this contract. If the delay in vacating the premises exceeds 30 (Thirty) days,
the Tenant will pay the Landlord for each day it is late in vacating the premises pre-determined, agreed and estimated compensation
of a sum equal to the rent owing to the Landlord for the last month&rsquo;s rent as stated above, divided by 6 (Six).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">The parties
declare that the said amount constitutes agreed and appropriate compensation for the damage the parties see as a probable result
of a delay in vacating the premises as stated above, and all this without derogating from the Landlord&rsquo;s right to any other
relief and/or compensation at a higher rate, including but not limited to compensation the Landlord is charged, if charges, toward
a substitute tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">25.7.</TD><TD STYLE="text-align: justify">Without derogating from its right to any other relief in the event of the premises not being vacated
on time, the Landlord may:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 40.5pt">25.7.1.</TD><TD STYLE="text-align: justify">Immediately stop supplying to the Tenant and/or premises and/or instruct the Management Company
and the latter must comply with such an order, to stop supplying to the Tenant and/or the premises, electricity, water, air conditioning
or other services of its discretion and the Tenant will not have any allegation or claim in connection thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 112.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 40.5pt">25.7.2.</TD><TD STYLE="text-align: justify">To enter itself and/or through others the premises, including but not limited to by breaking the
locks and to this end to use reasonable force and to remove from the premises any belongings or chattels found therein and to change
the locks or prevent access to it by the Tenant or someone on its behalf by any method it deems fit and the Tenant will not have
any allegation or claim in connection thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">25.8.</TD><TD STYLE="text-align: justify">The Landlord will be entitled to vacate the premises as stated above at any time it deems fit,
after giving a warning in advance and in writing of 7 (Seven) days. The Landlord will be entitled to do with the property and the
equipment found in the premises as it pleases according to its absolute discretion and <I>inter alia</I> the Landlord will be entitled
to remove the property and equipment from within the premises and may, however is not obligated, to store the property and equipment
at a place it deems fitting, and in such a case the Tenant must pay the removal and storage fees and the rend determined by the
Landlord of its sole and absolute discretion. And the Landlord may also sell such property and equipment at a price and pursuant
to conditions to be determined by the Landlord of its sole discretion, and this to collect on its damages and expenses, and the
Tenant waives in advance any allegation and/or demand and/or claim in connection with the Landlord&rsquo;s said actions as stated
in this section.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">25.9.</TD><TD STYLE="text-align: justify">In any case the Tenant does not vacate the premises on time the Tenant or anyone on its behalf
will be considered trespassers and a &ldquo;new squatter&rdquo; in the premises, and it will not have any allegation or claim against
the Landlord or anyone on its behalf of the damages it sustains or its chattels sustain as a result of such action.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">25.10.</TD><TD STYLE="text-align: justify">To prevent the Tenant and/or any of its individuals and/or any person on its behalf access to the
premises or to spend time therein or to use the premises or any part thereof, including but not limited to the facilities, equipment
and inventory therein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">25.11.</TD><TD STYLE="text-align: justify">The Tenant will be responsible to pay the Landlord all the expenses and/or damages and/or charges
the Landlord and/or anyone on its behalf bear with regard to such actions and the provisions in Section 30 below will apply.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">25.12.</TD><TD STYLE="text-align: justify">The Tenant hereby gives its consent and authorization to the Landlord to perform the actions stipulated
in this section above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">25.13.</TD><TD STYLE="text-align: justify">The Landlord will not be liable for any damage of any kind the Tenant or its equipment or its property
sustain, if caused during or due to performing the actions stipulated in this section by the Landlord and the Tenant will not have
any allegation or claim against the Landlord or the Management Company due to performance of such actions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">25.14.</TD><TD STYLE="text-align: justify">For the avoidance of doubt, and without derogating from any of the provisions above, the Tenant
must pay all the Tenant&rsquo;s payments for the period it is late in vacating the premises, including and in particular payments
for which the Tenant was required to furnish confirmation as detailed in Section 25.4 above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: -36.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 35.45pt">26.</TD><TD STYLE="text-align: justify"><B><U>SECURITIES</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in">As security
to ensure fulfillment of all of its undertakings pursuant to this lease contract and pursuant to the management agreement, the
Tenant will furnish to the Landlord, on the date this contract is signed, all of the securities detailed below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">26.1.</TD><TD STYLE="text-align: justify">A letter of guarantee in the format attached to this contract as <B><U>Appendix F</U></B>, signed
by two guarantors approved by the Landlord in advance, as guarantors for all of the Tenant&rsquo;s undertakings, jointly and severally
with it (Hereinafter: &ldquo;<B>The Personal Guarantee</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">26.2.</TD><TD STYLE="text-align: justify">An autonomous, unconditional bank guarantee, that can be endorsed and/or transferred, prepared
in favor of the Landlord and the Management Company, as beneficiaries, jointly and severally, and which can be realized in payments,
in the format attached to this contract as <B><U>Appendix G</U></B> to be valid throughout the entire first lease period, and up
to 90 (Ninety) days after the end of the first lease period for the sum stipulated in <U>Appendix A</U> to this contract, whereby
the guarantee amount will be linked to the Basic Index (Hereinafter: &ldquo;<B>The Bank Guarantee</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">26.3.</TD><TD STYLE="text-align: justify">In the event this contract grants the Tenant a right to extend the lease period, and the Tenant
exercises its right to do so, the Tenant will furnish to the Landlord at least 60 (Sixty) days before the start of the additional
period a bank guarantee as detailed above valid for up to 90 (Ninety) days after the end of the relevant additional lease period,
and this also in accordance with the provisions in Section 7 above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">The Tenant
will bear all the expenses of the bank guarantee, including but not limited to stamp duty, renewal and the guaranteeing bank&rsquo;s
commission, insofar as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">26.4.</TD><TD STYLE="text-align: justify">A deposit of the sum stipulated in <U>Appendix A</U> to this contract (Hereinafter &ndash; &ldquo;<B>The
Deposit</B>&rdquo;). It is agreed between the parties that the deposit will not constitute at any stage of the lease period payment
for the rent, management fees, parking fee and/or any other payment the Tenant must pay in accordance with the provisions in this
contract. Whereupon the Landlord forfeits any amount from the deposit the amount will be credited on account of the debt and/or
the charge for which the Landlord chose to forfeit it. It is clarified that insofar as the deposit amount is returned to the Tenant,
or any part thereof, it will be returned in nominal values only, without linkage and/or interest. As necessary pursuant to the
above, it is clarified that in return for depositing the deposit the Tenant will only be given a receipt.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">26.5.</TD><TD STYLE="text-align: justify">A promissory note linked to the index without filling in the payment date of the note in the format
attached as <B><U>Appendix H</U></B> to this contract for the sum stipulated in <U>Appendix A</U> to this contract (Hereinafter:
&ldquo;<B>The Promissory Note</B>&rdquo;). The Landlord will be entitled to fill in the payment date on the note of its discretion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.55pt">The personal
guarantee, the bank guarantee, the deposit and the promissory note will be referred to above and below jointly as: &ldquo;<B>The
Securities</B>&rdquo; or &ldquo;<B>The Collateral</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">26.6.</TD><TD STYLE="text-align: justify">The Landlord may, at its discretion and after giving a written warning 7 (Seven) days in advance,
realize all or some of the securities, in any case of a breach of this lease contract (including but not limited to the management
contract) by the Tenant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">26.7.</TD><TD STYLE="text-align: justify">After 90 (Ninety) days following the end of the relevant lease period, and after it is proven to
the Landlord&rsquo;s satisfaction that the Tenant fulfilled all of its undertakings in accordance with this contract and the management
agreement, all of the securities will be returned to the Tenant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">26.8.</TD><TD STYLE="text-align: justify">For the avoidance of doubt, delivery of the said securities or any part thereof and/or realizing
them by the Landlord and/or the Management Company does not derogate from the Landlord and/or the Management Company&rsquo;s right
to collect that which they deserve from the Tenant through any other method, or to release the Tenant of any of its undertakings
pursuant to this contract or the management agreement, or to limit the compensation amount and/or damages the Landlord and/or the
Management Company will be entitled to collect from the Tenant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">26.9.</TD><TD STYLE="text-align: justify">The Landlord will be entitled to charge the securities in favor of any bank and/or financial institution
and/or to assign and/or endorse and/or transfer the securities to substitutes and/or transferees of the Landlord and/or the Management
Company (including but not limited to parent companies and/or subsidiaries and/or sister companies and/or affiliated companies
and/or integrated companies of the Landlord and/or the Management Company stepping into the Landlord and/or the Management Company&rsquo;s
shoes for all senses and purposes) and/or in favor of any bank and/or financial institution and/or to any third party constituting
the Landlord and/or the Management Company and/or who purchases from the Landlord the rights in the premises (Hereinafter in this
section: &ldquo;<B>The Transferee</B>&rdquo;), provided that realizing the securities is done in accordance with the provisions
in this contract.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">It is further
agreed that in the event the Landlord and/or the Management Company request to endorse and/or assign to the Transferee the securities
in their possession as stated above, the Tenant undertakes to furnish alternative collateral (as defined above) in favor of the
Transferee and this within 7 days of the date of the Landlord and/or the Management Company&rsquo;s demand to do so. In return
for receiving the new collateral the Landlord and/or the Management Company will return the previous securities to the Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">Insofar as
the Tenant does not furnish the new collateral as stated above, this will constitute a material breach of this agreement and the
Landlord and/or the Management Company will be entitled to realize the collateral in their possession forthwith and to keep the
collateral realization monies as a deposit in accordance with the provisions in this agreement (including but not limited to the
Landlord and/or the Management Company being entitled to transfer the said deposit monies to the Transferee). The Tenant undertakes
not to object to any realization of the securities proceeding as stated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">26.10.</TD><TD STYLE="text-align: justify">For the avoidance of doubt, in any event the rent and/or the management fees and/or payment for
the parking is increased, the Tenant must also increase the collateral accordingly. In any event of forfeiture and/or realization
of all or some of the securities, for any reason, the Tenant must complement them for the full amount of the securities within
48 (Forty Eight) hours of the time they were forfeited or realized without any need for a demand on the Landlord and/or the Management
Company&rsquo;s part.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 35.45pt">27.</TD><TD STYLE="text-align: justify"><B><U>NO TENANT&rsquo;S PROTECTION RIGHTS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -70.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.55pt">It is agreed
that the provisions in the Tenant&rsquo;s Protection Law (Consolidated Version), 5732 &ndash; 1972 and/or any other tenant protection
laws , including their regulations and orders (hereinafter in this section: &ldquo;<B>The Law</B>&rdquo;) will not apply to the
premises and/or with regard to this lease contract, and that no law granting the Tenant status of a protected tenant or granting
the Tenant a right not to vacate the premises in the event and on dates that the Tenant must, pursuant to the contract vacate the
premises will apply to the premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.55pt">The Tenant
confirms its awareness that the premises is located in a building whereby the construction thereof was completed after 20.8.68.
The parties declare expressly that this lease was concluded explicitly on the condition that the law will not apply to the lease.
The Tenant declares that it did not pay and will not pay the Landlord in connection with this contract any key money or any other
consideration other than rent and/or management fees and that the Tenant or anyone acting on its behalf including but not limited
to any of its individuals and/or shareholders therein will not be a protected tenant in the premises pursuant to the law and will
be estopped from filing any claims and raising any allegations in connection with it being a protected tenant or that it has more
rights in the premises than that granted to it explicitly in this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.55pt">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.55pt">The Tenant
declares that all of the investments to be made by it in the premises and/or the complex including but not limited to the equipment
and facilities will be done for its needs and that it is estopped from arguing that these investments constitute key money or a
substitute for key money or payment pursuant to Section 82 to the law or any payment granting it rights in the premises and it
will be estopped from demanding from the Landlord full or partial contribution to the expenses or reimbursement, for such investments
and the provisions in Section 22 above will apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 35.45pt">28.</TD><TD STYLE="text-align: left"><B><U>CREDITING PAYMENTS AND NO SET OFF RIGHT</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">28.1.</TD><TD STYLE="text-align: justify">In any event the Tenant owes the Landlord several charges, the Landlord will have the right to
determine at the time of payment, of its discretion, the charge to the account the amount paid will be credited. So long as the
Landlord does not notify the Tenant to the contrary, the payment will be credited firstly toward linkage differentials and interest
and/or interest in arrears, thereafter for the payment for parking, for management fees, for rent for electricity paid to the Landlord
(insofar as paid pursuant to this contract) and for the rest of the payments according to their order.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">28.2.</TD><TD STYLE="text-align: justify">The Tenant will not be entitled to set off from the Tenant&rsquo;s payments in accordance with
this contract, including but not limited from the rent, pecuniary charges that the Landlord and/or the Management Company will
owe the Tenant, if at all, whether by virtue of this contract or by virtue of other transactions. The Tenant will not be entitled
to delay performance of any of the Tenant&rsquo;s payments no matter what the circumstances.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: left; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 35.45pt">29.</TD><TD STYLE="text-align: left"><B><U>FORCE MAJEURE</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Tenant
declares and undertakes that the Landlord will not be considered as having breached this contract or did not fulfill any of its
conditions and the Tenant will not be entitled to any relief toward the Landlord, if the reason for the breach of the contract
or nonfulfillment of the condition derived from circumstances that the Landlord has no control over, including but not limited
to a fire, explosion, natural disaster, strike, war, act of terrorism, emergency situation or cease works orders on behalf of the
authorities, force majeure and/or upon the occurrence of any other event of this type.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 35.45pt">30.</TD><TD STYLE="text-align: left"><B><U>PERFORMANCE OF UNDERTAKINGS INSTEAD OF THE OTHER PARTY</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">So long as
an obligation is imposed upon the Tenant pursuant to this contract to perform an action or work or to pay a given payment and the
Tenant did not perform the action or the work or the said payment by the date stipulated to do so in the contract or in the law,
and if no such date is mentioned &ndash; by the date stipulated to do so in a written demand received from the Landlord &ndash;
then the Landlord and/or the Management Company will be entitled, however not obligated, to perform the action or the work or make
the payment instead of the Tenant and at the Tenant&rsquo;s expense, and this in person or through others. In such a case the Tenant
must pay the Landlord, immediately upon its first demand, all the amounts or losses or the damages the Landlord or the Management
Company paid or incurred in connection with performance of the action or the work or the said payment, in addition to 15% (Fifteen
Percent) of these amounts for general expenses and in addition to index linkage differentials and interest in arrears stipulated
in Section 24.8 above, commencing from the date the Landlord and/or the Management Company incurred the expense and until the date
the full amount is actually repaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 35.45pt">31.</TD><TD STYLE="text-align: left"><B><U>BUILDING ON THE LAND</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">31.1.</TD><TD STYLE="text-align: justify">For the avoidance of doubt, it is clarified that the rights granted to the Tenant pursuant to this
contract, insofar as they as they are awarded to it, are granted to the Tenant solely in relation to the premises, and the Tenant
do not and will not have any right in connection with the existing or additional building rights and/or existing or additional
building areas to be approved and will be built by the Landlord or by a given third party, and/or in connection with use of any
part of the complex, whether it exists or will exist in the future, not within the confines of the premises including roofs, passageways
and such like. The Tenant gives its consent in advance to any such action and/or use and the Tenant undertakes not to interfere,
object or interrupt in any manner whatsoever in relation to all planning actions in connection with the land and/or the complex.
Similarly, the Tenant undertakes to avoid raising any allegation against the Landlord and/or someone on its behalf in connection
thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">31.2.</TD><TD STYLE="text-align: justify">It is clarified that the Landlord will be entitled, at any time, without the need for the Tenant&rsquo;s
consent, to perform any change or addition or renovation on the land and/or in the complex, of its sole discretion both before
the start of the lease period or thereafter, including but not limited to adding and constructing floors to the complex including
changing their designations and/or correcting building permits, additional construction of the various kinds including but not
limited to adding floors to the complex, turning public areas to areas for exclusive use of various users, change of openings and
passageways and any other change in the complex and/or the complex plans, all of its sole discretion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">The Tenant
undertakes not to interfere and not to object to any such change or addition for any reason, including but not limited to interruptions
it will sustain, if sustained while performing the addition or change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">31.3.</TD><TD STYLE="text-align: justify">The Tenant is aware that during the course of the lease period, it is possible that additional
construction works will continue and/or start on the land and/or in the complex, which may cause noise, dirt, passage for laborers,
placing work means and/or work tools, including placing a crane.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">31.4.</TD><TD STYLE="text-align: justify">The Tenant undertakes not to interfere, object, or get involved in any manner with such construction
and not to raise any allegation and/or claim against the Landlord and/or anyone on its behalf in connection thereto, subject to
the fact that the access ways to the premises are not materially impaired.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 35.45pt">32.</TD><TD STYLE="text-align: left"><B><U>JURISDICTION</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The unique
and exclusive authority to rule on any matter that a dispute and/or differences of opinion arise between the parties relating to
any matter concerning the concluding and/or validity or breach and/or performance and/or interpretation of this contract and its
appendices will be granted to the authorized court in the city of Tel Aviv-Yafo, and only to this court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 35.45pt">33.</TD><TD STYLE="text-align: left"><B><U>MISCELLANEOUS</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">33.1.</TD><TD STYLE="text-align: justify">This contract and the appendices hereto formulate and express the rights and obligations between
the Landlord and/or the Management Company and the Tenant exclusively and absolutely.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">33.2.</TD><TD STYLE="text-align: justify">Upon signing this contract constituting the complete and binding contract between the parties,
any contract and/or memorandum and/or consent and/or declaration and/or prospect and/or covenant and/or publication made, if made,
by the Landlord and/or the Management Company or their representatives or anyone on their behalf are null and void and the Landlord
and/or the Management Company will not be bound by any of these.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">33.3.</TD><TD STYLE="text-align: justify">The Tenant hereby declares that it reached this contract following independent inquiries and inspections
and that it did not rely on any information and/or representation made to it, insofar as made.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">33.4.</TD><TD STYLE="text-align: justify">The headings of the sections in this contract are solely for convenience purposes and will not
serve as a reference or aid to construe and/or understand this contract. Any reference to a section in this contract is a reference
to the section and to all of its sub-sections, unless expressly stated otherwise in the provisions in this contract.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">33.5.</TD><TD STYLE="text-align: justify">None of the conditions and the provisions contained in this contract and its appendices derogate
from any other condition or provision of this contract but rather add to it.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">33.6.</TD><TD STYLE="text-align: justify">No change and/or waiver and/or deviation from the provisions in this contract will be valid unless
made in writing and signed by the parties to the contract.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">33.7.</TD><TD STYLE="text-align: justify">Consent on behalf of a party hereto to deviate from any condition in this contract in a specific
instance will not constitute a precedent and will not infer an analogy to another instance. If a party does not exercise a right
granted to it pursuant to this contract in a specific case this will not be seen as a waiver of that right in that case and/or
in another similar case or in a different case and a waiver of a right of that party will not be deduced from this. A waiver made
with regard to one matter will not infer an analogy to another matter.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">33.8.</TD><TD STYLE="text-align: justify">This contract does not create a partnership and/or agency relationship between the parties nor
does it grant rights to any third party not mentioned in the contract, and this contract does not derogate or prejudice any obligation
or undertaking of a third party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">33.9.</TD><TD STYLE="text-align: justify">It is further clarified for the avoidance of doubt that the Tenant will not be entitled at any
time to record a caveat notice by virtue of its rights pursuant to this contract or in connection with this contract. Should and
notwithstanding this provision the Tenant record a caveat or record with the Land Registration Office, this will be considered
a material breach of this contract.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">33.10.</TD><TD STYLE="text-align: justify">The parties addresses for the purpose of this contract are as stipulated at the top of this contract
and any notice that is sent from one party to the other will be by registered mail pursuant to the aforementioned addresses, unless
a party notified the other party in writing of a change of address it will be considered as if it reached its destination and the
knowledge of the recipient party within 72 (Seventy Two) hours of it being delivered to be mailed, and if hand delivered, upon
delivery.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">Any notice
that is placed in the Tenant&rsquo;s mail box in the complex and nay notice that is sent by facsimile will be considered as having
reached its destination within 24 (Twenty Four) hours of its being placed or transmitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">33.11.</TD><TD STYLE="text-align: justify">For the avoidance of doubt it is clarified that the use of the phrase &ldquo;complex&rdquo; in
this contract is solely for convenience purposes. The Landlord will be entitled to determine the name of the complex in which the
premises is located, as it deems fit and/or to change it from time to time, all of its absolute discretion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.2pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">33.12.</TD><TD STYLE="text-align: justify">It is hereby agreed between the parties that the provisions in the Rent and Borrowing Law, 5731
&ndash; 1971 will not apply to this contract to the exclusion of the provision in the law which cannot be stipulated upon.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 36.75pt">33.13.</TD><TD STYLE="text-align: justify">By signing this contract the Tenant gives its consent to the fact that its details, including but
not limited to the data in this contract will be included in the database of the tenants to be kept by the Landlord and/or the
Management Company and/or the Melisron Ltd. Company and/or one of the subsidiary companies of the Melisron Ltd. company, in accordance
with the Privacy Protection Law, 5741 &ndash; 1981, and this for the purpose and the needs of the Melisron Group, including but
not limited to direct mailing of information and content to the Tenant, and delivery of the information to the Management Company
and/or partner in the complex and/or vendors and/or third parties who require the data for the purpose of the works in the complex,
to manage the center and all associated thereto and such like of the database manager&rsquo;s discretion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>In Witness Whereof the Parties Hereto
Set Their Hands</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>At the place and on the date stipulated
above:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>InMode Ltd</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: center; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Sha&rsquo;ar Yokneam</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>514073618</B></FONT></TD>
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Limited Partnership</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>[Signature]</B></FONT></TD>
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>[Signature]</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; text-align: center; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>The Landlord</B></FONT></TD>
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Tenant</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Through Messr. <U>[Signature]</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CEO</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Tenant&rsquo;s Attorney&rsquo;s Confirmation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I the undersigned, Adv. Sagi Omer, of <U>16
Derech Hayam, Haifa</U>, hereby confirm that the Tenant is an existing and operating corporation and that it reached all the resolutions
required to engage in this contract pursuant to its incorporation documents. Similarly I hereby confirm that</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On <B><U>16.4.2018</U></B> Messr.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Moshe Mizrahi</U> I.D. <U>051825396</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing Messrs. are authorized and
entitled to sign this contract and its appendices on the Tenant&rsquo;s behalf and their signature is binding upon the Tenant for
all senses and purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Messrs. Sign this contract and its appendices
____________ binding upon the Tenants pursuant to this contract and appendices ___.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In witness whereof I hereto set my hands</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sagi Omer, Adv.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: <U>16.4.2018</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX &ldquo;A&rdquo; - &ldquo;SHA&rsquo;AR
YOKNEAM&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&ldquo;InMode Ltd&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; text-align: justify; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B><U>The Landlord:</U></B></FONT></TD>
    <TD STYLE="width: 80%; text-align: justify; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Sha&rsquo;ar Yokneam, </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: justify; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Registered Limited Partnership Number 55-001466-6</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: justify; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">&ldquo;Ofer Sha&rsquo;ar Yokneam&rdquo;, Hakidma 28, Yokneam</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: justify; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">(Hereinafter: <B>&quot;The Landlord&quot;)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: justify; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B><U>The Tenant:</U></B></FONT></TD>
    <TD STYLE="text-align: left; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>InMode Ltd. Private Company 51-407361-8</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: justify; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">&ldquo;Tavor&rdquo; Building, Sha&rsquo;ar Yokneam, P.O. Box 533, Yokneam</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: justify; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">(Hereinafter: &ldquo;<B>The Tenant&rdquo;</B>)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provisions mentioned alongside the
sections in this appendix below are in addition to and supplement the provisions in those sections, however do not derogate from
them. The Sections that are added and/or amended and/or deleted in this appendix will override the provisions in the contract.
The rest of the conditions of the contract will remain intact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>By signing this appendix, the Tenant
declares and confirms that it read all of the provisions in the lease contract and all of its appendices, including but not limited
to the management agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the &ldquo;first whereas&rdquo; the
following will be added:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;And Whereas the Landlord declares
that to the best of its knowledge it engaging in this agreement and in the documents mentioned herein, does not conflict or breach
any provisions in the law or agreement that it is privy to, or the Landlord&rsquo;s incorporation documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And Whereas the Landlord declares that
it is the rights holder in the premises and that to the best of its knowledge there is no hindrance preventing it from engaging
in this agreement and leasing the premises to the Tenant&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Section 2 To The Lease Agreement
&ndash; Definitions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 127.55pt 0pt 0; text-align: justify; text-indent: -127.55pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%; text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>&ldquo;The Complex&rdquo;</B></FONT></TD>
    <TD STYLE="width: 4%; text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 74%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The complex, on the land known as the commercial
        name &ldquo;Ofer Sha&rsquo;ar Yokneam&rdquo;, including ahi-tech industries building called &ldquo;Beit Tavor&rdquo; and will be
        referred to below in this agreement as: &ldquo;Beit Tavor&rdquo;.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>&ldquo;The Land&rdquo; </B></FONT></TD>
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Parcels known as numbers 33, 34, 3, 37, 40,
        41, 42, 43, 44, 45, 46, 47, 48, 49 and 50 (in full) and part (areas) of Parcels of land known as numbers 21, 22, 23, 24, 30, 31,
        32, 35, 38, 39, 79, 80 and 82 in Block 11098.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>&ldquo;The Premises&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Unit No. 205 on the second floor of the building known as &ldquo;Beit Tavor&rdquo; in the complex, and units nos. 305 and 308 on the third floor of the building known as &ldquo;Beit Tavor&rdquo; in the complex and 27 parking spaces in the parking lot (Hereinafter: &ldquo;<B>The Parking Spaces</B>&rdquo;) all as marked and outlined in red in the blueprint attached as Appendix &ldquo;<B>B</B>&rdquo; to the contract.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&ldquo;Area of the Premises</B></P></TD>
    <TD STYLE="width: 4%; text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 74%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As defined in <U>Appendix A</U>
to this contract and marked with the color red in <B><U>Appendix B</U></B> to this contract. Insofar as the premises also includes
a storage space, then the provisions in Appendix K will apply thereto.&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%; text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 74%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The area of the premises is as follows:
        566 gross square meters on the second floor of the building known as &ldquo;Beit Tavor&rdquo; in the complex (Hereinafter: &ldquo;<B>The
        Premises Area on the Second Floor</B>&rdquo;) <U>and</U> 390 gross square meters on the third floor of the building known as &ldquo;Beit
        Tavor&rdquo; in the complex (Hereinafter: &ldquo;<B>The Premises Area on the Third Floor</B>&rdquo;).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The premises area on the second floor
        together with the premises area on the third floor will be referred to jointly as the &ldquo;Area of the Premises&rdquo;</B>. For
        the avoidance of doubt, the premises area as defined above includes the loading areas as defined in the agreement.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%; text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>&nbsp;&ldquo;The Basic Index&rdquo;</B></FONT></TD>
    <TD STYLE="width: 4%; text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 74%; text-align: justify; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">The Consumer Prices Index (General Index) published on 15.1.2018 or a date close to this for the month of December 2017. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: justify; direction: rtl; unicode-bidi: embed">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>&ldquo;The Municipality&rdquo;, &ldquo;The Local Authority&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yokneam</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: justify; direction: rtl; unicode-bidi: embed"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>&ldquo;Linkage Differential&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Will be deleted: &ldquo;or the ratio between the other indexes&rdquo;.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 162.95pt 0pt 0; text-align: justify; text-indent: -120.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><B><U>Section
4 to the Lease Agreement &ndash; The Parties Declarations</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><B><U>Section
4.1 &ndash; at the end, the following will be added:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><B><U>&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">&ldquo;The
signatories on this agreement are authorized to sign on its behalf, and their signatures in addition to the Landlord&rsquo;s registered
name are binding on the Landlord for all senses and purposes., are the owners or entitled to be recorded as the owners or the registered
lessor, as applicable, and the exclusive possessor of the land, and is entitled and may lease the premises to the Tenant in the
manner and pursuant to the conditions detailed in this contract, and in particular for the entire lease period&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><B><U>Section
4.2 &ndash; at the end of the section the following will be added:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><B><U>&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">&ldquo;Except
in relation to concealed defects or flaws, insofar as applicable&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><B><U>Section
6 to the Lease Agreement &ndash; The Purpose of the Lease</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><B><U>&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><B>Section
6.1 &ndash;</B> Subject to the law, the purpose of leasing the premises is solely for hi-tech industry as defined in Plan No. 245/Bat/C,
and this alone</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><B>Section
6.2 &ndash; </B>Notwithstanding the provisions in this section above, it is clarified that in the event the Tenant wishes to change
the purpose of the lease and to operate in the premises and/or in any part hereof a different type of business, it will contact
the Landlord and obtain its consent in advance and in writing, and the Landlord will decide whether to affirm the Tenant&rsquo;s
request of the Landlord&rsquo;s sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">Sections
6.5 and 6.6 will be deleted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><B>Section
6.7 &ndash;</B> Notwithstanding the provisions above, it is clarified that the Landlord will cooperate and assist insofar as possible
the Tenant to obtain any license and/or permit that is required to operate and manage the Tenant&rsquo;s business in the premises,
including signing, within a reasonable period of time any plan and/or approval and/or document required by the authorized authorities
from &ldquo;owners&rdquo;, to uphold all the provisions in this agreement, provided this does not impose upon the Landlord any
liability of any type including but not limited to pecuniary and/or legal liability that was not explicitly imposed by this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><B><U>Section
7 to the lease agreement &ndash; the lease period</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><B>&ldquo;The
First Lease Period&rdquo;</B> &ndash; a period of 45 months to start on the delivery date (as defined below) and to end 45 months
later, i.e. on 31.12.2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">Section
7.5 &ndash; the Tenant may suggest a substitute tenant or substitute tenants to the Landlord (Hereinafter: &ldquo;<B>The Substitute
Tenant</B>&rdquo;) to lease the premises pursuant to conditions that are not inferior to the conditions in this agreement, and
subject to the fact that if the rent by the Substitute Tenant is less than the rent fixed pursuant to this agreement, the Tenant
will continue to be liable to pay the difference in the rent, and this by giving written notice to the Landlord (Hereinafter: &ldquo;<B>The
Tenant&rsquo;s Notice</B>&rdquo;). It is agreed that the Landlord will not refuse to accept the Substitute Tenant other than based
on business and/or reasonable grounds only. If the Landlord agreed and engaged in a lease agreement with the Substitute Tenant
&ndash; the Tenant will not be obligated to pay the rent, subject to the provision&#1491; above, commencing from the date the lease
starts for the Substitute Tenant and it will be exempted of any liability toward the Landlord, to the exclusion of the undertaking
to pay the difference in the rent, insofar as the Tenant must pay such a difference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><B><U>Section
8 to the lease agreement &ndash; The Rent</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><B>Section
8.1 &ndash; &ldquo;The Rent&rdquo;</B> &ndash; subject to the provisions in the lease contract, the Tenant will pay the Landlord
rent for the premises (without the parking fee) and a parking fee for the parking spaces, all as detailed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 18pt">(1)</TD><TD STYLE="text-align: justify">Commencing from the delivery date and up to 31.12.2018, the Tenant will pay, for reach month for
the premises (without the parking spaces), monthly rent of a sum of NIS 48.5 (Forty Eight New Shekels and Fifty Agorot) for each
square meter of the area of the premises, whereby this amount will be linked to the Basic Index in addition to VAT stipulated by
law; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 18pt">(2)</TD><TD STYLE="text-align: justify">Commencing from 1.1.2019 and until 31.12.2021, the Tenant will pay for each month for the premises
(without the parking spaces), monthly rent of a sum of NIS 50 (Fifty New Shekels) for each square meter of the area of the premises,
whereby this amount will be linked to the Basic Index in addition to VAT stipulated by law; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 18pt">(3)</TD><TD STYLE="text-align: justify">Commencing from the delivery date and until 31.12.2018, the Tenant will pay the Landlord a monthly
parking fee of a total sum of NIS 275 (Two Hundred and Seventy Five) for each parking space, whereby this amount is linked to the
Basic Index and in addition to VAT stipulated by law.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 18pt">(4)</TD><TD STYLE="text-align: justify">Commencing from 1.1.2019 and until 31.12.2021 the Tenant will pay the Landlord monthly rent of
a total sum of NIS 283 (Two Hundred and Eighty Three New Shekels) for each parking space, whereby this amount is linked to the
Basic Index and in addition to VAT stipulated by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Section
8.7</U></B> &ndash; instead of &ldquo;7 days&rdquo; will read: &ldquo;14 days&rdquo;. <B><U>Section 10</U> (and all of its sub-sections)</B>
&ndash; it is clarified that insofar as the payments and/or taxes and/or levies for the use and/or possession of the premises and/or
operation of the premises as stated in Section 10 to the lease contract is concerned, these payments will apply to the Tenant during
the course of the entire lease period and will be paid by it on the lawful date to pay them to the authorities, insofar as they
are applicable by their very nature pursuant to the law upon tenants and/or possessors of a property (as opposed to owners).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 12.11
&ndash; it is agreed that insofar as the Landlord executes works as stated in this section above, the works will be executed upon
coordinating them in advance with the Tenant while minimizing the interruption to the Tenant&rsquo;s activity in the premises,
insofar as possible under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 12.12
&ndash; will be deleted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Section
13 to the lease agreement &ndash; delivery of possession and the delivery protocol</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section
13.1 &ndash; &ldquo;The Delivery Date&rdquo;</B> fulfillment of the suspending condition as stated below in this appendix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section
13.4 </B>- will be deleted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section
14</B>.<B>4</B> &ndash; Notwithstanding the provisions above, any malfunction or damage sustained as a result of the Landlord&rsquo;s
works in the premises will be repaired by the Landlord and/or the Management Company and at their expense. Additionally, the Landlord
and/or the Management Company undertake to repair at their expense only damages to the shell of the premises originating from water
penetration defects into the premises, subject to the fact that they were not caused due to an act and/or omission by the Tenant
and/or someone on its behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section
14</B>.<B>6 &ndash;</B> And all provided that reasonable use by the Tenant of the premises for the purpose of the lease is not
prejudiced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section
17.4</B> &ndash; will be deleted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section
18.4</B> &ndash; after the words &ldquo;the expenses&rdquo;, &ldquo;reasonable&rdquo; will be added.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Section
19.4</U></B> &ndash; in the second paragraph, instead of &ldquo;3 business days&rdquo; will read: &ldquo;10 business days&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section
20.2. &ndash;</B> After the words: &ldquo;Any expenses&rdquo;, &ldquo;not imposed upon it explicitly pursuant to this agreement&rdquo;
will be added.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 21.4
&ndash; Notwithstanding the provisions above, any malfunction or damage sustained as a result of the Landlord&rsquo;s works will
be repaired by the Landlord and/or the Management Company and at their expense. Section 21.5 &ndash; Notwithstanding the provisions
above, the Landlord undertakes that performance of all such works will be done insofar as possible in a manner that minimizes the
damages and inconvenience to the Tenant and that the Landlord and/or the Management Company will in any event put the premise back
to its previous condition immediately after completing the work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 22
&ndash; at the end of the Section the following will be added: &ldquo;The Landlord will not refuse to carry out internal changes
that are not related to construction and/or adding space unless based solely on reasonable grounds, provided that the Landlord&rsquo;s
approval was requested to make the changes in advance and in writing by the Tenant&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Section
23 to the Lease Agreement &ndash; Conveying Rights</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 23.1
&ndash; in the third line after the words: &ldquo;Pursuant to its sole discretion&rdquo;, the following will be added: &ldquo;The
Landlord will not refuse such actions unless based solely on reasonable business reasons&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">At the end
of Section 23.1 the following will be added: &ldquo;Unless it receives the Landlord&rsquo;s consent in writing and in advance.
The Landlord will not refuse such actions unless based solely on reasonable business reasons&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 23.1.5
&ndash; after the words: &ldquo;As determined by the Landlord&rdquo; will read: &ldquo;reasonable and as practiced&rdquo;. Similarly,
at the end of the section after the words: &ldquo;Of its discretion&rdquo; the following will be added &ldquo;however reasonably
and as practiced&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 23.3
&ndash; The Tenant declares and undertakes that as on the date this agreement was signed there are no &ldquo;controlling shareholders&rdquo;
(as defined in the agreement) in the Tenant. It is agreed that insofar as a change applies to the control over the Tenant during
the course of the lease period, by such a manner that there will be controlling shareholders in the Tenant, the Tenant undertakes
to notify the Landlord of this as soon as possible and remit the controlling shareholders details to it, and that from this moment
and onwards the provisions in this section will apply pertaining to a prohibition against changing control in the Tenant, as detailed
in the lease agreement. The Landlord will not refuse a change in the controlling shareholders in the Tenant unless based solely
on reasonable business grounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 23.5
&ndash; the provisions in this section is subject to the fact that the Tenant&rsquo;s rights in the premises pursuant to this agreement
are not prejudiced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 24.3
&ndash; it is agreed that no breach will be considered a material breach unless the breach was not remedied within 4 business days
of the breaching party receiving a warning to do so. Section 24.3.2 &ndash; instead of &ldquo;7 days&rdquo; will read: &ldquo;14
days&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 24.5
&ndash; the early notice will be 30 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 24.5.3
&ndash; Instead of &ldquo;45 days&rdquo; will read: &ldquo;60 days&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 24.8
&ndash; Notwithstanding the above it is hereby agreed that solely in regard to the first delay in making a payment during the course
of the lease period, not exceeding <B>7</B> (Seven) days following the date determined for payment thereof &ndash; will not entitle
the Landlord to a right to receive interest in arrears from the Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 25.5
&ndash; Realizing the securities as stated above will only be after giving a warning of 14 days to the Tenant, at the end of which
the Tenant did not settle its debts to the authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 25.7.1
&ndash; provided that the Tenant was given a written warning 14 days in advance pertaining to its intention to act as stated above,
and an opportunity to remedy its breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 25.8
&ndash; For the avoidance of doubt, and notwithstanding the provisions above, the Landlord will not vacate the premises before
giving an advance written warning of 21 days to the Tenant, during the course of which the Tenant did not remedy the breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Section
26 to the Lease Agreement &ndash; Securities</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section
26.1 &ndash; </B>personal guarantee &ndash; none.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section
26.2</B>- Bank guarantee &ndash; the bank guarantee will be of an amount equal to rent and management fees, paid by the Tenant
for 3 months&rsquo; rent, i.e. a sum of NIS 198,063 in addition to VAT thereon, whereby this amount will be linked to the Basic
Index, in the format attached to the contract as <B><U>Appendix G</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section
26.4 - </B>Deposit &ndash; none.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section
26.5</B> &ndash; Promissory Note &ndash; none.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Section
26.6</U> &ndash;</B> instead of &ldquo;7 days&rdquo; will read: &ldquo;14 days&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Section
29 - will be deleted.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 31.4
&ndash; at the end the following will be added: &ldquo;and that it will not prevent reasonable use by the Tenant of the premises&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Appendix
D &ndash; The Management Agreement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>The Management
Fees</B> &ndash; it is agreed that commencing from the delivery date and until 31.12.2018, the monthly management fees that the
Tenant will pay to the Landlord for the premises will be a sum of NIS 9.75 (Nine New Shekels and Seventy Five Agorot) per square
meter of the area of the premises, whereby this amount will be linked to the Basic Index and in addition to VAT stipulated by law.
Similarly, commencing form 1.1.2019 and through until 31.12.2021, the monthly management fee to be paid by the Tenant to the Landlord
for the premises will be a sum of NIS 10 (Ten New Shekels) per square meter of the area of the premises, whereby this amount will
be linked to the Basic Index and in addition to VAT stipulated by law. Notwithstanding the provisions above, the Landlord will
be entitled, at any time, in accordance with its sole discretion and for any reason, to collect from the Tenant monthly management
fees in accordance with that detailed in the management agreement (i.e. on the basis of cost +15%, whereby this amount will be
linked to the Basic Index and in addition to VAT stipulated by law), all as detailed in the management agreement and provided that
the calculation based on COST will not exceed management fees of a sum of NIS 15 per square meter. The Tenant undertakes that it
will not have any allegation and/or claim and/or demand against the Landlord and/or the Management Company and/or anyone on their
behalf insofar as the management fees are concerned as detailed above (including but not limited to the amount being fixed or calculated
pursuant to the mechanism fixed in the management agreement, provided that it does not exceed the aforementioned fixed sum of NIS
15 per square meter). For the avoidance of doubt, it is clarified that the management fees stated in this section above include
the Tenant&rsquo;s participation fee in the expenses and the equipment renewal fund.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Insurance
Premiums</B> &ndash; it is further agreed that notwithstanding the provisions in Section 8 to the management agreement, the Tenant&rsquo;s
relative share in the expenses to pay the insurance premiums for the areas, as detailed in Section 8 to the management agreement,
will be collected as a separate charge and not as part of the management fees and expenses, as defined in the management agreement,
and this according to a calculation of the total premiums paid to the insurance company by the Landlord, divided by the total built
up area of the complex and multiplied by the area of the premises and/or pursuant to any other calculation, as detailed in Section
8 to the management agreement and/or the lease contract, and in accordance with the amounts determined from time to time by the
Management Company and/or the Landlord, of their sole discretion. The Tenant undertakes that it will not have any allegation and/or
claim and/or demand against the Landlord and/or the Management Company and/or anyone on their behalf insofar as the insurance premiums
are concerned as detailed above (including but not limited to the amount being fixed or calculated pursuant to the mechanism fixed
in this appendix and/or pursuant to another mechanism fixed in the management agreement and/or in the lease contract).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Special
Terms:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 18pt"><B>1.</B></TD><TD STYLE="text-align: justify"><B><U>Suspending Condition</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.3pt; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt">1.1.</TD><TD STYLE="text-align: justify">The Tenant declares that it is aware that as of the date this contract is signed, the premises
are not vacate and that it is occupied by the existing tenant whose lease period has not yet come to an end (Hereinafter: &ldquo;<B>The
Current Tenant</B>&rdquo;). It is thereby hereby agreed that the Current Tenant actually vacating the premises will be by 1.5.2018
(Hereinafter: &ldquo;<B>The </B>Suspending <B>Condition Fulfillment Date</B>&rdquo;), constitutes a <B>suspending condition</B>
to the validity of this contract.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.3pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt">1.2.</TD><TD STYLE="text-align: justify">If and insofar as the Current Tenant does not vacate the premises of any person and object by the
suspending condition fulfillment date, the suspending condition fulfillment date will automatically be deferred to the date the
premises are actually vacated by the Current Tenant and the rest of the dates fixed in this contract will also be deferred accordingly.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt">1.3.</TD><TD STYLE="text-align: justify">Notwithstanding the provisions above it is agreed that insofar as the deferment of the suspending
condition fulfillment date exceeds 30 (Thirty) days, for any reason, each party to this contract may (however is not obligated)
to notify the other party that this contract is null and void, as if it was never signed. In the event one of the parties decides
to cancel this contract as stated above, that party who decided to rescind the contract is released of all of its undertakings
pursuant to this contract and the other party will not have and hereby waives any allegation, claim and/or demand in connection
with this contract and/or the premises.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.3pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 18pt"><B>2.</B></TD><TD STYLE="text-align: justify"><B>Technical Specification</B>: The premises will be delivered to the Tenant in the condition it
will be in on the delivery date (&ldquo;As Is&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>In witness
whereof the parties hereto set their hands at the place and on the date stipulated in the heading to this contract above:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>InMode Ltd</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: center; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Sha&rsquo;ar Yokneam</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>514073618</B></FONT></TD>
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Limited Partnership</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>[Signature]</B></FONT></TD>
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>[Signature]</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; text-align: center; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>The Landlord</B></FONT></TD>
    <TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Tenant</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Through Messrs. <U>[Signature]</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CEO</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 87; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Tenant&rsquo;s Attorney&rsquo;s Confirmation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I the undersigned, Adv. Sagi Omer, of <U>16
Derech Hayam, Haifa</U>, hereby confirm that the Tenant is an existing and operating corporation and that it reached all the resolutions
required to engage in this contract pursuant to its incorporation documents, that the signatures above are the signatures of Messrs.
<U>Moshe Mizrahi</U> I.D. <U>051825396</U> and &mdash;&mdash;&mdash;&mdash;&mdash;&mdash; I.D. &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;
who signed and is authorized to sign this contract on the Tenant&rsquo;s behalf and their signatures are binding upon the Tenant
for all senses and purposes, and signed this contract <STRIKE>in front</STRIKE> of me</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In witness whereof I hereto set my hands</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sagi Omer, Adv.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">License 57764</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Derech Hayam 16, Haifa</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt; text-align: center; text-indent: 0in"><U>Sagi Omer</U>,
Adv.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: center; text-indent: -35.45pt"><B>FLOOR
3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: center; text-indent: -35.45pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: center; text-indent: -35.45pt">&nbsp;<IMG SRC="tv498959_ex10-13img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: center; text-indent: -35.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 89; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: center; text-indent: -35.45pt"><B>FLOOR
2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: center; text-indent: -35.45pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: center; text-indent: -35.45pt">&nbsp;<IMG SRC="tv498959_ex10-13img2.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.95pt; text-align: center; text-indent: -35.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 30%; text-align: left; direction: rtl; unicode-bidi: embed"><B>InMode Ltd</B></TD><TD STYLE="width: 40%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="width: 30%; text-align: right; direction: rtl; unicode-bidi: embed"><B>Sha&rsquo;ar Yokneam</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><B>514073618</B></TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD><TD STYLE="text-align: right; direction: rtl; unicode-bidi: embed"><B>Limited Partnership</B></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">[Signature]</TD><TD STYLE="text-align: center; direction: rtl; unicode-bidi: embed"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="padding-right: 0.35in; text-align: right; direction: rtl; unicode-bidi: embed">[Signature]</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>10
<FILENAME>filename10.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>InMode Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>List of Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 52%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Subsidiary</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 47%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Jurisdiction of Incorporation</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Invasix Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Delaware, USA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Invasix Corp.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Canada</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">InMode M.D. Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Israel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Invasix UK Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">United Kingdom</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">InMode Japan KK</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Japan</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Invasix Iberia S.L.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Spain</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Guangzhou InMode Medical Technology Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">China</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">InMode Asia Limited.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Hong Kong</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>11
<FILENAME>filename11.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF DIRECTOR NOMINEE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">InMode Ltd. (the &ldquo;Company&rdquo;) is filing a Registration
Statement on Form F-1 (the &ldquo;Registration Statement&rdquo;) with the Securities and Exchange Commission under the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), in connection with the initial public offering (&ldquo;IPO&rdquo;)
of its ordinary shares. In connection with the IPO, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named
as a nominee to the board of directors of the Company in the Registration Statement, as may be amended from time to time. I also
consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Hadar Ron</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 7%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 42%"><FONT STYLE="font-size: 10pt">Hadar Ron</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">23/7/2018</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.4
<SEQUENCE>12
<FILENAME>filename12.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF DIRECTOR NOMINEE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">InMode Ltd. (the &ldquo;Company&rdquo;) is filing a Registration
Statement on Form F-1 (the &ldquo;Registration Statement&rdquo;) with the Securities and Exchange Commission under the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), in connection with the initial public offering (&ldquo;IPO&rdquo;)
of its ordinary shares. In connection with the IPO, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named
as a nominee to the board of directors of the Company in the Registration Statement, as may be amended from time to time. I also
consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>
</TD>
    <TD COLSPAN="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.75pt solid">/s/ Bruce Mann</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 7%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 42%"><FONT STYLE="font-size: 10pt">Bruce Mann</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">July 22, 2018</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.5
<SEQUENCE>13
<FILENAME>filename13.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF DIRECTOR NOMINEE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">InMode Ltd. (the &ldquo;Company&rdquo;) is filing a Registration
Statement on Form F-1 (the &ldquo;Registration Statement&rdquo;) with the Securities and Exchange Commission under the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), in connection with the initial public offering (&ldquo;IPO&rdquo;)
of its ordinary shares. In connection with the IPO, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named
as a nominee to the board of directors of the Company in the Registration Statement, as may be amended from time to time. I also
consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Michael Anghel</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 7%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 42%"><FONT STYLE="font-size: 10pt">Michael Anghel</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">July 22, 2018</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>lg_inmode.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_inmode.jpg
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M  (1 0,1 ?_$ .0  0 #  ,! 0             %!@<#! @" 0$! 0$!
M              (! Q    4"!0,"!P$  @,      0(#! 4 !A P0!$U(& T
M,A90,1(3,Q05<)"@(R0E$0 ! @$&!PT%!P,$ P$    ! @, $!$A,1($,$%1
M<8&R<R!AL<'1(C)"4G(3(U-@D8*2-*'A8L(S%"1 HH-P\-*3D.)#8Q(!
M                P!,!  $"! 0' 0 # 0$! 0   1$ (1 P,5$@06%Q0&#P
M@9&AL<%0T>%P\:"0_]H # ,!  (1 Q$   '5
M
M   06YE=1,MTZ*[30  !%,AB8)9H   Z[,UJ:Y6:I%V'-
M                                '39F%S1*GL8Z^NUC39N^S7T #J%>
M9TCD.,[986]T  H]3EU1T==K'5U=YK48KOM
M                    'R9_4YG4<&K]-:;%1NLHJ*U63F;J\79<T0[*\<A/
MDLV+9 '"2A/MYCY,6OG4JR?S=8BYK&:5.>W/)C29K0YOD
M                             *MLY3<PVY:)W5IN:S0!3-G++B.U<IK4
MXJ2;&,[[>0 ^2#9"GZ3A--ZS*ON7'*_0")9E5Q4JR6S=4BK=E
M                               "*9E=Q4*R3S=4BKCE   <)G%1G-3^
MFCS6C3?*  #KE?9''.6 DF@  5/9RJYB-RUSNJS<QF@
M                      #@,VJ,[J?HTB:T6;Y0  =8@62!+MC&97<4ZLD\
M:G%W+* INS1JG2INPYL>ROG6.^6%O9  !\&>5.:U'%K08K2YKLM
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MT   "C5.07&GQ6DS8   %>9$EW:   !^'GWISL&;L<6
M                    ,@N*KL^B>?4    4EDH6)H   %&J<@N-/BM)FP
M *^R(+NT    >?\ ISG<W8XL
M 9!<579]$\^H    I+)0L30   *-4Y!<:?%:3-@   5]D07=H    \_].<[F
M['%@                                    #(+BJ[/HGGU    %)9*%
MB:   !1JG(+C3XK29L   "OLB"[M    'G_ISG<W8XL
M                    9!<579]$\^H    I+)0L30   *-4Y!<:?%:3-@
M 5]D07=H    \_\ 3G.YNQQ8
M R"XJNSZ)Y]0   !262A8F@   4:IR"XT^*TF;    K[(@N[0   !Y_Z<YW-
MV.+                                     &07%5V?1//J    *2R4+
M$T   "C5.07&GQ6DS8   %?9$%W:    //\ TYSN;L<6
M                     ,@N*KL^B>?4    4EDH6)H   %&J<@N-/BM)FP
M  *^R(+NT    >?^G.=S=CBP
M!D%Q5=GT3SZ@   "DLE"Q-    HU3D%QI\5I,V   !7V1!=V@   #S_TYSN;
ML<6                                     ,@N*KL^B>?4    4EDH6
M)H   %&J<@N-/BM)FP   *^R(+NT    >?\ ISG<W8XL
M                     9!<579]$\^H    I+)0L30   *-4Y!<:?%:3-@
M  5]D07=H    \_].<[F['%@
M#(+BJ[/HGGU    %)9*%B:   !1JG(+C3XK29L   "OLB"[M    'G_ISG<W
M8XL                                     9!<5/9]%<^OZ    4EDF
M6-H   %&J<@N-/BM)FP   *\R)+NT    >?.G.P9NQQ8
M                     RRHSJYGLW58NRYH   IS.N2A/MY@ #C,_J<UJ.K
MKL8TF:T.;Y  #A(%D4<Q<V@  "O;F4W%>W+_ #6LQ8
M                   %*V<NN(W5RFM3BI-H  ^2#9# FR:;] J.SE5S%;EL
MG=!FL^J:G62N;J<5<,H?A!LA03)-M^P  1[,NN:34][&H3=XFOT
M                             '"9S49S4_AHDUI$WS@  X"OLC3G)\DV
MQK,XN;A.VG* JFSE=S#;EGG=6FYO-Z+(PFF\X  .(SFHSFI^30YK29OG
M                                    !',RZYI53WL:A-WB:_0  =%E
M>.J=TL+>V  #Y,_J<TJ.MJ^36G17<:  !2]G+;B-U<9W4XN4:
M                               *[N93<5_<G\W5HNQYH'P42ILV;,9L
M0R".(EB>;R@'"1C)9O79F5S0JGGQI<WH$U]@$#N9345NLG,W5HNS9H
M                                      H]3E]1T-72:U**A]S*+F'W
M+=.[+'3E/@@F0Y]$V3#8AD&?)/DRT0NYE515JR7S=4BI_-R^YH]3V\:=-WR:
M_0                                             <!F]1G=3^:XR5
MS=5BK=E  =<K[(X_3\)$L#>P  5'9RNYB=SD!H$5I<UV6@
M                                ",9E]S-8T6;Y    1[(8F20:   /
M@SVIKNSJ$7+M
M
M
M
M
M
M
M
M ^#[           /@^P     #Y/H
M   @MRM;DGBWY0     QVXUJ*[#0  (+<K6Y)XM^4     *=LR#;#F@    ?
M!FM1ILV       .$KVS%:^#OXL.;WV@      #A*'4@#E)/%BS>PT
M4.IX0  "PYM>W,IN+7.[;'0     >>NG.0-MYWV&@ #/:G*;BUSNVQT
M%+V<NN=[YWVF@   #+*B%W-MCH      .FS,[FC;/!H ?I:)W4)N?S0
M!T6>=>O,  <N+SE:A%=IH      \[=.70T  !ID5VFY3<6N=VV.@     \]=
M.<9N62=VZ.G,  9[4Y3<6N=VV.@     I>SC?2+E.[-'0   "I[.*=(M4[ML
M=      ('<Q2^?0T)+%@S>1L/N06Y^'V:K%Z!-      =%GG7KS%DG?H^-0S
M.KH2V;N?.^^T     #SMTY=#4]F]C  %YRNL93<6N=VV.@     \]=.<9N"S
M3NV1TY@ 9[4Y3<6N=VV.@     I>SC?2!K,7?YH  "/9@?3GT]6N=VV.@
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MIN+7.[;'0     >>NG.,W-NYW:LJ!W,.OGUM6:=VR.E#J<IN+7.[;'0
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MKH;+SNYY6>U.4W%KG=MCH     //O3G$[EFG=QCI^@  &=5.67'Z;]SZ3.:
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M-DS=<BP    !A]\X_6N1=DS0  *!4U'9VV.@     J>SE=S,8VB.@ ZK.TT
M4>IS>ILF;KD6      !UF4JLJ^Y%[GP=_%AS;ME2^:      !TV87T@ <A(8
ML.;>)J3:      !A=\^GH  #0)K0)H            5W<L6:
M
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M:DU#*<0A;[IG6O\ W-(UF5JX53[F+HIRG$(4^\9UJ^S>$@:83:4?<-\P%O\
MGO;_ $1F'+$PJW'G-\_U$T*BT?,8-3HX\DO[=X_R&A7VDY<^%O&S7JRM=Q/!
M*4K 4DU@TB"Y<O*=]/JGD@H6+*TT*29 E9_CO<US>R*PUXVB]:2[9CK'=W?O
MG@D:S*U<+>]LYK&1*B)@KHG+),>==E=-'&(2ZTJTVJE*AN+OWSP2-9E:N%&T
M3P&5+C9LK29TF X*'4T.HR'D.Z*B9@*28YOT[=#8R_BTRM9E:N%_;I/E7>CX
M\?)(AEH3N+,P@-MTJ/ZCF-1W90L6D*H4DQS:;NY2V?RZ)&WV^D@S\HTPAU%*
M' %)TX2\;->K*UW$\&Y-\:'G-#S/Q(^Z5I9I6CRUYT_=A;QM%ZTEVS'6.[N_
M?/!(UF5JX6][9S6,C;3E"@5^&O&DVH4P\)E#'B(RB28\Z[*Z:.,0EUI5IM5*
M5"6[]\\$C696KA1M$\!W >32BIQ&5,)=:-I"Q.D[DW!@[=0U>7<-9E:N$=>/
M_P TE7N@J52HTDR+OJASE<QK,*S@7&>OTF^\*I5,FMA4P[JJ>&?"7C9KU96N
MXG@W,QI!K$/,8D*YN:L?9)>6.ZL<!XL+>-HO6DNV8ZQW=W[YX)&LRM7"WO;.
M:QD:SJUHL+H<'Z;F0\D*9>396G_<XDF/.NRNFCC$)=:5:;52E0DN_?/!(UF5
MJX4;1/ 9&F"9@X9IX6PZ)EH,QD_:O'R'3S3V5<AW$R/J'*&QD_%!)I)K,C-Z
M<H4^KF)_#-7ID:S*U<(]^*RG^X2W9 ],'2JD\."O*!5;)'Q4\<EX1B* ?<?O
MPEXV:]65KN)X-T%>HV#[B1Q2+'::/",+>-HO6D"&[PZA J2E:@(^K>_[%<L?
M5O?]BN6/JWO^Q7+'U;W_ &*Y8*G5J<5XA%I1)-0RR7?OG@D:S*U<+>]LYK&1
MK.K6DF/->3^FYQ'>A3+J;+B*"))CSKLKIHXQ"76E6FU4I4(N_?/!(UF5JX4;
M1/ 9+MWX_<M#SV12.TG[I?VKQ_D-#FD]9/*)%ONGFH^W>$*?=K54,@Q 26W!
M_&:I7OGLQ=^^>"1K,K5PB]Y23]LMW5VFTG[,%>9NU-[A(\?_ ,_S#"7C9KU9
M6NXG@W32<C0UC(=DKA&%O&T7K;L[17 )+OWSP2-9E:N%O>V<UC(UG5K2T<V\
M(_37Q'>A33J;+B:%),DQYUV5TT<8BZNM*M-J42E0S2-9E:N%&T3P&2[=^3]P
MT/X[QJ[*LFF1+S1LN(,Z3 ?%!'ZJ>R8L-G^,UT-\]J1##0G6LS??"&&ZDUG*
M<9B[]\\$C696KA+RV*[$X^'G<4J$]=GF'B^S J<70A *E'>$./*K<45'29+P
M_E(0-%)X<)>-FO5E:[B>#=/K'1!L)^&B1]SLMV?F/_KA;QM%ZTC+SK9+BP;1
MM'+'Z1^94?I'YE1^D?F5'Z1^94>$P+*)YYIYZ9+OWSP2-9E:N%O>V<UC(UG5
MK;BTCFWE'05EWC"FW!96DS*$GA6O+GM6=^1K,K5PHVB> R7;OR+8=$Z%B8PM
MARM-1RC$9'$-K*4O"RX,HE_<.C^0\*NRG))=^^>"1K,K5PKK'5!G1W35)S_T
M'>:YO9#HB<4@U' ?L6CSE4O;PQ#3*TR>G-:<[QI.$O&S7JRM=Q/!N5*!\Y?-
M:&_ET2N/&MY=&9/WSX6\;1>M)=LQUCN[OWSP2-9E:N%O>V<UC(UG5K;GQ6A-
M>DU?BWC!0L65)H(,K696KA1M$\!DNW?EM-C^0U2C?&-.X_<NCR&C0.TK[I;O
MWSP2-9E:N%_<-#SF,65&31*+M>J;OU%XT_= 6VH*0JI0I&Z4S=B%WFJU6$??
M!6LVE*I),G[EP>0R:-]>+W86\;->K*UW$\&X\5]4W93C5F@O.4"I",21(AIL
M3K6;*1GAMA-3:9L+>-HO6DNV8ZQW=W[YX)&LRM7"WO;.:QD:SJUMUX[%%Z2*
MNV.6"DB8B@B1K,K5PHVB> R7;O[C]\R/+6?.&1673(AAO'TE9!C,(8:$R$"8
M2W?OG@D:S*U<,J^75,[9I=;'5WQO2SW=R88T5I.B)KTP0>TWR'EBEXHWE)5Q
M Q]1/F2KDCR6UNG?YHXS]D%%KP6CU$<9KELIYK(_4=R??"66DV6T5#"WC9KU
M94((<G2D \T8M,5.?*.6.:AU1S#EB:[-!K\2N<>2"X\LK6<9E_?/B9:AY*<@
M/6TX:\;1>M(RPX%VT SS"BO/%3GRCEBISY1RQ4Y\HY8J<^4<L5.?*.6'/ M>
M7-:M";I3\D7?OG@D:S*U<+>]LYK&1K.K6W9O-V3_ "1TDCK_ 'Q,:X:S*U<*
M-HG@,EV[^X4TX+2%B90@L=))I:5VA$ZQ_(=I<WLB=Q=^^>"1K,K5PY>N4S;F
M-KJG-D@MO(*%C$=W,*X#E[\EGL=<\D!IE(0VFH##7C9KU< $H!4HU 5PF\7X
M4BE+'_+DP]XVB]; 7S_'^:& PVIPA1GLB?%'TKGRF&W'6%H0 J=1%%6%O*TW
M9PI4ZLI(2:BJ/I7/E,-MNH*%@JG2:Z\ ;W=1YW_T;'6WQOPUF5JX4(907%^(
M#933ECZ5SY3%W6Y=UI0E5*B-RVMQ 4IDVFSD.Y8##:G"%&>R)\4?2N?*8;<=
M86A "IU$45?T%A]L.)R*B>[.%D]D\X<L<RP[W53:TT4W96B8\$?2K]TT4M!&
M^I0XIXGO+_PMCC/)'DM"WVS2KW_T#Z4B=1;4 -$?2N?*8^E<^4Q]*Y\ICZ5S
MY3'TJ]-$4MAOO*'%/$]Y?^%L<9Y(_CM!)QKK5[_Z!]2;LX4EQ1!LG+'TKGRF
M/I7/E,?2N?*8^E<^4Q]*Y\ICZ5SY3'TKGRF+UX[2F[5BS:$T\UK^K1?V>9TO
M%1EG%8_U@__:  @! 0,!/R'_ ,N3ELY[W;.]1YR9>72&'\5+!HFE[+'[[T/>
M.?([#4>CDR7?N3_=*WO3R[1I4+^^?ZH1)+F1K5G>/8W>A6RO(7^I=^J>R++"
M[HKJAS<KQ[NGLOT\PH^6?,MM1>U00="7T<O;>G[E2EU7FM/2I(('6*0@Z 0C
MLE%3OGH38:)WJ&;3/^P_/:@(&E$B;CPDPOD/?:K*OQGOOA^,=L&8>YH?\J!#
MZRV_"@2!=6H4@V?[C\VZUML$Z&P6*!4 E; 4H8E<)'2:%$1A+B5#!&UUCN_O
MYKV:!-LESRZ<<Y= -U:C2T$[.RS^.]/>=)^@T#H4B!D"E78"I%-4^V7/UVKW
M&J'5=5ZM+VS\H.^SO4\P.3H?-^.N <N_.+MNZE:VKGZOQ?KICJ9.2ZT5676I
M;?5K4+^;?[J"(BVU27;N;_57W7)Y/9P@._<GOSKO,CF=S"(Q"NW/(F\5TOK)
M;OZ:8%+CY/\ LNU&MRG].GLOUK4R,<__ !ZUNKREO[=GY:>$L%@>HUIA.6'M
MU.E;4Z%]/3N?%! 66B'1/+4JH;37/C.VM2. L_1'-ZN%Y O'H]I_'6M=81>'
MOR=#ALH:Z"YU'V^%2(SZW;+.%U)VNL_9V^145,->WVG\I!(;CJ4-F["?]5$_
MTN!^1N30I>3?K[-/A0U&C;"YE"P</JD_U1PR:)2]XY<CNM1ZE7\_,/XD?.CY
MA0%@.G!=D!'P5_#:H)P7BM?/[EL+,B9N.[_1>I)"6GN^NS]^5XYU)^$/Z;5/
M92T]CTV/O"7TFI;TFFM68G>3>^WN_61H2W,E NIJM^OY\JM5Q*A[-:Y%S(^*
M^!0_Q_?A5UB*9'XXX]>Y'1[U+]W-3N832 YK5[5!=K=79R()R7BO?'[EZLR)
MCX*_AOA(N*TUCWT[-JG=H3_W(=2WE/7"<L';J]*VLQ+[>G=^*1(LM4>JUI 7
M,M 77F-^/Y\JL>S+![''[*(U443EA?YWJ _=O]4(DEQT:@?(BP])II5Q)WDV
M_M[GUA-2%NW^D_M6$O:Z[]';Y/!9*=KK_0U['U3(2M(AVW])FA)!UM^[I[+]
M,)/L;1[E1;I#JPA%^-V:%]RM>,X2P60ZC6ZO*7_EV?DK5R.<?_3K2-3E\!Z)
M4NNB'9]7LOWKF=8_I-1Z/D]0%6 NK4, ;77.Y^?FO9L'T] PNH:X"QT7V^%0
MPRZWVCQP7%S:EBZS7V.5($E:K1MC<BA0\MNGNT* #0,;P1>&R^-[ZUKH;%X>
M_)Z.&GBY^A[S^.E(2$6^J-G6:E5+:2X^5[:8:<ECY*W="]1<UT%WX_=OBB 3
M4:EGENT]FFKBY-("0FB5 ETGZWJ%[>./VY!=;4*EPC?8=C\_%(BB0ED:.\TH
MT-DL^]1Y-..IUY^^W6A2EP%Q/)MG6]P@Z-=%G .W3EAVW="HY@<G1^+]=<E!
M>"AT)Y807;N;VY5;=<WF]WB/.&#2)LC4 VHZ_NU_':GO*D_8Z)U,-,)PR]^A
MUK<FQ+.WKV/EHX2P6 Z!Q0>CEN=FI?\ */\ =:4B-3>/[DCNQ3CV=/=?K3;O
MA_V7?"1VBG<!N)TUY>3NQ0&JN(D1HZ0T @#H97WG[3V!99<F<HK2P!YPR?F'
MPV/O_P Y0E &XWO7WC*0!*LCHE$Q&&@#D#R>H[>K;,O[S]KU?4S.WV,J^\_:
M^\>6G%';U;9E_>?M>KZF9V^QE7WG[7WCRTXH[>K;,O[S]KU?4S.WV,J^\_:^
M\>6G%';U;9E_>?M>KZF9V^QE7WG[7WCRTXH[>K;,O[S]KU?4S.WV,J^\_:^\
M>6G%';U;9E_>?M>KZF9V^QE7WG[7WCRTXH[>K;,O[S]KU?4S.WV,J^\_:^\>
M6G%';U;9E_>?M>KZF9V^QE7WG[7WCRTXH[>K;,O[S]KU?4S.WV,J^\_:^\>6
MG%';U;9E_>?M>KZF9V^QE7WG[7WCRTXH[>K;,O[S]KU?4S.WV,J^\_:^\>6G
M%'8H#56 #*M'S"D+B=,K[S]HQJ##+G?*9'SECH?[,/EL?;_O*0(BW#:]?>,I
M D"ZM!%6.D3F'R<HN&7H ?1I87P'7;S?5'-=JUM7/U?B_73)&7D5<GMA =^Y
M/?G7>9',[G$$!9: =5K8!DK?B>Y^Z=MG-TZ!H'0PT<G/#_TK:C0OIZ=SXH4@
MRT3LG%VF1S>Q4MW[F_U2JRZTB-3?IWR1(!TO^[I[K]*?=I/W-?=@=<1G9*Q+
M73EY-02&XZE3]&N@N=?0VJ7B?6[)9PO**UUK[>S4"9>H#WTXWY&Y-*2\GO>S
M3XT-1H6P-$K1/U<S_5 2)HF+RMT_I/:I,R_B']-\+F3>.U[;[L%"D35]A.GM
M$5$N"\5KWWW),)LU9](FY>K2GL#O_3V?O$$6A=K4/U<C_=(6)JM'G)H%*AX>
M][M07%R..)$O6[1=J+"]HMCJ/1SI59;KJUM: MU$L5-D"_\ K-_?;I0 (%@-
M \GZ4%S)7SBO^_Y\JM 3##3EAEL'N5M)P?T]>_PK3"<LG;H]..*2O(:GO4E[
M?H[F%C'?D>Y4+_8>_+"(Q!!V^T]M*?@.R>@GX590N79>^'V\$8I+P7/;'N0U
M$KQC[RY/1OA-D*T^CWG\=*/EGY0[;.IA(0]-<I3#'J+VJS#OS/OQW6(I@/FB
MU7DG^_[\*U<3F6E2#!5.P5O)@GT].Q\UHY&.#OU?*</$>EV2Y^5?B5X%CJ/M
M\*1&&R:E;6@+]!+-19$MON[?WVZT 25<31..0AZ:YSIG4Y=#_F$ 'UEMJ)A[
MFI[;\9QS@THV1J./6=?\C^.U*RKD:]5HG4HZYTHA'HU/AH?H<OWUHOS"YNA+
MCWXU ETJT(K2KG7\/E4MD.G]!A?&]Y-KZ>[]U"FWH$]M/*X$BZ#"]NGZZTV[
MP?\ ;W8&N^7_ &7:A)?YMUZ]/UTX#9/+0#JM.T==81[%>[4[M"?^].Y:D$A)
M'4J0];?%2V^K2A1DUJ'_ "C_ '4#HY[G<X.VZ.;V*0AN3J?<HN9N93GEV:CJ
MM1[5/!JOW33]]Z1 R!0CLC6AU)_I-$Z-;<.%=\SW%NU"Q>6B&XG ^[Q?\AWJ
M[/:+9/F_'3 _[.#MNZ%:6+EZO>/UU\M( E61J?(E]]V/S\5[L@NL%FA1DUJ\
M(K2K'3\/E4-D->WV%22AYUSWP[:UI-6?ICGW;X/! +D76P^]J1#DHK7. $X0
MG-R:EFZS7V>=( 0U&B["YE*@X=NGN5R7S7V^:%)R[]/8IVQN;1H5- H2K[WX
MQY&"+0]^9T:M1%X;CYSOIAJ$V?FK^B]3JDM)>]OX:WE"738+M1%4MLN_\WZT
M@11*75:+\PN3J2P[U'AJ?H<_S1TAH! '0\NZ03S)_P#:WI9:_OZ]OE5JN)4/
M9KDF&54.MS"8L7DN[_!>H- 7BN^N[]<42Z0V'O4IV=J=S#F#S;)P@^_M7L5'
MKW-ZO?BBD->*YZ[GW4DHF/@K^&^#PH"1K :!/*D8O!5'8"I]=<:[YCL+]J/\
MK#]KJO5\PP/LTK>@TTJ!<J#1-\G<K<O!+>SKV^5&<""P'8R9'Z,>Y3H>.JD'
MW]H=C).D\%$.HUO8BE_W=C2VX8OW&UKWTK6(D?/7)V+?_P!K&PRBJ86#N)'B
M$B*N7."P>QG"L$@/-";>QY(,3N1A$$\\(![$A@[#MFZ_>JE@^Z"@63]63F9!
MB=R,(@GGA /8D,'8=LU1UILB"$H)'#%OR/3,!I4L0"ZM+HI-U;S?P+H*K'Y8
MIQ##E]HC[42?95SYTS[@_P"E*>YS?JGM"IZG;P)A)('.,Q]<,$$$"HZ]_L4*
M@NT ?<'W70@"/UX%I,@7)Q/UD0000000=>&(SL1C@]+W9V+G]OH]!]T% LGZ
MLG,R8/2]V<HN2:.0VI_.M7H^',W'J-G+U)6QR?PM>O:O2]V>Z.])U6PU7M7)
M!, O8O\ 93A?U8OOA1"0+B4E"N\H^![R5;G";+^0[9_JV[C*:N #W*Y$ M"Z
MZ'U>M<KX;D[)J/1S_5MV7<'I>[/Q0^;NS_-]T: O($R(/2]V>HTQW"Z:1VNG
MRRBT%)\5]&O:E5596ZM>E[L[I,JW?P%,GIVO9Y&-Q7\D/GC[4&)GY21\:@ST
M2B@T#VCWUCWI$8;)J8(@;+H1.8E 2+L#9L['GWUS?5MV,VXQ.2W,-<P ZE\+
M4P6Z7WM.(2<[/[1Z[-2\K;]WU#.]6W80P=-W0QH+J<5====?S"7_ )(Q@]+W
M> Q7!MZX_O\ M&@+R!..#TO=X!1 <VGE?K\]LASN5SWT>K4^(3T#D.@8>E[L
MVXN6\Q]#O4OF^PY!R#!\]\[&YR*#0.ZF]]O?Z4 "!8#@?0'+:??G[S6M1033
MH>;ZP%&36F:7:/72]C1S?5MV/HFS&P% 8G<:(XU+_CW_ %2?VZ B<G"$B@#H
MOX.O3.]6W9>B#TO=GXFYC5"P&&/<PN#;UQ_?]HT!>0)Q0>E[O *%BC%U$J(B
M!]Y/D.(Z0U%@#5:N>D_VRZ_C'TO=FH=41W6OV_K"RGI_5Z!=H6K);W/0.1QA
M_+J C6J,I?+==?L8(59PW.9T%J3>1'03F>K;L?1-G#'UT3D<^^OM[8HAA2>P
M/O!S?5MV7H@]+W9^(O9$/,+FX\RN2!([).8X7!MZX_O^T: O($X8/2]W@5$_
MJ?JO<U*/Z('9X=@?^3U=-^#TO=F:"T=NB0]VF6DJN:W7"XZ6;EI7=M[9,5IA
M+M_9H]&D1AUP=S+?@&8>K;L?1-G"R*!":(UO&R6_^HP6$;6/SFCU;=EZ(/2]
MV?B]+W4D(GO._LN97UIDG).8X7!MZX_O^T: O($X(/2]V>H3M:O4D8?FK1!C
MD[)T2YA"\Z/1?0]??@GH)NR<UVY=:?M5*75=5PFQ0Z)D+K^,/2]V8D-A?R2?
M1COJ/L?ME#MP$;%G ;F4]XC,^K;L?1-G$)_-GK^",'Y/\D?-]6W8:.4<'8&.
M'%BQ8M&.TT6)D\$'I>[/Q>E[L.:JNTOR*G](E?IN/+"X-O7']_VC0%Y F,'I
M>[/4?3?C6JNT-=5.^HQUI[A'S_3YWP@K%,<URZBTCU[HG\(P34"2Z<KW<^E
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M?5L7,(Q]NFKR)>57W#(2%UA8=@_N%PZ26&PKL>[V)8*@IYV!$M'J;Q0 !0:
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M-.P)*]#?RIME6[+H0'"K\A\KW#?DP\P=0X49'V&@(#!->AOY1PDU\.*(NL>
M6W.09GFV[U0TYF7!AZ)>^:(X/RB'4 &B(6"N5-KMMI12GAC_ +M'"7Z!FL4M
M%"")QG>"A40=$2EY.JRVB=/ "64N1X#55BO0W\KT-_*]#?RO0W\JQI*"'Y3A
M[UR .B(ZH/Q0X^<HGL59980"-U+%=CV> 4MH8O %Q&:]#?RO0W\KT-_*]#?R
MO0W\KT-_*]#?ROX=6IA.J[^+OSH&0<8M6QTZD_\ L#__V@ ( 0(# 3\0_P#+
MA-!*V*2/"!6Y26D/,(36Y@L8)-;'@MV@C <):2/+VY01AL4LT(H7!#2F># "
MD:&MS!*V/+:M ,!*4\*E". M(F:,4KA$4+@AI3RN)H3!0I7(&MS"*V/"*4!P
M%I1Y3"MS":V,P10N"#2G K2:0SMRAPV*2/**$8"4JYZE <!:G0F""E<\8Q4F
MMCR<,$%*^#W*&<%K8\&A0. MY-T4Z>&U>(:*T>3=%.GAM7B&BM'DW13IX;5X
MAHK1Y-T4Z>&U>(:*T>3=%.GAM7B&BM'DW13IX;5XAHK1Y-T4Z>&U>(:*T>3=
M%.GAM7B&BM'DW13IX;5XAHK1Y-T4Z>&U>(:*T>3=%.GAM7B&BM'DW13IX;5X
MAHK1Y-T4Z>&U>(:*T>35@AI3P>Y01@E;'@T: P5O)T-". M*,^6@& E3H7!#
M2F>"U#@L5L>4)K<J<-BDS12@4KP*4!P%I1F;E!AL4OE,4J7!)K8\)N4,X;%)
M&0K0!@)2GRNI0."&E.$HHS1BMS!)K8X4:$P04KY;W:&<!:1*5H!@)GB*%P0T
MI036Y@L5L>7AK<X$%*^"4H#P;%+/F$10:V/#;E)I3_\ @:DP,<VXI(R),#'-
MU5!FL/ HH=2J52I$\"<(2I=)X$R "#%IS=%24D9+3FZJ2:2,OG5ISPFC=0<2
M6D,\UR'921GFF6:<W1A)29#3FZL)LJ;#3G24$8J%0J% X-G.-<8U&HT.+*DC
M.-,$%1J-1J-1HG%IS=&,E)QM.;JQYV0$T$8:<T)H(P6*5X1%28Q9IKB\&YC,
M9QIAKR6G-T<$E)Q-.;JX(..#'3FF#!8J3(DP2:3,-<7AY6)AS33#7DM.;HP@
M:&<)*3A:<W5P":3AYW!IS Q7+)4.(OF&N+Q#)@,TTPUY+3FZ,-=04,X24G T
MYNK!8*&<)K\$V)=AIS->.K*T9PUQ>+1AHS33""H5"H5"C?@:<W1AKP@H9PDI
M,6G-U8:*BQBP":",(L6G,UXNN5IPT9AKB\6C#1FFG'JX&G-T8:\8*'"2A?#3
MFZL-&$V"5 U%@L4LXM.8KXF^48+,-<7B$&&C--,%&IU.IU.EG@:<W1AKX(.'
M3FZL-& Q0SA&,W TYJDPF,GF8J7,-<7AD<5?--,->2TYNC#7PQ<&G-U8:,8N
M"+A:<V+&?CEQBS37%X FH,%I9S33#7DM.;HPU\4>.G-U8:.#E8+%+/"TYW+Q
M0TTG4Z%03&"EG--<55*I44",>5G&F"K4JE4JE4J@Q:<W1AKXX\-.;JPT<,A4
MW$TY^[0SD;-+G&N3LYYIDE%0ID9H(J%.^1RZTYKO4*".$>%14*9'@!BA4"HU
M"HTT4^ -:A4*A4*A4::*?  BH5"H5"H5"H4I\7HC_P!@_]H " $# P$_$/\
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134JE4JE4JE4J$>+U3_[!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>lg_pwc.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_pwc.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ )@ Q P$1  (1 0,1 ?_$ *,   (" P$!
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8]?<9X?Z3SCZ?#;O<_ W>B)B>B(T1?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tv498959_ex10-13img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv498959_ex10-13img1.jpg
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MK*A65"=+?@=8J%C4$Z6_ Z5"SJ"H?3XD#]; ?UG64JK5[M*(D27:<9 )(>U
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M'S!-X;\=7LYBKM:KX^X;B?&'#%X[C<O'(E0W.238B#F?(\U#'OW+$5BECY)
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MDG>1G8J 0 @+;$[ZVO\ R[\^ZG"1]NP@Y:P:^X?%<<[\V'IJ#0"Y/^8NRO\
MS(O$-D#;CO-X7Z]G5ZN'ECACZTCZIIHL@524$M] !&X )!8:E_Y?.= =)?;=
MNO\ H54?YKO3][R!;;F17 AC*'LJ:TZ*XK9CP/[@N+>?L7G\KQ:CEJ-?CN0H
M8VX,HD"226KM-KG3$D#2 "%1LY^'5\/37G7.G(V]\B7D&W[N8G32QE^!^[6G
M4*U7L/I[ZC;%ZD[?/NO+OFFUC>&_O&Z2#Q^"]^UT]>AIHB:(FB)HB:(FB+"9
MMPHQ ,;2&7.XV$=/^I]4DG6W_@3H]=3CKWJ8=TK5N&M?I8[%NH'VA9O]7P^6
MH+:31$T1-$31$'^7^?6'$C)1<2,DUAI)S6&DG--24TT1<0P8L ?53LWH1\1O
MZ;CU^/RT1:G^YQ@>:>S>MU1A['NNQ,BHYV9Q3\(><;4G;^99$CZC^@:1]YKR
M<Q]JB<BMLM!DI)H<E@Y*NJE2@(V._KK(S49PVF2B/.03Q3+@?'IIG^C(5#_9
MJT9JJT_';^T/BI:WYOVG6!DMF/Q%-%:FB)HB:(FB)HB:(FBB_P )[%B,'$L.
M+I1(Q=%@/2Q.Y.\CMOO^LZME\9[5"+\!IXT"R^JE:FB)HB:(FB)HB:(FB)HB
M:(FB+BQV!.Q/H=]M]]MCZC;UWT4)*AA(SHOSK1>5LM:2X?XI;#W<MF76/[VX
M\($><S->".Q%7GLM5OP ;%0GIT,I *[Z\YWEH;?N#</\JIM7.=%5Q)-5%KW-
M,@7CEL97) "8UJA:W;CD1Y9TBMQK&SS[%+P)CEAV<?4&4_3MQ#]>&EH=V\%M
M![F@@' YJQO<D[-V#+I3FMV*=*O#>OV;<LDL588N;:O$LY:(FN,>[#98W#-N
M".G6M<E^D/<-+P>'0L0QL\XX#PK'VL]1CHW72"-I[,:35YI;<LX%*,)##%%'
M%'/'&8ROYHW638';<@Z7+97LC<''@HC&M>DKLAR%NW?J9.>#'R8_&I8@8+5E
M6Y (/O)8*^Z)*DB1Q=$:+'T],D9^DC=M67%6LS.KI21S@T4-,$NS/+#%(K]F
M"9()/N9IKT\@K02*TZ4[2P]HQ-WUF5HV+J3L>K<:HMJO)U8JAL4CFAU34K'1
MYAJF-27J1V:K/:CK V'BCCB:K3=8A 8)/MXXI?IAL/(PZ#U$C91;J=\SIJ=*
MF\DCO8T6%CS%6&*LU]\A]U3N8XBJ>ZO<LVWJ&*"$M)-%$L,,0D9Q(\DG^J64
M?3FKJ9E9B[S#JQP61Q&0DIQ5UDJK"]/^*6(NW$DCJ]I'#"U*L*6*L-@TYSU2
M,%?<$[,HV@_PJ-!T+*R76CFEMQRO'C8+#6[%I+'>A6PK=FLLA2+>,".P(@ K
M!M]SM]1.M(]\;=3"0:TJ%%X#149K&7(&QUB_7&0AGJ7KF*L0*HNQBK62)+-N
M&:])*N]J-(B\A=GD2(IU'T.^[!/<::M)<:*NI72N3@Q<T;U:LT]>OD9[%:K+
MVK7VI[3=L1V[1=GQXAD/<987W+LRMM].MGS9GM(EPP0$JMZ_6:[6@LRY&8T+
M,+S68YA+WGEA;LQVK=O%%(\52MPO)&"1TRJAW8!-N/:QE20!6JP27-TG%JQ4
MV1N3168H+=L*U>^E/>.\)[Z26)TCRDYB@CKSJDMH?5%U[A5;T4C5@ !KQ5C
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M>P^8:4U4]M%N3_$5$]./J9#(SC>-D#S-!,D,B,K=2=!D]"%&X(^ .NN[<W5
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MFLUINKF?YND$-[ :X+Z?:^>035?6()JJ:L5J:(FB)HB:(FB*.\@D*-QY1_\
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MAE?JC"[#6U(*N*R1TJW>_%CZ3((;:06T>"-4M5^N*V9H4L2T[06)ZD,C5?J
M+DQJC'I!7?1BMSYKC7,E4EV- 5>QVI5@FN14K:IB4R-N7&U8!;FG6W9CJUXS
M9+VHFL*M@D+.TIWD#;>F^I4!.&:P5AK&0-FL>VDS9))*K[S+UQ27GHM1@C"&
M%7KPE+3J6=@&,;'8;G>SY<5S5./!9C$7?MU>C<K+#>CH689IGHPSF0@AH@TM
M6"S _P!S.614W.[=1"J?5L.MJC$K.*N+V?QLT$M6"M*RB]+';BK8^>&%8/MT
ML"DT+J@FG2!D8B-S&9 %9E8ZI%OH.K-86.N7Y;5B)+D<@6ED[=HRQU*IQ3(Y
MMJ9K-#IL?3?,("],DGJOU$JXVM9$7G TH@5UDK->BLMR?%J9+"6Y%Z'I2-7J
MP6;5R[/CW';6.S=CKGI,9&XZ"Z(C$:M;+YE6_JJMU=;58I:DRDE5JD/W1ACB
MFIP2V)*ENY9ELQ+,J3#[:L)Z5&L2 I*[.SQ@AAK7NJ",4SJMFF"Q^1Y+#8RF
M'I?8'H[MB,5J<ST_NA97[TMN18M-]I8@0.5>,N@7=&'43(TH">@+/D>9WE9R
MY*+^*K]REBQ0_C,U=$QT^0C>D9)(\C:FAKH)%,LZR=)5'Z2B';YZA*6^5@15
M6PMTOTG@KR#D*/8R>2_A4DI@ANIV[,U?&SV*CVY+L<4,=@)#;6U&77H<!MD9
MOI&QUEG@'8K'>(]JL#D$#S7\=CY8Y+:4YE#+V9&E;I+X_LF&>M9A>G6B3N@(
MR]'2Y+^NI"E5K*XR60:F^/M49+4=!E@BM8^=I5CN0W9H)EF[\J239#(59ZDR
M)&I6-XV?JZ&!.MA8->.:Q]G(6S927[JVM5\U6I5X>RK5S>5;5D1K:9)HG@%8
M "(,D($8"[L0NLJIU:+8OVMX_C6<\NU<-Y"JTCP^_P 5Y&%7,Y6/#5$O0I;E
MKJV4JYK&92*S9!=DB#A NX  *Z\Z]177L?+<[K!FNZ#X]((J#WV\%OV/EC=H
MR_!FDX^Y;F5,'Q)O=1B^#\>@OY7Q?F^#<;M0PX#F-;,<4H<FXSC.=4,GA,K7
MJYO*<JI7<ACOLII8IS!3N?;P-WVECDB;S^UAW'_!AW2: #=Q/=-E8V+$Q$@-
M#0&USRI[%R-S/:Q[RQSG'R0YM3KH!G0GACEDM ?)WEORQ@?-?++N*Y[GL?+P
M3EG)N/<25;U>Z,3@8+EVC%B1'8I3"6*K4MS)&\C2/!UL%<%CK]B_27T0]*[_
M -+]C9NNPV\K;K:K>2X?*USB7N!(TZ2"#GJKCDOS9]5O6[U+VOU'WG;-EWN6
M+9X-PF$+8HVNH-61)&0H-(&"Q-_W0^XB.W<:QYFY=$[0FQ7FCR5.&*J\E=97
M>O#7Q\,$4;R!.G8;E]R3U,3KO-O^7'T3,S2WEW;HH(G5C?1\?L+23JQX\<EY
MU+^8#U>B:XLWZ^EF>TM+/*9BTYD&F']"UTLY*<R6Q*T5FS<NO8GL;.SW)L@[
M6[5ANA7Z_N;$DDCGK7Z]QOZZ]WL[46ELR.-L+(8F!C&Q5+ Q@HT8XUIFO(;N
M[FO;I][<.E==2N+WF0 /+G8N)IPKDNXNBRCJD1SL%4L'WEB-:98^A4ZDCCCZ
M@S(=S\MSOK8U!PU9 ^Q1?^"#Q6;Q$A<0[)60=9.Y#*)0(P8G>0.B*\C;*HZG
M 3X;'TU0X8XA<;1?<W^6! H\;>2;ZJJ?=\WQR-&L\LXC>MQ^J3N\VTJEA./1
MO7Y_/7Q+^9( <WVD'!MM7WDK]%ORDM'^ [PTSW9_]AJ^G^OG@9KZN&:IJQ7)
MHB:(FB)HB:(L'FXA+-QW=>H1Y^&7X;])CH9%E?\ ,-NEMO7UU./[_P"RM:7Q
MM[5G-06RFB)HB:(FB)HB:(FB)HB:(M1/<-^]\Z>QJKV4D!\\>0+YD+LK0FA[
M:O-(#( ZA^HVND@AO0_MTSKV*)X]GVK;O1230Y+!R5=5*E/]53\R?4?AZZR,
MU1/P[0H?SW_A#,_JH?[SIZM'B"VK;\=O:I;\_P#VF_K.L @Y(SQ.7+16)HB:
M(FB)HB:(FB*A] 3^ /\ 5K(S4)/PW=A6,P;*V&Q;(%"M1@90IW4!DWV!^8]=
M3E_%=VK6LOX1G8%E-5K<31$T1-$31$T1-$31$T1-$31%T62!6L]1('V\^Y&^
MX':<^G3]6_IZ;>NGVJN6N@T7Y9(LYBE4XY&SE2*?-YG)+#)$S7 *V>ECD^VA
MI3V;T[B*0*592!U@^BG;7F&]Q3R;E(8*^'/VJZR:Q]MI<0*.5I'E*M#'9%JN
M.,C3TWCOS.[TQ:FK-*AKUNF#IMO7*+^Y8J VZO\ ]X=<%K=.<?,=I->*V2QK
M/":^U<[UG'2P/5O25N@1UY?M62BD3+4IVY5[5J&.W(]US,"Z.&D3MHH;8CJM
M%I>-P:25*%D#I2Z88Z<UB\WG,192F*:4I :,&.CML_18@KQ*LU:>U;D>1;#T
M8[#-(8U5@9/4@N2MK(;MHH30K5=#%J.C!M<BL#))CTL+D<@B6UM&1Y8WWBLU
M!! ]+[99HJKHT+".-T60D)#'ON=@QF(KLG XI)01AH.(66R$TBV(%WD'::[
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MXZA>4:2T\*JMA!:*="^_/\LZ/M^'N:CM+%T^09(R%D64[Q\?Q (>17=6900
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MZ@?L^*VYUD9*::')8.2KZ?C_ %_Z-0TE5Z2A^'[=8&:UIAA50[GOKQ', ?\
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M<6Z>/J24Y).TTE%S7#7K#B)%6,L>J(L.GU4\;*Q[G]TX+872,O:IY1Q8ENF
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M'Z>"DLC-1IW<I%2C@KW'HWT::>:6*\,A%$\)DL(<>+D!FK%)(Y59PQ;9^D
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MHB:(L/R!^W@\VYWV3%WV.W_[K)\/GN2=39XF]H6I>?PA/4LA!_Y</_V"+_\
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M3X#+XZ:.'$T)Q<ORV3?B22*[$]40@31LDL:ANSV&^60Y'DV5L;CN1FC>2&G
M-U5%:89JF:W_ +^VX)P#2/>MHXUD/).,.K/'&D/(NY$%!61VHU@C%B.N/MG<
M@ ^N_KKV;T&<YYO-;=)\AF8_Z4=*X_>/XNVH:C6[^P<UZ3Z]3?[*_P#XVOH;
M[H6FSP?YQ^*Y:PI)HBCMDI_BO"J?SG"YTKZ^G3]UA0Q(_02-6#\)W[06M+3S
M6CC52+5:V4T1-$31$T1-$31$T1-$31%J5.W5[[L2I/K#[1>1D#]%CS-Q@,=]
M]@1]J-/M^I0X^U;:Z*::')8.2KJI4JK  +L?F"?T:R,UKS\.U0[GO_"&8_\
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M;H5"PND+S&"&JB5I)8W:=%5#+*Y/1&O1.&Z74.=]SO\ '7LQ@#!5F)7SY)>
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M&3ELAFKQTIVF50&9H^@]8"$@/N#\/GJ40-0WC5:MW_#'I644;;? #I &WZ
M-8ZE;%^"UO$47/6%:FB)HB:(FB)HB:(O(/*)WS7B5!8[1;G]PB(G;[GM<"YE
M(T?Y6W,2J9 /3?I^.O)/5P'_  5>]'S5O\0MFR_BAV+)9:HE_'7Z)FEJBY2M
MU&LUPO?K+:K2U^_"'5T,L(DZEW!'4/4:^0;BY9:SMN'Y1N#O]$U^I=C:"X:>
ME:Y^*<1P;P/Q*?@^0\M0YZ=>1V9IK_,L]B:V1IW\A5H0QX?[9KI&/A05A)'
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MIR('*+U;-ZAM]:[!('=[*BFX@C!6\\E5,C1:[>[$?[A6LV+/WM&]7$C"I-/
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M=1<SD[4ZHG\35**D=18.%9>Z^G3FVEU=@,>7F-^0J,6.;4]&)6ENA)T@G$D
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M:(FB)HB:(M5^'%YO>9YZ9VD*TO 'MPJPJ92T06US/W!VI2L))6)R\8ZB-NH
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M4TT.2P<E752I56VV7;\1O\?VZR,U1-P[5$.<G_Y%\R/D$ID?HVR-/5HX=/\
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M-)(;*U?O?OE[LM:2+O0S&K/UNH8]TC<$?4-;S+J4VK87FL,9J!T$K3$$0<7
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M-(!61>+5&6$'JV#RV7#]19V8R]763OZEM]AOMKSC?2?YO=#K"^]]B%-CLO\
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M/17V*$C3G3!;/^('GEXGBYHZ,</\0OYBU#4[\&0AKQVLE) $FED6-'EK?8R
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MWVW/I/+C'Q[;&UXH1FOD/U4:[_%4S:=[2/B5Z7%%!#9:.S&J*AD+++&1/)6
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MB:(FB)HB:(FB)HBU+\%;-[AO>ZX!]/*?B*$L8R@+1>W+Q>Y52?\ S !*#U?
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MS'8MN=84DT.2P<E752I56(V&P_ ']>LC-:\^040YR?\ Y%,O^A:G_P!/U/\
M3JT9A9M,+AO[0^*EK?F_:?[=8&2V8_$>Q-%:FB)HB:(FB)HB:(HKRL%Z>-42
M&/\ ^2?BY) !+*F<I.8_7T DZ-B?CMJZ+,_LGX+7N<(17I'Q"E6J5L)HB:(F
MB)HB:(FB)HB:(FB)HBH=96"*KX2_SC5Q1YI[:FR%R[$[XSRA6CK4XHV*O8?B
M;5<@\A>*0+5L0F,J76,][=MR%&I._@G_ +;?K2W<&S:3G0KXF9U<"!2EA-S[
MBE#&KS5T+-%))&&>)H^RWWDHZ^E_K9"9%0,%7<]:E%20MTNKAUJ#P4Z31%8X
MFLP217*\'=DA$F*C,*I H->66-KTL@1EZ(]QN#T_F(XMK3YOE\7+>?,V"/6X
M$CJ5A/B<$D"V&CO)8/;IO-D+,=>!JE>Q!"9('EL,EB[*]AG'03)Z*"=CJX0N
M)(PP*RVY8YH=0T(77>86$>A'CUFKRY.Y1?MPS5Y[%5Q+V9@9^I8XPL2R=QPR
MA_56'U$[$+?+K7BM660.?6BQ[X^G7^TJ3UKQ85*M''6(F<1L&:W9=HZZ3PK,
M).XHW^E/@S=(V.IQ-KW*BH62*,#SD5C[53$?=M.V+BI3PXTP(J=Q1;^ZG=);
MHE>S/%6BG,C=MFV,8ZV#>OKDN8TD%PJ%&H5K:OXBOE*L\*-75,;;AKV'6*.6
M6?)SUH!6,,L$G:FI,(FF7Z4^IF9BN^W'R-T''&JAK"[,9)BBF/:G]PL:V%22
M2P8[=S[BY9EA:Y':[R1RU)+07Z.X-V]50 [C H#CDIK-X^&.*SC[D\$=IJN2
MA8?;V$C>K'%C9Y/MZTE:X'CBCGDWE*_29&+$JNPU-[H]/=!JBS6'I8U8([*X
MVM(HPZP46IV"ZN9999P.]T_5) SSCMMLR]90L?0"FH*B_)9WA53%9C,X+!V@
MD=O)Y3!X6I'*T\M.I-DK\M>M4C6HCFXL==A)(@+I&BD;$[J*+F5L%N^X<:-C
M:7'K X!0!T@NZ*?25]2LC_*C\AXV2X_'>?\ C^626021U;S\EQ40GB:R[26+
M]3C]Z>TD4LL<<+"- J)ZJQ  \8'KORO!,]MQ!= M#V_ZO$C G!RY]W+]V2QP
M<PY.XY9]"@UKQEE?"-X^(^5'"39WAV-P=G*9#C<V6N8.&3.4OX]&*ES(8W#V
M)&>"Q^\ZZZA9$8[GI]?HGD#G#9>8>6[>_M;B&"-[RS3-(QCJT#JT)Q%#2HX@
MA?*'JKRIO3>9W206\URR:/4#%&YX;WB-)('BPKV$+I-*(V@5K"NMB-[<$LL?
M<F:%YH.Y.I$9BZ(V8]>WH2/0'?;7HFW3VM]<.BM9X97L)#BQP>!3K%<_\J\8
MW3:-SVH1_P TMYK5DU=)D:6U(ZCCV(HHF&&*.JYDC:Q)!.9%DCDA9AVV*[O.
MDLDBGZ=CU*WJ  =N=@D8UH+S1W1Q752V.?NO:]LG716\L58S3,:(C#F1DE4
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M-&>&02RHK+(S2;#\IZ=C&BB6U-5A[TDTD0^QI43"D?V[5I)F>Q4N&(R5^S<
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M='=[<JB1>M+&^\1 '4/GZ:D1J(/0M!P+!0'-=D=GU'[UV5>VT;6>GLQ[Q%I
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M!AK#CJ=JXJ)!(H,U)*^4QT4F)DKL]ZQ:K0XV$6)XU>>>&S)!+'/9KQ1)W0L
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M\@6.8^)*^7\@\NJ8[R[X:L\7P>3PV1LYK+\I:MD\//:Q$ENUB*#R7%@1E&W
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MV]3JR-S&XN\2P0"L+_#89,B[@74CDQC"E!;DECKO)8,,T,ML8R3OLG:M@,Y
M(*LK $KO)\I,FMO0%8U[FL\L>%8OD*K#7FOFW+16O?'<>L_WU1I[-^0-]S8D
M M35#"-@QC_=,R!3\2=IAUM#G 5/4JRT'%1>>GAK[4[2WA3HS5Z]JW+W7F62
MTB2I$Z0"9X8K';*22=P?ZA&YW(UKNN) 2T4H#T+*Y44JMD:M4/8@@^Y"=J*U
MW!+7,E<17[=B"4K7E6.PDLL,2AE,1+$=.XGY[?/T?=I]2V_)92N-:*4U?X96
MK=4$]WM6YK_VT\_5:MITPO\ =]M@'E6"29WF>)>O:'IV?J'3K6KYCP7=*U%=
M5*D,M..W8>]CZIM5ZR(*.2KS/76L8(;5B%FD$-F"W$[!I(D#1L>A0028L[VN
MO X++7%IJ,UVU8JUZ":.CW6AQ]N6MVY+D].02")YI8U62!_M3/++W&+(ZNBE
MNI_390.S4GO+VZ74HMC_  ;0@K^7?"[RRY.QC+'.^#W89EMU)UZ),_BZ4+".
MU8:2NP=/S;(K1NO2-T4:ZWS1(^+EV^D934V T]N"A$*7,5/UE^E'W(^>L)[?
M^*5\_E:45_(9V[G*&(KW,UAL!A$L8O'6,Q<O9[,9F]3EK8:E1K]<J4(,ADYR
M1%5ISRLJZ^&.5^69^9+VYAA-&QQRO)X:JU'OQP7=;R\-H(G,H'N+1['9K1?G
MUWDW'>7>XK$87R-S3C=/_F+R;-K9'+\OQJOCERD& S5M:5RNTL&)QE>Q;G2)
MDA1^T-I=R&8?6_)/+G+F]<M[,^]L;>;<HJL,KF]XAKC@T@BC>KIJOF_F3?-U
MLN;KNVAFE;:!P.D'I *UESE3E-VWQ?,>1.8Y?F>=K\(>K'R/)\AN\BMOA'Y=
MFK="./.VCV[RLLJM)+$D,#2'Z5"A=OH?EO9MHVBWO[;:;>*WMY'-U-8*"O$C
M/$G->0>I6YW6Z"VO;ASR^ G0">G.HX]2LIJ9:I)V7/= C)'>1-MV*S0F.-=N
MU'7">G4?K.N\11@R<<A\ O(YGEL6%.GWFJP\L<<T\H5E)D=HB[%MI'W'2[(7
MZ8#'_P"'8[#;?8D:RYQ#B.M<8<5Q-."NY/W#R>HB9H6:,E"-C%$I/62C,3\O
M0;C?60QN>*V61,:#Y^=,."QMFG5:Q =BQ1%*2AI.AY&7H6950R='3OTE?0L-
MV(U8][BTCJ6HUC20#TJU@J0I*OKW([/<E:,$@-T+NDCR*_5'U;[_ $A6!^(.
MM>/2)&:C1I< 3G@2 5O6T$7S#&N=H:YX%<Z5-/K6YN+]BV(\M^+.$YB?R+D<
M8G+,5Q;E-B@>+T\Q6AK6Q%=FQU>:;-TD[%F%36FE8,1$Q95#;:^1M_\ S(7V
MS[Y>[9#MK)H[>\FB;(Y_EMTL. /2[KXK[9Y5]$^6=OMK?=))993/#72!YF+J
M&H;3AT\%/<Q[%H,1C<W;E\EY*>GC,1D<A#3BXO4J&08O'7+D]:2U8Y2:,:SK
M%&HED"J /S;'TXFT_,]O%[=-LV[7 USW- +)-=*FE7##"G'I5,_H!RN^=]S\
MQN'E2.+BW30 ]6&'Z!>3>W[VRXWS9XWQ_D ^1!1@LYN_6JPX"EA>4P5\?2J8
M^:I(_(,=G1C+-JW7O1S,8_HC$JKMU!M=DYR]?MTY<WG^6Q[7&Y@A8[4^734N
M%33I'P7'V/H!RGN$!>9]S,K7$8-8WCQ#OJJK[SA[7:/AW@F=\C)S3(9R/&9;
MB6,AP:\7_AT;G/<GQ7'I[+9),U9"?:Q9-INM8%1NUMN/0ZER-Z\[GS5S+!LD
M^ULCMY30O9)K ]O ]70N/YJ]"N5^7>6[W>+>:]^:MX"]@E+0:C^JRH+<.)!J
MM6#% 86,<C%Y52.)(I/JA:1W8 R/&1U+V_I]1]/S.OI>-LHG< X.:''&G#@.
MT<>E?+#A%-;,D<\ASF"O=.?%<JZT2H;[>3J9%1(B%92D91_N'W9W:<D%1L ?
MV#7*1M\PZ79CHP*U8G6P8X%Q);_5*EN(2-D!-82+,QB>&7Z8S'+%MUA!$"C(
MJ[1AMA\&/IK:MY&1W#80UQ:MJPAE?.T,:3&X5RSJOTA^(8%K>*O&]=0H2#@W
M%HTZ>@+TKAZ>P41 1@ ?@-OPUT.[POWTRU.^)7WS$T1MBC'A$3/[(7HFH+83
M1$T1-$31$'Q&BPOE'[Y/<ISWPKY;P^*Q_N8X3[=N#)XR3E>4RWD#VB^3/,6!
M^Y@S>7IW;L7ESC6>QO$<%?2M%#TX>U']P.V)2QCF'3<Q@<RIJ?;13#&N;4U)
M7LO\N# \%P'MHXNGC7E',N=<+S/<Y3C.=<_X_P#X5Y3SJ]R^S=Y5R/FUWC_:
M@&*J<LY'F;5^G"JA4I3P@;@;FR[<[1%6F#3\2M<"DI'7]2WV'P'ZM:RN.:KK
M")HB:(FB)HB:(FB)HB:(M3_;!))+R7W>/(@0#W:\JBC V/7'#XD\+PB0D?-C
M&?TC674%*?JA1;T=2VPUA230Y+!R5=5*E4/_ &ZL "UY\JJ(<] /#\U_L4O]
MXU/]&LCQ!76;6^8T\:_6I>WYOVG^K09*R/Q%-%:FB)HB:(FB)HB:(HOR17:7
MBW0'*CE6/:3H.P"+1R9WD^H;QAMO3U]=M3:/%^R?J54W#M4HU!6IHB:(FB)H
MB:(FB)HB:(FB)HB:(OSG_P Y*W4K^X/PIU5ELW4\/Y]HUDJRW-J;\T5YGAC+
MO3C:O:JQ.9&B,JGIZ''KJ-P!\D3QUCX*ZW<6R5;@:+X[9:*NU^=J\<EBRZP6
MHK<[_<V4>=HX[\C6&E>%DL/#&>TS/Z.& &Y&NJ7/C6XY[G>(JRCL3IFB[WHJ
MUD1R38\*D*1)B8(ZZR,JPM'4N1&#I5AU)('4.RG8#48&-=74*J*B=NX8I9<G
M-9LPS]"8U'Q[5U%AF_O"UZB1+(I^W:4(H]$?UV^N+UQ+#WNX,*(L?=@;M2I'
M,LW3+2G1I#,DLC312PO)3M6)VFEDBW1WCD555_5@P U.*)NCOC%0<2"J9R2Q
M6M5Y4->=A%+5L1UB%0W1&L7;M'MILE+8E77K">GH$&M@  4&2FTU&*A[S"Y2
MQ_2EBG6:O)]RUN 313&"N9(X2]>V:ZV[,MX K-O$84ZU7I8[5S>0QM=/?*+O
MLV>U,L[9&H;95+D9HTJ:5U*PUJ\O="PE:RK#,T!V1GD:3MD#IUCR(@?,#>_1
M6B5Y(!*E$,]^P)&J5J)!I-L+L<0@ :"R[R585>L4M/%4[>Q]1*WU[](UIU(Q
M&:A<#0^C< N>,B:K7RE7)=T5))+T<\^/DDJ+1IVH5>E'(+36+MM+,R&/KAF,
M2S$?2I4[[.AHA<\#O%4%Q!6<QUJZEJ6,UY*ZXUYHZ[3TC]K(*-6M.7@A"6D+
MUYX#]8WB9BP=BIV.NW,]B:G+93V^2UW\Q^'$M5,: WDS@DLE<XYDEG6;D6*L
M=,4->NO13W$3Q$!5"G< 'K)ZSS4 >6]PK_L/K4X2?F8J_K+[M^^_@?DOF,?@
M?(>+>(\GY5R+AWER;.7WXWEJ&'BHX!\9]KD8,Y-;H7)$IY39.S-%+1:&:N.N
MTB.5?Y"]/MRVW;&[K_,9 R&6VD: ?O/(.DUSPZCQRR78]]AGD%N^%I(;(RJU
MP\^9'&1>4/.HR^1FJTYN72X=ELX:]?4U+_&,*U:)<:M*89''2Q5GE5U#Q21N
M3N I&OK?TEL[J?D[:I+)C)#'&X:B:&ID<1Q_5(7S/SI+?VO.EW=2L;'""T5<
M:5.D&N*UC>VN1''(\?-E+=+&<6H8>7)93%3X*T7J\@S,U:O'A[$<BXVBD,L3
MPQ;LT54Q!O52=?0>U63K1\OSS&M$HJ6@X$]-5X[SYN+KN:U@8]KM52[32A'
M>SJ1W:JW<G,8$E9XHWZ8@!'//&^^PB4"16_,NY8'\?AKD[5DK[@X]VN'8O/9
MG:H@?TSHK"62&&2P[S2,Q;8*O2B21PA0&4N8G^E(U;9 5/KL=];+[*8O)&55
MQYE8,*#!8RT+/T,91%([]2Q#NRGJ*+W>X2W3',(U4+Z^@'3\]3T-Z$?-))XS
M56<=EZ\H)Z9&41U9'F?J2P(%9OWA3_S&"OL2=CUKL-]M1<QNDX*+7&H*[EE$
MDB@2=)ZRYDK%>VP)790KQ;&>95#'<[AA^C;5%"WO1BL@RXX\/<5OV9DDO(FA
MS0?-::FE,' FOL"^K/A/SWX:X=X:\4<<S_D_CE/)8+@''Z5^M<?)]ZK<Q.'@
M;)+92#'RHEZA:<J(V+=PKLNYU^:_./IKSM=\W;I-8[5//;/NC(-'%SR=3N]5
MN/9V+](]IYLY6&TV1?N%NRX9 &N >!B0!]2]+R7N4\&+A,E+#Y&XS<B;'3S0
MUZUR<W;4=W$6YZ5:"F<?:7[RV8"@[\3 /TJR]1"'KL'I5Z@QRMT[+<0,<]@<
M^0@!HU#$%FDU[</:MV3F[EAQJS<X-=#_ *PXX=9]JUM]I7N0\83>.>2'E/.L
M3A<[FO)G,^1Q8O/7N6C*Q8S)5L/'AK.:LYW@G!(%R-G'8[9Z^/P^/Q\;1_NH
M=V+OW[U$]+N?I-[9%%ML]S"RVCHZ,AV8QU%]>C"G75<#L?-W+$T$CI+N GS#
MF^O'K.'L6=]WOE;QYS/P/R7C?'><8++YC*YC@\M''8._9LWK:8?FW&\Q*@K5
M>S/'2CI5R\DCL%2-6Z@5W!V?2/T]YRVCG^SN]SV^XM[4''70<<^Y0=6.*XKG
MWFSEL<G;DRSNX3=?*D@-(=7,<:XKYAS01=E5DKR@O'&D0,TZDNYVZ9.W.L9^
MF)=P0Q/Q!W)U]\M!;</:?UST+X3DYAOS;QZ])_=-QT,RX?=2MCX'D[\T9ZP(
M9995N3J.I%4HK+W-C&RML"NVQWWUR36M\7WBM%F^;C0ECPUKN&AG_-4YQ\$'
M3$4BZ S/+*\4TLBRL?H=Y&KS=+=MEZ-@0!\];]O"\W3#PH%R5ANNX?,LI)P_
M5;]B_2OX>*'Q+XR:-0B-P#B!10S.%4X&@0 SDNP&_P 223KS2\_\0?\ MN^)
M7WDVI,9.9C;_ &0O1M5J]-$31$T1-$3?;U_#U_HT6"OBM[ULMY(X%[J<[R_Q
MWS[WB\5?E_@?Q_Q#D6)\1>R4>YWQ5?QW'N7^0,I6GI\BR^0;CN'YG9;D4L61
MJO39OLXJY=RK #8BQ8, :$\:&J-)I@MW?8?P[BOCWV\<2X9PFOY1I\:P=6M%
M1K>:>/GB?D])LA4AS.3DY9Q;[3'Q\:MV<KDIY8J$5>O7J5GCBBC6-5&I7==$
M>H"NDY=I549+I7EV8=]06YFM56C$531931$T1-$31$T1-$31$T1:A>TYY)LK
M[M;#@A)_>#Y+2 GJ!:.APOQEBI"0S,1M9HR ? $#<#8Z9TKT!0;]2V]T4TT.
M2P<E752I56&P'Z?ZM9!-5KSY*'<].W$<Q^'12W'X_P#J5,?VZM'B"E9D_,,%
M<-0^(4N/Q_:?[=!DMAGB<JZPK4T1-$31$T1-$31%A<MT=W!!R03FH.CZ0P9Q
M2O-TL?\ 5&P^/XZFW[W[*JEX=JS6H*U-$31$T1-$31$T1-$31$T1-$0:*+LE
M^>'^;]CA;]Q/AR26D\\1\-<AK?=5[$L4U19>6V8Y)&15,3I%!,\@63;K=1T'
M<>D+HTL'4_7'P6Q8T,]'8C2?J7R._P#2K4!L-'*LAN'$U:Y@#?95B(VC>:V@
M@ J6OMT=(T((,IW^GZ==/G)+LUR<S6M:* 9J.&S2DMW5NTX6V5>HF!XYZLTD
M44-C[.VT3U2E@-&W1ZK6"A^A@ROJ,#CYH%<*+$+0:U%5=&&N4I-]HD4MBK&U
MQ;/1++(C7*5R21-GKB-FDF4_20Y^D?#IZ<F1^MPJ:549P&N &&"AMIH(8ZL_
M3"8UL7GJT\@D45FW+-$\BQ]R)5G$E9Y=YXVZE^++N=]FM_2530%8G*5&GB%:
M.@)H3#1CL9A9Z3Q)=BDCF8UP\D4T*]NT&C;H5&#!6(!W$@+IPJP$M*=7!8"P
MF+AR<-"P+5"M/#%42-),?VX,7<$C2?<6)3%5ZIY*K(S0Q]0C.RE(]FU6XN)_
M>>)%)XDQ?0U:UC*UA)+5N&.:"%:,*KD!M66I'$&,AFF9Y9&;H6-7ZCZG89UO
MI2IHBN<=)0;'P":LKK51(DC7[![=J1HHELP$).DB,C/]?0O2%Z@X]=]55*/)
M(J<2NVK/3AQ=J*54_>7K..21%K_=T8;6'CO)"D,(WL(@98>Z4)#-^8,NVK-3
MJ4J:*A9C$R4YYZ$U*,78J]*Q5R%FTU:.90E*E:D9Z364'9HV G6#%N1'OZDC
M66%P/<%744FYXK:+V\PP6/-?B?&TY8Y)YO(G&&KQ4UJV[L\4&=HV*-C[NXH"
M=NFO22KF0)L58D;GJ?-SYO\ #=_J&D>2<1VK8@ ^9C_:^I?JDFC!:9PL7HTC
M'Z01L9"K!@1MZ-O\/F/0:^!(8XY;F-D@#FNG<"#C44)Q]J[T,0T&I%0OBO[F
M<=4;W)^3K :"2U._$Z[M,IF:)9>$\9@5>V!LB&$F-00RHCGU&^OT)_+[*X>E
MME(6!\OF2]XXF@>0!7H R'!?&_KO)(><!$2?*-NTD5P)U.&/3A@O)K%:,37F
M D,0CD,#=F.19FZX2[!5F4F-&;IV._KZ^GPU[U9ROG@#Y<]17@-VT-(H*:<N
MJO0L6TTU>!Y[-5TL"1E<KV^V*WW'7)&%"]#MWW8; '<?$ZWXG.;,S22*D9+C
M9<(13*GUK%B%+,;._3W CQQI*/J3J=9592I*#TB?Z.D #U V UR#YKL/(:VK
M:KC',MR35Q!73"B.DB2,SK%9EB[$K E6,0ELS+T!&"QQMUJ=B"#]6VK86AU=
M0Q5H ]BL+P0JH,C/!LG>D5$$+F,=2Q2D+W.X9MOJW8]._IM\-9WA/8E N<3;
M6G6.)G'<[@=@I+*TD1>.+J,:&%RH<[#<D>FP]=:I<6C4TT<%9"QLDH:\ MZ"
MNN"I7C:R\2?W2-Y9(D+M&VWU,GV[OW>IFCEZ5)7Z23TD:I+WD$$FCC4]9'$K
MD?EX*ZBP55PA[L,FT<3S")>^$CC#K*%,:?NIU$=B+J )W *L=]P-M4R.:V,L
M>*QOP(X&F(K[<58R"'572*J[Q\45=H.EDB4 S[$A8Q.8G)#$LP2!7 9!N2S?
M'TU1.^:Y(+.\6BF/ < IMCM+=NB@8VN & ZURABKM)*\<2]DHQEBF7KCB,D2
MAH$@=_JV9B?3XCX_#48O/B(+NZ\&HHKH3$][HV'5"]E'#@1T$<0L.[)U=4;1
MF,.?J:)YY0A'1+V09 V\!A)5CN3^&MF&5H?5PJXFI/2N*N0&LT#!H%!U < K
MG'AI]HS''(@603QM$$[DC3="'?N=2N_66Z?1/IV] -<LTA[=0&!6E &N?1PJ
M**7X^'JD8]?;Z9%C@4F81*JKU.[&-S'"!UL3Z$E=O7U &VQ[VT<TD$+E=HMW
M/W*W!/==,13A2N1ZE^E/QO%'#X\X+%%UF./A_&HT:0@R%%P](*7Z?IZMOCMK
MS6[)-\\G/4?B5]_4H]HZ&@>X*9Z@KDT1-$31$T14/J"/Q!^0/^8@@Z(OE5Y$
M]J/D/QCY\X[YK\.>-4\Q\)PLE#.9+A66]TWG_C/E!>8G-7\E?S''\7RGFM[P
M;GL#4BDB$6*R4%3O'JB[JQ](%\;QH+":$UQI58ZN*][_ )?O"/)_CKVU<4XA
MYHALU?*>+R.>L<SJWLO%R#(5,AGLWD.2U*>0SE?)9>KD[E/$9JO"\D5F:+>/
MI5@J@"^_+'%A8 &:,/>M>"OGRUZ?J"W;UHK931$T1-$31$T1-$31$T1-$6I/
MM/(>3W/2!S)W/=UYB!8QQIL:]7B53H_=DAQ%]OT!CLQ"^NLOP I^J%%N?L"V
MVUA230Y+!R5=5*E58[[#\!JP"BHGR"AO/O\ A',?[-+_ 'E2U(>(+-G_ !+/
MVA\0I@WYOVG^K6!DMAGB<FBM31$T1-$31$T1-$6!S$BI9XXK.5,N<1% V^LK
MB\I(4._RZ4)]/7TU8W[W[)54W#M6>U6K4T1-$31$T1-$31$T1-$31$T1!HHN
M\*_.S_-SE[7N5\;L9H.E/" ,G5#8G>F@YKR64R% YK*+<*.H7MLTHC*D[!08
M7CXV6!,GAUA;-@/W_5H/U+Y3S6H<@ET9".M>2J+(1Z4,,<M>P2TT<D:R0NP)
MKS(I':)#[J?7IVZ=/<VFKBN4C9YD0!Z5"Y,=6E0B!4>_7M11-6LRU^W?^[HU
MMH^EJY^WA6.G()>M4E.Y"L"6&J?FK4<'55C8_+]JL8*R57,]NI4<(DU.@S@-
M^<!DVMS.)#!%%#%VUF4],; [D@$6,N8J5C&%>*E2N84<R<;W(:]?*U)I;4U<
MWIHDR54B?'QVV2NX@:$1N1$7+-L)%B1CU!>DZRYX>=2U)AW\ JY!0:A@^ZAE
M[R00I3E@+NM2S((I$2G*B,P>.K(@WV58AT  [/JQUQI@ ' *JA6$JH/NI;S5
M:L0:2U4H2QQRVIOMVM7VC807H!''%&\K= (D1$*A.H@C4&W-6CH2A7:V(M=Y
M)/N:=2*2N[30PR-W+KV+ C^\O14BD\E:S-TA5,J;)&"D?HP-(N"<A53^7Z2K
M[%55[LKI7DAI=J^B)9BMV;$=BS&\A6A(SR T9Y^D3>IG0'ZOI4 8^8'WQW>*
MPZ M:37(+,A(H,)DLKUS=9B+2M9QT.3EC*89&R+UYGKB=89HNB%86E8A1UH
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M*HA_$D_:^H*3:H5XR5=%E-$31$T1-$31$T1-$31%J1[2&#1>Y8AUD'_5WYR
M9"67Z+N#1T)('U12*48?)@1K$_CCI^H% <.P+;?65--#DL')5U4J50_+]G]>
MK 0J)LAVA1+G?KQ+,#]%'_>536?O!;-M^.WM"E?S_P#:;^LZR,D9XG+EK"M3
M1$T1-$31$T1-$4=S0;[_ (KL"?\ UV0G90VP7!Y@[^NQ4?I&K&8AP_J_6J9<
M:4Z5(M5JY-$31$T1-$31$T1-$31$T1-$7%OA_E^.LA9&:_.W_-=FQ;>ZOQ]%
M-#//?B\.X<.*T4DYBJ6.7<N2.>=.@QQK'*[;GJ'4A8MZ+K4O/X:O2<.M;.V^
M-W8OEAG#Q9KD=MLJT4T4#)/&T*Q4+\.[CLPLD4ZQ3QS'N.YCC+])]"@VUTN=
MKA*21@N;9FH'(<+!";,N1O5LQ:$R+0GEAEJVYQ6+O+$)HHY._+5&QZ65 05V
MZCL-=P.H++G-;340%93?PJY'0/W%U8Y:J&&HUGO-++,\$\G]S=D4P3(.A4"A
MY"W0IV!VN>0:4Z%EKFN%6D$+"Y1,!'-65$R,5ZQ(UR*5>TH:M*9GMJ6E*22)
M&X5F"R!%*HG3MU*8*#_$NS*6\15-&,6K4\H=:Y>Q&OWD^/E"1P*?W,TKV9!N
M%9SU?'I/KOK9:]HMG-KWE!8-*W&\A/3L!9+7\/Q%A^@1B:"*&M)L18N%K->6
M>!ZK;$'=%]>DNVVM1C2&##@BS$D^*66M6>+*)0^WED9*L<20],,M28-%8D:$
M/;CBLR(R1DML/7Z?76S#_=VD,XJ$\#'$$$$KOQ-S'6,W;46+RBI>D=HT>3[)
M&^W4,CFS.\"U'CJ,S@E>F0J #\3KGNX' K,G@/8L[CDPPHR6#/DY2[W88V$D
M[.K]$IG*P)'/%6CDDC158MTLI("*-; ?2 EIQ_I7'D@"IR5*QPH?K@F:L;5:
M@T=(5Q>3$4; M?</2<0+<$%1W9#*?5&Z69MO0:_FN<"'8!61!KW8D::+:/VO
MC$3^>_#@A@SV0N4N8XR.IA:L\%J_DY<;8M9&.C7CMVJ5)ZL\U7IBE$T*"1PL
MC"/IUU#FSO[!=QZ@UKHJ$DT%%MLMXO.8]XJ [W8+]*]/FV7LP&:7QWS^E9^L
MR4;5?BK6XRD,DR1]57EMBC*#^0%9?S,-]AU%?B.RV@.OXXI;V#Y?Y@T.L4'=
M=UKL\ESH+*1.+*@8##WKY%^=+-ZSYZ\HWK. R?'9;N5X_;?'YRS3FO6(8^)<
M:IQ6BM"[D*%>*Z(AT1),Q &[$,Q4?H;Z$6S['TQV^T,C98W&4AP((H97#AV+
MXM]:9VS\[R-:*.;$ 1Q&+C\%YQ.E:6Y-$[^J221S.Z[)T/8W,35G8;=#N!N"
M.D+^K7MMO 6>$$MZ5XS<LC>"XD+ STH%7=D60K,\857"O*@E1>['.X60D(^X
M/JHW_+\]<K #K-0N+EMFNCHW%6]B*I&9I&ZNKNVHHXTC^GL]<>\TB).[E@Z
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MI4#J&V^A>WS1B,E='$8Q2BM)#$[P13 H(0T#]-?Z6B4R.9.GTZC(2RG<;;_
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M_-^(5,V:DFH*Y-$31$T1-$31$T1-$31$T1-$5#_:/ZQH14$=10+\RO\ -$R
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M#L>Y3CQQ67C668%UV"JNP9.N,-$O27#HR]1V  +;?$?+UWZM1>GD@-!XU5\
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MBG]/Z]C\]M5.)H_JHL<"HKPTN<(S2*%=LWRAM@ -E;DF5Z=]O3=E )_3K?O
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M[MO]8K[\>E6Y\@<FFK]R:P8&=*2QAZZ-()+BR#KD[*#8U0@)!"+M\3L25O\
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M%9>,2#K*!4C5 UA3M*VX1FV&ZG?8>NJ__+UZDU\%G3]I7_\  ;U&P!LH.O\
MO+5B;'O;\35*LLKT>:OV#TRQ_P %Q*O&PD*(&1LNJ$GI4^A.X;X;C;2X_+YS
M_#"Z:4V(C:TDD.%0!T*I_H+ZBNE9_<H14X?WD"JMW]\'B"-;Y2KS69*R"5'C
MP>.1;74\B=N 2YF.1)%C4.>XJ+TD#X[@<:ST7YH+-!GML?ZP^U;A_+[ZG?\
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M6^X6S]-ALTDMI:R#]ZT5%6G[QX-Z2K72L T$A>E^-."<:X)B\SA\#RBWR/\
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M=2$$CA44IVJCYO(Z7:J="Q5J41RUU6RG9B@5I.[&%9HHAVA(1],DDAE.Q8?
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MQ$C9?4-M\QHV%[\J+6EN&EK2 [2:_1Q6H7N%ALQ\SXZL4\4?VN*O&+LQO--
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M:</T]BM8A6AELO&\\C0P6 1^]):.,2HTI!/:&T@]-@%!ZCOH6-KDCGO<T!V
M-*KKG.W9DCAC+-)TIT#J^VW52^Q57AVE '3MONP^)U%H!FTTJ-/N6Y"ULATO
MKI#?>NZ6&$/7VV/]W'6-O4=;]8W+J&W'0=MP>@C<:U&&LI:<1541N>YI-?O*
MR[E?JG;=BRAHUE4CT00D,).D@!'5@!\EWWU<X &BV#$\^73(Y]>*M+-:E-#&
MSA]VK$NJ/$BRB& $E7!,@.\H4'?U(!U#0W5K(&L<5%C?WKFTR=3CTK&V<97F
MKJ97,=I82D025B3 65_RMWNX$7JZEV*[ C_6U@L81B![EN^>P&@ H>K]/>KZ
MEAJA6>>578.W5O\ O(2D9=@OV\:F/UZ4^K<;;D#U&J2R-K" UN70%J/N-)\M
M@H#V$^\U/N77_#ZM:*RL,?=]"IG:8O,>VOHP98Y0L960#H;\#N"-:;VL9&]S
M0T'0[@/U2H.<7"AI[NE06+[>*$VX(PT@%J=)3(QG3]X$"&!&^M6F4;+MT*Y!
M]/AKY FGDAN[L![PSSZ^(])Z_H7:8XVNCCA+6A@;@*#Z,/I6-N35[ 588)+'
MWCB.9)#&[SUI(E=GE58YY>I&!;;H!!!W7;UUV/E#S;W=N[+(&QL+CWW8C*F:
MZAZARMM>6S'*QCA)(UH&D8&M:Y=2Y".>[9F660HZ,L*M,J#HE",".E)$$O3.
M_P!*['T.V^^NL7[WNOKEM7B+4XCO.-2.TG)=RM8[:SV^#1&QSS%%7 888<%X
M!Y.QP_QC3ECF=HGPN(@NFO!&T@DAFN&"6NTG<<QIU/)L63ZOG\=?;'Y>?WG)
M3GR$EYNCB2?U&+\=_P ^MT^3U9M'- ;IVL4  S\^;'+->8QJ8<@\-K[8RTI%
MM_<2QR33!K-1ZD*]Z7I,#1$]3J.H])!V^8^A6U\S0/#0+\_;ID\D+GAL1U.)
M)<<:UQ7&W(*L07Z5CB=Y:ZQR2L\S('*.C+%8B+[#I ]&=7_$:Y",:149KJLI
MD#C&^@H<AE[%"+]_M3+%"C015*,\4$ER/:9K;K9=ZOW,T@1Y7=1)\I(XU/5M
MOKD6>1I!+16BZY>;K,S5;0MI/4@'BN#3VBM.YF$H"98;$DQ$1@CKFU4A*+'-
M*T*+)6$CN2@W!7<!B3JAC&,;Y;11E<E$7,Y/G73BR4"OM"BN1GIR/52<V+4$
M\D=2IT.:D-&R]6>426(*SQ;,T;NQD/45CV(<$A-6NB8UA\MN-%Q4U[(V1EQ*
MX&:4@ FE*GIX*VQ<&,JSV%B:K]NUKJ;&6&2W7,,E$#["O*#6;[6S:$<O?19%
MD=@"5WW.NUTS::VT97_)]*SM4$T)N#;>3YDC7:N\37 DX5P]E%<<8@Q$$>>F
M@^XEAL)722E?L1F2MD;IH6XZE0*[=VLM>=NUVI'5&Z_AL%UPMPR9V\^>XU8Y
MA)[12B]6M9K.#TSC%OY3)O/;J#7$D^*IH25FYDQ$G\2#2]WI(?\ ?1S?>5YX
M;$=<S]QRLK*QG:(OTD*=W)"@#6Z3KF:7XDFBZ1;SL^5?59<28YE-(H1'8%6=
MX5D9)X:OWFTLT;O*4+=,0<-L0^Z](U&21L,A:, MFT?%1H: 'N!'VI7JPV8)
MZQ,AF[D5F)1*L<MF-7MPC8UW)N&16)&P#%1UD;CU@7B0ZAF%NV\<XB= '?N
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MJ6-^;]IU@9+9C\1316IHB:(FB)HB:(FB*,2#_P"32#\1Q2R-MAZ]69I_5O\
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M.5"[]:K$R((9(F5$Z6#JOYC^.^VB[?K4O( <5WMOYOO34 .&W[J,/ZOM5+7
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M/*\WT ,W[O@6??Z5(.[>GH/F=!XO:%AV2DOAL%?$'BE3ON/&O! =P =QQ;%
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M1@CLBYP"Y4,$REXI19O4(2LB@,2FS^OIZ#4XW4D!Z/L*P>"VV( .P] /0#\
M/0#4!CB@R31930Y+!R5=5*E4(]!^O\=9&:UYU$^<G;BN7/\ X*G^\*FKF %P
M!R6;3^(;VCXJ6-\1^LZJ82:C@%LQ^)R:FK4T1-$31$T1-$31%'*NQY7F?3U3
M"8%3]6Y];F<8?1\ /T_/5A_";VE:X_B/8I'JM;":(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HBC'-?^#^4?09/_D<S@[:DAI-\=..A2/4%O@-3
M@_C(OVOL6E=?P\W8%GJ?_P '3]-O[I6]/P_<1^GR/IK#O$>T_%;,7X3>P*YU
M%6)HB:(FB)HB:(FB)HB:(M1/?KT_]'WGSJ8J#PL [='U;YK$@1GK!7:4GI/Z
M#^.LL_$'Z<%$\%MXWQ/ZSK R61DJ:+*:')8.2KJI4HVWH!^C?]>I@<51/D.T
M*(\[.W$LP?D$I_Y\C3&I@T<"K[9C1.V@QJ%+6.[?M.HM  ZRI1^(IK*M31$T
M1-$31$T1-$4=I@GE&?8J1MB^/)U;#9OWF:<['XD@M^H:G_JF]I^I:X_']BD6
MH+831$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$48YH0.)<F+'Z
M?\.YLMZ[>@QTV^Q.^WIJR#^+C[?K"U;D V\O8%GZHVJU1MMM6KC;X[;0H-O@
M/AJ!-7$]9^*OCP8!U*XUA331$T1-$31$T1-$31$T1:>^_P ;H]GWG$@1$OQ[
M#Q*)G*1EIN7<=A7J81RD>K^GTG<^GI\=!@X$+!X+<-OS']>L#)&Y*FLK*:(F
ML:0HZ6H?B/V?UZR%IS9#M"B7.QOQ',C\5H_[RJ:<0MFV_';VA2P_']K?VZR,
MEEGB*KK"L31$T1-$31$T1-$4;H*3RCD3[[[X_CR;?5LI099MMS]/J) ?35AP
MA;VGZEK97'51235:V4T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31%4?V:%1=DA_(1\]SL?U_#U^.L<>I194E4&L.67DA#K+<EEN2:RI)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBB_-NG_  CR3JZ>DX'+
M*W7^7I:G(#U>A^G8^OIJRUQO&=H^*U;G^'E[ I%!Z00C\(HQ_0BCT]!Z:J''
MM/Q6PSPCL7=K*DFB)HB:(FB)HB:(FB)HBU%]]X=_:CY8BC)5["<)J*RH9&!M
M^1^'U@50!B6_>^GIZ'3B%$\%MVWYC^LZP,ED9*FLK*:(FB(= M&;)0_GW_".
M8_V:7^\J>LCQ!9L_XAG[0^*EY^/I^)U@9+99XG*NBL31$T1-$31$T1-$4:QS
M,>3\G!5@%K<= 8KLKDU[Y/2?GT[['\#JP_A,]OQ6L/QU)=5K931$T1-$31$T
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$51\_U?VC6'9*+LE4?E*_B2
M=_UZBW.JJ5#J84V<5316*OR'^7S.H.S53LU34FY*;?"FLJ2:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB*)\[W/"N6*/B>/Y,+^LU9 /\^K+;^-C[?K
M"A)334Y*41#:*,'XB-!_^"-5#ZS\2D?@"[-94TT1-$31$T1-$31$T1-$6HOO
ML^X_Z7N>K5CBDDDY%X@AD2:5X$-6?S3X\AO?O8U9E84GD*C;I9@ =@2=!X@H
MG,+;MOS']9_KT&2R,E31931$T158[[?H]-8%%HS9!0_GO_".8_51_P!YT]2'
MB"E:-(G;4?>'Q4N/YC_MO_[S:P,E>SQ'L"KHK4T1-$31$T1-$31%&,5T?XIY
M81*7/1QX-&3N(O[A8Z=OD.X#OJ3OPF5R-:=>*U:'S_8I/J*VDT1-$31$T1-$
M31$T1-$31$T1-$31$T1-$31$T1-$31$T1-#DL')5U6W-5M\2#Y_J_M&INR4W
M9)\M_E^/RU6JDT1-9H4H3DFE"LT*IJ8R5C<DUE231$T1-$31$T1-$31$T1-$
M31$T1-$31$T1-$31$T117F[F/B/(Y &)3#W#LI(;<IL.DC<@ZMM?XV,=?UK5
MO6EUJ]K15Q4H7T4?J^7^;5+<O:?BMEM"T4Z%RUE931$T1-$31$T1-$31$T1:
MC^^>M);]L_+ZL0F+3\U\&1$0/)')VV\\^,Q-LT0+] AZNH? KN#Z;Z#Q!1.8
M6W+?F/ZS_7H,ED9*FBRFB)HBJ00!^D@ZK&:T)N':%#^>_P#".8_50_WG3U8/
M$%M6_P",WM"EI_,?]M__ 'FT&21^(]BY:*U-$31$T1-$31$T11/#Q@<GYDP)
M+,_'E8%M]NG$GI 7?Z0>K?\ 3J4A_<0C]4FJH'XVK[JEFHJ]-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$30Y+!R5=5MS5;?$@^?ZO[1J;LE-V
M2K_\S9?F2=A^LZK52IJ0-$5#J0Q5C,DUE331$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31%#O()(X3R<!@A.(L*&)"A>HHN^Y! VZM76?\?&3DJI
MG-9&7NP:%,?3Y? >G]'IK7;E[3\5)@(:*IJ2FFB)HB:(FB)HB:(FB)HBU0][
M)D'MWSJQ=75+Y']OD/T^IZ)O<+XMBD&VXW4QL01\QH,U@YK;!OS']9_KT&2#
M)4T64T1-8U!1U-56)V&_R(U 9K3FQH.L*'<_.W#\UO\ ]VA_O.E_IU8/$"MB
MU(-R&#,%2\_F/^V__O-H,EF/,JOX_P"7S&BL0_$Z(FBRFB*@ 'P^9)_:?CK*
M*NL(FB**X4;<EYGZ@G[C  [$^FV%B('3N=O0_@-9D-8FT!X_%5<:J5?Y>FHZ
MNHJ>H4K5-OU?M/II58UA5V_2/Z?32J:PFWZ1_3I7M6=;>E4]?P.@->I9J.D)
M_E\O].LIJ;TA/V?L]-]$U-K2H5/7\#_F_P!.B5'2%7U_#;]>VB%S1Q";?Z-1
MU=16-03_ #?KV_TZDA<T<0G^6_IMHFIM*U";?J_I&A*:V]*KL?U?IU'5U%-3
M>E.EOP.FH=!34WI"$$?(_L!TUCK6=0Z0G2=M_A^OX_T::NHJ)>T9D*FLZNHK
M(<TBH(38_@=8U=J%S1Q3\/TZS5-;>E/7\#^H#U/Z1^C6"[#(I5IPJ%78[;_Y
M?Y#40:'(J H#F$V(&_XZD37!2)#A0$)_F^'Q]/CJ-"JS09D*H&_Z/UZP01P6
M*MZ0J,"-OZQZC4FF@R*L8YM*55/\O^W6=745DR,&9"I^CX^NWIZ_K^'X:E7"
MJR'-/$*NQ_ _C^']>L534T)_3_0?]'PUFJ:@J;[>OKZ?AZ_#]6L5X4*:F](5
M?C\C^WT_KVUFJ:FH 2-P#_FUBJ:F]*;'\/GM^W\-9JFIN=50;GY'^CX_CM^K
M2J:F](5?7\/ZOZ/UZQ7M34U/7\#_ )M*IJ;TJGQ^'^7_ &:RFIO2J_Y?Y?+2
MJ:F]*>OX'X;[?/\ H&E4U-Z4^6_^;Y_MWTJFIO2J>OX'_-_IT6:MZ0J_Y?$?
MZ=*K&IO2%3<?#Y_A^D>I&LK-1TA-Q^('KMZD?Z=86-3>E5^6X(/[1_;MHFIO
M2%#>?KW.'<BC^G=\<T?2Q4;]<\('YCMZ_IU;;.#+IDKO"*K6O*26[HFD:C3L
M4Q_']9_K.J6B@HMH$$"F2KK*RFB)HB:(FB)HB:(FB)HBU2]ZA'_(*Y$>G>QY
M9]N%=.M@J=<ON*\6!>IBK*H]/B?309K'%;7-^8_K/]>@R09*FBRFAR6#DF^H
M:2H:"J_$?J._KZ#]I^6HY&JHF8:CM"TE\L>ZSCV*PW-,-8\1>XYI,->KXZ3(
MTO"G*KV&OR5\]6KM8Q.5KJ]7(4Y1#W(Y%8*\3JP_,!K?CM)'O;&QS#*6ZM.H
M5[.U6VS7QW@,@TE[J-J11Q.6.0[30+.S^\?B-6)YK/AGW21%'FW@'M]YU-.W
M22V\<=:I-W P/IL?U['TU6;>5LORXTF0CI%.S4:"OM4#)Y57Z7.BK34T:FDC
M,5"X_P#6IXQ*(7X)[BH9)$C=8)?;OY76;>5D5(B!QLH)26&Z]7TCU.P&M@;?
M<U[PC:.M[?M*NB=YSVQM!!<>(('M)"NE]YOBN1D6'B/GZ=FB[KA/;SY>3M?6
ML;)(9^)Q NKMMNO4I^() WUCY"4X-?"3T>8WZR%:(WXEVEK0[34N&)ZJ+JE]
MZ/BZ%UC?A/N%ZRG=(3V[^6Y D/5T=UF3B[(%[OT; ENKY;>NHNL;AF)T4ZGM
M/P)6'-TMUDLT#,UR6.D][G /C3\3>Z#(KV9)@U;VZ>2(QM%VRZ;7L35D[VTG
MHO3N=B!HRRN)#ICTN=Q >VH'202,.M9,3W1N<PL+VM:0W50N#C2K:BAI0DBH
M-%US^]SA4 B;_DO[KI5ED,2K#[</(3-U (2[@T%*1 R =1V#$';?8ZB;29K_
M "SIU_M CWBH4G1M:7TE@+6->2=8%2PT+16A)/W<*'I5^GO/X0\)E/B3W/1$
M.L2PR>W?R*9GD8'I54CQ4A"DJ1UG9%_UF&XU?%MEQ,_0UT0H,29&@ ]&)&*B
MV,NC9-J9Y+Y"RH<" X-#L:5P-: _K8*W/O4X8J%AX<]TLDABEG2M'[=^?-8>
M.(;GH!H"(N_P5.H.Q'PU%VW7+>Z[2'#/O _2,#VA5-+G-!TO%1^J?L6'B]WW
MC_[W(Y%?!_NWJ6;#5%O2#V^^2D2R:T'1#((X(&BD,,9",5'5Z@'< D4_O3&(
MPYAIU9?0JH)8;DAL;AB:$D. ';48*Y;WA\$ACDG'AWW:.K2)&W;\!^3I&^J-
MINXD?VY,<<:H>H@#ZOI]3Z:SY4V'>9^GL5K;6/2YX?&'-ET :\2>D84I[ETS
M>\+@$;6>KP[[OGC:."1YH_ /E=XF:8-T0U^FGU++LAZPH C].HKN-\ADW3'A
MV?8LN8T.<&OC<&#$AU<>@88E8V;WF^/@M>2/PK[S+)Z-A'6]OGEKJB?ID#PV
M8FKP+WHBA!)ZAN5V8AAIHFX%E?9]BUB^-Y$9U:SPHX4[32GTJ\E]W7"$F>%?
M!_O&LR=J.Q^X\"^3V5@[2KVXW)6-YD,)ZD4[@$?(Z".<FA+!VT^Q6&W: '4)
M9Q(R;UNZB<.*[W]WO#!;$(\&>\5F4+&DJ> /)_VKA$2PA$GTH"S'H^O8E]U/
MP.C+:>1M3HPZ2&_'-626D,;_ "WOB#P ::Z9Y9A7'_5OPZS:DK)X/]W\UAFD
M@Z4\ ^4*\9>%!.1'.\<-50VW2'ZP&/H"?74)(9(J:BVAZ"#\*K'RMM0'S8J5
MIXZTZS0'!43W=XZ0-8B]LWO-=HI8:\<;^#N0P-.LO;!E2*SF8E[4+.0[/TD=
M+$;CU-8 (P<RO02!7L!H@M(7C5&]CA7,'[:*TR'O'I4$JR_]*OO<N?=,L;BC
MX+R\TM.1U=W6W$>11]$<70 9%ZX]V #'UUES"UGF.=&!JI34WC[<D%FP\6T[
M?Z5>#W;8F2/?_IN]Y 662)#U>#^6+(CRSM%]0&1+0QQ$=3MZ((_JWV(WSI <
M6APU H;6 &FJO96BM9/=QA(I*R0^VOWJV%G4SB2/P9S&..-EE6%X[)N92!HF
MW;J"L.DH"PUGRYOUX/\ 3;^E5G03W?J*[E]W&/M6OM8?;-[RY=Q45K+>&,U4
MJC[J);"GOV<]795A!Z9F"_0XZ3K)B<TT) 6/DV@T<*=JN*ONKKV"H;VP^\.J
MKSFO,UOQ3<'V_1' PG:.'E,LDE:3O=(>(2$NC;@ ;G(A)Q+FK'RD0%:K*1>Y
MWJ[$$GMF]UT"V!.R2S>-XI(T>+K5$FD@Y;8EKFQT#H+@(.H=14$D/+<#4/8L
M"UC)IDNBK[F7E53%[7/=JDCLXEAM>.H(6BB[DD33-+/S(P/N4Z@J.TO0P8+Z
M^D:/_7C^C[%DVT0X@C].M5?W,/&G6OM=]VLK/8,$,<7CJL'E DEA6PW=YHD=
M:NQ7JWE:,A&#$#UV4?\ KQ_1]BB8(N&7Z=:X6/<I&A:/_I?]VEFQ&/WB0>.5
M[*(8U9>FZ_,H*<[L6Z2$=BK EMA]6LTDK0/C^C[$\B.JMF]S+R.L(]J?NX^H
M/*N_CV".$S1AR8I)EYGTQENCZ2Q[;$C8^N^FEW&2/]/8H&VB)Q*MS[H;25K$
MB^T;W>&6".*0U!X^QQGG@F])/M)6YO\ ;RV8#^:/N*^WJ-]2##3&6/\ 3V*0
M@B 7"U[GLM 5CA]GGNTO*&4*T/#\#']+0/8$F]OG==BH*"-@?K$C ;=.[#&A
MQ_UD=/TZEGR8_P!/\JL:_N;SUF2LQ]E'NVA.5@L/*]GCO"XOMDCBD/:R /DL
MBI-/T!45.H]3#<@>NIAHR\YGN_H6/)C6<@]PF7W99O:%[GJ_2TD;_P#R.\2L
M#]TR&!E:/R!TR13M+NK DJ W6!MJ1C/^WBK^G4GD1=/Z>])_<=EJ:'H]GWNG
MF4R3JJU^+<,D8K$)0TCJ?(Y*"5D 0>O4'!'P.T3'Q,T?Z>Q/(BZ?T]ZK4]QV
M?F[+6/9W[HJ/6I<B7C_!IG@V[?\ Y@I^1YD+$.=@&)^D^F^V\1$'8&9GZ>Q8
M,,7Z?Y5B+'NESM>W'37V4^[BPG=$/W=?B'"GIQF3NN9&=_)"3& /'L76-@"R
M_(DC)@C'^NC/O4?(B<LG'[F<W*3U^SWW4QLH#GKXEQ+HZW"=:!EY]L[+U#<@
M%?0[$[:RV%OW9HQVU^PI\K%T_2N-OW)9FO/54>SGW3W#(UD1SU>*\*:.O+"P
M2/[@S^0Z[PQVB04?I(V]6V .I>3_ -/%]/V*3;>(?I_2KB#W!\GMVBC>S/W)
M0AA"[V[>.\:)#W))WK%1T^2I9BT*+W&/1MVV&Q+;J(%E,!,SZ?L6#;1$UJK&
MQ[A>8-!:9O9)[CK"003%(U@\9"6TRS2(*\$;^1XSO.B!P2579AN0=]9I_P!,
MSW'[%D01#!=I]P/+?M:,MCV5>XY))8(W%:&MXQL249'"=5>R\?DH*C1]7U%.
MM=U/K\]3#,/XB/Z?L6?(B_3_ "JU;W!\S%FJB>R+W'2)=FD62R%\9(M/H"],
MUU)/(Z2)'(20O0)&]/4 :QY0R\^/#].A/(CZ?T]Z7O</S6O71X/8][C\BTLE
M:M]M77Q9%*M6:))+,\K6_)5>%(JA<H4+]QV4]*GTW>7_ -/']/V(((B0":!=
MD'N!YE(8EE]D/N-KQ_:2.S,OBN00NH^FET1^3&=WE"C8J"@^9!]-"R@KY\?Z
M>Q6.M8 *AX)]JX+[B^7M0CM'V1>YJ*66(N^,EI^+C;A>'J'8D-7R=:I;[#="
MLK*V_P ?PQ_ZYGN/V*OR(OT_RK&6_<CS>K'#9A]AON;O3VTF@,->/Q0)8$B4
M.HNFQY/@BBCG.P4J7._Q&WKHUM<//8/9_0GDQ_I_E58?<9Y :2TT7L+]Q\;+
M)1:0SS^)8A85D+-)78>2I%EDHA0"I*]3;!2?CJ7EX?Q$?Z>Q/(CK^GVKMG]Q
MO/TGMK![#_<?891;=9C+XDA6V84;L*KR>2]@]QE"KU>B]6[;#?;'E_\ Q$=/
M;]B>3%^G^5<(O<;Y->U0C_Z"O</&]N FS8DR?AT08U@L#I7M2CR.QE+=UAO"
M)$#1MZ_E+9\L4IY\?T_8GD1]7Z>U9*7SMY13:&#V+^:IJL8CDZUY)X;@"]R6
MJDHCAG\@1N\D<<SR;#T*PL >HJIB6D&GGM^G[$$$7Z?Y5UOY^\K)3I2'V&^=
MY5LV+,3THN2^"VGH= M?;VKB2>3H8OMK7:&YB>65#*NZ?FZ<4_Z9OTJ8MH2*
MEP4*XE[M>9>1Y.8U>&^R7ROG)_'W,<MX^YG6M\S\,8V3!\PPE"CD[F&(M<X*
M71]KDZQ6: R0L9@"PZ6Z<R12, )E;B*C/)3^4MO]HWZ5/X?-7FD5N^?8SY,A
MFZ(@:K>1O"@EZ9+4"F/N#F8KD012/,VS[=,1 )9E!B1A^,T^]0^6AIXA^GM4
M(XG[ON7\ZY#S_C/&/9EY:R_(/%7-9/'WD.*OS'PT*/'>1MQ7C?,:4$60M<[@
M&5K7<!RFJW76C<PR]4<BJ5W.76_E!KS*T!PPS4?(B&?Z?2IS'YL\Y'I=?8QY
M'0F*A(%;R9X65DFM!FMPO_\ ):8U.- '6X8I(3^[+;:@]O=_%:[JQ6/(C]GZ
M=:A6"]W?D;D?D3G?B[&>S#R:>:>.,5Q7/<GH6>?^(HH*N*YRF8/%+U>^G)YJ
MEL9?_#UL=N-FFK]@]Y(]TZL^0-.ITC0T]13R(J_I]JD__/'W 3) +GL*\@H[
MA)[$?_-GPA92"<HG<C5DY3_>)XY&*]2KT,J[AO4#60QH\,S1["GD1_I_E46L
M^[/R!#Y1A\+2^R_R2.=Y#QS?\G8?%OS_ ,0+0RO%,-R+#<6SLZY/_%+4:4^/
MR^?K(L-AHIIT8NJ=(WU9Y9$)E$[:5IQJI"VB<*U"EMSS1YTZ8%_Z#/(.1#F9
MS&GE#P<176 UI8Q.;_+*\8GGE8E%4LH,1+,NZ[P+&G%TS:]A0V\(-,#^G:H]
MF?>5Y,X[Y!\<>+,M[/\ RE5YQY4QO,<QQ'%'G_B>>"?'\ 3CLO+ILADX.334
M*+8N'D]9U4NQL+U=OJ8!3'R8R*^:VG85:V.C.Z1I"]!L^>/<*D\T%3V6^0[(
MBD5$L2^5?#U2M8!FBC:6)FY)),(DB=G^M%8]&W3N1K'E1?[5ON*P<#F%X'YQ
M_F(<B]M7^ [OG'VP<RX1@?(_*;?".+Y=?)OCG.27.55L/<S\>);&8FW/:!O8
MK&V7@D!8,\)5NGXZOM;!UW-Y,+VD]A1]6\05!6_F[^)(;<8L>,.>U\;+U=%B
M?(X&/(MV]U=_X>THHB/K*@?WP,022HVV/)_X:O.+F =A4"]6K?S??$]O^*18
M;QKRNQ8QMCM+_$\[B*=>PJE3*&?&PYBQ7L+$=UC>(!I!T]0'U:?X;NLFR,)[
M"HB2I5M0_G >,96L'(^)^:1(AG:!<=G<)?L2010HR3S5[,.+6 O,Q!4.Y1!U
M['?IT_PU><7L ["I&2F*ND_F^>+&Z$/B+R(DWV[SR2/E>-C'+VVCZNU<%DRS
MH(F+L>R"J@>FS*3@\N70'=>PGL*CYJKBOYPGABT\XR?C7GM%%6)J[4<EQC)R
M3!B%E,E::]C+5=8]]P2C%@"=AL-S>6KYWWF^XK#I=+"\Y!9 _P V[Q,]E:]+
MQASJVDEN."O(<KQVNYA*L\LUF*:RH@GKJA+PAI&]/0D;D6-Y8NSXI&-/6"K6
M'6P.K0$+O@_FV^()[,B+XQ\BM4(85;,-GC$\EJ2-/WI-5,GU0UEF#*)"QZ@N
MX7?=1AW+5RTT\V/W%'&AI51/GOO8XA[J8^ ^!>&<*Y3@^3\V\Q>#\G#?SL^"
MFQ6.QW"O*/%/(N7>Z:UN9VDL83B-M(%168RE#Z ZU;C9)K6)T[Y&$-' %0#P
M7+[&;[[D? DD?J)UPHR5HR31931$T1.G<%3\&^D_^UZ:JXK4G=J[O3ATYK\S
M'G_W!^=*7,/+O':?ECF5'$8WGO)<;0HIG\BM."C1Y;VZ$")#:->.M42).D!=
M_I _'7VOMGI1R/<\B6.[OM7#=)MO,CI XXG3T4P[5\G[5^8SG^W]11RC#'M!
MVEMZ^$!UC YVF-^FNL-#@7#B"".E9WD_N"\QT^0X5!YAYZD,G!^*RW*\?,<_
M6D$]G)\L[]V>2M;K,F0LI2B16/5W0%'X@?/MU9V6Q<HVE];P0S2R7]U&?,C$
MATQ.T@=ZM:G'$8+ZT]0[&(>K^\[-!+-;[1!M=@Z."!WE1LEGC9*^2E'5KBW3
M49UKA18%O<3YWJ/=[7G7R+8K56ELBW=Y[GA%-%1621UZCDHFKPNI!/4J]:D$
M,0I&NK1<RQRW+;>2PLP[%U'6K&@AH)(JT XT6I8[+$RDWGW4L8H.]-45<0*T
MIF*KLX;SCRWY<\Z\6\;\I\_>;X\,WA[F?+)(N-^3.48.>3)5?(V!K13W,CB[
M%6Q=6"C.]>%^G]W"Q ;;X]SYMBV^QBM9H+*R:9[>*2@BH&^9&7:1WL:',\>@
M+LWHGL^W<S;ENUMO;7S0VTLC65><"R4,K[0<N'6MR[?@_D-F!9G\Y>X>&11,
MG<3SEY%2.."<M^>)LS&=ZT(V20;L6.Y!V&W0Y9F7 T,AABHTDEC:5I3/$_T+
MZ!CY*Y%MG.\RS,L6G%ID(J:@#$#"E5H;5\C>8N+^6><>.\3YQ\V3X#!>5N0X
MZC3R_EGF&5RCQ5/$?C3(5*U[+-G9;IQT>7SEBU%5=D$33ANDC<:[Q<MV_9.0
M+WF&."R=?AEM&P2Q-DDU32/;J9J::4T](K7@O+-GY-V+?/S"[?R%>%[>5FQ7
MD[VB62,5AMHY6@O814 OI32<J\:#.0^5_)ENY2B@]P7.Y:D^5E+Q/Y;\DULZ
MTU?[D6N/R8^+E&02Z_=A9'<FH\83<J-P#Q3^8[ZSY7N+^;8F0;A;;<)B7[?;
M/A?3 /\ //>!?XG#2=!PQS7HMCZ3\C[ES!M]A%N&W[AM]UNWD^9'?744P$<9
M>Z$V]:.+:!NO4-==1 R4LM>8?*W'K7(X<;YH\G1"'B6"S%;[[R)RC(P);/)\
MS1D>#^,9.ZRO-# (W1#TR)$ P)(UM\E^1S?R;;WFZVUA\Q)N8C<Z*%K*M+(W
M_<+10:Z4 &+:\5TGU-Y2V;T_]2-QL-DB>-J9RJZX;#(YSPVY$CZ2ZG%Q)T@"
MAX#/@O.#[I_<"[K3G\T^1!&%;J>OR:Y7<'N,T83IDZV4*-F(((V&P^6O7SR+
MR?(?,^5TEV- [+J&&07P#%ZU<\O>UAFLM-,3Y%OA[XB?>2>DKT;BON.\UY"O
MY)6;RWY!L-B_$?D+-T&FS>06>ID:/'+)K7JH2;:*U4EV>-R-D<=2CK((Z;S=
MROLUBRW?9Q!@F<*C.E"![5[AR#SCNO-O+O,4^\^0]]E%!(SRXQ&:/>&EH(\.
M'$>P!>H8_P A>7<O5QUB7R[Y19PE64/7Y[R>&&=OMQ^YG6/*QB1%W[I_*DCI
ML0=]=0=MVW-E<P0-PXK]%+#T,].H=OMIYK>=\HMXSC/-BY\0DU>/@33'//!6
MW)/*OE[#7>+6)/+ODZ.+)<GH5+JMS7.25IZ#XS+RR0&NUZ2O&DG9$C]/U$J"
M-B!O3'96$C'D0M#FA>->LOIMRAR9L>U77+K)H[U^\01/<Z61P>)FEQU-<\CN
MTI3&N>"\?XOY>\L38' K8\U>7)9),!B9Y;J^0^7E[(NXN"T9UD.4=Y9'9B-M
MQOOOOOK=%AMX=WH6D+X>YV]7>;MFYOW+:MO;8"Q@NC&ULEM'+01X5[]15W94
M<"L^?)OEA<C@+U;S'Y4:5.2<8@,,W/\ F-E9*=O,X^K:$E:QE)H9(YXYW60/
M$=E]/3;?4+FPVTVDH9"UK@S4"/ZI!(]J[OZ-<_\ ,/._/UIR]OK=O.URPSE[
M8K."-SM$+W-JYK*X. ."Q?'?)'EK(39"Q<\R>4;DSYGE8*S^1N71I$4Y+FZ$
M-2"G4SL56*K!#!'%$$"&/HWVUUOG;<&[+S)-8[3;6C88XX@1(W5J.AKBYHPI
M74:C'$ K[J]!/2+D+G'TEL.:.9H9;C?KVXN37SYV#RV3%C6=QU.X&YT%:X 4
M5[FN=^5SB<S8;R_Y8';Q&6>H:GDGFL$ZRUL?;D+0]G.=+=#H @(8[KU _+77
M-CWR;=-_MK6XCM##+-%$6LC  \R0-KF:D!U:85R7;_4GT,],=B]/M[WG9K25
MFZVNURRM?\S.X,=&Q\@%'/QKISPI7);.>T+A4OF^OY@Y!Y-\B>>,UE,#Y'P.
M"QWV_G7RYQJA5QTGBS@N5EJ5\/QGF>-QBP')Y&:;?M]PRR-UG?7F_P"9;GS=
MO37FW;]OY>=%%9NVXW#F>1 =3O.=%0N?$]W .Q) R XKX ].HAO.UR7FX%S[
MB,Z*ZG8@-:1FXFM'4.)RJMS(O:YXW588O\2^=C')952LGN5\^N[ R$LJR-Y&
M#HNS>J@G?]FOG:R]<.?@ZLUS%(QLT9H;>U%0^0MI^"?"/?U+O)V+;Q')#I?0
MMK74>A?*7Q7R?F/+O('+>+Y'RIYHR&%XZOD#&8GO>5O(]<T:V)]P'E#B^.6W
ME*W(8[F5O1XC 5ZT,DW>E2*$!FV^/W_SPYNT[;87-K'#Y\UO"7G0T!SG6L<S
MG:6T U.<<  !PZ%X^WF/=H=I8^)[0V2>YC;5M2QMO(YC<?O$@=5.M;04^)7Q
M2:*/R+YILD*Q0Q^:O* L2]0Z$9FEY29RK2$H/6,=P@C9=M=*9S3<%H+K6QH0
M*_NL>O&N?7[5P_\ B_F'3C,RE/U!]JW*]D5J[)P'R)2M\CY5R9,%Y@Y-@J5O
MF/(LWRC-4ZM3CO$)VQLN7Y!8LY&:.M=M2L 6*!G;I]#N=_<WQNDB=&P,;(QK
MJ#A4$^U>F[7=RWVU0SS?B.:"2MSM]:%%NAI!K54!VTHI$5%$)W_R_9I18 (X
MIHI)HB:(J?T?T?\ ;I@F":(GJ?B1\?P_[=,$P5>D?VZKJ%#7U(1K(I5 ZIH@
M^?P_H_5^G4G4HLO\*J?7]GX^NWZM0! X*#314V_RVUDD="EKZDVUBJQKZD(_
MRV_[=3%"%,&HJJ;;^AV/[/\ MUF@6<$UC2$332$3^O32%@@$4.2KN?Q']'_;
MII 6 Q@-0,53^C^C_MUF@4DT(")K&D(FVFD(FVFD(G]']'_;K- BJ/B/A\OD
M-*!1(ZUHM['DL?<>\N6;_P N;WU>=C5ZCC68004.$5B-\=-*=ON89"!8"6%!
M 9=@";9,F#CH"B&,Z,:+>@_#U(V'Q]/@-54'#-2IUK0GV@Q0GSM_,5M5H88X
M;'NNX[%)-&_4UJ[3]MWA&O<:>,@&&2$],>VY#*H8?F(%\W@B!RTH.'8M]OZ/
MZ-48<%):,>';"3>_;WL0=3F6EXL]HJ'<Q&-(K5#S'*BJ%5958O&Y/464[^A'
MJ-7N-;=@_K.4>/M/UK>?;]7]'_;JB@4EH-?AK3?S2.-3/&[VZ'L&YF(I"D0A
MA@R7N%X2DZAQO.TMAZ">A^@+%N/4G5U&_)FHQ,GU!5TJM^?Z/Z/^W5- K!@%
MH-YH,I_F%^Q>,)^X3Q#[S+#RB64$2"GX,A2/L*O:=769B68[J5  .Y(F&-,;
MG<01]*:L".L?4M^ #L/A\!\O^W4,$P7Y]/Y^5F>K0_E["K'.SO[O<VI>O ]@
M0H/ 'E<M+-"E.YTUX@>MG/;"=&Y<?/LO+%/GG5_4^U43OT1E]*Y?6OC3=NV\
MG-))(6A-.,Q7*,,$DCI;69=K,5QZ\"[VNN)9D";IZ]# 'T[9KE.!=AV+5\_J
M7/%9!JEJ0QXI1<*,S_<UE2)A2M)"+;1V8N[8BM3R?NRIF98V/^JH&@)!JW J
MJ28AA(&*N&Y-6M0=Z]'8CFB[MB/LP3.36J,O>*-7$TY=Y(G="450J_4>G;?)
M?([!QJ%)KG:=9-5QQ>8DM*TYR%6S$V-AEIS2O!-<FJW?N.U D4CPTY1)#$0&
M9T=7(V V&^62.C-6K/F]2O:F;BG+AJD36(VK.._*967^(5D"PB7Z^Y)%(K%X
ME[J@=* CXB]MU*U1?*2PLIFN/\:L01TLC9A>O.LYL20*JK!'VHU6S!:8":S&
M++2*%VD;I8*Q8#?63(Z7%V866S.+0!A046;HY.3*XVO/]O\ PR"9YVA><],S
MQRHRVI43OQD6:X3K11LA9AL3OOJB3!RBY[B:U6VGLDR=?(>ZOP7#]JR22<RQ
MYB2>>Q*XDK8;+69+$=BV%>64Q0 E K%%'3N-<9NK*;?*[^J5LVYKFOU?@[@'
M\1OKSY;JKHB:(FB+E\A_M#50S6E+F.T+\E_N9=#Y!\W1AXD2OY&Y9.P ;NJP
MY>P5P05'4@&XZ02=M?I#LC!_PRVUU<?Y2?[*_,K:R6^N /\ ^+3_ /6K-<UG
M@3EO'K/18LRV_&?%($$LD45"V);?,)62></$1%77I$BLR]+[>J_'7RE/'')R
M[M$4KBR-V\WH)#7.I5]/"UKB?8"OTG]4WWT7J]S3+MX:^\&S;66ASFM;W;9I
M.+G- P!S<%YC]M4WNQRRM%NEJ0U+EFS+#% K_8=GMK):->Q*KDRI$Q3=4 &R
MMU<#S3<V[K&,-,/S N)6 "*9CBV-C\27L:WM%<> 7!\IP7K;M]P'3FR%O"YP
M?)"\"21[<&B-Q=I%#0TPXG); ^U=FG]U6#DGAJQK'[=^95);:QC[@-7\Q)#4
MAGG92U)'6$=0"QK*5^'H0>2YVC#K/;,__#[7_J2O4_R[S.&X[[( -3KFX'NG
M&76OK[>:D$K-TAA""SL7BVW$;;((XU,91F"D$]#%?E^/GK8&-+CC705]$PLF
MD>]CSA)0#II6M<>SK7P\Y&L3^Z/S-']O#9/_ #JYZZ2&PT4<)@\1^$DK,T@W
M4O!\7 !"DE1Z :[AS*7_ /!^^))\HRV%1H&D?OI>]YF;3U9+I7ILZ1WYH[&Z
M9&XRBPO^\T-DQ-O%'I\DT<X:6AU01B2%)T:S>SU!<A#:!IY*Q>6_+QFGC*[2
MUTLQ0RV<W-GLC:LQQDJ4Z88FG9AN>DLI\NO[S:MOY)N8]JO8[NYNK(0O9-N;
M7.8UQ-=,'EM(I]VI((7OFS6UYOOJ';P[K820,V[<'S1.AV66U#W!GECS)W2O
M806FI+6@UQRP5WS#>6YRF3K2!(>$<9*5^WUQ6$;E_*V>*&1"_P!4KL'^O;I
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MNG!X;H_Y05TF9B6S!<L7I[C]IVLRUY9:@23LV*\<].*!C+-3D=PO01Z.1MZ
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M((Y-D;JH5-S([!IBZE&!'Q+;>FKG7$@&%*K\@N?[#<;CFW<;HV\CHY;N1[B
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MJ#ZU\DER-:#(VL;7DN8:UE*H.+RAKFQ ;*OW;U>Q'11K$$MN&3I5XPP8[@
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M:[EBS7D7(8RW9IX>UC[,45Q+=8XI<<<AE:3(89(++6"PZ6;U0KOT?F^*S/)
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M8DX@&Y9F>SBO=>4<@M5%-''C,]N3%P(\=#C%C,U/N;.,F2%6M=V-(4A<AF4
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MCV1R9REVI9?'P"3S!YHN//E4@F@,E.O"W6ZQR+*J=04@[:_0#UB>;B?9[=P
M+G.)ZO[G:\5\_P"UVX_D6WXU_?W_ /UCEM+XN\@6>66<M0LU<?%+B%21OMQE
M,?D,K#96G+1RV-XSR"&'+8K!SO.J]V9YNZ[@ILNQ/FW,.SV>PEAC.IKB,L1B
M?<MK<]F^4V_5'T5P[%])_9S)"_CWG@KRI+#%YN\FP*4)(5H<I42>-B4C7KCL
M!PW2-@1\3KD=YJ+N*O"W:O6-C!&T6?\ W9OUK;37%KETT1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$7)?[5_KU@J+EHS[
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MU^Q?)%*<.7R6/R.66]D/M\+S"U!CXFF@NY:;!86UD:V.H5$<3R6K=B+K_=Q
MM I!*]P@=S<30K3XJ.8:GC..<.Q'(>2<;L9>[S#*9&'!8J'(9'BUBGQ3 O57
M*YN),:E_-6+<60808W8I$DD<C_(:UJ D Y5'Q"R1J:1_5/P*S65X_%7YGSVI
M:REGD24,SD*-:3)R=JYFI\G/&S+>L1,MBQ/!5@#60OK&R$=?U$Z]1]-^5IN;
M-^E9<X[;&0XTQ%6THO&/6'GMO('*3)+$?_-Y1H97^O4$]8%!BL;E,B*<EJM+
M$V<OQ5HS52K8>NE15C:U!0N7IJTR03I*>KLQ@_N7&^Q(&O9^;?5#9^49!R[L
M,#9KJ%O>( H,*9C"M>%:KYCY%]#N9O4NW=S3SS>OMHYW$QD5(=4UI3*E,:A=
M<]\GJ@D*8RP>P18F:"W0-BQ)U(;$C+4N+7F#*"\3R JOK$0-<)L?K=)->PMY
MELFG:C4$ BN-,US/-?Y5&V>USS\D;BZ?>6T=Y+@6"2E:4?A2F. .-5'^:4K>
M.A@Y'C5JT\AQB%!G9J\,-R&>D'9Y6CAC7MS68*%DO$X;:5682=7IJ/JERAMD
MNRNYUV&+1:/R:W' XZCIK08TKU+F_0'U.WN/?1Z;\[S&1]N=&EU1Y+P*"(.=
MXA][#I5SA)LF<69\;)7G:*@DCVXHQ498;DSB2X_=$J$F.PTWUR=,/<]" #M\
M]1$.B:YU*D K[,:Q\9<R0BFLZ?V?N_0OI7_+V6:U[O?"UJ&[+8FAM<DDCQU.
M:)NB).(6*=\VPLJQM'5K222[E6<J#T$_'7 [^:V,HKW:?8MBT!^8-<OZ%^K1
M?@/U#^K7FPR7,*NB)HB:(JGX?+X_/X?#Y_HU50.[IQ!"T9C2A%*]>7M7Y)_=
M%//3YUY3P5.!(:5SR/R_)7)[&-P[Y":63R.\@DBMP):O4D3K*(.XCRQ[%E W
M&OO'E&*&]].KO>KBZE<(=MBMX8HB2P.$="' 84!P=7)?-_.6X?R+U'Y2Y)@L
MV1NFFCNKB6>RCBN!KOI'L$+M9<(7M<'!X!P((&*OO(,%YN=BM"0[1\/X U2*
M.0P2F<>-N.RQ2U[/:9*DLSML']!)(% !.VOG:;;[>XY=Y:?=&%L;)KAS_-)$
M8 E=X])!#:]'P7N?J7?O'JISR((Y9FNEMF@1DAY+8&M=I(XL..GCEQ4/8VX<
M/")Z[UD6>S<49">K)+-:/W->W<I6*5>-Y6F6-9B;$2NLAW!V&VN%YK_ETNU6
MK8'[>+Z.YE)BL2]T6ATL9UR5):'4%6U%3C1<+RS/=-W2YG<;FXV]]K /,NHS
M!,Q[6FL;(W"LC!]YXRH.E;+^UK.U>)>8O+7.V>2S7XW[9\+=>M71;.0M05?,
MWF.W8I59+UVI4DO2R*(X YA[\\BJTB^@UV/GRV<+MHE:1W(/_NL-?B/>.E>C
M_E]N[=T.ZR/9(86W1J&C%W>. ''II[5N%P?GWD#R9Y:PF7?Q[Y+\;^.<-P7E
MASD7D?$X+C4G+N6YJ_QG_#+X[!U<EFL\DW&*>/R/?EG:K !=Z.F0D%?.+BU8
MZ/4" YI"^BK/<+N_O6-M&S0V(^Y(T@TSJ!^E,%\X*78?SQY>DB6$Q?\ /#W
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M;IL"O.JXFQCPT<:+,LK+D+-N9WE4H&BB*R*H'66.V_1^:>6]JV2-C]LC#'S
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M:.=V<5@>,8>MFO'7%ZEJ6W7CM\=KP6XH'A^X,?VIB[,D4U*:40V-]V**.H$
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M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(J?/\ 1MZ_CO\
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M<DO>=?&U"ER>CC,3E;7'YV]LOAZ2EF<;BN1XVYB+\ABE.ZV8K%=V'P]" ?\
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M2X-#:N[HZL5XG#C1UN:@L--,@D63MU["?OVDG<P_0$ ,>P !"JK!@-]P?<7
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MG"VNI YS#,W67AXH2'=[%N2Z5^9.!\?H=S';/+6M=M^@:1&P5?,RM& MXXG
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M&[<S'V*Y7+++9CJQNHI=WL( D?JMFL9$"36JF"ZM=#JE>F6,A5I>.Y[&1O\
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MCC@(LR2A"=U8(H;<=08L.0$36- (6I)<R%W<;4+[/_RKLC7M^Z)(I(IHY_\
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M-[%%OU+=745):+^##')[X??JRL3+!@_:/5EB/3T*@\?<ZM)(I_-U/]T0=_\
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MBY(Z_J7Z3-=+;X0N63645!\%_5IQ6%7197)B3M^CTU@46C/D%$.=';BF7/\
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M/;G<KO[F?YA;IC9:T]'RYX;BLV^Q&C900^V;QE9ADAG$:2V4@CE,:];,$8$
MCU&H/;1K75S'UJ3FTTGI"T$]D^0X#SGW&>W_ ,MP\TX/RCF7DKQ;YPY9B^'>
M%?%'C3QD?'''[]WB\DT_N-M<,Y+F\IR++9"6X8<"LL=>NEVQ=E*M*_6;Y6!D
M6FAPICVT."R\U6^/AV)S[^_>Y: 9H_\ E9[0J!?N!D6:&CYELB$1DAXY E\,
MQVZ2K+Z[@@4.;2%AZRH#  K8C!>?O$W)5X2V$Y=7O#R+S/G?CWAA%#+P#.<P
M\:?XI_QOAH/NL?#V7P?^"LIU2R]N"85"8GD#(6CI(P/Z!2JOS;?S8,HV/_FE
M\8L"E*9*?L'XUV;4%B<=R:Y[@.;=I9*Z%HNY5EJ HY'5LY W&XUVWEO&U=^T
MN'W#-O;]:T\FLB#*4<S5R-_&V%@ME;5>Q-6V9XY.N6&6O+#,DLZ321L&[:D.
M6V)UV,BJK/0HH]=8HZ:QSH('FR&5M3UYYF,E?KCM&4JLL!L2V)E8RHCLI$?I
MM\3$M "B 6FI-5C&FN05\A9^YMS4[UDV>\]DP/7[+&L&8S1RL@E4"10&^C<
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M@E=))Y78;5S4Q@X9#B3_ )%$U JMR_"TQ_Z_/?/&9G)C\;^STI5_=$=HX7S
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M4])]Z4"M']NGM[D]9/ _AB0_B_B[@['T^'YL&?PTJ>D^]8TA=0]MWMU5BR^
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)E@Y*NJE2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tv498959_ex10-13img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv498959_ex10-13img2.jpg
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M/X_F>3\ER$6*P6 QMWF,OD9HYIH['&V$+7%Y=216T4]Q)'!$A8A$9C3H"=2
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M*_,5E?WAV^ZK:,! _$Q?2:\]'2T>KH6G=;3?PRLC$[!JKPZ*?.LH&Y=R=99
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M,,HH[J2I%=4R-$;M(5@:3DIZW<]PR/+=*1<);/>=I)([B*CNL$<DW=MU>WC
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M\@NUO(5= $E91^*J[@.GH1N[?^:'V3\BYC8J?C\?[,]X59VGB4[GWD0[HT
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MTZO-;6\RJ6^DFMREL\4=M<(!/-+<QM7KVUC+,!Z4.0:&H128;5XKWM3R"/\
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MEJ_"?P2BMN')&YAE5[:%IW2[@ABE*1K%N$,+F5A(\B&.!=\=2K2=%W-0:V=
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MCO?=VE1M?R[:]'R*KU!7)HB:(FB)HB:(FB)HB\B\A7*)RKQS:R$%;R3EI$3
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MMM-;VL,45Y;37KB:6,P6LPMRT;/91JI:".=_E6-6VC=]A.L4;T!2HKQM+_\
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MTNTM//,S6W8C!V($7I]H.N\;)>&SLJLSJO&O,=MYXUGI=B 3@O:N518F+DG
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M4W#6EK?7D[HJ;FI&7[:M\VM>1S+.U?/<'1;PQ@O<<FMIF>I4T+GZ6XN*V,^
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M&UR8R1&PCW=0"/74Z.]:K=I+S48 X+@\KO&IFN$VJT,KL=C;031"S=K?(IJ
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M/-9;_@W!./9+EV&Y%@.%O8\"QDTLG-9N-Y6[P^V6PQ$TF.DBF@W1W$A14D(
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MOE,EU#:W<T#FPDCN(4MV5(8XX97"3P+<+^ LI!!%0%U) *X!=?E+ZYBNN_\
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MY;.YMKBX;(37][CK&*TGM()(I));B!(U=FWK2NNS\D/VR3FBVM-XDC_".N&
M@.#JBN5 N,W$O$+GQUKI)5K^UK+6&:\&<&R%A)>36;MRB!/J8[3Z>V>VY?GX
M)K##7&/O,GC\CQO%W"-:XVZ@NKJ.YLX8Y!/*6,C<MSO;1V/-5V(PUMCH:(R"
M*'$ 8#$>E1L=<EMJ?[Z]LSU6L;%65MO]Y^'*I1@A /+,(:5Z_'H>G4=/VZ[U
M^GZ1I\V]MI4^$Z3505IJB>T=HJ14C*M5QV]"EFYO$D+(D'X5_P W0?SZ_2R%
MP9&YS@:, :<.(&-.G/,+HL3: UZ5'6VUP< YN1"N36431%:7,$>2SPJH:?\
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MV@K&<05,40QQ=HE5?>\@K(9&D4;BE 5(C#]**/@!U.M>6A91'3/+A))[M*4
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MB)HBP_\ >4L[<8\#"#90>\/VL-/O?9_LZ>6\"\FSJ-SDJ*#XZRW$GL*B<UF
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M+-<3L[-):]LO&DC AHPJF.2@8J9 6:M1N4 #KZU_0*U&J!A=GIXKM+-(B''
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M0I!.M!P(EU'*BQ1=ABI=N/@$,$$DG>G_ .V12V4DZ16]O(T/TYEF%N^Q@FP
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MX9:Z>I>8>:[:RR'E+Q3!D;"QNP>+^4I+);ZUM[DP7Z7? 566W$ROV9! 6_,
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M#*/#=R'B.>,D3A(X)\MQ2-F4TJZ,N8$!CA1/G5F);:0 =7?Y0WPX>%GUJ/\
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M4@^O0CXB,<S9'EKL KJ.: 2 2,L,<%VD4KQ5"WM5+!&4N2BT6-=T@(=0%JU
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M)HB:(O(?)*(_(O&V\O5<MR=D568(U>)Y!&[H5@I 5S3<#U]*:^?_ -23G?\
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MI9YI[]+*XQ5RT"K##&!?.I#%-Y[Q>^2?FC)R'#RN=KLS+%("P_B'>S5V.G'
M=-**EOZ>_-;QP\[=*!2I'C0]N6?HJO>C[T/!4;"-LYR [C("1Q3+LJ%-O22B
M50LK C]FNH_^6/S;R=:[?I_OW?.MD^1GF5(-+=N<"?Z8&?6<!VG!<8_>AX.,
MI09;D?1%D+?W4R(&UB5V$M)0LK @UZC[-1_\KGFD\Z66VWM><B9W$#MQ3_D'
MYGM]LV#R!TS1$>IHKZE*?WK>#D-/XCR<[*M^7QB[<'=(T992)J,JE?V]#761
M^EGS:C.I[-K#>D2E2_Y%>95?R&/VPKWX)[HO$O/\_!Q?#YC(6V4NJ&RCS>,?
M$V^0E+F-;2SNI)9(I;R:A*1':S@=*GIKKG-?D)YD\J;._=]QBMI+!A&OP)'.
M<UN=3T#AVX+KO,OE?SIRK9#<MYM#%:DZ=0.K&E<0,A3BLAQ/\Q"BH!  :M0Q
M!(J!Z@4/[]>.$>+>E\+'LMFAM-1)J<:^I>>Z:MKQXK7I[MH.4KY4X4V&Q%MF
M+?-< SR6D<^8.%BMKOBV:M)+^TO9)<=?*5S0Y;;" JM:6\VZ@'7[S_2?M5US
MA:7W+>SR,CW."7\2YI ]J/0QE3U5!7@'G6RWV\V>_74K8X&$1D.%:XEWRK'O
MQOX\Y+AN7097*\>XSQW$6^.SZ65G@<[E>0WIR/((>)1Y%[Z6^Q>/A>*#^ ND
M,B,%$"QJ(@:D?I!R'RCNG+=VZYN9"_5&.. -/= K0 <%\V\Y<P[5N5C'#:3>
M*2\TI[N>5.I9-I$=FSM2*LL D5]OR[J(5?=#5@&(H=OI4?8=>F:R_P!IWO5Q
M72&Q",!A ! 5$B2M),6*(P,L2SF*DI#-\H;YF0Q)LZ^GVZNJ,.*CX+B:U*DA
M.\K*4VH'V=352HDD96ZA0=[J.A&U1\:'61_ ][$GTYK'W^+,*=&"YPS'Z<H#
MMVQ2*/D4(L&\'>*BA 4(%*GIMZ5U&5C0\8 8A;4#1353VCZU1W;E6^J$QE1!
ML8/&5J6C"$"(*O<DC4UZ$*5ZFFIZ=5(P,WM'QCN6R'&,B1K/$#2"X#ZH/MGT
M-J?0L>W]V7C+PMYNN&SB9_/R8GA&=XUEL?Q&QM[BZPV9S66X/G,=#D;K*75A
M;I]7C;4R+%&\KA&4L 2!KXX_5SR7=>8O+^T;)LMPV+=;6[G<[7BTM  (/2<1
M0\,:+[S_ $H>2_/_ ##MM]S)M5I%'RQ=R5M9)GZ&O:/>J>+AA2N.:]?_ /PF
MWAL1$#@WE0'M+*Z-9<65XT,18LA_O"20Y4BGK7IKX+MOTS\[?B:/W*V;5I%0
MT#ATK[&B_3EYC2R N_EH'#_$'/L6.$/OW\=2^X@>4UX3S2SXTG![WC6RTQ'
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M&>"Y*3VHPWB%-+%YI!*Z[ .XD;QHJQCY1$7<,>XNXT"B@->O35K<E30@ <5
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M0#7)5.'#_P *CC>.*(;I5D#S!$B:2X8B4NYED,DA/]IC0T)IT75FYVXMKQT
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M%N>8<DW ;NY)V>.!]D8#JM-K$L2I/3H177)[._6]YZOE*^IOTC4'F3=U%?\
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M>=H'PU3X[^@+DFMH #FJNUC4*$>EH8WE5C,"&2(++'W+,/*2):QAO1D<_$T
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MV6.).%*JM\GAC4J.TM;>8]YH'BE:)]L@0(41!6C!G&TQ^HH >I'4:M<]T?'
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MVFN*S'&]QJT$A4M^E2+>-9:))&O=H9-\1  9YFZJ0G4$,.G74XI=/M#.BS/
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M<"A^&[?^_4A]V\]G>M>7[QOI5Z'U/WZBKQDFBRFB)HB:(FA .:P0#FF@ &2
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M*R'=\"34:A" 9 UV2VH6/:PFI4GM[%E:&/<@ F6:2/>LNW=0+5@?S/P@T(!
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MF2[KQ_@N5[/T/>>KFBC-K /3<@'TX+H(/=#Q^XOLKB4X]SM9[%K6"9CCN/\
MYGUT$5U'-'<R\IAC[#03%3M! 9"M.AURM]YW<BV%E:;G(Z0V%U70\#!M.!KQ
M[EUO:?T9^<>[[G>;2QEC'N%F1J:Z7W@>((& ZRN_7SY@I8Y8OX+RM)("H/U$
M.'B216:&C+_XAD994HP"'8>A(!Z:XL_J'\NZ$B21QIEABNQM_0AYV%X87;2
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MB5XX9F6:1J;=P*#<JI(%KZ$D>E1K!Y.Y@K5MK+3[*E)SIRR!5U_9:L_S$/\
MM*K7BN21'>VL;E;=W0W$QMYWABEE0V\9=Y$)+2W*%5/Q(IJ)Y/Y@$K8_PDM#
M_16L.?>51@Z_LM7_ 'B'_:50_%LS&9;48>Z6Y1XR@-O<-),9+=B0K"%F.^E"
M>G0?92N7<G\Q"H_"2U^RM<<^\I$ZCN-D!_?P_P"VNH7C>5BG3'RXB[WMV'D>
M*TO=B1%HA(J!8_E 8'UJ=M?2NM:/E#F,R!KK.4 D8TR6T>?>5 "X;C9U'_\
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MRWACC-K"7#3I&?&IZ1G2B\RVCS)\M+;G7<GLWH_S61H+P;B+0&C'#V<E>/\
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M*D5VUH; $?-]NL>!/]4?ZS?G3QXTDY)B8QN+WQ% ?EP^8)H:_ 6!->F@@F/
M>L?.HNNX&>^ZGH*F)G\;(NY3?$;D7_[DY4&K^G1K)6I]IIT^.L^!-T#_ %A\
MZRVZA>*L-0I3\FQ4;A&&4W-4+MP6:<':*FC)8,OI]IT_#S= ]8^=2\>-6_:7
MB97G$%Y:VV26UM>)W]K+=7>+O[&#ZFYS6*GBMTEO((!),T5L[;5K114ZQ(PQ
MVQC>1K,@/H *K:-=R)F^Z&$*_P"FM?Q6'&JV4U.HS64H=0\1G2L52FLA[2:
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M5MG]U_CR8@;W!/=A\<F/=M"L/_*IT(ZM0_M'_&HF. ^Z*^A1D\M^^9IH1%[
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M/U*6MX6;P'[-8;CM0&Y@/N*\L21"<.WU(MYE\!)NA" =LLBL2?F &HEUN/\
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M?'^Q>NP\*_5 AL;CZSW$>S)[[ZBZF@GC]M?EA+2&Q1"UO;R0?X]F::53_K)
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M:N%%9B?J]^\](+B:ZRWBM%MIH7N8Y?&;JD$,UR$$3,O*W$TBA&12"A;J2H(
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MB-9&P,:!F"YE#T45%9\ON9(1)%QC<DUI'+:*<U?K.;78Q$TDQLHPC#H*;O1
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MW-X3K,^.@UIB11N5,@M\'Z(MP6\[><85$95?$G'VDDVS1S,R\PI &CG4.J+
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M877%;3(<EN[WW+^6A+CK&YYS8Y?AG\2EMWD> 92WFL))E59EV,:;,CJ7-3@
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M9%;92TNILM-DIK&R>RLHIC&B6UL#;&9IEMX5EFNW6R1-[;?D6@05).\'AV7
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M+OOW';>.ES KF2$*S_*1KVN]Y1\H^>96;I YD3I 2&Y8YG6.!Z,^*^8H^?\
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MF(\?P_'\V\>\TM!R#'PE(+B/(0VDJ@QN&1ZK[_>0VLD.J5X;<-:TMSQKGAZ
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MGJ<\-Y#SSL\MS%:04N;/V;>5LII$\ AQ;Q-<SUU78;=D'^4=RGMIY+D.8_\
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M &3K8N?O!]AO<L\?0MC/KTU0LKX1_<3'!-[[OU-DO$NS8O[M7$L"3%'N+C_
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M;I=KN&MK7P7' TX+7K[B/&GE+R%Y-\C8*3P%X\\T^-<EPBS7@T_DF\X+A;/
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M?=/L4ZNC!;%?TM(E^M]\#6;&?_\ >\C^L8,ZK&R^ ?#,:1*2J$E(HE/0[09
M*CT'HV^?Q.8+]V7^)=^\5Z/Y2D#DBU;)@_2.X+;-+L[EN-@4]VV9A+3:A,H
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M!;G53.)\,XIR2TGY-E)>375ODLKD./Y.YX_RK@?%[7Q[B[7CV)O[+F?)>/\
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M?-O.T'%\A@?'S6Z0R^&_ /$L1_!_ 'A-;< )CKGB?"W_ (CE[>-41>19B_\
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M5B=:RM*V.FL!=SV!LH[2:TOHS%>7!9?DDO9KC>1=&U@:6XB--SM^+<I#71
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M9#^,,3ZZD_[YRR,RLP$_%^[^HZP<D=[JUY_I2$']/7VRD.T@/$^1T=FW,?\
M[X'+OQ'[1Z?LU=/]\>P?NA8&96PL>H_\H?TC5)R679+7/^ET[2>VSFC-N_\
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M3B7)+@R.(PP6Y\A<PN8X_P I50K#'*$4@?,J@_'5LU/&=3J[@L#,K8H/5?\
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M?^817Q'Y4%2O_P![?G/S 1L5KQ?*"H28K$]/L8A3\>FL--'M^T$/RKPO]/\
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M$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$30K!Q"CT_R_\
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MV.Y!88UI)K2^.0M8[*51-)(%4ZDP$W;J?#-9^DLO_8#P^;A'ASS#8VGAO%>
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MD&'POB]\C%>W4V&FM4N\?<)=V<X[D,R, ^K0[P;ESQ\2SQJO8?8YR;PS[2_
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M?SZQ[/4GL]2?/_TOY]/9ZD]GJ3Y_^E_/I[/4GL]2?/\ ]+^?3V>I/9ZD^?\
MZ7\^GL]2>SU)\_\ TOY]/9ZD]GJ3Y_\ I?SZ>SU)[/4GS_\ 2_GT]GJ3V>I/
MG_Z7\^GL]2>SU)\__2_GT]GJ3V>I2QM^'_P_'[>NL'105I3@I'K7+XC[>M/M
M].M/W:S[/4H^SU*'2OPW?#[?\^L#17"E5)1Z=?M^/VTZZ.ZE!^2?'IZ_&GK\
M:5_?76&K#.M/C^W^?4O9XT4QU9)]O\__ ,.L>QU(:<:)]G\WW?LUD4X9+'L]
92AT_9J2D.I1UA$T.2P<E'5?M=:K]KK7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tv498959_ex10-9img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv498959_ex10-9img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ +@!1 P$1  (1 0,1 ?_$ '4   (" P$! 0
M      8'  4#! @! @H! 0                     0  $%  (! P($ P4)
M      0! @,%!A$' "$2$Q0(,4$B%5$R%F%QH2,8T?%2TY25U597$0$
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)O\5_P_V>!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tv498959_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv498959_img1.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M 1$  A$! Q$!_\0! @ !   & P$!              0%!@<("0(#"P$* 0$
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M\DQ;EE$0.';J *08"7ZM6SX9Q]&ST_B5/\GMZV^M0:_3QZN+0@BE+84?&
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M01 !$IAR]91!,41^M-R&$-0\ B%<+XB@?RQ)_O8_]I?5OW*"1]XO"@<#!?\
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M:\NX-98SYA4+=6F/L+EM8IA7J)HNEA-+/C"\!T^:)F*  GYN4P:Z:#H"H'U
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M9UVJ/V(OK%^KP'2N<GU<M0Y9,6H.J"?'P (=O;I6HFKN*PY-%<Q,1[H.'\D
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MI:[@W2Q#"@JFBIP$1 ODF#3ZW0 $1U&K$EE*]OL':0LB+(0M(W@N"I=6WKQ
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M;Q"MO8AAG:>D+G\F]_PSVFI%/G"N?71KCUK<S]^<XZ<GX#^H-_U?:A4=*J'
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M0WQN-QVT+?XWMN)>8;RWM!D\<)$O7"N;KDFX28<77>0Q</<%FY'MZW\4S<U
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M!C:"C6C;'&-H)VL!:#48^W;U(XC'^VUAN$ONSL5+QM^9'LK&>%G&+-Q#"_\
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M"8!*/U*WD=W9_E2QZ_I+F9,9E 3_ ,O/I^B54L;-0#TW*TDH]X( .H-W)%Q
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M;D #0 -'MXM%8W9]D.HH?ND_#P*(UK_YIM&1T8)99A^B&@^?H"WP\.\K+/\
M6NMX+?KWF0@=@ U*E*.X0Y1.=Y9AC#K]B!E+ 8H!_P H1=!,G-ZH5C,YL?\
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M]JN'HI4),',WC'/UV/<C(&;HK>PQUL),;*R]CQ DPN"?G()9==C&E$W(+[E
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MO'P%T *U;FO<\RR$OD/$G4KIF,CMX6V]NUL<#10-:*- \@X]M5&%*(]NO9Q
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MP74*=8A><2 =4R)!UU#01'C6YBL>\(]L<::#B?+H%Y_/'EHW$FT+0T5.YX!
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M)Z%&MFATIE4R9S&!TB@S4=+/&[@>8R8 HD= 1(9-=4I=.'$HC5;6N$U6DZ@
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MN_=LH<;<92#INHZ<J(II6PY4$Z"A"E(14P:";GTTI!E;&#,WUO=2Q,?I0.<
MXT:?=KQ5CF/E41^'W*?P[6,FD[US&N#6@DS@4(U-.@46O'&>4V,ALXSQ<Y7S
MH75VY@MVU(MH]4*3S@@REOM3J'**G, AJ/*(=GAKG;2]!P%U.*_63QM -.D
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M%,)V./LO]KB:5+01T4*IR:C;K@VIC34:U?F*BKI(VZ*H]V0XE'NUFHI(&6,
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M-D&SXX/'Q3ZD.)TQU XZ &M>/<U&//9C&WGQ9=<77M5<'U.^9W"@X ':*TT
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MJDN.5Y, XX6ZAN;Z)X=(Z[@:'L9^:RC3NJ=?RCU478WUE:'"&3'W3+5_Y3)
M'%P_0T=Z!17P<.5'*_,J0B?,!2]P"90Y2\ *4>[ Q1'3AVCQKAWOLY;@S"_M
M1(X:-$,@ _\ +7"Q1-@CVL<XCCNK]*BQ@6SU$2E1*DMRZ\W>D#7Q@(  "&O@
MK+DDO9(S!!)9N>!Q+&5/[3!18XRDMO)N<XNC!IP*MM<L8WCT#K'*N/<@)M&K
M]^FX.)!YM$SMERJ <1#@ :Z]E::WNYC>-?\ "V,TC74VO+6 GJT<QOG74XN[
MDN)0&EFX\-S&%OGW"GG4YMBY%+@@74@1VY8QK X-"!-(.FCHS@A=%0[MVV16
M,D01X*:<I^WCVUU&>Q6/EQ\%VVY;C[AP^MM27S1,-='1R#<XM=QVU.U866Q3
M,;D66\D;'W<@WGNG-<VAX:M) /6.A2J4BIN0$ATR,W2!Q*)E43<!3$VG.)Q+
MR\H%XCKX*TF+P6-^)$C<[;V]#JYD=SNIT_D!M>PGBK]K=V=L2Q[GL>*BA&M1
MV UJI%%7EBBQYF7M&V()5:Y'ZB+J?<1ENRJR"K]P@8"JJ/FS)1N35(H\ .'9
MV!K74Y&ZR=]:F+$[[C&B,L$TLL43I"-"\M!'FKJ!2JVE]@>=>8;&#-Y2X Q4
M8+86OFC!#&GAL<\.X]A54><PL6F$J>*635$W,*GF[HRH$'B.J9DN\* >M7"_
M96;+?AV[7MW5+?B&&I\@>M3\-D+MWPK9P64I3<*>FM%+&V8K DYI*!&X6:4P
M;ZR)=.2-7RI2B ?86ZX)JG* >$ &J;K%91TS7WEK,13@-=.PA9<G(_,=G8NR
M+;9YL0=9&@N:/*X5%5<=5]'!H8=$TN7F'F6*/#4.P*Q9K)D<A#[:1D8Z#6OK
M7,-M[NAI4O\ (5(9"3@2#WCE1 4=!-J=0@"4H (F\HPZ:Z5A_#PF8AL3C%6M
M.D+86]KDJ;8PX/\ (3\RME/9RQ5'(K0C66%P^,4R8-8Y15VJ)]>!.1L1<0$/
M%6^M<3>RM$F,M;AO;NVBO:":+J<=X?\ .-R\7\D%+<:[G@,%.OVJ!=N';HQ.
M_>2:[6YTW%RE.JF[@'CMX@];'Y>8#^PKA1(2ZE-]>5+00#UZZJXEL[+'Q1\Q
M00C(^VXN;$QQ<V@#&N<SV0X&I)&IKJ51SOAN=K2TA@FM"W&D MF8UI8X TIW
MC:UUZ"Y5Z\B6LFZ%9-<I]3&$"<RZ1- ,/#5$Q!'4/'K7F\=W#O/L0%FM YFG
M9JVAJN?ANYK6(->W2@ZC\O2N0PBYB<A$N7E[.[<"7AK_ +8IA'ZM;2VO\6P$
MW&*LY .)[RX;_P"I10<A&#5Y&O93Y%;B>*^B#"963?L4S'Y0,91LLW()M0#F
MY116*37U!KI,3E?#&[F;;YW%W%HTG62"=SFCMVOJZGD)*Z&R?!<4(A9(>RH/
MFK4551XR7CI)FXE):X6[]('SA@5%B[1=(HJ-3\BI%54^]/WXB'$@\HE :W7,
M8\*<=<Q6N)MI+BW=$'F5TL@X\&AE*D]9-%@<U1W5E,RTL;9\<AC:^LC2TEKA
M4&A %.T<5RO#&\'<4RUEV9E@!D;O6XDDY)@<A].(=ZT<MSJIFTXD/J4?%7$N
MSD5K/+'8,AEQ!IMCFW/#?U=QJ/,51A>:,GC+*2TFV[Y11P+&/:0.&CFFAZB*
M%=!;<NA!V@=G)OV#=,2Z@0S-^U4*' 2JD6[MUS:>'O*V%CE.39(BW,8<AU*=
MY;S/!'E8]SA^'!7?M7%OC+9X8I)3^LQP\E*M\U**Z:+.*&'2!^<SJ3*3150Z
M0ID,/A,4 ,;E ?%S#6NOV\FOM7OQK;EEP7>RV4@T'E: /2N3FFO/CC\,-EI7
M05K\JML]O&PXN2,QD9YG'"F.HD$B?,(@/E:J+G(0@ /A"M3CL=97+ZW'Q)BK
MIW48=N/54F@]:ZBWP^?NX1+:6SY:].M/[H7)_#-IMXUF+<>.%Q,5-9LZ0<%Y
MN[+H)#D2.B=H< 'CQ*(#XZZW',CQ=RXQ8:6XB>-NZ61['[3[P!9M:">O6BI@
MNIK"-]KDHVM<*AS7#KZR"'!1UPR@VK$%=S:CEX_*F90%5(X5CK F43:*$9]X
M(GT#0.4O'P!55SC<+=Y-D6+??8J_EI1LQ[R.H_\ $80^G:02K&/MAE+SX>P:
MQD#C2@?1H)[74H/*52-I9F:W.8T<A%3"8%'4P*V[-MT@U[-%5V!4P'CXZHRF
M+YM;&+>ZGMKB$&H/>1_+)0GR:K>9?D6YQ0%U++ 3^C/$X^@/KZE6[ZYX^)2(
MHI%JG4-Y13D9N%5@$>/UB2)CAJ(^$ K5G'Y^YA^&?#"X UT?$T:=8:YK3Y35
M:&##75X\M9* SJ+F@'TE0YYFY)IN5Q'(F:)&'@J]1415(3AJ(-UR$4Y0#Q%\
M%84N-N_BF09NZ@MHOSMW>4'ZL6\CLK3RH,?C+&7NKDASZ5]D@^L5"M/*3]DQ
M.8</M[BDFB]PR>0K9C&O>HO#*F?&DD5&J39-$"("('( B(@(%TXZ5ZIX:8W"
M6O/N/?R[DXYML\/>&6&1DCJN&]K&ZL /!I=KTZ+J;;&9^_Y/SDF'8YME!BKA
M[R-I'=[#OJ3J*C@-*]"W/U^E:^$%JTNVSK=PQU8\!7;C:,:VL\WC[;-R\-N,
MCXH@L(7)4UMPFL"3>&,AST4P,U:/\D67'Y(N"&2F')5W"L)*G:'U*BV,C'2J
MN(\BVEU*I2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41>4=US/S:W1M_#YUT/\0&(J3Q5+>"U[?B8?J@?V^=0JE<#$W[R/
MC3]-]9OQ\8VB+TQ>CS_=YOQ_2Z]3;XT5XU)^94M^=92;II9@Q?0J#U%-R"L4
MY-W1ETT3$*#@ YP[TP$$/X:^-_O,<K<QYO.8R]P=J^X;% \$M(!:XNJ.)'0%
M[WX.6=S<073X"YNV1FH!-=#IIJM8N0-M-E;@(MZS@91Y:<@*3E,KV'G'T:8K
MERD=$>=*/=(-ED>]4 XE O$0KYY@P?-]G<L&8L9C;TW;A$)" #KN(T'3[U5]
M><K>*O,/AM>1W64@CO+:K3W<L+)#M:0>+VEP-!0&O2LF\88RL/#5JVQ8%H6R
M@@O%QK9O)/VK0%5I"032*5V]=2*B)G+A=PMJ<3',/;IX*UF2@S,K7/LX[N2S
MC=0EK=C=QU#0.)ITGAU+ROFWFSF3GS-7G,N:NR8IIG&-CG4#&$^RT1@[0&C0
M !75=H"BD"CEFIRCX%0/IIX0T'M&N/N+6\A.ZYBD8X_GZ?*N/@D#W]W%(-W3
M2BL??;Q@#5R@E /5S+%,!CD;J.4N7CJ8R )*@IJ'@TXUE8["YVZE$6+C?N-/
M=>&\>O7@NVP45VZ=KHYV,<#QW!A]-0J;PKA::L)6;N%O=4M%VE>K@DQ'6"BV
M8-XV$=*)@5T^;%<H*N&CF1.43J)$$$P\6M;[.X]^.N(K7),?+D&-I(\.VM+N
M.T?G;>%:+><\<^V/,$-MB[BTAGSN/9W<EX7/,DK0?9:[:X!P8- XZGR+*M@@
MW2(8JIEU3%* %55<)E,.H '$J:9"B/"K5N^Q;N#X V3@';S6G;7Z%X]<RR/=
M]6&M:>@--/62NPJ+==8Q43F;E*74X@H'E\HZ=H@(#KIV5$8M9Y'-BC;'&./M
M>L'14=Z^)@[P!YX#3@L>,E8V?W#=EK7<WD2-O0Z>0N)JW70*M'/EFB2R)6TD
M <J@(<JQA*8HZE. #X-*JLKJ"&X+KEC^Z(IN:00T'IH1KZ=5Z7RGS1;8K$WN
M)EA+Q?VQ@<6NH]@<0:LXU.FM>C17,B[M>74[43\YA6P-6H'.L+I($.\X@9%'
MRRJ*:'#PD#U:Z"7EN:^M69N6]MCBZF.-P80ZK14M(-&AU.TUZ%R-WC+#"6XD
M^N<USZ4H:^4] ]*P_P![&))W*^,$I>UIZ 9Y5PU<#7*N)A(N@1Y(W';('7/!
M'*NH7OF4^U*9#D*)>93D'7A48E^.QTA_CR135BD(B&W:>)J#^2:.!IQ XA>E
M>$_.^!Y5YB^$RH>.7\O ;2[WO :R*702]AC=J30Z5"T(QF7$QM.Y6\6NPCIW
M$N2V6Y?'UI+$,W?LW4\L2'SSC,K<[@%T$K?<&,Y*V H*BT(94=0&NIELM\K6
M3=Z8;F/X9Q'N^R Z&4$ Z/ 8*\/9-0OMZ;E^W^T;>YN'%^-RE@<9<7&YI8YK
M:OQ]UNIM<9 =F^I'>.#10A5]9N8(%OMYVI+-;@B09XGWCW^Y1%9=,BB,,HR=
M7&PDG29EBF(U5\]$H&T*41#0..M8U]:W$=_?1/CFJ^PB/'B:Q AOL\=#7BM-
ME>7'O\0>9()8W?%9/E6WJT<2X$Q%HTXB@ZU:Q>_)+^RG#<*G.VLG$XQ1R/N@
MO(9,#J)GO>Y)^4;V';C\J+L#.9:8 J2R"  4X)J\XZE :S66<<M[<4%PRXE[
MNT8=#5K W>]NE0*-#22::D^3I;.PQ+>;,C?3Q7+KK(&WQ4 C<T'N(8V&XD94
M:,C)<V1VHW-VU!HJ\Z;&/W>X;,<=)9'/'-[!MF\6&5K\N9T\CH]I.WK;3<[6
MP;,*L_4(B=E&IN5';A-$#F.50"F$*V><L9(X3!CI1&_NN[:'U&V,DF1_:][O
M9&FC:]E.?^\CSGCN0N6Y&6%PQO,UU9FU@@W5<R"4_73!H.ZKMH:TOH X5;5?
MI[F9^PR Y<FN2T#G+S#WHST80I2E[!+R.@\@"]GJ5Y#)@KI[R=_UCB?;=O%*
M'CH.!Z"OSALKXDL9WAH1PKKZU3D+<UN76C(1Y+DMM!BT1%0CTT_&%;+B8# !
M&YC/!,JH&GE!H&E;F/DK,36(OGW39+#6ACWO>2W4MIIM(Z*T6PO;NQQ+HKET
MK7S/=[@(W-[3U#JZUC^\Q1"M,B-;X@LZR%J"W;';.;:MRX;9):DR=0XG6=RD
M,^*Z15?GX *I.0^@=NM:.>=CF?#3VUY-(.#G [].@$-^E>EVWBACYN5G\NY+
M&8^]:YX<V>??\3$!H&1RL<TA@_--0KS,95%!4IW.38!RGJ',#IS#:Z</Y362
M1+IKZE8'<6M=S[2]!_6)^5A7"W&3P,C"V*W:QWZ,QI_>!*J21N*)78&2:WW:
MI-2"'>%D&6NH@(!H'LL ]GJU=FMK7NPT6UXZ.G1IK_\ C6MM[[%,GWR,-:\.
M\;\NU648)S%IW ZNB/S3$K-%6QTE[:DE(!U;QB\W>"Z)YL\2E47H &@'%8Y0
M\)1JJ"'',(:;6\C-??!J1Y06T('4NWFYBY0R>*&(NL;&)0^HN&3.$_50AU8R
MWL#0>U7#LO-+"Z9]>+<R-JMV[=(%59@9Z++'#VE "JJ/"G[PQ@'R--0TKI).
M1YW63,W'=0FRE-&ES'"0NZG-' CI_&N:S>&PV+QC;R"[#WN-!'7ZSMJ!73M5
MV(Z]K.6=J)+WE:"*9.?57TCB@[-?K0,[\(UJ['!Q/E<'W+01Q^JD:33J)T*Y
M"[,#+<21$ND---%+96\K&Y'!2W9:;CEYA( SD6<##KP'_I0"(UH)[*6.9\;(
MY',#M'"-Q!'7H%E64E2WO';0>T*W2]P6E>T/<%N3-]VI!-!:"E'FC;JC2R+L
M7!3)J]X@94QVH(@;R3:CJ(UT%OR]WEE\782W$]['[1A$,@( XEPH:-71,R%M
M@[VURE@WO[CO*OW@=VW;J*&OM5X$::*R&,;-@\'RS)!KN O&[X@BYE"VU=UZ
M04M"%1=+ )P!RBQ))I]T0WD$%42:<*R,+B[O*7Q;/C9R PFL<3PT$"HW-(I0
MGI[5Z#S9X@6//]O(^?$X2RO7- [^VC,<E6C2K3+W=3TNVUJLCY+(6.&$B;S6
M6@$SN5"*B9&8CQ()U.P.8K@-1XZ  ZC6%/RMS+DIR^TQ]^Z,$C:(Y"UM/-0#
MI^=>7VPN9K7;-<,=L!&KA]/I4]7O"T?-1%6>@ ,=(0*F>:CBCH(< T.YUU ?
M#6IFPF9LZQRVDK'\/:C+1Y:\ L&.:'OJ-F90.Z""L=FU_-8W*5ON#VWCZ5BS
M+.&3R['DM"*RL*U<%T0\Q$7@+F3%73O.&@ -=5B,-EH+!TTEY$+D$%D+I"1I
MUNJ "1P )7I5,1=<I74)S4T%S1KF6S7$,E<WCOZ :<%DI,7/8*ZQ@<W3;!DS
M@!AY9J)43 ![2@(.-.7C6EN;7F,73WPQWA:=26M>]NO;0B@7F%A?211AT3QO
M'6:'R\53RLUB1( 25N*R4P,41 JLO$")@$/$9<0XZ_P5KGW>>:[C<BG_ (9'
M^%;-N7R9]ILKB>QU%*9.0QXPCEW$!+V85TL02(F0DH)),#&_E"9)0A@'CXZH
MDDST[Q&]US[9XN#P /0LF#+SW4X9?W+RP=<A/J)HL?L>X[QZK?EQY)R,SQA(
M72L9!M:\VG>?F[ME&MBF*1.0;D<$15<'.(FYR\=- 'LKM+27&XJU;:RR75Q(
M!K2%SFU/'WAP' 47I7,'B/)%RQ:<J<MY.[9B&@NN(BR-S72..I834AHX4/EK
MK1951S_$L"<)&/O*W"/'&AG#/TQ0<M2'#M[I%:1$I2Z^#E"K%[-:6NVXLXVS
MD\6O@((_9 7D-WG,GDA\)=;3;MT:_8QKCY2!Q[5&2F3K5[DPMKFM W$/(+-Q
MP#ZX?UH?7K43MN\@=K1#"QVO\*44IUT:5CVMG;;QWLA':2%8"^;CQY>S)W;]
MVNVIF3P#)&4AKE8MW!R&\*1V<@5YKZP5M;/E7+N8#828R:5W!A.V0GH #P"3
MY%Z-R_?/P5PS)XB\M._8:@2AK@*=>X;5CA ;<L XZ5-,V9DW*D$@>0-,*VW&
MY&408.7HF!505&T@=8HBY$-#B(@(AX:MS67,$DS8;RTQ[7L(:=SFB@&FM'="
M]4R?CIS/S.T6>?M^6KB01=T)WP1%S6< &N8X>[T=2SDQYDBW+[@#+/73"R'\
M6'FP1TA<4,X.Y21$2)NP=B\5(X.NF4!$> @(B A69?\ +EQ/W@BBL9&MC!:8
M:D:<0X!U0>H\"OG_ )EBM.7LB&6]W;9"VF.[>P;=I/%NT4(#3H/E59&OVP&#
M44G-ZVN14!T!1:X(DHCH/$="N +7%]ULMS ;65MP3J0UY'K!6@(DN)Q(S;M[
M#])4*7(6/ETU )?-I*&,40#EN.($0U#AVN=0K#%J=A'<W'>>0_NJ^0]CP".'
M%8)YRVV8_P VS,9)N\POK=+#OCOVXVO=<"@+E514BG=ORK&5!RV*8@:)Z 4>
M.NM;[%9*YQ4#H&6MRYCP:@UH*]+1MT=U&J^@O#CQSG\.[*XM;:QQ]Y\2S:X7
M +@P $5CH1M<0?>XCH6;%L7PRB;<9PSZ^K*=*,&S9FW=)*QC%<R3=(B('<E)
M)JHF7.4NIA("9=1'0/!62<P[X 6'P^0$6ZM2=QUZ 2WAU+PC+_8]YF),C V1
MD<KG.<TRA[022:-J := K6@Z5V/;KM5RV.9]=UI/#%U$I#2T;RAPU_E/C#P]
M2M+/%!*\/,&0=3AN.H_N*F&XM8I-D'L-)_.'S*20N0\;M3NT9>]+%:'U3\S(
MSG&)5S<X>4+A([OE('-IH(&'7Q5L[7 V>1@=\*S(ON6BKF"%\G=M_.<6_D^9
M9N0;+*&/QQ>[COW%M!Y.D^A3&Y+^L:(CRR:%UVNZ3#0"'-/1P%$1["Z^<ZA]
M7A6I.!N7S]U;UH32KVOC /;4:><K$QSQ<3&VE>&.''AZ5%V;D:P[GB%7Q+TM
ME Z1CD.W+.1A5$S$,)3%/SNN8#:\0\85OKGDR[Q+WVV4;(VY[L/ :TECP?S9
M*$.H*5 X*WG(I,5>-@.U[2 0ZHIJ%1[AOC)/*F*9]K)6O)SQ[\@FK5VK*QCM
MPV!=^B4_FA?.#]RLH.@<Q0 P]E;/P\??6W/&&MH6/9;G(P;SL(+J/'O.(X>@
M+:'F+).Y-R^+9.8K-]C(7,8ZF^C30.IJ1V<%N"K]5E\:+6YG[\YQTY/P']0;
M_J^U"HZ54.!6R.I5*41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B+RCNN9^;6Z-OX?.NA_B Q%2>*I;P6O;\3#]4#^WSJ%4
MK@8F_>1\:?IOK-^/C&T1>F+T>?[O-^/Z77J;?&BO&I/S*EOSK(;='CQ:Z<CV
M%/K2I?8F$AY$'UNG:<Z<GSK:D5.Z\X)W/<F'704S@;2ODW[QW.E_R[>V6.Q_
M>-FGMWG>VAVT<-=IXZ=J^C_!GF6/#\MY2P;$?C+B6/9,'4,= :@-H:U\H5O&
M#F+@T@181K%@4!T(4'29"Z!QU I$4P(.OKU\G2<QV]Y+\5?Y&^-TX"I<#3S-
M:X#3JHNSN8;O(/+[F:20TU]DU_VCI^%%*KQO5K9T,I<(QCV:5(7G%O$ H]77
MX@7NFZ:)1[Q;CV<*Q&L@R-PV&RO)I7NJYSY6N8P$:BM2:+*PO+\^;OQBQ+'!
M&32LE&-':2>A2*W,L!=Z:?\ [+7:S[P@&$LI!/FI4Q, ^2)E  @@&O@&K-]A
M<G(0+F6W>P=/>CZ5L<CR4<&\N^+LI #_ )<S75]&JK4L0A)%,N9DLFJD!CE$
MY>Z$O*&H:<=0TK$;B+AC#()H 6C\F37R>S6JT#[IUN0WO&%GEJK5RB&2).8!
MJ#F/0C6_.+==;SQ11-, $$T002%(ABE[>83:ZCV5N[>^Y4GL#!GC<7.3[RK7
ML<6[6T VESM#PZM%U=F_EFUL3-.V5]V^E6MV@>4N-37S*JTHFY4D"%5ETCF(
M &$Q8Y8HF$ ["&-("(!XJLB7EE\1B='<.<-1]:T$=6NS7R+3RW6)=(3% X-/
MZ8_=5KI#(UW1]^6S93>*,\;W*\5C33 2 HI1BJ*)USF>-Q;&,'.D41( ''F'
MAVUD6F&P%W:23QWTS2UGM,+ 7-!X4(<*^6@76V7+&$O>7KW.ON-DEG&'F(LJ
M7@D ;'5'2==-%>*Z(-R[@G48$FN=8R1@.9( 3$WDZB B*AC" ^/LK61SX&.4
M13MN9K5I (+VLK3R!Q%>G7SK@[&_CBG%TV$; :BI_%HM0&XF0SA8"<FYQ<L[
M-<10,DS+)N#)QXMA'[*BDFFB*)7!OY!E ,4#<1KWC'\Q<OY/%QXBXMHX\:VF
MUHU#=*;N@[NWCUK4\]<W\Q93#28[ 06D-T-6E[2=?+U]5=%J?O?>?G.U)U:*
MR5MW3NBYD@ 5IV7;STX9^D CR*LG;,09IL]=>0B12%+XJ[;%V.';:-;CY;1L
M Z"T U[:NJ2OB/F6'GB7*R'/?$OO.MH?LV_H;=*+'I9<,Q7!=&8F]LVIB"Z+
M<7AG;?'4TP?1L)?HB5P:769!)<B/?'22(1=$P"183<1 1X]'CN7OB89KNQNK
M1TL1:X1;FMW5K4,JZG1JW2M33C1?H-]U?[TIPW*+?![QBM[F3E05BM\AM>9;
M5CCNC9(W:7N9$_VF2-.YE!I0+'Y_=0K6U-6FE:S=FVDKL)<C!R=!49"-021>
M-E(E)91$BBK$XJ$$.P ,GKQUK2.F:V)UL T!LF[H+FD @M)XG0CCTCM7ZN<O
MV& SN2LN?,=D+>_ QIM3+&063#>R1K^-&EI:3MU][CHL/,KY<G\8H.F5N8^N
MZ_Y]THL5G&0EO7$I#Q"9R ?OYF919ND7YQ="!BI)% 2AJ4--.:NPY?Y?;FX&
M.N9H;;'!U2]Q9OD(Z&BHH *Z]I.O!?+?C/\ >0Y)\(L_<OY:A9FN?A"^&*"/
M<+;'MD<7R/DEH>]FEDH][&@"@#2X=.-C7=ONN:(E01P&H( )C&.-@7EWBIC#
MJ!U3$Y14.!="@8>/* !7M./M>4L;:"TMG6AB:2:N<QSB3QJ3J>KR:+\J>>N>
M>>?$?F2;FOFV:>XS$S6M+@"UK6, #6M:-&@#4TXDD]*B???[M!#0V U1 > @
M:P;V, AXAU-II6<9.6^NQI_PUR'_ -H#4"?^\N(;PMV20:%P*HD''R26%>Q
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M=J.2+!MC(S)F\BH>[K:@+JBFTN1FWD@87%%M9ABDZ19.W[=)V5L[*50J:JA
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MR(C=]IX>!KB!1S( P>KV2L"^Q%_D'=ZR1K6CB!I\@XJ)/=T(_5^QD* &[$C
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M&2K8=W7F*QV63<18FPACBV8^6S5DRZ\92#U@PRE.,6ESQ,3;]M/548J3F9A
M\BKYBV<(.(/4JAU]2I?8ETJ\0["/8AS8.<MV5_N(Z,FVQ[5OW/MWLL#MY.Y1
M:'F)2VMK]@K69MYM)-N=N<D6W:6[R1:"O*D854TUBRHK^'X?,J&ZL6)<6;B+
M<Q7@7<ILPR/NLVKW>RR7<>5+WPW;-QW-EG;%=EM*X\@\9Y9LF+LN13R%<;@X
MWO,-W<':L9<%RR+0AW"46^C6,JW4<"FA&J_/9%[%-[$1TT>M!M9P@QW?YLV1
M2-L8F:=.^P-UV/;ZLS<V_E;;NV(OK,L)CS$=^PUHY&B[ :"D!6"3ZVH)2>?M
MR+1D<1<[[OU=?.HIH1V:>C\**F=O6)=PTKOT:7NIM$WCVS9<G]'A9;1F=X7E
MM+S]9D \W$67@6 3GL=O7]Q8^CO8*;)+V;(0[$)4K'V8D6Z"<=YVE(1:KU^1
M3IK\RFOUE>BGSJ$V8;*=T-Q6;]'YV[M]J6>\)YGZ?FY[,V==WF1<BX1O/&V/
MK5QG.Y42R='P\5FR0AF5BY6F<MV0LRB/8NWI67>LG*)FDL@S!N<I1X^50. '
M2/H/X:+%#*FRK>F/34N[8],[&-S^0MZMI=8RX-QMV7];VWZ[)2Q<F8YN"SY@
M767[7W"OXYKC2X6-VN"(LU$VTV9=N9!$C\C?4FL'YOFHI'KK\]:^A9YNNGYE
MC+W4OZCUI;U;.ZF5AXZW39CVY;F-LM_;7L58IOZT[BFL6+24MCW%N1=R$SA+
M.<%@:\,+!<#1BQ,6^;3L\H1DBF[?KH^Q1W,]':HZ:5TT]7F[%FKTB=NT?<'4
M@ZU5W;A=HV3FEM9@W66;FC;?=^Y':/E&V;$N6WK"R%D&65O+&UU9@QC&6I&W
M(TO%];LNV30<MIEX+1I(-TE21PKM5.O\-5->-.OY@OSGYCVJ;E+JV?=6&Q(?
M8;O<D[ZW!]6RQL[XCC$-BFZ5E,7Q@EI.9\D4+MCGKK#S%2,B8F*N54OFSM5H
M[9&F"IBBF=T)35=((ZE2:%KJ_G?./QK8/<F$9.PMW776D\-]+C<SE3:9EK9+
MMTQGMEP'[U3>!M[QIF63Q!9^W>R)FVH&5AL>X\O)FG9D_#2<R=@Q?1<Y=#6,
M=$8+G5<^<!'0$'%U?PT*LSA+"F\:S\C=5J^\E[6-[LDCN=Z$%O[?L9JM-FFX
M@Y+CSQ-;:L$8?BL*PT-$6+<4XDMC"YH]];[=Q<CIQ/G@X8\I)NW1U5WJ\#H\
MOT*7=/:!\Z_2=TO8N^,6] [&5F9"Q#G:S\E8RVN9AM&ZL07%@O+<-F8MT,#W
M\*4%!8DDK.:Y!NE_- _;^QH1L<Z)(]^3S<RG'0>)4MZ#V!?FJVDX-W7X[V"]
M*3$\ATY=V#3,N/-Y.[9.[\US. -RT1D+:%:5XGQY*24W;V)SL+;M&[6V=[)N
MD8IK<-Z14_8S 8U^V.@L\(Z*TEW$_AU*(S3;7\.*NKM@Z;^<+Q^C>9(LS(.*
M<N;<=Z>QS<%E/>+M[>99QG=^)[VM&=QM[!WVJ>SI6_[2C7#N$O6V8.3(B>)<
M Q/-HL%W*H W !$C=7H_$H .T#I^>JS2ZE^U[?->^VKI>;JRXUS5>.3X[>/C
M[>;OYQ]M<L>"R/F>VIVZ+:L)G:,O8N'[VL:][1R#<VV'&EIH6A%MY2VY9H5P
MU24<MCHN':M0.U5.->&E/P\ZQRWN;$(#%-J])^T-OV&>I5N0P%$=5*9WA9MF
M,F[3<DW;D"TL1W-=6'9+,4RXQ;A3;E8<WB.S9A\SE'<;:$U:,%<SIZ$BLUC5
M&9FIAD<3Y%!T Z34'Y?I7[;K*QWC_&S&6B\=6+9U@QL]<DW>4['65;$):K&:
MN^Y7/GMQW5+-()BP;R-R3[S[,]?+%.Z=*^4J<QN-0E2>*K&B)1$HB41*(E$2
MB)1$HB41*(E$7E'=<S\VMT;?P^==#_$!B*D\52W@M>WXF'ZH']OG4*I7 Q-^
M\CXT_3?6;\?&-HB],7H\_P!WF_']+KU-OC17C4GYE2WYUD3N8QHPN[*N/9]W
M>.0(52(B7**<';<L[9V])<ST% 5F&:29F[M0HARASC];7R3]XK 9',9S&2V]
MO#)9,A?O>]S-S?:K1K7.#C4#B*T7T7X0\T7.%Y3RUA!98ZX%Q(PF6>-KI8Z-
M(^K<=6^;I5!W5)GCGPHD9F,5$I4P#G(!C<A0*!C%+J)C#IX [:^3+G$29#)2
MMAMX61L(:/KHHZ4_1<[KU778BW9<6O?.>-SC7IIKU%64O&Y,I(IL#V39K:YA
M4=#YVC(/DHA!%( $P'55=@110HFX !"#6>W$8FT#+;)2VL<K=11S)=_EV5 H
MNYP6)Y6E=+_,5^^S :-I8PR.)Z=&Z#3K(79"EN"[=2W]A&$:'U H+'?6Y+-5
M#CH7E3!15%P4OBU(-4R6LC';L9?0!KG:-J]@'4!T*J^.-PU3RYS!</93@&31
MN'ET(KYU,WF$L</2N ?XSMYNKV""<3':D*(<P%!9$ODB ^(U6#;YFVW_ !%V
MSO&&I/?MH*\-"?4L2#GWFBWVFWRURYO;*_Y"H>S,+8XL2;7NJVK<E(J96:J,
MUU6LHMYGYNJ)3&*2/=NE&A1$0#02D 0K*@RE^VC;B>V#0.)<' ]6C:ZJ_G.?
M>:>8,<W#Y:[@FL6O#@#&-^X=;VM#O+4E57;=JVK<$J]D'DY?3A5FJ90&Y+E.
MR8"H!AY4#"DJ0- $/K/%708RULW6)S.7=:?9SGEC7!P-7TJ&N U;7HJ!5:/*
MYG+8^SCM[6WQS6/%">XWO';0CUE?DPWK6MBS'>2]TV[_ &3;LLE;#=XS#)>7
MV5[;2[_=O+AL'?5=.-,DW'8C:1Q1BFYHAA(9?>Y;?6ZHLY=0K*]()O)O!9ND
MXU0KY\/T?RW)<Y>PQ_+/-.,LLSRB;> Q7<0I)CV20-EI+*TN$!A:]@87/MI3
M&T2,,A+&+PS*6UE"^XSF,R!L\[WDFZV,;FLN',>6@QLI1XEH=&M>UKCM<&^T
MY8H;JY*6M+?!/WYN:P!C["%R[A.B-<L7/X^>0L5&04]E<EBOH5& @8H8]<UP
M9 QZ2UXV.CHE$CB6CVT(Q(F"9&Z EVO*,8GY0;9<LWTE[;67. +9=QD<+<SA
M[G.<#HV42/>^31CC(\Z[C7;YZQY6CY@;+=7 @CN.4^]>.Y< ,AW)K:-%*NV2
M-;&U_0&@\ K=6I)(7%A#Z/-<5U)8NF\(XM5W>,\B3UUN49C&-EQ2U\8A@+E0
MW&.U$5[<LRS3S5S1C%Z6:.DP.WD"$=?85P V;<MO+?.\^PV3IH\O<0V+H QI
M$KG?#W!:;<#VY9*1O+>[JX.8=NK=,;'LY*EM.37926X?8-ENADJ-;MB9WL09
ML));J#[?>;6Z@'0KG/N-W]B]-_-$M:-NW.OTVW_5 D;OBXNVO2E2%?;+6UP2
MXRB5JLB)DG3[8;EEF,6B F$6:RZ9C%(!5G)U5O<<NWG/]C:9">W/B#'RYL=N
M+-PR!:PBO%HNFL,KJ#VA&[6H#:+FSPL& O;RP?=?RT>9P(FEIWG$;I*R&FFM
M(F[:T+MU-*DW?WR6GMTBMO6S7*6$\3V78N (+J78UR7)Y)L*<E[CQ)9\3EV(
M;3F30LVY):2E+=QE8TFO:D&:1A;>/&VY&2<:DW5:-GR!DBZCD*YYGN\WEL;S
M%,]^:?@Y(6Q2F-L[^X<YD>]C UTA'>2;)90Z1['[VO=&X$^A>+."\*<)C,/E
MO"F_9=VS<O&^5SV2M;&7M#]P,H#&Q$L:'M80UCP&N#7 A8YWQ_8C<^T/Z0O9
M&)8.SY>/8;K<,Y7PU%MHA!67MO']LYU51=7]9D6NQ&7BXGT%E9)JI+-DDD1C
M'ZY3+ V<'Y^JL\3S7%S'R-?W0?W=MC+B&_=WO%[[1@:Q_M?6UG8UU/:HYC7<
M6@CR:\MSF,=S7?,,3YH[UD^V-K6MHZX(?+'&T -C#7. <P;6L=2H:5=#?7<6
MTZ>Q_M[QAAG&$2#UWTO<HWI&MVUKVRWVP)33:S+Q=RE\8VQ<QL)K(7!NRF,A
M0:APO:+F&!(U@HFY5"43652' Y.P?.MEE,CD<]=,%H_/L+/K'NO'1]XP,CDN
M#*YC;-L1H+1T3BYY(#HB&E9?,S+*#&V&-BWB"3$27$8<!\+4M>'/BB#/:N'R
M1EO?-<V@ )WBH7<K>F&<B1_T;62S-)8UGY9=?(=O9=N*[[MM929N2Q6MQV1;
MMMP&695>8)*>B))1N]C4&L\<C)UWCYN!5"*/"&L_9.?QTO/PQ3Y(X961OM6Q
MLDI%,89'2/C:T$=X26/)B&\48>.PJB[N[&^AY5N,C?B>YVO9-O<YSH8VO:UC
M'N<-6$%P#:N;[PIJ0K0V!D2ZF_2]!CCBXX)_MHL#K+3#?<W$1T<_R1:]M;6)
M2+LFY;%89&QO9EX6?=,_MBN&783*[F-:RL/&SCQOYNF_;N!!8G17F'@=ST^\
MNCMS\W+366IJ(GFY:9A+)%))'(QMPT.B:'EDCXVFKF.8=IYIF4NQRX+&"=YQ
M+,HXR1@N=&(CL+=S YM8W$.);5H<1Q!U6;>5=O;#"US].EU<N>,*[I.FW);Q
M]PEVWA=#;&ZMA[+\;QF8+7QW<6)</R3:[\BYFL22V[V1=2DR6WW;V;>L(EX\
MD(QTL#QFH!/-,=FG9>'F*.UM[O&^(XPEM&UAD$N0D^'=.R6Y CAMY1=2M[OO
M&MB:7M;!(QNQ[*]HV*&V^R+7)WS[CD@W\SY0QA%O$)&L+&!CY'Q.8';]I+J-
M)>TFH*P]O*/N:ZNEU9V5[A1;S6)<(]:=U X OB<\\DCXRVP@5\F\;PUQNS.$
MK;P]Z;<C93E<E:&>M&Z9M/-VVG:60@M?%6:P@=LO[SE)K[IC0&B:[#P&O>T4
MWSB*O$5#'&FCG+17%U#/R6P/8XV]OGR8)"&DLMBW5FX@D-W 4 =L)XC1JO\
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M6VQG-5WW[70P7>V 6SF,FEA=,6M,)#7!L!.S>[:6-8= 26@V:PL:<N1AU?\
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ME#UB@ 6/2^1-X1G:OL1@F)0;"H/E/;M8B<0 ?$W0T#0:,@Y*8PB3O'R'IWD
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M+ZU;'RSTX-Q5_1K_ #9L5ODN+;1N)V^1;?VM;=GP**X4N^!.[7(L_0CX!$K
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ME@8*,CA:9F@DGO"[<Y_C$.=OA:Y::YB<;&WE$5(KAT4D='%OU3S!(*DU<7N
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MN:T-K1SJ#=3BL@I2UK&MM((Z8D[@F>8"BJYN"76 _,8/*(H1 Z#8!#40$ *
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M.<=.3\!_4&_ZOM0J.E5#@5LCJ52E$7$QBD*8YS 4I0$QC&$ *4I0U$PB/
M HBQ89;OL1SCQXUM68:W$5A)/HM=5F_9D,9U'.E&;KN4%%.]51!=$P%/H &
M-0X5YIE?$W%XV^?9"&60,-"X4 J.-*ZGRK3'.6(D,0<.\#B*$@'3J"KE+/\
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M,_U7^@*D\EV!X2/'F"ZQZ3>3R_T6Z=,/%WF-CFXZ=H\EW)^&H_IECO\ 6?Z
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MTU:X*R-T8G5DG:TC.0<I(KJ:F,X]-U79^.NFBB=P:Z?4JZ.5<#'_  [6-O8
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M\?.IYX(%U[>-5-BC;HV@",[I@+8X6M;T"E/F4=Z.V%'F*1U,IM#C]:*DJHL
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MF2L=.7F);AQ_&(W&VDFN(\82S.3 '2$::'FTK\LF\F!8I89 %0,U(T=@NDF
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M)NW3!R/G#$7A2 <"E.J!==.8>VO),GC+:P#G0RU8'4 (U/:N%O+*.W<7,DW
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M?F4 XLW([D!]DI*W #P]]<T*(B(^,#.N-"^AJXT/E'TJ]'G,.XTAAG/D@?\
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M@1MAL9'=6L8]6]3]*S;:Y.9:_7#GG !$J+*2 #>+05D$"_Y:G?&#Q6+\?FN
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M*-#F_A&J2SIT]7T*W]G85[AN9=U_6E'R$*%3=W^\YO.9ZS0 .//YO:J(&\/
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M<LR.#1[]8&:3%-R4ACHB\YDQ!4$S!UG)MA99',&*Y:V39 ][6.U:YXH&@CI
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M8OS6^A5-%8VQY!Z##6)9T4(#P-'VU#M#AIV:'09D,&GKU<$40X-:/,%70#@
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M##V<=(Q *C7I&BF/?'[5W-&X?H@M^5Q40SN*]'(ZL<8SYPUT ?8QJ0./A\M
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M>CDT] Y0Y0:QZ0ZE+P :E*E7&101;)E1;HI-TB_6I(ID22+P#ZTA *4 X>
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MTL,JH)B4[W&IU!#0#J&?*\@CPY@ 6W$0[:#PQSO3=0>@K F^^%RI,=8,F!U
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M5;K]/,H;;L"9(OCN6#;TSOW#V/+PNOS>+#2,0](KAMV1E^YC@#1 O?<J(?6
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FOFWG/F.0^Y[GY>3SSV0Y?0/SCS/SC^J<O=^<><<>Z[C[-1%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tv498959_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv498959_img2.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M P,# P,# __  !$( /0#KP,!$0 "$0$#$0'_Q #Z    !@,! 0$
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M^[<WTCQ6WE)Z&R2(NME_FWZF*=-%-1J85%'&.@Z3U_IW6W/3K#/2[O$C)GS
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M!G**WC7EE%&264Y5KC*ZMUO8]$KC;U"<H0D6# R]RW>B^6>J>8)SKZ57&R<
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MO\B>9&?\N&^_#\248?=;^X+G4O'Y*N@[*.)_D;SP/X#>UQ(>=O+QROE^Y/\
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M_A3_ .2O,!__ &X_?A^)&']TW[AZ-=3^2+H,!4C_ *H\Y\1F1_RAA?YS\O\
M_'/[D_PI_P#)/F'_ ,<?OP_$B-U[JSW"5E'XMQY)^@T: %J_R/YV;("IR6^/
M9BR/F_H4Y1A&XZI%AW9_8JK/)_7:P93H  '].'XDUW]V[^[Y)(\3>33H2'C)
M5A_(;G_)@2"*^TT[,=%38+ZXVU%X3R7/W;>6WME3:&LAF.2_1[MS]WR(J/)I
MT(I6E?Y#<_>BO_RG%C3<CDJC&(SXKU_Y;/[OI2O_ ',^A%/_ -1^?O@_^583
M32:"_![MK]WT-?\ W,^A&7'_ *#\_>BO_P JPFFF:"]?^6Q^[Z_>9]"/_L'Y
M]_\ JK"::7<1:]]W'^[W;?9W5_=>37H3':V5M/=W$@Y%Z@.4@MXVEE<(ER6<
MJBDT )/9A-).(Q. "UJ\U=4OW0KDSF3F/E/F#H%TBM=[Y4WK<>7][MH^A76Z
MX2VW3:KJ2SO8$GBLVBF6.>(@,I*L,P:8 LZA17(QD9."V2V*N@;^ZL6UPB8$
M C$9%%-HZO\ [H#OEP+7;>@O2.:<AB%/0?K@@HHU'O-8A<A@6_KFQVXU6RD!
MZ"BZ/*?5]R6IKB3]X#WJQ'*_3G]UHYP6%MA\LG1>Y%Q$LT7B=(.KUOJ1R0I(
MFA0BM.W&1;YZ\O4'3;=,'[DOL6O5\MO-=XU5;>$A_P!2'UR4KV?E._=JK](7
MMO*=T/=9Z>%7IGU0357U,12F*#\P_*XSW$OW)_8K3\K_ #B,]K'_ +E?XDM)
MY+?W;Z053RC]##4T_HYZE#LKVN..&_U#\K?^1+_MS_"HCY9>;SEM8_\ <K_$
MEFT\A_[NE?!#;>4#H7()!5?]'W49:BM/KI1VX1^8GE88'<2_[<_PJ!^6WFV)
MTG:Q?_J5_B2Y#[NS]WHN #%Y..A+:C0?]!.H S]&=P ,./F'Y6/_ .XE_P!N
M?X56?EUYKB6.U#_]2O\ $CP]VW^[YGAY,^A/_P!@W/W_ -58F//_ )8EEN)?
MN3_"JS\O_-$<]L/^Y7^)9%]VK^[[N R^3+H00U*?]!^?1Q-.VZ';AC\P?*X.
MD[B3_<G^%2_T]\T_^,/^Y7^)>![MG]WU9WC'DSZ$%D;0P'(_/V3=HK[53+$?
M]0_*SD?F98?U)_A3_P"G?FHC4-J&_P"I7^)>V]VM^[[K0'R9="*FM!_(CGT\
M,S_\:Q9_G_RQ_P"1+]R?X5'_ $]\T_\ C#]^O\2])[M3]WX<@+Y,>A!U</\
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M<2R&-9C4)0YLF)/<$1M+HEC$3#QE$!J7D8KK2J$:*U&"MIOQ*,JP/H6GX$B
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MIQ1F>(7R[@UJ S1&/;[>[+S2,1* (WC/&F8P9#'<PJK#DG!EE[F0JV5E\BP
MQ/)3?SARD+:+GS;Q&ZKML>[VYAU B-WLF,?AC36C/2O;B.XB;:;:\Y S!0VQ
MLC*RF?\ 28^EU G0'FF#;>=-MBO[B-K.\V>]LKF*0L5DN;>..1%EHRT8&I';
M48YW8;EFUY@-[LTW6]O,$&K"3_6KN=-><-TV?K-L4B,OV,N)[GE7=$N8P\)L
M;N&>,U61Q&)$9XZ/\K++'KGD#?3V?6J(F3;>1(/(Z@%Q?F_IL-]Y;NG3%]S
MB8_]./VJRV^3;%L.[[QO7.7-<'*')T5S//86,.]36;;[H433R6]E"TMQ+\]/
M"&">&>]CZ6J-,&NG(1VY8YY^A>"6&R<177#Q-SD2SZ2.#X<NU<@?,W,=AS%Y
MC>NM[M,S/9?SF<Z-M\AU$-9R<Q[M+#J,K22:S!(I[QK\>.3Z^83D)U8U\_6L
M?8ZHWV1L86:C@M@?3!XI[+;O#,9C,3+(@ R<!:JU,P*TKCEA.,ILMT@P&*L%
M!;0BP<"7PA(LBUB;YP$"E8P U!GVX)$'CAFGE:'#IG[UN4T%A)K<D@Q^"\P"
MLX#A6(J5+$J:X.VX+][-4[B<1$2CFJQ<USJ^ZR3EUD"1I5 2#(2K5&16OSC5
M.8X8TH1$(^)V+&LM\2?A%3/T?V(7.UINI4QSK=2M"5)4T ?3J!5M?=("U)P+
M&6N1)S$EL[24:ZA#F,E*&_PR7#P21%Y/"=H&FGRTHP9O#!(R-4&1SP-N(@'4
MCMO9*$BQ"L-T_M;5=NB\=H/#"R!O:'+W# *BLH #.7"@E:"@I@K;V4:1K+%"
M[RV=@,1FG][?&QGM-MT):P)'&S!55A*:JKL9"&-9%[P44IV9XE9N(SF8U_"$
M#&B41&9'>*(21;I!(#8PQU?.98E5UD;O%G>N?=!! R&!+IR#:<N**JB9S:;,
M$ZMHVV$6B75TB>TTE=.\'AAE92BR.J%D(-:5[P%?CP739 5^)+%E&XS\3PX@
M".'I2WR?[=9WK?9*VL%<S TCB#/'&T;+JS[H9NRA) 'P8+V]F.I^ZZKWT82I
M:M]0"GK;Y;1"T4T4<<+PVZ5A ,DDD7BM_C'9@90:$G*HKQQN1MA-B N6L,Y1
M9W2SME]MQN',Z0*TZR0!)AKUW#(%I*I=E4R,IH104/9A5W4SL+$99)KJ;HTZ
M@[ XJ-^IG3JRY@L)9$L[:7>K:SG?:+^!BDB7,;),D7C*NCPP\0%&'UQ]. MW
MLXWU2C,:BV!3[/?6TVQTR:+C!0STXYQN[>ZN]OWMIK>>V/@3I)!FLL2F*4%B
M25^<3(B@/IQPL)3V5QC(''UKL;80W50,&U#-6$EM[^Y]CO=N_P JV]BB]^K2
M$2:ZHYH P2H/$XCO3N+*Q.O%V5VSMHK_ (=KB8='GVP!F\01_-N"L6K42**Q
M 55S8DY9U!QG3@82_B$:D?7<".X#IXED3-LDQ:,5<T4F-R#*C:LB@IJ"D U^
M#%'BFR1@/C'#BK)5B+2_8*+;5;02-,;N%#<6MS,D3 5?V>.CH3Q!:C=N#-L/
M$@9R#RBZIN$JY1$#W)=O->KRUDN4D"1M)+*C1H^E0$5@%85ID&6N?IP'893,
MO1]2.KTUPB_]+/UJ.YK=HH)H'D76'C151L@BDZM60^N4 '&?"4S7I'Q#@CY!
M['R/-1AO&W&.]N69-,4L021":DR, 0%K4Z2:"@RP(2!,QD.Z1]*T@281;X@H
MCYBVVV@VNZM5TJS12%DUEPJ'2S N=14L*T /'&/=",(RKADM.BR9L$CS5<%=
MH)9XY(")B[-"I-0L:,5)&E\@0>!SP!5881(F"SK0MKU99HI=SP66UW;12 NZ
MRZ$-6=VD0D,6<#+X\L%ZAX;<^:S_ />J"MZFN)=N:6+6WA1S-)5%H6U#2H#?
M*K3!.P@(R]:'W\GCVLE[I+#/N_,-MJA5UB@F.F4::'PJ $'T5_AQJ6:K=Q$9
MLZS!*-.WD>T+<%R]9P[_ ,X<H\J[<3-;;-M>W[G=P!@8XY[*V:6:1W(8,([B
M0, /53'<]-H&YZM7M\#313KER<1^TKS7<W3VW3[=Q)Q;;<1'F1*6 'J7<MM(
MIM6V#T;?9_YM'CK\\5Q9S3=ZC9]/>>QZ>3>9_P#^R7V$G&87PF+#E[=N9^:9
M-CV2QGW'<MPWJ:T@@MT9WUW.YFWC9J A$,LH!8Y"N(7[FG:T&ZV0C  XGL#X
M*>TVE^^W%>WV\3*R4@,. ) ^M=8'E/\ +7RMTFY'V&VVSERULMX_D]8C=;O4
MD]]?;@YEN+EY[KPU>6D]P]*D!0:#'SCY@ZMNNJ[N5ELR:-9,1D&X8+ZT\N=$
MV/2-G"BF A(5@2;,G//TDJ2NI7*,DDDS&S%!$SN&.DT5E("  KEI[#C $R,E
MT-O>BW+W**N795M9?"""+0P(UJ<F9U/<(.;4Q;J)CWABZ&)&#*RW+VY@QQQS
M2H0D2D%A1@V9*D_7 C Y/=/!%&.H.$]HI)Y6BFMA2.O?*$KJTG(YL/1E@=ID
ML#@I0BV."E3EK<)88W,DZC00P)X\2:4X$Y8<QB"[AU9H-CJPG*W,<326YAN
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MZS<JPE#+K*MD:$ D4)I6M!BV);!5!N.:,1N'(9F!?Q74TX4)X@5]>)J0R=*
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MO#C.D$BK'CVG'E]D)572C+)UV]=NO;B8S96>6YO$MFFBAD\(PY.M%"N5*MQ
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M/RGUG:[><<)SS>)RRP3GO>9MKOYH[C;]X@N8"K^)!8W ==,GSB*9(V4+0 5
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MN%[TSZ_[US1M^V6\7)_4A&YJV.YM8YC%;WDTL,.]V=QKDD*W,6XOK.84K*I
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M[H7@$'HP)N+YUTQJ!>6E_2Z.Z;MQ=N/$F!A)AV<$WMM>SW*U#3:B7D/BHO\
MC=(1'34PU,J"0CM&>+MG?M]Q1I.>'N5G4J[>GW Q!$6/;Q4;WSVTD]_: 2^%
M$SJ\E #%,I3,MF5<(13+A3%T1"8-(^%\_P!:J,I^''<2^*38</8J^\]6L[75
MZ+=E-L86M_G7T-(CJJR,!W=5#(23Z,6?"/"X,CZ+>Y S82!^M>.4HX8+67:K
M)HB0L'B2J6U!T6@'B@4TE4:OQ8"-;'P8#N/](4]S;JL\6S+T)R[G-&H>"$L)
MVEB29JUB9VTAM+DD]X$5!P<0Q CDRS:SWW_8X!0EU!N;SVIK&)R8EL4\=0RB
M(M([U#D'O (@H.-<3E41; 1XCVHZF=9IE.1Q!5/^?-[\"Y$$]T!&/$:H;_%@
M2.JH2"2@%,AC8IILK&DA"76ZRMAWD%W!6Z*6%TY,MEN&Z<T7DK*H9K@R;C6$
ML?E>&-"U'#NX%HCHNLC,!F+H3K!%IKT'$1BWTY)S<R[G9V'6G8YH652]Q=/\
MG-@\4ITN% - KT X8'Z>U?4)2A\.KZD3N82LZ.TQWA$>\+77YC);4\R[G-1#
M6\OIH5/?)2?=WT>(#J.L1JV1J1@*Z6O=2D1D_O*5^BO;P$OA('N4.^9*^WO=
MO)->7FUN/9[7F"YVR-H#2;1:[AN=W+'H!8T]B!U&F>8QV_E(1/5(B?PN?<%Y
MIYEN-73K/".)]SJGWE7Z[<S<@6_+VPCFS=-KV"^N[<;E MS<)#;I-&Z2/$OB
MJ(=+RDO0''LNUW-FUL_A2(J!X9+RQJ95@2^.9+^U:\^O$S+UJZF75ONHW4R<
M]<USQ[JD[3&[6;?+XK<&5TC:0S@ZJD9ZL>DB?BUPF[G0%Y1N("K<VP P%DO>
M5LQ\K?/D&Z<O<LK<WBO,MM*CLRT*S1(L>ER"1J#Y4QYUU:L[?=3$@T2775]-
MN\;:QCG,+8CMMS/?;03',@B<$#7W XH*Z<J!:C+&9382'SQ1,YQA/O9J(.I+
M2G9;:12D36MVR:I2H^;>)P.)(.:]F.FV< (XE@RQ-[('+/\ 6M<ECS+N\TTP
MBO7)CNKI50-\SH\5UT^&I)!J:\,&PZ=&_O2#Q)7<;#?0VU<(1+2 '#'(*4MG
MYUY@VR*QDCO)U191[1<QJXMXY05,25.@DQZP&J",^W!L.E;< :0TAVKHZ.JP
MLCHM+D#B%8'9N84OA#?<P7<\DJ)XA$8)BE,R)5 2"P.IV;BOR?BQJT[*NHNV
M+)I]4E.!JH8#T,GFDNSZQ<6DUTK>.L$DBT >+Q?%@F4E=0%-&>1J,7#;T:R9
M#%$T7V>'_$(?ADG=<7O(5EM\=WNMN]SN$T(,MT]Q.9_&1BL<B11W4<;,591\
MDUIPQ9';4CX8DDJHSW\[N[9&-(^GZ$V4WC9]VNXX-@L+^5HP[>!/!<(JJ 0C
M^+*X.K37,MGBR-4CW8P3[F!C#5*4B3R_4$MQR63NMG?6FX1.89'D^9DDB&F)
MB1XD?BBH ^#$;.FR()E#/V(6,[(C57J?GQ46[P=XCNWFY5DG%K;HIIX$\;^*
M0.]WH4U,#6GP8SK.B1L+QKTGV%/;U*^H:92./TI*OO,+UUZ7[.^]65GOF]6Q
MNX[);>+9KC=V4LM$D:V$D;HH3Z[A@#<]!W%,19MR=3\3]J!OOV>]CHW-1E)O
MV8X_0I:Z8>;7K#SEO&V1'I+U%N&O8A#-N$/)XAVQ9M*"OCS[P!&4<BN5*=F,
MT].W@EJ,HDMP(^Q8OY3:F)J%-\(@_M!AZ5<>+FKJ&FVW5[NG)N];;>02*B7%
M[8P06\3N4"2NHOC6)-:DD TQE]0Z%U"5,K8"$F&/>#^Q!6RV.WNA69X\AB/<
MKA]*]Q;=XGAD?2ES8QM</'\V_ML444K %B=41U-P!!QRNR>-\]O,]TQ^D%0W
MWA:8V1)($N/:K,=(8(YO8A)"'\ 2Q5TT=H4:,U4FE7S-,^.>-/H<R;=!!8.@
M^K%@2#WBS*5MYL(6N%$,(5D#L'6L6EM"%!;J:2*S,*/1?7EQQH[L0,S&O,(7
M82G&DGM33W6."QLA[''X<CD"=IBSRF<%3.0"S%4.5,AVXYKJ9 I>KXR<5T>P
MU6W?Q T0,$T[.=&O]OMY%\1SN"3R$#4'D0-I!?Y/%1D<3Z=(>+4YP$_J16]!
M&WLFV)@0G-O,=L(S<Q*$E=2)=- ND,$JL:=P]PGTXT.HVP$6K88<$'TT6R+6
M\#Q]"AW?;CVN1(+8O',@=EFTM$BQ!PA4R   OZ.)QR>[G*V8JJ<3;C^M=?LX
M"N,M04+\U6,O>D@GD:[@:)A LA-MW'+%WU+E(:UK48RK=MN(3$HR<AN/M6A7
M=48^$8]P\640<WW4D*II)241.2& 9E)*:DKZQ_'AMS;*(8'$A6;2$'X,ZK7S
M!KFW#,G2"SU*D++J:4 BH;4 ":?#@&<)&8/!BCZ[(Z= .+I&W0R^QH%J NAR
M32K,')*Y?64[!AS;+P14/B]""L:4R>"@?J5%,T;$ZF46S.[C457O)]?2H!TT
M-<$[>,XS:67ZE$FN=;@E*/32Y&V;3+-<2JC3F!5()8>&(8RH )H&S-?5@NFK
MQKFX*NV6BDF6!6\_I-&T70C9WMT8&6SA<,V2%);JW/?X4!7'H^_)AT>R-7"
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M/B8D=U-$VC1V-G(X(9R*2.I96/@@F@-1F>'PXM$9"(.959F/%(.3?6FKO%P
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M,&SKN%PU$# \1QQY#;<)'#F5]![6J4(MQ3BGN6BE$E2E6H6  ;,>CZ[&7?\
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MZ;OK-G=%A&1]CX?0B:MD.]D> ->WMSX4IC1Q=8UAC*0 XKTDA66#2V0N;84
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M@MI'0R,S33)HUL93 FM(U*!V/#@:8Y^KI,($B<=/UKV^OSW3O:A';^&*AP?
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M9?$EZVL5B5 J%CFFK,$UJ=).>53Q]6)1B1AP4-0!>.24X;)*4I)JI4JU>.9
M%,RN>)ER&3.#BOV:(1A2<S4J*&E*9T^+"3QL(P"3IQ3Q-/8,@>)[>%,Q7"2*
M:][:O*E*K6C-4AJZ203I ^##%\U.N,9@NH[WO;02$8:2I)UT-6S.0'#.N(F(
M.)48#PYZ#DH#YYV5;F"]@D'^,CH&76 #1]/P\/X<$=/WLMENJ[(#^7-T)OMI
M#=[:S;SRLB8^U5$OK1]NNI+64.70(P=@55@ZURJ 2.ROIQ]-= ZG7U;8?GHD
M"0DS8+YOZYTBSHO4?R4B368N),46C<F2*O=I<VIX#,&= *5QMG!8\<<5N/\
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MY4U44()90HK7A7&5<_B>&,"^:LVOB2I%A+P=1,H\*Y),4ABE=VN)B@5D50]
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M!:%30  U[<\$4 2)A+(<4+NWC$$<E'/4'F*-5#13:51C1\O##>(4)J10%LJ
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MDAF]X7@_S#Z!5TVRK=[ 2E5=*6H<(R=_K;V+;K[P7_Q/^Y/SK_[\_-6?I_\
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MZF+G;%/V%/JRW,YC)2%":F:F0^N45KB0D_Q!D,6X.G'!='YHZPHDJS4IE2I
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MQ3$&8"@(5@/2.!KV^C ELP0RV*:@0"<&2-N.SI#'66!=,M1WU-%[ORZ'(#+
MH(Q#H@U53.(Q91%S!RO*$D=(@PU%@50TH ""6/'!--FE@3P6==2"\HX ?HR:
MEC:3V<PUDQJ)!J(7O#( -Q!HI_@P2091<<D#CJ<# *QW)&[^$._(TC,L* $
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MJ9^_6,<\4TJ(OC0A&,M:,*-5NW,C5B5+1+'-T\I0TL<T>Y0G%LZI-(6#2QL
M.-0I&H5J .'U,6S^A"X&3A6FY8W.X2CI,%'=5@"M" @IF :T)'JP)$L<51?
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M3&/] D>Y+6V/KLX7.9=(V->!K&A[>W'3;/"D/^F"RK@7'-D? 'HJ:TR' 8,
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MW?X,L>!WZC9,')U]&;4AH\Q]*DF*!)8Q$ '1U'?%*ZN.D&N= !@";'U+9KD
MT<W1.ZV^"14CGC22LE-+*& J* @UJ,FP$6X8*YDR]\V:!8I:Q@1U*D*,@12H
M J?1B4)EQC@H2A&0+J']VVN"*X<I&P$@H 5.5>!/H%3Z,:-=ID-(X!9ML(B6
M XIU\J,(2PT@.FA5/R_DE*,*9#A@6<8N_%&48%6.Y6WB2*:%'DK50D:ZSIU'
M54AA50*'^#&;,%\2V*TX 3S^%E8/ES>[F..(*X"ZU5P66K9?WX(X ^G$&+8E
M*=$,^#*9]LWKVC3&)4J IR.03(4_APV "SYU 2P<J0=DW:1;AEE9"BJ=%7/U
MNJFFAJO]W$]>*HE'2,,4^;7?W:D23HOUI!XD 58#40*BOIPX)(*H,0>],-V)
MTVN\,P\-90*%134:,HH!G0#C\.'$CZE4*XC$!+T&Z,K +(%*"NH'/+ZVHJ "
M<O3B0)&2@:X$8A+UGO3J(W,]!JH5U:C49?X1S.+1:0,<TTJ@0P2];[Y(A#37
M!MAW0';4":D95(&66"82)Q."%,!,,,TZ[?>9)"Z+=K%&5%"B@LY'#O,*YD8*
MA80 Q"I%0!)(.*7[#<YV1>^D]&T$L14T-1J"GLQ:+3+/-0E'3EDG!%NL$*UA
MH'>GB9U8/P8*NG@>W%D;'54B0&X)7UEH5G9C&QK(0T@49 DZ1D*G%@*9@2Z+
MF:[?1<P:/"C[DKE02RJ M:DK0D$T(&)'+-2C+%@,$E[@[R(0K%(]0+.Y[[$5
MTCO$,5''U8CBIMW=29^YVVJVF8N8XUADTL *LV@US!!/;BV@/? <YQ]ZIOD(
MT6$C]B7N57-Q4?9+<JMJI>W(4UH2/&<$D'/,8^D^EDCIE$1_P8?V0OFKJG_Y
M*\G FZ?]HHJQ556B)4CC7T#M%>)QH@2(Q)6?I&162.4LRU(7NDM3.M *5PA$
MQXX).<&R1H$@ CO#CF<J9'LQ(!0\/5+4>"RAJG@5'H'I]/#L.%D2G8QF(NX9
M5[\T]A[1T?W6]"U?9MUV?<8BGRA6[6T<FAU %+D@G/CCBO/&UCN/+]\B"\90
M(]6:[WY:W_E/-NW ^&R,@?9@M?'+F]OX< 65:47Q-=.X>\=-6 .0(Q\U[JJ-
M<R &7UOM3&>>;J7]JW(.S-)*H+1(\94C,5S%:'@&P#)Y89(^=3!P4=W2=?9V
M9 @32IDE;Y+BAK6M!0X&,B+@.U#R&HND?:+N-)PY-%615U(2452#WB &H 3Z
M<%R'$9J$(!V)5AN6K^BR.I$@(C(4M0"JT+@&A *_%@70TM+I[8"<6.2L'LFX
M:T@D *@@'N,50$JH^4,@V>)Q.@Z/I6/;#3(P.2E#:]T9@BR,%,>:-J+ 4!9M
M9S!6@Q<Y![$'95$8,Y*>=AN\IC<%E"]W05.;4IPH,Q3ABV-L@,,%7"$':6 3
MAM>97DB2'1%&&% X#Z@.%=60U'!$+L&*HG&()X@+.^Y2(RQP RF4 ^(S$-&?
M2 0*@U.+?$#/Q31#Y9)P;?=RR,%N9_FPNHR5S4T%%H*BM<2\>(&(<*,ZHE.&
M7>Q# D=O<3-(U(PH9EJ6J"5!0G*F#(6@1!=NQ5FO#!"#=9@R>.\C$,"@S! .
M=254FH;,G(XEXDM0(/=XJ+1&$LPGE8[@9 !++&V0 T1Z6X5'?)-%%?CQ;K#L
M^*IL .&2*W]N\K:K:)7?6K%59B@T$L6SD"ZA3/TXF)<T.:VQS*)S+/(#[1&:
MN#I\%T2-:< -(8*Q^'".,2EXLGTD)%O;&,4326B8U8, 64C/CD,_4*8#=L%;
M&<H?!FFEN>WHZOX)8QD*II33J4?)% #D13%>CD417;*9:3)BW-J07C>-::00
M,EJ/E5R/"N)"PLGM R!3:O 96C3O($N+=1PHP$ZTH32ARPG(:<<"2$/*!@,3
MF#[E;WWAO_BF]RM_7LYN_(G\S/P8^IZ/Y,?N#W!?)U_\X_>*^2/Y'OZ9^=?Z
MH'O"?R!?,MB:BK_]6?[2/U+_ -=]SE^7CN6$DNZCE05_=_/>KCT]0??$C\97
MS!8>6?L489'UKY9B#NK_ (*_Q##A0;%U^G#J)&*]IQ&'CFZE%&HY7B>.9208
M9%D0@T97C(9<U(8'4..'D 08GB%9"1A(2CF"#[%OK\E'-L7.O+B7S0^');I:
M6<ZU9F:XAVNU>1RTAJU6F.?$X\W\T[>.V,1F&^M>]>0-[+?QE.?Q@X_NK?5T
MDW%+3;=O8O(6>0QE4!^8D=XE%,QJ&781QQYCN*91D9!L2O>Z@;*A#@ K=\L;
MIXLBV3A8UFDA83,&+C7J*N0#EWAPSQ';F4;HD.55N(Q%1LF>\!P4P1B&SU+<
MLY5U18VB7-YG#L^HFI"HD.1IQ;&V]LBT@.QECBCQAIJDT\W/N1O:I9WFAC(E
M-NR$NX=49M$O==UUO6164"M#D,650N@7_937U0C5J'%/.ULQ=7"+0%XV#*[4
M*Z6&M2<JO4J1V9BN)GOSTP $RL\G3 NC=[8%\IVB2*:LBR@,S*0P(CTZ2V0K
MGZ\0G(Q+L!P3PEI..)9TU[F=[(!08G1D \!RY@FB?4%E "Y2.@%:CTX!NM\.
M)E5WID9' $(J,-0'B=V XC,) .\6\B7$(I!X3,;EE4HQ$3,ZI%I#:0-)4<<L
M8PW$+G +2!+CZNUE?9M[1I(R(P/,<TR]SWT!9)Y(E"M(" M6DD5BU-8R%!7*
MIXUP)9=$52C:!I)P;XEI4TEXA\0D#=MV@DLWCA5O$C".KRG,K32(V/82A^#/
M&;=/1#1%R.W-.*?#L<GBJV<[W"K>37"T5VAFD%N03"&BJ9 Q%:B0>K/$:A,U
M9HN!B+!@H4V3>KC<;\6ME9H\LYD:LDGAA$A&N1RU34$LHX9GX,65>)$ZX@%:
M$CJB2<@EWF">TB24P51?$C4R"B7)G%"4[JE?!U#M/#!%A$R0,)DH*$9!ISQB
M%"O,%Q:UN;JXENC':K+I52"SR.BAE8MPTY4-*9G#[>GO]XN5*4WCV%52YUW^
MW20RO:NS &**-"ORVE8T:H )"J36H%<:,(B&)0TS(X!0#?6TK3+/(VJ:2($0
ML28U64M(:DU^=4$^K%T,\%FV F;G)33T\VAX["SF9(T22X6:2A4.HR44HO"B
MUIQ%<0E$Z@.U/41$EU;?DS;0]Q<WE-"V\2)"#I-1(<SDIH2OP<,4WM@/VEI1
M]ZLSL\<UMN&TO!''-+KA>1G;2J05+E$RJ2 !ZL9EAM ;#6#FKH0K\"<'.15B
M^2889MSEF>9?:/'6=&\-I##++ _S89@"0B*H!!XX'JB;MR<GB']H/V+&WL_!
MH;@?M3^WAE:/3!X@>1M<I)530'(U5AK74<NVN"IURA  #O%#;=Y3>1!B F=S
M'=6]MMT\K,YD$$<5'!*-(5X$+GI910#%)G$0U2^,8(JJDSMU JB/6[<XP+ZY
M8:1]C98T0 D.QI&M.)T:F -<%[4RLL$A\(1MT&IE%\ %K]Z+;-!M?,7.O,SQ
MQW1Y=* 6Y11XU]ND]Y9H [(=*Q0F1B1Z *YXVNIRF8PJB6,ERE,#*R4AP*U4
M]8GW*VY-YGY9W5H7EW#GK>^:K:=7EFF%_/NFX2QV\I?4H1H$*Z@:BHQZ9T.8
MMNJMK#5QK$&] S9>4>8J? A?MYXRE<9#TDK7Q>Q2M:\QLQ1&CN+=I(:&OB&5
M0Y0\,U )QW\2!* 7D6XKD#N#DT\1ZT>VO_B,%>(CCX#+_%+CIML/X0;G]2Q[
M#CV,E(9]OPCTX-B,$-+/Z%^]F?H] I\&)@8*!.*] T](X9U]?'XL2!90(<>A
M2;T<YG_DCU'Y8WF1IO 6^%K<K [*S178,%2 RZPCL&(/HPC4+08/F%"<M(U
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MLJ*^K02*MJ*ZN-6KPQCFRR0U.66EH@#I R":E]O:( G>HP#2LI;56HTT&1S
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MD.F)/?00EP9#$&4MW@0#0$$$BM0/7EGB1=#F)!3 O-RLVFA+*K.+J,"4A?\
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MM[3:);R>/&BQZK>CS54?.%%5H!0@TRIB49#XHLX6;J,^Z<REZTMQ(P<QD@$
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MY>76?'+TE&=W_P"2=T_YNO?\VEQ:,U!<5Q?5/<G0%I<W+ =H_P H?A7CV8.
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MH'93+&-9'5+L)6BQ=QFF/S&6%PMU$TBAAJ:A)!HRJS=ZA%5XXNK'A]W@559
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M=47B<'9-"<Y6$'-1?S S[T!M<$8$]XR0:<HQK)<O1ZLJ1+QH:\/7@O;:IR8
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M*!=)D>1P0,P<B.W%VWD-$:QF[K.MKUG5P4R;3)'<6HN$7PHI/$4*^9'AZM1
M7U</7C7JE*RHV9!9NX_AS$,RF[NDZNO"2I<D9J 14^L '/ /\V;' J_&H:B<
M"JH]165[UT)_Q<EH\A S.BY#A":9J6I7U8S; Q(Y(^H]T2(P/UKOIY<SY>V$
M\/\ U-M>7H_R&#'J5?\ +C]T>Y>93^,^DK/O.6T;J?\ ^6WW^:RXFHKBC#KX
MMR>]_P 9N2"2,J3R"GJQH(99M15:A@0RT-0> I]2M,)+TK.DQ4*",CD2#]6H
M[>.%VIUGCD'=));.E&%:&HIG6A!I\6'RP5<@265:?,SR9]FN4!S78"-;SE=Y
MI]QA*(C7>V70@AN")2NJ26U:%"JLU"M>VF..\W=,&YZ=+=P/\2HZB.S+/L7=
M>1NJ#8=4&VM),+QI&>!&*UNWMDDSK=VMP8RR>*8"M%8D_))! H,\>';F.DMF
M,5[[MI"<-4<DD7>Y&U5$EU!CJ(,;,*#MJ,N]Z\ 3B<QBM*%IBT6Q**/O4GAA
M@ P4:JDMJ('#62Q8D<,#SBX1H=-S<-\>59R58,1334T[,U[V0P-(1&(.*<]^
M2CMC<SEA$_RBSLQ8@@GMX]E>&"(V1 ]*:ROD73BV&4B6C,3(J,*9BL@U5J>P
M5&6+HR$0QR0VH ZAD,U(6W[A/$BZSIHQ[BEBS Y<=5*D'XL46Q?$9(RN;Q[$
M^K+?$M2>]*58*:%F90:BE%!%, 2AJEAPQ1%1D#W<E(VT[@T\BN:"/0&J=52@
M([P%<B1PQ19!L0M*N<AZ5+^Q;M;Q+:PK+.&)!49T.H5HA! 4#.M<42TY%&T&
M6O%31L;WMR'6-RRZH]09W%":5I5A04/KX8#D#$M%$R\*.$LU.>PQQ1S12&0O
M+$NHJ5^;U"O=J220/33LPP.KTJHM86 9U,6RPR7UJTT,H@*G0"5/AHZBH"Z6
M#$4[<$TXCM=9^X@(VL<U(W*RN S^&3ITBBD:)35"7?50U:GK-#@DUB QQ=9N
MZMC,C3F%*.VZHYH#(J!I-0B1,ZUKDY(H,N&%VH(R8,>">]H_@ U-3(:A<R$&
M==/#3QQ97'OC@70LCJ?2E<W;B1/"%4"4D<,5%1F*IQ;/&E%HD%#&.ON\5ZFW
MRUL%/^,,KE1H13J+ 5I7(?PTQ9XD0,U6-M,3,C\ 3#YFYMALT\>\>6VA*-)I
M5F:4A6 .HJ66CD]E>.+(3!@0YQ4J]KXD^[B257OG/K+:V=L6GB>UM@V0MVF\
M66CD*S  *..!Q8:@W%:\-D -3K4%YL/>;=-^CTEKL5I:;KOO->Y;_:[/8;#;
M+=VT0FEDL@\U]N#A;=((DN58A-18FE,=3Y?\M;_JV[KN@1#;@ZB7X8\.TKE_
M-'FS8>7]E.%@,]R>[&+<3Q?UK;AT5YR?GWHWTKYU>T%D_-W('*_,4EGXGBBU
M;=MJMKLP>*U&D,7B4)/&F/H'8T?E-G7MY'5*, '] 7S-U'=#?[VS=@:==DI-
M]XJ5M:A0,Q0@5IQIV]M<L%]B $9.X2K%)K(I75I!R/HIB*NTE&" Q# T(R(
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MD\SBC[=8(;J*W9]U$2/"LLH\-J>)*6<2,]7"5-*U8#+ =^QG9,#3G]*M'4*
M"3,)C[_UFM8HVBO=Y57(K&(F050/_C&/BACJ(H/3BN>Q,@:V.7!0_P 3HB'U
MA5XYN\PR;=830C=V^>0M$)HD)"R"0I)%64/H&C*G'.F#-ITDQ$01W5E;WK-6
M)C)E2KGGKI-?S7@FW>5@S.T,\2R:165>ZR&7-ET#(J<SCH-MT^%403$.%S>[
MZJ9S)A)P0G=T%Z(\P=8=YO>8.?=NO#RI8P![-9+CV(WEW>+XL,LD(5]:"&4,
M*Z:,<4;[>1KCI!Q"'KHOL(E(''(?6M@,')FW[:(-MMDM;&SMHHK>SV^.70R4
M 1&954KFO$DXYB[=&R>J18%='3LA7$!D>EY5V^%XA=1H8F8%E$OBR:@5[U5!
M)620Y9D4PWBM)A(Z5+P8C42!V)L[WM4=Y%,EC'!5).X* DC7WF*E6/#@<$U6
MR)($BA#5 $:5&VXW]GRU"RW]B](4/BBUCK2=P[*S@21Y:N)/ 8EJC(N,9)@1
MJP*BO?\ GGVB-XXII(8)D8Q0(O>TU&AF(D<BK 5SS&+A5J#LIQD02'XJ)+[?
M5N05$AJA- 0:N]1J8U8U73Z.W$!%LLT2 #FR=_)>\7^X[IMNTH =JBD$D_<H
MUS<"FM2X+.RCQ*4H!W<#W3:+#)$5B(K9N]P6P[IK9(MC9- #'WT5@  _B%65
M50$ \2!\>,G<AXN,UH[<-5WL2K\<I\KKL^W!YR(KJ^2)YZSDM*RQ1LP4H.[$
MKL2!45KZL4&B.9(?TIH[F5EC $AN2>6WQ/HB>U$(BC#B64T=HV6NK4[54%<@
M :FO9@"1$8O#/WHR^,M/B3+GEV(Y*^N1?%!DE8.L2J:M+2I9I%1A15J"#ED#
MA CPCK'>/%9DG$M4?A1RXD"6T7B32NMN5$DL<FA$!0*L:$E!4-_'BV#$.V*M
MC-Y'0.\W)(*V<]M!>[Z\BV\4=K.MI4@.TTJ:;6,@J6#ZI Y[PR'Q8VJHQC0)
M# LA+K(VSC1$:K-32?(#BJ,]:97N;W<)+F43,MO/).Y8L&=BLCJ"15@ !BJN
M E9XF9!1-U34 0P(BH@\K]Y_ZGZC7$,R*\N\VD4; T"J)/$T>KNXMWLQ*67#
MZT'M9-%AF"I@.VO<<S<Q74UN&C-E/&"/D,W@6ZJ0.#'4:_#AHDNV+:49X(L@
M9'BF$NQ/'?QL8]$#7<_BJ#1622=U*LNG/(TQ*<B(A\D(*90F0 %S3=>(8K;K
M/U3MXD5(XN?N:T2-10*J;Y>JM!_@KCZM\ND2Z+MWS\&O^Q%?&7FN)AU_=-@/
M&L_]R2BKL]!XC+MH.S+CC?&2YGBOWT'*O;PRR%<NSCA!1/T+\[/13MSX#AGB
M3!1?'M6:,GB:E:4]1(^'@<L61D8M)\ JY $L -2DKD\1V=A>[C-'\D.T3D!O
MD0R*,LJYD?'CENL7>/NXU@X/DCMO$0@_[025M6_WNT7DE_M]W):79\1%DA8@
ME9#5PP![RD'*O;C5C1HJ#@.J92E*T"LEE8[I_P"9CF6PN[:VW2^O6EB$L N[
M>&JO&$588Y7%RA8DBARQS>\\"$R9@!ULUV2C$8EE9O:/-)S!;6Z>T7CO%(]8
MU:UU2&/+0-1N5SJ16IJ:8QY75:SH."TZ;8& !S3\L>NO..]%/8Y]VCA=2&FL
M[29S4 2:F*2S4#@CLQ?IEA+'2RE^9#F/%/ZPZB2PVBC<+[F=[B6KD2V4X5F=
MAI7Q#$I)I7MQ?*-<8#^DJQ999/"8$4K;3S1L^\7<$%]'O$?M4@BC\>W>)0<P
MY>8LWAJ0!G48JC" EWAB4?#48N9 GL5T.EFU\C; 'O8K;9I[]HD(ED2&[2%'
MB4/W95(\1CEG6@P+N;O!'\-B5=';FPB,W,58-.:!=PJT$P15! CCB2*,LA.G
MP]'".E !D/5C%MW&XW$"(EL?1DM&C9T4D=T:F=$UW.VN 4N0@<*>[7YTDABI
M!:0FE1C.T63>5V:/,1J[HP4><P4:-P-#:Y"8Y=)8H Q(7@2!3CD1BN(D,9?$
MK8U<4PHS>JP1*R0%FDUAFT@G)J4T@4/H&0P=77"8$OVE1N Q+C$)X[8DHG5K
M59R"=+DLQJ2K @DMG1&RI7$S @]W!#"42"+ _).027$@6*W?_*@-.O*BQ@#4
MK$ D-D<SBFV#XQS3,8ESB"LCQ>%$:.C&A5EUY!J5<L,BS*P]>'A,:3&7Q*4)
M2E9J P3=G$"&,R,DDCG2G R::Z2,O1JP!<-,NU;-(E*+\$J6*2K+&8D 4 AB
M8QI;N\0 HU-3C\.*7B,L$0Q(TRQ4AV.WPF-9?#4=[5'V'22#GV5S.6+("+LH
M2LTAB5(FR;?& DLD4O<8M;E@360:EI1<M(90#Z\3!I@.^YFJ]43$@%BI LMN
M59!=21LQT,%\*O=E:FHM2@"A:_'3%?AEM1&"HE<6T\/I2U9V$<M[;N&8L)%B
MD9"0-)R98SIXDFOQXLIB-8#]Y"V6$5N<E*%E!)8I+K:,+(Z-%',VK2 -%$44
M )<U]>-BB)JKE$EXG+ZUE6V"[&([X30YEN3:3(3182C#3D6ED\0BM U0 #ZA
M@*R)C,R& 5T295@3<E5(ZB*+1+B?5)[9=7-K)+J:J1QM<*%2F0C 6,'&993H
M[QS*T]M/6 ."[_>6C7ES8#Z=DVH__08,>HU_RX_='N7F=G\R7I*,[S_R1NO_
M #;??YK+B:@,UQ)RRN\\RDU NKDD#*OS\@]0-1@_5#FAV1E6&E032JL "14$
M\/2,L)QQ3!9PV2#4"0.VE"<LAP-1ATN2RI)I)!U*1F*TSIGD:D&F$GQ&:QWM
MK9[K:7>V[A$DUEN%O):7<$@^;EAF3PYE8G*A4G_=Q5;5&ZN5=@>$L#Z"IU6S
MIMC;5)K(%P>2T[]9^6IN5.HG.&V;:ILK6TW.XDLH%=BJVES2XMO#!45C$,P
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M@GXDD;;MC-,DA[N8&@J#I&I&\0$G(TQ LW!T;B<%83E"P$DEL)&8#0#I8"C
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M@D9>O^+! 8#U(.WPS''$J3;&X6%4)G1V11WWD T\ PK4 D$TIB0[,EBV#62
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M/UHR&T^FM34=@S^M]&(YI_AP1F.8 !N)[*]O90]O;AO<G=_2C0D 4U8 C@K
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MK=8;OQ'M?:-OWBR:304#@1W4,-'!8=M#@;>=(ZCT]_S=>G3F001]!6GTO?\
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M-CM]C#3M8@!AP ]P7A'5>J[KJEPLW$LG[KDC$]I[4REM9+J4D:(X"Y9C4Z$
MH?FHQPJ#E\.- S#]JR-+SQR1F>]2&-H;966,#YQV[I<DALE4+P&1PVA\2ISL
MC'N1<(A971FW';=",2NY[<QU-E_QR"@ KD"P&6)\%0YX+Z^WG._IK]Q#_6_N
MOR#O,;B(R*>?Q>M?)U\CW],_.O\ 5 ]X3^0+YEL,G5_^K/\ :1^I?^N^YR_+
MQW+"27=1RI_9^_>L?]H'OB?RE/,%AY)H9'UKY9B5T+_@C^+#JK%?HPDP1J,T
M44/Q9U&?'T8F,E-'$<.M&H:99#A]7+AAU+@DUZZC7C4_QX@5%><127YATR&$
MD5Z61D*NC%74@@CLXX<XADA*42XP3OVJY]LC56<>.C4(^3J!J5(7@V5<"6PT
M%V[JV=G;XL6?^("K(=%[':;O>98K[PM0A)3456A\(U + ]N.3ZZ;1 :2="].
M\M5[?Q>^ [?4MIW3U-LVZWLII!$I5*%@4J\;",:&-5X^@YX\[W($R1)UZI3A
M "#*SO*W,&V@*D=Q$+8LB2UIXJNQ8 (T=2J*:#XCC"OK,)$Q#A;>WM$8B,OB
M"F/;=XM?%5([B.X0:A*(F+&NFBC666I!%<C@("-8>+DE;5=@G'O,"$H3)I6X
M<7#2(ZDZ Q<(K:2$)5:,X)])RP+IFY,797&42-)4)\^;0LIDN6:L1@;3$2$)
M:JU5PZ!C1J$4."Z"S:CWEG[BL2E@.XRJIO7)&X;B:+93%3([%F8K5JDT! KH
M74*>O&U1:,B0RR9P+]W-->\Z3[A+:*WV/FFNW*B)%9V0(,O$E!04% >)K6F6
M+9[F,(X'$I54F4PX<)R<H^7S=MSN[2>[VF0+[0F0D92_'3D(31% 7T98"GO+
M'P."U:=H"' 5Y.6>DUCR];HSV2QTBC4"$J\[/X:H5($09C4#X*' -EK=Z>3J
MVG;2=YAU9?I1R!%%,M]N$*V<LPN46>2;PY4M7:)=$5%(C;2"*@5K7&;&T66:
M'8/]')%;FN5=>N(X*;;Q5V>:WLMF:4VX!:29C',CR5^=E,C#4[-6G G >[!J
ML:HN$^VCXU;W#).#;FD4,Y(M79 IN)_EZ!0L\*@NP:1B!DO G!%#RPD,>?Z?
M8EQ;]GDE'=)H1$8GDF<N !-(-4/AD-E6FKQ#\'&N+R:A%GP^M-'Q)R[HQ3&W
M^RW>3;5DV.Y$"0R0 L'"%O%N8O%*HR%G)C)'#/LP+9"=@%E1.B)[S<%I;4PA
M+3N "XX^M/&YV:ZVNR\*8O-N.X-',8U)DG6%%U,BA41DB25CEZ<&"$H%KAWI
M?"V;=JS1;"V4I_[N)S.7H38WU(=JVV>W9DAN- FNW)+3-*PU2!I.)50!EV4Q
M9*$:V;$*#RLGJSK.2IASZLF\7MTA :T::1':0%?%B$B&3174S A3G3#T2 D8
ML&=/N014(C-DW>C*>T=1K**4_-6>T[M)$NK2J(XAAB45-/DJ<L6W RCVJ.TK
MCE)\5?;E2"+[+6TD\:BW@MY9$( !J 0'(IF>]@*@1 8C %:=T2*6CFBG.EN+
MF]2Z@5G19: _74\:,  '/%6XAG9'ABKME*6$)9+CA\RRZ>O_ %C0Y$=2N=0:
M4I4<Q[B/X,?8/E9CT';$9FFM_P!R*^$O.I;S)NN7CV_^Y)0?44H,Q_MFAX\,
M=!(L,%RL1WGEDO2BM/@^I_MXE'+%1DVHLLD2:WTTK4D]O9D.&*GB"7*E(D ,
ME>:X2WMO9T&EY$'B46N3944UK3(8S8Q-VXUR'=13>'4SXCVI*H2P J:URKV^
MB@SX#&N(1C$-DR ,R9$=J76<0VBHN3,X#@<<@N0-#EQQF@FW<-/X61;::G''
MZ58'I3RM$NUC>[JW(:6.Y6&5Z*-+/'0BJCND*3QQQ?G'>QT2VU9&K >]'],J
M.H3*F'8K))I-QOF53!8AXUD)[B+'%*&*G@:&O#'D]VJ-H$N)73P8@GBH6W.>
M.YFF:(:AXT@!"GAK8^OL&-FL&$0^&"H.)]:;%S;$DEE+$YU]! -,Q3A@^FT!
MHC)-/'$\0KQ=']MDON4=CGC1Y)#=WJ3R5[R,ETY6K#Y-5QUVVCXFRA.!)9_>
M@*K(U[@CAA[E;;9-L>2(:4#F-49U<E5!*JM1DM6PI",@Q=D;XLJ@P(?@GY>\
MLI>0+=/;*ES%$A=(FH2JB@)502=0:M:UIC/G$BR7(!%PE+0,<$7V_E5Y;B-H
M81%&C*_?-0&4,Q*DJY!8  >O$/",XZI829'4;DU3%9^$E2MRON$UC>+X@/=2
M18G5"<BH&>8S(7/ X[PQS=;,*S+X,U<ODN/[)6=C,X5S-)226-=#M$-)T5I4
M G*I&*K:]43R5]=LZY,<E-EB\4(6R747C9F?2I\%]7SBT- &HH%?7C)LE&,C
M!7V5^)#Q.!2JFV6<P)BMB(EH[J&S#.#0FA)"GZN![(X-'-9=LC66BDB?EJSE
MUA[5#I?68LP"0O$EA1F+G/.F!(UG5CF%.$I@C45GL.7O#! @'BZJJ%/R?1WR
M/D]N1RP>(3D0SJ=LSJ#Y+!!L]G>W,MM/"(H%=Y+HHVE9'4E5CUU8FD@!H*8(
MIKKE,B8[@&*KLLG "=7Q$HQ;1QVNLM)[-&)72WMV[BB#52-HQ2M2!E4YXA7N
M(Q!,SI#D#T<%;,:F;&19_K3OVL27,<SC4590 ='AHORPQ;(9T% ?5@H0G.HO
M\2"NF(2TY )6O;&*&WBUC6]00TLFOP]2BNC,$!J4Q PT5,<9/F<T+3<3,O\
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MHB02=XJTB1U1,L]+!A4$CC3$TPB!%W3&WO<+=S)-/+5$#%D6@D==2_-J%(+
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MHH:I.A2%[,*5<H1R[RMKNA*>F6:E;ESFNV2QM(UNT#LHJ":=\UHF3U6OK].
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M;Q5=81J^6E"#2G#CCF]QLY;?$@K<IW)(P((96CV7</:Q:I;%)8IT'C &C*S
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MI<2F65V)![,LLA\GXA3!&V@(#FHW2D>Z,%[AH*.:U!J*UX"HJ.W/!K 0,^Q
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MK84TBA8@BG D9?"?CQ&08I@99?LHPDM23D2*&ARXC/*N(>Y2[H.&:SI)WJY
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MVDU+!G5V"<*L2?X1PQCSV4+9:B2.Q=/#J5]'(CTG[4^>5NK=YM.YK<QEXY!
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M.K%@GC5(%.TX].Z/Y4VFQKC.;2L#'(?8O&?,/G_<[RZ=.SB16QBY,@[\6=0
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MNW"("A3=#(ZALPA4DGB3P!QW/0IZMO)_Z:QMS :@?V@%L5Y VVQN)&>!%+%
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MDEU!!(\<CK:7RA+NV;7&K5C=:$8KW&SVV[K$=Q7&8(]?M16UW^\V$]>UNLK
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M(:I!4A@ G!3I]%>W%?%PK;(@#!/M.97:T:,W498PDE30.>[FN9&8.#MG(FZ
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MYEM.49UPE]#'W+U+Y0S-OEJHC$QG('Z66[/H-S+'[ ZS7'S8A@52@4/J-LG
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M^9 U-ZEK4=\XG!LT6W&VBM;M;H(\VYR".X>341;P@FE#&*DE%7U5)QGVR$;
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M6EP8^7;?9;W:;M? >LJ/<2;LNB0"@*4KCO\ Y<=)_P 1ZE9N+7$-L8R#<29
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M![QK0^K'U)TG'I>W/_)A_9"^0^LD_P",;KEX\_>4:AFU  Z:]E3I6BBN=*T
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M6Q+A>P=2JE:01P5O-NYG>5BS(5BTEF.I*NRHHHK:: '",B ?0L&_:B/Q8NM
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M[U-J5YV\II/_ &E\Z=O$9].*98;4$VD?I_L7XW[G5[U+LYV\IQ]9ZF<Z#_\
M=OA:PDPY_I[%C/[G3[U7*G.OE-/8:]3N=!\'_LU.(F3IM#\1]/V+R?W.GWJU
M<N=/*:?_ -I_.GW-,,ZCX?:/I^Q9(_W.KWJJLK?RU\I@H1_[3>=#EZ:?S:4.
M$ZE&.DYCZ4J)^Y[>]24HW\N?*:&2A!'4?G7(CAF.G8Q48DHB,Q$@OB"K^=(?
MW9OWC_*7+4W+W-O,OE7OH2EEX7L_./-LYUVUO%$VN1N0HV(U1 YUKCA^H^7>
MHWV&6VT"+G.7;Z%ZMTGSQT?:T"O=BTR  PB#P':I*?\ =J?.O+X4@W7RVV<X
M $DEESMSG$&IJHYB;DLP-(<JU6A(P)'RQU?]KPO3JQ]R/EY^\OZB8B_3]T?B
M3/Y__=?O.US/M0.W<X]!8M\A@*VTTG//,L$"2B6*2,ETZ?O( H4UI0X(K\M=
M2C$B1@3][]2IGY\Z$9B4!>"/ZH_$I6Z!_N[WO ^2I9CU$YN\NE];06R1;=;;
M7SIS?<Q22B%(3+?"7DJ%Y&"K5>]2N=*XR]QY,ZE9C4*@7XR_4NAVWS6Z%3#3
M8-R2W" _$%=:R]R[YR8=M%C+S3T11KAV%Y-!S+S+XO@,2##%*W*6H)H51IX4
MQCW?+WK5D3I-&LG$ZCER^%:%?S>\L1MU3ANS6!@-$<_WTER>Y*\X:2,MKS-T
M16W1F:)6YHYG#,^3"673REWI#)G@0?+7K<7TFAN UG/G\*-/SE\JR#2KW?[D
M?QHFGN//-\%?7S7T8+/-XA?^5?,Q85!U$5Y0TZV-!PX5Q93\N>NP?7.DO_7.
M?[JA/YQ^5)2!%>\8#^A#\:4;#W)7F_BNIKJ[YJZ+F61BHFBYHYF\4052B"O*
M05>Z#D!3$#\N.O&4I$[=SD=1_"K?]9O*41IA7O!#EHA^->?_ "7/.['S*UQ%
MS=T.DY;BM;>.UL9^:.:6D:?PYQ=//&.4M+:Y61N.=,,?EWYD%T=,J!2 '[Y_
M"IQ^<ODWP2)5;SQ<6[D/5^VI'Y9]S;YG]E,LT_,/1XW%P/GFBYAY@8"J@E(=
M7*BE$UURKPP=5\O.K4XUF@2^\?PH?<?.;RQ>P\/> 1R[D/QI3W7W/WFDN@\=
MIS)TB2-@I!?F'F'7X@))?4>5V()K\&&E\ONMR<&5#$_TC^%3H^<WE2&,Z]Z3
M]R'XTW+7W.'FZCO_ !Y^:NCDEO'H6)/Y2<QZF15:GB@<J*'8.WIX8HC\N^N^
M+J,J-'+6?PHF_P"=/DVRK1"K>B3?T(?WB6(/<^>:Y4E\?F?H^TDDAS3F+F*A
MB&:*2>5:CO&IIAC\O?,4@=4MN[X=^67[J"/SA\HN&KWC ?T(?C33W3W,'FYO
MKHR+S5T<,% 41^9N9!IDSSTCE,C+5QXX)'D#KCCO4,!_2.?[J4OG'Y3D&\/>
M ?<A^-->Y]R'YO+F=I)N9NBDB44(&YHYF) #$D4/*.0KZ\2_R%UTYRH;[Q_"
MG'SC\IB+>'O/W(?C3PY8]S!YK]HDN)+SF7HV3+\DP<S<S$@>@_\ 11*#/AB4
M?(?6P^-#_>/X54?G!Y5/^[WC?<A^-.$^YP\SIO9+T\Q=(S))2M>9.8RI72%*
M ?R6R! Q15\ONN0M,Y&AG_I'\*,K^=/E.%'A>%O'^Y#^\2K;^Y_\S<#PG^4/
M2,()(VD0<Q<Q:56-@>Z/Y,C,C!9\B=9D&)H;[Q_"HGYS^4R'\/>O]R'XUSP]
M<?W4#WFO4/K!U+YXY?YQ\K2;%S9SOS/S!M4=]U!YQAO%L-WWR^W&S%U"G(3I
M'<"WN%UJ&(#5%3QQ[-TV<-IT^K:V?S(0B"V3B(!7S9UO>5]2ZK=OJG\*RR<@
M^!:4C(. ^+''%10?W0SWINJHYS\J%*ZC7J/SG4FO_9_PIC2AU"J//V?K6-.K
M5R?T_J0D_=#?>GN?^NGE1 H!_2/SEZJ_^S[$I]0IE_2]GZU"N@PY9G],EY^B
M%^].K7^6?E0X4RZC<Y@_5_F_IB,-_5$OWO8K)U:A@WM_4O7T0WWIW_\ FGE2
MI_VC\Y?<^Q;_ (E3_6]GZU5^7EV*4.GW[IC[R;ERYCO-ZYJ\K4]Q%<1R1M!U
M"YPD$:*&#:0W3\=^K=N M[NQ=2:ZGQ"K&TD;O$D1I]:L/O7[L=[Q>_M?#MN<
M/+6DH9 -7/W."J8EJ2&IR"<ZTQQT>F;D3).ECVK5,H:0'^A&^3OW8?S_ /+U
MH%GYK\N O![2=<7/O-[KJE;4N9Y!4XY3JWE/JF^L,JO"$2>,OU+2HWU%40"[
MCL3*WW]UQ]X[N_,5YN1YP\LQLIY87C5^?^<5DTQ_*U*.02 2<^.);+RGU+;T
MQKGX>H9L?U)6[ZJ9U1)]83QW/]V)]X+<+8I:<S^6E1#"([C7SUS<NHJ%TD'^
M01U=X8HW'E#JUL]4#4!C^U^I74=1VT TM7L3$E_=:_>/3;U)N#\W>60PDJL?
M_3_G#6(UTY:?Y $ \<6#RGU84BO^'^]^I3/4]L2[R]BG_D[]VU\_/+<T#/S7
MY= J3B23PN=^;6) +<!_(5 <FQK=(\O;[8VB5NC2_ OS[$)/>TRXGV?K5H=H
M]PSYU-O92_-'0@T4$@<V<SM1Z:32O)@[M,=6*;1)\&]*%-U1BSGV*1+/W)7G
M-@2*)^:.B C@&J'P^:>9@4<&H /\D02F9XXLG5*4-.#JFNR,3B3I3NV?W,7F
M\CK]EN9NB\I5B8FBYFYE9T!#9ASRFI4UIPQ3^6GQ9%'=5C"#@>C]:3N8/<D^
M:;<0K6N]=$GE !UW7,O,P97U%F*,.56IK#9^G =O3IF3UB'K1-7481CIF9>H
M?K1+;/<B^;=(_"W/FSH]+'X;!(HN:^9M,3]TQE .4D&E6!XUPCTV<H 3;4.T
MHF/5MO"3PU-Z/UIQV7N8?-GM;V\UAS!T5$T4@=I)N9>9I">]QHW*VFJH33+%
M7^%WQ \/2)#BY^Q/_B^WD_B"1![!]JF;9O=0>9W;TFGFYEZ4&^98T1TW[?C&
M5'^,U_\ 1=3756F"*]E>(DW$2L.1_0(:6_VYF!'4*1P;]:$_NFO,@YFNEW[I
M0^Y3*5>ZEW_?V:C  @-_)BI [*CLQEW>7Y2)NK$/S4L#(YL<P,%I1Z]MHP%0
MU^&,@P^U-C=/=">9^\:)(N9>DIMTBHZ2\Q<P_.2!V=0^GE;-*@5I3+ LO+FY
M) !AX8& <Y]N'-%5^8]C %A9CV#[4R;?W-OF^-S<2WG-'1<QN/FUCYAY@8ZA
M(653JY1!5%4Y 'MQ3M/+_5:C*5QJ,CECD/8B+_,?2+(QC"-H &.&9_>3_P!L
M]TGYK;6&*&XYFZ0E5:DBQ\P<P@>'6ITTY76C,>)QLT]-WM31>.CTG[%GW=:Z
M;-R(SU<' ^U+P]T]YF"K,>8>DXE<%6T[_P PA . H/Y,CY0)K@G\A<8L=+H.
M75=J;-0UZ?1^M.E?=:^8F.WB2/?^EHFCCCCU?9K? H55*L%(Y;K3/+*N++-A
M,L:]+_IV*L=4I8@ZF]'ZUF@]UYYC44B3?NE;$O\ *^S>_EM)9>\">7 =5 <5
MG8[B7Q:6]:1ZGM_V-7L2F?=A^8 H_P#Z[Z7&4?XICO6_T4]I('+U"3ZP>&*[
M.FWR#1T^T_8JO\2JD>_J;].U(,WNL?,5-#,LG,'2]Y)2I&K?=^T@AJT%.7!0
M"IP.>D;HQ9X>T_8G/4*&[NI_0J\<X>Y@\UV_/)+9\Q=&$E-U;SQ-+S+S*E$A
MG5P&_P"BDE6T#ZN,6_RUU*R)$#4^I\S]BZ7:^9^FTQC&<;,(L>Z/M741M-K+
M8[5MEE,4::SV^SM96C),9EM[:.*0H6"L4+(:5 -,=[ &,!$Y@!<#,B4S(9$E
M>]RMGO-NO[.,JLEU975M&SEE17G@DB0NRJS!0S9D FG9B2BN8U_<I^:AI97'
M4#H!22:60 \U=1:A9)6< G^:HYT(KQSP9^8AVH?P9.^"RI[E?S3@U//W0#+A
MIYIZB\?7_HK'##>/#D5'PK>!C^GJ0;W+7FLR"<_^7X#54D\U=1M6FH-!_HJ]
M6'C?4,P7_3M43M[27)C^GJ2DGN8?,^O'GWH*?7_*CJ&37L_]EP''#'<1)=C^
MGK5HJ,0P6?\ \FCS0::#GOH*".##FCJ'7.M>/2ZG;AO&AVI_#EV+(/<U^:"E
M#SYT&.0'_6?J">!/_P#JX87CPY%U$U2)X:5D'N;O,_V\]=!3P_\ KFZ@Y4KP
MITO&%X\.U2\.78O?_DX>9X Z>>N@P;L/\I^H/&M<R>EY-*X1O #P?4,O3VI"
MLN!+X'Q]'%E%6\^X[\WFZ;I<WYZC>74K<3$D2<V]2UD%N#2*,!.D;*I5.RIS
M[<>8=:\J]:ZIU"W=QMV^B<G D9N!RP@1])7L7E_SUT#HW2JNGRIW6NL8F,:V
M)YN; 3[ B$ON*/-BZ,%Z@^70,5*J3S=U,]! !_T1G+TXPY?+[K1RMVK_ 'I_
MW:Z"/S3\O ]ZG>?N5_WR:N[>X'\V=]$RV_4+RV1R.P9S)S=U.TFFG++H\]14
M=HQ6/EYUQN];M'^]9_=*_P#U6\M8?P-]^Y5_?+3?U_\ W/GWB_4GJYSCSUR5
MUJ\D.V\O\RWT.X0VF_\ 4KKQ;;I%<M:01WIF@V[RT[E9QK)<HS*%F?ND<.&/
M4>B;/<=.Z55L=R8RNKBSQ)(]I /T+QCS)U#9]6ZW?U#8QG':W$%I@"0+8X1,
MA])4-']S ]Z)1@.O/D'K]:3U1\PW\/\ [K6-<2&')8)CR6[OH+^[M>;?I#TI
MY!Z?W/4?RT/><J\NV.V[C/M?.G5.>SNMS4>+N5Q;S7?1>QGEMY[MW9&>*-R&
MS48\HZ[Y+Z[U7>V[JNW;",YD@2E,-'@,*SBP'$KVSRY\P_+G1.FT;*=&[,ZZ
MQ&1C&L@G/ FT%G[ K 6GN.O-1;F$GG_R^=PJ7T<V=2*L1740?YIE(U#X,<_/
MY8]>G\5VT_?L_NETP^<'EH8>!OM/W*O[Y5H\\W[N-YMO-)T9VWD#E7J3Y:=L
MYEV?F3[/;??<T<\]5[':8Z;%NNW"-Y]KZ+;_ 'C:KVZA9E\  QHQK6BGI/*?
MDSK7E_J9WE]NVE1*O21"4R?B!XUQ&0YKE?./S \N^9>D?D*J=V+XS,HF<:P
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MW4?F',;+%SGT85R",^8N>0OJK3IVW9AQ\L/,0E_.V6C[]G]RD/G'Y89C1O\
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F7L7V _[DOF#_ )5^![!\_P#9C^2WMGV/U?,_9#P?&^9UX22__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>tv498959_img3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv498959_img3.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_[@ .061O8F4 9,
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MNE*?81>F=]5^?_R_?4(_C2Z4I]A%Z9WU7Y__ "_?4(_C2Z4I]A%Z9WU7Y_\
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ME*?81>F=]5^?_P OWU"/XTNE*?81>F=]5^?_ ,OWU"/XTNE*?81>F=]5^?\
M\OWU"/XTNE*?81>F=]5^?_R_?4(_C2Z4I]A%Z9WU7Y__ "_?4(_C2Z4I]A%Z
M9WU7Y_\ R_?4(_C2Z4I]A%Z9WU7Y_P#R_?4(_C2Z4I]A%Z9WU7Y__+]]0C^-
M+I2GV$7IG?5?G_\ +]]0C^-+I2GV$7IG?5?G_P#+]]0C^-+I2GV$7IG?5?G_
M /+]]0C^-+I2GV$7IG?5?G_\OWU"/XTNE*?81>F=]5^?_P OWU"/XTNE*?81
M>F=]5^?_ ,OWU"/XTNE*?81>F=]5^?\ \OWU"/XTNE*?81>F=]5^?_R_?4(_
MC2Z4I]A%Z9WU7Y__ "_?4(_C2Z4I]A%Z9WU7Y_\ R_?4(_C2Z4I]A%Z9WU7Y
M_P#R_?4(_C2Z4I]A%Z9WU7Y__+]]0C^-+I2GV$7IG?5?G_\ +]]0C^-+I2GV
M$7IG?5?G_P#+]]0C^-+I2GV$7IG?5?G_ /+]]0C^-+I2GV$7IG?5?G_\OWU"
M/XTNE*?81>F=]5^?_P OWU"/XTNE*?81>F=]5^?_ ,OWU"/XTNE*\T[UB9*6
MEL/>E"[FYJ<L,B7AGEI@>7LDW*V.;=-HGG7RKBHXC^<G'DA+R2C6.9)(E4<+
M**>6F4!,.VE*K3^P#TI5 XF_Q(^-/Y[ZF_GXQNE*]+OT(OY,[%_[?_/W^L(Y
M2Z4K+_I2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2
MFE*:4II2FE*:4II2FE*:4II2FE*:4II2OS ^M[G+*5SY_>E'Z9J5YMV*N,W,
M#)<C/\BYVB668I%JRS!4^=B46&$T;M .HV=@:U.['0E46+E)P^-+- [T_(*"
MLP[$^M2,>H'I63VX<">'O%:%I7(/ F*(#C9&<1C7?.,_2^/T:;&E/S3"5C!^
M1*I(5W+-,J3F(J>1)L&DPWD65@G(^5G6<A%("DX BK@BL+D]*FL!U%8T^)_K
M2\F[TY]++(7(*A8'5Q%ZL,[R IN/ZIB:LWVK9$XZW'%5@DHN@,K;=KAE6\UK
M.$-D1--JB\=-(&DJPRRAU2H/2[(ZC;O]E2ACTOZU2. _6[Y=6/U#.(_$7.F,
M^-4-%\J97DA2+93,2KR.0+-Q?R3A@EC=UNN2?)*EYWR1@GD8XDXB'8N+#'Q$
M34I>L.)86+]N@[9]CQ86O0,;V-0LXX>KGROXO\?/6KY_<A+;0>0?XI^=%EXX
M47$;''%LHR[C*,*YQQB[&#Z!O!\P6J&Q]Q_JM2:O'+RHA7).<>OC*.C64SI=
M;XB) -@*@&(!)J:>1?7 YB85P_>H&_<;6SC.UFY9<6N+7$S.^0.*/,#A[Q?S
MBYY/U&:L#^YEQ%R368YK%MQ]G*5,Q-B9DL#7YV,K&NVR[-!X74-(J.HU2GI.
MT*?QI_>$_6HJ=L98B:6Q/$W%FP6IQ@K'LABG&5@L]VQ]CJZV&Z0V/9:TWF4K
M$O?9BPK3<T@XFYE8\Y(/%#OGACBX4B?PB@_$:FKG3G7Z@1/6!F/32X]N.'D1
M49_A&'+"AY S#B'-%KL]8F8^U.*4YI]K;TWD/1HB\Q]AL=?<$3<-$:XI$LI=
M-P8)%2*,TF( "US423JL*Q1POJPSO/F_?W=_.]PX^8+4>YQY19UHUBCIA/.*
M=DPAF[$CJHTRQY$PQ9*CG6I5*=K5[IU\05;P]QK5C)#+%,F*STVRQ8VM>I=5
M[57F4/7?]0S$-)YZY1FZ5PRM-.X(>I97.&$G$16-<WUVRY?QW,V^PUQ[.L73
MOD!88O&UT8,X9LND[4)8F+A5\HF9@B5F51\TBFH]?L-90YKU(L[17JL27!B\
M36 >-E,6M&._Q&5S.^'<PKVGFAC"5IC"5R5;>/\ R<@\N0N'(?(E2N4F$0UI
M;ZH2;MTHV,47WGG40:0MTO4USJM6<[4M34TI32E-*4TI32E-*4TI32E-*4TI
M7CA^KW^POZ4O\#_-?Y_?+32E7 _L ]*50.)O\2/C3^>^IOY^,;I2O2[]"+^3
M.Q?^W_S]_K".4NE*R_Z4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4
MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2F
ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4J%G-C@%QQY]4ZD5G
M/$#86]AQ1=HS)6%\MXYLSZAYBPOD&(=L7K2VXUO464[N$D17C&YE45DG3)=1
ML@LH@9=JU51B#:H$ ]ZYF,N'QJK+QTWF'DKR1Y;O*_%2L+56?(:1PNUK%>8S
MU?>56=46HG'[">!J)>)F6KLF[9'E+3&3TJDU?.DD'*2;E<JB]+5"K&WH:<3L
M97WC'9(W)/).>QWPPE^0$QQ9X^66\8_<XCPPKR1:J$OC>!E(K%4/FR?1B)%4
MS^ 4G;C+.85V(>0J")$T2-1J&D5;?C__ '>?AUQJO'#J_P"-<P\K@FN#MNRM
M:,*M[!=,.RT2LTS)(NI*Y5*Y,@P4U&9KQU9)X1NLW.QF4TW9@,_4%)J*$=1I
MI _15V5_0YX62=(YT8LL4AFJTXEY^Y5G<XY5QC-WJ$^B]$R[8[%"6Z3O^(W4
M738RU0T^%EK3!TU--R4^DQ*BHV;$1:.WS=S"YII'7[:N!D7TFL,9KXAP'$#/
M6<>46;X:BRN.)_%>:[[>L?-\\8ELF'QDR8RM=&GZ3BFGT#Z95=E-O6BDU*UN
M4EIEHY%*6<2!$FX(K];U'3<6-5CQQ],?!_'+E3FCFPSR)R RMR9Y UJI57*N
M1,J9)9_-]FC:?4*34(\[C&N,:QC+$X.#I49!XCO!&2B7#IRC$IQ[ R3)%?I;
MTH  ;^M8<.3.#LK94_O'D#;8N,YS87Q.\].=#C@GRXP!@6^NJ96\MV*\VF[G
MK'XU[=@S*F!%HAU0K/Y3F3E&CZ)AY=0@%<LIIBBJTB/PU*?Q?HJ>"?H*\1(!
MOP!C\7Y+Y'X9A/3?G[)=,!0>/[#AMXSF\@WFTQ%NR#?\L/,B8/OLY=['>9"#
M;(O"%=LHYJS)Y+!JS+MLU&HZ1T^RK99!_NZO&7)E,Y/T"T\L.<BM8Y?<F8OE
MMFIDQLW%IBK*9CBY&URZ4A!/$N)HNZ[!+R=J!91@W."0#'-"IB0A5RN&HTTB
MLAN0/3[I&7+UABX9;S=R!R=$X1S'3N1%>QU<I7$S^DRN=,=@S/1,CNW+;#[*
M^U!2KOV)'B$#49RM5-9V8ZCF*7%10#0O4;5/G4*C32E-*4TI32E-*4TI32E-
M*4TI32E>.'ZO?["_I2_P/\U_G]\M-*5<#^P#TI5 XF_Q(^-/Y[ZF_GXQNE*]
M+OT(OY,[%_[?_/W^L(Y2Z4K+_I2FE*:4II2FE*:4II2FE*:4II2FE*:4II2F
ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4
MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2L0GJM^K=C3TU,)WS(
M-?\ Q YZS%BTM#L5ZXK3/*BNX<SN7&5_M\'C^.OM1I#3'V6[78D65KMD89=-
MU&1;'YJ,Z=%?"HW3:N8@7J4M:IO-^7_'V$JV!97+V8L.81MO(BK4^>QSC[)&
M6J35[':9:VQ$5(IUFDM+/(UV3O,BT=RQ&H? ,Q464$NR11.!-+5&XK&1?O6>
M=XOY?^H)Q+O^#,24USPLXY0V?*1E"\<Q:=C"@YO?WI:AL<58ULEER[C#'U'P
M3.W>;R$QC#O9"=F&+.1,"1#.B'(J*W2]0U=2*GQAKG_QBR0PP15K=G_B[0>1
MV<,:XWOL=QMBN5.$<E7D'N1*@QMS*&HSBJV8A\M0QFSE08V<A&:L?-LT@>-!
M,@<HZ6_54;C]-5HOSIX2-<<L,PN>8O%=OB25M;NAQ>4E^0F)$<<R5YC_ "_C
MZ8PNZEN+67EK9><3SHY-T9XGW!W)AN&EC2XJH;)R[XGTV[J8SM_)[CQ5<CI4
M=UDY7']DS5C:#NZ6-F,,]L;W(2E4D[*UGB4=G7XQR_5EA;@P39MU%S*@FF8P
M0M2XJ*T7ZG>!YCE#;<1Q^3.);[C[2.*\7R4L_)R/YS\;G[BO&EYBN*,H2R8*
M:V12_P!<QTZQY<8>R(7]VNE67#659HD.)G*)SQM2XO\ 94G\<\R>(68;9 T+
M$G*OC=E*\VJK+WFKTO'.<L8W>V62DM7+EFYN,#7*S:).8F*LW=LEDE)!NBHT
M(HD<HJ 8I@!8TN*I2Q^H+P)I^17V'[;S>XAU;+498T:=)8NL?)3#,)D6/MSA
MTBR;U9]29.Z-;*TL:[QPFB1BHV*Z,J<I ()C  K&EQ4:_5,]1^R>FO6>+UY:
MX%ALW5#D)RAHO%R=77S"\QC8*!9,DQ\Q,52R1<*3$N1&%WA@BZC,F?IJR$*L
MV71:)I?$%=*J,P%Z@QM4V)_E/QBJF7X+CW:.1N!ZWGRT?!?1K!\_E['T/E^Q
M?.3=5W'?,6-)&PM[I+?'M$#JH?#LE/-3(8Q=P 1U"QJ-QV]:W7[E)QEQ3D&I
M8ERCR+P3C;*M^,U)1,97[+N/Z=D&ZG?.P8,BU*F6&PQUCL9GC\?(2!FV6%1;
MW"[FZ:4N*^,YRLXNUG,,+QYLG)+ =?S_ &7X+Z.X-G,Q8\B<PS_SDFZ6COF7
M&;^Q-[I*_'I,EC(^0R4\TJ)Q+N!#;1L:7';UK#G+^N3)U?+7J@X4N?'K"M(N
MOIZ.L:1U%?9 YT8[Q'C_ )*S67E9:1HE;/DS..+\5TC"]C?U!@1ZLW>O9M,C
MSSVB*K@B!72\=/:H:NI'PK)5+^HWP>QXSJ4?GCF'P^P3D6Q4.E7N1QO?^5F#
M(J:AV-VKS&PQJK1>3N43](H!TV>]S"7:H_ RC8"N&YC)*%'4+&HW'K5Y)[E3
MQ?JTOBNOV?DA@6N3^=6,;*81A)[,&/8B7S'&3)&RD/(XKC9"Q-WN0F,JF]1,
MV6B"/$UP6()!,!B[PJ-Q4'_5&]5#&GIRX1OE]AW> <RYLQU&0-RF>*MJY0UW
M"F:)_&4M*H03ZWT.L(T/*]KLSJ(DI)HL9LK#LF*D:#MQ\X$4;)MW,0+U FU3
M_P  Y3_'E@C"F;/F+Z+_ (X<28WRG]&?G/Y[^COXP:=#6WYB^>?F^(^=_FCY
MW^'^*^$:_$>7W^4GW=A85&KMZ4II2FE*:4II2FE*:4KQP_5[_87]*7^!_FO\
M_OEII2K@?V >E*H'$W^)'QI_/?4W\_&-TI7I=^A%_)G8O_;_ .?O]81RETI6
M7_2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E
M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T
MI32E-*4TI32E-*4TI32E?@^YA\0^6Q^//]X#XKSG$K/F9.1W+[G9AKD9QAR=
M1<&7*[4#(>$G_(3'+RKIQV9V$*ZQY4I7#U!*ZC)"$=2S>9BVDJ[4!!2*;RCU
MK."+@UYD&Q'K>KFY!X(YWR=STN,!S%Q]Z@^-.*7,GTU^+F!HF;XR8<Q1G:3H
M-AQ%7\:*6?C;F:S,\*\KF&"FK[+%=?V)M,Q$E QQ)11LY<2WDE759K_"U+&_
M6]K5:[FKA//BW,7UL#USC!SLR/5<I^EIB;B]AK(;OB?R R"OF;,=,:\<ZW)1
MC2Z4C%TA5+A8?G.'>+O9I@?YD='8/'K9P9F0JPK]!]]#>Y[]JEQ:>*G)^.X8
M?W?#FUQ@P+DU/F5P:+Q\XXY:Q)=L79+QCD5[A^\049@O-U8R36IZL1-[@Z/3
MK-&.CC*O(\T2RKTT^GT%%(TX+KNER/2HV-@1WJOO4KX6YEK7J'>G]<B,.6DO
MPE8<2\X<5<LY-XA8-J?(;)^-<D9E+=U<KY/N6)9[!/)59&,Y$L+&U;6BP,*L
MZE%1^+/\8180*Y ]/MH1U'PJG@XD?B;]7[T;:77\)<T<I<7>,/"J^8+E,NY?
MX_Y&R9"UY];6>3&&%ZSF?)./L6%Q"@:$))QO^]!LRJI2,E)(&"S8YDH7Z'XT
MM\P^%JI#D!B&U8S]:+FE8L>\1.1L?QS5]%C)/$?%TYASAAGJ:PJZR:A2Z_::
MSB?'\EC7$\A1569:K#_-K &!_FL))(D0DH#[L:ZB.WZ:'\1^%JAYP!P/G#'N
M<?[M@E*\/.7^/!XWT7FO6>3MA=\,N1U2B,5V;/\ 8LMU''[C(5N<XH90$=](
M).4([=OW#HS>-C7B<A(*MVBP+#$GO4!W%6%].Z_\*VO*7T^.-5NYR8_QPIPH
MYW<JL@45_DC&?)FC\P<^WO,%N2K-?QSGA*?P8TX_8<6GG]73+(/3Y/L;F?C'
MK1DY91$D*K) ;VJ M<#X5^A+^\M4W*&2L%\"JGB/"&?LVS]2]1S"&>K:PP9@
MC+6:3U7%N):?DN-N=CLI\8T^U)P1D7N08TC%HZ%)Y*B*_P &DN#5SY4J]ZF?
ML/OK$_SFXK\LH#%7KD8&A^-O)?+.;.<W-[B[R;X79.QG@W+5MJCRB*9;HUH*
MZ7RC6JM)0&%K7@JMM',%)M;.^KLDW15,X;$58IKK)1!'2H$'J*R'\6<)9(PS
MZFWJ24/GYQ R-RQK?+>P\7,O<=N02/'%WGS"%JE<%4N6B(6C6.[2M=E:'@VT
MT23DTQ@5K:^@(U@O'N%2O&_FL%7L#VZ5$=S>L3?J$X&Y<92SOF.3QAZ?/)W%
M-'Q_ZW>&,UJPV-\.<@LKLLVP4)"9&A[WS@6M[QO=F[[Z8IM84K:*QVWC(&#8
M'!.30=OBMG2<P('KZ5 W_IKJ><>(>161<C_WE-.G\.^;ME2Y=M>&43QK>1_"
MCE(ZB<NO<$YCQBTR*O59@,2C$':0R48O(-'"ZR*<G'-SNV1ETB]VH"W2H$'K
M4ON7CF[<H9STU.&-ZX>\XJ?P/Q?B; G(KGU=:SZ?'+^>F^0N7L5X<JT7C?B^
MO%4S!4Q.RZT>I -XJ>7ETF[%L58B?QK5>'0!0.ESZU$];#TKYY3X69:Y)^I!
MRJ>\J\=^HGAOB5ZC7$OA[-XF-Q:PC1;Y^+Z2Q!4L96%#BQF:V67CIFA]Q7ME
M)RQ$KO6CA)Q18T)-F=S(R )*%,DOTZ=Z6N>M[&K?\I>)?*J'Q]_>"N.-LXL\
MD<]YOYIY/XX90XJ9>@<)6')5?RIBVN7&OQM8@YS-%9@EL7U"[8/@&ODR,;(2
M$4_)YCAVR:J,]U0 ]J6/45^O'@O!W&J\+.)E1R%2+#C>]4WCEAFF6ZCVM:NK
MV"N6&H8^@*W*L))2J3UF@A4%Y%G4("+U4Q4SE!4$U@42)*>]3CM4JM0J--*4
MTI32E-*4TI32E>.'ZO?["_I2_P #_-?Y_?+32E7 _L ]*50.)O\ $CXT_GOJ
M;^?C&Z4KTN_0B_DSL7_M_P#/W^L(Y2Z4K+_I2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*VG*!R&(83 !RF*(D.=,X 8! 1*HF8JA#;#T$H@(#U =*5BPI
MWI-XIJU&Q_@R5Y#\I,@\3\5W"HW:A<2;Y.8,?XGAY7'U^9Y/H;*5O<'@.O\
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MK'J"RO ^X0M!XM\J[YDFE52(ATF4ES(O'*>L,GO%6G4&%O4FP))X^>,@ML?
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MIZV26'SI9<R0&56'4_;2YN/M%9+?2!Y_W7U$.,%PR-E2E5.CYCPIR"RKQBS
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M^!_FO\_OEII2K@?V >E*H'$W^)'QI_/?4W\_&-TI7I=^A%_)G8O_ &_^?O\
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MGWUZQJ?#'BH)2%/0F7F=A-^^V68IS#V@.X@2>(43#XCV@ ?(&J?\QB^KI?\
MVA_;7JHRS^!7(^(4V_JK=_Z,>*70/H$PZ] _^KK1X_)_]H?'0Y.&.IDC'_2'
M]M1MG7L$D_NG^RK.9_XI<;*OA^]SE:IS5C/1L2FM'NFUJL:SA!0T@R2.=-)6
M=5(8124,'4H^.BY.(Q"K)&22  &!/7[C4LB9RH7:.30._P IK'7QDQ5C6T9B
MK<+=6"[ZO.V,C\6V>V"6;-SK)HIG0$RB#ULH'7?P,&II)\>%#).RI&!>[&PZ
MFW<_=7G"<F>01XZL[G_1%ZRR_P#I'X@#X4V)'Y1"XV;8.GM_^H0U2?Q;:/\
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M'1^&]OF)'W6ZF_V"@FDN%'7I?IZ?\M2+K/*+/ST[<766;(J!A()A!PS)N)A
M *':V#WAWU  $-T.I2+CUZ^OW#UH)Y#V[5=B!M,[.N3.)29</'3DXJK.53I>
M<L)O>4/[I #O$0U-[3ZM.DAM.JWQ'V=>X[VJ9<ER;7%ZD_C:!C)*PP971W"A
MBOV:X$^)[1!9!=-TDL( 4>[L4;AN'W=0(4#Y;$]+V]+W[]NUNM2C*LP!/5OZ
M/L^^OWD8NL\$7&6/_B)N.\Y.D54%^YXCW%4""8"<! 3]VX;]=6R;>]H@4O+D
MPA0;$ZU^)'QOW!JN&U;E)8QP2E3V.AO[*K$UUJ9#=I[!&%,*(+["Z3_W([AY
MG01 "[E$/\FJ#_%O&O\ ON/_ 'Q7NO'][?\ !BSG_H'^RMA;S4#]2V**$.G7
MXM( ][;M'<1#H.^H_P"+.-?]]Q_[XJ8\=WT-I.)D:O\ 8;^RA[S4$SF(I8HH
MABAN(&=I!TW -^IMMNNHCE?&S_\ .X_]X47CF_.+IB3D?8A_LK4;Q4@'89^,
M =MP_P":3V$.G@._W=/\5\:)M^=Q[_[8J X[OQ_^3R/[AKZ#<JL"8K#.QWEE
M,!1-\078!'<0#Y?9KR/,N+ V_/8]_P#:J0;#O+/H&--K^&DUQ"9!I2AQ3)9H
M@QP-V]H/4=^[Q$NW=X@'CKU7E?'&&H9D&D^NKI7N>,<B5=1PLFUK_@/;M6[Z
M?TP%2HC98D%3 (E3%XD!A !VW .[J ^S4C<OXRIL<['O_M5'_"_(2I<8>04'
M<Z#TKA2&3J'%@F+VS1B0*F[2?AP/N/3_ %.[;;?VZH,OR#PS" .3N..M^W4G
M^H5[XG#^39I*X^'.6 OU6W]=<$,OXY$>T+0P$0 1VW4#H'CU$@!JB_\ JEP&
MU_XGC_\ M?V55-P/EB]\*7N!Z>O;UK:;,6-RF(4UICP,H43)EW4$3@ ;CV@!
M!$>FHCRAP(__ -RQQ_>_LJ8>/^8$,PP)K*>O;^VMB69L9KE,=.V1QBD/Y9]_
M-+VG_P!4>Y,O4=0'E'@1-OXE!_[7]E3R>/.91$!\":Y%Q^'M^NJQ@;+"6=J=
M[!/DI%H18[<SA#<4P63*4YTQ$=O>*4Y1_P H:RG9M\VKD&*<W:)EFQ@Y34O^
MD "1^HBL=W3:-RV7)&)N<313E UC\"2 ?U@UWVKM5MII2FE*:4II2FE*:4II
M2FE*:4II2O'#]7O]A?TI?X'^:_S^^6FE*N!_8!Z4J@<3?XD?&G\]]3?S\8W2
ME>EWZ$7\F=B_]O\ Y^_UA'*72E9?]*5CHYZ4-YD)#'4*CDK*6/&99:0=/ QA
M;Y6H/)XS9HNHA&S$A#JMWOS4978RI2*$,8I>T#!OKF;Z@IMSPI=NSMNR9X"J
MS*50D*2ZVU$#H67K:]Q:_2]B.G/IYS\3!BW5\K;-LW :(NN7"LIB&L$M$&Z!
MB/B"/B"+BHQ2=/0D4V!)-UDZ;(DU!J]>Q.5LI,5U%R W!!ZX^;[<@8JZ?P@%
M]WM((&/N41,(ZYJBW3?XHM<NZY_N_'\S)?[/EU?YOZZW5A208JS_ )9=K@+R
M:U63!P6  U=%U8YZ'5U[_A7X5S:S-KT:QLG<7(W"-?Q$:M$QTC9+C:)XBK-Z
MY!V[!_'S$L[BEE ."8$751.X  V\S;IJ]P<HY"DZY\>=E.Q4+I]V2QL+$VU6
MN?6J;-XIM^^[0T65'BY$,DFMUA@AA(([:7BC1^O4D!K? 54C7(.02.Y8*??%
M",9]5RK, S7^<'*+HPF*Z,1:0.]-&]P_>%:?#]H>&WCJOQ>:\IQ\:>-<_-03
M'H"Y)'Q"EKLO_1(^-4 X/PO'BB?=]K_XN CV_<+ ,+#2  1J%N^O4+WO6DE9
MLJ-J8PI9KK.S< !"-%5T9*1864R;DXK V-80<_/"G>"VP&.L8Q2B  .P &D7
MD#E4F$F%)N.4D2BP+,Q)Z^K"Q/7IU)/VU[8?&>"3;[+OO\-Q\?.(OI95>$6%
MK^R1H';J%4#UM<F_008V^L((LX9?+S=J0JJ:Y5[Q.R;I4@"8YD2K/G#E80[@
M]T=]]6Z/F._P,ZG=)[N"+^[)U]>VKI59DX?%=QU29,&R%@?E_P"%C0 _<H%=
ML>?MC7M64<9?9F3 J1G*]RF/*;IK&*!CN2J*"B4GLZA[?EU3Q\HY.DFD;IE%
MFO:TL@/Q_P!+X52P[/Q^4>U'C[(R'LHQTN3]ENM^U=F:_P!Y*=J=H[M+I@LI
MY0/T9YXZ1<D*F<>] Q#[*+D.7WA 0'8->_\ BOD['1_%<OW/A[K]?_:KR7B7
M&&23\S!A192B^CV5!'7U'P/W5]SVF^FE$))-];7C=!IY)TR3<KLB<YE#=QFY
M7(%%0"[=!#4S<PY2JA6W3+#_  ]U[_JO4O\ AWB9PORTL& CE[B\,77].FM4
ML@6OYS;MC3%M;+*HG6'XJ7EP3!(HB!P%,70$)N._R:@W*.4Z=2;KN/3O^\>W
M]=0DXCQQ<9IEQ<$J#:XBC/7[]-<:7FW*BIIN2"3=,(]JN]?R<E.2:L2U8D3%
M11T)73Q1'N0( B()]@!MUZ[ZIX]TY/OTT>V1YN=D;A-($BB5G,DKM;0JF^JY
M)MTJ3'VK;=NQWQT&-#J;HBPQAK_ V7I?O^FH#1D53N;<_&Y2D,:61Q1L=7!X
M%2E%'7E1F4D(L546SV4*9L61=1C!ZW**: +@B<I.Q0I@$Q1ZEY)N.^?31L,W
M!VW'$S^8[WMM\MF17FVT2+8I$22#=2=)D4MJ^8&U@*?%VOB^ZI^9S!C! Y]L
ME5 < %2YTVU)<775=2;$W'2K3Y QW#TR_P"2L[R>)*C,XUQ=BMY TN"C8"&?
M1\AD&6691C<\_$MF1D%U&<BY[-U2"9(AA$/O=95P;-BY#P+CWB-<O+@YAR+>
MUR,Z:0/'*FW0>YDR""9OF"LD2QHRFQ#].]>^Y<<V+'RI<E8<(QKCW2!8UU2'
MHS?);OT"J;7 8FOM9J+1F6(\-PF=, 5":N.8;C5:V\-6JG5Z,]:NGJSJQ)/4
MUX*'CW8(132( KDA3%!9,XE4W#?7GQK&GS_*G)MW\8[F^%Q3C>WS.IR&?.BD
M=5,;HRY#R?BU$H;W1DN.]>?^'^,X^%"1BX3YDCJCK$FDABKN3=3<*JH;V/6U
MCT)J;BO&W"3(S99O@;$LK',V1(]RT'&=+>.42IIE[':IEX15PLH8B7O',81,
M/7QUQY-S+DF1DR9,FX92Y>3,S6$CJ@9F'0+?2 =715 T@=*0;%Q,XYQ9,7%B
MF+7#,B_-;]D7'7^NL8E]1Q/8;H>Q2O%+#K?"4#E:!QM4XU;&-7JMAEKJV^+4
MG;2^DHV'CW\A"HBNFW*Q7.JS4\ON[.[O$?H/PGQ]A\>XT>-[=O61_P#5+,V"
M3<,N<-^9A3$9R(<=8IO<A1SU)D51*3<EM.D"6'8-FQX\B?.V^ 0/+'$@T6D8
MD&\MNWM@G2.GS%2;VL!D/7X^X,;RKV2B>,N #_-;@11<M,/8Z<G9.R&%1)Z\
M<!71,S5;CL8H)BF8H_=#7SVAW_?,F()-N.>>G3][+<CXD!_ZK5=X>(<0:"(9
MD,"S2 ="BKJ Z606&K[S>]2&;3MG\IH:492:TFHGY[4C)_(D.\ 1]TT>F+DP
M%1[ W$H (![-6R3<<\$LF=EF/X^Z]_Z23WKWFV[8H6=<0XZX40LQ:-+)Z?,=
M(]>E;T;!;"K@FO#6$$055*JLDLNIY:)BGV$#& YBGV'?<!#II_$-PT_-FS$W
M_:=C^KK4[[1L137'/AF2PZ:56Y_1:J R'*RZE?GTU&4ZFBM'$!TF\'O;F1!V
MW%-QN9(J@)@H ;CW=NX_H:SGQIFYTG-MNC;+9D.0 REB;C2WQ)^RL5Y]@[;%
MP7/G#XI9(Q;2!?5J MW/7KTZ58/%SD[>[1*I&YGRA$710;D;D<J>\EU,F0Y%
M!'LV*'3VB&NF_-0*<!RD4E4#)<CI<%S87^^N:/$\,>1RZ&(N(XF0DDG3V!O8
MWO4IW#F8=R;5FV23AD5R>8LI+11BKJ" B/:B1;9,2[ ( (%UQ*9/:B&AG8_[
M76NRHXL"##;(E)R=)L DEP/OM_;7"?RD"9RX:EL#=RZ06*DE'-VR2KMA)D $
MP43! "G$JHD 3%'< '?4T29[_,3+T -]3]CV/XNQM4V'!DR6D7'.@K=F+D*4
M^!OVM\>E_6NVA49YL0Q9LB*2 '6,5R98J0+F,)@%,4!'W]C#V[=>NO/(E4D1
MHSF0#K9W/W_M5X9[[5*P_AVHL;?*.MOTU&W-:B86Y,$Q#I&H@;R^W?<02]P
M H'VZ[[;Z["\ MJXG(26U-D'JQ) ZGU)-<H^9 S\CB]T_N5Q_P!9M5S,5JJI
M5*(,G&R+Y,SIZ"JK1 YT"#NEMY@D+L!C[]-_DUI3S6\G^/\ (CCD9%$<8 U,
M!UU=K$?"MP^'8T/!8_=EBCE]Q^C$:CV_JJX;QV^^)8MVU>D_PKG<Q_+.@7L(
MDJ)B@82['';KV^T $?9K5 DD0V:8EO\ ;?\ ^U6U(8<<1222Y$)LO:X/J/\
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M1?I4R,*Y7@+5,VK%2S2:A;QBDD?"S4).-DHV5G8TD:S296UBT3;M0*QDQ0.
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MG'Y.K]WQ=*/G+=CD2 =QTO3E312YV$D>,MK0R\/'-6+UJHD=PFX(EYA#>]K
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M9BIY"B84R!L[BGZ=54KD[4,A0[1K*M5PC$J[67LS4V47*R\<9,I%&2"QETP
M-R[:Q_DVT<?R'DW7CT.;_!HENSS@IK/HL:M9M*_AN0#<&PM8UFW#,#E^<WL<
MW@19P"4>&2!P;"Y]UHY6"@#]HG[ZJV/CY\[=1JC)PRS=R[7CU6CEJ\<M@,8Q
MTWAUW;%J[2;]A^X!(J).P?'80VU@H9)8K >Z=2D@,&-]0!'>_07O:YK*<K+V
MX3?F/;G]Q(Q(&5E#$CJH 8J6!Z6T@D^@M74XU+Q\E7-YR[EV+QM:UHOYYHU
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M=;QVS)>< <=8#*=1KUFO-WY4SL,XCC.+C4+MCTS&"*R;-8F/I8IPDA!2:;A
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MHK&R.&<NU-G6K/3,LWK!M@NZS; MNR]C:48!&30L9&8:V8K*R&C[+7J776C
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M3^>^IOY^,;I2O2[]"+^3.Q?^W_S]_K".4NE*R_Z4JP6?)>\Q5/>J8YCZ+)W
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MD3L7";MX=TFHP3,0_DK&-VZQK%DY#S7^(\8WW:\+&S,*,(,B4_NY/<)]O&B
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MB7NTNAP;7* 5AQ=,RPTZ:*:^0W^!F$6C8J31XU:(F(]1$ABLWKAP_;I$4'S
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MY$0?6QN 9/;,=@P4$JRLP&FQM5LP.8[KR7'W%^=<<V_/V:1XXI)L(IBY$7L
M@" R"6+V]-@VF,%B+EM6HGYX^IF.KW4)W),!ZDW*&(:M)@TQ<9%POBIG53V9
M9NE)/65;BK%A16RDJS9PL*:+8JYU12+VB<QMSFR:'D&P1X,NR[CRHP\HQL>T
ML[1GVO<(-RB!_=9;W(7W #Z "U6W<HM_W3=L)=MX;M\VT90)PXD$WN-C*Y0?
MF'6<()&479SI%S< =A<W Y'>8KO-V61YPW?*LM28R2B92CURI53'N.X-1^T7
M9IVI2,>P=IL\@YBT''Q+<"S10%P0AC% NZ8X6T6V\FP8H,GD\^9E8_[V.5U_
M+/C^V.L[ ,\<RJ03I6.-R?VQVJ\<_P 4<1AP8\3A>+M&!E."LC9,N7)D:6U>
MQJU1*A9AH8E+:=0^;O5&T:]LIV6=8IPGS:2L-[^.;N4,D9(J#JUV-W\.]06F
MJ@E"QK7'541A%8Q-P5%V4PNTEBI]PK (E&7$AVG:YSD-R'&2?(QM"Y83+_,3
M3.N@"&.7*,01=1D)8.QTV%K]*O?.-YN)COR/D_#YH-L1U:7!QYHX\=8B#IE,
MA_,9!<OH!4'259OPFS#LL@2D3AV<M5-R_P"I'=6;O(46U@A;$J-4;RN.X]NI
M\ZJOX&1CZV[90TB[107:E</T9 #$<%*"7>4#A?-]VW/VW+VW,FYQ(<>-3');
M&+ZXVTEA,R3 1D%0%9$U=2#T-Q6\>C/D3;8#POQGB'+P9&FUQY,P_,,R,BAX
MY7/N1H=,FA&CZI<M8E39'D,UX]\<\>5B:Q9R:S&M;<BMR5BM2D[;%\GL[''7
M4@L[#:7M;<A7V*+ALBQ\P%45VH-3F-V(;#L7,_'W#MB\F^18Y^";E,J<<1-S
MG;)D:;#R$!*:6C C>,NZDW]X@:1\A -46V[]S?*P<KCO-^,8,NU+DF-A!CKB
MYD62HU)'',&>X"FX#1N"!<L3WX6*N.7%>HT4[?"//CD#6YZ#DBLYFQUR7@92
MH-[*]02<VATI3Y+'[T"QDZX$QCG,[453,39-8-A$U1SCG''.=<HW;?\ /WK(
MQ]RF*HP02F*!$C6+VX8XRA]H! 5E#!V;46U$W-8<CR!M<VVQ;WP7:9]DD5GQ
MH9@ZSSJ'*@R3ID+JD!%V 5%-[Z1<BJUR96>,=MLU297"YYKS]=H*-IT-6*7A
MMQ<:TM=Z$]C(_P""7RFB[DCURSMI9515=T];E8N ;+ 02;E =:EV#CNS;?M^
M3DYFZ[AO>V/*?9BQ8_9FE2,?BR6D60MJL5!0*S6U,;M8-OW;F6)N4R;3@[7Q
M^*#\QD9$F>8IXL;):1PWY/0JO&8K!5CD:90ZD@V-JMAR_P 48.GN2'%)E2LJ
MHL6E7LD79VN&G!6LK$N8>DSZ9"5+'DNR:E=)2DDK#?-J+)RHNB0YP4\W8.W7
M9OBOF6%Q'P/RWG&U0Y4>'/CRJJJXE&+DRQB*.*(:%;0)9$-V+68]PHK7F'G<
MJY'+#MF]XD*;FKF9LM@R2R(ZZSD92LS1LJ!O=9E1&*#3;K>I%UBC^G[E_+=\
MDW_XUG=[K4/,6*],YB_988TFI/5T3M9E.,*A8HE@6=:F=G @-TCH@8!\LH"!
M1URGA9'C?9-MQTWC=\S]] 9?;E?7&GREC'K41R>XO<$FQ(L1;I5ZS.1>8=MV
MZ/\ (2;8<$9$6'"8\;%]Z90"(SI,3#VV &MF.KKW[UC(QC"</<E<OKT@RKV;
MV-$Q[9&$9AI?!GTC5E)9[+N'9']@R-:[;.R%G1520: 5-,BB:*B2BP"GL&QN
MN.8;WQOQU]/FSX&'F[A)Q[?OWK"_O94B(%?VL>X58H]>EG.DV5=(_$35>H\@
M[W%[VX+LHW3'B:*5\H)%"@(,M@D*@&3]WI4@6&HBWS7&16]S7%K!5OL6)Y?,
MO+Z,R?DE"*2FW.[>?D+E#20*)1*3%RG DAX5M7R@HB"D>6-6*943+"N;8P<E
M[MMG#R)MWQ-[Y!A;S[*A9&$)$<)TR&)D"#H2H4,#?N.EC?VV[.\@<RP<!7VC
MBL^SX_O+ HUPB%HQ^\=G]S6_NW! E,H^4! @N#;ODGQFPMAKBIDR\P67N2OS
M[_R#YVRO5M:6MI?5F(M7<%4[/%25<?N$JDQ:N![PC#QRRBIC"LN<P%$,I\/9
M/#.:\SV[:TW?>H>2SSC';(0)"=%G<"!F$C1W!&IVUJ6U#0.PHL#GW,#OT&$^
MS\=GP\1'<1I"^B,D")W+"1=4C: RARP'=0+FM>/MHJ/*U*FSDCS8S%BO)SK'
M<(R#'^$8^I53%5!C(>!:H/&!VN3\<7<599HLFIYBQ9!5$#?[HI2 4 KN1)A^
M/^;[GQ/FW),F6;^,9"XC,JLR8_N'V/S$ALK2B/3[CHBZFNP O:J/=75-F8\5
MXSCY.TPRJ<F?(,DF5-D3G4P3V)(@(06TJHCO8=2:N8Q%&T7.NX%0]2K*DW&%
M?(I5UE 4Z@LL@7%"*3!23A;/D%Y39*MOOBS(*I%6:0<:!2"&PJ&#N-K8;AMF
M=GY6V9G+9L[:I2Z^RL+11N6)"1QRF8L&(LEWUH;EM%C:LHRMBR]@X9)R";Q_
MBX^ZQ1H\N3+ERL(=# K(N*I&D&P,BF1B03;0>UP,GWFB8KS%(0[WE;(IW&P"
MBQ3QM;&;B0IV+U9-J<6EA@4ZO6XA_*S#1YY9T&[^248J=0,GX=MGQ^/;7M,)
M;)W[$F;!=SJE_-%,",*0X'M3QQSF(']VNE%N 6U6L;1Q_9]ZY/Q?%R5XT8]L
MC@94R,8Q++G,A!(E]\R^V"H(9T74";@7JDL\43)T)C:.M&4^<KR?-)I+ TQW
M 4>M5>IY.?$*7X%NFT5/9+"Q2:L%UUE2$D>TZJ:9MR]O8?;?!\'(W3<<?<H.
M5G-QILH2QP,@4E0C#2FB0=#>XUAA:_35I9<8W3EG&(N.;IL.T\%QTG&.8CF2
MS3R3XI9U);4IBB+DI8$Q]%U6%0LQTC5'EG;%N]LGZ! -6KJ06LU7<.&\M$OV
M1FZT>!/A&[MP]:'==@+-@*'FIB(=Y=;/\LPX>9P;(P<S(EP(IRL?O(26#*=0
MN+$E>I! (ZD=1UK4WBW+W/;.88^5M.!B[CE@,AQYQJB*.I#7NR_-IU%6+?*]
MC8]JE<I"8:R[8&2.5^?>2)3)$=#JKU^(P7__ ,QA8^GF!):&1FJS,0U\7E;<
M@[%599P9XD"Q3@3R"%(&_.&R+Q;:AC1;OR?-RI9HQ[*K^[A0(70Z0J$^[K5B
M4<,+?M"NF\G_ !7MNUY,W#N![?C<=29?S,V8QRIO>D%SHD$L"I 450BB-BO4
MZR3TV6NOX)2QTSI69>7.4LN0<E8I1TM86#&?KN9W5P0;- KT)!3]'2@*]$J1
M4#\"DX;+1@MW3CO5-VF4, 6N'9MFRN4S;KB\DRLC;4NTL0AD$ZRD &/'EF:4
M*IMJ*.KA7)TV4@"GW/<^2Q9<8VWBF!LV;DPQ0Q)[D<F&T!N9)9TDURL7D,C+
M(DR,B%5L=-ZN_3L7<>4L)Q#F$M^6^+;./@FMGOC:=G81;)<O$2'1]8<G'F(2
MT.VMDMD><55'C,S95(RX&1[-B[99A2<7RE;8\3.SMAS!>'W)&262?7<!Y4,:
MJ"VJZ,@2WRC3;O8MYY=SO$Y//'FX6T\FCUE("(I5Q86C6XAQ?;FBO%C$:-$A
M<'00Y;K42N3-BCI^XP+F&%ZZA&=89,H2=D#*@G:XMNF@6.L;-%4QETV#Y(A%
M2>8<QS%-[W76SOI\Q8,#A<N!A/E9&-#.Z*\PTF55)"LJ=TN #;43\2>]:*\D
M8;X/(!/FO",G(!>2&("^*[_.\;&Q4E&NI"@ 6L*[S$%ZXOTC'UR7F5,H-<J6
M"'^BV0W^.)2QKV/YEEG+56(0JT*\=?1D\MYK8ROG-$4CH))G,<Q@]PV">7LG
MCF)SC 09>X8>]9!_>9,4GR8Z*+E/:*Z9/<Z* Y(!LW6Q!V;X[VCR%OG$D_A\
M>VY&PXDXGCBECC%W :/7+(+2! )#T+D,VGIZBYLTPXH8'I^+\R7#)7,RL1#U
M.4B\;*622^?75+E3$3=2JTG$EBI$[R2M27E@4)3YQ1*1J8&_PPB<3T&1'P3D
M^)%DY.;R'%>/))C8B)2TT:M\X^3J&N& L.BD=JS+;]R\@12;CQ'#V_B.4H]I
MLLA7(D5R?;59!(A41F^KV?;-V&HL *[J@\=^/^5B/\[-<V\OF[F=C96:@;)-
M6QE#DKZI!\F7G(BIOX&1KR3QTV12(DDZ:.$2D)W))D.8PCC.W[YPJ/<GV?D&
M\[OGS0OKBFT(MG75J,H8,A9=:A531JM\17EOW)N:\5B_PS!M/&%]R1%DCQXV
ME+K($*1^XSF0("A+'5J!8W8@BT:YC,&(;)3FV*F?-?*T_5J,O-+5M@RJK^$R
M=>;"M(.3J0^3K+*UJ4@)V#:.0$O?'MH;<AA*&P$ PY)Q';MVV#EB[EF\FFRN
M,3RF2*#V664RRV*J-4C#0HLI!)OUM:O;DV=C[A^>?#XGAX?-,K'"SWE5\&.*
M&)%:;%C4H\<K]6*O)(-74=#86=J\XT@9EA*2>19'#R#?HKDF"C6<L_IIU/P0
M2;&/D&,HR<J(F^]!5NL7W=Q ?;TMSS)_+<5RLE9?R*BP$H!8@>M@&4]?6QO\
M"/3GGQ?@3;GS' 2/:8=YUD%,65VB$R@#]I6%AZCM?X5DIRE%4_!E&QT^N?,/
M)[0(AL^=1JEI4K;O\?#_ +%I%-M?5*CCMBX8PTHY  5^:21KM)F)O+7*< /K
MCF7C>PSYTDV-O6O#SE=UQ"T[+DW?I,TD,D;P*]_PN9G538/<:JWOQ'^,\GES
MMNP>*XLT4<T1FGAU"7;XT90XA$TS1O(%!'[Q'C,AZI;I6JT'D?*%$L^16/.U
MMC;%@I-'L2\H- CF8U&-<N$4)>)?2UT<61W.-U6ZWE-5S,VKE-00-W*#N4<E
MV#%CW6,0X/+L?%AQHFCDACC=H#*RE= :2<Y#%.H_W@)OTZU41;MQSA&_Q[5N
MG!?XOOC/J'YO)<-*H^8/HQEC16L+N S)IN++>XHN!2XV\C;.=Y9^;&4\@S%)
MJK@(RB5.?2Q5#L6T*HV:RMZ>-6$ ,Q,3"Q7Z:9C*/CLQ(H8Q&8& #ELVW9NP
M;/L.5@\RY-E[SE(Q$*1J^$\8]3J+3 Z>A0]6/SZ@1:U]WC:O)/!8\;>-AX/A
M;9M69E F69?SRRR2W*07=U"(HOT"@WM>3M4<<Q2$.$) UZDY[_&MC:!EY5G7
M:K9(.4+D2N/S^2ZDI"<NSYZB6U13@S@J;421S3RNTVYU-P NT/ &V[=AY6Y-
MA;U)N'N:)"DHL\43@Z07L/<Z@V;I<] H]=4>:WR=PQL7<]VX_'LW(YI65Y\>
M0#$F"A 43&L_M.A"E_WK AA8"N7@9>GLHS(LI:\LDHB*,(1F^K;R-GI>+D:P
MZ*8LS.'95QY&R991 H%2;N4W!3(B41 AM]3^>]F@WK)VOV-W?;-QN5$31&6&
M= QO,]B"DB]E(-@ /E-4/BC<L_;<'+*;*,W$ARUE.4DJ1R1Y 0!(D]U)4]HB
MS.I1M1)ZBI%\<,2<4'(6MICI7.T*$M)(0U)SKE"UJ2<U/QSIJW=EK^*E+8TD
M1=5>.*\\HR+QBHL?8Q53F^^'"M?#<+<6P,J?<UFD5;;G*Z @HHC/Y=!"$M=;
MZ75^EAJ Z5LOD?)/(V#A865G1['EX4:O//MN/$WMI[K&0S99C=&$C W'MR*J
M=E7I6M^GN*$-C"9J>6<OY5R3CV+D5'4YE"#F[!&6=/(C9<1?0**M#9P*0R;E
MV4YD6Z#9O'MR""8$[2[ZQG;]CXYC\YRLR??]QGPLL#),\=HOF=>D85]:/T-E
MLJJG2ZL1<R+N?.9]R&[;%MVT;3N&2K8J831K)&,9[J'O.TL@"7LTC2/(Q!8G
MTK['H?I\862P[9&$=?&-K=-E+5CLLED'*[J;35;LSR,E/61!]:).(+)-X])4
MPINTC$4$12*01. A<][WOQ,>/Y6X8V9FY>YQQC0D4C13EVD50TG1U70Y#?(H
M'2QU7J3;]Q\W\AW+)V%FP9,%)9()2N-B%#KC=-$3")'*O?3J!NM]5P14 [3.
MLIJVS<\U6>A%R4\K)I.9!(49$&97!5CN54=S&%=-N4YMA'J(@(@/AKKCBYU\
M7PB97DB;& +$WDL8V!U$B^JQ[G]=<P[[@Y6U[_)@9,44.>N2%]M#J74IO;5?
ML?4"WWU,"GU'C?S(>LWB.9N6MAC<=M(BORS2/EOH'5U_,$5OF3_RJ&B59EJU
MD&YSBMLFL"92%%0Y1$!Y%WK-XOQW>3A;CO>\9&Q9#N&QO;0R168C2DBV73(9
M"29$8CVQ8CK74$6X\SX;LF-NV'M7%\;)RE.@D/-(QC +N4DE?0Y#*.C:3<V
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M7F+-]:KU6)6]Y3CZ54)],IBRS=R1I8(B&3G(]Z<R92-B@W!4/<*'3:Y;7D\
MVO9\:;?MTSA+DQEC'D-KCC)C)9&=?;DUCJHZCYK#M5;/R#R[LFT1OLDNV2;3
MAS1XV/-'CXIFFC5U6$A6B?7&UEN7NQ4_,6-R:'D+/P?4I<3B?&2G(].@V"YM
M)(B6([!<I&P2TW$NP5<J3,C:I56=AJZNX $UA36_#E4#M H==6H[MPC$Y9*-
MMS=V@V7$Q/<E$4@F.<2 OMB)D"):_=?F;TM>KC%LOEG=X5WK>8-C,Z@PA\J*
M.*/'!(?4##I#$!?4-I%QU)KE99GN,7&^;LU3F<Q<L([*F0JLD#9Y*?"V<EH@
MWC=1&.KZ*2-=^8F,?#'5'SE4$V3PH*B)UU=M@N'+]IX?F[;F;O@;MON%OW\-
MF$9=8@B12(']J2,(+AC&%+ ZE!-K$DU-L&Y\TY7C8N&VT<4EX]CY+A5M+$4E
M16+R^X)?=9F7\ =G1B+!5/6LG'$(Q38>AA3%4R?F$%,ZH!WG2-&1PI&4'WA!
M8Q.IPWZ'$=8'_+6Z>'N0KJ+D<UW#YB+:C[6+<COW/VG[ZT/Y9O\ XM;4 K>T
MO0=A\S=!]@]/LJ4NOHE6LJ:4II2FE*:4II2FE*:4II2FE*:4KQP_5[_87]*7
M^!_FO\_OEII2K@?V >E*H'$W^)'QI_/?4W\_&-TI7I=^A%_)G8O_ &_^?O\
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MEF?,V(C-*IFF5C5K;.*_'7&AT&"C3"%/;3;!^H^A8M>2FE&8*.TTT2$= 3N
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MD)YRB<JZ/QZ9TVK=FL<!)W=<?/'_ "KO/\'R\'*W3*6?+%X]#VCCD*Q!)ED
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M?#E9#-[;]+,P;5(MK#3J-U"^EJU5Y!QCM6ZP;2V7CYLN'CF)984T>XH%AK)
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MG'.9$7[9%<\6F8B"J*!BF[R$[2B!@#8 UUIM)9-JC]T!IS%\VE2-9(ZE5L+
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M5RR1+(ZJBLUU5BI&IEN SGJQ!( !%KE'N_Y"!<+:P8L>$D1'H3I^VX-R>X[
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MIGGS4:7/R))&]MLNZRB'0S>Y(HD<*^M50*&?HQ-Q:IJ5C'],IB23>NU^/CC
MGY8/$"%4?"5,PF$RCI0%5E#>\(>][.@;:^ '(.6<@Y3,'W_+R,JQ9@"P 'Q^
M11HZ_=;T'7K7HVX93!HPP$3G\(_#]GV]*K)0P)>88P&$#!YA3E[2= *4H'.8
MPE H[ 'CX:QQ5LQ6%39NP ^/QOW/Q%4Q$CL$-V?TMW_140XI"Z)<NKHF\"9/
M0IC&5/GZQ+,"@A%PUDCW#R/DFOQ;<@I.GKHK,JATU/,#M,7IMTU])H=ZX=LG
M\O[C7,^'3X6V^:MBYKG8V80Y_-Y>/(5R(-</9H8UR8QV"Z8FL;DBKY/DSC:D
MP<D(V.J]4<78,9'U W(8?+IM8?IJ3=^N>0UZ[9V\/A_$]^L\C C 1$G9YM_"
MQOP0-?)2%]!-JY* DFGX'!NX(8VPB AOL&6\8_F#<+W@AO+O$QG;_-BB"?*A
MD @T !5"8YL5!73=2Z_-<!K=:M&S;+@8^=ALN\;A@[1!/[[11QAG$@;4?:DU
M#U_"7#6%KJ;5;#'62\WF@E(ZP<:>/\!;85R#&M62!FWXUV.2%,[1VZ=Q"M.C
MW<BJ5(YBE*8XAL;<%.FME[]_,6\08NU"/8N.ID-^658@(PK1,+%=<98HZ]!=
M7F0CU-Z].4\;3)SY)\+?MT$&1J>09+&61Q?5'I=#93V)Z >G05:;,>-T/F"Y
MY4RO8(JT7I2'"+K1DXY*+B:RHHJ4YV%9;K*KNU%%BDV#<_\ NP,/:&V^M$>%
M/J&Y?Y:^IKB6V8.-^2X\V\%Y(H"69T]N0CW %"QQH0/E^8%F7]Y<!6LN\P21
M</S</:4R9D6 -.6)(TAU#/8?*MR1<W))L*C%Q:<(AF6 %PNDE_Y;+^3YI_*$
M7*A&GE)]PB)3G,4I]BZ^H'\R!)I?I7W=L4$D[AA7 [V#R@W^ZM+<"C+\H5L8
M2,%BDO\ 8O[N]9:51'<2D$ )VB BH4#"8^W7<G@'C_\ =K\S<OO1 (#J  L2
M!W_M'^7I6]]76Z=*HZ3H5<DUE7JR+A)==(B3@K&1?1R8F QU!5.BT732!0P'
M#KMX!\O76;[!Y'YYQ/;5PN.;MFXF'K+>VC@+<_$6)ZVN!\23ZU72;A-/#[&2
ML4J_%U#-_>/I5"2/'_&\NJFYE&$B\6:J)+D%6P2QQ/Y*A54"K&,ON<I50W$
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MP'M#V;ZMV-S?EVVHLV#N.4@D-R=99B0 +$G[;GX]>]^T^1N^=E2"21K,!;H
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M)5;VUN2(U+*KD*";L48@&P4=35]\M\G>5>4J'9(NK,ZLSK]?K$V_M=OB(5[
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M#TJWE)QG7:>T7)\(G*2THY<2$O8))(KB4FGKM4SIS(29E!4,FHNJH;\&4PE
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M 76,31:1T5;7)N0/A5K(V2>,':;^->*,WS(4G"#I(X@<JJ;@AB"02@F)0$0
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MD$X'YS<]OF>Y !6$*50 ]^MBW?K>HCHJ=_?W]Q">2H/F!W$\LQ$^HB(#T\H
MW 0Z_+K[>_4U[B^&=\CB4O(4#$#X%KM<>MNO>N#?IG,Q\S<?6*P0S@%3UU
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MP[  @ =  -?GJGBFB0Q3!TF1RKKZJ0QO?[OT_P">M19N/-B9DN'D@#(A=HV
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MAY=Y&V'+WKC@QYEPY0K0LQ$KW74WMD#H5Z=""&O:Z]ZW+X\\$\I\D\9R^0[
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M4?\ +W\?Y_*>>\J\A1<@W7C&+PKA6?N0S\$0&197D@QH\9UR(9X_9R(I\C6
M@?2G[MDM>M>[3NLG\6_B&<JNJ.& LH4.EY%73;3ILC74"QM<]>M62XV/Z3AS
M*O(=I*6]>44F;I4X-2?=-EDH:,<5^MI Q@'#PQP(9TRCY1/8_<'N'*40$2B(
M[;^MS*\G^3?!GAR'/V1=M&W\<W',$8F$L^4,W+B]W*2+N%<XZO:VK5(QZJ5
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MZ\1\*.JCC]];9^QISMGRC9GN1):<CAW3D"R3P\C%+F<J[N712H* )04$0 ?
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M#J?T7JX!3^ZE[PBJHF54Q3&$Q2% OWWDJ")2B'R[ (^W6&+J>-65_G8@]@0
M+VL#T]._KU]#6&,P5PI4$*/CW^\_Y6K>) ('3L,EW'#RP)U5$2AW&4-MN78=
MMNT0#4^A@==_W0)&FWXNUR;_ -%NUC:UZ:HA&4"@N?7KTJ9_'P0^A;P"B7;Y
M^=>Z'B ?!,!#7Z(?Y5NC_P!.>=[?;_%&5T^'_"8-:1\A?_GM+]_RZ_\ 6>K[
MZ^EU8)32E-*4TI32E-*4TI32E-*4TI32E>.'ZO?["_I2_P #_-?Y_?+32E7
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MU:=ZAC' AB$[^X>\2B;RQ'< /VB&Q@)OOL.V^IXIY)6:/4--F/7TZ'[/3O\
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M%,4WCUU]./!D>[>=?HZY=A2Y>*?#G%-_7);;FB;\\S3M%+)FQS!K10QR3M*
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MKQ]O&[_2TNQYF_\  .5;)_"7APCBB:3<V<+A!&R<C&AT RR+,SRH!J0J696
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MV^G?P;SK+\O0OONTY<.V[#FA\PR)H"M$PLJEK*Y+#II)4@@WL0:QY>GVXBK
M\NUGCY,5G!6#.)4C5_P#QL?S4'HD.V4$IR)IBB "< $OW=? ?ZQ_"WEK@6+A
MXNZ['E/L$,DDGY['4Y&&YMI2^3%JC36&) D*$$6(':NK/JAY'@/A;7L(9$E>
M0SV/1[:67JIL;]>HM\:C];LB0LYS[D7<Z('98R?-3$$0!0&I$6SMD0PK[^0
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M;=OC([C-!.X+"]+*] "/9)@>?5;"4R9D G%E)%JEW"4?,/\ ".$Q'< #WO\
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MT'#LZ)?-(F9$P&$1-L4=ON[Q3SCQM?!B^0-YF"OB8XQW4Z@7R@A$<"$ ZGD
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M*^GGC^;AG(_IVWO<.*A1E2R^[/C&P]J8H PL.@#6U#[[FLX[%5=1%N1"1.^
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M!2>DFH7L:U3]2_.(N,\<EVI61M\W:,(%3H$B%B[?JL@[=6'2UZS<B8H'+W%
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M@/@3U-SW)'4"]?&O<<MMQSI=SD/[[)E>5OL+N6/7U[US@[ V[R', %.IWF4
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M@4P]HB(B4! P;?)OUUB9=LCI"&1@;EK@FW>WI]P^ J  7\745H @IYI@(/>
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MW^POZ4O\#_-?Y_?+32E7 _L ]*50.)O\2/C3^>^IOY^,;I2O2[]"+^3.Q?\
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MFQL6-$,*:??4JW<-9^1<@WKEI&[[YE/D[BH-]0Z*@9%Z6L!U=>EJF0!RF[Q
MP#N<=_,)N(;E$![1)V!OX;;[Z^?"OK346)TMW8 GJ.@6VD @VM?4*Q3I^NOF
MIL("8A3"!-OO=NXNP??=H]3:.L4GS1EQZ'H"0?\ 2L3VO^J] 2IZ@$5$]9KD
M+(G).R1<VP>,\#42@Q4<,<^CV#F*R%=+&1=Z^DT%E45%P"MMQ1:B5(Z0D7(?
MJ.^VN]7QO"GCGZ&MNSH)</<?J6Y;R.2;WHI9%S=EVS =((XI(E=1;,,,DX+
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MJB2P[@"YTWZVO?K4UU8YH=FI'BW(#19D9G\.03($!J9,S<Z6Z.PHAY9^WW!
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M2Y$\KS3.;6N\DA=W/0#J2;=STHS.[:F)+?;UKZG4$Q!5.8IA)_K *294P$
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M*3WQ, "4AA+L ^ @ [ (;@/MU\5F>)R40%NUA<#_ #7Z_;?[JVF :T]P4Q2
M ()E-O#M H; 40W\1'N 1W'_ +M+PM&8G)5=7RBP^7H >HZFYZW/7MZ4ZVZ#
MK0"'.F*9S'3$AQ(4#"'<<I?](0_T=QZA\H==2A'GB&/(2CJ38$];?$C]=O\
M5M]]1(T];@UJ4HG*4##W]W@<H] #P#8/'V:]1$LL:H2NKT:_ITMTZ$W]*EN;
M^MJT$0$O:':8!\LQ2G 0'?< -W&$>GN^P? =>;N%58>AMI('4=_Q7_7^L6J(
M%^M:F* &* "( !MP'N, ;B&WO  ]IR[#[0Z#UUZC0)?9*E4ZBX)O<BWQZU W
M N#7#>-47S!XT.;=!\U<M%%$E3D$$W"1T% *HD8JI#@4X["40$!\!U6[)FR\
M>W;%WS'>/\QBY,<T>H*ZEXG#J'5@59=2C4K AEZ$$$BITD*N'47((-?G*Y+U
M*[XILG'QA<G;5:8I66;I$0CXDD,J^"DS\K!S=<4D5#J*K H+AP]*0B@B(@GT
M]NOV2_2!Y'\9>=.-\YY%XMCRAL.\\<V[\X6QGQ8#ND.+EXN6L"LB*Q$2XAD,
M=UNR]>HK6'EZ*7 W;9-_6[_.JA^MV8-<W)]1?3^BL\M/2EA=+-CFCC@@Q@GJ
MDH9)8JCI-RT Y$R-DUB DH)0W$=O$=?CJYUL&!M'+MSP4]Q7P=VSH"A(.@P9
M#(/G(NX/2X[V'?O726[[CBY/'<+<&:0G)B<:+]+WZG]?:KLE$.BGO$V[3$,?
M8?= WWH&#;NZ!N/Z.VL=A6*_O/<(&Z>M^E^A]>_IZ]#6NFN.@^%ZPD<^G#KD
M-R*Q=QH@P(=)C+1QYY1,=Q\Y^JDHX.KL;L2% 5MAW   "Z^@?TQPCQGXLWOR
M]N0)F:&41"UBPBU"]O4R,&(M;H5'I7TV^E;&A\2>(-X\N[G\LDT$C17[653:
MWJ;A;_>:E!C:]3N'+SD+BW'Q%9B(FHP49.X^D8Z+^!.YK,H";1TN_2;'30D)
MLJSHAE7  !C* /< B/3,_J;\?[7Y.\"\!^L [AO6Y;GOLLNU[[^=RWRG_/XZ
M2LJ8YGUMCX=X<@+&IT@,A33<WXOP8(O(_(LSE&>K1Y$D_N% +(23<Z>EK*;"
MPZ=>M5!A^J9'Q[G*W2-QD"S&)<M0B;J(?3\XL8T)?VRZ;<8.+:/USK%2F81T
MZ.1!(Q0_ "8H!VCK&O*7-_#OF[Z4>(XW"-L7$^HOQ]F/#/%AX!T96Q"/YL_+
M>&,)*V/D1X@,KW$;3LA ]U;6SF$@2>;$VMRV(@5G4&[(RM8CK<Z&)5A:RH4M
M^U5Q>/E9FL,3U[Q+:+;"/X>5L4E=L,L'<L1Q:5:L^43-:6+F/56^),PKTRZ1
M\H^PB7XSJ.VP!2_6)SCB/U)\2XI]0G -GS,?DN!M6/M/+)(\1TVW'SXPQVQQ
M*$"M/E0)EAF]QOW>/"&"M^+7N8T>1&L\6LZ5*F]S8#3:[,26ZENOH-*BUJEH
M82 )]P,4.TFYPW*/O!XIGW\0VV'Y-?/V40(7E9FU'U%QW^!Z]NWV6L:MHN>E
MNE1PSO2LIJQC*YX#G64#>X"8"?DZ\ZC8L(7**)&;5@,):W9F82!U@8L$T6[@
MKA,R = ,  7;L;Z6O*'@./,R_'7U68.9NGC3<<$8>%GK-DR97'9#)++^8VY0
M[)$DDLSS31K"T;2"[Q,KO>LQF=F$3E3&/1K6M\ 3U2_Q4CKWN*KFF97K5K?A
M3Y*3B8S*<9!0<O<,?H3#1]+5QS*1;2269""8]ZQ&OQ/9WE+ML&XZU=Y2\ <Q
MX=LC>3=IP\[</!V9N>5C;9OHA,4&;%CY,F/',5_[)IO;Z(;=38>E_-H&"M(A
MO&I^\VOT/W? ]C5V#$*MOU]X!(*I2E-L78!$##WB8X@&WCOK0;JTI#3-=A8'
M2O0#XF_6WQ/W5Y'22=';[37S$Z)@'VF+W !C=A=NG^[*;8.T#"'R]-3!HI/]
MV&9P21<@#I^R.GZ1<]_LZ5 :;@,0!ZFHPGKN0(7E82W-EY"0Q1;<1FKTNS6E
M7*D=!72OV%L\BWK>.5<':H+2T;+N$]TDRBH" B(CVZ[:3F/ASE/T%OX_RX\+
M$\W<;YPN;CR)BH,K-VO-Q9(IXWGC17=(9HXV8R%@NF!>FL-5R5H\C%_+1]94
M4L3_ ++?+I'^N';W#W_=QBKTY$R'4L6U&0NEVF$8:NPI1.Z>+"(]ICEV;H))
MB/<LZ<'(($(3J(] ]NN=/$'A[GGG;GV#XT\<8CY_(<QCH N%CC6VN:9[$)&E
M_F:W0%0+D]:!$]PA5(!]22 !_ET_348F=0:\QH['^0;S#W&LXTB9>6D8[$]A
M\II&WXK1YO5KE9F:35J_59.VI"JH,EU#H^6/<!1[Q,/<F7Y F_EW;KRKQ)XS
MSMCY#YIW+;X()N2X:L\VQ,R%<W:<4M-/%[T3W,N1$L<IF*K+_N41*\O'AQB-
M4MEZKW-A\0 ZD>GX@O;K9@UK5-!---%%-(B239!%),B29"@F")$R 'E]I.U)
M)-$ V   -@#;7S/>?)SP9LN2[.?<9G8EV9OF=G8GJQ)))-R3U)JW2 )(1W()
M%Z^J8%[3=Q2J%5+[GOE*4P#N&X&$-AW]FI%1HH6#$,KVL-0L?M'Z/UU :6;K
M45N3\Y#XK94//+BF14])X[N$+7W5AD%WR3BFTK(KU*H6>7:%:NT$ESIFE$"B
M54JB8=W=MN4!#O+Z(.,;WYPW#DGTJ/RC<MDX]RG8<G-AP(4QWBW7=]G5-PP<
M:8S022(BICS2L8'AD80A=97H;C@R I+B-^&55 L!<'W$ZW(N%4#4UK?*IOVJ
M4#5TF_:M7+0Q%&KU!!\S63,4P+HN4B*)*[!][NF8!_0'7$.\[3N&S;OF<=W5
M/8S\'+EA=#;5[L+F*16L!8HRG^FXN*H)$$9"@W?U^PU0F39R8@Z;-EJJT6I>
MI9B]CJ:REI!!BE)V [<_PK-,[@Y0.)-C*;%Z^YK:OT]<2XYRCR;MDW/TS_\
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M!!1: ;LVKURL(+I)%.901ZZXF^J'ZC=K;>\/QSX:X.OBO9^+3Y"+[,$F!O\
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MY[D)X)PO'GB9<+!7V99'Q\AI?S3S)(L3A)8V)/[L"JR8H\*%8T9)&=-7RZ2
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MWG3EQYGY+SMSA*MC0N,9"2>L<1(OZDKK+6"W/J!9JPOSWRK"Y[Y9RIUGTX<
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ML M]"9QK84K:FE8Q>-03-,QS)U)-U&(,!6$.U,VZH% 0VWU5\XX?_+VX3O\
MQO,\;\CYAY PWWI1N^ V(^ [X'L3$C%D;&P7:=\G\NH"R7T%CWL:G9=LB/NK
M(SQCLMBO2QZL>@'6W8]KU3,/1H*!A[!%\G,KH9^F+/(P$D:EO(=K,0==?5_Y
MQ.U/6*9&-G)X\KM:0-YJIVZ8J>4F!OO==F;=XH\^>6N0;#O?T6^,\OPWQC9<
M?.Q_XQD2-@;CN6+N Q+_ )R29ER,M81C%HBLDX4RL59"3?%]XYML&S1GWLB"
M/M?\ ;T-KBY(! (OZU>=')DC\"BG5,-WM5HU3*T9E4AT*]%(MFQ")M4T@?\
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MR;O/!)'M84J);, ).JG22.I5NBD7&H"K;QV2J=F29Q@P:4+++C$W&VS-V\M
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M ;N*0H>^8X]H]"CL(!L'4?N:]G,<,@F4ZP>H4 ZKCT[=+>I-A7F 6!!%A00
M#'[>[W1$HCVG)L(@._:)@#NV^4-3^U''JDN=74"UQU^()MV^(O4+F_2M"D][
M<=N@ !3COYAC#N([CU]@:B(L>.)7G+$GM\2?B3^KK4+L6-@+5,[C[UICP0'I
M\_N^FP!M_P DP\=O'?7Z%/Y5C*WTZ9Y067_%&5_^28/K6FO(7_YZ0'_NZ_\
M6>K[:^E]8'32E-*4TI32E-*4TI32E-*4TI32E>.'ZO?["_I2_P #_-?Y_?+3
M2E7 _L ]*50.)O\ $CXT_GOJ;^?C&Z4KTN_0B_DSL7_M_P#/W^L(Y2Z4K+_I
M2HN<C>OT; !#?9Z([^P-TPW_ ,^OC%_-NC>3#XBJ6O[N4?T:5K:/C@@')O\
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MUU/ FEEA!)#=P>C6 OV/]7>]NEB2'RZ26[^GZ_[*%$G<(=YTNOB7J/Z B'4
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MU'V]\68"@U"1N=QY-28G8BNDC#,EI!_.23]-<Z)(]B@DL*1W"J@!VB90I?>
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M12/Q*-/2]Q8^H6QO<D'TK/*CVKF743)Y8+*)G(8Y.WSR @B4QTP$W=L8Q3
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MK^]!6P'4GH-6JY[AKDL#:Q *J5-Y>IJ=Z1%2^6)5>NY??(9,1_\ E'(;M$!
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M'33=C?K4EH*:B['#Q4]!OD7\9.Q;.7BGS;=5JZ8R+<CEJN0^X")5$E '8=C
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MD(%.NNH(;%3( F'6X_"/@GR?Y\YO#P?QI@OG[I*P+R$E<;'0FWNY$VDA$'V
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M?J':  &XCMON(CX=?T=,BT@$A90JCK;J;#UM;^C^FHJ.M@*^?:;N+VG,)3^
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MH+,E2HD(5NL41%8R:0B;RE #M.4Q2B(;[=-<%XT851'&P>,$D,!W%^O0]K_
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M$2B(8V*NEKB,K.[.Y:8@1K')@<?\C960L^=MN;%QUDOJ6,QN[&Q!'3JJCH%
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M*%04<IM \M/L Y1W$2]=[^2]QYU]*GTMYGTEYO&,W:?)W)=P&3R+<G"9,4^
MC^YBXN(Z+JA#^WCB76?V' 4>Y>K.N'GXNU+DPK*1-_HJV@H;C5JOU)!T_A
MOZ]:F*\C(]Z9(5FC)X"#LR@&4225[ ,U72,!3%3V$XF4#<! 0V^Z :^7TJ/
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MY_&N$5XIEY2,>6JR[!K&*0[IJT+L/:;94X *@'#IKZ#_ /JA^BGZLMNS]O\
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MMZ?KJRMJU$2W+CH:WB "(*")2=Q._P HHAT FP' @!MW;"8-4YCNP>ZZF%]
M[]!U"@=_L%1L3=A?2/6MPB4# 3M[NH*=0ZF$ $2"(>(F#V>.VO<L1/I"'18$
MCK8V^/;J.MK]014O2W6K'9LS!AO&U><MLLV2'81]E:+QZ=<>]CN5L3=V(,W+
M5A"@)W<@7=;M-V%$"[[ZZ@^ESZ?/J+\R\YAWSP)@9*[CLV2F0=S):+$PIDO)
M'[^3I94+!3:,ZM:DZE*$FJG'@FEM+$0J!PNHG2NH]=-S;J1Z?#[*@XTL%UPS
MD_#>!:E.O,7\=IPRMCIUYLJ3>S2MR+.BE8U,9MG,ZD\9U=I&*S)F;=MY97()
MD*/>/<&OI]NG#/%GU ^'_(OU0<^VS$YE]6^R8WY#=-IVZ:3"QMLEV\/@Q[V8
M<5X9,YLF/%&7),7>!])@AB0QLIN;B.>3Y,<:A\M@Y/SJ3\B DFQ'X;D] $CT
MJEJR-4;&5#QLVD&M"JL/5TIJ4D+!*!'H"1W*2DJZ5?OWTD[7.J\=JG66-L"B
MABI% "$ I"E*'QS\H^:O+'F?)Q-Q\G;]G[P-MPH,;%2=PL.-!!$D,:18Z!((
MB$1?<D6,/,^J29WD9G-JEGFG(C8CH38*%4$DDDV4 $DDDD]3ZDU6P;>4<4S)
ME3,!#>9WE$3";8J9=@ZFW 0ZZU2]O8_$H!4'5?I8] #ZWL1W]!7CI(8K8@@V
MMZW'V51&3Z:C?,>7*E..I;% /XL ,&Q#.U4#'8&(8-NJ;PA-QUE/"]ZGXGR3
M WZ(?O</,CD<D$_)<JP6W7JC,EQ_I?"LNX%R-^(\TVWD:&PQ<I&/^S>S?^R3
M6*3@IG5QC:T6?C??4UD9"#DWIX7S^Q-9P0%TDP;MDU2B9=0R>PAMU  'Y==<
M_4]XTAY5L^)Y?XR1)M^3 @R0AZ:;%M9;LMCZGH0;5WE]3_B^/F&R87EWC&AH
M985]ZPU6Z$DFW:QO_168,Z1)(ODN62*K!RW4\UNZ[%2J%5!+M17;B7RC(>6)
MO,(?N 1[>G37$&'-F8.=#G;=+)!FXTB21R1R%9$="2CI(A#*4(4JRL"&L;WK
MYUEHX YC<G)U6N!TMW)![WN!:UNEZQ1<Z>,V+Z/A#(\]18J/KBUPGH5^M7S#
M*.(<9W95%4*9 IO"QT)-3@F+YAFZ12B*(>[X 'WB_EI_6CYQ\M_4EQWA/D_/
MGWC"VC8LQ$RUC@BRC#&\.AMTRA&)LN#&#%4]URVJ5G<L[%Z\-RV7'Y?Q[(V3
M-B]P#5("-1;4P )6QZ$D7^4 ,UV8%B2;'^FEE"B5.[V.AY5*C"9>:I1U.AI>
MW.W2<L6)C2)I-:@W"47,E%*-/O 1;D1!4H@!@-MOKKS^<;XM\G>5/!^R^0/$
MD^1N/CW%R3FY^'@*LD4Z.OR;@6A4O/'&+,2SO&JK[@&I0:P?Q^V8IRN%XA;(
MBP+,O74P0BYC%CU"-J8J.@8DVN36=XQC=HJ&,.X]J8B0!,(@)NGN@/LWW$?D
MU^6"-M:-[H;WK6![D@=;6^ [G[.M^U9D;]P1:FX GW%$^X"!1.("4IQ-[2=?
M>+N'CJ57!PS) &*W'S6L".UQ\1?^FIG0H^E^C?"J(NUZAJ0R:&>@L^FY8ZC:
MN5]F;=_-O0[=TD$@ QP;("8IEE=NU,GCU$-=L?1C]%O//JQY1[>-KP/&VWS(
M^X;DP(15_P#<0$BSSR =!>T=M; Z0#C7(^28''<1LG*;][;Y4'XB?L'K4">0
MJTW9J[+5I>G1.8<IV]B=D2%E?,>4C%L.<1.46#1-4$1GQ4[5%%RF!4#)!N.W
M37ZK/$O&O"7T\\4Q>#<'3&VKC6$/F3'L<G+F 75+.XO+)(][%I"QLP4$*% U
MUL?C;S)Y'STY-"K[3LD;:HYLFT*,K7! $@_>#M\J_83Z$8U:CQ RK5KM'3:-
MFJL*2LPJ%@+>+6#>4JC^4^-?-R5",:O_ (E!ZG&"R$C@AN_RS&#NV 2ZV5R?
MS7Q!^-28^Y)DX\&7(T1QTD,65'$PM[Y*%9(RP.I"MCZCK6\>.^$]S7D$&<3'
MN^\1(I:1(+(TFIK)9+$A0!=[WZ]"*O[:^:-<J$%#MLTMH/(]M1D7T0_KF/IQ
MK$U.*A8XJ:4.Z;-&I'*(G=-RAN0# ">VW3PU\YMC^FCZ1Y^:YV];9GJF=.JR
M?F=YG?*FDE8DR R94ER%/0]0>G<VKM7:_$WFW_#L>9L'&B6D:\@C!>3J39@,
MC6S=+?*.Q^RJ=6Y_/7S04</X$ JOD]B3E>&7F1%90H]ODN 0< J8GRE#;?6V
MMG\3OD[SF<>X;F<?2#;C$1,@C]N74%<677I^0G2;'N+=ZR3<O'NW<3XYM_)?
M+.7OD/YUF#8<,3M/CZ+_ "SQ1V,8;3\M[7!%JI6R95]1ZY0[*6CZA9:W7I5N
MX<(K1-8<)$:-4!V65>JJ-$B,2>4 FW4$NP>S6%3[5M./O69L'-.=<7V3-Q\B
M..S9&/[D_N, !"C2W+'\%@K&[6[U>9.2_2KQ+!P\S;=JW/?=WR5#>RY]IHC:
MX$VLG0U["Q%694QWR6RDR7=16;U;FYC5HU&Y0S&TM8Y:LNWZJQ (]4;' 73)
M#R3><HGMY70!-U#5QY'C^ _!N5BY'U&[QN5]R&2^W*HFCAS(H%0MI7'591.P
MD&B,2 N";*>HJV\G^I#;<7$CQO$'$-HP\M=23S9B_F#CM;H%%Q$S+^(Z@RGI
M\OQDO0N&/'Y*OM768LTS=AM"NZCMK%2IDF46H)NJ+5P\5<.EC%,&QE1/VF';
MM /;RWSO^8W)QV.7A/T_\'W3&X8 0<EM*SY :]SKF+3*"+?[P^X.P(M:M.97
ME/=]VWS'Y3S:/;-VW[$L(#-:/$@L2VJ/"A,>,)+GJ[QNYTKUZ"NSD.(O$Y]\
M8K7LHY!@UVBH-V[\MC7="?M2*H)QW4$G0ZG:&P;^Z(;] VY[Q?J3GR)UEW7B
M>[8N5+\YDBR%D>[,=8</J[D!NEKWN;UNS#^L[E.,!'N<6Q9&/;YE,**OW+;O
M;U^VK?AQUGX1RZ+C'EO*HG9F)Y36?= 9(2J$*H0!6<&[.O=L8? !UM3;O-_%
MY8XRT^[8!<W"S8\K6(/S O$MAU[7-K?$5E6-]5WBG?P%Y5QG;G!Z,\5E_38>
ME6XG;/S$LZUUP1$WTF5V+>)(6SFKAT?>C3% 5XY258 4PJN&WN*I]P[@)BC[
M==N<&R-_\?<-P?,^?G8.1#F2#^&8N7\K9:2$%9H@64J54ET !NH!(-ZLFY[S
M])_D?=UXU^1SMHAR("TN9#,8EA9A=8AJ!U&0$7L.B-?OUJ]E8YJ7;$41#T_)
M/'3Z.5^!9-XQH>+@G+-!DQ:)E33*1PV BRA^PFXJ&,8XF]X1$>NM3\AYMD\D
MS)-QYKMZ9DF1('D]Y%8.;^@=2+#]E3=0!VK,Q]+_  G>H+^->31NH4!(C*K6
M^ "L2 !VM:I38UY^X*M2Z;>-NLM27RH[F9RS\SID"ON[@=M*@OWB(CM_^S6B
MN6_3Y],OD=&?==CQ<3<)/^U@1L:1>O<&!HP?N((^-:IYC]+WDO9XF?<-MQ]S
MQA^W'&%>WV/'8C[ZFY3\M&G4?B(R4@+DQ6[!26AG:*,F8I@$1,+055$=QZ;E
M*F _)KEGG_\ +3V3-C?+\6[XT3'YO:R2LB=!?2C75EO?J69[=.E<T\@\<XNW
MR>UDPY>V9(OJ$JL\8_Z1%_TEJI;.6>W5"I"JE/@)66R3./FU=JD2YCW'D-)>
M1,<B$C*&* )IQ4<4AE%3[ 4P]I3#MX:V\"_R\>4;KY<&/YS9-N\4;5BR9VXY
M:3%?S&- 5(QH7LI664MUTD,(BVDAB",.EX+O*1F?&5<O!0WU1&YZ_$#J!87-
M_P#/5VL85)>L5MN]L+6NN\CSS".D,B6FNP47$FMEC;1K1@X?KA%M6Y'0(HLR
M))"(#^#3 0ZCKC3SOY$VSF?,<W#X=-NB>&]IR\F#C^!E961DC;]N,SR1Q1#)
MDE:,.SM-(M]0:0JWX0!BV09I)_RAU(JGHKEK#H ?Q&XO;I<D@6%S:KD"3N I
MTT1[@ Y3]^Y# )^OF)[CW% Q=MQ#QVUI#0TL"O$KZ-/7N!U%]0^/3I?J+"]4
M9U(2E^_?K\#6P&J)Q.)D0.N<B7F&.4JFY2&!,A![P-OM\FHO"LJ!60-* "-0
M!-KVM<C[OM["U>L<^1&MHY'5;]@Q O\ <#72OZO!/W**[J'CU5D$W (@+%$
M$JW8D;_=IE[MRF'Y1]NI1)N&.WL83S1X\@)98V9%:UM/X"+6)Z?=;UO5WQ^1
M;SC0NL>5*&++W:YZ?#5>NAD,:T61^#,[K,:/DO/B ("*@ OY;9REVJ;GVV Z
MP#TVZZO.'R7D6$=&+G9<3RJR?[Z0G2+.;%V:QNJKTMT8^M5$?+-[CCD!E5@P
M'>.,];C_ %:Z.5PICF1*0%JNW2+YZ2@"V(950  #@/<4WF&32+[3>SY=7+$Y
M[SS;I/\ AMTS=96VDN&Z$][:;]".Y)[]:J<?EFX,Y?*BQ)5TD7>%!_2 .O\
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MXC[B5(8#X,#V(-5L8!.FGML0$B)G[S'+[_N%$=Q ?=$@^[U^36L#!9=8*@J
M;ZEZ]!U-CV'8?T5X:BP ]!0XG,8IE3AL)A3+OW%[C% 3;)^U7H3P+OJ2:2.6
M4.ILH 7U U =;=.MO]6_4@=ZB%>USUKH)FKP<ZJ+B2B63B039R,:WE0:I%F6
MC&39*L7Z<;+)D^<8L7+=<2]R1R&ZZSCCOD+F7$HD@V'<,J#:X\W'RI,3W7;#
MR)L25)L9\C#9C!,$F5"%EC87ZVO7JF1D*HA#L8=6K1<Z;CKU7MZ5&^DX$N^(
M7-P=8[RQ;K'%OJ\\0JM R1+R-DKM:L2[Y!VB\:R3E5Y+MF@MDUDQ0*(%$5>X
M0'Q#L[R)]7'B;ZB4X_A^8N!;5LN_8NZ1ONN^\=A@QMRS<-8)(WB>!(HD9F<P
MO>5G*)"1&02*J9<A,@J)8PB7O?YB;];_ #&[,+V&FY"C\-KUNK64>0$'6+M)
MYEPB=9Q3&D:M H8J?IVQ]>U7!W)'9(J"3<.9=N[9D(FH9(Z9>BW0.@ZI>;>#
M?HXYES/BVQ_3WY+_ "^W[WDY2;C+R2$X$.SB**.6%I\B:'%B9)&9X@PF?YU_
M%<]8-CP$HGO*+]^C!0>W2_7X=_T$VKE0W+;'3NE6:\6V!R/C:/I[B/;6-&[X
M^N$3(MW#XH_#IH-!A_/D#D*3W_ARJ=@;".P"&J;?_P"7SY7@\B;5XZ\<[SP_
ME^X[[!-/B9&U[SM\D<D.,55GEOD7B6[@)J-G-PA9E:TTF#(W2%O<M<6*NAZ
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M$J@3;;CO/$F5%C8_MK$R+[<!() D=Y7/%6\19VQY+;3*CP2(5)#(T; VZWN
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M=PZ)+I$]YL?V"4X%$/DU\[>1<4Y+Q'=SLW)\#+V_,1RIBGA:.X!L;:@ P/\
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M'*=6(R@,OHP ZW_IK\NV4L,UKC+R\<4R83^<\9O9%V_78N/PQ6]6DDE'3Q$
M$>U+RV*X^6!>H;=.NOTM\#^I;E?UH[)Q[F/$W.S^8,?#,$<@N(UW.%61267J
MV,TZ6<$ .A((ZU])_IUXCMNQ_1?R'"=E?:E_/Y(##_LC[LC(PL>PN#Z=*R]8
M1S<UPM(TG&)JS(N,#SQV5;HF1HQ5S8G\797JJ:4;%W)@R05D(YC++=J"#@"J
MID5.0#"4@F.7Y_\ FKP#G?4MQOE_EO<MSQ,#ZP..R3YG(=@D1,#'FV[%#^]D
M;<\KZ)IH(U$DH,EW"R*+R&%&X1Y+@X^[8^)NVPAIML?'1593KL0M]+@ %18$
MB0C1<:69690<F1BG,!/+3.FD(F'<P$* ]P ?H4#"8.X  0$P!TZ;;Z^0[8\F
M@B%2$U&X/>_>_P#9Z6K )B0X#$&P'4?U??7T-^$+VI["8"D[S%$.H[F[=QVV
M^74'74J^Q;W;#5;J?73<_K_IO4G4]^U:]!#M$-C]G<)P^\  $?<'VB._7Y->
MZQR"/V&%FMJO=;?#J+W^WM:I;@F_K49+=@=C"Y.=<A\?M95.^I5V01L%5@7;
M&-891.BQ!.&:2RCUXP8HR28%!(CE4P@)0(!A "[Z[;\;_5#G\B\)XWTD>7GV
M]O%TNY1'#WC)BEGR..Q2RF3(FQXX8)I9XKLS+%'I9-<EBZ$*+KB9"R$8>4VF
M!P!J]!\"P[DKZ? ?T5+@K.]6S= O#Q[*6K]OKIR1-_HMAC'L?.U">!(H.X]Y
M\0W3;/$#G$3(N$3J)JIB CVCN4,"^IWZ4N9?3%R;'@W7(P=Y\=[W&\VR;Q@S
M1Y&-N6&5#1S 1L7ADTLHE210ON7]J26.TC4>1C20@FQ"!K&]@P/>Q%R";?M(
M6C8?,CLI#&^FY3";8X_?  "J';MN.P=HB.P[B.N7E.AF))O:UST[] #UMU)'
M]/:J;HW0?&M0*'<)#" F,0VP#N8!$ $W7;P#M+^AJ$46CYI5N"2 +="=+']5
M@?TV^-1/7Y0>MO\ /6I!4V$^Q.\I3$ VWOD*(E'M#V^) _0U! 2K2GI.O8^H
M'_)_1UJ;4P&D?@-: )AV,8%!'O 1$@;G,  .P=? -Q\?9J9'F9+N&90P["Y[
MV]?3XGTJ6PO]M?$44E-Q6(BH"AP*9-0A5"&.([%!0FQR[@ [=0Z:]<.3)Q<I
M<B*5XG#VNK$$$GL"IN#^JW<U$,5.I?Q_TUPOF>+\DS8T='F0\\#F0.T;^695
M, !)0Y?+ IE-B@'</75='OW(?S:Y8S,MLZ%&56,\@=4(/RB35J"GU%P.IL*J
M/SF4']SW7#GI<$WM\/NJ(%SK$;Q2;7;+V+L>SUKB[=8XF6R+2*V])\+"L2."
MJ6"W5V!,0I7LBBV%50R1.WS $=Q*&XA]&O'GD'+^O&'C?T_^=.3[7LG)MEVS
M(Q^/;QDQ2/-G9SQ^WA[9G90#>SC2/[0=S=I"B!0TNE6J84&;[I=B)@0W079^
MH#:5Z:C8ERH)=[$(K.54RDH]VK&2JK#W2FODY2L6%BA(QK\K5=GYJ*Y!$ 5;
M.T6[MLN0=RF(HF0Q3!U#7!_E7Q1S'P_Y"W+QQY"P%PN5[7*8\B,/%*O;Y72:
M)WC970AE*MV/S $,!22B:%O;D)N.WW'M;[*JXQ#F AS&+V_Z10/W;"4-NF^Q
MC;%^YK7ABDD1)>@0GJ/@0#^DBW;^JO(V!('6M!$-Q.0H;GV$Q@W#O  [>H[[
M@';KVDLKVC'R.1<_Z5@.OZKBI ;B_K01,!TR$( )=I>T ^] /;UZ[AOXZD=V
M@D,,'^XO8 =K>O\ G/4U-WL3^*K.YNPG4\W4M:HV!5XQ,BNWDZW-PRODRM9F
MFIBK1\Q$JD43("R"H%,)>\ 4 -MPWWUT=],/U+\R^EGR&O-N(0XV;M>5 (,_
M;LD!L?.Q'_WD#_B"L59PKD,$+DE&'0U469/!,TMV+$];&QZ&X(/H1Z&QM5O*
M[FUAC2R4O!>9K'+&R!*0$82-R')P_P U4>_SYFZ7FP\5,?$*HHSQ]Q$47(("
MLI[J8F4,4@[F\@_35NGFGA/(?JH^G#:<*+Q7#N63)D<>Q<L9&[[+B(SG\SDX
M@10,6P$@7%><PPN':-84=T]LF)9A^9BTJC'HMK'X'L-()ZD(#?3<@%1>I2"0
MO8'F'\X#>^"1R"8H;AL&P#L.X .VN#G6-H?:<:WN" ;W'W COZ?Y7JWJ71@R
MD@U;/+65ZIA:DO+K;U7R,0T<(1C)C&L',C*S4N_$Y(R&AX]H151=[(KD["=_
M8F4?>,8I0$=;I\#^ N>_4=Y'QO%WCR&$;B\3S3RY$T<./BX4.G\SES/(RVBA
M#J65=4C%E$:,38>^/#-D,7BNS*-1L"2 "!T %V-R  +U >X<=(+DXZKN4,TT
MZS8\6?5R291U2(HV>)P_Q,@"T7-3CM@X,@24?,3%$[0PB*'9L8=]@'M=_J<R
M_H>VWDWTZ?39NNU\GPWW"!LO?]+Q9$I]C1D[;C*R+J@QI@YCR%=D8S.$1OF(
MW[PGF.X83[=EI)'D9&VSB5,7(<:#):PD$?S+[D8Z(QZKK8 ]34<);'7)+A@]
M^DV);:VR/C)N=1<\.+\5U6K8P$,JV<QJQ@4((%#8-P$OL =8GL?)_$?U+1IL
M_+L%]KY_*!H;VR'=NHO'(!8V-[J2K$==!4@GLG!Y;X=^HG'?8N<8+[7S"P4R
M&/2">MF60"QO\5-_LJ_LC=$>=V$/HU=:#(4LO<+E[.S;EJQ91;M#9-9XS%4X
M.]CBCW% J?0.@:["^B;P'Y5^F3S7-Y.V/=8!QX1-$\4@8-D1,3\KJ!;]W<Z3
MZ]2!UKDORY]-W#N-;G-Q_<=S_B6UR2 QPXP9IB#U"Z@+ ];7O5H[KRLP1QKK
ML+C^EO'F5K968U"#@F;<BC]HS^&2*W1(W*IL(GW*&XB4HC[ '7:W,M]X;D<U
MS_($F+CY',]R9??E6%!J*V4$L>OIZ]:WMXH^F+F&_P"TPXD.,G'>!Q*.CL%<
MH/5V'<D=S^LBHQSDWRIY&N2.,@6Z-PK17QO,08RTFJWFEV1@[R%:0#(J\NL5
M5(-@$$"@'M$ U1XW&^?\QPY\\0-C<?0%I)Y![4"6[EF-OU"]S8"];2WOG7TK
M_37$(#+'O'+E%@J*)"7_ $7O8^HO5NK8;CEQU,R;5*-+EK);Q5%60LUS I*W
M%M@-YCM1-JX.X.\>+>6($(8J9B!N8>H%*;.?%:;%@;#O7*MRWZ7%X=A1MC*(
M99!DYF:ZM[<,6(![@AN"WN.%5M-[^TLCIS#Y-^LGE_/,(';88]LV 2?)I4+(
MH2WS7"W#6;2J EB6)L$5V6*,_=8>:FRC 0C-L+R47?',4I3'247*45"-%1]\
M&8'#\&3H!>NVM5<@\T>6=_Q9L;=-ZRHMG?&$'Y>+]S$8E)L'1;_.5MK(;K]U
M<+;CR?==US)LAW83O(6+H 2Q-[LQ[ZB#8GU^VU7=HN-I"ROFOP\,DX6$PN%A
M(D45C=YS=I=R=Y@$X#[1VUJKDWG+FN)QAN,[CO\ G?X9$ A_+M,?:]I>R%3:
MZCX&_2P["HXF9R//7\O TYC:RWMW/8=1]W2IST[B#;9INGY-:(1R[$ZS)$B9
M$W"RAQ$16W,(%01#;85#" =!UQOROZG.*[?,<7,W.2:.!50@L\BHJ"RH -5R
MJCY44$@6Z5G.-PG?I,<9>[SK%B*H4ZW Z?<3WJ=-$X3Q_P $W=6)PD10A2?$
MQX);*HK)[ LF9( $@>68!V-O[P!N&N2N5_5=O61D38_&8%6)&(665[:AZ$*
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M\-NG7I[=?&?^;6/^#XBU@UI,OI_T5/Q%;/\ '!^;)'V+482@H8P"<O4#=FY
MZBGVB?N.!A$G0Q0 1  '7Q0199)E8IV-C;U7J;D$VZ$#J #8D=>E;5]#>M"&
MV >H]Q=Q 2^(@(AN4=]R;#]P-_NZF5CD2A;A"M_P=+CO8@W'I\ ?@:@/D4^M
M:E4'N,/:!1V'N[@'H'4?$!W -AU!<B9IB2"/0WZ"W]%O^6E@!6T@]HE*!0V
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M)LF7D'+MQ;(W&3NSLH].@51I1!\%4*H^%5^S;!O_ ";/5(]9E%R6/RHB^I(
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M9T?A-JV"V1**A@11!5<H&6 J(%%QM[A16,&X*=I  -AWZ!\FH- [HK6+36L
M>UK^GP[FZCH>Y^WU]^4 +J8*O4=3T^ZK*7_ &/<@+O'$A%(MY0S,6Y7#1)(
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M4O\  _S7^?WRTTI5P/[ /2E4#B;_ !(^-/Y[ZF_GXQNE*]+OT(OY,[%_[?\
MS]_K".4NE*R_Z4J+O(S</HYU\?C=N@"(;BD @ ^.OC'_ #;I)%P^(:#8^[E?
M]5:VAXX OE7^"_YZB^8Y@$@%$^W>;<![AZ;![N^X@ ;Z^*LDDB,I0GJ2?C8?
MY7Z5M/TM0Q2$4$.W<#" ^Z8P;E'J/>._00-\FVI6]N-F5U#%_@6'3[P;@W^!
M']-1([6]**^[VB ]PF^_[Q$2B&_NE$.@#L78/N^WKKTEE,,:JMF4CKJ 8GJ>
MA-NMAT^T 7N:EM<W/>OH(]I>A=RB!.WMW 2; &X#X@(_^S4S22(GN@)I-@H
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M50X[$%,NW41U&"+*R\D8N,KOD,U@B#422>P O<D^GKVKUQ\>?*G3&QD9\AV
M50"22>P K!!SXY*36;;$QX^XD.X<QSUZBRD7#(HF/*NBJ%1%0P$[A*T((]B>
MWNF -_$=?3[Z>O!N/XNV4^3_ "(JP[P8O<BB?I[,6FZW]"Q4 FP&D6%KAF;Z
MG?2SX7VSQEM4GE'G&D;@D190QLJ"Q( !Z:O5O6_V 6R,X?PS$<:N-9*8D@W+
M+/801GSJE*J=Y-/6W_,)'!3N'_E14$FWAW!X:XH\F>1]R\M>5TW/W&&WC.48
MX TLD,;AKW%B"VFY/2U]/>]<B>1/(FX>9?,#\@8E]FQIS[0_9$:'HWPZV!'Q
M%8@,[PJM/]0G"TS&HI1[FQ)Q[1)3RRE245?^4P XH[>6<H"[$>W;WO#Y-?HM
M^AG.@\A_RN_('&MY?\UCXFT[PNEB6TF/'R94^VZO&K#[0*X]\JSC9//&U[I"
M "^5&?OO\A_KK]#=49G"O,"R+QT]5:=QC"*YV@HK(%*=,"@T,W'LV.8! V^X
M&V]NORRRY&)+D9$J*(H#,P"W9@@!-BH8D:FN1<"X-M%C:VU^3SM)O;RX\: 2
MIU  .J]B3UOV([CX55R:A0[3[")5?PGE]H[ ([!WF -A$P^ B/748'9 OM >
MU(.G0];]+_'[S>_VUB3'K\_<&K(Y/X]XMRK.0MEL\ HC;ZXY;N(.[5Z1?UJV
MQI&ZAE2,4YR$<L7KB,$YC&^'5,HF G-L =P[]*>&?JV\X^ =GW'A?!]V$_C_
M ':.1,K:LZ&+.VV0RC2\BXF2DD44I6P:6((\@51*7"H%JH,QXDT:5,9-['H;
M_8P(=0;#4JL%;IJ!M5'Q%EY%U+*<A WBO5ZZXGF9*0<5_(%;[(J5I4< &=)1
MMRCC*+).B-&YR #HI$Q5'<1$>H!N'>N _1QY#\%XW*_&._[IQ[SWM.#CP9NR
M[@WOP[MF?@>7;Y=(9&R)M3:$E=8$*!X48UZ2KCSW,*+$-((&HDDV%Q9B;W:]
MB.@%@1?J;JXQS'CG,$2:PX[MT-9V3=3R7@,WZ2Z[%7NV^'>,RJ"JR7$!#H<
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M3R9^V%@&5VNX N.C#O86^4]3WO;OD\VY;?O2C$W^%(WM\LL:A2#;H6'8_&X
M-8S<BXK?0S*3HV6JF>^4Y!^LWBE7Y3!8JP8J" BM7IT !\"'X;N^&5.JB AN
M0A1'?7U&\3_45MF_;=#"DD.3@21*7A<@O'<L/W;7U1$$$:?P$CJ+W-9SX\\I
M^2O"&\1[GQO/FFXYINRDW1U!O:S7'Q!Z7J.$(AFGB^NK>,'6>0R'B9%<5):O
M*@9U(P&_:*S*7C=E%6XD3V'?8I#E'?8=]]=9\8Y#(57<^/RF;$"W>!C=XU!/
M1D]!\)$ ##U-J^B7%O)7A'ZK-E7;^1)C[=S@KI#@A"S6[@W'6Y];G[?2LEG'
M+ESCO,7P[NKR[:CWU1-,DQ5GJ@)0LDZ.  L4T8J((-C+'$??2 G7J [AK%O*
MO@_Q1]26VG%Y)B08O*.OMY4*JF0G2P^:QU*+=58%3\*YY\N>".5\"#XN^8[[
MEQ>Y]K)07FC4'I:0 L0/@Q/3H>E9"*[?F\BX^:IE 8&>6.8A&+E0!2?;F'RS
M1C@QMG)# (" ;F-M[=?&CSS]*GDOP9G9$^1'+G\6UDKE11L$2,_A]P"^@#H"
MS$C[0+BN1]\X7D84)W':&_.;2JW9U%W3X^XO4@CU-@/6U5YL)DP >X_FB0!*
M8=BE[![@[! 0-W=Q0]NN69'D*6=BSM86)[6-_A<$].M^O]-8, +?97U%10"B
M?[TI2B0P"!!*8=PZB(E$^X  ^WKKV,[F(S]I+Z?3K?K?M>_3X_YJ6]/2IB\>
MQWICSP'_ ,^=]0Z=N[*/]G_Q?^S7Z$?Y51O].FX&]_\ _:<K_P#),&M+^0O_
M ,]I_P"'7_K/5^=?3&L$II2FE*:4II2FE*:4II2FE*:4II2O'#]7O]A?TI?X
M'^:_S^^6FE*N!_8!Z4J@<3?XD?&G\]]3?S\8W2E>EWZ$7\F=B_\ ;_Y^_P!8
M1RETI67_ $I47.1@F$:X4HB @5Z)=R^[W]R6VYA#;7QH_FU*YQ.(E%U/[F60
M._72O6MG^.>^2";"R_YZC !U!$2B1+8P#YNZ9??$0V$3#V[F'8-?$I&8N4*J
M%<_-T[_I^(]/A6UBS=#?J.U;2^]VHE "F*7M('40 -]PW 1 -MM5$;1H_P"6
MTK[8Z+\1]_K4AU-U_:K7N IQ1[!$1-T[A[@[@ "B)0'<"]0\ \?'3W(C(8$4
MZ2>ES>UA;H/3K<GTZTZ@=>];A-OL7WRJ>[W[?>B( '0"_>%W /9KT5XUE]EB
M1\PN>XN+>G4 &WH*&Y%_6M2G,4>@"'=OOY8")NWVCL7<?T-!)DF<12DZ2?3X
M?&P[=.Q_33H%NO>MO</<4H$,<";&$%"["(D'?N$#;" AXZ\A(WOB!%!0$=P
M21UO\;^O3]=1MTN>]!'W3 ;N,8QNX1-N/;X[;=NX% ORAJ "IJBE9W-R06_9
M/IT]!]W:A-^M@*M]=<HT>A1RKRR3S!DHBF<18 X35DUS$$.A6A!,N4@;_?G
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M!'N$3JC?A?O&_P#LN+JWZ#?XU./CZ!0J#_M2,0OS^[ IS=.\H,(X0'MW[B@
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M;8J7?VB8AP*0I2![VQ1V,!C?Y U+.0$UZ/E=0.Q!%KWO_1;K\10??6NX#N8
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M519_4SPT[%%E UW.ML54,#9!,5D&_G**CV$3%$9 3]RIQ* #MX".MD[?]/O
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MCDN&**RD D$J03E^Y^;L7Z=^0Y.S\6Q^/Y.UP3RI&\323Y<Z+<1R.QA2*)F
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M'Q]+5H)@*02E(38PB %$1[3%W#8=S 40$1]@:A)I2'V]"DM]]B/2U['KZ_H
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M =90KY9.8DS$%,Y>TS;RVR0F+W;A[VVX==;IV7R3]031>[S;E<<3V!98H[6
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M /)76.^2G"Z# OD1EAFCIAN0GFI'%0V_W&2AO;JKQN(^&, _N]K9E^+/(_\
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MI_@Q+OV&';6B=T\X\#,C-!GR[SDK?5%B$:+@VLTS%E N?] FJ/>OJH\?^/\
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M][=_MJ()-!V Q]P[>O0=OOO;W%#?<-_T=>>A5ZO>]_U]._J:7ZUN P"/3<0
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M4O\  _S7^?WRTTI5P/[ /2E4#B;_ !(^-/Y[ZF_GXQNE*]+OT(OY,[%_[?\
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M@J'EF*95110%N],NQ$QV$ #J(!JKQ?KB34?S.!/[>DZ2"K?,!T7Y6N.ES<]
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M?[JNA1N*.2;P_.H[9%318F %?B>_RE?-*(@(',)2I^Z7;J.V^WW-:SYA]1W
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MQT-D^4FWQIWH =.@@( .P]>W8/T0VW'4--OF4CO;O;_(VI6NXF,.WW@AMOU
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MW'<VP[= \=3M[<FDM9K"W?N!W/Z/@.I^RGX;UH';W 7<Q^POWW:!E##W?ZI
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M7!ZW&GM?M?N#<6M_S3Q2R0OKC-F_MK:HU\Q= YUP%(@&4(W,GY@>>;_YPKF
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MHGJH)^*GX7ZW^P@55R[YQC$C1L#;TDE]3)Z$?=?]%7PJ>,JG46I&L=#M#$2
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M >X [=@#O$1[A$V_B&I%$;!20VD=SJ!_7<W-[^E3=[GU^ZM!$!#<YAV$0V
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MVEU21L#8D"X(Z^M_T??4;&]FZ5M "%*)Q$.]3P$=M@/T#<2F#V[>WV:@JK
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M!J<] ARG*2P/"#L(;@)6$;UV =^H[^/R:_0M_*N<-].V?[?^['*<L=2+],3
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MWO=C_P#,2_WC6@46I ._T?BO#;_PB?A\FG_IY\'WO_A;9;_^&3^RH_QS=_\
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M\:T^@M2Z_P#D$7U$1'_E$_$?;]P=#]//@\_CXMLI_P#Q9/[*?QO=[6&1*/\
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MK>/^\S?WC6T:+41__5^*^[_RA.OZ.H?^GCP=JU#BVRWM_P!V3^RH_P ;W?\
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MC>[_ />)?[QK8-"J(CO\P1@=-NC1/P^35.WTX>#FZ#C&S ?^&3^RIOXYN_\
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M_9J0_3OX-;OQ79>G_P"#)_943O>[D_\ Q$O]XUJ-&J0[]U?BQ[MM]VA/$
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M19G=4'5& MJ(N;D=!<^IZ=:QJXKHN:.*V7N)G)N.Q#R2Y+8+MN)J7A[(&/\
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M,9=H@6:)E:,:U:/6$D4Q&YZ@:U91W.CTJ=N.[=#D[ECRM,1AQAT(*BX*ZM+
MJ>O6UP1\;>E=*V]6O*E?XWWRW7>BX_D,SP?/"5X/UI]3ZSD%;'[QVV:HRJ62
MW^.V4_;LAR2<?%).0- 1LJX?R3D$4FRI#*B"?JWC#;9]_AQ<.:==I?95W!P[
MQ>Z 3I]H2E4B%VM^\= J"Y8&W6<\5Q9-Q2*%Y!AM@C).HKJ^&@/94%S;YBH
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M,06G'%077:VS(%<R73)ND5=RU:M'KIO8K7&33J!A5VS*0064(Y<)&(DNF<0
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MYZ5;JG<\,<Y#R1@RGT2=P;:ZSE3&%GR%<+1#\H,0N;'C5Y781>6^8$,7 _\
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M=<?K]R2:Y3Q_?\<42-EU1D*#?J786]DLL:U<*LZ)7I9M.C"/+E-O40:M60N
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M ,I?"_Z]=*4^T*X"?OXN'_Y2^%_UZZ4I]H5P$_?Q</\ \I?"_P"O72E/M"N
MG[^+A_\ E+X7_7KI2GVA7 3]_%P__*7PO^O72E/M"N G[^+A_P#E+X7_ %ZZ
M4I]H5P$_?Q</_P I?"_Z]=*4^T*X"?OXN'_Y2^%_UZZ4I]H5P$_?Q</_ ,I?
M"_Z]=*4^T*X"?OXN'_Y2^%_UZZ4I]H5P$_?Q</\ \I?"_P"O72E/M"N G[^+
MA_\ E+X7_7KI2GVA7 3]_%P__*7PO^O72E/M"N G[^+A_P#E+X7_ %ZZ4I]H
M5P$_?Q</_P I?"_Z]=*4^T*X"?OXN'_Y2^%_UZZ4I]H5P$_?Q</_ ,I?"_Z]
M=*4^T*X"?OXN'_Y2^%_UZZ4I]H5P$_?Q</\ \I?"_P"O72E/M"N G[^+A_\
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8*4TI32E-*4TI32E-*4TI60#^S_TI7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>tv498959_img4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv498959_img4.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_[@ .061O8F4 9,     !_]L
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M2'X@?ZPK]7KU/_H77S[>PDD/Q _UA7ZO7J?_ $+KY]O822'X@?ZPK]7KU/\
MZ%U\^WL))#\0/]85^KUZG_T+KY]O822'X@?ZPK]7KU/_ *%U\^WL))#\0/\
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M_P#H77S[>PDD/Q _UA7ZO7J?_0NOGV]A)(?B!_K"OU>O4_\ H77S[>PDD/Q
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MY>PDD/T _HV_U>W0#^*-]_E["20_0#^C;_5[= /XHWW^7L))#] /Z-O]7MT
M_BC??Y>PDD/T _HV_P!7MT _BC??Y>PDD/T _HV_U>W0#^*-]_E["20_0#^C
M;_5[= /XHWW^7L))#] /Z-O]7MT _BC??Y>PDD/T _HV_P!7MT _BC??Y>PD
MD/T _HV_U>W0#^*-]_E["20_0#^C;_5[= /XHWW^7L))#] /Z-O]7MT _BC?
M?Y>PDD/T _HV_P!7MT _BC??Y>PDD/T _HV_U>W0#^*-]_E["20_0#^C;_5[
M= /XHWW^7L))#] /Z-O]7MT _BC??Y>PDD/T _HV_P!7MT _BC??Y>PDD/T
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MW\\)P\L>826&RW+_ /#E\D5?SL>4..FOS*]%4!["W4/EH#]W[H4PW^(N1?\
M5T?T@NCRMYC/_D=S_=R^2P_CP>3RI'XS71*HS(_I%Y:KW_\ PP^#"/F'D8Q.
M[H _G!+^%O,?_1;G^[E\E\'GB\G1R'F;Z)5]G](O+5?W/?ZX7\0\CS_%T?T@
ME_"_F+_HMS_=R^2+/Y[O)A&Q63S1]#$92 5;J1RP"">X@[A\.&GS)R %OQ=#
M_P \)X\I^9I!X[#=$?\ #E\EZ3SU^3.0 IYH>AK ]A7J/RR>^G_P0POXEY
MYWE#?SPE_"?F;_H-U_=R^2]_CS>3<=OF>Z'C.F?4;ED&OQ'<*XY_$OE__K-O
M_3"X/*GF4Y;'=?W<ODLR^=_R>MFOF9Z)M\743EH_WMPP[^(N1?\ 5T?TPN'R
MKYDCB=CNO[N7R0_'>\GP-#YF.B8)[CU$Y:!_<]_KCO\ $/(_^JH_I!+^%?,F
M?X'<_P!W+Y+(/.UY032GF6Z*G42 1U#Y:(J.W/W^@QT^8.2#$[JC^D%S^%O,
M8_\ );G^[E\EE_'3\HY&K\9+HO0]A_I"Y;^#_P"?_AQT<_Y*<MU1_2"0\K>8
MR6&QW+_\.7R07SI>4AQ5?,CT88=E1U!Y<(K[/_=_MPX\\Y. YW-+?S@E_"WF
M-V_ [I_^'+Y+*?.9Y30 Q\QO1L ]A_I Y<^W\+_'.3Y_B:?Z03?X9\PY?@MR
M_P#PY?) ^<SRFJI<^8WHT%':W]('+E/_ -OPO\=Y. YW-+?S@N?PUY@_Z/<_
MW<ODO)\Y_E*45/F/Z,@=M?Z0>6_@_P#G_P"''1SOE!#C<TM_."7\-\_. V>X
M_H2^2\?CI>4BA;\9'HQI7M/](/+E!_\ K^$>=\H&>XI_I!</ESGP+'9[A_YD
MODL3>=GRA* 6\RO14 Y GJ%RV 3[ ??\\<'/.3D.-S2W\X)'RWS\9[/<?T)?
M)?6\['E"45;S*]%0*$U/4/EH9#M/_N_AW^,\J_ZBK^D$W^'^>.WX2]_YA^2Q
M+YWO)ZS:%\S/1,M_BCJ)RT3^Y[_CG^-\H=OQ-+_S@G'R[ST9[3<?T)?)>QYV
M_* 20/,OT4) J1_2'RU4#Z?CO^,\J_ZBK^D$T^7^=C/:7_T#\EY?SO>3Z,D/
MYF.B:D"IKU$Y:%![3_XAA?XURG_J*OZ03?\  N<_]+?_ $#\D5?SU^3)!5_-
M#T-499GJ/RR.WL_]^'?AIYYR@#4=S4W\X)?X#SIV_"W/_-*ENSZX]'-PMTN[
M'JAR)=VLD"7,<]OS/M$L3V\J:XYE=+HJT;H:@]A&(1YD\OEO^=VV/^\C\U.?
M+'F(!SL=TP_W4_DLG]-?2"JC^DSD>KC4H_G+M7B7VC_.<QC@\R^7I$@;W;./
M]Y'YKG\,^8@'_ [IO^'/Y+X_6WH^@!?J=R*H)H*\S[1F3F!3WJM:87\2^7_^
MMVW]Y'YI?PSYB&>QW7]W/Y+&O7+HVXD*=4.16$5.)IYFVDZ*]FJEUX:X[_$O
ME\_^=VW]Y'YI2\L^8H_5LMT/_P".7R2;<^8KH-92)#=]8>G-M+)71'/S=LL;
M/2M=(:[!--)_<PT^9_+H+'>[9_\ B1^:DCY4\S3&J&PW9C_PI_))_P"-!Y<S
M&TO]-_2_AI(8F?\ GGL6E9!6J$^^9-X3^YCI\S>7AGO=M_>1^:7\*>9G;\!N
MW_X<ODLJ^9CR\O&)EZU],6B(4B0<Y[$4(<E4(;WVAU$9>W'!YG\NG+>[;^\C
M\US^%O,CM^!W3_\ #E\D7F\TGEP@N#:S=<NEL=P%+F%N==B$@4=K:??:TQT^
M9O+PSWNV_IQ^:=_"?F=M7X#=M_PI?)?7\T?EPCB$[]<NEJPG_P!H>==AT_N^
M^Y=F&_Q3Y</_ )[;?WD?FN?PIYE_Z#=?W<ODBZ^:WRT.P1>O'2EG*:PHYWV&
MI3_& ]]S&$/-/EPY;W;?WD?FG?PEYG_^W[O^ZE\EG3S2>6^3Y'7/I8W:<N=M
MAIEVY^^TQW^)_+O_ %NV_O(_-+^$?-'_ -OW?]U+Y(F?-IY8E^5U\Z3+XBOB
MYYY?'B #$9WHS ..?Q3Y<=OQNV?^?'YKH\H>:3ER_=_W4_DO?XU_EFTH_P#3
MUTGT2$A&_GSR_I<@5.D^_4-,+^*/+G_6[;^\C\UT>3_-1RY=O/[J?R0E\V'E
ME@ :;KWTFC5GX0+\\\O@&2E=&=]\JAQW^*/+O_6[;^G'YI?P?YJ=O\.WC_\
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M3F%-UVU881$)XM$S5/: HU*!4UKBU\7Q8#I 59I$)DYN5'FZ[FM[ 8HU6.5
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M"WA 5"0":@TH01@O[N.;,%%N8B3 8ATM.+<QM/I0T%"= K\8\-:XGA*)#YE
M_>/I+A9MMOHF<1K;QLS$J*H !D#4]PK7')SB0S%U**I,Y3JX]N56-T1)22-
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MQC1>P@"@QS6(ZHDX**V1C88\$V;F:[@LM$[46:21H(W=)+8A9'D1&;-=)0@
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MI!O=[UQ+_K'O^D7J!_:_^J)_NL^D!CTM8A4 _P!C#_A _P#/SPDD_P#R!_\
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MM[M+G:69HA=(8DDC%#;JI4DH<P X%/9@21$B7(#CNE#[:VV%L=3..U5CYBY
MO+J:QVBS17M+:X59T=2O'6 M\ZQ#JKMD#V&OLQ:[0RA #4=+%R>Q;/9[BJ$#
M=8'D(X-TJ3WY:OX-OCM[:VCA2W'C*QZ8]( )75JS+ C#/NXS$XD$G!O3BJG<
MWPW!(D<&<=HX*M/6'8)HMGN9[<;CN%Y<3V\9M[>IX2B0:C0@MI112G>#@^F8
MKL[H!(&7#IQ5GR,5SF3:(QB!@^1(^"A;:AM7*TEGM\EC=6ESNZ"Z>6,,KO<R
MQKQ6?(JC IF,L,NM-M@$<Y9CHZ@F[[;SWD9S@1IB2Q&6?!.CF/:1NT/N\4G
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MQ-"9%!&E2UP&I53VCLP3;6+*'<Z@!@LM=RP3V\]W1-HB3-Q_4I)WL0P6DSO
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MWIDFMO\ #"T5Y#;*$N7#!W)HHE!]HSJ:YG!U-4*Y=T%^D]"IA5"4HSLQ)R'
M=2ANZV<[GL]TFZ6*6]S:2L&2 BC(H($J%@:EP>^F>"X7"$@8DESVJOWFUJG+
M5 YY?J44/:WFW>\V5O=2<".)VM&HSR>[RQDU#'2"4+5[J'L]F)K6F=-42Q],
M%0V0E#2)9CV9\$PKBPGM]PCMS<EX'XTTDLC,'U2*5*%156HS4[Z8X(1T8#%O
M6NPW5)@:+0>+*"^>TNH-QMX+Q;BUE2!N#=0Z6$T>MCI+%@7#4KW=GP8 W$3*
MK1@1[EP76[:6JK$G@/M5:N990UPZH")IB6BCC325"A5,JAF"G/X>W&9W5%9)
MV\QW&X]:TNVW<Y1C:[DG+B6Z>KH4W]$>H;2.^QWT<B36J0HC.$"SJJNNHDS9
MY*.[&"$;.5;V4).*GP;TX+0RC'=Q$\8V:<>A=0/IA2PS=$.;VA%%_I+W/5D!
MXCR_RZ3V$COQ]%_ES;&[D]MD22#>?ZL5X3^8=4Z><51FQ_Y<-V:I+\ZC]8]_
MTB]0/[7_ -43_=9](#'H"P*H!_L8?\('_GYX22?_ ) _^H5\O7]I_9?Z_+["
M27;3TL2.3]58\LB2_P"3;HCT?U"M*_?EM2!4^TXSWFD:N36 8=Z/]8+9^0'_
M (IV^G M/^I)<YS;?;"]%W:2/"\>E"E0P(([_@./*I3(CHGBR^C?Q!85RQ*5
M6V&3<;=KA;I[>6-Q1@S:7R 9BG>"#]C \G4'CBN1<.Z3MMN+BY6:*=8H;FTG
M,;S*65)XQ4*]" 033M[,#^!39]0Q2G9*N6N.,#P3[M$.F$F4R#4I&60 /?W&
MN!+-K^P_=338?K;%'W=5(\(#:@0X[L^_L%,1F/AXC/)#B9D<5EGMXIX@6I%6
MI#H!JJ>Y@:"AI@L^%X?^4R9&4JYD#$+%96*!')56'9WU.517$==1@">"DG8+
M2(Q7AX=$ZD/PT'M)K6OPT%,<)U-@Q4DH:(YN4;9(Y8VCD\0SHSM4@MV$,:=G
MQUQ.(1 >9<H4&1(E+IX\$F)!- TL8F#*[ZHPPKI49CM!KD<13$1C%$ZHD89L
MA>-(( 02TM&53F*9-2BKW G#( $.2FU OWF=TAV6YN04>-M0D*EB/#4=E._2
M:89'2"7#R5I!G #)S)>LRQD4;50%0!X:Y%J5[L1:]+GBZF$<'(1J(^/7&VEX
MV[2S4!+4[*@4.(P7+\4I 1'$NC5SN4VWKK!XS,2O@%0"/E8GE)HL$R,!9AD%
M[VO<VN9V22-BKJ34F@# 4I[*4'QX'$CJ'64^=4:AP*<4<2O+%IDT$@ZE)% *
MG("OAU8(,S*>F*CU$C4V*78)EM P!05(R8@$U.9H>\G#H@ZW?%LTTF5@8I<$
M_$X?#R\-:ZNP&FIN_-33!0E$08Y]*C-)B=3X=")7-Y,"8K<U(&DR'Q4%2*U'
M?0?OXDJ/#@4)>0^*;-^TQE7AR5XFE**20HSU:B#4'+/$IRQR5:72#%"J7$LA
M5W+-X#3P @UR%.W*@PZ-8&+8*6I[,)?2$OV]NQEFN'9Y'B0JNMC\V"V:*M"!
M0C$0G*5FD8!3RMD*]#]U*]C"07F6BU4@$=HIVD&E-7_;AY(CF0$-8PBQQ+I4
MA9WB#+E/+5%7.H49>+,M4G/$$P; Y!;J7(5@8G!*DD6C;TUL1(VD,?X6K5J.
MD&A[<L\=KF:ZV.;J"3&WI'2FVT"M)0 :R1F2: FE%^,'VXC!C*6N8[P3M1!8
M9)P6NUBWX3%^*?ER,150PJ:"@\(P9 DXY* V&1(D,@N8+SW<X7O.WF5ZB7$3
MM)8[/NMCR];RHPE!3:N'#(B/&SH*S:FTUR';GCUWR[3&KE<)G"4HDKQ?S'=?
MN>;2K@2*XS'K8K9IRKN-X-BV*U613''L>U@3Q5UR*EE"P5B2P#1^T=M,>$<R
MIKEN[<'/B''UKWS:S->SJ(P)KB/<$O1\R7AG*2<10BL"[T%%6OBH116D[@"
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M/#\/5#3JR;BK^JRFBL0K ?CA\UAN>6=DVZ&YO+:XL;7=IT:<W=W=?.QR2U
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MF.#:SC/&()'U'TP1.TJ-M,Y2(BT<7P<GTX*>=@D:5;.:W4\(H$F#A ]&5"S
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MZNIKJ2:TFEA)RI'&TD<X&0+$=@(J!3NPP,)8APBX4D'2V*;IVZ]EE$LVE"]
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M>7TN AYTQG+4!B4M'F."",<6.:7Y*I$C T;+)37M [*X7X>1B\2'4,J)@'2
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M<%SKB "2<]6'>QQ+X]85KL^<;W:%C(V4L!ID20 .CH]7L7Z17DR\XW)7GO\
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M Q3J\:AT5Y@:/Q1D%0"M4J,\/D:V>*E(K![A#)U6^J9#',6BB9EXCA2)'7O
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M)\5SIB/3!=*GEYY!@V?EJ';MG@B:&.6SO-SDN:ZIG,'#E72 #4J%H*=N*<2
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MU[KN$EU<LU[N6X;SNLLUW=7ERS7-U-*TDC%F./E+?;S><UW\]WO9ZMQ99G\
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M"7'L4,8&Q])^\?/@W0FI=PQ7*&2'26C5VGJ7S*@D4 8T*C[-<6-/='@R&H'
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ME_K\OL))=QWE_L9=Q_5=/*W:PL$D?H9TH=692P^;ZO0/0A<P#II7NQ2>8?\
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MZ58#:#<#PP&(&!5<=KYCDN-5PDT<R"X($(13<14)1C*A)("&H)Q+9%J9"/\
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MBT(-0CAD8I*OL.6.D ]8]R-HLD/NY%B$U]QV*87!N;71'(5U2(*'1*I^4IC
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M8#V]F " +A&>%?IQ0,H"-L8UR=NC-1'MLEUN]U.S0>[%9IH5EE@J7T!A5 =
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M7-N/L(R2;/$U'>A8@J$*H/"I))2FM<JBM</DT[#(>@;I],4_5+%L@,.U(=]
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MVW"UGXMW-*\8MV!,:T1S!&R!2*UJ1VG+^_C02HA"HY.V?%21W% I%<"]PP+
MASZ88J+]W6)Y94MTXJ"-0J\*$(Z9,?%6@(TG(D98HK19:38"1*(X<> P1]-4
MI $MI</C\0HEWM0>/I128Z#AL$5=2N*C2Q"U'M/>,56ZJT1!'$8HDU1LF &
M]RB;?$86\DC:8U=LVK$612I#E5U4(%<O;^[BM$(FMV+GIQ/K7=J8FSPPQ:./
M8^2BS==OCGL95CX;".9'UTC5B6IJH"0:O4]E0#]C$4"*I@=O9A\G4\MS&N>H
M8QRPR] HVW?:&N8[E=(*&(1<$!0634: T]@-<_[]<'0W,9RC.7'T?J5CMMY0
M3&(. P55>=^E>UQW]YN'N<#RJHNHBT,.N:6*$! #4T=-.D5]GLQ8PW6K[N,C
MI&?5^A;.GGETZH40BT9%L^&7O4';8-UW3<[S:-PV,P6ELZ^[W$\L6F34&9D2
M.M*JPI3O/PX=NQ"8BQU=;9H_>;:&VVPW5-@$SF!^SUHK>V%C;7LMG<6L=I=P
M1DJQCC=5@ 8"2BDJ&J*#OQ2 [CQ,#JK<OPQZ%65V;F36">H'!%!LEI- BS21
MSF A_>I(4:5E)[6)/%!75\?9\ Q(92L,9!\\OTKEVYLC%WTQD,1]OJ23)RIM
M%\TT\MG:RNHX<;M!"LC$+V<3M342!W?W\2U;NY_#(PXAP<"N'?7@&ML91QQX
M!-G?^6GL+%G@N/=B5BB-E2%D D:M !(00I[:5%<64#$G2PTD>SL59&=<K7Q9
M_?Z<5">\VZ[1+=>\*LDEP1"541 PQLH/':C$>']W'+8QKAX8;2<71)W&[A,$
M$B#X!\'"AC>+&[N;+=(]K:,WD89]ON)FC83$T+#-]2!"",^WXJ8K)"/U<!GA
M[$'O2=Q/7,=X<>A0EO;;H4V^*_X#;M%'!)<NLL0(D12'$7B#4#UI3%EM96V4
M^'('$X8IM$(QC(YANCWGK3.YUVV62?;K])&:YDFA]ZCTQI&(@E'E8@Z251?A
MP9"<I52C-\,<?GTJ&=-<-JUI[WIB.E?-AN&FDO+>^M5FL571'*3&VM8ZJ#I!
M(-10YX[&0+1K<F68&'7B4JJ(RKC97)A@^'1TKL']-I8U\L/3N-&5(TV]#'4"
MB@VMK1 !7Y(RRRQY5S>PPYM9$ ZM1RZ'XE>C;4R/*:R<1I ]2V3VIB)1T954
M,:,JT"$Y'):'Y6>+#9;AY1!=H^_MZO<J6^,P#$ARRP;A?):1R"26,F0,(P5[
M:U!8D^(9D9_]^+<S$GK#%\3U-P4>WH\2T2(((^"I#YENL5ATDZ<<W<U[J0YM
MX)X+)-;1B2=XG95+Z" %X1S^3^]@N&XC1MC:^7 =".WNWJNC&, 2X&62_/.\
MU?6_<?,CU%YFW9KJ[EM8-[LX;7B7+-:J1'%83+$TA1<I 2:#*N-7R+EVXA:.
M86AI3C])8Z0^!ZGSR"JM_.K9[;PV^\8@]?KZNU.SRK]*MRZ?]9-GWU8HR5EN
M(+#2;68K=>[2$J&25FU,K#,=HQK9C<RW,9[H#PXEXG-W^#+ G?U6U3V^WB8&
M>?JXKJJ@ZT<B="NCNY]5NJ&\V/*W*G*7+4.^;WN6XR\*&"EM;I!:1"*.:>YO
MMPO72WMH8D>>>:141&<A3%NI2WFYAM=M%[IE@![ST89GJ78BG8[6>[W<A#;U
MXR?'#@/6< ,WR7 +YI>O_,_FE\P757KYS<O!W?J/S3=;M#8DVKG:-AM8X=KY
M7V$W%I8[=%>G8>6[&UL_>#"DD_!XCC6S''I6TV\=IMH;:&(@&[3Q/K./P7B'
M,M]9S'?6[VWZK)$MT#*(X9!@[=J@'!"!0PDD,))6+\I'EOYK\W7F1Z/^7'DN
M4VN]]5.;[/8I=R"V<K;%R_;QS;IS9S(MK?7^V0[@>6^6+"[OO=A/')<^[\-#
MK91@3?[ROE^SLWEOT5Q?M/ >LL%8<KY?=S7?U<OV_P#:VR;A@.)Q(=@">M?K
M>^5WI/L'E_Z']'^A/)VX;EN/+72'I[RKTZV*_P!W:U&[[AMO*NTV>V6^X;K[
MG#:6)W&^$'%F,:*I=B?A/@',+Y[O>6;JT-.V9D0,L3D/TKZ.VNQCR[9U[$=Z
MJN B">(''#IS5S]ON98K<D*- 41A3I"N&\1DKF"5.653AVVLURC@0&?TZ%2[
MNBN=K/WB7[.I>WNFJ0Q 5J (=- *4 S/B[>\4^QC1[:X 1)& .'I]G!0"@9A
MR>G%9(Y"2[(544!8KHKH9@!IKF2PI_Z<7D-/AB!B V/!075#2(R#\,419IA.
M433HR41_-G0,ZLV9 J#W]V#:XSG 8G2V/1BD*ZXU!QCZ?!)U[#(3IT*#1@8P
M(O$2P.LFNE:4PX,; 1P#=3]/K3:17JU1#XG]*;%Q$D:R2.=2K7515\)%: *#
M4U%.RN&RCW!K^DENW-6$6 C G GC\>I,:]0@L\<BJHU>$+FE1D0#VU(/P?8I
MB/Q) D$9/CA[D3(6:"!(D,_IT-[TSWGN/?>#) 6C#%DD+*%8$FFH9U.DXKKM
MSI#E]3^U1>#7&&N>+C'#$^G%(>];>LH"\!)(XTUT^; XE"3E6A&>?=@8DMI)
MQ/VJ>FQI/)M,21[,E$F]VK6\DFD1_,9:ZJ-#-0U0G/+XJX:,6(<@OZ8HPR$B
M9%HQ.'2R9LMF_O*W5-.1)70A+  KJ)!KX]7LI3'<8R$"<6S0S@/&9P)P25=0
M.9=20***S'28]3D,/$:FHK7][!4HU@ C&1"[*L@B3X=.::.\RUCD$P"1HA"9
M1 %F!)#Y@-F/[L\<C(UR#'$_#Y(2Z-DHDUAP[^[%0AS':N;>:-Y.(LX9XM0B
M98]3*0J ,1G0U]@I\&))2 GJ)[H]Z&TS$#  M[EN ]+.R%CT.YU0?^UZH[K*
M1D *\O<N*:!25'R<:[D4A+;3D/Y?V#VKS+S35X.^A Y^'_\ %)?G;_K'O^D7
MJ!_:_P#JB?[K/I 8O%F50#_8P_X0/_/SPDD__('_ -0KY>O[3^R_U^7V$DOT
MN?0+_P#O-/I\_P#W/^T4^/[O;]CDLEPY+;A4T.?L[_L?9PSA@FH,JR1LLJ)*
MK4#(ZAE;/^$A\+4P@V4A@D'&(7/3ZH?IK;CS7O<767R\=.4OVW*._N^H?+7+
M\D44PNX+6YO9-\VS9%@3Q7<<)618I"6F*Z8Q6IQ_/>1BZ7XC:PP;$#Y,O4_)
MGFV&W!V7-;3X0;03UG(E\ER[\X\O;_R]=723;9/''8M/'=P2QSK=6[Q/HDMI
MX7$>B: Y%'&H'+'FNXIMJM,2X(7M>TG1NP#48X^P]8Z5$6V[M8;S<W6T2+ ]
M]><8[>HB6*542-6*/(=(SX;Y9DG+$D9$1:)=.W>SW%(\>+^'$A\?3J3=WKEB
M.:Q==H9DW*S65[F.WN&202H/!04$I",#4"F7P8[&R,\"R AN[87 VN($\4R>
M4-]W^PLYY;K=)WO(=T%O;QR3<:.;YM0R21ODR#3VFF'6&LL SJ6^RPSU1P!"
MLQRSNMMNS-#> !Y8R%5$5$=@Q%&%34@TIE@:=>N1? $(..YM@P=+D?'MS+;(
M7T)(@CC"^-=:ZBX( H*]Y[\#B&@Z)9(J6XUQU3XIK\S&]L["6]A+2.TZ$@,'
M<5.AV8 @D=@&>'QKB^)&E2[655UN@#(="2VF?=]J6\0/*#$!"K(#+&8XV5V-
M0S*=1'?@*^(U8*[&W%4S"0PS1Z>T40%+NU!EN[)1;.HJ#*L9UF3Q45M1&=/A
MPP.0[=2?$#4\3@"L_*\\5Q9I;( #"D\<BL:L#&I_R8.HT!.1PX53(;C[U'NZ
M;(S\1G!;'M2_8;C(ZPSJ(D<*T489*FIJA)34U7&C++MP\QE$P?-_8H/"\,L,
MD9L]I6.&X>;7)-+<-,VM]3R$BH &66L]@RSQRT\!F5V5Y+1X(Q=2^ZV[<1-,
MS@H@1=+#54 @"FD>+,X)I&B#6_6Z!OEJ((.':L6PHJ6Q2DAE>1XT343J=E.D
M%F-=(%2<\L*T\8D:D.:2?J#@)T)I6#W<Q4D!JY%6:H-6&JIR!Q"8$CQ)!TT1
MD,<D4O)N" Y5BT*B1@12)*5;3_!H3IJ?B& Y@DN<D?MVD.]BRQL9I%C9F*17
M"H]PP%'?4?DQC,A0K 8[7(LW!2QT.>!1FX/"A1HPXA3Q/JJ96B16+:5KJJS
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M9IBCLH,,8C-;.C=L=)($@/<4T7V2=FD:UMC#*H$L6HB)&%"0649$ZQF*4]N
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M7C52P9B.QBI*Y&I_[<%"T_ZP@-DROH^-9(0G+3VX^Y17N7+Z[GN8NYD<!HA
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MYF$_#G]8]ZKY44VF4W+M@BFYWJ,CNQX\@&I%=E(U 592>X9_NXTT*XVQ!&!
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M9*A0&CTE5RU$!37(4_[L75$B Q## @]9X*20E7$QCD<\W62(:51Y!H;-: J
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M:4Y=DBVYH5M87W%DMU23C@*/G 7 "T \+LHIGVXAE87Q.:EC9JFQR7RVL)A
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M&X26'+W+VVP[7M5K)>WC2W=U);V=LH:21V9B#4X^=+=YN=S=/=;F0\:R1D2
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ML 0Q+=:AMTB).D>(V#Y%1[S*W$@8W$JJ@8A75\^'52H!,?:2:?9PB2,/5VJ
M0C+( EG/4?L6UKTW[5;3H]SA&IJ&ZD;E)F:T!V'E\ 5"J.[V8UOE\G\+-PWW
MA^ 7F?G.49<RKT%P*1C_ )TE^<?^L>_Z1>H']K_ZHG^ZSZ0&+Y9!4 _V,/\
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M $^W_JQTMGVWF'F*PZI=,N6^8>8=DVGEOE^XF-W<]0;>TVV23D7<+3:Q%=W
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M9:+"-9'K?B_:O0K][9NHZ9.8]?IQ2[;R\26+P$/7(L6!)#$ECIJ0')_>P37
M!X"41'B.O#%5]L=,#CAZO9BA?">YMY6MQ4(<D-5.I5/C- P:@[NRF"VGX8$?
MJ;]3)FW-5-H%N9X_8DBW681CWA5,E2&U,]*TJ I"D=N0[\6.W\?2TBY'LSQ]
M:+N-1E]W]/J7V*25I#Q8Q&W$H &?L4=I(7+LK@FH@Q<%,LA #N%PW4E:UXM3
M5 ZJRL_BDKH%>PD?PNS[.+>HRB +#@>'7T]:KK]'#"1RRS1J6[60NC+I5%57
M&JJDG4%(3M.D>SX\%QNTR FVD=/'H*#%&@:RYD^:;.[627=H\4C%U(H#&TE4
MSU!:Y$F@R![CGW8DNA*$@8' <>GTZ413?.BPSB^HEL@Y]J9\VW2Q3(5),8J
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M<MNL^7MCW/<KO;.4=FL;K?+AH[+;8[>W5650FE$"NYOS_=\\JKIW=@GX).G
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M%%3T@D/]/5FZM[M?)6WVL0FMXGBK%PT)XKC5K&5)&8$-2M?\-,65V]%-8AI
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M]?E]A)+]++T$S3T9/3Y/LZ [-_\ 3_?<<EDFRR6V(RY4-*D9]N7L]M:TQ'I
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MJQ)^4**N?QG%U"SPB"9=X\<F'S="60,2TAQX]*B'F7;8VDETLM7D#!C&6U>
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M<+';,\?AV*JW$9:)$@B6/L P;W>M?7=W5@\SZ!0G2!5LS1!0FH/?@^$]#:<
M_#!BJ&4Q+O2R'3FZ:FX79B29(68-0L695#*WB##-AX3B<WQ8@DN<NO\ 2C17
MA&V0!8L'Z^E1]'-Q@"XDD:-FFF=D5B4! &9>CT'=W8= 0E+'H+<<>U*P??RB
M3C+@FGO9AFMKF:./Q@Z S*H8*7=6-"U4R7*ASH,6&TOB&C:22^:*HIT1B+,
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M8;V7;++9^I^S1[K<<@\Q;G?;HU@EAOEA(M[=<B+!;7<+&[GN;BP98IGEEM_
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M+#JX]JK[=I8.[@"0_J2;>\T4T2*"$!73D@-?L-72?@^/VXLZ]Y&!,)$&1+?
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MN[L @QS"3+S<Y(YC'%<)*LD;!"KOX6.2JVK24CU5)-.[$U-1U"9R=5)F+ZB
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M.7@#^M)?G)_K'O\ I%Z@?VO_ *HG^ZSZ0&-*L4J ?[&'_"!_Y^>$DG_Y _\
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M LW>/\.#-W731 ^$&?T]:#YA59L]>UW#FSK+Y'I2AO\ NJ*)K<L63A&C$R$
M%?$P)3.3/MR(QE+-Q#41('6'QR['ZNI9:J!-D=.),LE V_77+45U)/>36J2"
M-:K(A9YEH%-5*%C\/;48"-AS?%7FUNYE6357K !QQ.#]7K=-^&]1IX9[2:--
MH5:/9PQ$1RYDQR*B@*M:BN1R&*R5M9G(RD01[5;RE*6WE"PF=K!R>/7BE:XY
MBWP<*:R,L\32I&%,QCHH["H;/M%?CP=R^ZN5TJMV=,1'# GL&'Q55M]IMY/X
M\@27.(<]0?[4=W,S[O8IQ8ECFT?.1,%7B$4!UOD#D*BM<6-%M=.X J)..)_0
MB-O;7LK=$/H&.G[%!DO(J7-W+-N'SUO%=&6T5)#2%E;54FI+#22/CQ;SW+UF
M$P')]W!:"'-I1J\2 .K2W0E3==ENY5XC?-V\3Q"-5:@0*OA) [:#X?@Q16W.
M>]BWIFJ2>ZC"R4XXF1Q?CZ?I4<;]RHUU(CR)$P9F\>GPL JZ RL/EBE:_!\6
M(97DO&(+/\,5P<QE.)T@QD.@^F:A/FZ*WCGC@=67W>-XM-)!'56(&I=!U5/>
M<23MLC!X]6(1E419(6R!!(R?IS5?]UM[*)VD>S'&J]2T;ZE4 $.&T%J57(?#
M\6%+=7RF(2,@ W'I^+ILMQ:9$:ONW9B?<HCYRV>>^%E<V%[+;QVSR37<,9DB
M]Y9M!CC)4@55>_VGVUQ:TAX.),P&'HRM>63JI<61U3.3X^]1AS58;KN$EE)M
M\\EM'"J"[5IW7450!U+$A214>T'#C929BN6$>.'%^C[4ZG<U[>VPRCC)P$P=
MVEN8-W.SK$[;;#:>\PW(=T,;!$DD705J!J=C4=_PX)D<Q42(F3=G!,G&LP\<
MER0<#Q+X**]WL+&:VNO=J27'O >1V9GDB74261F%=-?8?D_!AM9G&PPNXY'I
M/6R@UW@>++&#X=3=':MY?E VZ*WZ(<ISE$XLMHM9215J6\)4D@:F;(Y'O^''
MQ!^:5@/G#=TN&\4EVZS@WVJRJC.41.LG5+$=G1ZE9AHIJQD,16NG(^ 9YT![
M_@SQY%N8N7J<CI]/3BB28XS.1#/TGHZ?3J6+4L.HR%V!;4VHMXB6\) -2/%G
M^Y[!@8QUD:L)C+[7ZT2)1L$8PP+>L98*CGG'\D7EU\W6SF#JIR!MU]S8NW26
M>T=1]J4[7S_L:0V^XQ[<+7?[98[K<+#;;G<VN$L+LW%E)* 7B:F7IOD#\T_.
M?Y>7Q/EW=RCRK6)3VUG?V\W,3/N'Z)3$0#9#3,!V.)5#SWRYRCG_ '=_4#>0
M8BP861(<#$8D1=],GCT\%R"^<GTK_,5Y3KO<^8-OVF_ZN=';*SAOVZF<J;0R
MML\0LKN^W&/F[EB"[W'==@BV>*PE>:^/$V\0Z':9&?A+^A/Y:_GQY-_,.N&T
ME9'E_F64B#M+IAY=X1B:K"(PMUZ@T UCZAH8:CX/YB\D<VY#.5L =QRX!_%@
M,L"3JBY,68N3W<L7++9MZ-OD8MK?D3>O,-U6Y1CM^9>H,<>U=&7Y@VTM>;+R
M8UJ9-QYYV9'NG2)N<)+GW:WEEMXIEL[8R0R-#<G5XI_[DOS.LMW]?DOR_N3^
M%VIU[WPY83N<:-O-@_W0&N<8S(U2C&<1*"VWY;^6Q#;RYYO($7SPI? B#=Z<
M2_[3Z06=@6+%=&73WIYLEULFV[#>[3M\>X;0D4$%T]G'KN&M@D2581U/$IJS
M8C'S!L^=RNWHM%ED<3@YSZ.S@O<>4V Q\*9:0PZ\/L5]>E-IN7*N[;?=@-&D
M2B&6-"X5X3)&6T:!X6"K7LK7/MQ[#M.;^/7&P#3:,?7VK7UU671,;@U,H'$L
M7/#!;-.2^9(KJ&U5',VM(? 3(KJQ2JZG= 02<B3W8]8\M<TKWFF-CQEI;//I
M7EOF'E,ZC*1&G$XX9=CIX[Q9I-0A2#(ADDS9BI).H:OX2 T^#&Z,(BLQ?[OH
MZ?EVK.['<2@<>!8)DQVL<3-$ITZ6"DC4S &CFC YK3.G=7%7&LFUB>+-V_%:
M.=TIQ$R,QV=2,FXL;>.4SN$92-,QU99T(90"2:8U&PT5Q\.0#MCZD%.-\Y"4
M?HXA5HZS=3]MV>R>-+LPI!74O$E1F $M"5"5&ON]E*8L+)@Z8A\G=7'+MJ:(
M>-9_:G)\_;P6F+JEYI^19^:)]ACYDBW#=TN $V:R>ZN)TE"A5>000R(M)''R
MJ4!'=@/_ !"%]TJ*,;!@<?A\LE=R%QI%A!%1.!ZU$VR[+S!SSS?MW,E]#/#M
M=E=+<VVW3RLYNXY/%&>"2 E%H2",C\.)]K39'<1G,/C[^/8N[C?1ALVFVC2V
M?Q6T[8';W6SCD0P3<%7B'%*A5"KJC.D#PY9#LQI=Y49 3;!LA\>U>86[DZC&
M$Y:QAQ]/6IFVG<A)8VBK(T4[:U+H7)F9&R#*JJ<@,B<L8KF6UK>=FD.QR&7:
MKG8[N<("J;:6P)]_ZT:V?F99;FZM2[172/+!#%*SE9@A.F4$J0I0]H/97X\9
ML5:P</3[45N+YRB15T.3VIM\R<O<VK*ES#&DJ3,6EA$C E0K>)CIT2GL_>^#
M#J=E:3JCD1U!D%M]Q "0M#$<#CCP4"<_;RW+6UW=UNZ4B6WF;1<R\7@-&A.I
M 5=E#"F5!V8)_!7&1TAI#TS4E=\;CX-8&LLP ]GS6IS?O,ES=SQU$/(G3^SE
MW.*WOY[:_E%XZ6FWM&Q,2K#)$D<^H(:A20/;@VKE<IPUVDQPS^2UNUY'9#9^
M/?$@-B6S]86TKIWTBYVEV6VO-WF6/B!&:$ "KM'&Q8#B!0>T5%3C!<PG;'<2
M%;R ]P3C5MX1$X@:V;HPXJ8AR*UM;.EW$&=4%$II+DYFIJ0#_@^#$<96"0U.
M8CT] HZI1M)F"T2P &(ZQA^I8TVZ"S6-4B> D@TJ_@3(@$J*/5>T_P![%[M'
MNF<6AEV,HKZ;(SUQ+.[^A^'!%[B)S+*/>I B*"H19!5A4Y%!I4%?948L86#5
MJ([F/6ZKI2([T8O+C\\?@F1N^U6?,2/%>TE$)+%9-;:5*Y4#+F/#W=N#H3A"
M8B,QE@IMONK=G$RJ^J0SZ$E26:;1MR>[L8H;?P)#&L@!512GA7+M&>=/W<6>
MTM-EAA-F./0J7>GQ1*ZPO-W=W[<%ME]-:8S]'>=9&5E)ZF[IDS%V_P#>!R]_
M".9 [L>D>57_  -@/^U/P"\3\[RU\RJD"[T#J_:DOSE_UCW_ $B]0/[7_P!4
M3_=9](#&G6+5 /\ 8P_X0/\ S\\))/\ \@?_ %"OEZ_M/[+_ %^7V$DOT<O1
MC623T+O(E%%JUR] >68AH^4!)S?NB$CX@V):/[0=./P2=L\E%?G1G.^<]=(.
MEL<O'L-MDW'GSFFS<4A9;%EBV8W34*EFNG#(A45X?;EC!^>N8Z95;5V$@Y'P
M7I/Y?;+N7;XQ>P=V)^+=G%0IO5A%HLX+2.,0PPZ#"B@(VD *55%H2E*#V8\<
MW\;+[=4"T5ZYL+(TC5,=XJ*.8K<I(.(7CCC5P(M07B. 7*J!\H#LPJWC 1EF
MB(Z9S>(45;O?$*MO##)K(+2NBBD )72"VL!<E.6>+"@&6+%D4=F3+6</6F+>
M6]S:6-WN94+"L<I#EDXDDQ)HL8R8Y^SV'!TYPC#%F0VYE#5I"I%S7KN-QO1=
MH9/NE<LK\/4W )*G4Q4TB8#M[<QBMMA.<FAB#T)2CI G$]P<$W;JS>VVNXB*
MUA.MB"S:[B-$5&TFH+55JGLP7"G3407R2VA'C:QQ*C+G:XD_H^N);6W1+DH]
MD@9%+1S3W!7(L68!X7SS.> ;AHTZ>Z?BM5RXB6ZTDGZ2>I4UYEX$6\6<.S04
M3;K-;=O=U92EU=3"X85JI?5&WV,6VSE^T<N*L;I U2-A[IP#I>Y5GWF:WGCW
M9HN+#>2&QEB4"6*U8MHBFD U\0CM!/;BSG*N=;PQ65OB:;I$%HE6 O9$NX+&
M(2*;EXE232:*[!$44(&3$N/9BGLU&7=P"'HD(R,C])*:VZ-<PQ2PND-O/$/G
M6TMQ:%A21'&JO@%2?9AL)3C-RY'4NW;>,I:QDHKWJXO)'=;:20VRQ_/,BU12
MNIG?P UU/0]A[:X)FQ&H!E<;"FIAJ9TSK]N,EQ,"6D$1:&.=S4$!1-H1FRJH
M.7Q8DK ?4^*L)QCK&G)U+W0'?)=JN+Q+BY8J6N8O=P2]%:U1$B*$CY1&0K3+
M%7O8R$Q,XA32V]=L< '"FSF';VW#:)I["6(JL3R.NI8XD=9%!:4%00V@4[>P
MX&IL$KA+((+>"-9$8J I[>\3?9K.=HS&L=O?RQ.Z"*L"4JJU ,G#?(9UKBW.
MG2Y9DR$?N=0&+I]PV&W2;2]W:RQPUX*S%B5,MQJ)(6JGP1QCV@9XJ[7-G^0@
MSJ-FC').NROEN=OCN;-79 \$;Q"A&B*$IXE#&JG2>_"JK)&D(/=5B,LF?B4V
M.8G1=XV^]+\)N%Q0%?A(GNI+RDJ"/""#VDUI@N($6#8#CT("LR$) 8J7-DC$
MHVR-M5U<W&VW)")F\IEAN9%;4 IH0?;B&0$90;$X^]U5F1+D=**BVTVUK$JR
M23JYDFBD8L(2LM6&9TYANS.M,<C28UZI#'-=)>8E@S*3-D>#BNMMJ>Z2NMEU
M40Q+K5*#L-012F.55FR1(31BY*3.HR_=:TVGCQ2I$K325H(Y3<1-JB)().3(
M*?!@T1U[;2?K="@FO<8?2E?D;<)=QV=MFWAZNLC7$0FR  <"JN23_"PS:Q(^
MZGDBK!",O$K&*=VX3Q;;#%;MIC@*+P9ZDKIS\/$4Y5;X!VX,,(UQ/0A.].?=
MS*)6+R7=CQ49IV&JLE:Z>W0 3[*=V5,<[LX,<$\PE'+-.%+-XVAC,S*XC!;Q
M5(+ ]I*]E /L8' _8X!1@C4YQQ7HQW;!.%J,*/$3(33(2H6*C+(=QIA1(A8(
MR(S"?.416>ABN[WEW?[;8^D?)<LMQPG'(_+6F1LS0[)99]E2Q'[^/=]O_P#2
MUGAHC\%\Z[@&6XL(_ER^)5"NHO-[7QN':YGN2UQ.;2%D+--)Q'=**30DZOW,
M#2TXNC:8L0^$>M:ZN:>E'-GFHZY<A=%K:"ZON7(KFUYCZEBWN3:6=KRU:R(Z
M6=S>*LZH;MUSCTDN#VC#(5FVP1/TLCY6QV]1N</DNB+I?THY)Z-\I6G)?3_8
M;'E_8[:6>?W2RACC$DUS*TDLLKI&FMR7.9[!BR^GNQ&"S]DY62,YG%*?..Z#
M;-O #Z)9'2H !R)-!2HH"._ U\YAL67:8"<V9PRH!YI>JMSTOZ/\T;]:7$D?
M,6^;5S#MG+RI%QKA]T?8=PDLC&AEC"*+I4\1.1.,SS[>_@]H^IK"_P "M'R'
MEOX[F,*R'JC*)./^4%RC3<MW/+G)-CMNZZ'WJYBW#=^9+UY.-)=\P;O=F^W&
MXGN-*F8O-+0&F0R!QY*+)6'Q)8ZI%?4^P$=J85P#5L,.@,J<<X6=G+OUQ->0
M(\-NJ1 BA X9-"*$DG4<L0F$Q?J&06PU-LL#Q=NI)7*O%V/G9X3=MHN8$?AF
M4OI9!;R"A(!6J2FM*UK@G;6$F4"#BLESBJ$ZA,!B)=BFSF2&XN+/)\BP;PL%
MJ!XB^0J3H)[<<C$BQ^"S^D .!@HUW&RX1@/#CFME0ZVJ-.MVR4MX*'+#[]((
M)&*/VUIG$A\0DLADC:D: D93_P"*5\0#-4K2G;D< 3+=X9(^N;'-(<JRSR%I
MZS11ZJ<! 2VJF9*J-6F@[\18S+DX!%PN+,ZPW$;/#'-I32I(*2.:G34D?*J#
M\%:YX=&N4B>A(2+ELD6MD2X42!0\KL5#*H$3%2PD ! "NB?OX[&#G'--,"9N
M4X8['<KS<;>V@C$EA56,G#"W%55@"LQ0%:5%<\%1G&<=(R3([4_6R=7W.OK<
MR0HS1HC 9R$T*FE(V%14N:GVC$4)B,'.2=*J.:<MDD!B02+)!/K5VE?YL450
M2Y8G-PP)&6>!"2"YR3(#02V/O12_@F-U66X2^AD C"K(/G&(%"L>F,FE*&O;
MCM<L<,U)&SBDN"6PL;^$WL36MHTKP7#A*OQ" 8V< L-%#2O9B6;C'@5'?(3C
MW<PEDVMYO,KQ;0(IXHVUVHEHJ-$>PT*C4P4GL%,-$PS%0X&(!2YR[9W5E=W,
M\\)AAFBB#HJ!HQ*KD3H(]+!'4@]E,CB"[3(ZHATV<8P@,4XN8>#MMF][9W$B
M1"%[EM+>)9?#K*(0"%/>!E@83+X8!0$DRTA,/D7;[+<[I=UW1Y;O<;V69EB7
M4_@)0Q(R: %*Z<\S3 X$YV._===/=## *:UVF>SG46WNW$E_RZ+4FW *LF11
M:,J]M*X*E*$8/AJ1M5=8J,IX8+U>VD[:&<2.JEM>H,+<LP()92%+..[#'8:F
M()0-C,2!^E-F^LKAY$73&\('@5Z_+I4L01G0C"A&9D_2D',4@[MM"_<R[E>.
M*20I(H04T(0I)8 !2>SVG!]0\,]+J&402QP+KNO\CR"/R>>65  NGHET[72H
MH!3EJP% .ZF/H3D!?DNU/^YC\%\N>9@WF'>C_P#R9_UBK3XMU1K\_/S53$^:
M+S'KJ*$]=.JF9#FM.<]V&D+'WBGQ'X\?-G-]/^+[DC$?B+/;J/$K5T,*H2'U
MZ8^SYJ%(9P<D<U&1J)!E0 J20 37+ 4!(1'B' GCC[%%IPU C3P2C&YR.NG8
M=(XVF*G>145!.&S88'$_%. &+_6V'7AQ6;BL8F;4ND4#'QAB>S4*GL->[N^#
M'#$1EIX^F!Z4\B)D-7TMT-C\D2FD0N[J58JJLK$24)# A13Q9^SX/;C@U8 /
MGE[/3%*8UB.G"+@/Q'5]JZ>/()OUEO\ T.Y)W:]GA==HL[K7Q6=HP]I?W@$1
M5BQJ HR[J_'@OED:)[\V3(.DY'$K?T7V6\ICMZ-1S#C#V_:FGYCNJL<&[[I=
MFX]WC@6X:TAC64 CCL \9!TA6 %._+V4P7S/<RG:9Z1H'#'@>*T?)MA9#91!
M^M_7[?0+D=]5OS"<UW?(%Y9[3O5[9S[[ND6RW#6-Q=VTK6DD%_QHV82C6K*W
MB[C]C"\JTU[OS!XEP$JXP=SU$8*_\Q&>TY#X>S</(9=F)[5IO\MG1V^YRGGO
MKFQ>Y$A5?>)V0O*6XP8:YZ,S K0^W]S&_P";\SCXOX6HM$<!@LIR;E-<J?Q.
MX<RD<2?3V+H^\E/E!@VGEI'VFQ5+K=9W>2U/!,!DDMHF:0JBH-6HUK6N,Q;9
M7?;*R1UR!Q$CUXX<5>;GFU/*J]&UQCUC$E=%OEX\N-ETOV.'[FP&3CP27#12
M.AAX[2ZVBBT!*)4FN9S';3#C=1M]MXDG@"<6Z?4L%S+S#+?[B<K"1;D_4K1;
MGL,V\[:NR7<4$T5W0<&Y#- :$/5!4T*E._.N(:-W&1=\)'/$8(?;;R>WM%\)
MZ>+C[&1B+D"SV#9%9Q;VLD4!@3P,D4:A30OX::2105/:<7-E0MB(2R(!?X>M
M.NYU/?;J(,C*38G''V\51KK5U5VGDY;RWGW:W@>WC9BXEF !$6HZ &S/>0,\
ML9S=;.$9F<M).7;T.MKR3DYW4A<(=P=66*TM=??.6=JWB:_VO>1<IMA9&0"^
MT7'$6$(L@5U$A!+4IG@*K9V[C<QJ#")Z/3ADMYMN4U;;;SLD'G(CMP]_6MAW
ME$YDYUZQ](=KZA7,,<<-])P5C,=P@]SC@@DAF19Y209!-0^VG93"YKRNG:Q$
ML#8(XK*<P-,-U*%D1&WAEDYS]_4K<K:"UM^'J"2*"D;2EF193\DT-*G7F,4N
MUJE*6JTDS.?4LQ2!9<TLW8]GI[EF6026IL;XB2X:(@F'6A%"22KUTGP_#BWC
M7*F/B,T"<^)7;MM.B_QH!ZX\"V)ZOM3$M[BPFE-M!<'1!=.CE^* W!>C @@,
MQ!%:FH^S@X@6UB<BP. ?,HN=>XC7X\@Q;U,>'J1O<VADEETW"&VF4"*V5'4(
MP  -6&@&E<C[<#FN$Z^ZXE 'KX(#1K(%L&U?M8..SBF)>Q2E"TH#%'E)C E"
M*  $:A[3F#EG45'=BO,):NZ[<#V^C)LVI+08XL>#^U55ZG[@VS+<7D\ EM!+
M5YM$TC@M*$ 4 F32"U?C-<6NTV9)TS()8>KTXK1<M@+X:)-H SZ,%7+G?>I8
M$MKBT57CN@(^(Z2J7C9#D*E!J5J#LKEB2>VCXNJS2\>'0,U)#9U&1$6+ES@H
M<EW=O\\@N;EAK9##"W$U!@NJ7203_"-0?A^/'+I::A&F+P.+\5W=0E3 2B"<
M3EZ.FO<*TUP+9+LLCZ9^"[.":UUJ2:(<J?\ HQ"!9*6IR&4,M0CXEH).D!_D
MFWO]B][%?M"-+-87$(N "LD),)\1)-2$[?#_ '\'US?3*9,<<0,B"?CVKFVE
M"5D ',7P]O6JD;)MF][3<;L^Z7TM[#-=30P,S.Q1%DE5,F.H@J0/97%@]=AP
M&DA6W,YP,8Z(Z&P('$^I="?E.1/Z">3  -)M%-2K@A_=DJVG(@@^W'PC^:,8
M_P =[S2&)D?BHMM-Z01J?+/+'@K%N[(->K6H:C* X[!4%*FI9J4^SCS25(DT
M01XA]/M]&1U4Q8/#(;KS/'BL4JF5&90CNRH5!5B%4G4P8'('3G\8]M,5MFV,
M9$$D1!+HBF(IF'<.[=F&?V)*NK.&Z($FOP JCJ)!PCJ-6H:LHJO[_P >(8ZX
M3TD@ _:G'2+'?!W)/2>M-#F;D7ECFK9-QY:YDVR#>^7]\M;C;-]V;<81>;=N
MNVWL+P7FWW]G.KP7=A<V[F.2*0,CJ:$$8L=IO=YRO<U\PV%LZM]5,3A9 D3A
M.)>,HRSB0<0<PA[*ZKJ319&)HG@0<1*)SC(8N#UX=*(<N]->4>5[+:-HY:VR
M+9-GY<M+7:]DV?;819;5MVUV,*VUCM]A90(D5K96=O&$CC0*J* !V8=ON><T
MYE*V_=62MWMTS.RR1><IR+F4I'&4I'$GB4ZJFFJL;>B %48"(B  (@#(#)FZ
M$^+>R2UF6>WU1R1.)4<-)D5\1C8 Y@_N86UW=E1$RV0P^U3URMK:RC"3X_:>
MU71Y WC:]^V[;[U&A2] TW=GPY0('5R#(R$5(8+4$$]OMQZ?RKF%]D(^!,$$
M@.2?FM[RC?1WVU +>* [#XJQ_*NYS;;?*BO6&15$!4R>(HKAJ@GQ4#>RGLQZ
MSY6YQ97N(56 "73P^:#YWL:MSM7;OC-VX_J5I-GODW&SA68)(_!R;2W8%7PN
M34]IK\8Q[IL-Q#=5:@7(;T_6O%.8;6>SOE*MQ'5T_!-F^L4M))R7HZZY&56I
MPEI49GO8=V#MGL]5W>!+'%6M.[-L(L.Z<.U5EZH<X_<RV=(Y)8B.,[R$N"""
MJJ:@BI%,\L7-]-;"(<%VPS*T^VGMZJ#.;$L/5V+F5\^OF ZX=0.MW+GEQZ)\
MQW-AS#S#;KOW-._)<W,4FQ<KM>WNW\>VEDN85BGXJU  9L^S @INW.]CLHRE
M&(&+9^LK5\KERROE=G/^9")HA/1&+/JDP.7VJS70;RE]".EUAM&Y[@]]SCSO
M?Q(F[<U\QS#==SEW"68 <2ZEM@_#JB@#V 9TQNMER3DW+MF90,);E\R.\2<<
MV7FG,?-/,N9;J8+0VP/=C$$1 Z>U6OCY8Y=V6[>ZD14@M&HK0I(BQ !D1QPU
MT$4/\&O[N.Z*1'7  NZSV_Y_:2-N[1;'/W]:+;AS9O\ )N4.V['$]V]KMRW;
M,%GU\%9E4R1U==2QD@&E?W,"[G?1^@8=69]RK-G$6SUR,A$GV_%6ZZ>;)=[I
MM3W\,\]S=W$$,L]E)+)&]K-&6 :U9BBA9!4D5([,8_?W2E,QB7@<_9T+252&
M4@\1EVJ5>7NG"RSB_N_!>0%F2-JZU64'C&8L"*A0?$,L!0J-Y$J6! ;H]/M1
M),*H PD?$/#AC]BC[J_ULY1Z5;;(LVZK=[BFH003B:[)ETLH%(T(5 5RJ?\
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MN.<SYG_A\3M-L!XDW]6 ^:]:MY17RN,)U8\9=HRX+;!R?R]8\O,;.R5I(8M
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M!;X._%/7M]M*^?B -CQZ_BJ^[;446F ,26?/CT%2G;W<=KM,*WRB&\FMV><
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MWT.+;:\K%\B)]#XJPJVMIIU5C[N*::[7>W^ZW>YP7#I9F!4>V*TC:BO5]/\
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M)6I9NT#.H'9]C"D-47"913$=XYI Y;W>^3=I;*X=VMHYHBDP+#.21:JM0%(
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M<W$C^"5(G,T]2W#/R>[OIV@8)%\O$9GBKX",P)D\%4_>MN'W2>V^Y2JUQ<"
M#@NK(Y9"=&E12I'[AQ/(C4"8LY45T8S!!QBRD#[@QBR)EM W C%517U^%5HE
M2M05(P3/1+ #@5E=S7743*+.Z*,L44,)DBD%L\C*REB98U%"=6J@97)R!I3
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M?4!Z?H4FD %\9'WAQ\&6-CDVL!J"E&TCB %3K]BBII\>&Q$M)(S(=\.I(![
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ML.E.4BF2@SQ"6ULYCHN 1HUQ^%C5B.(O?[#[,%P@"(CH(*%LG(0('7\%L_\
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MY4_-K<U[OG]%U7T':C^O-<&_ZQ[_ *1>H']K_P"J)_NL^D!B]7EBH!_L8?\
M"!_Y^>$DG_Y _P#J%?+U_:?V7^OR^PDE^CYZ+ #>AKY#T8(4?H!RVCZWT*(V
MYLW4.:T.HJI)"_PCEWX?6-4M/2"N@D$$9NJ4>=OE*QY7\PO+^X11FVL>I/*D
M< =:K$VZ\MOPI$"FHXCV=RA/MTX\I\\\OA5O(&'T3C\%[Y^6_-I6\JNI.-E4
M_CBH, @MH_<QPXUB5!',SD,@_A%6SS<C]S'G1C&$C XKU;:6&R'B2S*)[W<-
M<QVX$W"4*$D9*AGDI3,DY@K7$,8-+!%42\)S  @I%GWR."UFMK:D4L<;+XAF
MSA1XZT/</;B:4R#IR*KS"=ESS.+J((;^>[8VZQ,[279:71J5*E@7+D-XA3M'
M97!L:A*(("O-$*Z'F,67G=;UK0S00JCDAPT#-216"AETJM2VIC\&)("1FS]T
M*EE6Y) P4 7T<EU=W#7%SI589/>((V<"@D9B"S4!TL "!F1@B<A&..,%.P$1
M$C%58ZJ[O+%<6T-BVN2'AR0Q3('&XWSHW BT48<.V3Q$9]F>*V9C*P:2"%:[
M3;Z:39:&? ]BA^RVF61WW"[N3/?@JEM8B&12)C3.-@ 2Q1:UH  3@P6QK <=
MU WS\>7AP^D<4LVVURPFXGW,P1M</'HM:F1D/# !9:D@!$S/:6.&6;R)[D(N
MHCM)680Q9.S;=O2:.WCDX4,!)]TA909)49]*R$T%(<J*!G0YX!A;(3)CFHK=
ML8?0'/2B7.FU6L5O:VRPIPQ9/I2-RH+-)J*H%HI)/:#@N!E&W5D^:6UA*)[P
M)+J,;3;FMDABD@ CBC6H@AK,[%JL:@FNDN:_ ,&QD[@RQ==MKL).#XYK!S ]
MY?P75O:[?,FLK)+.$T)&B (&B-*@'5GVYXEKC54?$=RB=M3&):4L3P6"ULUV
MFSC:6Y6990L4\6:RLIBH00VEI=))\0K4XBW%TKAIAA)%5;42L),7 R3\Z:BU
MGN7.A6*2)&:AB8II"]&B[@7A%*>WMQ6V&VD#6<RG;NHQJ/ LI#W:RBM=U@N(
M[R11P7C&V5)JY74AGJ:$/HJ/9EGA1E"<P8GO+,;@&=1#/BFWOEG+=QPBS@MH
MY_%+/K75(CEE7)J9)(!VX+KG.O49XQ.2"IA&LGQ?I/!(_P#-J]OYC+N-S<%I
M)4$$4!58HETHU5J"026[>W$PGKK$<BE+<54@QH@\3F5*&U[?[G#)5S-4"15F
M&L@C5JT'L\0[<=C&1&3A5EY<G!G3BG23W?WAK91;%0C:1H9T*D :NTTR_<P_
M3D$&2#W1FFI9&*+<4OK#B.DL_"N90="Z6D$3J 1X@A!_<PH5QA)P<T^<3* C
M,M$*;MAL[6W.L</PG55&#:D  +*G>2/;@K0(G41@A+-9'=+1X):W23;F@:"
M*1>T0(R OJ4&I44[&!'V<.@[N0T62JC:3@76'8]H>QFD FD"J@8U -:D@ J*
M4!K@9XC,8*TC(2BY'>3CG@>]3W>DC, &9V.G2@.21#^""0">S"AJ?#Z5R=>D
M"72B-EM$S74FM'6W18U)6C.S@BJ$G.M*YXDE3 =^1#J(W:(Z8XDIQK=6D,R+
M 7TPOPW)4$>&@*L:^WV8CB(DXD.H(SOD#@4[(89[BUBD108Y)(^"B=F@2*RE
MNSM/[V#*HF$V.3*"<A&.B7U,?@5TB<Y='=EZ^\Z>1?8MVLH[R/I/S9M_4RY+
MQHZ0)R]R<.$KDJ:E[R>$4./9]M$PV]5C8FL?!?/6[(_&W'_>2^)6X4?X?_1^
M]B5#+"Z:I 2,@O;_ (._#ADFOBFK>-KN;J/+*(:*=B^$9=AIE6M<,M?2W!*
M>76M0/G8MVV?G2VW @H+N">/6U *E4;M(((.GV8Q/.QHL$QDQQ7J?DQITR@<
MXL3ZUIRL[\+:@0NP9?>'$I0:&!FDKJ8BK4;OQY+N*S*TOTX^TKZDY=03M8Q
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MYBG#_G;NN8)4BM:X\ YI_P"H[GI_$3_K%:JH=V!)>&B(ZW;](4-I<"K%0'#
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M'KU*R,#4J "PS'9A^NR,7?NA!PC(S<Q8/FDC:]_LEO7MKFR6!:$0F,*&<U-
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M-D,1X-5,P 0*'^_BNE)WZCC[?DNO%CF;&<]C,RR<4,5JYHY 6KOXB Q+'PY
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M;9.3&,FP.0? ]/O7H"13_E@&((-6?209'K0Z>VHRKCL82E,QPR?L_2GUQE
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M)*Z95L9?5''CQ7IO+N<;?>V53ML$9#]EQP&?L4S;781"YCDNPR2H6N/=V#-
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M],6N5F>8&,N#0U*Z=5*5[L&"8E4X3+Q&J6FH$A(0LY9;J=)1J1AIC;VG25(
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MP5;NJ8O$/@E*::QFV=+DS0H"0DQ$B!XV=U*^$T).6GXL0V4M:3UI54,'&(3
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MU_\ 5$_W6?2 PEU4 _V,/^$#_P _/"23_P#('_U"OEZ_M/[+_7Y?822_2?\
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M_-C\ELH_FGYO@&AN;!V66?OKY<>G;Y<KE4$G+<!**JAON-RP6TJ% %3L9R\
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M@E #:]FY6;,+2HKL6'Q\K\JBS0&'5'Y)I\_>8B0?&EA_E3_>2*/3+\KX)/\
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M]_S7UO0_\M3.6_I*ZUK_ .J-WY0"CXA_-"F.GR)RTG^UO]L?W4V/,;(AM$"
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M>H6X;9O%E/87UK=7O+=Q%+;W$;12*8Y>6V4U5N\$5P7MO_:QY)VFXANMMO\
MFL+JY Q(LJ&(+C_5)D_S#YO96:YU;<Q(Z)N.SOX+2SSK^IW^G[SIS!O6^S=?
M/-;M,>[[M>[LFR[;S#TV&T;7)>RO*]OMMK<=.YA#;QZM*@DG2!GCZ'Y9RN'+
M=I7M8SE8:ZQ#7)M4@ SR( Q6.WV[_'7&^<!&9STY>]TSI/U+WT\9$51YB/-O
M&P-6D3?>E>IQ3Y)#=-&4"OL%<68U#B60/AULS'V_H6 _J6_IZ?60\W@IV?\
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MPTPDE!'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P _E2X22'WN_P
M_E2X22'WN_P _E2X22VS?^2/Q/?_ +3' _1,?_[#>Y>Y?IU/XQ^X_P!T?_T_
)W_\ ^<L))?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
